StartDate,EndDate,Status,IPAddress,Progress,Duration (in seconds),Finished,RecordedDate,ResponseId,RecipientLastName,RecipientFirstName,RecipientEmail,ExternalReference,LocationLatitude,LocationLongitude,DistributionChannel,UserLanguage,Q1,Q2,Q3,Q4,Q5,Q6,Q7_1,Q7_2,Q8,1_Q9,2_Q9,3_Q9,4_Q9,5_Q9,result_1_type,result_2_type,result_3_type,result_4_type,result_5_type,result_1_id_1,result_1_id_2,result_1_id_3,result_2_id_1,result_2_id_2,result_2_id_3,result_3_id_1,result_3_id_2,result_3_id_3,result_4_id_1,result_4_id_2,result_4_id_3,result_5_id_1,result_5_id_2,result_5_id_3,result_1_date_1,result_1_date_2,result_2_date_1,result_2_date_2,result_3_date_1,result_3_date_2,result_4_date_1,result_4_date_2,result_5_date_1,result_5_date_2,result_1_trns_1,result_1_trns_2,result_1_trns_3,result_2_trns_1,result_2_trns_2,result_2_trns_3,result_3_trns_1,result_3_trns_2,result_3_trns_3,result_4_trns_1,result_4_trns_2,result_4_trns_3,result_5_trns_1,result_5_trns_2,result_5_trns_3,result_1_comments_1,result_2_comments_1,result_3_comments_1,result_4_comments_1,result_5_comments_1,Q11,Q12,result_1_source,result_2_source,result_3_source,result_4_source,result_5_source,result_1_type,result_2_type,result_3_type,result_4_type,result_5_type,result_1_id_1,result_1_id_2,result_1_id_3,result_2_id_1,result_2_id_2,result_2_id_3,result_3_id_1,result_3_id_2,result_3_id_3,result_4_id_1,result_4_id_2,result_4_id_3,result_5_id_1,result_5_id_2,result_5_id_3,result_1_date_1,result_1_date_2,result_2_date_1,result_2_date_2,result_3_date_1,result_3_date_2,result_4_date_1,result_4_date_2,result_5_date_1,result_5_date_2,result_1_trns_1,result_1_trns_2,result_1_trns_3,result_2_trns_1,result_2_trns_2,result_2_trns_3,result_3_trns_1,result_3_trns_2,result_3_trns_3,result_4_trns_1,result_4_trns_2,result_4_trns_3,result_5_trns_1,result_5_trns_2,result_5_trns_3,result_1_comments_1,result_2_comments_1,result_3_comments_1,result_4_comments_1,result_5_comments_1,Q14,Q15,result_1_source,result_2_source,result_3_source,result_4_source,result_5_source,result_1_type,result_2_type,result_3_type,result_4_type,result_5_type,result_1_id_1,result_1_id_2,result_1_id_3,result_2_id_1,result_2_id_2,result_2_id_3,result_3_id_1,result_3_id_2,result_3_id_3,result_4_id_1,result_4_id_2,result_4_id_3,result_5_id_1,result_5_id_2,result_5_id_3,result_1_date_1,result_1_date_2,result_2_date_1,result_2_date_2,result_3_date_1,result_3_date_2,result_4_date_1,result_4_date_2,result_5_date_1,result_5_date_2,result_1_trns_1,result_1_trns_2,result_1_trns_3,result_2_trns_1,result_2_trns_2,result_2_trns_3,result_3_trns_1,result_3_trns_2,result_3_trns_3,result_4_trns_1,result_4_trns_2,result_4_trns_3,result_5_trns_1,result_5_trns_2,result_5_trns_3,result_1_comments_1,result_2_comments_1,result_3_comments_1,result_4_comments_1,result_5_comments_1,Q17,Q18_4,Q18_5,Q18_6,Q18_7,Q18_8,Q18_9,Q19,Q20,Q21_1,Q21_2,coder,cutoff,trialid,source_register,date_registration,date_enrollement,retrospective_registration,normed_spon_names,recruitment_status,phase,study_type,countries,public_title,study_category,intervention,intervention_list,target_enrollment,web_address,cross_registrations,included,pcd,scd,rcd,tabular_results,potential_other_results,hit_tid2,auto_id_1,auto_id_2,doi_1,doi_2,results_pub_type_1,results_pub_type_2,pub_completion_date_1,publication_date_1,publication_date_2,batch,Create New Field or Choose From Dropdown...,trial_status,study_include,coder_n,pmid_1,pub_type_1,date_publication_1,cord_id_1,url_1,title_1,date_completion_1,crossreg_pub_1,pmid_2,pub_type_2,date_publication_2,pub_completion_date_2,journal_article,preprint,rcd_correct
Start Date,End Date,Response Type,IP Address,Progress,Duration (in seconds),Finished,Recorded Date,Response ID,Recipient Last Name,Recipient First Name,Recipient Email,External Data Reference,Location Latitude,Location Longitude,Distribution Channel,User Language,clinical_trial,covid,withdrawn,screening_comments,no_auto_completion_date,auto_completion_date,completion_date - Primary Completion Date (PCD),completion_date - Study Completion Date (SCD),cross_registration,1 - trn,2 - trn,3 - trn,4 - trn,5 - trn,results_registry - Type - 1,results_registry - Type - 2,results_registry - Type - 3,results_registry - Type - 4,results_registry - Type - 5,results_registry - Identifier - 1 - DOI,results_registry - Identifier - 1 - PMID,results_registry - Identifier - 1 - URL,results_registry - Identifier - 2 - DOI,results_registry - Identifier - 2 - PMID,results_registry - Identifier - 2 - URL,results_registry - Identifier - 3 - DOI,results_registry - Identifier - 3 - PMID,results_registry - Identifier - 3 - URL,results_registry - Identifier - 4 - DOI,results_registry - Identifier - 4 - PMID,results_registry - Identifier - 4 - URL,results_registry - Identifier - 5 - DOI,results_registry - Identifier - 5 - PMID,results_registry - Identifier - 5 - URL,results_registry - Dates - 1 - Publication,results_registry - Dates - 1 - Trial Completion,results_registry - Dates - 2 - Publication,results_registry - Dates - 2 - Trial Completion,results_registry - Dates - 3 - Publication,results_registry - Dates - 3 - Trial Completion,results_registry - Dates - 4 - Publication,results_registry - Dates - 4 - Trial Completion,results_registry - Dates - 5 - Publication,results_registry - Dates - 5 - Trial Completion,results_registry - Additional trial registration numbers - 1 - 1st,results_registry - Additional trial registration numbers - 1 - 2nd,results_registry - Additional trial registration numbers - 1 - 3rd,results_registry - Additional trial registration numbers - 2 - 1st,results_registry - Additional trial registration numbers - 2 - 2nd,results_registry - Additional trial registration numbers - 2 - 3rd,results_registry - Additional trial registration numbers - 3 - 1st,results_registry - Additional trial registration numbers - 3 - 2nd,results_registry - Additional trial registration numbers - 3 - 3rd,results_registry - Additional trial registration numbers - 4 - 1st,results_registry - Additional trial registration numbers - 4 - 2nd,results_registry - Additional trial registration numbers - 4 - 3rd,results_registry - Additional trial registration numbers - 5 - 1st,results_registry - Additional trial registration numbers - 5 - 2nd,results_registry - Additional trial registration numbers - 5 - 3rd,results_registry - Comments - 1 -,results_registry - Comments - 2 -,results_registry - Comments - 3 -,results_registry - Comments - 4 -,results_registry - Comments - 5 -,additional_results_registry,comments_results_registry,results_search_trn - Source - 1,results_search_trn - Source - 2,results_search_trn - Source - 3,results_search_trn - Source - 4,results_search_trn - Source - 5,results_search_trn - Type - 1,results_search_trn - Type - 2,results_search_trn - Type - 3,results_search_trn - Type - 4,results_search_trn - Type - 5,results_search_trn - Identifier - 1 - DOI,results_search_trn - Identifier - 1 - PMID,results_search_trn - Identifier - 1 - URL,results_search_trn - Identifier - 2 - DOI,results_search_trn - Identifier - 2 - PMID,results_search_trn - Identifier - 2 - URL,results_search_trn - Identifier - 3 - DOI,results_search_trn - Identifier - 3 - PMID,results_search_trn - Identifier - 3 - URL,results_search_trn - Identifier - 4 - DOI,results_search_trn - Identifier - 4 - PMID,results_search_trn - Identifier - 4 - URL,results_search_trn - Identifier - 5 - DOI,results_search_trn - Identifier - 5 - PMID,results_search_trn - Identifier - 5 - URL,results_search_trn - Dates - 1 - Publication,results_search_trn - Dates - 1 - Trial Completion,results_search_trn - Dates - 2 - Publication,results_search_trn - Dates - 2 - Trial Completion,results_search_trn - Dates - 3 - Publication,results_search_trn - Dates - 3 - Trial Completion,results_search_trn - Dates - 4 - Publication,results_search_trn - Dates - 4 - Trial Completion,results_search_trn - Dates - 5 - Publication,results_search_trn - Dates - 5 - Trial Completion,results_search_trn - Additional trial registration numbers - 1 - 1st,results_search_trn - Additional trial registration numbers - 1 - 2nd,results_search_trn - Additional trial registration numbers - 1 - 3rd,results_search_trn - Additional trial registration numbers - 2 - 1st,results_search_trn - Additional trial registration numbers - 2 - 2nd,results_search_trn - Additional trial registration numbers - 2 - 3rd,results_search_trn - Additional trial registration numbers - 3 - 1st,results_search_trn - Additional trial registration numbers - 3 - 2nd,results_search_trn - Additional trial registration numbers - 3 - 3rd,results_search_trn - Additional trial registration numbers - 4 - 1st,results_search_trn - Additional trial registration numbers - 4 - 2nd,results_search_trn - Additional trial registration numbers - 4 - 3rd,results_search_trn - Additional trial registration numbers - 5 - 1st,results_search_trn - Additional trial registration numbers - 5 - 2nd,results_search_trn - Additional trial registration numbers - 5 - 3rd,results_search_trn - Comments - 1 -,results_search_trn - Comments - 2 -,results_search_trn - Comments - 3 -,results_search_trn - Comments - 4 -,results_search_trn - Comments - 5 -,additional_results_trn,comments_results_trn,results_search_keywords - Source - 1,results_search_keywords - Source - 2,results_search_keywords - Source - 3,results_search_keywords - Source - 4,results_search_keywords - Source - 5,results_search_keywords - Type - 1,results_search_keywords - Type - 2,results_search_keywords - Type - 3,results_search_keywords - Type - 4,results_search_keywords - Type - 5,results_search_keywords - Identifier - 1 - DOI,results_search_keywords - Identifier - 1 - PMID,results_search_keywords - Identifier - 1 - URL,results_search_keywords - Identifier - 2 - DOI,results_search_keywords - Identifier - 2 - PMID,results_search_keywords - Identifier - 2 - URL,results_search_keywords - Identifier - 3 - DOI,results_search_keywords - Identifier - 3 - PMID,results_search_keywords - Identifier - 3 - URL,results_search_keywords - Identifier - 4 - DOI,results_search_keywords - Identifier - 4 - PMID,results_search_keywords - Identifier - 4 - URL,results_search_keywords - Identifier - 5 - DOI,results_search_keywords - Identifier - 5 - PMID,results_search_keywords - Identifier - 5 - URL,results_search_keywords - Dates - 1 - Publication,results_search_keywords - Dates - 1 - Trial Completion,results_search_keywords - Dates - 2 - Publication,results_search_keywords - Dates - 2 - Trial Completion,results_search_keywords - Dates - 3 - Publication,results_search_keywords - Dates - 3 - Trial Completion,results_search_keywords - Dates - 4 - Publication,results_search_keywords - Dates - 4 - Trial Completion,results_search_keywords - Dates - 5 - Publication,results_search_keywords - Dates - 5 - Trial Completion,results_search_keywords - Additional trial registration numbers - 1 - 1st,results_search_keywords - Additional trial registration numbers - 1 - 2nd,results_search_keywords - Additional trial registration numbers - 1 - 3rd,results_search_keywords - Additional trial registration numbers - 2 - 1st,results_search_keywords - Additional trial registration numbers - 2 - 2nd,results_search_keywords - Additional trial registration numbers - 2 - 3rd,results_search_keywords - Additional trial registration numbers - 3 - 1st,results_search_keywords - Additional trial registration numbers - 3 - 2nd,results_search_keywords - Additional trial registration numbers - 3 - 3rd,results_search_keywords - Additional trial registration numbers - 4 - 1st,results_search_keywords - Additional trial registration numbers - 4 - 2nd,results_search_keywords - Additional trial registration numbers - 4 - 3rd,results_search_keywords - Additional trial registration numbers - 5 - 1st,results_search_keywords - Additional trial registration numbers - 5 - 2nd,results_search_keywords - Additional trial registration numbers - 5 - 3rd,results_search_keywords - Comments - 1 -,results_search_keywords - Comments - 2 -,results_search_keywords - Comments - 3 -,results_search_keywords - Comments - 4 -,results_search_keywords - Comments - 5 -,additional_results_keywords,keywords_search_strings - Search 1,keywords_search_strings - Search 2,keywords_search_strings - Search 3,keywords_search_strings - Search 4,keywords_search_strings - Search 5,keywords_search_strings - Additional Searches (separate with semicolons),comments_results_keywords,comment,flag - team_review,flag - non_english,coder,cutoff,trialid,source_register,date_registration,date_enrollement,retrospective_registration,normed_spon_names,recruitment_status,phase,study_type,countries,public_title,study_category,intervention,intervention_list,target_enrollment,web_address,cross_registrations,included,pcd,scd,rcd,tabular_results,potential_other_results,hit_tid2,auto_id_1,auto_id_2,doi_1,doi_2,results_pub_type_1,results_pub_type_2,pub_completion_date_1,publication_date_1,publication_date_2,batch,Create New Field or Choose From Dropdown...,trial_status,study_include,coder_n,pmid_1,pub_type_1,date_publication_1,cord_id_1,url_1,title_1,date_completion_1,crossreg_pub_1,pmid_2,pub_type_2,date_publication_2,pub_completion_date_2,journal_article,preprint,rcd_correct
"{""ImportId"":""startDate"",""timeZone"":""Europe/Berlin""}","{""ImportId"":""endDate"",""timeZone"":""Europe/Berlin""}","{""ImportId"":""status""}","{""ImportId"":""ipAddress""}","{""ImportId"":""progress""}","{""ImportId"":""duration""}","{""ImportId"":""finished""}","{""ImportId"":""recordedDate"",""timeZone"":""Europe/Berlin""}","{""ImportId"":""_recordId""}","{""ImportId"":""recipientLastName""}","{""ImportId"":""recipientFirstName""}","{""ImportId"":""recipientEmail""}","{""ImportId"":""externalDataReference""}","{""ImportId"":""locationLatitude""}","{""ImportId"":""locationLongitude""}","{""ImportId"":""distributionChannel""}","{""ImportId"":""userLanguage""}","{""ImportId"":""QID25""}","{""ImportId"":""QID26""}","{""ImportId"":""QID36""}","{""ImportId"":""QID84_TEXT""}","{""ImportId"":""QID85""}","{""ImportId"":""QID39""}","{""ImportId"":""QID51_1""}","{""ImportId"":""QID51_2""}","{""ImportId"":""QID38_TEXT""}","{""ImportId"":""1_QID53_TEXT""}","{""ImportId"":""2_QID53_TEXT""}","{""ImportId"":""3_QID53_TEXT""}","{""ImportId"":""4_QID53_TEXT""}","{""ImportId"":""5_QID53_TEXT""}","{""ImportId"":""QID104#1_1""}","{""ImportId"":""QID104#1_2""}","{""ImportId"":""QID104#1_3""}","{""ImportId"":""QID104#1_4""}","{""ImportId"":""QID104#1_5""}","{""ImportId"":""QID104#2_1_1""}","{""ImportId"":""QID104#2_1_2""}","{""ImportId"":""QID104#2_1_3""}","{""ImportId"":""QID104#2_2_1""}","{""ImportId"":""QID104#2_2_2""}","{""ImportId"":""QID104#2_2_3""}","{""ImportId"":""QID104#2_3_1""}","{""ImportId"":""QID104#2_3_2""}","{""ImportId"":""QID104#2_3_3""}","{""ImportId"":""QID104#2_4_1""}","{""ImportId"":""QID104#2_4_2""}","{""ImportId"":""QID104#2_4_3""}","{""ImportId"":""QID104#2_5_1""}","{""ImportId"":""QID104#2_5_2""}","{""ImportId"":""QID104#2_5_3""}","{""ImportId"":""QID104#3_1_1""}","{""ImportId"":""QID104#3_1_2""}","{""ImportId"":""QID104#3_2_1""}","{""ImportId"":""QID104#3_2_2""}","{""ImportId"":""QID104#3_3_1""}","{""ImportId"":""QID104#3_3_2""}","{""ImportId"":""QID104#3_4_1""}","{""ImportId"":""QID104#3_4_2""}","{""ImportId"":""QID104#3_5_1""}","{""ImportId"":""QID104#3_5_2""}","{""ImportId"":""QID104#4_1_1""}","{""ImportId"":""QID104#4_1_2""}","{""ImportId"":""QID104#4_1_3""}","{""ImportId"":""QID104#4_2_1""}","{""ImportId"":""QID104#4_2_2""}","{""ImportId"":""QID104#4_2_3""}","{""ImportId"":""QID104#4_3_1""}","{""ImportId"":""QID104#4_3_2""}","{""ImportId"":""QID104#4_3_3""}","{""ImportId"":""QID104#4_4_1""}","{""ImportId"":""QID104#4_4_2""}","{""ImportId"":""QID104#4_4_3""}","{""ImportId"":""QID104#4_5_1""}","{""ImportId"":""QID104#4_5_2""}","{""ImportId"":""QID104#4_5_3""}","{""ImportId"":""QID104#5_1_1""}","{""ImportId"":""QID104#5_2_1""}","{""ImportId"":""QID104#5_3_1""}","{""ImportId"":""QID104#5_4_1""}","{""ImportId"":""QID104#5_5_1""}","{""ImportId"":""QID105_TEXT""}","{""ImportId"":""QID107_TEXT""}","{""ImportId"":""QID96#1_1""}","{""ImportId"":""QID96#1_2""}","{""ImportId"":""QID96#1_3""}","{""ImportId"":""QID96#1_4""}","{""ImportId"":""QID96#1_5""}","{""ImportId"":""QID96#2_1""}","{""ImportId"":""QID96#2_2""}","{""ImportId"":""QID96#2_3""}","{""ImportId"":""QID96#2_4""}","{""ImportId"":""QID96#2_5""}","{""ImportId"":""QID96#3_1_1""}","{""ImportId"":""QID96#3_1_2""}","{""ImportId"":""QID96#3_1_3""}","{""ImportId"":""QID96#3_2_1""}","{""ImportId"":""QID96#3_2_2""}","{""ImportId"":""QID96#3_2_3""}","{""ImportId"":""QID96#3_3_1""}","{""ImportId"":""QID96#3_3_2""}","{""ImportId"":""QID96#3_3_3""}","{""ImportId"":""QID96#3_4_1""}","{""ImportId"":""QID96#3_4_2""}","{""ImportId"":""QID96#3_4_3""}","{""ImportId"":""QID96#3_5_1""}","{""ImportId"":""QID96#3_5_2""}","{""ImportId"":""QID96#3_5_3""}","{""ImportId"":""QID96#4_1_1""}","{""ImportId"":""QID96#4_1_2""}","{""ImportId"":""QID96#4_2_1""}","{""ImportId"":""QID96#4_2_2""}","{""ImportId"":""QID96#4_3_1""}","{""ImportId"":""QID96#4_3_2""}","{""ImportId"":""QID96#4_4_1""}","{""ImportId"":""QID96#4_4_2""}","{""ImportId"":""QID96#4_5_1""}","{""ImportId"":""QID96#4_5_2""}","{""ImportId"":""QID96#5_1_1""}","{""ImportId"":""QID96#5_1_2""}","{""ImportId"":""QID96#5_1_3""}","{""ImportId"":""QID96#5_2_1""}","{""ImportId"":""QID96#5_2_2""}","{""ImportId"":""QID96#5_2_3""}","{""ImportId"":""QID96#5_3_1""}","{""ImportId"":""QID96#5_3_2""}","{""ImportId"":""QID96#5_3_3""}","{""ImportId"":""QID96#5_4_1""}","{""ImportId"":""QID96#5_4_2""}","{""ImportId"":""QID96#5_4_3""}","{""ImportId"":""QID96#5_5_1""}","{""ImportId"":""QID96#5_5_2""}","{""ImportId"":""QID96#5_5_3""}","{""ImportId"":""QID96#6_1_1""}","{""ImportId"":""QID96#6_2_1""}","{""ImportId"":""QID96#6_3_1""}","{""ImportId"":""QID96#6_4_1""}","{""ImportId"":""QID96#6_5_1""}","{""ImportId"":""QID97_TEXT""}","{""ImportId"":""QID108_TEXT""}","{""ImportId"":""QID100#1_1""}","{""ImportId"":""QID100#1_2""}","{""ImportId"":""QID100#1_3""}","{""ImportId"":""QID100#1_4""}","{""ImportId"":""QID100#1_5""}","{""ImportId"":""QID100#2_1""}","{""ImportId"":""QID100#2_2""}","{""ImportId"":""QID100#2_3""}","{""ImportId"":""QID100#2_4""}","{""ImportId"":""QID100#2_5""}","{""ImportId"":""QID100#3_1_1""}","{""ImportId"":""QID100#3_1_2""}","{""ImportId"":""QID100#3_1_3""}","{""ImportId"":""QID100#3_2_1""}","{""ImportId"":""QID100#3_2_2""}","{""ImportId"":""QID100#3_2_3""}","{""ImportId"":""QID100#3_3_1""}","{""ImportId"":""QID100#3_3_2""}","{""ImportId"":""QID100#3_3_3""}","{""ImportId"":""QID100#3_4_1""}","{""ImportId"":""QID100#3_4_2""}","{""ImportId"":""QID100#3_4_3""}","{""ImportId"":""QID100#3_5_1""}","{""ImportId"":""QID100#3_5_2""}","{""ImportId"":""QID100#3_5_3""}","{""ImportId"":""QID100#4_1_1""}","{""ImportId"":""QID100#4_1_2""}","{""ImportId"":""QID100#4_2_1""}","{""ImportId"":""QID100#4_2_2""}","{""ImportId"":""QID100#4_3_1""}","{""ImportId"":""QID100#4_3_2""}","{""ImportId"":""QID100#4_4_1""}","{""ImportId"":""QID100#4_4_2""}","{""ImportId"":""QID100#4_5_1""}","{""ImportId"":""QID100#4_5_2""}","{""ImportId"":""QID100#5_1_1""}","{""ImportId"":""QID100#5_1_2""}","{""ImportId"":""QID100#5_1_3""}","{""ImportId"":""QID100#5_2_1""}","{""ImportId"":""QID100#5_2_2""}","{""ImportId"":""QID100#5_2_3""}","{""ImportId"":""QID100#5_3_1""}","{""ImportId"":""QID100#5_3_2""}","{""ImportId"":""QID100#5_3_3""}","{""ImportId"":""QID100#5_4_1""}","{""ImportId"":""QID100#5_4_2""}","{""ImportId"":""QID100#5_4_3""}","{""ImportId"":""QID100#5_5_1""}","{""ImportId"":""QID100#5_5_2""}","{""ImportId"":""QID100#5_5_3""}","{""ImportId"":""QID100#6_1_1""}","{""ImportId"":""QID100#6_2_1""}","{""ImportId"":""QID100#6_3_1""}","{""ImportId"":""QID100#6_4_1""}","{""ImportId"":""QID100#6_5_1""}","{""ImportId"":""QID101_TEXT""}","{""ImportId"":""QID103_4""}","{""ImportId"":""QID103_5""}","{""ImportId"":""QID103_6""}","{""ImportId"":""QID103_7""}","{""ImportId"":""QID103_8""}","{""ImportId"":""QID103_9""}","{""ImportId"":""QID109_TEXT""}","{""ImportId"":""QID16_TEXT""}","{""ImportId"":""QID33"",""choiceId"":""1""}","{""ImportId"":""QID33"",""choiceId"":""2""}","{""ImportId"":""coder""}","{""ImportId"":""cutoff""}","{""ImportId"":""trialid""}","{""ImportId"":""source_register""}","{""ImportId"":""date_registration""}","{""ImportId"":""date_enrollement""}","{""ImportId"":""retrospective_registration""}","{""ImportId"":""normed_spon_names""}","{""ImportId"":""recruitment_status""}","{""ImportId"":""phase""}","{""ImportId"":""study_type""}","{""ImportId"":""countries""}","{""ImportId"":""public_title""}","{""ImportId"":""study_category""}","{""ImportId"":""intervention""}","{""ImportId"":""intervention_list""}","{""ImportId"":""target_enrollment""}","{""ImportId"":""web_address""}","{""ImportId"":""cross_registrations""}","{""ImportId"":""included""}","{""ImportId"":""pcd""}","{""ImportId"":""scd""}","{""ImportId"":""rcd""}","{""ImportId"":""tabular_results""}","{""ImportId"":""potential_other_results""}","{""ImportId"":""hit_tid2""}","{""ImportId"":""auto_id_1""}","{""ImportId"":""auto_id_2""}","{""ImportId"":""doi_1""}","{""ImportId"":""doi_2""}","{""ImportId"":""results_pub_type_1""}","{""ImportId"":""results_pub_type_2""}","{""ImportId"":""pub_completion_date_1""}","{""ImportId"":""publication_date_1""}","{""ImportId"":""publication_date_2""}","{""ImportId"":""batch""}","{""ImportId"":""Create New Field or Choose From Dropdown...""}","{""ImportId"":""trial_status""}","{""ImportId"":""study_include""}","{""ImportId"":""coder_n""}","{""ImportId"":""pmid_1""}","{""ImportId"":""pub_type_1""}","{""ImportId"":""date_publication_1""}","{""ImportId"":""cord_id_1""}","{""ImportId"":""url_1""}","{""ImportId"":""title_1""}","{""ImportId"":""date_completion_1""}","{""ImportId"":""crossreg_pub_1""}","{""ImportId"":""pmid_2""}","{""ImportId"":""pub_type_2""}","{""ImportId"":""date_publication_2""}","{""ImportId"":""pub_completion_date_2""}","{""ImportId"":""journal_article""}","{""ImportId"":""preprint""}","{""ImportId"":""rcd_correct""}"
2020-10-21 14:46:10,2020-10-21 15:10:01,IP Address,77.247.85.71,100,1430,True,2020-10-21 15:10:02,R_3qjqeCNKNh7ihvm,,,test@test.com,,51.4499969482421875,7.016693115234375,gl,EN,yes,yes,no,,,no,2020-05-12,2020-07-09,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,google_scholar,,,,full_results_journal_article,full_results_preprint,,,,10.1038/s41392-020-00286-5,32855385,https://www.nature.com/articles/s41392-020-00286-5,10.2139/ssrn.3680611,32864128,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3680611,,,,,,,,,,2020-08-27,,2020-10-14,,,,,,,,,,,,,,,,,,,,,,,May not be a result of NCT04288102 but rather a phase 1 predecessor,Not able to get full-text to check for dates,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Unclear whether the full result is from a preceding phase 1 trial, but same research group and time frame.",team_review,,MSH,2020-06-30,NCT04288102,ClinicalTrials.gov,2020-02-24,2020-03-05,FALSE,Beijing 302 Hospital,Not Recruiting,Phase 2,Interventional,China,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),ATMP,Cells (mesenchymal),Cells (mesenchymal),100,https://clinicaltrials.gov/show/NCT04288102,,1,2020-05-12,2020-07-10,2020-05-12,0,0,,,,,,,,,,,1,,,,3,,,,,,,,,,,,,true,true,2020-07-09
2020-10-22 10:31:13,2020-10-22 10:53:42,IP Address,86.31.166.235,100,1348,True,2020-10-22 10:53:42,R_2EtyAfgthxOzbjb,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,other,,,,,https://doi.org/10.1093/jmcb/mjaa014,,https://academic.oup.com/jmcb/article/12/4/322/5814655,,,,,,,,,,,,,2020-04-01,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"This result is an application note with preliminary results ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029542,ChiCTR,2020-02-03,2020-02-03,FALSE,Sun Yat sen Memorial Hospital of Sun Yat sen University,Recruiting,Phase 4,Interventional,China,Study for the efficacy of chloroquine in patients with novel coronavirus pneumonia (COVID-19),Drug,Chloroquine,Chloroquine,20,http://www.chictr.org.cn/showproj.aspx?proj=48968,,1,,2020-07-30,2020-07-30,0,0,,32236562,,http://doi.org/10.1093/jmcb/mjaa014,,interim_results_journal_article,,,2020-01-04,,1,,,,4,,,,,,,,,,,,,,,
2020-10-22 10:54:54,2020-10-22 11:34:47,IP Address,86.31.166.235,100,2392,True,2020-10-22 11:34:47,R_1FEOX8EH3PIly9u,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,,10.1101/2020.07.11.20151365,,https://europepmc.org/article/PPR/PPR186561,,,,,,,,,,,,,2020-07-11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,tocilizumab AND SARS-CoV2 AND pneumonitis,"tocilizumab AND pneumonitis AND Gabrielli ",Gabrielli AND Covid-19 AND tocilizumab,,,,,,,,MPJ,2020-06-30,NCT04315480,ClinicalTrials.gov,2020-03-14,2020-03-12,TRUE,Universit Politecnica delle Marche,Not Recruiting,Phase 2,Interventional,Italy,Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,Drug,Tocilizumab,Tocilizumab,38,https://clinicaltrials.gov/show/NCT04315480,,1,2020-04-09,2020-05-01,2020-04-09,0,0,,,,,,,,,,,1,,,,4,,,,,,,,,,,,,,true,
2020-10-22 11:35:05,2020-10-22 11:40:00,IP Address,86.31.166.235,100,294,True,2020-10-22 11:40:00,R_DPhmueQWIkkNlN7,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04352400,ClinicalTrials.gov,2020-04-03,2020-04-01,TRUE,University Hospital Padova,Not Recruiting,Phase 2/Phase 3,Interventional,No Country Given,Efficacy of Nafamostat in Covid-19 Patients (RACONA Study),Drug,Nafamostat,Nafamostat,256,https://clinicaltrials.gov/show/NCT04352400,,1,2021-12-01,2021-12-01,2021-12-01,0,1,,,,,,,,,,,1,,,,4,,,,,,,,,,,,,,,
2020-10-22 11:40:15,2020-10-22 11:48:08,Spam,86.31.166.235,100,472,True,2020-10-22 11:48:08,R_3GqrexHLnCWW9uA,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04338958,ClinicalTrials.gov,2020-04-07,2020-04-22,TRUE,University of Jena,Recruiting,Phase 2,Interventional,Germany,Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation,Drug,Ruxolitinib,Ruxolitinib,200,https://clinicaltrials.gov/show/NCT04338958,EUCTR2020-001481-11,1,2021-01-31,2021-08-31,2021-01-31,0,1,,,,,,,,,,,1,,,,4,,,,,,,,,,,,,,,
2020-10-22 12:36:40,2020-10-22 13:07:56,IP Address,86.31.166.235,100,1876,True,2020-10-22 13:07:57,R_28IiVkoZRQ1D8SR,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Covid-19 AND chloroquinE AND Post-Exposure Prophylaxis ",Asymptomatic AND Covid-19 AND chloroquinE AND Pakistan,"Covid-19 AND chloroquinE AND Sarwar ",,,,,,,,MPJ,2020-06-30,NCT04346667,ClinicalTrials.gov,2020-04-13,2020-04-14,FALSE,"Government of Punjab, Specialized Healthcare and Medical Education Department",Recruiting,Phase 4,Interventional,Pakistan,Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds,Drug (Chemoprophylaxis),Hydroxychloroquine vs. Chloroquine,Hydroxychloroquine; chloroquine,400,https://clinicaltrials.gov/show/NCT04346667,,1,2020-05-30,2021-06-30,2020-05-30,0,0,,,,,,,,,,,1,,,,4,,,,,,,,,,,,,,,
2020-10-22 13:08:51,2020-10-22 13:11:47,IP Address,86.31.166.235,100,175,True,2020-10-22 13:11:48,R_1eQc8hT20AjEIRE,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,"The intervention is a pulse oximeter for patients with mild Covid-19 symptoms to track their health - this is neither preventing or treating, but monitoring patients. ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04373161,ClinicalTrials.gov,2020-04-30,2020-03-20,TRUE,Swedish Hospital,Not Recruiting,Not Applicable,Interventional,United States,Home Pulse Oximeter Use in Patients With COVID-19,Other (device),Biosensors,Biosensors,209,https://clinicaltrials.gov/show/NCT04373161,,1,2020-04-22,2020-04-22,2020-04-22,0,0,,,,,,,,,,,1,,,,4,,,,,,,,,,,,,,,
2020-10-22 13:12:47,2020-10-22 13:24:51,IP Address,86.31.166.235,100,723,True,2020-10-22 13:24:51,R_2rARUhEqp1XiPlK,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,,"10.1101/2020.05.23.20111054 ",,https://europepmc.org/article/PPR/PPR167128?singleResult=true#impact,,,,,,,,,,,,,2020-05-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Do-it-yourself AND Covid-19 AND PPE ",PPE AND Covid-19 AND Pettinger,,,,,,,,,MPJ,2020-06-30,NCT04375774,ClinicalTrials.gov,2020-04-17,2020-05-01,FALSE,"University Clinic, UCLouvain",Recruiting,Not Applicable,Interventional,Belgium,Verification of Alternative Do-it-yourself Equipment Respirators for the COVID-19 Personal Protective Equipment (PPE),Other (device),Masks,Masks,10,https://clinicaltrials.gov/show/NCT04375774,,1,2020-05-01,2020-05-01,2020-05-01,0,0,,,,,,,,,,,1,,,,4,,,,,,,,,,,,,,true,
2020-10-22 13:58:38,2020-10-22 14:08:07,IP Address,86.31.166.235,100,568,True,2020-10-22 14:08:07,R_2AG7kmPcIaK74UL,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,," Naltrexone AND Ketamine AND Covid-19",Covid-19 AND Naltrexone AND Sims,"William Beaumont AND Covid-19 AND Ketamine ",,,,,,,,MPJ,2020-06-30,NCT04365985,ClinicalTrials.gov,2020-04-26,2020-04-29,FALSE,William Beaumont Hospitals,Recruiting,Phase 2,Interventional,United States,Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19,Drug,"Ketamine, Naltrexone",Ketamine; Naltrexone,500,https://clinicaltrials.gov/show/NCT04365985,,1,2020-05-01,2020-08-01,2020-05-01,0,0,,,,,,,,,,,1,,,,4,,,,,,,,,,,,,,,
2020-10-22 14:08:16,2020-10-22 14:09:45,IP Address,86.31.166.235,100,89,True,2020-10-22 14:09:45,R_3Gwi0it4Mc7tFOJ,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,"Intervention is use of a meditation app by health-workers to manage stress. ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04374786,ClinicalTrials.gov,2020-05-01,2020-05-15,FALSE,University of Arizona,Recruiting,Not Applicable,Interventional,United States,Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic,Other (psych),Psychological,Psychological,328,https://clinicaltrials.gov/show/NCT04374786,,1,2020-09-01,2020-10-01,2020-09-01,0,1,,,,,,,,,,,1,,,,4,,,,,,,,,,,,,,,
2020-10-22 14:09:56,2020-10-22 14:31:09,IP Address,86.31.166.235,100,1273,True,2020-10-22 14:31:09,R_2q2B5aQAmOi0bnx,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-05-12,2020-07-09,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,google,,,,full_results_preprint,full_results_preprint,,,,,,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3680611,https://doi.org/10.1101/2020.10.15.20213553,,https://www.medrxiv.org/content/10.1101/2020.10.15.20213553v2,,,,,,,,,,2020-10-14,,2020-10-21,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mesenchymal Stem Cells AND Fu-Sheng Wang AND Covid-19,Fu-Sheng Wang AND Covid-19 AND Beijing 302 Hospital,,,,,,,,,MPJ,2020-06-30,NCT04288102,ClinicalTrials.gov,2020-02-24,2020-03-05,FALSE,Beijing 302 Hospital,Not Recruiting,Phase 2,Interventional,China,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),ATMP,Cells (mesenchymal),Cells (mesenchymal),100,https://clinicaltrials.gov/show/NCT04288102,,1,2020-05-12,2020-07-10,2020-05-12,0,0,,,,,,,,,,,1,,,,4,,,,,,,,,,,,,,true,2020-07-09
2020-10-22 21:19:46,2020-10-22 21:24:21,IP Address,81.109.92.226,100,274,True,2020-10-22 21:24:21,R_1DvU0v9nkb9MLfB,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,Prospective cohort == Single arm Trial,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Worth noting that while we call these results interim, it's not 100% clear that's what they are.",team_review,,ND,2020-06-30,ChiCTR2000029542,ChiCTR,2020-02-03,2020-02-03,FALSE,Sun Yat sen Memorial Hospital of Sun Yat sen University,Recruiting,Phase 4,Interventional,China,Study for the efficacy of chloroquine in patients with novel coronavirus pneumonia (COVID-19),Drug,Chloroquine,Chloroquine,20,http://www.chictr.org.cn/showproj.aspx?proj=48968,,1,,2020-07-30,2020-07-30,0,0,,32236562,,http://doi.org/10.1093/jmcb/mjaa014,,interim_results_journal_article,,,2020-01-04,,1,,,,1,,,,,,,,,,,,,,,
2020-10-22 21:24:35,2020-10-22 21:51:13,IP Address,129.67.117.86,100,1598,True,2020-10-22 21:51:14,R_BxPpO3L7bCFgcMh,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,google_scholar,,,,full_results_preprint,other,,,,doi.org/10.21203/rs.3.rs-42117/v1,,https://www.researchsquare.com/article/rs-42117/v1,doi.org/10.1101/2020.07.11.20151365,,https://www.medrxiv.org/content/10.1101/2020.07.11.20151365v1,,,,,,,,,,2020-07-22,,2020-07-11,,,,,,,,,,,,,,,,,,,,,,,,Secondary analysis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"""Giovanni Pomponio""","""Armando Gabrielli"" AND Tocilizumab",,,,,,,,,ND,2020-06-30,NCT04315480,ClinicalTrials.gov,2020-03-14,2020-03-12,TRUE,Universit Politecnica delle Marche,Not Recruiting,Phase 2,Interventional,Italy,Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,Drug,Tocilizumab,Tocilizumab,38,https://clinicaltrials.gov/show/NCT04315480,,1,2020-04-09,2020-05-01,2020-04-09,0,0,,,,,,,,,,,1,,,,1,,,,,,,,,,,,,,true,
2020-10-22 21:51:35,2020-10-22 21:55:39,IP Address,129.67.117.86,100,243,True,2020-10-22 21:55:40,R_1gectEo3D1WAPIY,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04352400,ClinicalTrials.gov,2020-04-03,2020-04-01,TRUE,University Hospital Padova,Not Recruiting,Phase 2/Phase 3,Interventional,No Country Given,Efficacy of Nafamostat in Covid-19 Patients (RACONA Study),Drug,Nafamostat,Nafamostat,256,https://clinicaltrials.gov/show/NCT04352400,,1,2021-12-01,2021-12-01,2021-12-01,0,1,,,,,,,,,,,1,,,,1,,,,,,,,,,,,,,,
2020-10-22 21:55:54,2020-10-22 21:59:00,IP Address,129.67.117.86,100,186,True,2020-10-22 21:59:01,R_a9OsUbYydgixeEN,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Just nothing that this is not a result for this trial: https://pubmed.ncbi.nlm.nih.gov/32518419/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04338958,ClinicalTrials.gov,2020-04-07,2020-04-22,TRUE,University of Jena,Recruiting,Phase 2,Interventional,Germany,Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation,Drug,Ruxolitinib,Ruxolitinib,200,https://clinicaltrials.gov/show/NCT04338958,EUCTR2020-001481-11,1,2021-01-31,2021-08-31,2021-01-31,0,1,,,,,,,,,,,1,,,,1,,,,,,,,,,,,,,,
2020-10-22 21:59:18,2020-10-22 22:36:05,IP Address,129.67.117.86,100,2206,True,2020-10-22 22:36:06,R_RLwlatnQYeFUNQ5,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ammar Sarwar AND chloroquine,Ammar Sarwar,"NBC-COVID19-02 ",PEACE AND Chloroquine,"""Government of Punjab"" AND Chloroquine",,,,,,ND,2020-06-30,NCT04346667,ClinicalTrials.gov,2020-04-13,2020-04-14,FALSE,"Government of Punjab, Specialized Healthcare and Medical Education Department",Recruiting,Phase 4,Interventional,Pakistan,Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds,Drug (Chemoprophylaxis),Hydroxychloroquine vs. Chloroquine,Hydroxychloroquine; chloroquine,400,https://clinicaltrials.gov/show/NCT04346667,,1,2020-05-30,2021-06-30,2020-05-30,0,0,,,,,,,,,,,1,,,,1,,,,,,,,,,,,,,,
2020-10-22 22:36:22,2020-10-22 22:37:16,IP Address,129.67.117.86,100,53,True,2020-10-22 22:37:16,R_3p5senr8qIFMYOr,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,This is diagnostics/monitoring not treatment,,,ND,2020-06-30,NCT04373161,ClinicalTrials.gov,2020-04-30,2020-03-20,TRUE,Swedish Hospital,Not Recruiting,Not Applicable,Interventional,United States,Home Pulse Oximeter Use in Patients With COVID-19,Other (device),Biosensors,Biosensors,209,https://clinicaltrials.gov/show/NCT04373161,,1,2020-04-22,2020-04-22,2020-04-22,0,0,,,,,,,,,,,1,,,,1,,,,,,,,,,,,,,,
2020-10-22 22:37:25,2020-10-22 22:38:40,IP Address,129.67.117.86,100,74,True,2020-10-22 22:38:40,R_1hShSYng3VqZMYb,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,no,,While this is 2nd order about prevention of COVID they aren't actually measuring any COVID outcomes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04375774,ClinicalTrials.gov,2020-04-17,2020-05-01,FALSE,"University Clinic, UCLouvain",Recruiting,Not Applicable,Interventional,Belgium,Verification of Alternative Do-it-yourself Equipment Respirators for the COVID-19 Personal Protective Equipment (PPE),Other (device),Masks,Masks,10,https://clinicaltrials.gov/show/NCT04375774,,1,2020-05-01,2020-05-01,2020-05-01,0,0,,,,,,,,,,,1,,,,1,,,,,,,,,,,,,,,
2020-10-22 22:44:05,2020-10-22 22:44:41,IP Address,129.67.117.86,100,35,True,2020-10-22 22:44:41,R_29040IaRJlIoSLv,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,no,,Mental health app,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04374786,ClinicalTrials.gov,2020-05-01,2020-05-15,FALSE,University of Arizona,Recruiting,Not Applicable,Interventional,United States,Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic,Other (psych),Psychological,Psychological,328,https://clinicaltrials.gov/show/NCT04374786,,1,2020-09-01,2020-10-01,2020-09-01,0,1,,,,,,,,,,,1,,,,1,,,,,,,,,,,,,,,
2020-10-22 22:44:48,2020-10-22 23:10:08,IP Address,129.67.117.86,100,1520,True,2020-10-22 23:10:09,R_3PzTFEs8TmoePR9,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,no,2020-05-12,2020-07-09,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,,,,,full_results_preprint,,,,,dx.doi.org/10.2139/ssrn.3680611,,https://ssrn.com/abstract=3680611,,,,,,,,,,,,,2020-10-14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Fu-Sheng Wang AND Mesenchymal,umbilical cord stem cells covid,,,,,,,,,ND,2020-06-30,NCT04288102,ClinicalTrials.gov,2020-02-24,2020-03-05,FALSE,Beijing 302 Hospital,Not Recruiting,Phase 2,Interventional,China,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),ATMP,Cells (mesenchymal),Cells (mesenchymal),100,https://clinicaltrials.gov/show/NCT04288102,,1,2020-05-12,2020-07-10,2020-05-12,0,0,,,,,,,,,,,1,,,,1,,,,,,,,,,,,,,true,2020-07-09
2020-10-27 09:24:30,2020-10-27 09:31:24,IP Address,77.11.144.175,100,413,True,2020-10-27 09:31:24,R_A4chRec8F99SCR3,,,test@test.com,,52.483001708984375,13.341400146484375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,ChiCTR2000029542,ChiCTR,2020-02-03,2020-02-03,FALSE,Sun Yat sen Memorial Hospital of Sun Yat sen University,Recruiting,Phase 4,Interventional,China,Study for the efficacy of chloroquine in patients with novel coronavirus pneumonia (COVID-19),Drug,Chloroquine,Chloroquine,20,http://www.chictr.org.cn/showproj.aspx?proj=48968,,1,,2020-07-30,2020-07-30,0,0,,32236562,,http://doi.org/10.1093/jmcb/mjaa014,,interim_results_journal_article,,,2020-01-04,,1,,,,2,,,,,,,,,,,,,,,
2020-10-27 09:31:36,2020-10-27 09:51:07,IP Address,77.11.144.175,100,1170,True,2020-10-27 09:51:07,R_3KPhM9VerlcXPUd,,,test@test.com,,52.541595458984375,13.3903961181640625,gl,EN,yes,yes,no,,,yes,,,1," TOCICOV-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"There are a couple of other studies added to the registry entry, but none are to a trial result",europe_pmc,google_scholar,,,,other,full_results_preprint,,,,,,https://europepmc.org/article/PPR/PPR186561,,,https://www.researchsquare.com/article/rs-42117/v1,,,,,,,,,,2020-07-11,,2020-07-22,,,,,,,,,,,,,,,,,,,,,,,"This is not really a report of the primary outcome, but an analysis of RNA levels in sera collected from this trial, published as preprint",,,,,,https://clinicaltrials.gov/ProvidedDocs/80/NCT04315480/Prot_000.pdf <- link to protocol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tocilizumab AND COVID-19 AND Gabrielli,NCT04315480 AND Università Politecnica delle Marche,,,,,,,,,PG,2020-06-30,NCT04315480,ClinicalTrials.gov,2020-03-14,2020-03-12,TRUE,Universit Politecnica delle Marche,Not Recruiting,Phase 2,Interventional,Italy,Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,Drug,Tocilizumab,Tocilizumab,38,https://clinicaltrials.gov/show/NCT04315480,,1,2020-04-09,2020-05-01,2020-04-09,0,0,,,,,,,,,,,1,,,,2,,,,,,,,,,,,,,true,
2020-10-27 09:51:35,2020-10-27 10:00:43,IP Address,77.11.144.175,100,547,True,2020-10-27 10:00:43,R_6sagvFxZ8Uro6c1,,,test@test.com,,52.541595458984375,13.3903961181640625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"SINK COVID-19 AND ""2020-097""",Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19 AND matthew sims,,,,,"Press release by sponsor hospital at start of trial in May: https://www.michiganradio.org/post/beaumont-launches-study-whether-two-common-drugs-can-treat-covid-19 

""Sims said they’ll be able to do an interim analysis once they have results from 75 patients.""
","There is a large disperaty between estimated primary completion date and study completion date. ",,,PG,2020-06-30,NCT04365985,ClinicalTrials.gov,2020-04-26,2020-04-29,FALSE,William Beaumont Hospitals,Recruiting,Phase 2,Interventional,United States,Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19,Drug,"Ketamine, Naltrexone",Ketamine; Naltrexone,500,https://clinicaltrials.gov/show/NCT04365985,,1,2020-05-01,2020-08-01,2020-05-01,0,0,,,,,,,,,,,1,,,,2,,,,,,,,,,,,,,,
2020-10-27 14:08:55,2020-10-27 14:09:49,IP Address,129.170.194.72,100,54,True,2020-10-27 14:09:49,R_2aXfLANopfUJXk3,,,test@test.com,,43.701904296875,-72.2826995849609375,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04374786,ClinicalTrials.gov,2020-05-01,2020-05-15,FALSE,University of Arizona,Recruiting,Not Applicable,Interventional,United States,Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic,Other (psych),Psychological,Psychological,328,https://clinicaltrials.gov/show/NCT04374786,,1,2020-09-01,2020-10-01,2020-09-01,0,1,,,,,,,,,,,1,,,,3,,,,,,,,,,,,,,,
2020-10-27 14:10:03,2020-10-27 14:30:01,IP Address,129.170.194.72,100,1197,True,2020-10-27 14:30:02,R_3MF01QuPd1ixULk,,,test@test.com,,43.701904296875,-72.2826995849609375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,(covid OR coronavirus) AND naltrexone AND ketamine,(covid OR coronavirus) AND naltrexone AND ketamine AND Sims,,,,,,Completion dates on ct.gov only have month and in our database have the 1st of the month. We should decide if this is the default and add a note in the instructions.,team_review,,MSH,2020-06-30,NCT04365985,ClinicalTrials.gov,2020-04-26,2020-04-29,FALSE,William Beaumont Hospitals,Recruiting,Phase 2,Interventional,United States,Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19,Drug,"Ketamine, Naltrexone",Ketamine; Naltrexone,500,https://clinicaltrials.gov/show/NCT04365985,,1,2020-05-01,2020-08-01,2020-05-01,0,0,,,,,,,,,,,1,,,,3,,,,,,,,,,,,,,,
2020-10-27 14:30:12,2020-10-27 14:43:59,IP Address,129.170.194.72,100,827,True,2020-10-27 14:44:00,R_2aY9nRhBpC0MXr7,,,test@test.com,,43.701904296875,-72.2826995849609375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04352400,ClinicalTrials.gov,2020-04-03,2020-04-01,TRUE,University Hospital Padova,Not Recruiting,Phase 2/Phase 3,Interventional,No Country Given,Efficacy of Nafamostat in Covid-19 Patients (RACONA Study),Drug,Nafamostat,Nafamostat,256,https://clinicaltrials.gov/show/NCT04352400,,1,2021-12-01,2021-12-01,2021-12-01,0,1,,,,,,,,,,,1,,,,3,,,,,,,,,,,,,,,
2020-10-27 14:44:42,2020-10-27 14:46:58,IP Address,129.170.194.72,100,135,True,2020-10-27 14:46:59,R_AGUDwkCQeqbXQPL,,,test@test.com,,43.701904296875,-72.2826995849609375,gl,EN,yes,no,,device for home monitoring oxygen levels in covid patients but not to treat or prevent covid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04373161,ClinicalTrials.gov,2020-04-30,2020-03-20,TRUE,Swedish Hospital,Not Recruiting,Not Applicable,Interventional,United States,Home Pulse Oximeter Use in Patients With COVID-19,Other (device),Biosensors,Biosensors,209,https://clinicaltrials.gov/show/NCT04373161,,1,2020-04-22,2020-04-22,2020-04-22,0,0,,,,,,,,,,,1,,,,3,,,,,,,,,,,,,,,
2020-10-27 16:17:08,2020-10-27 16:45:50,IP Address,129.170.194.72,100,1722,True,2020-10-27 16:45:52,R_1hFrEdjlKuV30B5,,,test@test.com,,43.701904296875,-72.2826995849609375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,(covid OR coronavirus) AND choloroquinE AND (PEACE OR Sarwar),(covid OR coronavirus) AND chloroquinE AND (PEACE OR Sarwar),,,,,,,,,MSH,2020-06-30,NCT04346667,ClinicalTrials.gov,2020-04-13,2020-04-14,FALSE,"Government of Punjab, Specialized Healthcare and Medical Education Department",Recruiting,Phase 4,Interventional,Pakistan,Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds,Drug (Chemoprophylaxis),Hydroxychloroquine vs. Chloroquine,Hydroxychloroquine; chloroquine,400,https://clinicaltrials.gov/show/NCT04346667,,1,2020-05-30,2021-06-30,2020-05-30,0,0,,,,,,,,,,,1,,,,3,,,,,,,,,,,,,,,
2020-10-27 16:45:58,2020-10-27 16:52:30,IP Address,129.170.194.72,100,392,True,2020-10-27 16:52:31,R_8jCBM2LdpIPo8Uh,,,test@test.com,,43.701904296875,-72.2826995849609375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Trial followed https://doi.org/10.1038/s41375-020-0891-0,,,MSH,2020-06-30,NCT04338958,ClinicalTrials.gov,2020-04-07,2020-04-22,TRUE,University of Jena,Recruiting,Phase 2,Interventional,Germany,Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation,Drug,Ruxolitinib,Ruxolitinib,200,https://clinicaltrials.gov/show/NCT04338958,EUCTR2020-001481-11,1,2021-01-31,2021-08-31,2021-01-31,0,1,,,,,,,,,,,1,,,,3,,,,,,,,,,,,,,,
2020-11-01 11:02:09,2020-11-01 11:11:43,IP Address,86.31.166.235,100,573,True,2020-11-01 11:11:43,R_3Msuon1SQmhNMBc,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029431,ChiCTR,2020-02-01,2020-01-29,TRUE,Affiliated Zhongshan Hospital of Dalian University,Recruiting,Not Applicable,Interventional,China,Clinical study for the remedy of M1 macrophages target in the treatment of novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,45,http://www.chictr.org.cn/showproj.aspx?proj=48907,,1,,2021-12-31,2021-12-31,0,0,,gzao2fo6,,http://doi.org/10.1101/2020.04.07.20054767,,full_results_preprint,,,2020-04-14,,2,,,,2,,,,,,,,,,,,,,,
2020-11-01 11:25:12,2020-11-01 11:38:33,IP Address,86.31.166.235,100,801,True,2020-11-01 11:38:34,R_2X09JpDOwOT5GIF,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,coronavirus AND Donghui Huang AND Guangdong,coronavirus AND Donghui Huang AND TCM,coronavirus AND Donghui Huang AND CHM,,,,,,,,MPJ,2020-06-30,ChiCTR2000030188,ChiCTR,2020-02-24,2020-02-15,TRUE,Guangdong Provincial Hospital of Chinese Medicine - Zhuhai Hospital,Recruiting,Not Applicable,Interventional,China,Clinical Study on Syndrome Differentiation of TCM in Treating Severe and Critical novel coronavirus pneumonia (COVID-19),Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,120,http://www.chictr.org.cn/showproj.aspx?proj=50025,,1,,2020-03-30,2020-03-30,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-01 11:38:44,2020-11-01 11:48:49,IP Address,86.31.166.235,100,604,True,2020-11-01 11:48:49,R_RFgltA46f1MYTEB,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Huo-Shen AND coronavirus AND pneumonia,Yuan Yongming AND Huo-Shen AND coronavirus,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030118,ChiCTR,2020-02-23,2020-02-24,FALSE,Shenzhen National Medicine Inheritance Medical Research Institute co. LTD,Not Recruiting,Not Applicable,Interventional,China,A clinical study for ''Huo-Shen'' particles in the treatment of novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,120,http://www.chictr.org.cn/showproj.aspx?proj=49594,,1,,2020-06-29,2020-06-29,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-01 11:49:17,2020-11-01 11:57:25,IP Address,86.31.166.235,100,487,True,2020-11-01 11:57:25,R_1gqgPWJonyEHotF,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Is this an additional trial ID - 20200101 
",team_review,,MPJ,2020-06-30,NCT04275245,ClinicalTrials.gov,2020-02-06,2020-02-03,TRUE,Tang-Du Hospital,Recruiting,Phase 1/Phase 2,Interventional,China,Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia,Drug,Mepolizumab,Mepolizumab,20,https://clinicaltrials.gov/show/NCT04275245,,1,2020-12-31,2020-12-31,2020-12-31,0,0,,6g34qwer,,http://doi.org/10.1101/2020.03.21.20040691,,full_results_preprint,,,2020-03-24,,2,,,,2,,,,,,,,,,,,,,,
2020-11-01 11:57:37,2020-11-01 12:06:04,IP Address,86.31.166.235,100,507,True,2020-11-01 12:06:05,R_22nMdh0zv2pttLc,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hua Shucheng AND chloroquine phosphate AND coronavirus," chloroquine phosphate AND pneumonia AND COVID-19",,,,,,,,,MPJ,2020-06-30,ChiCTR2000029975,ChiCTR,2020-02-18,2020-02-24,FALSE,The First Hospital of Jilin University,Not Recruiting,Phase 4,Interventional,China,Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19),Drug,Chloroquine,Chloroquine,10,http://www.chictr.org.cn/showproj.aspx?proj=49592,,1,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-01 12:06:14,2020-11-01 12:13:50,IP Address,86.31.166.235,100,456,True,2020-11-01 12:13:50,R_1jCjYRIcMeGtdKN,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Xiuming Song AND Covid-19 AND LIUSHENWAN,LIUSHENWAN AND pneumonia AND COVID-19,"pneumonia AND COVID-19 AND Xiuming Song ",,,,,,,,MPJ,2020-06-30,ChiCTR2000030469,ChiCTR,2020-03-02,2020-02-27,TRUE,Shanghai University of Traditional Chinese Medicine,Recruiting,Not Applicable,Interventional,China,A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,96,http://www.chictr.org.cn/showproj.aspx?proj=50082,,1,,2020-05-27,2020-05-27,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-01 12:15:34,2020-11-01 12:25:37,IP Address,86.31.166.235,100,603,True,2020-11-01 12:25:38,R_2R7Z5slNtE59sjY,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Ulinastatin Injection AND Covid-19 AND pneumonia ","Shanghai Changzheng Hospital AND Ulinastatin Injection AND Covid-19 ",,,,,,,,,MPJ,2020-06-30,ChiCTR2000030779,ChiCTR,2020-03-14,2020-03-16,FALSE,Shanghai Changzheng Hospital,Recruiting,Phase 4,Interventional,China,A clinical trial for Ulinastatin Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,100,http://www.chictr.org.cn/showproj.aspx?proj=50973,,1,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-01 12:26:00,2020-11-01 12:41:49,IP Address,86.31.166.235,100,949,True,2020-11-01 12:41:50,R_pbWdcKpeSn5QcF3,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ixekizumab AND COVID-19 AND pneumonia,"Pinhua Pan AND Ixekizumab AND COVID-19 ",Pinhua Pan AND COVID-19 AND pneumonia,,,,,,,,MPJ,2020-06-30,ChiCTR2000030703,ChiCTR,2020-03-10,2020-03-10,FALSE,Xiangya Hospital of Central South University,Recruiting,Not Applicable,Interventional,China,"A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19)",Drug,"Ixekizumab + up to three of interferon-alfa, lopinavir/ritonavir, chloroquine, ribavirin, umifenovir",Ixekizumab; Interferon alpha; Lopinavir; Ritonavir; Chloroquine; Ribavirin; Umifenovir,40,http://www.chictr.org.cn/showproj.aspx?proj=50251,,1,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-01 12:42:08,2020-11-01 12:54:01,IP Address,86.31.166.235,100,713,True,2020-11-01 12:54:02,R_2WPuTaFPgGA9tmT,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,honeysuckle AND COVID-19 AND pneumonia,Yang Yi AND COVID-19 AND honeysuckle,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030545,ChiCTR,2020-03-06,2020-02-04,TRUE,Hubei Hospital of Traditional Chinese Medicine,Recruiting,Phase 4,Interventional,China,"Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,300,http://www.chictr.org.cn/showproj.aspx?proj=50126,,1,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-01 12:54:56,2020-11-01 13:02:56,IP Address,86.31.166.235,100,479,True,2020-11-01 13:02:57,R_vvKptZvPl9OxcPL,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mesenchymal Stem Cells AND COVID-19 AND Adeeb Al Zoubi,Wharton's Jelly-Mesenchymal Stem Cells AND COVID-19,,,,,,,,,MPJ,2020-06-30,NCT04313322,ClinicalTrials.gov,2020-03-15,2020-03-16,FALSE,Stem Cells Arabia,Recruiting,Phase 1,Interventional,Jordan,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,ATMP,Cells (mesenchymal),Cells (mesenchymal),5,https://clinicaltrials.gov/show/NCT04313322,,1,2020-06-30,2020-09-30,2020-06-30,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-01 14:30:46,2020-11-01 14:50:08,IP Address,86.31.166.235,100,1162,True,2020-11-01 14:50:09,R_3hc4GnkcRFPhALG,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hasan Abolghasemi AND Mesenchymal stem cell AND COVID-19,Baqiatallah AND Mesenchymal stem cell AND pneumonia,Iran AND COVID-19 AND Mesenchymal stem cell,,,,,,,,MPJ,2020-06-30,IRCT20200325046860N2,IRCT,2020-04-01,2020-03-28,TRUE,Bagheiat-allah University of Medical Sciences,Not Recruiting,Phase 1,Interventional,Iran,Mesenchymal Stem Cell therapy in COVID19,ATMP,Cells (mesenchymal),Cells (mesenchymal),5,http://en.irct.ir/trial/46789,,1,,2020-04-29,2020-04-29,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-01 14:50:23,2020-11-01 15:04:49,IP Address,86.31.166.235,100,865,True,2020-11-01 15:04:49,R_2R3cEUfWch8y0ds,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Wuhan AND Mesenchymal Stem Cells AND COVID-19,"Yang Jin AND UC-MSCs AND coronavirus ",,,,,,,,,ND,2020-06-30,NCT04273646,ClinicalTrials.gov,2020-02-14,2020-04-20,FALSE,"Wuhan Union Hospital, China",Not Recruiting,Not Applicable,Interventional,China,Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19,ATMP,Cells (mesenchymal),Cells (mesenchymal),48,https://clinicaltrials.gov/show/NCT04273646,,1,2020-06-30,2022-02-15,2020-06-30,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-01 15:05:13,2020-11-01 15:17:59,IP Address,86.31.166.235,100,765,True,2020-11-01 15:18:00,R_O3dZtG3NnNJxNbr,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,," UC-MSCs AND COVID-19 AND Wuhan Union Hospital",Human Umbilical Cord Mesenchymal Stem Cells AND Yang Jin,,,,,,,,,MPJ,2020-06-30,NCT04273646,ClinicalTrials.gov,2020-02-14,2020-04-20,FALSE,"Wuhan Union Hospital, China",Not Recruiting,Not Applicable,Interventional,China,Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19,ATMP,Cells (mesenchymal),Cells (mesenchymal),48,https://clinicaltrials.gov/show/NCT04273646,,1,2020-06-30,2022-02-15,2020-06-30,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-01 15:18:11,2020-11-01 15:32:46,IP Address,86.31.166.235,100,875,True,2020-11-01 15:32:47,R_3m9pHSyUfdtfPTJ,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ruxolitinib AND SARS AND COVID-19,Ruxolitinib AND COVID-19 AND Grupo Cooperativo de Hemopatías Malignas,Mexico AND SARS AND Ruxolitinib AND COVID-19,,,,,,,,MPJ,2020-06-30,NCT04334044,ClinicalTrials.gov,2020-04-01,2020-04-15,FALSE,Grupo Cooperativo Hemopatías Malignas,Recruiting,Phase 1/Phase 2,Interventional,Mexico,Treatment of SARS Caused by COVID-19 With Ruxolitinib,Drug,Ruxolitinib,Ruxolitinib,20,https://clinicaltrials.gov/show/NCT04334044,,1,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-01 15:33:09,2020-11-01 15:40:06,IP Address,86.31.166.235,100,416,True,2020-11-01 15:40:06,R_3siaCtA81oq9FUN,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,John Engle AND COVID-19 AND Hyperbaric Oxygen Therapy,COVID-19 AND Hyperbaric Oxygen Therapy AND Ochsner Health System,,,,,,,,,MPJ,2020-06-30,NCT04343183,ClinicalTrials.gov,2020-04-07,2020-04-01,TRUE,Ochsner Health System,Not Recruiting,Not Applicable,Interventional,United States,Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection,Drug,Oxygen,Oxygen,48,https://clinicaltrials.gov/show/NCT04343183,,1,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-01 23:51:53,2020-11-01 23:54:59,IP Address,81.109.92.226,100,185,True,2020-11-01 23:54:59,R_Di30Ip6ZWZiFhJf,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,no,2020-06-19,2020-07-23,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,This was an interesting case as the revised completion date put to BEFORE the cut-off but the original completion date was after. Might be worth thinking about a sensitivity analysis that uses original and adjusted dates.,team_review,,MPJ,2020-06-30,NCT04332991,ClinicalTrials.gov,2020-03-31,2020-04-02,FALSE,Massachusetts General Hospital,Not Recruiting,Phase 3,Interventional,United States,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Drug,Hydroxychloroquine,Hydroxychloroquine,479,https://clinicaltrials.gov/show/NCT04332991,,1,2020-07-01,2020-07-01,2020-07-01,0,1,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,2020-07-23
2020-11-01 23:55:35,2020-11-02 00:15:34,IP Address,129.67.119.102,100,1198,True,2020-11-02 00:15:34,R_2AKyTsVn4Fb6SnL,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,europe_pmc,,,,full_results_journal_article,full_results_preprint,,,,10.1093/cid/ciaa1009,32674126,,10.1101/2020.07.20.20157651,,,,,,,,,,,,2020-07-16,,2020-07-26,,,,,,,,,,,,,,,,,,,,,,,Early Treatment,Prevention,,,,,"This is 2 different parts of the same study, not the same study in pre-print and final journal form. As far as I can tell, the ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Interesting situation where there is a preprint and an article but they are for different parts of the same study.,team_review,,ND,2020-06-30,NCT04304053,ClinicalTrials.gov,2020-03-05,2020-03-18,TRUE,Fundació Lluita contra la SIDA,Not Recruiting,Phase 3,Interventional,Spain,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Drug (Chemoprophylaxis),Darunavir + cobicistat + hydroxychloroquine,Darunavir; cobicistat; hydroxychloroquine,2250,https://clinicaltrials.gov/show/NCT04304053,EUCTR2020-001031-27,1,2020-06-15,2020-06-15,2020-06-15,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,true,true,
2020-11-02 00:15:44,2020-11-02 00:17:40,IP Address,129.67.119.102,100,116,True,2020-11-02 00:17:41,R_323bUoxeNoTq0BD,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,no,2020-09-27,2020-09-27,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04383535,ClinicalTrials.gov,2020-05-06,2020-05-15,FALSE,Hospital Italiano de Buenos Aires,Recruiting,Not Applicable,Interventional,Argentina,Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia,ATMP,Plasma,Plasma,333,https://clinicaltrials.gov/show/NCT04383535,,1,2020-08-15,2020-09-20,2020-08-15,0,1,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,2020-09-27
2020-11-02 00:17:48,2020-11-02 00:18:31,IP Address,129.67.119.102,100,43,True,2020-11-02 00:18:32,R_w0niVCaUevnV4l3,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04426305,ClinicalTrials.gov,2020-06-03,2020-05-21,TRUE,University of Ghent,Recruiting,Not Applicable,Interventional,Belgium,Community Health Workers Against COVID19,Other (psych),Psychological,Psychological,140,https://clinicaltrials.gov/show/NCT04426305,,1,2020-06-20,2020-10-30,2020-06-20,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-02 00:18:38,2020-11-02 00:20:16,IP Address,129.67.119.102,100,97,True,2020-11-02 00:20:16,R_sSblpXfkE6GeB5T,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04382768,ClinicalTrials.gov,2020-05-06,2020-05-01,TRUE,Quimica Luar SRL,Recruiting,Not Applicable,Interventional,Argentina,Inhaled Ibuprofen to Treat COVID-19,Drug,Ibuprofen,Ibuprofen,40,https://clinicaltrials.gov/show/NCT04382768,,1,2021-01-01,2021-01-01,2021-01-01,0,1,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-02 00:20:29,2020-11-02 00:31:50,IP Address,129.67.119.102,100,681,True,2020-11-02 00:31:51,R_31i7k75MEM2QTJD,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,full_results_preprint,,,,,10.1101/2020.07.20.20157503,,https://www.medrxiv.org/content/10.1101/2020.07.20.20157503v1,,,,,,,,,,,,,2020-07-26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The preprint was linked to on the ClinicalTrials.gov page,google_scholar,,,,,other,,,,,10.1158/1557-3265.COVID-19-S05-02,,https://clincancerres.aacrjournals.org/content/26/18_Supplement/S05-02.abstract,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Abstract,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COVIDOSE,Strohbehn GW,,,,,,,,,ND,2020-06-30,NCT04331795,ClinicalTrials.gov,2020-04-01,2020-04-04,FALSE,University of Chicago,Not Recruiting,Phase 2,Interventional,United States,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",Drug,Tocilizumab,Tocilizumab,32,https://clinicaltrials.gov/show/NCT04331795,,1,2020-06-05,2020-06-05,2020-06-05,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,true,
2020-11-02 00:31:59,2020-11-02 00:33:18,Spam,129.67.119.102,100,78,True,2020-11-02 00:33:18,R_3vzHNXHaoqx0BBn,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04418128,ClinicalTrials.gov,2020-06-03,2020-06-10,FALSE,Gyeongsang National University Hospital,Not Recruiting,Phase 2/Phase 3,Interventional,No Country Given,Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia,Drug,Nafamostat Mesylate,Nafamostat Mesylate,84,https://clinicaltrials.gov/show/NCT04418128,,1,2021-03-30,2021-04-30,2021-03-30,0,1,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-02 00:33:35,2020-11-02 00:46:18,IP Address,129.67.119.102,100,762,True,2020-11-02 00:46:18,R_3q8z7ANku5iCoWc,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"""Hyperbaric Oxygen"" AND Ochsner","""Hyperbaric Oxygen"" AND COVID",,,,,,,,,ND,2020-06-30,NCT04343183,ClinicalTrials.gov,2020-04-07,2020-04-01,TRUE,Ochsner Health System,Not Recruiting,Not Applicable,Interventional,United States,Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection,Drug,Oxygen,Oxygen,48,https://clinicaltrials.gov/show/NCT04343183,,1,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-02 00:52:36,2020-11-02 00:56:54,IP Address,129.67.119.102,100,258,True,2020-11-02 00:56:54,R_3pg4K6cfVXeuCKz,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,ChiCTR2000029431,ChiCTR,2020-02-01,2020-01-29,TRUE,Affiliated Zhongshan Hospital of Dalian University,Recruiting,Not Applicable,Interventional,China,Clinical study for the remedy of M1 macrophages target in the treatment of novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,45,http://www.chictr.org.cn/showproj.aspx?proj=48907,,1,,2021-12-31,2021-12-31,0,0,,gzao2fo6,,http://doi.org/10.1101/2020.04.07.20054767,,full_results_preprint,,,2020-04-14,,2,,,,1,,,,,,,,,,,,,,,
2020-11-02 01:07:12,2020-11-02 01:24:01,IP Address,129.67.119.102,100,1008,True,2020-11-02 01:24:02,R_2fjJ6pIN7S8A3Ni,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Donghui Huang,,,,,,Treatment was not specified so only really had the PI to go off of,,,,ND,2020-06-30,ChiCTR2000030188,ChiCTR,2020-02-24,2020-02-15,TRUE,Guangdong Provincial Hospital of Chinese Medicine - Zhuhai Hospital,Recruiting,Not Applicable,Interventional,China,Clinical Study on Syndrome Differentiation of TCM in Treating Severe and Critical novel coronavirus pneumonia (COVID-19),Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,120,http://www.chictr.org.cn/showproj.aspx?proj=50025,,1,,2020-03-30,2020-03-30,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-02 10:42:04,2020-11-02 10:57:19,IP Address,86.31.166.235,100,915,True,2020-11-02 10:57:19,R_31Au1hM56yBe0LR,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ruxolitinib Plus Simvastatin AND COVID-19 AND Respiratory Failure,Fundación de investigación HM AND COVID-19,,,,,,,,,MPJ,2020-06-30,NCT04348695,ClinicalTrials.gov,2020-04-13,2020-04-12,FALSE,La Fundación de Investigación HM,Recruiting,Phase 2,Interventional,Spain,Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.,Drug,Ruxolitinib + Simvastatin,Ruxolitinib; Simvastatin,94,https://clinicaltrials.gov/show/NCT04348695,EUCTR2020-001405-23,1,2020-05-13,2020-05-13,2020-05-13,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 10:57:29,2020-11-02 11:05:52,IP Address,86.31.166.235,100,503,True,2020-11-02 11:05:53,R_a057erf960YHuDv,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,nivolumab AND COVID-19 AND Gerry Gin Wai Kwok,nivolumab AND COVID-19 AND The University of Hong Kong,,,,,,,,,MPJ,2020-06-30,NCT04356508,ClinicalTrials.gov,2020-04-10,2020-04-14,FALSE,Dr. Gerry Gin Wai Kwok,Not Recruiting,Phase 2,Interventional,No Country Given,COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1,Drug,Nivolumab,Nivolumab,15,https://clinicaltrials.gov/show/NCT04356508,,1,2020-06-30,2021-08-31,2020-06-30,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 11:06:07,2020-11-02 11:08:20,IP Address,86.31.166.235,100,133,True,2020-11-02 11:08:20,R_BzXWfsOELE6dc6l,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,"Intervention for mental illness as a result of isolation from Covid-19 ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,ACTRN12620000482965,ANZCTR,2020-04-17,2020-03-17,TRUE,Juan Pedro Fuentes García,Not Recruiting,Not Applicable,Interventional,Spain,"Impact of high intensity interval training and aerobic training on stress, depression symptoms, anxiety and resilience in self-isolated people during the COVID-19 health emergency in Spain",Other (exercise),Exercise,Exercise,34,https://anzctr.org.au/ACTRN12620000482965.aspx,,1,,2020-03-18,2020-03-18,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 11:09:03,2020-11-02 11:20:42,IP Address,86.31.166.235,100,699,True,2020-11-02 11:20:43,R_2DUD8LzCXzgwiE0,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anluohuaxian AND Covid-19 AND Guiqiang Wang,pulmonary fibrosis AND coronavirus AND Peking University First Hospital,,,,,,,,,MPJ,2020-06-30,NCT04334265,ClinicalTrials.gov,2020-04-01,2020-04-01,FALSE,Peking University First Hospital,Recruiting,Not Applicable,Interventional,China,Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019,Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,750,https://clinicaltrials.gov/show/NCT04334265,,1,2020-06-01,2020-12-01,2020-06-01,0,1,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 11:20:59,2020-11-02 11:23:52,IP Address,86.31.166.235,100,173,True,2020-11-02 11:23:53,R_1ds13V8KlrFJBDW,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,Device to maximise capacity of ventilators so could be used for all illnesses requiring someone to be in ICU,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04355754,ClinicalTrials.gov,2020-04-16,2020-04-15,TRUE,Medical University of Gdańsk,Recruiting,Not Applicable,Interventional,Poland,Ventil Device Usefulness in Mechanically Ventilated ICU Patients,Other (physical),Mechanical ventilation,Mechanical ventilation,40,https://clinicaltrials.gov/show/NCT04355754,,1,2020-05-01,2020-12-31,2020-05-01,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 11:57:31,2020-11-02 12:04:31,IP Address,86.31.166.235,100,419,True,2020-11-02 12:04:31,R_1P1vJd1SeIbyEz1,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Low-Oxygen Consumption AND COVID-19 AND Shanghai,"Coronavirus Pneumonia AND Shuihua Lu ",,,,,,,,,MPJ,2020-06-30,ChiCTR2000032456,ChiCTR,2020-04-29,2020-03-01,TRUE,Shanghai Public Health Clinical Center,Not Recruiting,Not Applicable,Interventional,No Country Given,A Randomized Controlled Trial for the Effects of Low-Oxygen Consumption Instruction on the Prognosis of Patients with Novel Coronavirus Pneumonia (COVID-19),Prognosis,No Intervention,No Intervention,100,http://www.chictr.org.cn/showproj.aspx?proj=53048,,1,,2020-05-01,2020-05-01,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 12:04:45,2020-11-02 12:10:57,IP Address,86.31.166.235,100,372,True,2020-11-02 12:10:58,R_1oHD3xqF5LAE0A2,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PEAC AND COVID-19 AND Xijing Hospital,Aspirin AND coronavirus AND Cai Yue,,,,,,,,,MPJ,2020-06-30,NCT04365309,ClinicalTrials.gov,2020-04-24,2020-02-10,TRUE,Xijing Hospital,Recruiting,Phase 2/Phase 3,Interventional,China,Protective Effect of Aspirin on COVID-19 Patients,Drug,Aspirin,Aspirin,128,https://clinicaltrials.gov/show/NCT04365309,,1,2020-04-01,2020-06-01,2020-04-01,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 12:11:16,2020-11-02 12:13:31,IP Address,86.31.166.235,100,135,True,2020-11-02 12:13:32,R_4MYhPJONt2ysYA9,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,It is a treatment for a side-effect of a condition associated with Covid-19 - so does this directly treat/prevent Covid?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04351906,ClinicalTrials.gov,2020-04-09,2020-05-03,FALSE,University of Giessen,Recruiting,Not Applicable,Interventional,Germany,Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome,Other (device),ECCO2R,ECCO2R,20,https://clinicaltrials.gov/show/NCT04351906,,1,2020-07-01,2020-09-01,2020-07-01,0,1,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 12:13:51,2020-11-02 12:23:33,IP Address,86.31.166.235,100,581,True,2020-11-02 12:23:33,R_248KMzBuh2Y2xNc,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COlchicine AND COVID-19 AND SARS,Maimonides Medical Center AND COlchicine AND COVID-19,,,,,,,,,MPJ,2020-06-30,NCT04363437,ClinicalTrials.gov,2020-04-23,2020-04-26,FALSE,Maimonides Medical Center,Recruiting,Phase 2,Interventional,United States,COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19,Drug,Colchicine,Colchicine,70,https://clinicaltrials.gov/show/NCT04363437,,1,2020-05-31,2020-06-14,2020-05-31,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 12:40:48,2020-11-02 12:41:44,IP Address,86.31.166.235,100,56,True,2020-11-02 12:41:45,R_2zFOM71MIFxpAhe,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,"App to support mental health of the unemployed ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,ACTRN12620000555954,ANZCTR,2020-05-11,2020-06-01,FALSE,UNSW Sydney,Not Recruiting,Not Applicable,Interventional,Australia,"Randomised controlled trial of an app-based intervention, Anchored, to support the mental health of Australians recently unemployed due to COVID-19.",Other (psych),Psychological,Psychological,492,https://anzctr.org.au/ACTRN12620000555954.aspx,,1,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 12:42:02,2020-11-02 12:42:54,IP Address,86.31.166.235,100,52,True,2020-11-02 12:42:54,R_3HH68dMrGilWkiy,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04354389,ClinicalTrials.gov,2020-04-15,2020-05-25,FALSE,"Ansun Biopharma, Inc.",Not Recruiting,Phase 2/Phase 3,Interventional,Italy,DAS181 for STOP COVID-19,Drug,DAS181,DAS181,82,https://clinicaltrials.gov/show/NCT04354389,,1,2020-06-30,2020-10-31,2020-06-30,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 12:43:09,2020-11-02 12:46:01,IP Address,86.31.166.235,100,172,True,2020-11-02 12:46:02,R_265OPCgsiYX3Tf8,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04335097,ClinicalTrials.gov,2020-04-01,2020-04-22,FALSE,Lars Wik,Recruiting,Not Applicable,Interventional,Norway,Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation,Other (device),Biosensors,Biosensors,214,https://clinicaltrials.gov/show/NCT04335097,,1,2021-04-08,2025-12-20,2021-04-08,0,1,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 12:46:15,2020-11-02 12:54:13,IP Address,86.31.166.235,100,478,True,2020-11-02 12:54:13,R_3NL486q55B990PP,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Shuang-Huang-Lian AND COVID-19 AND pneumonia,Chen Yongping AND Shuanghuanglian oral solution AND coronavirus,,,,,,,,,MPJ,2020-06-30,ChiCTR2000033133,ChiCTR,2020-05-21,2020-02-12,TRUE,The First Affiliated Hospital of Wenzhou Medical University,Not Recruiting,Not Applicable,Interventional,China,"A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of novel coronavirus pneumonia (COVID-19)",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,60,http://www.chictr.org.cn/showproj.aspx?proj=53925,,1,,2020-04-20,2020-04-20,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 12:54:26,2020-11-02 12:57:25,Spam,86.31.166.235,100,178,True,2020-11-02 12:57:26,R_3IQRaIZw6G7xy8n,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04366960,ClinicalTrials.gov,2020-04-24,2020-05-14,TRUE,Niguarda Hospital,Recruiting,Phase 3,Interventional,Italy,Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients,Drug,Enoxaparin,Enoxaparin,2712,https://clinicaltrials.gov/show/NCT04366960,EUCTR2020-001708-41,1,2020-08-01,2020-11-01,2020-08-01,0,1,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 14:09:14,2020-11-02 14:18:28,IP Address,86.31.166.235,100,554,True,2020-11-02 14:18:29,R_ZeJH5WrgzEJKnF7,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Kermanshah University AND COVID-19 AND Colchicine,"Mostafaie AND Phenolic Monoterpene AND coronavirus ",,,,,,,,,MPJ,2020-06-30,NCT04392141,ClinicalTrials.gov,2020-05-15,2020-04-01,TRUE,Kermanshah University of Medical Sciences,Recruiting,Phase 1/Phase 2,Interventional,Iran,Colchicine Plus Phenolic Monoterpenes to Treat COVID-19,Drug,Colchicine + Phenolic Monoterpenes,Colchicine; Phenolic Monoterpenes,200,https://clinicaltrials.gov/show/NCT04392141,,1,2020-06-01,2020-10-01,2020-06-01,0,1,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 14:18:45,2020-11-02 14:20:39,IP Address,86.31.166.235,100,114,True,2020-11-02 14:20:40,R_27m35Ln2Rlry9Td,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04392713,ClinicalTrials.gov,2020-05-05,2020-04-15,TRUE,"Combined Military Hospital, Pakistan",Recruiting,Not Applicable,Interventional,Pakistan,Efficacy of Ivermectin in COVID-19,Drug,Ivermectin,Ivermectin,100,https://clinicaltrials.gov/show/NCT04392713,,1,2020-07-01,2020-07-01,2020-07-01,0,1,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 14:20:53,2020-11-02 14:23:54,Spam,86.31.166.235,100,180,True,2020-11-02 14:23:54,R_2VlOtO8xAXOtPBB,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04394182,ClinicalTrials.gov,2020-05-15,2020-04-21,TRUE,Fundación Genesiscare,Recruiting,Not Applicable,Interventional,Spain,Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,Other,"Radiation (with Lopinavir/ritonavir, Hydroxychloroquine, Azithromycin, Piperacillin/tazobactam, Heparin, Corticosteroids, Tocilizumab)",Radiation; Lopinavir/ritonavir; Hydroxychloroquine; Azithromycin; Piperacillin/tazobactam; Heparin; Methylprednisolone; Tocilizumab,15,https://clinicaltrials.gov/show/NCT04394182,,1,2020-12-31,2021-04-21,2020-12-31,0,1,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 14:24:02,2020-11-02 14:36:51,IP Address,86.31.166.235,100,768,True,2020-11-02 14:36:52,R_PTjMgMMGSyCNPvb,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,pubmed,,,,other,other,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,," leflunomide AND COVID-19 AND Shandong University","pneumonia AND coronavirus AND Hu Zhao ",,,,,"I could not reverse selection of the above. No results were found. ",Review this because I accidentally selected to indicate a publication when there wasn't one.,team_review,,MPJ,2020-06-30,ChiCTR2000033372,ChiCTR,2020-05-29,2020-03-12,TRUE,Shandong University Qilu Hospital,Not Recruiting,Not Applicable,Interventional,China,Efficacy and safety of leflunomide for Refractory novel coronavirus pneumonia (COVID-19): A non-Randomized Controlled Study,Drug,Leflunomide,Leflunomide,30,http://www.chictr.org.cn/showproj.aspx?proj=54408,,1,,2020-05-17,2020-05-17,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 14:56:31,2020-11-02 15:07:24,IP Address,86.31.166.235,100,652,True,2020-11-02 15:07:24,R_2AZRi8MF0rmZy9z,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-11-20,2020-12-20,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Convalescent Plasma AND SARS-COV-2 AND Grupo Mexicano,Convalescent Plasma AND COVID-19 AND Mexico,,,,,,,,,MPJ,2020-06-30,NCT04405310,ClinicalTrials.gov,2020-05-26,2020-05-20,TRUE,Grupo Mexicano para el Estudio de la Medicina Intensiva,Recruiting,Phase 2,Interventional,Mexico,Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial,ATMP,Plasma,Plasma,80,https://clinicaltrials.gov/show/NCT04405310,,1,2020-06-20,2020-07-20,2020-06-20,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,2020-12-20
2020-11-02 15:07:38,2020-11-02 15:23:37,IP Address,86.31.166.235,100,958,True,2020-11-02 15:23:37,R_23Uz4csg8DEt3vz,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-04-29,2020-06-26,0,,,,,,full_results_journal_article,,,,,10.1001/jama.2020.16349,32821939,https://pubmed.ncbi.nlm.nih.gov/32821939/#affiliation-1,,,,,,,,,,,,,2020-08-21,2020-05-20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Remdesivir AND Gilead AND COVID-19,COVID-19 AND Spinner AND Remdesivir,,,,,,,,,MPJ,2020-06-30,NCT04292730,ClinicalTrials.gov,2020-02-28,2020-03-15,TRUE,Gilead Sciences,Not Recruiting,Phase 3,Interventional,"Japan, Spain, Netherlands, South Korea, Switzerland, United States, Hong Kong, Italy, Taiwan, China, Germany, Singapore, France, Iran, Sweden, United Kingdom",Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Drug,Remdesivir,Remdesivir,1600,https://clinicaltrials.gov/show/NCT04292730,EUCTR2020-000842-32,1,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,true,,2020-06-26
2020-11-02 15:24:06,2020-11-02 15:30:44,IP Address,86.31.166.235,100,397,True,2020-11-02 15:30:44,R_3inkksX52fYfITn,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Melatonin AND COVID-19 AND NLRP3 Inflammasome," Baqiyatallah University AND coronavirus AND Melatonin",,,,,,,,,MPJ,2020-06-30,NCT04409522,ClinicalTrials.gov,2020-05-28,2020-05-12,TRUE,Mohammad Sadegh Bagheri Baghdasht,Recruiting,Not Applicable,Interventional,Iran,Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients,Drug,Melatonin,Melatonin,55,https://clinicaltrials.gov/show/NCT04409522,,1,2020-06-05,2020-09-25,2020-06-05,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 15:30:57,2020-11-02 15:33:14,IP Address,86.31.166.235,100,137,True,2020-11-02 15:33:15,R_2rZdhTxbQYJfOnX,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2021-03-15,NA,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04410328,ClinicalTrials.gov,2020-05-28,2020-06-21,FALSE,Rutgers University,Not Recruiting,Phase 3,Interventional,No Country Given,Aggrenox To Treat Acute Covid-19,Drug,Dipyridamole,Dipyridamole,132,https://clinicaltrials.gov/show/NCT04410328,,1,2020-12-15,2021-12-15,2020-12-15,0,1,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,2021-03-15
2020-11-02 15:33:26,2020-11-02 15:43:02,IP Address,86.31.166.235,100,575,True,2020-11-02 15:43:02,R_2uVx7LjD11CE929,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google,,,,,interim_result,,,,,,32931666,https://pubmed.ncbi.nlm.nih.gov/32931666/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hyperbaric Oxygen AND COVID-19 AND NYU,Gorenstein AND Hyperbaric Oxygen AND coronavirus,,,,,,,,,MPJ,2020-06-30,NCT04332081,ClinicalTrials.gov,2020-03-30,2020-04-06,FALSE,NYU Langone Health,Not Recruiting,Not Applicable,Interventional,United States,Hyperbaric Oxygen for COVID-19 Patients,Drug,Oxygen,Oxygen,20,https://clinicaltrials.gov/show/NCT04332081,,1,2020-05-29,2020-05-29,2020-05-29,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 17:23:01,2020-11-02 17:38:03,IP Address,86.31.166.235,100,901,True,2020-11-02 17:38:04,R_11YFHuChUm9BjN6,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mesenchymal Stem Cell AND Iran AND COVID-19,"ARDS AND coronavirus AND Mesenchymal Stem Cell ",Nouri AND COVID-19 AND Stem Cell,,,,,,,,MPJ,2020-06-30,IRCT20200217046526N1,IRCT,2020-04-13,2020-03-15,TRUE,Iranian Academic Center for Education Culture and Research,Not Recruiting,Phase 1/Phase 2,Interventional,Iran,Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection,ATMP,Cells (mesenchymal),Cells (mesenchymal),6,http://en.irct.ir/trial/47030,,1,,2020-04-25,2020-04-25,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 17:38:16,2020-11-02 17:44:32,IP Address,86.31.166.235,100,376,True,2020-11-02 17:44:32,R_xrqu4aq7lVITjTH,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,"I am not certain whether this is a prevention for Covid-19 respiratory issues or whether it is just using the circumstance of 'affected by Covid' i.e. forced isolation to experiment with respiratory exercises ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,RBR-6m69fc,REBEC,2020-04-02,2020-04-01,TRUE,University of Sevilla,Recruiting,Not Applicable,Interventional,Spain,"Therapeutic Pulmonary Telerehabilitation Protocol in patients affected by COVID-19, confined in their homes",Telehealth,Physio & Rehabilitation,Physio & Rehabilitation,99,http://www.ensaiosclinicos.gov.br/rg/RBR-6m69fc/,,1,,2020-04-15,2020-04-15,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 17:44:40,2020-11-02 17:57:56,IP Address,86.31.166.235,100,796,True,2020-11-02 17:57:57,R_2VJf4zi7NQS0RqR,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hydroxychloroquine AND COVID-19 AND Brazil,azytromicyn AND coronavirus AND Zampieri,,,,,,"NCT04322123 - a related trial? ",team_review,,MPJ,2020-06-30,RBR-9d8z6m,REBEC,2020-03-27,2020-03-30,FALSE,Hospital do Coração,Not Recruiting,Phase 3,Interventional,Brazil,Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus,Drug,Hydroxychloroquine + Azithromycin vs. Hydroxychloroquine,Hydroxychloroquine; Azithromycin,630,http://www.ensaiosclinicos.gov.br/rg/RBR-9d8z6m/,,1,,2020-05-18,2020-05-18,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 18:40:05,2020-11-02 18:45:29,IP Address,81.109.92.226,100,324,True,2020-11-02 18:45:30,R_eDuFV6zWsJorvsB,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IGNORE,,,,,,,"This trial is actually Withdrawn. See title:

Cancelled by the investigator A clinical study for ''Huo-Shen'' particles in the treatment of novel coronavirus pneumonia (COVID-19) ",team_review,,ND,2020-06-30,ChiCTR2000030118,ChiCTR,2020-02-23,2020-02-24,FALSE,Shenzhen National Medicine Inheritance Medical Research Institute co. LTD,Not Recruiting,Not Applicable,Interventional,China,A clinical study for ''Huo-Shen'' particles in the treatment of novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,120,http://www.chictr.org.cn/showproj.aspx?proj=49594,,1,,2020-06-29,2020-06-29,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-02 18:45:52,2020-11-02 18:49:20,IP Address,81.109.92.226,100,208,True,2020-11-02 18:49:21,R_2WuH8MU4iXsQ7AH,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04275245,ClinicalTrials.gov,2020-02-06,2020-02-03,TRUE,Tang-Du Hospital,Recruiting,Phase 1/Phase 2,Interventional,China,Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia,Drug,Mepolizumab,Mepolizumab,20,https://clinicaltrials.gov/show/NCT04275245,,1,2020-12-31,2020-12-31,2020-12-31,0,0,,6g34qwer,,http://doi.org/10.1101/2020.03.21.20040691,,full_results_preprint,,,2020-03-24,,2,,,,1,,,,,,,,,,,,,,,
2020-11-02 18:49:47,2020-11-02 18:59:39,IP Address,81.109.92.226,100,592,True,2020-11-02 18:59:40,R_UorME8eRT0lx0AN,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hua Shucheng,Jie Jing,Jie Jing AND chloroquine,,,,,,,,ND,2020-06-30,ChiCTR2000029975,ChiCTR,2020-02-18,2020-02-24,FALSE,The First Hospital of Jilin University,Not Recruiting,Phase 4,Interventional,China,Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19),Drug,Chloroquine,Chloroquine,10,http://www.chictr.org.cn/showproj.aspx?proj=49592,,1,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-02 18:59:54,2020-11-02 19:07:29,IP Address,81.109.92.226,100,454,True,2020-11-02 19:07:30,R_3noM49P0xCWysV2,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"COVID-19 AND ""Wharton's Jelly""",Adeeb M AlZoubi,,,,,,,,,ND,2020-06-30,NCT04313322,ClinicalTrials.gov,2020-03-15,2020-03-16,FALSE,Stem Cells Arabia,Recruiting,Phase 1,Interventional,Jordan,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,ATMP,Cells (mesenchymal),Cells (mesenchymal),5,https://clinicaltrials.gov/show/NCT04313322,,1,2020-06-30,2020-09-30,2020-06-30,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-02 19:07:43,2020-11-02 19:18:28,IP Address,81.109.92.226,100,644,True,2020-11-02 19:18:28,R_Qd0h3yVRYF5qBwZ,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ruxolitinib AND Simvastatin,Jesus Garcia-Donas,Jesus Garcia-Donas AND Ruxolitinib,,,,,,,,ND,2020-06-30,NCT04348695,ClinicalTrials.gov,2020-04-13,2020-04-12,FALSE,La Fundación de Investigación HM,Recruiting,Phase 2,Interventional,Spain,Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.,Drug,Ruxolitinib + Simvastatin,Ruxolitinib; Simvastatin,94,https://clinicaltrials.gov/show/NCT04348695,EUCTR2020-001405-23,1,2020-05-13,2020-05-13,2020-05-13,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-02 20:32:28,2020-11-02 20:35:17,IP Address,86.31.166.235,100,169,True,2020-11-02 20:35:18,R_2atxBfDPrSQ3YHc,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04418128,ClinicalTrials.gov,2020-06-03,2020-06-10,FALSE,Gyeongsang National University Hospital,Not Recruiting,Phase 2/Phase 3,Interventional,No Country Given,Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia,Drug,Nafamostat Mesylate,Nafamostat Mesylate,84,https://clinicaltrials.gov/show/NCT04418128,,1,2021-03-30,2021-04-30,2021-03-30,0,1,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-02 20:35:26,2020-11-02 20:51:48,IP Address,86.31.166.235,100,981,True,2020-11-02 20:51:48,R_2wBk1u7PPp6eUUP,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,,,,,full_results_preprint,,,,,10.1101/2020.07.20.20157503,,https://www.medrxiv.org/content/10.1101/2020.07.20.20157503v1,,,,,,,,,,,,,2020-07-26,2020-05-13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,,,,,other,,,,,10.1158/1557-3265.COVID-19-S05-02,,https://clincancerres.aacrjournals.org/content/26/18_Supplement/S05-02.abstract,,,,,,,,,,,,,2020-01-09,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tocilizumab AND Pneumonitis AND COVID-19 AND California,COVIDOSE AND University of Chicago AND Tocilizumab,,,,,,,,,MPJ,2020-06-30,NCT04331795,ClinicalTrials.gov,2020-04-01,2020-04-04,FALSE,University of Chicago,Not Recruiting,Phase 2,Interventional,United States,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",Drug,Tocilizumab,Tocilizumab,32,https://clinicaltrials.gov/show/NCT04331795,,1,2020-06-05,2020-06-05,2020-06-05,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,true,
2020-11-03 11:53:13,2020-11-03 12:01:33,IP Address,81.109.92.226,100,500,True,2020-11-03 12:01:34,R_3knqYyn60vlbSaS,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,LIUSHENWAN AND COVID,Xuan Chen AND COVID,Xiuming Song,,,,,,,,ND,2020-06-30,ChiCTR2000030469,ChiCTR,2020-03-02,2020-02-27,TRUE,Shanghai University of Traditional Chinese Medicine,Recruiting,Not Applicable,Interventional,China,A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,96,http://www.chictr.org.cn/showproj.aspx?proj=50082,,1,,2020-05-27,2020-05-27,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-04 10:07:08,2020-11-04 10:08:42,IP Address,86.31.166.235,100,94,True,2020-11-04 10:08:42,R_1FQAYs43AAYQUN6,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04382768,ClinicalTrials.gov,2020-05-06,2020-05-01,TRUE,Quimica Luar SRL,Recruiting,Not Applicable,Interventional,Argentina,Inhaled Ibuprofen to Treat COVID-19,Drug,Ibuprofen,Ibuprofen,40,https://clinicaltrials.gov/show/NCT04382768,,1,2021-01-01,2021-01-01,2021-01-01,0,1,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-04 10:08:51,2020-11-04 10:10:55,IP Address,86.31.166.235,100,124,True,2020-11-04 10:10:56,R_3n1J69FHECFc866,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,"Research on the psychosocial impacts of social distancing due to Covid-19 ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04426305,ClinicalTrials.gov,2020-06-03,2020-05-21,TRUE,University of Ghent,Recruiting,Not Applicable,Interventional,Belgium,Community Health Workers Against COVID19,Other (psych),Psychological,Psychological,140,https://clinicaltrials.gov/show/NCT04426305,,1,2020-06-20,2020-10-30,2020-06-20,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-04 10:11:08,2020-11-04 10:13:19,IP Address,86.31.166.235,100,131,True,2020-11-04 10:13:20,R_3RgO4OxSzvdTdDl,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-09-27,2020-09-27,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04383535,ClinicalTrials.gov,2020-05-06,2020-05-15,FALSE,Hospital Italiano de Buenos Aires,Recruiting,Not Applicable,Interventional,Argentina,Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia,ATMP,Plasma,Plasma,333,https://clinicaltrials.gov/show/NCT04383535,,1,2020-08-15,2020-09-20,2020-08-15,0,1,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,2020-09-27
2020-11-04 10:13:27,2020-11-04 10:48:55,IP Address,86.31.166.235,100,2127,True,2020-11-04 10:48:55,R_2b18USQWi5uLOWz,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,,10.1101/2020.07.20.20157651,,https://europepmc.org/article/PPR/PPR192214,,,,,,,,,,,,,2020-06-26,2020-04-28,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,,,,,full_results_preprint,,,,,10.2139/ssrn.3615997,,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3615997,,,,,,,,,,,,,2020-07-16,2020-04-28,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hydroxychloroquine AND Barcelona AND COVID-19,"prophylactic hydroxychloroquine AND Mitja AND coronavirus ",,,,,,,team_review,,MPJ,2020-06-30,NCT04304053,ClinicalTrials.gov,2020-03-05,2020-03-18,TRUE,Fundació Lluita contra la SIDA,Not Recruiting,Phase 3,Interventional,Spain,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Drug (Chemoprophylaxis),Darunavir + cobicistat + hydroxychloroquine,Darunavir; cobicistat; hydroxychloroquine,2250,https://clinicaltrials.gov/show/NCT04304053,EUCTR2020-001031-27,1,2020-06-15,2020-06-15,2020-06-15,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,true,
2020-11-05 01:36:40,2020-11-05 01:49:15,IP Address,81.109.92.226,100,755,True,2020-11-05 01:49:16,R_333kqRs8wcl7GCT,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,,,,,full_results_journal_article,,,,,,32931666,https://pubmed.ncbi.nlm.nih.gov/32931666/,,,,,,,,,,,,,2020-09-09,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Scott A. Gorenstein,Hyperbaric oxygen AND COVID-19,,,,,,,,,ND,2020-06-30,NCT04332081,ClinicalTrials.gov,2020-03-30,2020-04-06,FALSE,NYU Langone Health,Not Recruiting,Not Applicable,Interventional,United States,Hyperbaric Oxygen for COVID-19 Patients,Drug,Oxygen,Oxygen,20,https://clinicaltrials.gov/show/NCT04332081,,1,2020-05-29,2020-05-29,2020-05-29,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,true,,
2020-11-05 01:49:36,2020-11-05 01:56:55,IP Address,81.109.92.226,100,439,True,2020-11-05 01:56:57,R_O9eybtkaXJNj3s5,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ulinastatin AND Covid,Yi Shan,,,,,,,,,ND,2020-06-30,ChiCTR2000030779,ChiCTR,2020-03-14,2020-03-16,FALSE,Shanghai Changzheng Hospital,Recruiting,Phase 4,Interventional,China,A clinical trial for Ulinastatin Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,100,http://www.chictr.org.cn/showproj.aspx?proj=50973,,1,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-05 01:57:35,2020-11-05 01:59:45,IP Address,81.109.92.226,100,130,True,2020-11-05 01:59:46,R_22Y9WAQw3r9HVAk,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,no,2021-03-15,2021-12-15,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04410328,ClinicalTrials.gov,2020-05-28,2020-06-21,FALSE,Rutgers University,Not Recruiting,Phase 3,Interventional,No Country Given,Aggrenox To Treat Acute Covid-19,Drug,Dipyridamole,Dipyridamole,132,https://clinicaltrials.gov/show/NCT04410328,,1,2020-12-15,2021-12-15,2020-12-15,0,1,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,2021-12-15
2020-11-05 01:59:53,2020-11-05 02:06:17,IP Address,81.109.92.226,100,383,True,2020-11-05 02:06:17,R_UlPu13a3Buslg4x,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mohammad Sadegh Bagheri Baghdasht,Melatonin AND Covid AND Iran,Melatonin AND NLRP3 AND Covid,,,,,,,,ND,2020-06-30,NCT04409522,ClinicalTrials.gov,2020-05-28,2020-05-12,TRUE,Mohammad Sadegh Bagheri Baghdasht,Recruiting,Not Applicable,Interventional,Iran,Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients,Drug,Melatonin,Melatonin,55,https://clinicaltrials.gov/show/NCT04409522,,1,2020-06-05,2020-09-25,2020-06-05,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-05 02:06:33,2020-11-05 02:15:35,IP Address,81.109.92.226,100,541,True,2020-11-05 02:15:36,R_2RXgYySNiIc65SV,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ixekizumab AND COVID,Pinhua Pan,Xiangya Hospital,,,,,,,,ND,2020-06-30,ChiCTR2000030703,ChiCTR,2020-03-10,2020-03-10,FALSE,Xiangya Hospital of Central South University,Recruiting,Not Applicable,Interventional,China,"A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19)",Drug,"Ixekizumab + up to three of interferon-alfa, lopinavir/ritonavir, chloroquine, ribavirin, umifenovir",Ixekizumab; Interferon alpha; Lopinavir; Ritonavir; Chloroquine; Ribavirin; Umifenovir,40,http://www.chictr.org.cn/showproj.aspx?proj=50251,,1,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-05 02:15:47,2020-11-05 02:21:49,IP Address,81.109.92.226,100,361,True,2020-11-05 02:21:49,R_3VtqHVv9QwvKMjn,,,test@test.com,,51.778594970703125,-1.2505950927734375,gl,EN,yes,yes,no,,,no,2020-11-20,2020-11-20,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,YANET VENTURA,ANGEL A PEREZ-CALATAYUD,Grupo Mexicano para el Estudio de la Medicina Intensiva,Plasma AND Covid AND Mexico,,,,,,,ND,2020-06-30,NCT04405310,ClinicalTrials.gov,2020-05-26,2020-05-20,TRUE,Grupo Mexicano para el Estudio de la Medicina Intensiva,Recruiting,Phase 2,Interventional,Mexico,Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial,ATMP,Plasma,Plasma,80,https://clinicaltrials.gov/show/NCT04405310,,1,2020-06-20,2020-07-20,2020-06-20,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,2020-11-20
2020-11-05 09:20:13,2020-11-05 09:25:37,IP Address,86.31.166.235,100,323,True,2020-11-05 09:25:38,R_bwkAUxX5mQVC9Pj,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-06-19,2020-06-23,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04332991,ClinicalTrials.gov,2020-03-31,2020-04-02,FALSE,Massachusetts General Hospital,Not Recruiting,Phase 3,Interventional,United States,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Drug,Hydroxychloroquine,Hydroxychloroquine,479,https://clinicaltrials.gov/show/NCT04332991,,1,2020-07-01,2020-07-01,2020-07-01,0,1,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,2020-06-23
2020-11-05 14:03:05,2020-11-05 14:19:38,IP Address,81.109.92.226,100,993,True,2020-11-05 14:19:39,R_bd3IG94suKidwuR,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,,,,,other,,,,,,,https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/czh-1187,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,honeysuckle AND COVID,lanzhou university qiu tao honeysuckle,,,,,"This looks very similar but I cannot find it anywhere outside of the WHO database. Only have an abstract and it's linked to an ""internal database"" so no idea if/how it is public.",,team_review,,ND,2020-06-30,ChiCTR2000030545,ChiCTR,2020-03-06,2020-02-04,TRUE,Hubei Hospital of Traditional Chinese Medicine,Recruiting,Phase 4,Interventional,China,"Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,300,http://www.chictr.org.cn/showproj.aspx?proj=50126,,1,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-05 14:19:54,2020-11-05 14:34:01,IP Address,129.67.119.138,100,846,True,2020-11-05 14:34:01,R_2WO6pOelCyUJkzG,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hasan Abolghasemi,Phase 1 AND Stem Cells AND Covid,,,,,,,,,ND,2020-06-30,IRCT20200325046860N2,IRCT,2020-04-01,2020-03-28,TRUE,Bagheiat-allah University of Medical Sciences,Not Recruiting,Phase 1,Interventional,Iran,Mesenchymal Stem Cell therapy in COVID19,ATMP,Cells (mesenchymal),Cells (mesenchymal),5,http://en.irct.ir/trial/46789,,1,,2020-04-29,2020-04-29,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-05 19:34:40,2020-11-05 19:55:26,IP Address,81.109.92.226,100,1245,True,2020-11-05 19:55:27,R_qKNJ66UwIx7utDH,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bin Cao AND Remdesivir,"""A Trial of Remdesivir in Adults With Mild and Moderate COVID-19""",,,,,,,,,ND,2020-06-30,NCT04252664,ClinicalTrials.gov,2020-01-31,2020-02-12,FALSE,Capital Medical University,Not Recruiting,Phase 3,Interventional,China,A Trial of Remdesivir in Adults With Mild and Moderate COVID-19,Drug,Remdesivir,Remdesivir,308,https://clinicaltrials.gov/show/NCT04252664,,1,2020-04-10,2020-04-27,2020-04-10,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-05 20:03:29,2020-11-05 20:29:35,IP Address,81.109.92.226,100,1566,True,2020-11-05 20:29:36,R_2tc031E9nLd2fFD,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ruxolitinib AND COVID,Roberto Ovilla-Martinez,Pamela E Baez Islas,,,,,,,,ND,2020-06-30,NCT04334044,ClinicalTrials.gov,2020-04-01,2020-04-15,FALSE,Grupo Cooperativo Hemopatías Malignas,Recruiting,Phase 1/Phase 2,Interventional,Mexico,Treatment of SARS Caused by COVID-19 With Ruxolitinib,Drug,Ruxolitinib,Ruxolitinib,20,https://clinicaltrials.gov/show/NCT04334044,,1,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-05 20:30:40,2020-11-05 21:05:44,IP Address,81.109.92.226,100,2104,True,2020-11-05 21:05:45,R_vBmRxdeH9uAeMwx,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Gerry Gin Wai Kwok,Nivolumab and Covid,Nivolumab AND Hong Kong,,,,,,,,ND,2020-06-30,NCT04356508,ClinicalTrials.gov,2020-04-10,2020-04-14,FALSE,Dr. Gerry Gin Wai Kwok,Not Recruiting,Phase 2,Interventional,No Country Given,COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1,Drug,Nivolumab,Nivolumab,15,https://clinicaltrials.gov/show/NCT04356508,,1,2020-06-30,2021-08-31,2020-06-30,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-08 14:08:25,2020-11-08 15:35:26,IP Address,81.109.92.226,100,5220,True,2020-11-08 15:35:27,R_31MlZ5oZEZcenB8,,,test@test.com,,51.778594970703125,-1.2505950927734375,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,ACTRN12620000482965,ANZCTR,2020-04-17,2020-03-17,TRUE,Juan Pedro Fuentes García,Not Recruiting,Not Applicable,Interventional,Spain,"Impact of high intensity interval training and aerobic training on stress, depression symptoms, anxiety and resilience in self-isolated people during the COVID-19 health emergency in Spain",Other (exercise),Exercise,Exercise,34,https://anzctr.org.au/ACTRN12620000482965.aspx,,1,,2020-03-18,2020-03-18,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-08 16:01:27,2020-11-08 17:21:58,IP Address,81.109.92.226,100,4831,True,2020-11-08 17:21:59,R_21v4cy7Mt2mfrLC,,,test@test.com,,51.778594970703125,-1.2505950927734375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anluohuaxian AND COVID,Guiqiang Wang,,,,,,,,,ND,2020-06-30,NCT04334265,ClinicalTrials.gov,2020-04-01,2020-04-01,FALSE,Peking University First Hospital,Recruiting,Not Applicable,Interventional,China,Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019,Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,750,https://clinicaltrials.gov/show/NCT04334265,,1,2020-06-01,2020-12-01,2020-06-01,0,1,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-08 20:07:09,2020-11-08 20:09:55,IP Address,81.109.92.226,100,166,True,2020-11-08 20:09:55,R_1DIIXs9jiAUoCVC,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,unknown,no,Unclear if this should be treated as a COVID trial as it's for ventilation overall but not specifically for COVID.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,ND,2020-06-30,NCT04355754,ClinicalTrials.gov,2020-04-16,2020-04-15,TRUE,Medical University of Gdańsk,Recruiting,Not Applicable,Interventional,Poland,Ventil Device Usefulness in Mechanically Ventilated ICU Patients,Other (physical),Mechanical ventilation,Mechanical ventilation,40,https://clinicaltrials.gov/show/NCT04355754,,1,2020-05-01,2020-12-31,2020-05-01,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-08 20:11:46,2020-11-08 20:32:46,IP Address,81.109.92.226,100,1259,True,2020-11-08 20:32:47,R_27p6sYr9oRaw0Jj,,,test@test.com,,51.778594970703125,-1.2505950927734375,gl,EN,yes,yes,no,Not totally sure about this one.,,yes,,,0,,,,,,summary_results,,,,,,,http://www.chictr.org.cn/showproj.aspx?proj=53048,,,,,,,,,,,,,2020-05-04,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Low-Oxygen Consumption AND COVID,Shuihua Lu,Yang Yang AND COVID AND Oxygen,,,,,,,,ND,2020-06-30,ChiCTR2000032456,ChiCTR,2020-04-29,2020-03-01,TRUE,Shanghai Public Health Clinical Center,Not Recruiting,Not Applicable,Interventional,No Country Given,A Randomized Controlled Trial for the Effects of Low-Oxygen Consumption Instruction on the Prognosis of Patients with Novel Coronavirus Pneumonia (COVID-19),Prognosis,No Intervention,No Intervention,100,http://www.chictr.org.cn/showproj.aspx?proj=53048,,1,,2020-05-01,2020-05-01,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-08 20:33:16,2020-11-08 20:42:43,IP Address,81.109.92.226,100,566,True,2020-11-08 20:42:43,R_1ePmxNl4qDhbBKv,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cai Yue,aspirin AND COVID,aspirin AND COVID AND Xijing,,,,,,,,ND,2020-06-30,NCT04365309,ClinicalTrials.gov,2020-04-24,2020-02-10,TRUE,Xijing Hospital,Recruiting,Phase 2/Phase 3,Interventional,China,Protective Effect of Aspirin on COVID-19 Patients,Drug,Aspirin,Aspirin,128,https://clinicaltrials.gov/show/NCT04365309,,1,2020-04-01,2020-06-01,2020-04-01,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-08 20:42:49,2020-11-08 20:44:34,IP Address,81.109.92.226,100,105,True,2020-11-08 20:44:35,R_UswlTxQJ2ss9Xr3,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,no,2021-06-01,2021-10-01,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04351906,ClinicalTrials.gov,2020-04-09,2020-05-03,FALSE,University of Giessen,Recruiting,Not Applicable,Interventional,Germany,Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome,Other (device),ECCO2R,ECCO2R,20,https://clinicaltrials.gov/show/NCT04351906,,1,2020-07-01,2020-09-01,2020-07-01,0,1,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,2021-10-01
2020-11-08 20:44:46,2020-11-08 20:54:53,IP Address,81.109.92.226,100,606,True,2020-11-08 20:54:53,R_1MKcgw4hnqXQNun,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COMBATCOVID19,Colchicine AND COVID,Felix Yang,,,,,,,,ND,2020-06-30,NCT04363437,ClinicalTrials.gov,2020-04-23,2020-04-26,FALSE,Maimonides Medical Center,Recruiting,Phase 2,Interventional,United States,COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19,Drug,Colchicine,Colchicine,70,https://clinicaltrials.gov/show/NCT04363437,,1,2020-05-31,2020-06-14,2020-05-31,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-08 20:54:59,2020-11-08 20:55:39,IP Address,81.109.92.226,100,39,True,2020-11-08 20:55:39,R_25R7Lz3O4G9xYUk,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,ACTRN12620000555954,ANZCTR,2020-05-11,2020-06-01,FALSE,UNSW Sydney,Not Recruiting,Not Applicable,Interventional,Australia,"Randomised controlled trial of an app-based intervention, Anchored, to support the mental health of Australians recently unemployed due to COVID-19.",Other (psych),Psychological,Psychological,492,https://anzctr.org.au/ACTRN12620000555954.aspx,,1,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-08 20:55:49,2020-11-08 20:56:13,IP Address,81.109.92.226,100,24,True,2020-11-08 20:56:14,R_2b12M6vLC95Wvvj,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04354389,ClinicalTrials.gov,2020-04-15,2020-05-25,FALSE,"Ansun Biopharma, Inc.",Not Recruiting,Phase 2/Phase 3,Interventional,Italy,DAS181 for STOP COVID-19,Drug,DAS181,DAS181,82,https://clinicaltrials.gov/show/NCT04354389,,1,2020-06-30,2020-10-31,2020-06-30,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-08 20:56:18,2020-11-08 20:57:16,Spam,81.109.92.226,100,57,True,2020-11-08 20:57:16,R_2ePtOpDrT3QHSn5,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04335097,ClinicalTrials.gov,2020-04-01,2020-04-22,FALSE,Lars Wik,Recruiting,Not Applicable,Interventional,Norway,Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation,Other (device),Biosensors,Biosensors,214,https://clinicaltrials.gov/show/NCT04335097,,1,2021-04-08,2025-12-20,2021-04-08,0,1,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-08 20:57:22,2020-11-08 21:05:47,IP Address,81.109.92.226,100,504,True,2020-11-08 21:05:47,R_1Le65PsKXgzwRxX,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Shuang-Huang-Lian,Chen Yongping,"Liu Cailing ",,,,,,,,ND,2020-06-30,ChiCTR2000033133,ChiCTR,2020-05-21,2020-02-12,TRUE,The First Affiliated Hospital of Wenzhou Medical University,Not Recruiting,Not Applicable,Interventional,China,"A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of novel coronavirus pneumonia (COVID-19)",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,60,http://www.chictr.org.cn/showproj.aspx?proj=53925,,1,,2020-04-20,2020-04-20,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-08 21:05:57,2020-11-08 21:08:07,IP Address,81.109.92.226,100,129,True,2020-11-08 21:08:07,R_3248a4aSfufJ7rh,,,test@test.com,,51.778594970703125,-1.2505950927734375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04366960,ClinicalTrials.gov,2020-04-24,2020-05-14,TRUE,Niguarda Hospital,Recruiting,Phase 3,Interventional,Italy,Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients,Drug,Enoxaparin,Enoxaparin,2712,https://clinicaltrials.gov/show/NCT04366960,EUCTR2020-001708-41,1,2020-08-01,2020-11-01,2020-08-01,0,1,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-08 21:08:14,2020-11-08 21:12:30,IP Address,81.109.92.226,100,255,True,2020-11-08 21:12:31,R_2UWcZIXUEZR4NaJ,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,no,2020-11-01,2020-11-01,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Colchicine AND Monoterpene,Ali Mostafaie,,,,,,,,,ND,2020-06-30,NCT04392141,ClinicalTrials.gov,2020-05-15,2020-04-01,TRUE,Kermanshah University of Medical Sciences,Recruiting,Phase 1/Phase 2,Interventional,Iran,Colchicine Plus Phenolic Monoterpenes to Treat COVID-19,Drug,Colchicine + Phenolic Monoterpenes,Colchicine; Phenolic Monoterpenes,200,https://clinicaltrials.gov/show/NCT04392141,,1,2020-06-01,2020-10-01,2020-06-01,0,1,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,2020-11-01
2020-11-08 21:12:36,2020-11-08 21:13:33,Spam,81.109.92.226,100,56,True,2020-11-08 21:13:34,R_3RqMjAf9RBBIck6,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04392713,ClinicalTrials.gov,2020-05-05,2020-04-15,TRUE,"Combined Military Hospital, Pakistan",Recruiting,Not Applicable,Interventional,Pakistan,Efficacy of Ivermectin in COVID-19,Drug,Ivermectin,Ivermectin,100,https://clinicaltrials.gov/show/NCT04392713,,1,2020-07-01,2020-07-01,2020-07-01,0,1,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-08 21:13:39,2020-11-08 21:15:26,Spam,81.109.92.226,100,106,True,2020-11-08 21:15:26,R_87bccxvDLy4Mav7,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04394182,ClinicalTrials.gov,2020-05-15,2020-04-21,TRUE,Fundación Genesiscare,Recruiting,Not Applicable,Interventional,Spain,Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,Other,"Radiation (with Lopinavir/ritonavir, Hydroxychloroquine, Azithromycin, Piperacillin/tazobactam, Heparin, Corticosteroids, Tocilizumab)",Radiation; Lopinavir/ritonavir; Hydroxychloroquine; Azithromycin; Piperacillin/tazobactam; Heparin; Methylprednisolone; Tocilizumab,15,https://clinicaltrials.gov/show/NCT04394182,,1,2020-12-31,2021-04-21,2020-12-31,0,1,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-08 21:15:39,2020-11-09 00:20:13,IP Address,81.109.92.226,100,11073,True,2020-11-09 00:20:13,R_3MamLcPt63XwxBi,,,test@test.com,,51.778594970703125,-1.2505950927734375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,,10.1101/2020.05.29.20114223,,https://www.medrxiv.org/content/10.1101/2020.05.29.20114223v1.article-info,,,,,,,,,,,,,2020-06-02,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,leflunomide AND COVID,Hu Zhao,,,,,,,,,ND,2020-06-30,ChiCTR2000033372,ChiCTR,2020-05-29,2020-03-12,TRUE,Shandong University Qilu Hospital,Not Recruiting,Not Applicable,Interventional,China,Efficacy and safety of leflunomide for Refractory novel coronavirus pneumonia (COVID-19): A non-Randomized Controlled Study,Drug,Leflunomide,Leflunomide,30,http://www.chictr.org.cn/showproj.aspx?proj=54408,,1,,2020-05-17,2020-05-17,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-09 02:06:44,2020-11-09 03:27:58,IP Address,81.109.92.226,100,4874,True,2020-11-09 03:27:59,R_bfpfF4BkttbofUl,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Morteza Zarrabi,Hossein Baharvand,Mesenchymal Stem Cell AND COVID AND Iran,,,,,,,,ND,2020-06-30,IRCT20200217046526N1,IRCT,2020-04-13,2020-03-15,TRUE,Iranian Academic Center for Education Culture and Research,Not Recruiting,Phase 1/Phase 2,Interventional,Iran,Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection,ATMP,Cells (mesenchymal),Cells (mesenchymal),6,http://en.irct.ir/trial/47030,,1,,2020-04-25,2020-04-25,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-09 03:28:11,2020-11-09 03:50:35,IP Address,129.67.116.133,100,1344,True,2020-11-09 03:50:35,R_10r84JJ6sIkE8Ah,,,test@test.com,,51.7476043701171875,-1.2483978271484375,gl,EN,yes,yes,no,,,no,2020-04-29,2020-06-26,0,,,,,,full_results_journal_article,,,,,10.1001/jama.2020.16349,PMC7442954,,,,,,,,,,,,,,2020-08-21,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial,Christoph D Spinner,,,,,,,,,ND,2020-06-30,NCT04292730,ClinicalTrials.gov,2020-02-28,2020-03-15,TRUE,Gilead Sciences,Not Recruiting,Phase 3,Interventional,"Japan, Spain, Netherlands, South Korea, Switzerland, United States, Hong Kong, Italy, Taiwan, China, Germany, Singapore, France, Iran, Sweden, United Kingdom",Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Drug,Remdesivir,Remdesivir,1600,https://clinicaltrials.gov/show/NCT04292730,EUCTR2020-000842-32,1,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,true,,2020-06-26
2020-11-09 03:50:51,2020-11-09 03:54:54,IP Address,129.67.116.133,100,242,True,2020-11-09 03:54:54,R_1Qmv0cx1C0AYAVu,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,unknown,no,"Not sure if rehab counts for ""treatment""",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Searched the trial ID and didn't find any results, just a protocol.",team_review,,ND,2020-06-30,RBR-6m69fc,REBEC,2020-04-02,2020-04-01,TRUE,University of Sevilla,Recruiting,Not Applicable,Interventional,Spain,"Therapeutic Pulmonary Telerehabilitation Protocol in patients affected by COVID-19, confined in their homes",Telehealth,Physio & Rehabilitation,Physio & Rehabilitation,99,http://www.ensaiosclinicos.gov.br/rg/RBR-6m69fc/,,1,,2020-04-15,2020-04-15,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-09 03:55:00,2020-11-09 04:08:54,IP Address,129.67.116.133,100,833,True,2020-11-09 04:08:55,R_1FridN7jYPzhQai,,,test@test.com,,51.7476043701171875,-1.2483978271484375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,,,,,full_results_journal_article,,,,,10.1056/NEJMoa2019014,32706953,,,,,,,,,,,,,,2020-07-23,,,,,,,,,,NCT04322123,,,,,,,,,,,,,,,,,,,,,Coalition I Trial,Alexandre Cavalcanti,,,,,,,,,ND,2020-06-30,RBR-9d8z6m,REBEC,2020-03-27,2020-03-30,FALSE,Hospital do Coração,Not Recruiting,Phase 3,Interventional,Brazil,Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus,Drug,Hydroxychloroquine + Azithromycin vs. Hydroxychloroquine,Hydroxychloroquine; Azithromycin,630,http://www.ensaiosclinicos.gov.br/rg/RBR-9d8z6m/,,1,,2020-05-18,2020-05-18,0,0,,,,,,,,,,,2,,,,1,,,,,,,,,,,,,,,
2020-11-01 15:06:34,2020-11-10 13:27:24,IP Address,86.31.166.235,100,771649,True,2020-11-10 13:27:25,R_25NpSqpuwOieJtl,,,test@test.com,,51.5099029541015625,-2.635406494140625,gl,EN,yes,yes,unknown,"'Suspended' but because no eligible patients could be recruited ",,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bin Cao AND Remdesivir AND COVID-19,,,,,,,Other sources suggest this is suspended & terminated but not the trial registry,team_review,,MPJ,2020-06-30,NCT04252664,ClinicalTrials.gov,2020-01-31,2020-02-12,FALSE,Capital Medical University,Not Recruiting,Phase 3,Interventional,China,A Trial of Remdesivir in Adults With Mild and Moderate COVID-19,Drug,Remdesivir,Remdesivir,308,https://clinicaltrials.gov/show/NCT04252664,,1,2020-04-10,2020-04-27,2020-04-10,0,0,,,,,,,,,,,2,,,,2,,,,,,,,,,,,,,,
2020-11-18 11:43:24,2020-11-18 12:33:36,IP Address,81.109.92.226,100,3011,True,2020-11-18 12:33:37,R_1jOpfNZFkXeZ7Bd,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Qiu Lei ",Qiu Lei AND Longhua Hospital,Lu Zhenhui  AND Longhua Hospital,A randomized controlled trial for Traditional Chinese Medicine in the treatment for Novel Coronavirus Pneumonia (COVID-19),,,,,,,ND,2020-06-30,ChiCTR2000029941,ChiCTR,2020-02-16,2020-03-01,FALSE,Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Not Recruiting,Not Applicable,Interventional,China,A randomized controlled trial for Traditional Chinese Medicine in the treatment for Novel Coronavirus Pneumonia (COVID-19),Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,200,http://www.chictr.org.cn/showproj.aspx?proj=49596,,1,,2020-06-01,2020-06-01,0,0,,,,,,,,,,,3,,,,1,,,,,,,,,,,,,,,
2020-11-18 13:42:41,2020-11-18 13:49:19,IP Address,81.109.92.226,100,397,True,2020-11-18 13:49:20,R_111J1VSLfY2hy2K,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,no,2020-06-30,2020-12-30,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Escin AND Covid,Luca Gallelli,,,,,,,,,ND,2020-06-30,NCT04322344,ClinicalTrials.gov,2020-03-23,2020-03-23,FALSE,University of Catanzaro,Recruiting,Phase 2/Phase 3,Interventional,Italy,Escin in Patients With Covid-19 Infection,Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,120,https://clinicaltrials.gov/show/NCT04322344,,1,2020-06-30,2020-08-30,2020-06-30,0,0,,,,,,,,,,,3,,,,1,,,,,,,,,,,,,,,2020-12-30
2020-11-18 13:49:35,2020-11-18 14:03:21,IP Address,81.109.92.226,100,825,True,2020-11-18 14:03:21,R_2dBcCZ4R9FZBZUF,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,no,2020-12-30,2021-06-15,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ATCO Trial,Angiotensin AND Covid AND Erasme,Filippo Annoni,Robson AS Santos,,,,,,,ND,2020-06-30,NCT04332666,ClinicalTrials.gov,2020-03-27,2020-03-31,FALSE,Erasme University Hospital,Not Recruiting,Phase 2/Phase 3,Interventional,No Country Given,"Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial",Drug,Angiotensin (1-7),Angiotensin (1-7),60,https://clinicaltrials.gov/show/NCT04332666,,1,2020-05-30,2020-06-15,2020-05-30,0,0,,,,,,,,,,,3,,,,1,,,,,,,,,,,,,,,2021-06-15
2020-11-18 16:07:38,2020-11-18 17:13:51,IP Address,86.31.166.235,100,3973,True,2020-11-18 17:13:51,R_XXS2JSHB4jZc1MZ,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Qingyi No. 4 AND COVID Longhua Hospital,"Pneumonia AND coronavirus AND Zhenhui ",,,,,,,,,MPJ,2020-06-30,ChiCTR2000029947,ChiCTR,2020-02-16,2020-03-01,FALSE,Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Not Recruiting,Not Applicable,Interventional,China,A Randomized Controlled Trial for Qingyi No. 4 Compound in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,200,http://www.chictr.org.cn/showproj.aspx?proj=49599,,1,,2020-06-01,2020-06-01,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,
2020-11-18 17:14:32,2020-11-18 17:26:14,IP Address,86.31.166.235,100,701,True,2020-11-18 17:26:14,R_3lMLXi1yA3kSrRE,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,truncated torsion AND COVID-19 AND Huangshi Hospita,Chinese medicine AND coronavirus AND pneumonia AND Shanghai University,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029869,ChiCTR,2020-02-15,2020-02-10,TRUE,Huangshi Hospital of Traditional Chinese Medicine,Not Recruiting,Phase 4,Interventional,China,"A multicenter, randomized, controlled trial for integrated Chinese and western medicine in the treatment of ordinary novel coronavirus pneumonia (COVID-19) based on the ' Internal and External Relieving -Truncated Torsion' strategy",Traditional Medicine + Western Medicine,Traditional Medicine,Traditional Medicine,300,http://www.chictr.org.cn/showproj.aspx?proj=49486,,1,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,
2020-11-18 17:26:25,2020-11-18 17:45:58,IP Address,86.31.166.235,100,1173,True,2020-11-18 17:45:59,R_2PiHA5A4GMkXoj2,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"COVID AND pneumonia AND Yunqing Qiu ","Baloxavir Marboxil AND Favipiravir, AND Lopinavir-Ritonavir AND COVID-19",,,,,,,,,MPJ,2020-06-30,ChiCTR2000029548,ChiCTR,2020-02-04,2020-02-04,FALSE,The First Affiliated Hospital of Zhejiang University School of Medicine,Not Recruiting,Not Applicable,Interventional,China,"Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients",Drug,Baloxavir + Marboxil vs. Favipiravir vs. Lopinavir/ritonavir,Baloxavir; Marboxil; Favipiravir; Lopinavir/ritonavir,30,http://www.chictr.org.cn/showproj.aspx?proj=49015,,1,,2020-06-03,2020-06-03,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,
2020-11-18 17:46:12,2020-11-18 18:05:06,IP Address,86.31.166.235,100,1133,True,2020-11-18 18:05:06,R_3HHdotsGXTY7p3s,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"lopinavir/ritonavir AND COVID-19 AND Jiang Hua ","Sichuan AND lopinavir/ritonavir AND COVID-19 ",,,,,,,,,MPJ,2020-06-30,ChiCTR2000029468,ChiCTR,2020-02-02,2020-02-01,TRUE,"Institute of Emergency Medicine and Disaster Medicine Sichuan People's Hospital, Sichuan Academy of Medical Sciences",Not Recruiting,Not Applicable,Interventional,China,A real-world  study for lopinavir/ritonavir (LPV/r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of novel coronavirus pneumonia (COVID-19),Drug,Lopinavir/ritonavir + emtricitabine + tenofovir vs. lopinavir/ritonavir,Lopinavir/ritonavir; Emtricitabine; Tenofovir,120,http://www.chictr.org.cn/showproj.aspx?proj=48919,,1,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,
2020-11-18 18:06:57,2020-11-18 18:15:08,IP Address,86.31.166.235,100,491,True,2020-11-18 18:15:08,R_3JrzeJTHSSwKwaV,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Chen Chunbo AND lipoic acid AND coronavirus,lipoic acid injection AND COVID-19 AND pneumonia,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030471,ChiCTR,2020-03-02,2020-03-02,FALSE,Maoming People's Hospital,Recruiting,Phase 4,Interventional,China,Efficacy and safety of lipoic acid injection in reducing the risk of progression in common patients with novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,394,http://www.chictr.org.cn/showproj.aspx?proj=50421,,1,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,
2020-11-18 18:15:17,2020-11-18 18:21:41,IP Address,86.31.166.235,100,383,True,2020-11-18 18:21:41,R_w65rWU4gmNq59XH,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,,"10.1101/2020.04.10.20060558 ",,https://www.medrxiv.org/content/10.1101/2020.04.10.20060558v2,,,,,,,,,,,,,2020-05-07,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,ChiCTR2000029868,ChiCTR,2020-02-15,2020-02-11,TRUE,"Ruijin Hospital, Shanghai Jiao Tong University School of Medicine",Not Recruiting,Phase 4,Interventional,China,"Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a randomized controlled, open label, multicenter trial",Drug,Hydroxychloroquine,Hydroxychloroquine,360,http://www.chictr.org.cn/showproj.aspx?proj=49524,,1,,2020-06-30,2020-06-30,0,0,,32409561,,http://doi.org/10.1136/bmj.m1849,,full_results_journal_article,,2020-03-14,2020-05-14,,4,,,,2,,,,,,,,,,,,,true,true,
2020-11-18 18:22:51,2020-11-18 18:33:58,IP Address,86.31.166.235,100,667,True,2020-11-18 18:33:59,R_3JpZOB9EW9Rhd1F,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_journal_article,full_results_journal_article,,,,10.1016/j.bja.2020.02.020,,https://bjanaesthesia.org/article/S0007-0912(20)30135-5/fulltext,10.1016/j.bja.2020.02.020,32200994,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269901/,,,,,,,,,,2020-03-19,,2020-03-20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The search results have the same content ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,fibre-optic bronchoscope AND COVID-19 AND Bi-Xi,preoxygenation AND bronchoscope AND coronavirus AND China,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029658,ChiCTR,2020-02-09,2020-02-10,FALSE,Central Theater General Hospital of PLA,No Status Given,Not Applicable,Interventional,China,Nasal high-fow preoxygenation assisted fibre-optic bronchoscope intubation in patients with critical novel coronavirus pneumonia (COVID-19),Other (physical),Mechanical ventilation,Mechanical ventilation,60,http://www.chictr.org.cn/showproj.aspx?proj=49074,,1,,2020-04-06,2020-04-06,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,true,,
2020-11-18 18:34:07,2020-11-18 18:46:09,IP Address,86.31.166.235,100,722,True,2020-11-18 18:46:10,R_2aY7E1QKTU2Bap7,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mazandaran AND COVID-19 AND Convalescent Plasma,Shamshirian AND coronavirus AND Convalescent Plasma,,,,,,,,,MPJ,2020-06-30,NCT04327349,ClinicalTrials.gov,2020-03-24,2020-03-28,TRUE,Mazandaran University of Medical Sciences,Recruiting,Not Applicable,Interventional,Iran,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,ATMP,Plasma,Plasma,30,https://clinicaltrials.gov/show/NCT04327349,IRCT20181104041551N1,1,2020-05-20,2020-09-30,2020-05-20,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,
2020-11-18 18:46:25,2020-11-18 19:36:34,IP Address,86.31.166.235,100,3009,True,2020-11-18 19:36:35,R_3fJAdoLg8llt7D2,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Fasa University AND Levamisole and Formoterol Budesonide AND COVID-19,Afazeli AND coronavirus AND inhaler,,,,,,,,,MPJ,2020-06-30,NCT04331470,ClinicalTrials.gov,2020-03-30,2020-04-04,TRUE,Fasa University of Medical Sciences,Recruiting,Phase 2/Phase 3,Interventional,Iran,Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19,Drug,Levamisole + budesonide/formoterol + lopinavir/ritonavir + hydroxychloroquine,Levamisole; budesonide; formoterol; Lopinavir/ritonavir; hydroxychloroquine,30,https://clinicaltrials.gov/show/NCT04331470,IRCT20200324046852N1,1,2020-04-20,2020-05-20,2020-04-20,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,
2020-11-18 20:15:28,2020-11-18 20:25:24,IP Address,86.31.166.235,100,595,True,2020-11-18 20:25:25,R_2zXYc5ERttaRFRN,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,other,,,,,,,https://covid-nma.com/living_data/infos_participants.php?i=162,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Says the information is taken from a 'published paper' but cannot find link,,,,,,,pubmed,,,,,full_results_journal_article,,,,,10.1111/ijcp.13600,32603531,https://pubmed.ncbi.nlm.nih.gov/32603531/,,,,,,,,,,,,,2020-06-30,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,febuxostat AND COVID-19 AND Iran,Lotfollah Davoodi AND coronavirus AND treatment,,,,,,,,,MPJ,2020-06-30,IRCT20190727044343N1,IRCT,2020-04-05,2020-03-16,TRUE,Mazandaran University of Medical Sciences,Not Recruiting,Phase 3,Interventional,Iran,?Effect of febuxostat against coronavirus,Drug,Acetaminophen + Febuxostat vs.  Acetaminophen + Hydroxychloroquine,Febuxostat; Acetaminophen; Hydroxychloroquine,60,http://en.irct.ir/trial/46629,,1,,2020-04-09,2020-04-09,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,
2020-11-18 20:25:34,2020-11-18 20:33:08,IP Address,86.31.166.235,100,453,True,2020-11-18 20:33:09,R_3g6IZ3qOiwvYGYs,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,GeoSentinel AND COVID-19 AND HERO,pre-exposure prophylaxis AND coronavirus AND health care worker,,,,,,,,,MPJ,2020-06-30,NCT04352946,ClinicalTrials.gov,2020-04-16,2020-04-24,FALSE,GeoSentinel Foundation,Not Recruiting,Phase 3,Interventional,United States,HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial,Drug (Chemoprophylaxis),Hydroxychloroquine,Hydroxychloroquine,374,https://clinicaltrials.gov/show/NCT04352946,,1,2020-06-24,2020-08-24,2020-06-24,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,
2020-11-18 20:33:28,2020-11-18 20:39:33,IP Address,86.31.166.235,100,364,True,2020-11-18 20:39:33,R_2vkvumQCTbiIXh5,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,convalescent plasma AND COVID-19 AND Fontana,,,,,,,,,,MPJ,2020-06-30,NCT04365439,ClinicalTrials.gov,2020-04-18,2020-04-27,FALSE,Enos Bernasconi,Not Recruiting,Not Applicable,Interventional,No Country Given,Convalescent Plasma for COVID-19,ATMP,Plasma,Plasma,10,https://clinicaltrials.gov/show/NCT04365439,,1,2020-05-30,2020-06-30,2020-05-30,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,
2020-11-18 20:39:44,2020-11-18 20:45:31,IP Address,86.31.166.235,100,347,True,2020-11-18 20:45:32,R_29cx26pXNXaMirD,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hydroxychloroquine Azithromycin AND COVID-19 AND Pregnancy,HASCOPT AND coronavirus AND Marseille,,,,,,,,,MPJ,2020-06-30,NCT04365231,ClinicalTrials.gov,2020-04-23,2020-04-01,TRUE,"Hospital St. Joseph, Marseille",Not Recruiting,Phase 3,Interventional,France,Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial,Drug,Hydroxychloroquine + Azithromycin,Hydroxychloroquine; Azithromycin,50,https://clinicaltrials.gov/show/NCT04365231,,1,2020-06-01,2021-01-01,2020-06-01,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,
2020-11-18 20:45:57,2020-11-18 20:53:46,IP Address,86.31.166.235,100,468,True,2020-11-18 20:53:47,R_30kRgUdCnp6aD8J,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,,,,,full_results_journal_article,,,,,10.1093/jac/dkaa332,32812025,https://pubmed.ncbi.nlm.nih.gov/32812025/,,,,,,,,,,,,,2020-08-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Abbaspour AND Sovodak AND COVID-19,"Mazandaran AND coronavirus AND clinical trial ",,,,,,,,,MPJ,2020-06-30,IRCT20200328046886N1,IRCT,2020-04-12,2020-03-05,TRUE,Mazandaran University of Medical Sciences,Not Recruiting,Phase 3,Interventional,Iran,The effectiveness of Sovodak (sofosbuvir+daclatasvir) in Covid-19 patients,Drug,Daclatasvir/sofosbuvir,Daclatasvir/sofosbuvir,48,http://en.irct.ir/trial/46885,,1,,2020-05-04,2020-05-04,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,true,,
2020-11-19 11:12:06,2020-11-19 11:18:24,IP Address,86.31.166.235,100,377,True,2020-11-19 11:18:24,R_33jY3U0gg58jJ2y,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,"'to improve our understanding about COVID-19 prevention, management, and possible long-term effects",,no,2020-08-31,NA,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04391829,ClinicalTrials.gov,2020-05-13,2020-05-12,TRUE,UZ Brussel,Not Recruiting,Not Applicable,Interventional,No Country Given,Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males,Clinical Presentation,No Intervention,No Intervention,20,https://clinicaltrials.gov/show/NCT04391829,,1,2020-07-15,2020-08-31,2020-07-15,0,1,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,2020-08-31
2020-11-19 11:18:34,2020-11-19 11:20:29,IP Address,86.31.166.235,100,114,True,2020-11-19 11:20:29,R_3LaOhNE1R8HPkCB,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-10-30,NA,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04393727,ClinicalTrials.gov,2020-05-16,2020-05-01,TRUE,AOU Pisana,Recruiting,Phase 2,Interventional,Italy,Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19,ATMP,Plasma,Plasma,126,https://clinicaltrials.gov/show/NCT04393727,,1,2020-09-30,2020-10-30,2020-09-30,0,1,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,2020-10-30
2020-11-19 11:20:42,2020-11-19 11:29:21,IP Address,86.31.166.235,100,518,True,2020-11-19 11:29:22,R_1Fy4wXuKBpE128a,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-11-01,2020-11-01,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sodium Bicarbonate AND Pneumonia AND COVID-19,Mansoura AND COVID-19 AND Elbadrawy,,,,,,,team_review,,MPJ,2020-06-30,NCT04374591,ClinicalTrials.gov,2020-05-02,2020-04-01,TRUE,Mansoura University,Not Recruiting,Phase 1,Interventional,Egypt,Home-based Treatment of Computed Tomography and Clinically Suspected Novel COVID-19 With Adjuvant Inhalable Sodium Bicarbonate: A Preliminary Case Series,Drug,Sodium Bicarbonate,Sodium Bicarbonate,40,https://clinicaltrials.gov/show/NCT04374591,,1,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,2020-11-01
2020-11-19 11:29:33,2020-11-19 11:48:12,IP Address,86.31.166.235,100,1118,True,2020-11-19 11:48:13,R_zUPhRuuOa0pVEat,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-09-29,2020-09-29,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3714649 - this has the same dates/participant no as the trial but one extra '0' in the trial ID so it doesn't show up. Maybe because this trial is one arm of the multicentre one reported in this paper?,Argentina AND COVID-19 AND Ivermectin,,,,,,,,team_review,,MPJ,2020-06-30,NCT04381884,ClinicalTrials.gov,2020-05-05,2020-05-18,FALSE,Laboratorio Elea,Recruiting,Phase 2,Interventional,Argentina,Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,Drug,Ivermectin,Ivermectin,45,https://clinicaltrials.gov/show/NCT04381884,,1,2020-06-30,2020-06-30,2020-06-30,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,2020-09-29
2020-11-19 11:48:24,2020-11-19 12:11:58,IP Address,86.31.166.235,100,1414,True,2020-11-19 12:11:59,R_3hlPmKhSPcxu0rA,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Comparison AND COVID-19 AND Lopinavir/Ritonavir,Korea AND COVID-19 AND  Lopinavir/Ritonavir,,,,,,,,,MPJ,2020-06-30,NCT04307693,ClinicalTrials.gov,2020-03-10,2020-03-11,FALSE,Asan Medical Center,Not Recruiting,Phase 2,Interventional,South Korea,Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Drug,Lopinavir/ritonavir vs. hydroxychloroquine,Lopinavir/ritonavir; Hydroxychloroquine,65,https://clinicaltrials.gov/show/NCT04307693,,1,2020-04-30,2020-04-30,2020-04-30,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,
2020-11-19 12:12:07,2020-11-19 12:14:11,IP Address,86.31.166.235,100,123,True,2020-11-19 12:14:11,R_1lbOyD2GtZNGzRX,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-11-21,2021-04-21,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04355364,ClinicalTrials.gov,2020-04-15,2020-04-21,FALSE,Fondation Ophtalmologique Adolphe de Rothschild,Recruiting,Phase 3,Interventional,France,Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alfa Administration in Patients With COVID19-induced ARDS (COVIDORNASE),Drug,Dornase alfa,Dornase alfa,100,https://clinicaltrials.gov/show/NCT04355364,,1,2020-08-21,2020-08-21,2020-08-21,0,1,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,2021-04-21
2020-11-19 12:14:23,2020-11-19 12:16:43,IP Address,86.31.166.235,100,140,True,2020-11-19 12:16:44,R_3R2AX4j72sfyQWA,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04315948,ClinicalTrials.gov,2020-03-13,2020-03-22,TRUE,INSERM,Recruiting,Phase 3,Interventional,"France, Luxembourg",Trial of Treatments for COVID-19 in Hospitalized Adults,Drug,Remdesivir vs. Lopinavir/ritonavir vs. Lopinavir/ritonavir + Interferon beta vs. Hydroxychloroquine,Remdesivir; Lopinavir/ritonavir; Interferon beta; Hydroxychloroquine,3100,https://clinicaltrials.gov/show/NCT04315948,EUCTR2020-000936-23,1,2023-03-01,2023-03-01,2023-03-01,0,1,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,
2020-11-19 12:16:51,2020-11-19 12:18:16,IP Address,86.31.166.235,100,85,True,2020-11-19 12:18:16,R_27JPds9HnS9gp2q,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,"Intervention to support mental health of healthcare workers during the COVID-19 pandemic ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,TCTR20200601002,TCTR,2020-05-28,2020-06-01,FALSE,Self-sponsored,Recruiting,Not Applicable,Interventional,Malaysia,"A Randomized Controlled Trial on Effectiveness of Mental Health & Psychosocial Support Module (MHPSS) in Reduction of Depression, Anxiety and Stress among Healthcare Workers during COVID-19 Pandemic in Jerantut, Pahang",Other (psych),Psychological,Psychological,110,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=6322,,1,2020-06-30,2020-06-30,2020-06-30,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,
2020-11-19 12:18:26,2020-11-19 12:20:29,Spam,86.31.166.235,100,123,True,2020-11-19 12:20:29,R_4UyxfKmIXj0YGOJ,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04335786,ClinicalTrials.gov,2020-04-02,2020-04-17,TRUE,Radboud University,Recruiting,Phase 4,Interventional,Netherlands,Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease,Drug,Valsartan,Valsartan,651,https://clinicaltrials.gov/show/NCT04335786,EUCTR2020-001320-34,1,2020-12-01,2021-12-01,2020-12-01,0,1,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,
2020-11-19 12:26:19,2020-11-19 12:34:26,IP Address,86.31.166.235,100,487,True,2020-11-19 12:34:27,R_3JCu7FqR6aIXW5L,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_journal_article,,,,,10.1016/j.compbiomed.2020.103949,"32798922 ",https://www.sciencedirect.com/science/article/pii/S0010482520302845?via%3Dihub,,,,,,,,,,,,,2020-09-01,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Respiratory Decompensation AND algorithm AND COVID-19,,,,,,,,,,MPJ,2020-06-30,NCT04390516,ClinicalTrials.gov,2020-05-14,2020-03-24,TRUE,Dascena,Not Recruiting,Not Applicable,Interventional,United States,Respiratory Decompensation and Model for the Triage of COVID-19 Patients,Prognosis,No Intervention,No Intervention,197,https://clinicaltrials.gov/show/NCT04390516,,1,2020-05-04,2020-05-30,2020-05-04,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,true,,
2020-11-19 12:34:38,2020-11-19 12:35:36,IP Address,86.31.166.235,100,58,True,2020-11-19 12:35:37,R_1gUTa6CdwmQgj7J,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,'Monitoring' rather than treatment or prevention?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04423289,ClinicalTrials.gov,2020-06-06,2020-03-31,TRUE,Vall d'Hebron Research Institute (VHIR),Not Recruiting,Not Applicable,Interventional,Spain,Telematic Monitoring Through a Mobile Application of Patients With COVID-19,Other (software),eHealth,eHealth,150,https://clinicaltrials.gov/show/NCT04423289,,1,2020-05-04,2020-05-18,2020-05-04,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,
2020-11-19 12:35:44,2020-11-19 12:46:44,IP Address,86.31.166.235,100,660,True,2020-11-19 12:46:44,R_1GNVNw5qLWE6S3U,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Utrecht AND COVID-19 AND Chloroquine AND Hydroxychloroquine,"ARCHAIC AND COVID-19 AND clinical trial ",,,,,,,,,MPJ,2020-06-30,NCT04362332,ClinicalTrials.gov,2020-04-20,2020-04-14,TRUE,UMC Utrecht,Not Recruiting,Phase 4,Interventional,Netherlands,"Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19",Drug,Chloroquine vs. hydroxychloroquine,Chloroquine; hydroxychloroquine,25,https://clinicaltrials.gov/show/NCT04362332,,1,2020-06-08,2020-06-08,2020-06-08,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,
2020-11-19 12:46:52,2020-11-19 12:55:58,IP Address,86.31.166.235,100,545,True,2020-11-19 12:55:59,R_1NlVmptJykAEzVQ,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-08-08,2020-08-10,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Lung Ultrasonography AND COVID-19 AND Turkey,,,,,,,,,,MPJ,2020-06-30,NCT04432051,ClinicalTrials.gov,2020-06-11,2020-05-26,TRUE,Gaziosmanpasa Taksim Research and Education Hospital,Recruiting,Not Applicable,Interventional,Turkey,The Use of Lung Ultrasonography in COVID-19 Patients,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,100,https://clinicaltrials.gov/show/NCT04432051,,1,2020-06-20,2020-06-26,2020-06-20,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,2020-08-10
2020-11-19 12:56:07,2020-11-19 12:57:06,IP Address,86.31.166.235,100,58,True,2020-11-19 12:57:06,R_QbTUGv6MHhsEa8V,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,"Is detection prevention? ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04438070,ClinicalTrials.gov,2020-06-17,2020-04-10,TRUE,St. Joseph's Healthcare Hamilton,Recruiting,Not Applicable,Interventional,Canada,COVID Screening Strategies in Homeless Shelters,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,400,https://clinicaltrials.gov/show/NCT04438070,,1,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,
2020-11-19 12:57:13,2020-11-19 12:59:32,IP Address,86.31.166.235,100,139,True,2020-11-19 12:59:32,R_Tk0msYquFxOCrZL,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,Is this more an observation/measurement of prevalence of covid-19 rather than a prevention or treatment?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04441684,ClinicalTrials.gov,2020-05-20,2020-04-17,TRUE,"University Hospital, Strasbourg",Recruiting,Not Applicable,Interventional,France,"Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)",Clinical Presentation (Epidemiology),No Intervention,No Intervention,1800,https://clinicaltrials.gov/show/NCT04441684,,1,2020-05-07,2021-08-01,2020-05-07,0,0,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,
2020-11-19 14:47:45,2020-11-19 14:56:50,IP Address,81.109.92.226,100,545,True,2020-11-19 14:56:51,R_117Qaa7mKOpAFpM,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nintedanib AND COVID,Huilan Zhang,Huilan Zhang AND Tongji,Xianglin Yuan AND Nintedanib,,,,,,,ND,2020-06-30,NCT04338802,ClinicalTrials.gov,2020-04-01,2020-04-02,FALSE,Huilan Zhang,Not Recruiting,Phase 2,Interventional,No Country Given,Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19,Drug,Nintedanib,Nintedanib,96,https://clinicaltrials.gov/show/NCT04338802,,1,2020-05-04,2020-08-01,2020-05-04,0,0,,,,,,,,,,,3,,,,1,,,,,,,,,,,,,,,
2020-11-19 14:57:04,2020-11-19 15:00:30,IP Address,81.109.92.226,100,205,True,2020-11-19 15:00:30,R_22soM8QmPfrJ7hn,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,no,2020-06-29,2020-07-06,0,,,,,,summary_results,,,,,,,https://clinicaltrials.gov/ct2/show/results/NCT04410159,,,,,,,,,,,,,2020-07-21,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04410159,ClinicalTrials.gov,2020-05-27,2020-06-22,FALSE,Universiti Sains Islam Malaysia,Recruiting,Phase 2,Interventional,Malaysia,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Drug,Povidone Iodine vs. Essential Oil,Povidone Iodine; Essential Oil,20,https://clinicaltrials.gov/show/NCT04410159,,1,2020-07-15,2020-08-15,2020-07-15,0,1,,,,,,,,,,,3,,,,1,,,,,,,,,,,,,,,2020-07-06
2020-11-19 15:01:09,2020-11-19 15:16:34,IP Address,81.109.92.226,100,925,True,2020-11-19 15:16:35,R_3DwnjenXyvUScFF,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_journal_article,,,,,10.1016/j.jinf.2020.04.017,32592703,,,,,,,,,,,,,,2020-04-23,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"This was published as a letter to the editor. It doesn't explicitly mention the trial ID but it matches on details perfectly (PI, sample size, start date, treatment). I don't know exactly why it showed up in the search for the Trial ID on Europe PMC.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Baricitinib AND Covid AND Cantini,,,,,,,,,,ND,2020-06-30,NCT04358614,ClinicalTrials.gov,2020-04-19,2020-03-16,TRUE,Fabrizio Cantini,Not Recruiting,Phase 2/Phase 3,Interventional,Italy,Baricitinib Therapy in COVID-19,Drug,Baricitinib,Baricitinib,12,https://clinicaltrials.gov/show/NCT04358614,,1,2020-04-05,2020-04-07,2020-04-05,0,0,,,,,,,,,,,3,,,,1,,,,,,,,,,,,,true,,
2020-11-21 17:23:05,2020-11-21 17:31:04,IP Address,78.55.178.40,100,479,True,2020-11-21 17:31:04,R_1f7PNjeAEOdxwit,,,test@test.com,,52.483001708984375,13.341400146484375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"QIU Lei AND A Randomized Controlled Trial for Qingyi No. 4 Compound in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia (COVID-19) ",Longhua Hospital AND COVID 19 AND Qingyi No. 4,ChiCTR2000029947 AND tcmdoctorlu@163.com AND COVID 19,,,," Date of approved by ethic committee：2013-08-26  --> Chinese registry is not good. "," Date of approved by ethic committee： 2013-08-26  ",,,PG,2020-06-30,ChiCTR2000029947,ChiCTR,2020-02-16,2020-03-01,FALSE,Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Not Recruiting,Not Applicable,Interventional,China,A Randomized Controlled Trial for Qingyi No. 4 Compound in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,200,http://www.chictr.org.cn/showproj.aspx?proj=49599,,1,,2020-06-01,2020-06-01,0,0,crossreg_pub1,,,,,pub_type_1,pub_type_2,date_completion_1,date_publication_1,date_publication_2,4,,,,1,,,,,,,,,,,,date_completion_2,,,
2020-11-21 17:31:18,2020-11-21 17:37:16,IP Address,78.55.178.40,100,358,True,2020-11-21 17:37:17,R_2WHypCzFfhhSrh4,,,test@test.com,,52.486602783203125,13.467193603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,other,,,,,"10.21203/rs.3.rs-44542/v1 ",,https://europepmc.org/article/ppr/ppr189732,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"This is just the protocol that's published as preprint ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ChiCTR2000029869 Shenhuang granule,Zhang beidu covid 19,,,,,,,,,PG,2020-06-30,ChiCTR2000029869,ChiCTR,2020-02-15,2020-02-10,TRUE,Huangshi Hospital of Traditional Chinese Medicine,Not Recruiting,Phase 4,Interventional,China,"A multicenter, randomized, controlled trial for integrated Chinese and western medicine in the treatment of ordinary novel coronavirus pneumonia (COVID-19) based on the ' Internal and External Relieving -Truncated Torsion' strategy",Traditional Medicine + Western Medicine,Traditional Medicine,Traditional Medicine,300,http://www.chictr.org.cn/showproj.aspx?proj=49486,,1,,2020-06-30,2020-06-30,0,0,crossreg_pub1,,,,,pub_type_1,pub_type_2,date_completion_1,date_publication_1,date_publication_2,4,,,,1,,,,,,,,,,,,date_completion_2,,,
2020-11-21 17:37:31,2020-11-21 17:43:55,IP Address,78.55.178.40,100,383,True,2020-11-21 17:43:56,R_p0BszhSMmmTskwh,,,test@test.com,,52.483001708984375,13.341400146484375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients ","Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir COVID-19 Shentu Jianzhong","Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir COVID-19 First Affiliated Hospital, Zhejiang University School of Medicine ",,,,,,,,PG,2020-06-30,ChiCTR2000029548,ChiCTR,2020-02-04,2020-02-04,FALSE,The First Affiliated Hospital of Zhejiang University School of Medicine,Not Recruiting,Not Applicable,Interventional,China,"Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients",Drug,Baloxavir + Marboxil vs. Favipiravir vs. Lopinavir/ritonavir,Baloxavir; Marboxil; Favipiravir; Lopinavir/ritonavir,30,http://www.chictr.org.cn/showproj.aspx?proj=49015,,1,,2020-06-03,2020-06-03,0,0,crossreg_pub1,,,,,pub_type_1,pub_type_2,date_completion_1,date_publication_1,date_publication_2,4,,,,1,,,,,,,,,,,,date_completion_2,,,
2020-11-21 17:44:00,2020-11-21 17:50:18,IP Address,78.55.178.40,100,377,True,2020-11-21 17:50:19,R_1FhntRMdi6v4OEX,,,test@test.com,,52.486602783203125,13.467193603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"A real-world study for lopinavir/ritonavir (LPV/r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of novel coronavirus pneumonia (COVID-19) ","The early use of lopinavir/litonavir (LPV/r) and emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of the novel coronavirus pneumonia (COVID-19): a real-world study ",Li Ting LPV/r FTC TAF Covid-19,,,,,,,,PG,2020-06-30,ChiCTR2000029468,ChiCTR,2020-02-02,2020-02-01,TRUE,"Institute of Emergency Medicine and Disaster Medicine Sichuan People's Hospital, Sichuan Academy of Medical Sciences",Not Recruiting,Not Applicable,Interventional,China,A real-world  study for lopinavir/ritonavir (LPV/r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of novel coronavirus pneumonia (COVID-19),Drug,Lopinavir/ritonavir + emtricitabine + tenofovir vs. lopinavir/ritonavir,Lopinavir/ritonavir; Emtricitabine; Tenofovir,120,http://www.chictr.org.cn/showproj.aspx?proj=48919,,1,,2020-06-30,2020-06-30,0,0,crossreg_pub1,,,,,pub_type_1,pub_type_2,date_completion_1,date_publication_1,date_publication_2,4,,,,1,,,,,,,,,,,,date_completion_2,,,
2020-11-21 17:50:23,2020-11-21 17:54:33,IP Address,78.55.178.40,100,249,True,2020-11-21 17:54:33,R_3L5CA6aPdWUypTt,,,test@test.com,,52.486602783203125,13.467193603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Efficacy and safety of lipoic acid injection in reducing the risk of progression in common patients with novel coronavirus pneumonia (COVID-19) ",lipoic acid injection COVID-19 Hu Linhui,,,,,,,,,PG,2020-06-30,ChiCTR2000030471,ChiCTR,2020-03-02,2020-03-02,FALSE,Maoming People's Hospital,Recruiting,Phase 4,Interventional,China,Efficacy and safety of lipoic acid injection in reducing the risk of progression in common patients with novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,394,http://www.chictr.org.cn/showproj.aspx?proj=50421,,1,,2020-04-30,2020-04-30,0,0,crossreg_pub1,,,,,pub_type_1,pub_type_2,date_completion_1,date_publication_1,date_publication_2,4,,,,1,,,,,,,,,,,,date_completion_2,,,
2020-11-21 17:54:37,2020-11-21 18:02:57,IP Address,78.55.178.40,100,500,True,2020-11-21 18:02:58,R_3oYe5SRXGlsTLh6,,,test@test.com,,52.486602783203125,13.467193603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,,10.1101/2020.04.10.20060558,,https://www.medrxiv.org/content/10.1101/2020.04.10.20060558v1?versioned=true,,,,,,,,,,,,,2020-04-14,2020-03-14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,,,,,,,,,,"10.1136/bmj.m1849 ",,https://pubmed.ncbi.nlm.nih.gov/32409561/,,,,,,,,,,,,,2020-05-14,,,,,,,,,,,,,,,,,,,,,,,,,this was identified automatically before,,,,,,ChiCTR2000029868,,,,,,,,,,PG,2020-06-30,ChiCTR2000029868,ChiCTR,2020-02-15,2020-02-11,TRUE,"Ruijin Hospital, Shanghai Jiao Tong University School of Medicine",Not Recruiting,Phase 4,Interventional,China,"Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a randomized controlled, open label, multicenter trial",Drug,Hydroxychloroquine,Hydroxychloroquine,360,http://www.chictr.org.cn/showproj.aspx?proj=49524,,1,,2020-06-30,2020-06-30,0,0,crossreg_pub1,32409561,,http://doi.org/10.1136/bmj.m1849,,pub_type_1,pub_type_2,date_completion_1,date_publication_1,date_publication_2,4,,,,1,,,,,,,,,,,,date_completion_2,,true,
2020-11-21 18:03:14,2020-11-21 18:04:07,IP Address,78.55.178.40,100,53,True,2020-11-21 18:04:07,R_e9dDWGTCVkMSlJD,,,test@test.com,,52.486602783203125,13.467193603515625,gl,EN,yes,no,,"This is testing the efficacy and safety of the Nasal high-fow preoxygenation assisted fibre-optic bronchoscope intubation in the critically 2019-n CoV pneumonia patient. 

--> Not treatment or prevention, just intubation technique",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,ChiCTR2000029658,ChiCTR,2020-02-09,2020-02-10,FALSE,Central Theater General Hospital of PLA,No Status Given,Not Applicable,Interventional,China,Nasal high-fow preoxygenation assisted fibre-optic bronchoscope intubation in patients with critical novel coronavirus pneumonia (COVID-19),Other (physical),Mechanical ventilation,Mechanical ventilation,60,http://www.chictr.org.cn/showproj.aspx?proj=49074,,1,,2020-04-06,2020-04-06,0,0,crossreg_pub1,,,,,pub_type_1,pub_type_2,date_completion_1,date_publication_1,date_publication_2,4,,,,1,,,,,,,,,,,,date_completion_2,,,
2020-11-21 18:04:14,2020-11-21 18:10:45,IP Address,78.55.178.40,100,391,True,2020-11-21 18:10:47,R_1BVnWOzIv5IEW9m,,,test@test.com,,52.486602783203125,13.467193603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Imam Khomeini Hospital COVID 19 plasma,NCT04327349 Amir Shamshirian Imam Khomeini Hospital,,,,,,,,PG,2020-06-30,NCT04327349,ClinicalTrials.gov,2020-03-24,2020-03-28,TRUE,Mazandaran University of Medical Sciences,Recruiting,Not Applicable,Interventional,Iran,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,ATMP,Plasma,Plasma,30,https://clinicaltrials.gov/show/NCT04327349,IRCT20181104041551N1,1,2020-05-20,2020-09-30,2020-05-20,0,0,crossreg_pub1,,,,,pub_type_1,pub_type_2,date_completion_1,date_publication_1,date_publication_2,4,,,,1,,,,,,,,,,,,date_completion_2,,,
2020-11-21 18:10:54,2020-11-21 18:15:09,IP Address,78.55.178.40,100,255,True,2020-11-21 18:15:10,R_1CsiFVbEMGSCyzZ,,,test@test.com,,52.486602783203125,13.467193603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NCT04331470 Dr. Siamack Afazeli, Fasa University of Medical Sciences",Levamisole and Formoterol+Budesonide COVID 19,,,,,,,,,PG,2020-06-30,NCT04331470,ClinicalTrials.gov,2020-03-30,2020-04-04,TRUE,Fasa University of Medical Sciences,Recruiting,Phase 2/Phase 3,Interventional,Iran,Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19,Drug,Levamisole + budesonide/formoterol + lopinavir/ritonavir + hydroxychloroquine,Levamisole; budesonide; formoterol; Lopinavir/ritonavir; hydroxychloroquine,30,https://clinicaltrials.gov/show/NCT04331470,IRCT20200324046852N1,1,2020-04-20,2020-05-20,2020-04-20,0,0,crossreg_pub1,,,,,pub_type_1,pub_type_2,date_completion_1,date_publication_1,date_publication_2,4,,,,1,,,,,,,,,,,,date_completion_2,,,
2020-11-21 18:15:27,2020-11-21 18:24:53,IP Address,78.55.178.40,100,565,True,2020-11-21 18:24:53,R_2fa1g50BVrDcFQf,,,test@test.com,,52.486602783203125,13.467193603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google,,,,,full_results_journal_article,,,,,10.1111/ijcp.13600," 32603531",10.1111/ijcp.13600,,,,,,,,,,,,,2020-07-17,2020-04-10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IRCT20190727044343N1 Lotfollah Davoodi,,,,,,"This seems like they retrospectively registered when they were done already...also the IRCT number in the publication has no""1"" in the end...but it is this trial for sure. ",,,,PG,2020-06-30,IRCT20190727044343N1,IRCT,2020-04-05,2020-03-16,TRUE,Mazandaran University of Medical Sciences,Not Recruiting,Phase 3,Interventional,Iran,?Effect of febuxostat against coronavirus,Drug,Acetaminophen + Febuxostat vs.  Acetaminophen + Hydroxychloroquine,Febuxostat; Acetaminophen; Hydroxychloroquine,60,http://en.irct.ir/trial/46629,,1,,2020-04-09,2020-04-09,0,0,crossreg_pub1,,,,,pub_type_1,pub_type_2,date_completion_1,date_publication_1,date_publication_2,4,,,,1,,,,,,,,,,,,date_completion_2,,,
2020-11-22 19:49:38,2020-11-22 19:50:52,IP Address,129.67.118.117,100,73,True,2020-11-22 19:50:52,R_Q6ougRKH9xyhGDv,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04407689,ClinicalTrials.gov,2020-05-27,2020-06-08,FALSE,Revimmune,Recruiting,Phase 2,Interventional,France,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort,Drug,Interleukin-7,Interleukin-7,48,https://clinicaltrials.gov/show/NCT04407689,,1,2020-10-30,2020-12-30,2020-10-30,0,1,crossreg_pub1,,,,,pub_type_1,pub_type_2,date_completion_1,date_publication_1,date_publication_2,3,,,,1,,,,,,,,,,,,date_completion_2,,,
2020-11-22 19:51:15,2020-11-22 19:53:13,IP Address,129.67.118.117,100,118,True,2020-11-22 19:53:13,R_1gdtaX8TZx43ctE,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,unknown,no,This is technically prevention. I think it's OK but I want to discuss.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,ND,2020-06-30,NCT04399005,ClinicalTrials.gov,2020-05-19,2020-05-25,FALSE,The First Affiliated Hospital of Zhejiang Chinese Medical University,Not Recruiting,Not Applicable,Interventional,China,The Efficacy Comparing Daily and After-each-case Room Disinfection.,Other,Other,Other,240,https://clinicaltrials.gov/show/NCT04399005,,1,2020-06-05,2020-06-10,2020-06-05,0,0,crossreg_pub1,,,,,pub_type_1,pub_type_2,date_completion_1,date_publication_1,date_publication_2,3,,,,1,,,,,,,,,,,,date_completion_2,,,
2020-11-22 22:51:12,2020-11-22 23:15:25,IP Address,129.67.118.117,100,1453,True,2020-11-22 23:15:27,R_1FhQndIqxMQFfal,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Zhaowei Chen,"""Zhan Zhang"" AND hydroxychloroquine",,,,,,Check to make sure in the auto-results we had this listed as interim as it appears it was interim based on the preprint compared to the registration.,,,ND,2020-06-30,ChiCTR2000029559,ChiCTR,2020-02-04,2020-01-31,TRUE,Renmin Hospital of Wuhan University,Recruiting,Phase 4,Interventional,China,Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19),Drug,Hydroxychloroquine,Hydroxychloroquine,300,http://www.chictr.org.cn/showproj.aspx?proj=48880,,1,,2020-02-29,2020-02-29,0,0,crossreg_pub1,q8l3ra55,,http://doi.org/10.1101/2020.03.22.20040758,,pub_type_1,pub_type_2,date_completion_1,date_publication_1,date_publication_2,3,,,,1,,,,,,,,,,,,date_completion_2,,,
2020-11-22 23:15:33,2020-11-22 23:23:26,IP Address,129.67.118.117,100,472,True,2020-11-22 23:23:27,R_RmdpeCmQIAZouCR,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Xie Zhijun,Wen Chengping,,,,,,,,,ND,2020-06-30,ChiCTR2000029518,ChiCTR,2020-02-03,2020-02-04,FALSE,Zhejiang Chinese Medical University,Recruiting,Not Applicable,Interventional,China,"Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trial",Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,140,http://www.chictr.org.cn/showproj.aspx?proj=48860,,1,,2020-04-30,2020-04-30,0,0,crossreg_pub1,,,,,pub_type_1,pub_type_2,date_completion_1,date_publication_1,date_publication_2,3,,,,1,,,,,,,,,,,,date_completion_2,,,
2020-11-22 23:23:34,2020-11-22 23:37:51,IP Address,129.67.118.117,100,857,True,2020-11-22 23:37:52,R_OPZn64AUiD7elPz,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"https://jamanetwork.com/journals/jama/fullarticle/2770279%C2%A0%C2%A0

This review/meta-analysis notes that this trial might be withdrawn w/o patients as they contacted the authors.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Chen Zhenshun,Corticosteroids AND Covid AND Zhongnan Hospital,Corticosteroid AND Timing AND Covid,,,,,,team_review,,ND,2020-06-30,ChiCTR2000030481,ChiCTR,2020-03-03,2020-03-01,TRUE,Zhongnan Hospital of Wuhan University,Recruiting,Phase 4,Interventional,China,The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial,Drug,Corticosteroids,Corticosteroids,200,http://www.chictr.org.cn/showproj.aspx?proj=50453,,1,,2020-04-30,2020-04-30,0,0,crossreg_pub1,,,,,pub_type_1,pub_type_2,date_completion_1,date_publication_1,date_publication_2,3,,,,1,,,,,,,,,,,,date_completion_2,,,
2020-11-22 23:38:04,2020-11-22 23:41:17,IP Address,129.67.118.117,100,193,True,2020-11-22 23:41:18,R_XtQaJzvwmDYBhJf,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,unknown,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The study is identified as ""A medical records based study for Tou-Jie-Qu-Wen Granules in the Treatment of mild and moderate patients with novel coronavirus pneumonia (COVID-19)""

This looks like an observational case-control study to me, not a prospective trial.",team_review,,ND,2020-06-30,ChiCTR2000031089,ChiCTR,2020-03-22,2020-03-13,TRUE,Guangzhou Eighth People's Hospital,Not Recruiting,Not Applicable,Interventional,China,A medical records based study for Tou-Jie-Qu-Wen Granules in the Treatment of mild and moderate patients with novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,300,http://www.chictr.org.cn/showproj.aspx?proj=51136,,1,,2020-04-30,2020-04-30,0,0,crossreg_pub1,,,,,pub_type_1,pub_type_2,date_completion_1,date_publication_1,date_publication_2,3,,,,1,,,,,,,,,,,,date_completion_2,,,
2020-11-22 23:41:27,2020-11-22 23:43:25,IP Address,129.67.118.117,100,118,True,2020-11-22 23:43:26,R_2ygsCrGF0lISUJu,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,unknown,no,,Not sure if a trial but definitely not covid tx or prevention. Is about survival of tumor surgery pts during covid.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,ChiCTR2000031023,ChiCTR,2020-03-21,2020-03-16,TRUE,Hu'nan Cancer Hospital,Recruiting,Not Applicable,Interventional,China,Perioperative immune prediction and intervention of tumor patients undergoing surgery during the novel coronavirus pneumonia (COVID-19) outbreak period,Prognosis,No Intervention,No Intervention,320,http://www.chictr.org.cn/showproj.aspx?proj=50984,,1,,2020-05-16,2020-05-16,0,0,crossreg_pub1,,,,,pub_type_1,pub_type_2,date_completion_1,date_publication_1,date_publication_2,3,,,,1,,,,,,,,,,,,date_completion_2,,,
2020-11-22 23:43:31,2020-11-22 23:48:08,IP Address,129.67.118.117,100,277,True,2020-11-22 23:48:09,R_3FQ0LSwToQcWr50,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,I didn't find any preprints looking around either.,,,ND,2020-06-30,ChiCTR2000029434,ChiCTR,2020-02-01,2020-02-01,FALSE,Hebei Yiling Hospital; Renmin Hospital of Wuhan University,Not Recruiting,Phase 4,Interventional,China,"A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule /Granule in the treatment of novel coronavirus pneumonia (COVID-19)",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,240,http://www.chictr.org.cn/showproj.aspx?proj=48889,,1,,2020-12-01,2020-12-01,0,0,crossreg_pub1,32425361,,http://doi.org/10.1016/j.phymed.2020.153242,,pub_type_1,pub_type_2,date_completion_1,date_publication_1,date_publication_2,3,,,,1,,,,,,,,,,,,date_completion_2,,,
2020-11-22 23:48:30,2020-11-22 23:53:30,IP Address,129.67.118.117,100,300,True,2020-11-22 23:53:30,R_3M58XhCtQSQtQY9,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Looks like this trial is actually completed. It's listed as Completed on the EUCTR but with no completion date and has a publication. Could not find anything that looks like a preprint.,,,ND,2020-06-30,NCT04326790,ClinicalTrials.gov,2020-03-26,2020-04-03,TRUE,National and Kapodistrian University of Athens,Recruiting,Phase 2,Interventional,Gibraltar,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,Drug,Colchicine,Colchicine,180,https://clinicaltrials.gov/show/NCT04326790,EUCTR2020-001455-40,1,2020-08-31,2020-09-30,2020-08-31,0,1,crossreg_pub1,32579195,,http://doi.org/10.1001/jamanetworkopen.2020.13136,,pub_type_1,pub_type_2,date_completion_1,date_publication_1,date_publication_2,3,,,,1,,,,,,,,,,,,date_completion_2,,,
2020-11-22 23:53:41,2020-11-22 23:56:56,IP Address,129.67.118.117,100,194,True,2020-11-22 23:56:56,R_xo76UiPvHXrL6tX,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,unknown,no,"This is for quicker intubation which while it's kind of for the treatment of COVID isn't something I'm very confident in being what we mean by ""treatment and prevention""",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Didn't see any results on a quick look around.,team_review,,ND,2020-06-30,NCT04385576,ClinicalTrials.gov,2020-04-28,2020-05-15,FALSE,University of Malaya,Recruiting,Not Applicable,Interventional,Malaysia,"Taiwan ""Aerosol Box"" Versus UMMC ""Intubation Box""",Other (physical),Mechanical ventilation,Mechanical ventilation,30,https://clinicaltrials.gov/show/NCT04385576,,1,2020-09-15,2020-12-30,2020-09-15,0,1,crossreg_pub1,,,,,pub_type_1,pub_type_2,date_completion_1,date_publication_1,date_publication_2,3,,,,1,,,,,,,,,,,,date_completion_2,,,
2020-11-23 09:37:01,2020-11-23 09:54:24,IP Address,86.31.166.235,100,1043,True,2020-11-23 09:54:25,R_1qX19ilWBRtr7Ed,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Arbidol AND COVID-19 AND Zhejiang University,Yunqing Qiu AND ASC09/Ritonavir AND  Lopinavir/Ritonavir AND coronavirus,,,,,,,,,MPJ,2020-06-30,NCT04261907,ClinicalTrials.gov,2020-02-06,2020-02-07,FALSE,The First Affiliated Hospital of Zhejiang University,Not Recruiting,Not Applicable,Interventional,No Country Given,Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection,Drug,SC09 + ritonavir vs. lopinavir/ritonavir,ASC09; lopinavir/ritonavir,160,https://clinicaltrials.gov/show/NCT04261907,,,2020-05-31,2020-06-30,2020-05-31,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-23 09:54:43,2020-11-23 10:02:35,IP Address,86.31.166.235,100,472,True,2020-11-23 10:02:36,R_QgnQlSxBcXthcsh,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COVID-19 AND pneumonia AND screening strategy AND Yan Liu,,,,,,,,team_review,,MPJ,2020-06-30,NCT04281693,ClinicalTrials.gov,2020-02-20,2020-02-01,TRUE,Affiliated Hospital to Academy of Military Medical Sciences,Not Recruiting,Not Applicable,Interventional,China,A New Screening Strategy for 2019 Novel Coronavirus Infection,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,230,https://clinicaltrials.gov/show/NCT04281693,,,2020-03-01,2020-03-01,2020-03-01,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-23 10:03:20,2020-11-23 10:15:07,IP Address,86.31.166.235,100,707,True,2020-11-23 10:15:08,R_DuD6AXvQ2nHUMJX,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,IFN-α2β AND Tongji Hospital AND COVID-19,"Huilan Zhang AND Recombinant Human Interferon AND coronavirus ",,,,,,,,,MPJ,2020-06-30,NCT04293887,ClinicalTrials.gov,2020-02-15,2020-03-01,FALSE,"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology",Not Recruiting,Phase 1,Interventional,No Country Given,Efficacy and Safety of IFN-a2ß in the Treatment of Novel Coronavirus Patients,Drug,Interferon alfa,Interferon alfa,328,https://clinicaltrials.gov/show/NCT04293887,,,2020-05-30,2020-06-30,2020-05-30,0,1,,,,,,,,,,,5,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-23 10:15:16,2020-11-23 10:26:28,IP Address,86.31.166.235,100,671,True,2020-11-23 10:26:29,R_2RaCHAcKo0USjQ7,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Antiviral Therapy AND COVID-19 AND Tongji Hospital,Qing Ning AND Abidol Hydrochloride AND Oseltamivir AND Lopinavir/Ritonavir,,,,,,,,,MPJ,2020-06-30,NCT04255017,ClinicalTrials.gov,2020-02-02,2020-02-01,TRUE,"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,Phase 4,Interventional,China,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia",Drug,Umeprevir vs. Oseltamivir vs. lopinavir/ritonavir,Umeprevir; Oseltamivir; Lopinavir/ritonavir,400,https://clinicaltrials.gov/show/NCT04255017,,,2020-06-01,2020-07-01,2020-06-01,0,0,,,,,,,,,,,5,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-23 15:02:20,2020-11-23 15:11:03,IP Address,86.31.166.235,100,522,True,2020-11-23 15:11:03,R_3fpIHXzANSZDtAk,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Meifang Han AND ASC09F AND COVID-19,Tongji Hospital AND Ritonavir AND ASC09F AND COVID-19,,,,,,,,,MPJ,2020-06-30,NCT04261270,ClinicalTrials.gov,2020-02-04,2020-02-01,TRUE,"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,Phase 3,Interventional,China,"A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia",Drug,ASCO9F + Ritonavir vs. Ritonavir + Oseltamivir vs. Oseltamivir,ASCO9F; Ritonavir; Oseltamivir,60,https://clinicaltrials.gov/show/NCT04261270,,,2020-05-01,2020-07-01,2020-05-01,0,0,,,,,,,,,,,5,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-23 15:11:12,2020-11-23 15:18:11,IP Address,86.31.166.235,100,419,True,2020-11-23 15:18:12,R_z283HqIb2j63m4V,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bevacizumab AND COVID-19 AND pneumonia AND Shandong University,,,,,,,,,,MPJ,2020-06-30,NCT04305106,ClinicalTrials.gov,2020-03-09,2020-03-17,FALSE,Qilu Hospital of Shandong University,Recruiting,Not Applicable,Interventional,China,Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT,Drug,Bevacizumab,Bevacizumab,140,https://clinicaltrials.gov/show/NCT04305106,,,2020-06-30,2020-07-31,2020-06-30,0,0,,,,,,,,,,,5,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-23 20:03:33,2020-11-23 20:15:43,IP Address,86.31.166.235,100,730,True,2020-11-23 20:15:43,R_1E6xqQsYrsJOf1I,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hydroxychloroquine AND COVID-19 AND Umer Farooq,Abbottabad AND Hydroxychloroquine AND coronavirus,,,,,,,,,MPJ,2020-06-30,NCT04328272,ClinicalTrials.gov,2020-03-25,2020-03-28,FALSE,Dr. Umar Farooq,Not Recruiting,Phase 3,Interventional,Pakistan,Effectiveness of Hydroxychloroquine in Covid-19 Patients,Drug,Hydroxychloroquine vs. Hydroxychloroquine + Azithromycin,Hydroxychloroquine; Azithromycin,75,https://clinicaltrials.gov/show/NCT04328272,,,2020-05-28,2020-06-28,2020-05-28,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-23 20:56:46,2020-11-23 20:58:23,IP Address,86.31.166.235,100,96,True,2020-11-23 20:58:23,R_3PUeLUZq6Z1kV9M,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,Trial to develop questionnaires about blood donor recruitment during the pandemic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04306055,ClinicalTrials.gov,2020-03-08,2020-03-13,FALSE,Guangzhou Blood Center,Not Recruiting,Not Applicable,Interventional,China,Blood Donor Recruitment During Epidemic of COVID-19,Other,No Intervention,No Intervention,19491,https://clinicaltrials.gov/show/NCT04306055,,,2020-03-13,2020-04-03,2020-03-13,0,0,,,,,,,,,,,5,,Completed,TRUE,1,,,,,,,,,,,,,,,
2020-11-23 20:58:37,2020-11-23 21:04:01,IP Address,86.31.166.235,100,324,True,2020-11-23 21:04:02,R_yI0yQOHojMDLiuJ,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,full_results_journal_article,,,,,10.1186/s12967-020-02573-9,33087150,https://pubmed.ncbi.nlm.nih.gov/33087150/,,,,,,,,,,,,,2020-10-31,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04317092,ClinicalTrials.gov,2020-03-19,2020-03-19,TRUE,National Cancer Institute,Recruiting,Phase 2,Interventional,Italy,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Drug,Tocilizumab,Tocilizumab,400,https://clinicaltrials.gov/show/NCT04317092,EUCTR2020-001110-38,,2020-12-19,2022-12-19,2020-12-19,0,0,,,,10.1101/2020.06.01.20119149,,full_results_preprint,,2020-04-04,2020-06-05,,5,,Recruiting,TRUE,1,,full_results_preprint,2020-06-05,xv0jhsj0,http://medrxiv.org/cgi/content/short/2020.06.01.20119149v1?rss=1,Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial,2020-04-04,EUCTR2020-001110-38,,,,,,,
2020-11-23 21:05:19,2020-11-23 21:17:46,IP Address,86.31.166.235,100,746,True,2020-11-23 21:17:46,R_NUyoGdnD74xWhSp,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hospital of Prato AND Baricitinib AND COVID-19,,,,,,,,,,MPJ,2020-06-30,NCT04320277,ClinicalTrials.gov,2020-03-20,2020-05-16,FALSE,Hospital of Prato,Not Recruiting,Phase 2/Phase 3,Interventional,Italy,"Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.",Drug,Baricitinib,Baricitinib,200,https://clinicaltrials.gov/show/NCT04320277,,,2020-06-30,2020-07-30,2020-06-30,0,1,,,,,,,,,,,5,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-23 21:18:36,2020-11-23 21:20:02,IP Address,86.31.166.235,100,86,True,2020-11-23 21:20:02,R_1qaGyauqGQ9aODo,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,"Rehabilitation in response to isolation caused by Covid rather than a direct cause of having had covid etc. ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04334434,ClinicalTrials.gov,2020-04-02,2020-04-20,FALSE,Kubra Koce,Not Recruiting,Not Applicable,Interventional,Turkey,Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19),Telehealth,Physio & Rehabilitation,Physio & Rehabilitation,30,https://clinicaltrials.gov/show/NCT04334434,,,2020-06-01,2020-07-31,2020-06-01,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-23 21:20:13,2020-11-23 21:23:26,IP Address,86.31.166.235,100,193,True,2020-11-23 21:23:27,R_1i9AssPDsLrkO0y,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,Is this just a diagnostic tool rather than specifically treatment/prevention. Do note benefit of point-of-care diagnosis so less risk of the spread of covid?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04338568,ClinicalTrials.gov,2020-04-04,2020-04-13,FALSE,Hasselt University,Recruiting,Not Applicable,Interventional,Belgium,Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,50,https://clinicaltrials.gov/show/NCT04338568,,,2020-04-30,2020-04-30,2020-04-30,0,1,,,,,,,,,,,5,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-23 21:23:34,2020-11-23 21:35:35,IP Address,86.31.166.235,100,721,True,2020-11-23 21:35:37,R_ukA3vdOCjbPttyp,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Colombia AND Hydroxychloroquine AND Healthcare Providers AND coronavirus,Parra-Lopez AND Hydroxychloroquine AND COVID-19,,,,,,,,,MPJ,2020-06-30,NCT04346329,ClinicalTrials.gov,2020-04-10,2020-04-20,FALSE,National University of Colombia,Not Recruiting,Phase 3,Interventional,Colombia,Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19,Drug (Chemoprophylaxis),Hydroxychloroquine,Hydroxychloroquine,86,https://clinicaltrials.gov/show/NCT04346329,,,2020-06-01,2020-10-01,2020-06-01,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-23 21:36:05,2020-11-23 21:42:26,IP Address,86.31.166.235,100,380,True,2020-11-23 21:42:26,R_bO9M3Dq10MwWc6t,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2021-04-01,2021-06-01,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Aurélien Mazeraud AND Polyvalent Immunoglobulin AND COVID-19,Polyvalent Immunoglobulin AND coronavirus AND ARds,,,,,,,,,MPJ,2020-06-30,NCT04350580,ClinicalTrials.gov,2020-04-08,2020-04-11,TRUE,Centre Hospitalier St. Anne,Recruiting,Phase 3,Interventional,France,Polyvalent Immunoglobulin in COVID-19 Related ARds,ATMP,Immunoglobulin,Immunoglobulin,138,https://clinicaltrials.gov/show/NCT04350580,EUCTR2020-001570-30,,2020-06-01,2020-08-01,2020-06-01,0,0,,,,,,,,,,,5,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2021-06-01
2020-11-23 22:27:12,2020-11-23 22:45:59,IP Address,158.181.77.106,100,1127,True,2020-11-23 22:45:59,R_PSNisUffd8ICvrr,,,test@test.com,,52.4983062744140625,13.5247039794921875,gl,EN,yes,yes,no,"""efficacy and safety"" of escrin, but primary outcome is mortality, so I believe yes to treatment of COVID-19",,no,2020-06-30,2020-12-30,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Escin AND covid AND Gallelli,,,,,,,,,,MSH,2020-06-30,NCT04322344,ClinicalTrials.gov,2020-03-23,2020-03-23,FALSE,University of Catanzaro,Recruiting,Phase 2/Phase 3,Interventional,Italy,Escin in Patients With Covid-19 Infection,Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,120,https://clinicaltrials.gov/show/NCT04322344,,1,2020-06-30,2020-08-30,2020-06-30,0,0,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,,2020-12-30
2020-11-23 22:47:17,2020-11-23 22:55:37,IP Address,158.181.77.106,100,500,True,2020-11-23 22:55:37,R_bPF0aJqzlQ3yWOd,,,test@test.com,,52.5363006591796875,13.416900634765625,gl,EN,yes,yes,no,,,no,2020-12-30,2021-06-15,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Angiotensin AND COVID AND ACTO,,,,,,,,,,MSH,2020-06-30,NCT04332666,ClinicalTrials.gov,2020-03-27,2020-03-31,FALSE,Erasme University Hospital,Not Recruiting,Phase 2/Phase 3,Interventional,No Country Given,"Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial",Drug,Angiotensin (1-7),Angiotensin (1-7),60,https://clinicaltrials.gov/show/NCT04332666,,1,2020-05-30,2020-06-15,2020-05-30,0,0,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,,2021-06-15
2020-11-23 23:58:52,2020-11-24 00:08:42,IP Address,81.109.92.226,100,589,True,2020-11-24 00:08:42,R_1O2cpeBMpTp6kTf,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,,10.21203/rs.3.rs-83677/v1,,https://www.researchsquare.com/article/rs-83677/v1,,,,,,,,,,,,,2020-09-29,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hany M Dabbous,Favipiravir AND Hydroxychloroquine AND COVID,,,,,,,,,ND,2020-06-30,NCT04349241,ClinicalTrials.gov,2020-04-13,2020-04-18,FALSE,Ain Shams University,Not Recruiting,Phase 3,Interventional,Egypt,Efficacy and Safety of Favipiravir in Management of COVID-19,Drug,Favipiravir,Favipiravir,100,https://clinicaltrials.gov/show/NCT04349241,,1,2020-06-01,2020-06-20,2020-06-01,0,0,,,,,,,,,,,3,,,,1,,,,,,,,,,,,,,true,
2020-11-24 00:09:01,2020-11-24 00:17:29,IP Address,81.109.92.226,100,507,True,2020-11-24 00:17:30,R_01xmnKIbB9u5StX,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,full_results_preprint,,,,,10.1101/2020.06.08.20124453,,https://www.medrxiv.org/content/10.1101/2020.06.08.20124453v1,,,,,,,,,,,,,2020-06-12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Make sure to remove the ""JPRN"" prefix before searching.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Yasunari Kageyama,Jinhua Qinggan Granule,,,,,,,,,ND,2020-06-30,JPRN-UMIN000040407,JPRN,2020-05-15,2020-05-15,FALSE,Takanawa Clinic,Not Recruiting,Not Applicable,Interventional,Japan,Immunological efficacy of Jinhua Qinggan Granule for COVID-19,Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,15,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046108,,1,,2020-05-20,2020-05-20,0,0,,,,,,,,,,,3,,,,1,,,,,,,,,,,,,,true,
2020-11-24 00:17:43,2020-11-24 00:19:50,IP Address,81.109.92.226,100,126,True,2020-11-24 00:19:51,R_3gNJj25z0ljdmmB,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,ISRCTN21363594,ISRCTN,2020-05-18,2020-05-01,TRUE,King Saud Medical City,Recruiting,Not Applicable,Interventional,"Saudi Arabia, Oman, United Arab Emirates",Therapeutic plasma exchange (removal of the non-cell portion of blood) in critically ill adult patients with serious SARS CoV-2 disease (COVID-19),ATMP,Plasma,Plasma,80,http://isrctn.com/ISRCTN21363594,,1,,2020-12-29,2020-12-29,0,1,,,,,,,,,,,3,,,,1,,,,,,,,,,,,,,,
2020-11-24 00:19:53,2020-11-24 00:43:04,IP Address,81.109.92.226,100,1390,True,2020-11-24 00:43:05,R_1C1Lyl6JtUPhu0B,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,full_results_journal_article,full_results_journal_article,,,,10.1056/NEJMoa2016638,32492293,,10.7326/M20-4207,32673060,,,,,,,,,,,2020-06-03,2020-05-06,2020-07-16,2020-06-15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,,,,,other,,,,,10.1093/ofid/ofaa500,33204764,,,,,,,,,,,,,,2020-10-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"This other publication notes that follow-up was completed on May 20, 2020 for this trial (for this publication it was grouped with another trial).",europe_pmc,,,,,other,,,,,10.1101/2020.07.16.20155531,,,,,,,,,,,,,,,2020-09-21,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,David Boulware,,,,,,,,,,ND,2020-06-30,NCT04308668,ClinicalTrials.gov,2020-03-11,2020-03-17,FALSE,University of Minnesota,Not Recruiting,Phase 3,Interventional,"United States, Canada",Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Drug (Chemoprophylaxis),Hydroxychloroquine,Hydroxychloroquine,1309,https://clinicaltrials.gov/show/NCT04308668,,1,2020-05-20,2020-05-20,2020-05-20,0,1,,32492293,,http://doi.org/10.1056/NEJMoa2016638,,,,,,,3,,,,1,,,,,,,,,,,,,true,,
2020-11-24 00:43:23,2020-11-24 00:44:25,IP Address,81.109.92.226,100,61,True,2020-11-24 00:44:25,R_3eykedN9mZ6yoER,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,no,,"A trial for safe endoscopy during covid, not anything directly related to covid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04389333,ClinicalTrials.gov,2020-05-09,2020-03-26,TRUE,Changhai Hospital,Recruiting,Not Applicable,Interventional,China,Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic,Other,Other,Other,40,https://clinicaltrials.gov/show/NCT04389333,,1,2020-04-26,2020-05-20,2020-04-26,0,0,,,,,,,,,,,3,,,,1,,,,,,,,,,,,,,,
2020-11-24 00:44:32,2020-11-24 00:54:20,IP Address,81.109.92.226,100,587,True,2020-11-24 00:54:20,R_egp5lo1WO8kGl2N,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andreas Buser,Amotosalen-Ultraviolet AND Plamsa AND Covid,Convalescent Plasma AND Basel,,,,,,,,ND,2020-06-30,NCT04389944,ClinicalTrials.gov,2020-05-12,2020-03-31,TRUE,"University Hospital, Basel",Recruiting,Not Applicable,Interventional,Switzerland,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19,ATMP,Plasma,Plasma,15,https://clinicaltrials.gov/show/NCT04389944,,1,2020-06-30,2020-06-30,2020-06-30,0,0,,,,,,,,,,,3,,,,1,,,,,,,,,,,,,,,
2020-11-24 00:56:12,2020-11-24 01:01:07,IP Address,81.109.92.226,100,294,True,2020-11-24 01:01:08,R_3HFYy1VM82itXG6,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,no,2020-05-15,2020-07-16,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Scott Sigman,"""Multiwave Locked System Laser"" AND Covid",,,,,,,,,ND,2020-06-30,NCT04391712,ClinicalTrials.gov,2020-05-04,2020-04-30,TRUE,Lowell General Hospital,Recruiting,Phase 2,Interventional,United States,Cold Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Other (device),Cold Laser Therapy,Cold Laser Therapy,20,https://clinicaltrials.gov/show/NCT04391712,,1,2020-05-30,2020-06-30,2020-05-30,0,0,,,,,,,,,,,3,,,,1,,,,,,,,,,,,,,,2020-07-16
2020-11-24 01:01:36,2020-11-24 01:03:53,IP Address,81.109.92.226,100,136,True,2020-11-24 01:03:54,R_3EnZtH0DXN31agF,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,no,2020-10-02,2020-10-02,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04366232,ClinicalTrials.gov,2020-04-27,2020-06-01,TRUE,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,Not Recruiting,Phase 2,Interventional,France,Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV),Drug,Anakinra + Ruxolitinib vs. Anakinra,Anakinra; Ruxolitinib,54,https://clinicaltrials.gov/show/NCT04366232,EUCTR2020-001963-10,1,2020-08-31,2020-08-31,2020-08-31,0,1,,,,,,,,,,,3,,,,1,,,,,,,,,,,,,,,2020-10-02
2020-11-24 01:04:17,2020-11-24 01:14:39,IP Address,81.109.92.226,100,621,True,2020-11-24 01:14:39,R_3EMxHhg0pQwzpa9,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,no,2020-08-09,2020-08-31,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"""Bromhexine Hydrochloride"" AND Covid",Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease,,,,,,,,,ND,2020-06-30,NCT04405999,ClinicalTrials.gov,2020-05-18,2020-05-14,TRUE,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",Recruiting,Phase 4,Interventional,Russian Federation,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease,Drug (Chemoprophylaxis),Bromhexine hydrochloride,Bromhexine hydrochloride,140,https://clinicaltrials.gov/show/NCT04405999,,1,2020-06-20,2020-09-30,2020-06-20,0,0,,,,,,,,,,,3,,,,1,,,,,,,,,,,,,,,2020-08-31
2020-11-24 10:54:03,2020-11-24 10:59:54,IP Address,86.31.166.235,100,350,True,2020-11-24 10:59:55,R_23dksln0ExfNzeN,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2021-08-01,2021-12-01,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Isotretinoin AND COVID-19 AND Tanta University,,,,,,,,,,MPJ,2020-06-30,NCT04361422,ClinicalTrials.gov,2020-04-21,2020-04-21,FALSE,Tanta University,Not Recruiting,Phase 3,Interventional,No Country Given,Isotretinoin in Treatment of COVID-19,Drug,Isotretinoin,Isotretinoin,300,https://clinicaltrials.gov/show/NCT04361422,,,2020-06-01,2020-09-01,2020-06-01,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,2021-12-01
2020-11-24 11:00:09,2020-11-24 11:02:23,IP Address,86.31.166.235,100,133,True,2020-11-24 11:02:24,R_3J7WIPKTaKccYAF,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04359810,ClinicalTrials.gov,2020-04-21,2020-04-21,FALSE,Max R. O'Donnell,Recruiting,Phase 2,Interventional,United States,Plasma Therapy of COVID-19 in Critically Ill Patients,ATMP,Plasma,Plasma,105,https://clinicaltrials.gov/show/NCT04359810,,,2020-12-01,2021-04-01,2020-12-01,0,1,,,,,,,,,,,5,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-24 00:56:00,2020-11-24 11:10:13,IP Address,129.67.118.199,100,36852,True,2020-11-24 11:10:13,R_2WC14bAfhrhR90O,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NOT A TRIAL,,,,,,,"Looking at the preprint, and then revisiting the registry, this is a retrospective case-control study, not a trial, and should be excluded for not being a trial.

https://www.medrxiv.org/content/10.1101/2020.05.21.20109512v2",team_review,,ND,2020-06-30,ChiCTR2000033056,ChiCTR,2020-05-19,2020-01-29,TRUE,Guizhou Provincial Jiangjunshan Hospital,Not Recruiting,Not Applicable,Interventional,China,Convalescent Plasma in the treatment of 6 COVID-19 Patients,ATMP,Plasma,Plasma,6,http://www.chictr.org.cn/showproj.aspx?proj=53859,,1,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,3,,,,1,,,,,,,,,,,,,,,
2020-11-24 11:02:36,2020-11-24 11:12:31,IP Address,86.31.166.235,100,594,True,2020-11-24 11:12:31,R_XM5mw8gjL7Hapyh,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,NA,NA,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Baharvand AND COVID-19 AND Mesenchymal Stem Cell ",ARDS AND coronavirus AND Royan Institute,,,,,,,,,MPJ,2020-06-30,NCT04366063,ClinicalTrials.gov,2020-04-20,2020-04-05,FALSE,Royan Institute,Recruiting,Phase 2/Phase 3,Interventional,Iran,Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome,ATMP,Cells (mesenchymal),Cells (mesenchymal),60,https://clinicaltrials.gov/show/NCT04366063,IRCT20200217046526N2,,2020-06-06,2020-12-10,2020-06-06,0,0,,,,,,,,,,,5,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-24 11:12:45,2020-11-24 11:23:04,IP Address,86.31.166.235,100,618,True,2020-11-24 11:23:04,R_3mfAtmlXNeisfPv,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-12-01,2021-01-01,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PROVID Study AND coronavirus AND ARDS,PROne Positioning AND COVID-19 AND Hôpitaux de Paris,,,,,,,,,MPJ,2020-06-30,NCT04366856,ClinicalTrials.gov,2020-04-26,2020-04-01,TRUE,Assistance Publique – Hôpitaux de Paris,Not Recruiting,Not Applicable,Interventional,France,PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study),Procedure,Positioning,Positioning,500,https://clinicaltrials.gov/show/NCT04366856,,,2020-05-01,2020-07-01,2020-05-01,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,2021-01-01
2020-11-24 11:10:25,2020-11-24 11:28:32,IP Address,129.67.118.199,100,1086,True,2020-11-24 11:28:32,R_ZsoccpnbgFArJRv,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google,,,,,full_results_journal_article,,,,,10.19540/j.cnki.cjcmm.20200430.501,,,,,,,,,,,,,,,2020-04-24,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"A review (https://doi.org/10.21203/rs.3.rs-32800/v1) turned up a reference to the publication of this study, referenced by trial ID, in the google search. I was able to track down the reference. Difficult to confirm as it's in Chinese but the abstract is in English and though it doesn't contain the same TCM intervention and relatively similar sample sizes.",europe_pmc,,,,,,,,,,10.1016/j.phymed.2020.153403,,https://europepmc.org/article/PMC/PMC7642754#free-full-text,,,,,,,,,,,,,2020-11-05,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Jinhao artemisia antipyretic granules,,,,,,,"Having found an English language version of this study, I no longer think this is a study of COVID. It's specifically a study of stopping the common cold to free-up capacity for COVID through TCM.",team_review,,ND,2020-06-30,ChiCTR2000029479,ChiCTR,2020-02-02,2020-01-30,TRUE,Hospital of Chengdu University of Traditional Chinese Medicine,Not Recruiting,Not Applicable,Interventional,China,Research for Traditional Chinese Medicine Technology Prevention and Control of Novel Coronavirus Pneumonia  (COVID-19) in the Community Population,Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,20000,http://www.chictr.org.cn/showproj.aspx?proj=48773,,1,,2020-05-01,2020-05-01,0,0,,,,,,,,,,,3,,,,1,,,,,,,,,,,,,true,,
2020-11-24 11:46:50,2020-11-24 11:48:30,IP Address,129.67.118.199,100,100,True,2020-11-24 11:48:31,R_3eyJmo9n1QVCPgR,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04372589,ClinicalTrials.gov,2020-04-24,2020-05-20,FALSE,University of Manitoba,Recruiting,Phase 2/Phase 3,Interventional,"Brazil, Mexico, United States, Canada",Antithrombotic Therapy to Ameliorate Complications of COVID-19 ( ATTACC ),Drug,Heparin,Heparin,3000,https://clinicaltrials.gov/show/NCT04372589,,1,2021-01-01,2021-01-01,2021-01-01,0,1,,,,,,,,,,,3,,,,1,,,,,,,,,,,,,,,
2020-11-24 11:48:45,2020-11-24 12:05:42,IP Address,129.67.118.199,100,1016,True,2020-11-24 12:05:42,R_2z6I1FuCXgrsZo4,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,google_scholar,google_scholar,,full_results_preprint,other,other,full_results_journal_article,,10.1101/2020.05.27.20110601,,https://www.medrxiv.org/content/10.1101/2020.05.27.20110601v1,,,https://www.preprints.org/manuscript/202009.0240/v1,,,http://revmedmilitar.sld.cu/index.php/mil/article/view/926/625,,,https://austinpublishinggroup.com/pharmacology-therapeutics/fulltext/ajpt-v8-id1119.php,,,,2020-06-02,,2020-09-11,,2020-09-30,,2020-09-17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,RPCEC00000313,RPCEC,2020-05-14,2020-03-31,TRUE,"Center for Genetic Engineering and Biotechnology (CIGB), Havana",Not Recruiting,Not Applicable,Interventional,Cuba,CIGB-258 at COVID-19,Drug,CIGB-258,CIGB-258,16,https://rpcec.sld.cu/en/trials/RPCEC00000313-En,,1,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,3,,,,1,,,,,,,,,,,,,true,true,
2020-11-24 12:05:54,2020-11-24 12:21:51,IP Address,129.67.118.199,100,956,True,2020-11-24 12:21:52,R_O9fehQmNeiP4HoB,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,,,,,full_results_preprint,,,,,10.1101/2020.09.03.20187112,,,,,,,,,,,,,,,2020-09-15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Leticia R. Cruz,"""Anti-CK2 Synthetic Peptide"" AND covid",,,,,,,,,ND,2020-06-30,RPCEC00000317,RPCEC,2020-05-28,2020-06-01,FALSE,"Center for Genetic Engineering and Biotechnology (CIGB), Havana",Not Recruiting,Phase 1/Phase 2,Interventional,Cuba,ATENEA-Co-300 study,Drug,CIGB-300,CIGB-300,20,https://rpcec.sld.cu/en/trials/RPCEC00000317-En,,1,,2020-06-29,2020-06-29,0,0,,,,,,,,,,,3,,,,1,,,,,,,,,,,,,,true,
2020-11-24 11:23:12,2020-11-24 12:26:28,IP Address,86.31.166.235,100,3795,True,2020-11-24 12:26:28,R_3RfrDOzopz1oGMi,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,unknown,yes,no,Prevention because its about the preventing spread of Covid-19 via droplets on medical equipment?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04366947,ClinicalTrials.gov,2020-04-23,2020-04-14,TRUE,Lazarski University,Not Recruiting,Not Applicable,Interventional,Poland,Intravascular Access in Suspected/Confirmed COVID-19 Patient,Other (device),Intraosseous/Intravenous access device,Intraosseous/Intravenous access device,60,https://clinicaltrials.gov/show/NCT04366947,,,2020-05-20,2020-05-20,2020-05-20,0,0,,,,,,,,,,,5,,"Active, not recruiting",TRUE,1,,,,,,,,,,,,,,,
2020-11-24 12:28:17,2020-11-24 12:36:41,IP Address,86.31.166.235,100,503,True,2020-11-24 12:36:41,R_3IVOr9DL17Moojt,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,,,,,full_results_journal_article,,,,,10.1097/CCE.0000000000000263,33134951,https://pubmed.ncbi.nlm.nih.gov/33134951/,,,,,,,,,,,,,2020-10-01,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Zuojiong Gong AND COVID-19 AND DAS181,,,,,,,,,,MPJ,2020-06-30,NCT04324489,ClinicalTrials.gov,2020-03-25,2020-03-06,TRUE,Renmin Hospital of Wuhan University,Not Recruiting,Not Applicable,Interventional,China,DAS181 for Severe COVID-19: Compassionate Use,Drug,DAS181,DAS181,4,https://clinicaltrials.gov/show/NCT04324489,,,2020-04-16,2020-04-30,2020-04-16,0,0,,,,,,,,,,,5,,Completed,TRUE,1,,,,,,,,,,,,,true,,
2020-11-24 12:36:51,2020-11-24 12:54:20,IP Address,86.31.166.235,100,1048,True,2020-11-24 12:54:20,R_Qb1QTCPqSiR5xap,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Interferon Beta AND COVID-19 AND Tehran ",Interferon Beta 1a AND compared to AND Interferon Beta 1b AND COVID-19,,,,,,"Could only find study protocol
",,,MPJ,2020-06-30,NCT04343768,ClinicalTrials.gov,2020-04-08,2020-04-09,FALSE,Shahid Beheshti University of Medical Sciences,Not Recruiting,Phase 2,Interventional,Iran,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial",Drug,Hydroxychloroquine + Lopinavir/ritonavir + interferon beta 1a vs. hydroxychloroquine + Lopinavir/ritonavir + interferon beta 1b vs. hydroxychloroquine + Lopinavir/ritonavir,Hydroxychloroquine; Lopinavir/ritonavir; interferon beta,60,https://clinicaltrials.gov/show/NCT04343768,,,2020-04-27,2020-04-27,2020-04-27,0,1,,,,,,,,,,,5,,Completed,TRUE,1,,,,,,,,,,,,,,,
2020-11-24 12:54:33,2020-11-24 12:55:29,IP Address,86.31.166.235,100,56,True,2020-11-24 12:55:30,R_1PcsaFHyuUrVhUs,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04340050,ClinicalTrials.gov,2020-04-07,2020-04-10,FALSE,University of Chicago,Not Recruiting,Phase 1,Interventional,United States,COVID-19 Convalescent Plasma,ATMP,Plasma,Plasma,10,https://clinicaltrials.gov/show/NCT04340050,,,2020-12-31,2021-12-31,2020-12-31,0,0,,,,10.1101/2020.06.21.20132944,,full_results_preprint,,,2020-06-23,,5,,"Active, not recruiting",TRUE,1,,full_results_preprint,2020-06-23,x2t5h5gu,http://medrxiv.org/cgi/content/short/2020.06.21.20132944v1?rss=1,Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial,,,,,,,,,
2020-11-24 12:55:38,2020-11-24 12:56:45,Spam,86.31.166.235,100,67,True,2020-11-24 12:56:45,R_12Q3P14YBNp0bco,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04340349,ClinicalTrials.gov,2020-04-02,2020-05-11,FALSE,Instituto Nacional de Rehabilitacion,Recruiting,Phase 1,Interventional,Mexico,Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals,Drug (Chemoprophylaxis),Hydroxychloroquine + bromhexine vs. bromhexine,Hydroxychloroquine; bromhexine,140,https://clinicaltrials.gov/show/NCT04340349,,,2020-07-20,2020-08-20,2020-07-20,0,1,,,,,,,,,,,5,,Enrolling by invitation,TRUE,1,,,,,,,,,,,,,,,
2020-11-24 12:56:56,2020-11-24 12:58:41,Spam,86.31.166.235,100,105,True,2020-11-24 12:58:42,R_2rHLpwHxtWp210X,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04385043,ClinicalTrials.gov,2020-05-04,2020-05-01,TRUE,University of Catanzaro,Recruiting,Phase 2/Phase 3,Interventional,Italy,Hyperimmune Plasma in Patients With COVID-19 Severe Infection,ATMP,Plasma,Plasma,400,https://clinicaltrials.gov/show/NCT04385043,,,2020-10-15,2021-05-15,2020-10-15,0,1,,,,,,,,,,,5,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-24 12:58:49,2020-11-24 13:01:38,IP Address,86.31.166.235,100,168,True,2020-11-24 13:01:39,R_xcs7lI8oIGpsrn3,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,full_results_journal_article,,,,,10.1016/S0140-6736(20)31208-3,32450106,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext,,,,,,,,,,,,,2020-06-13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04313127,ClinicalTrials.gov,2020-03-15,2020-03-16,FALSE,CanSino Biologics Inc.,Not Recruiting,Phase 1,Interventional,China,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,ATMP,Adenovirus vector,Adenovirus vector,108,https://clinicaltrials.gov/show/NCT04313127,,,2020-12-30,2022-12-20,2020-12-30,0,1,,,,10.1016/S0140-6736(20)31208-3,,full_results_journal_article,,,2020-05-22,,5,,"Active, not recruiting",TRUE,1,32450106,full_results_journal_article,2020-05-22,uj5deryi,https://doi.org/10.1016/s0140-6736(20)31208-3; https://www.sciencedirect.com/science/article/pii/S0140673620312083; https://www.ncbi.nlm.nih.gov/pubmed/32450106/; https://api.elsevier.com/content/article/pii/S0140673620312083,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",,,,,,,,,
2020-11-24 13:01:50,2020-11-24 13:03:48,IP Address,86.31.166.235,100,117,True,2020-11-24 13:03:48,R_3ITfVhMFtc4IbLu,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2021-07-27,2021-11-16,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04362059,ClinicalTrials.gov,2020-04-20,2020-06-27,TRUE,University Hospital Southampton NHS Foundation Trust,Not Recruiting,Not Applicable,Interventional,No Country Given,A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19,Drug,Bovactant,Bovactant,24,https://clinicaltrials.gov/show/NCT04362059,EUCTR2020-001886-35,,2020-07-27,2020-11-02,2020-07-27,0,1,,,,,,,,,,,5,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,2021-11-16
2020-11-24 13:04:05,2020-11-24 13:10:05,IP Address,86.31.166.235,100,360,True,2020-11-24 13:10:06,R_RDDx2CIu3swm1k5,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2021-05-27,2022-05-27,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hydroxychloroquine AND COVID-19 AND Brian Kendal,Hydroxychloroquine AND coronavirus AND Portland Providence Medical Center,,,,,,,,,MPJ,2020-06-30,NCT04334967,ClinicalTrials.gov,2020-04-02,2020-03-30,TRUE,Providence Health & Services,Not Recruiting,Phase 4,Interventional,United States,Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care,Drug,Hydroxychloroquine vs. Vitamin C,Hydroxychloroquine; Vitamin C,13,https://clinicaltrials.gov/show/NCT04334967,,,2020-05-27,2020-05-27,2020-05-27,0,0,,,,,,,,,,,5,,Suspended,TRUE,1,,,,,,,,,,,,,,,2022-05-27
2020-11-24 13:10:15,2020-11-24 13:11:34,IP Address,86.31.166.235,100,78,True,2020-11-24 13:11:35,R_3oX9cO4MSkBz5FL,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04370886,ClinicalTrials.gov,2020-04-28,2020-04-30,FALSE,Guangzhou Blood Center,Not Recruiting,Not Applicable,Interventional,China,Recruit Blood Donors Via SMS During Epidemic of COVID-19,Other,No Intervention,No Intervention,456517,https://clinicaltrials.gov/show/NCT04370886,,,2020-04-30,2020-05-10,2020-04-30,0,0,,,,,,,,,,,5,,Completed,TRUE,1,,,,,,,,,,,,,,,
2020-11-24 13:11:46,2020-11-24 13:16:26,IP Address,86.31.166.235,100,280,True,2020-11-24 13:16:26,R_3Ok2ok36MF4QZT6,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-08-05,2020-08-07,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Viusid AND Asbrip AND COVID-19 AND Wilson Benites,Teodoro Maldonado Carbo AND coronavirus AND efficacy,,,,,,,,,MPJ,2020-06-30,NCT04407182,ClinicalTrials.gov,2020-05-25,2020-05-04,TRUE,Catalysis SL,Recruiting,Phase 2,Interventional,Ecuador,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19,Supplement,Viusid + Asbrip,Viusid + Asbrip,60,https://clinicaltrials.gov/show/NCT04407182,,,2020-06-13,2020-06-15,2020-06-13,0,0,,,,,,,,,,,5,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2020-08-07
2020-11-24 13:16:38,2020-11-24 13:19:22,IP Address,86.31.166.235,100,164,True,2020-11-24 13:19:23,R_1MQU24PSBI66M2A,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Convalescent Plasma AND COVID-19 AND 	Nana Sarnadi,,,,,,,,,,MPJ,2020-06-30,NCT04407208,ClinicalTrials.gov,2020-05-16,2020-05-01,TRUE,Biofarma,Recruiting,Phase 1,Interventional,Indonesia,Convalescent Plasma Therapy in Patients With COVID-19,ATMP,Plasma,Plasma,10,https://clinicaltrials.gov/show/NCT04407208,,,2020-06-22,2020-06-22,2020-06-22,0,0,,,,,,,,,,,5,,Completed,TRUE,1,,,,,,,,,,,,,,,
2020-11-24 13:19:35,2020-11-24 13:24:51,IP Address,86.31.166.235,100,315,True,2020-11-24 13:24:52,R_Y05Q1ftP1nc0zhD,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2021-08-30,2021-09-15,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,," 10.21203/rs.3.rs-64465/v1 ",,https://www.researchsquare.com/article/rs-64465/v1,,,,,,,,,,,,,2020-09-08,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Convalescent Plasma AND COVID-19 AND Evangelos Terpos,,,,,,,,,,MPJ,2020-06-30,NCT04408209,ClinicalTrials.gov,2020-05-25,2020-04-23,TRUE,National and Kapodistrian University of Athens,Recruiting,Not Applicable,Interventional,Greece,Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection,ATMP,Plasma,Plasma,60,https://clinicaltrials.gov/show/NCT04408209,,,2020-06-30,2021-09-15,2020-06-30,0,0,,,,,,,,,,,5,,Recruiting,TRUE,1,,,,,,,,,,,,,,true,2021-09-15
2020-11-24 13:59:13,2020-11-24 14:02:31,IP Address,77.11.136.247,100,197,True,2020-11-24 14:02:31,R_3w3nhZ3ygjad7ep,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04352400,ClinicalTrials.gov,2020-04-03,2020-04-01,TRUE,University Hospital Padova,Not Recruiting,Phase 2/Phase 3,Interventional,No Country Given,Efficacy of Nafamostat in Covid-19 Patients (RACONA Study),Drug,Nafamostat,Nafamostat,256,https://clinicaltrials.gov/show/NCT04352400,,1,2021-12-01,2021-12-01,2021-12-01,0,1,,,,,,,,,,,1,,,,2,,,,,,,,,,,,,,,
2020-11-24 14:02:40,2020-11-24 14:06:35,IP Address,77.11.136.247,100,235,True,2020-11-24 14:06:36,R_2RaVshIz6jbOoYI,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"One study is linked in the registry, but it is only collecting early data that led to the initiation of said trial. ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04338958,ClinicalTrials.gov,2020-04-07,2020-04-22,TRUE,University of Jena,Recruiting,Phase 2,Interventional,Germany,Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation,Drug,Ruxolitinib,Ruxolitinib,200,https://clinicaltrials.gov/show/NCT04338958,EUCTR2020-001481-11,1,2021-01-31,2021-08-31,2021-01-31,0,1,,,,,,,,,,,1,,,,2,,,,,,,,,,,,,,,
2020-11-24 14:06:15,2020-11-24 14:12:13,IP Address,77.11.136.247,100,357,True,2020-11-24 14:12:13,R_sj7OS3yVC0PKuWJ,,,test@test.com,,52.5155029296875,13.4062042236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds (PEACE),Post-Exposure Prophylaxis COVID-19 Sarwar,NCT04346667 Sarwar,,,,,,,,PG,2020-06-30,NCT04346667,ClinicalTrials.gov,2020-04-13,2020-04-14,FALSE,"Government of Punjab, Specialized Healthcare and Medical Education Department",Recruiting,Phase 4,Interventional,Pakistan,Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds,Drug (Chemoprophylaxis),Hydroxychloroquine vs. Chloroquine,Hydroxychloroquine; chloroquine,400,https://clinicaltrials.gov/show/NCT04346667,,1,2020-05-30,2021-06-30,2020-05-30,0,0,,,,,,,,,,,1,,,,2,,,,,,,,,,,,,,,
2020-11-24 14:12:19,2020-11-24 14:13:36,IP Address,77.11.136.247,100,76,True,2020-11-24 14:13:36,R_2712mTVZNYYNMb2,,,test@test.com,,52.5155029296875,13.4062042236328125,gl,EN,yes,no,,"The purpose is to see if home pulse oximetry identifies disease progression and need for hospitalization in patients with COVID-19. Additionally, there will be analysis of trends in home oximetry readings wand predictors of morbidity and mortality.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,PG,2020-06-30,NCT04373161,ClinicalTrials.gov,2020-04-30,2020-03-20,TRUE,Swedish Hospital,Not Recruiting,Not Applicable,Interventional,United States,Home Pulse Oximeter Use in Patients With COVID-19,Other (device),Biosensors,Biosensors,209,https://clinicaltrials.gov/show/NCT04373161,,1,2020-04-22,2020-04-22,2020-04-22,0,0,,,,,,,,,,,1,,,,2,,,,,,,,,,,,,,,
2020-11-24 14:13:43,2020-11-24 14:15:02,IP Address,77.11.136.247,100,79,True,2020-11-24 14:15:03,R_1reObFvOqqKibMt,,,test@test.com,,52.5155029296875,13.4062042236328125,gl,EN,yes,no,,"Enrolment will be a onetime selection of 10 healthy volunteers - testing mask seeling not covid prevention, ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04375774,ClinicalTrials.gov,2020-04-17,2020-05-01,FALSE,"University Clinic, UCLouvain",Recruiting,Not Applicable,Interventional,Belgium,Verification of Alternative Do-it-yourself Equipment Respirators for the COVID-19 Personal Protective Equipment (PPE),Other (device),Masks,Masks,10,https://clinicaltrials.gov/show/NCT04375774,,1,2020-05-01,2020-05-01,2020-05-01,0,0,,,,,,,,,,,1,,,,2,,,,,,,,,,,,,,,
2020-11-24 14:15:11,2020-11-24 14:15:40,IP Address,77.11.136.247,100,29,True,2020-11-24 14:15:41,R_80q2OPmUo9KxORr,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,yes,no,,Calm Meditation App,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04374786,ClinicalTrials.gov,2020-05-01,2020-05-15,FALSE,University of Arizona,Recruiting,Not Applicable,Interventional,United States,Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic,Other (psych),Psychological,Psychological,328,https://clinicaltrials.gov/show/NCT04374786,,1,2020-09-01,2020-10-01,2020-09-01,0,1,,,,,,,,,,,1,,,,2,,,,,,,,,,,,,,,
2020-11-24 14:16:44,2020-11-24 14:35:50,IP Address,77.11.136.247,100,1145,True,2020-11-24 14:35:51,R_2uDqcSQaree10fo,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,yes,yes,no,,,no,2020-05-12,2020-07-09,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,,,,,,10.1101/2020.10.15.20213553,,https://europepmc.org/article/PPR/PPR227690,,,,,,,,,,,,,2020-10-20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"trial was initiated after promosing results from this trial: NCT04252118 ",google,,,,,full_results_preprint,,,,,10.2139/ssrn.3680611,,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3680611,,,,,,,,,,,,,2020-10-14,,,,,,,,,,,,,,,,,,,,,,,,,"weird...second full results preprint, published before v1 on medrxiv",,,,,,"A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Severe COVID-19 Patients",Fu-Sheng Wang Human Umbilical Cord-derived Mesenchymal Stem Cells covid,,,,,,,,,PG,2020-06-30,NCT04288102,ClinicalTrials.gov,2020-02-24,2020-03-05,FALSE,Beijing 302 Hospital,Not Recruiting,Phase 2,Interventional,China,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),ATMP,Cells (mesenchymal),Cells (mesenchymal),100,https://clinicaltrials.gov/show/NCT04288102,,1,2020-05-12,2020-07-10,2020-05-12,0,0,,,,,,,,,,,1,,,,2,,,,,,,,,,,,,,,2020-07-09
2020-11-24 14:36:21,2020-11-24 14:37:13,IP Address,77.11.136.247,100,51,True,2020-11-24 14:37:13,R_0wz43snlmq6oM9z,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,yes,yes,yes,"Recruitment Status : Suspended (Lack of enrollment) ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04325061,ClinicalTrials.gov,2020-03-25,2020-04-03,TRUE,Dr. Negrin University Hospital,Recruiting,Phase 4,Interventional,Spain,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Drug,Corticosteroids,Dexamethasone,200,https://clinicaltrials.gov/show/NCT04325061,EUCTR2020-001278-31,1,2020-10-30,2020-10-30,2020-10-30,0,1,,,,,,,,,,,4,,,,1,,,,,,,,,,,,,,,
2020-11-24 14:37:20,2020-11-24 14:45:48,IP Address,77.11.136.247,100,508,True,2020-11-24 14:45:49,R_24tI2OSG2JWLYJf,,,test@test.com,,52.5155029296875,13.4062042236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial (HERO),Hero covid Connor trial,,,,,"From late august: ""As with other HCQ prevention trials, HERO-HCQ enrollment has been hindered by commentary from politicians, the media, as well as retracted publications. With all the information out there, it is easy for people to become confused about HCQ. Our message in HERO-HCQ remains the same: HCQ is safe, generally well tolerated, and the question we are asking, is HCQ effective in preventing COVID-19, remains important."" https://heroesresearch.org/hero-hcq-continues-to-generate-evidence-on-prophylactic-use-of-hcq/ ",,,,PG,2020-06-30,NCT04352946,ClinicalTrials.gov,2020-04-16,2020-04-24,FALSE,GeoSentinel Foundation,Not Recruiting,Phase 3,Interventional,United States,HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial,Drug (Chemoprophylaxis),Hydroxychloroquine,Hydroxychloroquine,374,https://clinicaltrials.gov/show/NCT04352946,,1,2020-06-24,2020-08-24,2020-06-24,0,0,,,,,,,,,,,4,,,,1,,,,,,,,,,,,,,,
2020-11-24 14:46:08,2020-11-24 14:50:18,IP Address,77.11.136.247,100,249,True,2020-11-24 14:50:19,R_3HBMTuRRfEc4PBp,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Convalescent Plasma for COVID-19 Bernasconi,Convalescent Plasma for COVID-19 Bernasconi Bellinzona,Convalescent Plasma for the Treatment of Moderate-severe COVID-19: A Proof-of-principle Study,,,,,,,,PG,2020-06-30,NCT04365439,ClinicalTrials.gov,2020-04-18,2020-04-27,FALSE,Enos Bernasconi,Not Recruiting,Not Applicable,Interventional,No Country Given,Convalescent Plasma for COVID-19,ATMP,Plasma,Plasma,10,https://clinicaltrials.gov/show/NCT04365439,,1,2020-05-30,2020-06-30,2020-05-30,0,0,,,,,,,,,,,4,,,,1,,,,,,,,,,,,,,,
2020-11-24 14:50:26,2020-11-24 14:51:23,IP Address,77.11.136.247,100,57,True,2020-11-24 14:51:24,R_3Pn1KplaX2IG47O,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,yes,yes,yes,"Withdrawn (no authorization obtained) ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04365231,ClinicalTrials.gov,2020-04-23,2020-04-01,TRUE,"Hospital St. Joseph, Marseille",Not Recruiting,Phase 3,Interventional,France,Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial,Drug,Hydroxychloroquine + Azithromycin,Hydroxychloroquine; Azithromycin,50,https://clinicaltrials.gov/show/NCT04365231,,1,2020-06-01,2021-01-01,2020-06-01,0,0,,,,,,,,,,,4,,,,1,,,,,,,,,,,,,,,
2020-11-24 14:51:32,2020-11-24 14:52:02,IP Address,77.11.136.247,100,29,True,2020-11-24 14:52:03,R_yDqDG5Ad0lHUdPj,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,yes,no,,"The objectives of the study, are to describe detection of SARS-CoV-2 in the semen of COVID-19 positive patients, the duration of positive semen and to investigate the impact on semen quality, thereby providing insights into the early impact on male reproductive function",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04391829,ClinicalTrials.gov,2020-05-13,2020-05-12,TRUE,UZ Brussel,Not Recruiting,Not Applicable,Interventional,No Country Given,Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males,Clinical Presentation,No Intervention,No Intervention,20,https://clinicaltrials.gov/show/NCT04391829,,1,2020-07-15,2020-08-31,2020-07-15,0,1,,,,,,,,,,,4,,,,1,,,,,,,,,,,,,,,
2020-11-24 14:52:12,2020-11-24 14:53:20,IP Address,77.11.136.247,100,68,True,2020-11-24 14:53:21,R_1JCm2WGlIhMLgYj,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,yes,yes,yes,"Terminated (Study was stopped because the Promoter was changed and a new study on convalescent plasma promoted by AIFA was started in Italy.) ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Study terminated, not withdrawn, yet the actual enrolment was only 1 participant...how do we want to deal with that? ",team_review,,PG,2020-06-30,NCT04393727,ClinicalTrials.gov,2020-05-16,2020-05-01,TRUE,AOU Pisana,Recruiting,Phase 2,Interventional,Italy,Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19,ATMP,Plasma,Plasma,126,https://clinicaltrials.gov/show/NCT04393727,,1,2020-09-30,2020-10-30,2020-09-30,0,1,,,,,,,,,,,4,,,,1,,,,,,,,,,,,,,,
2020-11-24 14:53:29,2020-11-24 14:57:45,IP Address,77.11.136.247,100,256,True,2020-11-24 14:57:45,R_O7DeQfISPIYyGMV,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,yes,yes,no,,,no,2020-11-01,2020-11-01,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,no search needed,,,,,,,"I corrected the completion date as per updated registry entry...now completion date is not relevant for us anymore. However, I was still prompted to search. Not a biggie, still wanted to flag. ",,,PG,2020-06-30,NCT04374591,ClinicalTrials.gov,2020-05-02,2020-04-01,TRUE,Mansoura University,Not Recruiting,Phase 1,Interventional,Egypt,Home-based Treatment of Computed Tomography and Clinically Suspected Novel COVID-19 With Adjuvant Inhalable Sodium Bicarbonate: A Preliminary Case Series,Drug,Sodium Bicarbonate,Sodium Bicarbonate,40,https://clinicaltrials.gov/show/NCT04374591,,1,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,4,,,,1,,,,,,,,,,,,,,,2020-11-01
2020-11-24 14:58:08,2020-11-24 14:59:50,IP Address,86.31.166.235,100,101,True,2020-11-24 14:59:50,R_scFibTi8KCXbEnD,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,Not sure whether this is an intervention to treat/prevent Covid-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04410692,ClinicalTrials.gov,2020-05-27,2020-05-15,TRUE,"National University, Singapore",Not Recruiting,Not Applicable,Interventional,Singapore,Can the Prediction Market Improve Predictions of COVID-19?,Other,Other,Other,560,https://clinicaltrials.gov/show/NCT04410692,,,2020-05-16,2020-05-17,2020-05-16,0,0,,,,,,,,,,,5,,Completed,TRUE,1,,,,,,,,,,,,,,,
2020-11-24 15:00:03,2020-11-24 15:07:46,IP Address,86.31.166.235,100,462,True,2020-11-24 15:07:47,R_3Ear6YN8yyYZVn4,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,full_results_journal_article,,,,,10.1038/s41467-020-19056-6,33082342,https://www.nature.com/articles/s41467-020-19056-6,,,,,,,,,,,,,2020-10-20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,,10.21203/rs.3.rs-44055/v1,,https://www.researchsquare.com/article/rs-44055/v1,,,,,,,,,,,,,2020-07-17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04316377,ClinicalTrials.gov,2020-03-13,2020-03-25,FALSE,"University Hospital, Akershus",Not Recruiting,Phase 4,Interventional,Norway,Norwegian Coronavirus Disease 2019 Study,Drug,Hydroxychloroquine,Hydroxychloroquine,53,https://clinicaltrials.gov/show/NCT04316377,,,2020-05-25,2025-03-03,2020-05-25,0,1,,,,,,,,,,,5,,"Active, not recruiting",TRUE,1,,,,,,,,,,,,,true,true,
2020-11-24 15:07:57,2020-11-24 15:09:55,IP Address,86.31.166.235,100,118,True,2020-11-24 15:09:56,R_8djlxJTPlltxNfz,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04420260,ClinicalTrials.gov,2020-05-25,2020-07-01,FALSE,Unidad de Investigación Genética Molecular,Not Recruiting,Not Applicable,Interventional,No Country Given,Primary Prevention of Infection by COVID-19 in Health Providers,Drug (Chemoprophylaxis),"Oropharygeal spray, Immunostimulant",Oropharygeal spray; Immunostimulant,300,https://clinicaltrials.gov/show/NCT04420260,,,2020-09-01,2020-09-01,2020-09-01,0,1,,,,,,,,,,,5,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-24 15:10:09,2020-11-24 15:12:37,Spam,86.31.166.235,100,147,True,2020-11-24 15:12:38,R_0SyQNVWQFuBC9b3,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04395170,ClinicalTrials.gov,2020-05-15,2020-06-01,FALSE,Lifefactors Zona Franca,Not Recruiting,Phase 2/Phase 3,Interventional,Colombia,Convalescent Plasma Compared to Anti-COVID-19 Human Immunoglobulin and Standard Treatment (TE) in Hospitalized Patients,ATMP,Plasma vs. Immunoglobulin,Plasma; Immunoglobulin,75,https://clinicaltrials.gov/show/NCT04395170,,,2020-12-01,2021-06-01,2020-12-01,0,1,,,,,,,,,,,5,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-24 15:12:49,2020-11-24 15:18:45,IP Address,86.31.166.235,100,355,True,2020-11-24 15:18:45,R_2TtwmoiK3Fo2oeN,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Chloroquine AND Losartan AND COVID-19 AND Mexico,,,,,,,,,,MPJ,2020-06-30,NCT04428268,ClinicalTrials.gov,2020-04-26,2020-03-10,TRUE,Hospital Universitario Dr. Jose E. Gonzalez,Recruiting,Phase 2,Interventional,Mexico,Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia,Drug,Chloroquine vs. Chloroquine + Losartan,Chloroquine; Losartan,20,https://clinicaltrials.gov/show/NCT04428268,,,2020-06-10,2020-08-30,2020-06-10,0,0,,,,,,,,,,,5,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-24 15:19:08,2020-11-24 15:20:18,Spam,86.31.166.235,100,69,True,2020-11-24 15:20:18,R_08LDOMEpgxJLBh7,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04426201,ClinicalTrials.gov,2020-06-09,2020-06-22,FALSE,Revimmune,Not Recruiting,Phase 2,Interventional,No Country Given,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-O ),Drug,Interleukin-7,Interleukin-7,48,https://clinicaltrials.gov/show/NCT04426201,,,2020-11-30,2020-12-31,2020-11-30,0,1,,,,,,,,,,,5,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-24 15:21:37,2020-11-24 15:22:24,IP Address,86.31.166.235,100,46,True,2020-11-24 15:22:24,R_1JQGwI9LfVZB16V,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,Mobile app to combat stress,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04329533,ClinicalTrials.gov,2020-03-26,2020-04-13,FALSE,University of Arizona,Recruiting,Not Applicable,Interventional,United States,Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic,Other (psych),Psychological,Psychological,150,https://clinicaltrials.gov/show/NCT04329533,,,2020-06-30,2020-07-30,2020-06-30,0,0,,,,,,,,,,,5,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-24 15:22:38,2020-11-24 15:35:06,IP Address,86.31.166.235,100,747,True,2020-11-24 15:35:07,R_A5Vaa5AyrgWQpGx,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,full_results_journal_article,,,,,10.1001/jamainternmed.2020.6615," 33080005",https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2772186,,,,,,,,,,,,,2020-10-20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tocilizumab AND COVID-19 AND Costantini,"TCZ AND coronavirus AND pneumonia ",,,,,,,,,MPJ,2020-06-30,NCT04346355,ClinicalTrials.gov,2020-04-12,2020-03-31,TRUE,Azienda Unita Sanitaria Locale Reggio Emilia,Not Recruiting,Phase 2,Interventional,Italy,Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Drug,Tocilizumab,Tocilizumab,126,https://clinicaltrials.gov/show/NCT04346355,EUCTR2020-001386-37,,2020-06-06,2020-06-06,2020-06-06,0,0,,,,,,,,,,,5,,Terminated,TRUE,1,,,,,,,,,,,,,true,,
2020-11-24 15:35:24,2020-11-24 15:37:14,IP Address,86.31.166.235,100,109,True,2020-11-24 15:37:14,R_2CE4KYNdifEhikE,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-12-01,NA,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04353674,ClinicalTrials.gov,2020-04-07,2020-04-28,FALSE,Lawson Health Research Institute,Recruiting,Phase 1,Interventional,Canada,Modulation of Hyperinflammation in COVID-19,Other (device),Dialysis,Dialysis,40,https://clinicaltrials.gov/show/NCT04353674,,,2020-07-28,2021-01-01,2020-07-28,0,1,,,,,,,,,,,5,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2020-12-01
2020-11-24 15:37:33,2020-11-24 15:38:14,IP Address,86.31.166.235,100,40,True,2020-11-24 15:38:14,R_2wFi3Xz6r3SW329,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04371419,ClinicalTrials.gov,2020-04-28,2020-05-13,FALSE,"National Bureau of Economic Research, Inc.",Not Recruiting,Not Applicable,Interventional,United States,COVID-19 Health Messaging to Underserved Communities,Other,Health Education,Health Education,15475,https://clinicaltrials.gov/show/NCT04371419,,,2020-05-24,2020-05-24,2020-05-24,0,0,,,,,,,,,,,5,,Completed,TRUE,1,,,,,,,,,,,,,,,
2020-11-24 15:38:22,2020-11-24 15:40:02,Spam,86.31.166.235,100,100,True,2020-11-24 15:40:03,R_ODpcO3bfN5Qu5AR,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04432103,ClinicalTrials.gov,2020-06-12,2020-06-19,FALSE,Centro Medico ABC,Not Recruiting,Phase 3,Interventional,No Country Given,Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma,ATMP,Plasma,Plasma,36,https://clinicaltrials.gov/show/NCT04432103,,,2020-07-30,2020-09-30,2020-07-30,0,1,,,,,,,,,,,5,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-24 15:40:10,2020-11-24 15:51:54,IP Address,86.31.166.235,100,704,True,2020-11-24 15:51:55,R_1lmd1Hm0vkiatMI,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,google,,,,full_results_journal_article,full_results_preprint,,,,,32920571,,10.1101/2020.06.24.20121905,,https://www.medrxiv.org/content/10.1101/2020.06.24.20121905v2,,,,,,,,,,2020-09-01,,2020-06-30,,,,,,,,,,,,,,,,,,,,,,,"Cannot gain access to full text ",,,,,,"Convalescent Plasma Therapy AND COVID-19 AND Iraq ",,,,,,,,,,MPJ,2020-06-30,NCT04441424,ClinicalTrials.gov,2020-06-12,2020-04-03,TRUE,Alkarkh Health Directorate-Baghdad,Not Recruiting,Not Applicable,Interventional,Iraq,Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients,ATMP (+ Drug),Plasma + Hydroxychloroquine + Azithromycin vs. Hydroxychloroquine + Azithromycin,Plasma; Hydroxychloroquine; Azithromycin,49,https://clinicaltrials.gov/show/NCT04441424,,,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,5,,Completed,TRUE,1,,,,,,,,,,,,,,,
2020-11-24 15:53:05,2020-11-24 15:59:04,IP Address,86.31.166.235,100,359,True,2020-11-24 15:59:05,R_1FwFvp3NneWYlNf,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,,,,,full_results_journal_article,,,,,10.1002/advs.202001435,32837847,https://onlinelibrary.wiley.com/doi/10.1002/advs.202001435,,,,,,,,,,,,,2020-07-14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"azvudine AND COVID-19 AND pneumonia AND Guangzhong ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029853,ChiCTR,2020-02-15,2020-02-16,FALSE,People's Hospital of Guangshan County,Recruiting,Not Applicable,Interventional,China,"A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)",Drug,Azvudine,Azvudine,20,http://www.chictr.org.cn/showproj.aspx?proj=49532,,,,2020-04-16,2020-04-16,0,0,,,,,,,,,,,5,,Recruiting,TRUE,1,,,,,,,,,,,,,true,,
2020-11-24 15:59:16,2020-11-24 16:08:22,IP Address,86.31.166.235,100,545,True,2020-11-24 16:08:23,R_2pS6lLl4HhFcerF,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,,"10.1101/2020.08.02.20166710 ",,https://www.medrxiv.org/content/10.1101/2020.08.02.20166710v1,,,,,,,,,,,,,2020-08-04,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"COVID-19 AND pneumonia AND plasma AND  Zhang ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030627,ChiCTR,2020-03-08,2020-02-01,TRUE,The First Affiliated Hospital of Zhengzhou University,Recruiting,Not Applicable,Interventional,China,Study for using the healed novel coronavirus pneumonia (COVID-19) patients plasma in the treatment of severe critical cases,ATMP,Plasma,Plasma,30,http://www.chictr.org.cn/showproj.aspx?proj=50727,,,,2020-05-30,2020-05-30,0,0,,,,,,,,,,,5,,Recruiting,TRUE,1,,,,,,,,,,,,,,true,
2020-11-24 16:30:20,2020-11-24 16:49:05,IP Address,77.11.136.247,100,1124,True,2020-11-24 16:49:05,R_2YfYykP9Jad4XCF,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,yes,yes,no,,,no,2020-09-29,2020-09-29,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ivermectin COVID-19 Phoenix,Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19  Lanusse,Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19 argentina,,,,"The trial was referenced in another publication by the authors (https://europepmc.org/article/PPR/PPR230035)

Additionally, we have recently demonstrated the concentration-dependent IVM effect on the viral clearance in a controlled clinical trial in COVID-19 infected patients (11)

--> These results are not publicly retrievable anywhere though. ",,,,PG,2020-06-30,NCT04381884,ClinicalTrials.gov,2020-05-05,2020-05-18,FALSE,Laboratorio Elea,Recruiting,Phase 2,Interventional,Argentina,Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,Drug,Ivermectin,Ivermectin,45,https://clinicaltrials.gov/show/NCT04381884,,1,2020-06-30,2020-06-30,2020-06-30,0,0,,,,,,,,,,,4,,,,1,,,,,,,,,,,,,,,2020-09-29
2020-11-24 16:49:13,2020-11-24 16:59:53,IP Address,77.11.136.247,100,640,True,2020-11-24 16:59:54,R_2zBEwa38zxjlfWX,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,yes,yes,no," Terminated (Terminated early because no patients were further enrolled since mid-Apr 2020.) ",,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sung-Han Kim mild COVID-19 Comparison of Lopinavir/Ritonavir or Hydroxychloroquine,Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),,,,,,"no results for this terminated trial found, would be cool though, it is one of the only ones with mild COVID. ",,,PG,2020-06-30,NCT04307693,ClinicalTrials.gov,2020-03-10,2020-03-11,FALSE,Asan Medical Center,Not Recruiting,Phase 2,Interventional,South Korea,Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Drug,Lopinavir/ritonavir vs. hydroxychloroquine,Lopinavir/ritonavir; Hydroxychloroquine,65,https://clinicaltrials.gov/show/NCT04307693,,1,2020-04-30,2020-04-30,2020-04-30,0,0,,,,,,,,,,,4,,,,1,,,,,,,,,,,,,,,
2020-11-24 16:54:35,2020-11-24 17:00:53,IP Address,86.31.166.235,100,377,True,2020-11-24 17:00:54,R_1LTJPhvdjOGMjcl,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"oXiris Membrane AND COVID-19 AND Xuemei Li ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030477,ChiCTR,2020-03-03,2020-03-04,FALSE,Chinese Academy of Medical Sciences Peking Union Medical College Hospital,Not Recruiting,Not Applicable,Interventional,China,oXiris Membrane in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19),Traditional Medicine (Other),Traditional Medicine,Traditional Medicine,19,http://www.chictr.org.cn/showproj.aspx?proj=50458,,,,2020-06-25,2020-06-25,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-24 17:00:01,2020-11-24 17:02:34,IP Address,77.11.136.247,100,152,True,2020-11-24 17:02:34,R_1Qc6GO80uURmQPv,,,test@test.com,,52.5155029296875,13.4062042236328125,gl,EN,yes,yes,no,,,no,2020-11-21,2021-04-21,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Study protocol published here: Desilles JP, Gregoire C, Le Cossec C, Lambert J, Mophawe O, Losser MR, Lambiotte F, Le Tacon S, Cantier M, Engrand N, Trouiller P, Pottecher J. Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jun 19;21(1):548. doi: 10.1186/s13063-020-04488-8.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04355364,ClinicalTrials.gov,2020-04-15,2020-04-21,FALSE,Fondation Ophtalmologique Adolphe de Rothschild,Recruiting,Phase 3,Interventional,France,Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alfa Administration in Patients With COVID19-induced ARDS (COVIDORNASE),Drug,Dornase alfa,Dornase alfa,100,https://clinicaltrials.gov/show/NCT04355364,,1,2020-08-21,2020-08-21,2020-08-21,0,1,,,,,,,,,,,4,,,,1,,,,,,,,,,,,,,,2021-04-21
2020-11-24 17:03:54,2020-11-24 17:07:49,IP Address,77.11.136.247,100,235,True,2020-11-24 17:07:50,R_2xWA8a1oBQdCx3B,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,yes,yes,no,(DisCoVeRy),,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Discovery trial, clearly the completion date is way in the future, but interim results maybe published already. ",,,PG,2020-06-30,NCT04315948,ClinicalTrials.gov,2020-03-13,2020-03-22,TRUE,INSERM,Recruiting,Phase 3,Interventional,"France, Luxembourg",Trial of Treatments for COVID-19 in Hospitalized Adults,Drug,Remdesivir vs. Lopinavir/ritonavir vs. Lopinavir/ritonavir + Interferon beta vs. Hydroxychloroquine,Remdesivir; Lopinavir/ritonavir; Interferon beta; Hydroxychloroquine,3100,https://clinicaltrials.gov/show/NCT04315948,EUCTR2020-000936-23,1,2023-03-01,2023-03-01,2023-03-01,0,1,,,,,,,,,,,4,,,,1,,,,,,,,,,,,,,,
2020-11-24 17:07:57,2020-11-24 17:08:38,IP Address,77.11.136.247,100,40,True,2020-11-24 17:08:38,R_0OIzG5f90AfHpD3,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,yes,no,," Mental Health & Psychosocial Support Module (MHPSS) in Reduction of Depression, Anxiety and Stress among Healthcare Workers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,trial of  Mental Health & Psychosocial Support Module (MHPSS),,,PG,2020-06-30,TCTR20200601002,TCTR,2020-05-28,2020-06-01,FALSE,Self-sponsored,Recruiting,Not Applicable,Interventional,Malaysia,"A Randomized Controlled Trial on Effectiveness of Mental Health & Psychosocial Support Module (MHPSS) in Reduction of Depression, Anxiety and Stress among Healthcare Workers during COVID-19 Pandemic in Jerantut, Pahang",Other (psych),Psychological,Psychological,110,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=6322,,1,2020-06-30,2020-06-30,2020-06-30,0,0,,,,,,,,,,,4,,,,1,,,,,,,,,,,,,,,
2020-11-24 17:08:44,2020-11-24 17:10:16,IP Address,77.11.136.247,100,92,True,2020-11-24 17:10:16,R_26m9Fn2bNNGyzn2,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Protocol/rationale published here:

Gommans DHF, Nas J, Pinto-Sietsma SJ, Koop Y, Konst RE, Mensink F, Aarts GWA, Konijnenberg LSF, Cortenbach K, Verhaert DVM, Thannhauser J, Mol JQ, Rooijakkers MJP, Vos JL, van Rumund A, Vart P, Hassing RJ, Cornel JH, de Jager CPC, van den Heuvel MM, van der Hoeven HG, Verbon A, Pinto YM, van Royen N, van Kimmenade RRJ; Event committee, de Leeuw PW, van Agtmael MA, Bresser P; Data Safety Monitoring Board, van Gilst WH, Vonk-Noordergraaf A, Tijssen JGP; Steering committee, van Royen N, de Jager CPC, van den Heuvel MM, van der Hoeven HG, Verbon A, Pinto YM, van Kimmenade RRJ. Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease. Am Heart J. 2020 Aug;226:60-68. doi: 10.1016/j.ahj.2020.05.010. Epub 2020 May 21. ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04335786,ClinicalTrials.gov,2020-04-02,2020-04-17,TRUE,Radboud University,Recruiting,Phase 4,Interventional,Netherlands,Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease,Drug,Valsartan,Valsartan,651,https://clinicaltrials.gov/show/NCT04335786,EUCTR2020-001320-34,1,2020-12-01,2021-12-01,2020-12-01,0,1,,,,,,,,,,,4,,,,1,,,,,,,,,,,,,,,
2020-11-24 17:10:22,2020-11-24 17:10:58,IP Address,77.11.136.247,100,36,True,2020-11-24 17:10:58,R_RxmhD5QnVwsvkYh,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,yes,no,," machine learning algorithm for the prediction of outcomes in COVID-19 patients",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,," machine learning algorithm for the prediction of outcomes in COVID-19 patients",,,PG,2020-06-30,NCT04390516,ClinicalTrials.gov,2020-05-14,2020-03-24,TRUE,Dascena,Not Recruiting,Not Applicable,Interventional,United States,Respiratory Decompensation and Model for the Triage of COVID-19 Patients,Prognosis,No Intervention,No Intervention,197,https://clinicaltrials.gov/show/NCT04390516,,1,2020-05-04,2020-05-30,2020-05-04,0,0,,,,,,,,,,,4,,,,1,,,,,,,,,,,,,,,
2020-11-24 17:11:03,2020-11-24 17:11:57,IP Address,77.11.136.247,100,54,True,2020-11-24 17:11:58,R_28HzKSz2wfBhW5V,,,test@test.com,,52.5155029296875,13.4062042236328125,gl,EN,yes,no,,compare the need for face-to-face re-consultation after discharge for COVID-19 between a telematic monitoring through a mobile app and the regular primary care setting.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Open-label randomized clinical trial, one center, to compare the need for face-to-face re-consultation after discharge for COVID-19 between a telematic monitoring through a mobile app and the regular primary care setting.",,,PG,2020-06-30,NCT04423289,ClinicalTrials.gov,2020-06-06,2020-03-31,TRUE,Vall d'Hebron Research Institute (VHIR),Not Recruiting,Not Applicable,Interventional,Spain,Telematic Monitoring Through a Mobile Application of Patients With COVID-19,Other (software),eHealth,eHealth,150,https://clinicaltrials.gov/show/NCT04423289,,1,2020-05-04,2020-05-18,2020-05-04,0,0,,,,,,,,,,,4,,,,1,,,,,,,,,,,,,,,
2020-11-24 17:12:03,2020-11-24 17:18:35,IP Address,77.11.136.247,100,392,True,2020-11-24 17:18:36,R_3DvB64IYlLnrFqS,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,yes,yes,no," Terminated (Currently, almost no patients admitted to Dutch hospitals. If any effect of HCQ is to be expected we need more than 1000 inclusions) ",,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"UMC Utrecht  archaic covid trial ",,,,,,,"https://onlinelibrary.wiley.com/doi/full/10.1111/eci.13297 --> Protocol

This study was terminated with 25 patients included: https://www.umcutrecht.nl/en/over-ons/nieuws/infection-and-immunity/jun-10-dutch-study-into-anti-malarial-drug-against-covid-19-discontinued ",team_review,,PG,2020-06-30,NCT04362332,ClinicalTrials.gov,2020-04-20,2020-04-14,TRUE,UMC Utrecht,Not Recruiting,Phase 4,Interventional,Netherlands,"Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19",Drug,Chloroquine vs. hydroxychloroquine,Chloroquine; hydroxychloroquine,25,https://clinicaltrials.gov/show/NCT04362332,,1,2020-06-08,2020-06-08,2020-06-08,0,0,,,,,,,,,,,4,,,,1,,,,,,,,,,,,,,,
2020-11-24 17:18:41,2020-11-24 17:23:27,IP Address,77.11.136.247,100,285,True,2020-11-24 17:23:28,R_1cZZTBD8jZMojgm,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,yes,no,,"This is a trial on sonography , not sure why they randomized and called it interventional even...",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"I think now I got it: They aim to improve the position of the tube via ultrasound of intubated COVID-19 ARDS patients. 

THis is not treatment or prevention of COVID per se, though: Exclude ",team_review,,PG,2020-06-30,NCT04432051,ClinicalTrials.gov,2020-06-11,2020-05-26,TRUE,Gaziosmanpasa Taksim Research and Education Hospital,Recruiting,Not Applicable,Interventional,Turkey,The Use of Lung Ultrasonography in COVID-19 Patients,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,100,https://clinicaltrials.gov/show/NCT04432051,,1,2020-06-20,2020-06-26,2020-06-20,0,0,,,,,,,,,,,4,,,,1,,,,,,,,,,,,,,,
2020-11-24 17:23:35,2020-11-24 17:24:19,IP Address,77.11.136.247,100,43,True,2020-11-24 17:24:19,R_1LbwsGwSsHwgWCs,,,test@test.com,,52.5155029296875,13.4062042236328125,gl,EN,yes,no,,Residents in homeless shelters will be randomized to 4 different COVID-19 screening strategies with the primary outcome being COVID-19 detection rate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Diagnostic testing strategy trial,,,PG,2020-06-30,NCT04438070,ClinicalTrials.gov,2020-06-17,2020-04-10,TRUE,St. Joseph's Healthcare Hamilton,Recruiting,Not Applicable,Interventional,Canada,COVID Screening Strategies in Homeless Shelters,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,400,https://clinicaltrials.gov/show/NCT04438070,,1,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,4,,,,1,,,,,,,,,,,,,,,
2020-11-24 17:24:24,2020-11-24 17:25:27,IP Address,77.11.136.247,100,63,True,2020-11-24 17:25:27,R_3pcoezBP8Skjuxv,,,test@test.com,,52.5155029296875,13.4062042236328125,gl,EN,yes,no,,Screening trial,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Screening,,,PG,2020-06-30,NCT04441684,ClinicalTrials.gov,2020-05-20,2020-04-17,TRUE,"University Hospital, Strasbourg",Recruiting,Not Applicable,Interventional,France,"Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)",Clinical Presentation (Epidemiology),No Intervention,No Intervention,1800,https://clinicaltrials.gov/show/NCT04441684,,1,2020-05-07,2021-08-01,2020-05-07,0,0,,,,,,,,,,,4,,,,1,,,,,,,,,,,,,,,
2020-11-24 18:08:15,2020-11-24 18:16:15,IP Address,86.31.166.235,100,480,True,2020-11-24 18:16:16,R_2U9hHW5y1TNmq4v,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,There was a download link but the file would not open,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Chinese medicine AND COVID-19 AND Chengping Wen ",Zhejiang Chinese Medical University AND coronavirus AND pneumonia,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029578,ChiCTR,2020-02-05,2020-02-06,FALSE,Zhejiang Chinese Medical University,Recruiting,Not Applicable,Interventional,China,"Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, sing-arm trial",Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,1000,http://www.chictr.org.cn/showproj.aspx?proj=49080,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,5,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-24 18:16:28,2020-11-24 18:21:05,IP Address,86.31.166.235,100,277,True,2020-11-24 18:21:06,R_2WHhldeSOlr3sos,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Su Wen AND Gu-Biao Jie-Du-Ling AND coronavirus,"Gu-Biao Jie-Du-Ling AND COVID-19 AND children ",,,,,,,,,MPJ,2020-06-30,ChiCTR2000029487,ChiCTR,2020-02-02,2020-02-10,FALSE,Wuhan Hospital of Integrated Traditional Chinese and Western Medicine,Not Recruiting,Not Applicable,Prevention,China,Clinical Study for Gu-Biao Jie-Du-Ling in Preventing of Novel Coronavirus Pneumonia (COVID-19) in Children,Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,200,http://www.chictr.org.cn/showproj.aspx?proj=48965,,,,2020-03-31,2020-03-31,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-24 18:21:14,2020-11-24 18:22:17,IP Address,86.31.166.235,100,63,True,2020-11-24 18:22:18,R_26bA110Z7wen4MM,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029381,ChiCTR,2020-01-27,2020-01-24,TRUE,The First Affiliated Hospital of Guangzhou Medical University,Not Recruiting,Phase 4,Interventional,China,A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,400,http://www.chictr.org.cn/showproj.aspx?proj=48768,,,,2020-12-31,2020-12-31,0,0,,,,10.3760/cma.j.cn121430-20200406-00386,,full_results_journal_article,,,2020-04-28,,5,,Completed,TRUE,1,32527346,full_results_journal_article,2020-04-28,,,,,,,,,,,,
2020-11-24 23:13:12,2020-11-24 23:23:51,IP Address,86.31.166.235,100,638,True,2020-11-24 23:23:51,R_Rf5EbLWn7oAITLj,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"COVID-19 AND inactivated plasma AND Binghong Zhang ",Wuhan University AND coronavirus AND pneumonia,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030929,ChiCTR,2020-03-17,2020-03-17,FALSE,Renmin Hospital of Wuhan University,Not Recruiting,Not Applicable,Interventional,China,"A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19)",ATMP,Plasma,Plasma,60,http://www.chictr.org.cn/showproj.aspx?proj=50696,,,,2020-06-16,2020-06-16,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-24 23:24:02,2020-11-24 23:28:47,IP Address,86.31.166.235,100,284,True,2020-11-24 23:28:47,R_R7TZf3s3Pw72jzb,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bai-Du Duan Fang AND COVID-19 AND pneumonia,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030940,ChiCTR,2020-03-18,2020-02-01,TRUE,Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Not Recruiting,Not Applicable,Interventional,China,Study for ''Bai-Du Duan Fang'' application on the acupoint in the treatment of general type novel coronavirus pneumonia (COVID-19),Traditional Medicine (Other),Traditional Medicine,Traditional Medicine,76,http://www.chictr.org.cn/showproj.aspx?proj=51061,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-24 23:28:57,2020-11-24 23:33:43,IP Address,86.31.166.235,100,286,True,2020-11-24 23:33:43,R_2Wx22cJKtdmXbbo,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sleep psychology AND music therapy AND COVID-19,,,,,,,"Not 100% sure if this should be included as treatment? ",team_review,,MPJ,2020-06-30,ChiCTR2000031328,ChiCTR,2020-03-27,2020-03-13,TRUE,The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Recruiting,Not Applicable,Interventional,China,The protective effect of sleep psychology and music therapy of novel coronavirus pneumonia (COVID-19) mild and moderate type patients,Other,Sleep aids,Sleep aids,60,http://www.chictr.org.cn/showproj.aspx?proj=51425,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,5,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-24 23:33:50,2020-11-24 23:34:51,IP Address,86.31.166.235,100,61,True,2020-11-24 23:34:51,R_rrq02Le0AXMZTVf,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,prevention and treatment of facial injuries from wearing protective respirators during the pandemic - not of covid itself,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000032013,ChiCTR,2020-04-17,2020-02-02,TRUE,The Fourth Medical Center of PLA General Hospital,Not Recruiting,Not Applicable,Interventional,China,The prevention and treatment strategy of the protective respirator related facial pressure injuries among healthcare professionals fighting novel coronavirus pneumonia (COVID-19),Other (physical),Mechanical ventilation,Mechanical ventilation,8,http://www.chictr.org.cn/showproj.aspx?proj=52483,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,5,,Completed,TRUE,1,,,,,,,,,,,,,,,
2020-11-25 10:04:04,2020-11-25 10:12:27,IP Address,158.181.77.106,100,502,True,2020-11-25 10:12:27,R_Bt5lROv9siJkJON,,,test@test.com,,52.4983062744140625,13.5247039794921875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Protocol: https://doi.org/10.1016/j.hjc.2020.03.002,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04326790,ClinicalTrials.gov,2020-03-26,2020-04-03,TRUE,National and Kapodistrian University of Athens,Recruiting,Phase 2,Interventional,Gibraltar,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,Drug,Colchicine,Colchicine,180,https://clinicaltrials.gov/show/NCT04326790,EUCTR2020-001455-40,1,2020-08-31,2020-09-30,2020-08-31,0,1,,32579195,,http://doi.org/10.1001/jamanetworkopen.2020.13136,,,,,,,3,,,,2,,,,,,,,,,,,,,,
2020-11-25 10:12:51,2020-11-25 10:26:06,IP Address,158.181.77.106,100,795,True,2020-11-25 10:26:07,R_YXEIdMG4KoA5jax,,,test@test.com,,52.4983062744140625,13.5247039794921875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nintedanib AND COVID AND Zhang,"Nintedanib AND COVID AND Zhang AND ""Pulmonary Fibrosis""",,,,,,,,,MSH,2020-06-30,NCT04338802,ClinicalTrials.gov,2020-04-01,2020-04-02,FALSE,Huilan Zhang,Not Recruiting,Phase 2,Interventional,No Country Given,Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19,Drug,Nintedanib,Nintedanib,96,https://clinicaltrials.gov/show/NCT04338802,,1,2020-05-04,2020-08-01,2020-05-04,0,0,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,,
2020-11-25 10:34:37,2020-11-25 10:42:57,IP Address,86.31.166.235,100,499,True,2020-11-25 10:42:58,R_eULQ1QYVndXUWB3,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Interferon alpha 1b AND COVID-19 AND elderly,Recombinant Human Interferon AND Feng Cao AND coronavirus,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029989,ChiCTR,2020-02-18,2020-02-20,FALSE,Chinese PLA General Hospital,Not Recruiting,Phase 4,Interventional,China,A randomized controlled Trial for therapeutic efficacy of Recombinant Human Interferon alpha 1b Eye Drops in the treatment of elderly with novel coronavirus pneumonia (COVID-19),Drug,Interferon alfa,Interferon alfa,300,http://www.chictr.org.cn/showproj.aspx?proj=49720,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-25 10:43:51,2020-11-25 10:54:47,IP Address,86.31.166.235,100,655,True,2020-11-25 10:54:48,R_2VluA4HkKCymjyA,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Xiangxue antiviral AND Wu-Zhi-Fang-Guan-Fang AND COVID-19 ",Feng Wang AND coronavirus AND Traditional Chinese Medicine,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030033,ChiCTR,2020-02-21,2020-02-24,FALSE,The First Affiliated Hospital of Guangzhou Medical University,Not Recruiting,Not Applicable,Interventional,China,A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,828,http://www.chictr.org.cn/showproj.aspx?proj=49703,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-25 10:26:15,2020-11-25 10:57:23,IP Address,158.181.77.106,100,1868,True,2020-11-25 10:57:24,R_3lJQ5fFc5Qn9ZkE,,,test@test.com,,52.4983062744140625,13.5247039794921875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,full_results_journal_article,,,,,10.7326/M20-4207,32673060,https://www.acpjournals.org/doi/10.7326/M20-4207,,,,,,,,,,,,,2020-07-16,2020-06-15,,,,,,,,,,,,,,,,,,,,,,,,"last patient last date is not last data, so chose later date: ""follow-up concluded on 20 May, and final hospital outcomes were known by 15 June 2020""",,,,,,Protocol: https://doi.org/10.1007/s12630-020-01684-7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Secondary analysis: https://doi.org/10.1093/ofid/ofaa500,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NCT04308668 AND preprint AND (Boulware OR Skipper),,,,,,,,,,MSH,2020-06-30,NCT04308668,ClinicalTrials.gov,2020-03-11,2020-03-17,FALSE,University of Minnesota,Not Recruiting,Phase 3,Interventional,"United States, Canada",Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Drug (Chemoprophylaxis),Hydroxychloroquine,Hydroxychloroquine,1309,https://clinicaltrials.gov/show/NCT04308668,,1,2020-05-20,2020-05-20,2020-05-20,0,1,,32492293,,http://doi.org/10.1056/NEJMoa2016638,,,,,,,3,,,,2,,,,,,,,,,,,,true,,
2020-11-25 10:54:54,2020-11-25 11:04:40,IP Address,86.31.166.235,100,586,True,2020-11-25 11:04:41,R_1I9LgTg91bIzKN4,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,,10.1101/2020.06.19.20136093,,https://www.medrxiv.org/content/10.1101/2020.06.19.20136093v1,,,,,,,,,,,,,2020-06-22,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,full_results_preprint,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"chloroquine AND hydroxychloroquine AND COVID-19 AND Yin Zhenyu ",Xiamen University AND hydroxychloroquine AND coronavirus,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030054,ChiCTR,2020-02-22,2020-02-22,FALSE,Zhongshan Hospital Affiliated to Xiamen University,Not Recruiting,Not Applicable,Interventional,China,"A prospective, open label, randomized, control trial for chloroquine or hydroxychloroquine in patients with mild and common novel coronavirus pulmonary (COVIP-19)",Drug,Chloroquine + Hydroxychloroquine,Chloroquine; Hydroxychloroquine,100,http://www.chictr.org.cn/showproj.aspx?proj=49869,,,,2020-05-21,2020-05-21,0,0,,,,10.1101/2020.06.19.20136093,,full_results_preprint,,,,,5,,Not yet recruiting,TRUE,1,,full_results_preprint,,t1vom8f3,http://medrxiv.org/cgi/content/short/2020.06.19.20136093v1?rss=1,Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study,,,,,,,,true,
2020-11-25 11:04:49,2020-11-25 11:05:35,IP Address,86.31.166.235,100,46,True,2020-11-25 11:05:35,R_2SHmcujRkgVRvLX,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,"Exercise programme for isolating students ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030090,ChiCTR,2020-02-22,2020-02-22,FALSE,West China Hospital of Sichuan University,Not Recruiting,Not Applicable,Interventional,China,A Prospective Randomized Controlled Trial for Home Exercise Prescription Intervention During Epidemic of Novel Coronary Pneumonia (COVID-19) in College Students,Other (exercise),Exercise,Exercise,400,http://www.chictr.org.cn/showproj.aspx?proj=49910,,,,2020-03-22,2020-03-22,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-25 10:58:36,2020-11-25 11:07:59,IP Address,158.181.77.106,100,563,True,2020-11-25 11:07:59,R_3kFj5fnWkpq1fFx,,,test@test.com,,52.5363006591796875,13.416900634765625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,,,,,full_results_preprint,,,,,10.21203/rs.3.rs-83677/v1,,https://www.researchsquare.com/article/rs-83677/v1,,,,,,,,,,,,,2020-09-29,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Favipiravir AND COVID AND Dabbous,,,,,,,,,,MSH,2020-06-30,NCT04349241,ClinicalTrials.gov,2020-04-13,2020-04-18,FALSE,Ain Shams University,Not Recruiting,Phase 3,Interventional,Egypt,Efficacy and Safety of Favipiravir in Management of COVID-19,Drug,Favipiravir,Favipiravir,100,https://clinicaltrials.gov/show/NCT04349241,,1,2020-06-01,2020-06-20,2020-06-01,0,0,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,true,
2020-11-25 11:06:19,2020-11-25 11:08:03,IP Address,86.31.166.235,100,104,True,2020-11-25 11:08:04,R_2QPMEbo1ciVAvbD,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,Trial of an education programme,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,CTRI/2020/04/024747,CTRI,2020-04-21,2020-05-01,FALSE,GSL Medical College,Not Recruiting,Not Applicable,Interventional,India,EFFECTIVENESS TO MANAGE COVID 19 PANDEMIC BY  TEACHING  VENTILATORY MANAGEMENT TO NON-ANAESTHESIOLOGY RESIDENTS,Other,Other,Other,26,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43115,,,,,,0,1,,,,,,,,,,,5,,Not Yet Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-25 11:08:15,2020-11-25 11:09:36,IP Address,86.31.166.235,100,81,True,2020-11-25 11:09:37,R_xbU9bhivzbsfh05,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,no,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,IRCT20151227025726N12,IRCT,2020-03-23,2020-03-03,TRUE,Shahid Beheshti University of Medical Sciences,Not Recruiting,Phase 3,Interventional,Iran,Evaluting the therapeutic and adverse effects of Interferon beta 1-a in patients with novel Coronavirus(COVID-19),Drug,Interferon beta + hydroxychloroquine + osletamivir + lopinavir/ritonavir,Interferon beta; hydroxychloroquine; oseltamivir; lopinavir/ritonavir,20,http://en.irct.ir/trial/46561,,,,,,0,0,,,,10.1016/j.intimp.2020.106688,,full_results_journal_article,,,2020-06-07,,5,,Recruitment complete,TRUE,1,32544867,full_results_journal_article,2020-06-07,m7rx8tv9,https://www.ncbi.nlm.nih.gov/pubmed/32544867/; https://doi.org/10.1016/j.intimp.2020.106688; https://www.sciencedirect.com/science/article/pii/S1567576920312893?v=s5; https://api.elsevier.com/content/article/pii/S1567576920312893,Subcutaneous administration of Interferon beta-1a for COVID-19: A non-controlled prospective trial,,,,,,,,,
2020-11-25 11:10:23,2020-11-25 11:11:09,IP Address,158.181.77.106,100,46,True,2020-11-25 11:11:10,R_1LzLt9psKNkQU4t,,,test@test.com,,52.5128021240234375,13.41510009765625,gl,EN,no,,,Retrospective,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04358614,ClinicalTrials.gov,2020-04-19,2020-03-16,TRUE,Fabrizio Cantini,Not Recruiting,Phase 2/Phase 3,Interventional,Italy,Baricitinib Therapy in COVID-19,Drug,Baricitinib,Baricitinib,12,https://clinicaltrials.gov/show/NCT04358614,,1,2020-04-05,2020-04-07,2020-04-05,0,0,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,,
2020-11-25 11:11:16,2020-11-25 11:13:20,IP Address,158.181.77.106,100,123,True,2020-11-25 11:13:20,R_3ninH89v4r6rr76,,,test@test.com,,52.4983062744140625,13.5247039794921875,gl,EN,yes,yes,yes,"""Terminated (investigator decision)""",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04366232,ClinicalTrials.gov,2020-04-27,2020-06-01,TRUE,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,Not Recruiting,Phase 2,Interventional,France,Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV),Drug,Anakinra + Ruxolitinib vs. Anakinra,Anakinra; Ruxolitinib,54,https://clinicaltrials.gov/show/NCT04366232,EUCTR2020-001963-10,1,2020-08-31,2020-08-31,2020-08-31,0,1,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,,
2020-11-25 11:13:28,2020-11-25 11:15:48,IP Address,158.181.77.106,100,139,True,2020-11-25 11:15:48,R_2QyQBdpm9GUH4IK,,,test@test.com,,52.4983062744140625,13.5247039794921875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Protocol: https://doi.org/10.1177/1740774520943846,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04372589,ClinicalTrials.gov,2020-04-24,2020-05-20,FALSE,University of Manitoba,Recruiting,Phase 2/Phase 3,Interventional,"Brazil, Mexico, United States, Canada",Antithrombotic Therapy to Ameliorate Complications of COVID-19 ( ATTACC ),Drug,Heparin,Heparin,3000,https://clinicaltrials.gov/show/NCT04372589,,1,2021-01-01,2021-01-01,2021-01-01,0,1,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,,
2020-11-25 11:09:46,2020-11-25 11:18:15,IP Address,86.31.166.235,100,509,True,2020-11-25 11:18:16,R_3husEhf4CNmuyc8,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pinen Hydronoplacton Ribonucleic acid AND COVID-19 AND Iran,PHR spray  AND coronavirus AND Mohtashami,,,,,,,,,MPJ,2020-06-30,IRCT20160131026298N2,IRCT,2020-04-20,2020-03-10,TRUE,Bagheiat-allah University of Medical Sciences,Not Recruiting,Phase 2/Phase 3,Interventional,Iran,The effect of PHR spray on patients with coronavirus-19,Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,64,http://en.irct.ir/trial/46733,,,,2020-03-24,2020-03-24,0,0,,,,,,,,,,,5,,Recruitment complete,TRUE,1,,,,,,,,,,,,,,,
2020-11-25 11:18:53,2020-11-25 11:23:13,IP Address,86.31.166.235,100,260,True,2020-11-25 11:23:14,R_2Po0YVFd88drz4y,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Volatile Anaesthetics AND COVID-19 AND Dieleman,ARDS AND coronavirus AND Utrecht,,,,,,,,,MPJ,2020-06-30,NL8523,Netherlands Trial Register,2020-04-13,2020-04-26,FALSE,UMC Utrecht,Not Recruiting,Not Applicable,Interventional,Netherlands,Volatile Anaesthetics in COVID-19 – a pilot study,Drug,Isoflurane,Isoflurane,20,https://trialregister.nl/trial/8523,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,5,,Planned,TRUE,1,,,,,,,,,,,,,,,
2020-11-23 22:22:45,2020-11-25 11:27:58,IP Address,158.181.77.106,100,133513,True,2020-11-25 11:27:59,R_1PTXqgsriyBCgkm,,,test@test.com,,52.4983062744140625,13.5247039794921875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"""Traditional Chinese Medicine"" AND COVID AND trial AND (lei OR zhenhui)",,,,,,"Since no drug name, challenging to build specific search strings, and to know whether a result is of this trial.","Challenge to look for results. In additional study completion date is confusing because June 2020 in date area of registry but later: ""The way of sharing IPD (include metadata and protocol, If use web-based public database, please provide the url): When the end of this study (After 01-June-2025), it was published by the researchers in the form of EXCEL documents.""",,,MSH,2020-06-30,ChiCTR2000029941,ChiCTR,2020-02-16,2020-03-01,FALSE,Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Not Recruiting,Not Applicable,Interventional,China,A randomized controlled trial for Traditional Chinese Medicine in the treatment for Novel Coronavirus Pneumonia (COVID-19),Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,200,http://www.chictr.org.cn/showproj.aspx?proj=49596,,1,,2020-06-01,2020-06-01,0,0,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,,
2020-11-25 11:23:29,2020-11-25 11:29:07,IP Address,86.31.166.235,100,338,True,2020-11-25 11:29:08,R_sv36zGwu71nzitH,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BCG AND COVID-19 AND Debisarun,,,,,,,,,,MPJ,2020-06-30,NL8609,Netherlands Trial Register,2020-05-11,2020-05-25,FALSE,Radboud University Medical Centre,Not Recruiting,Not Applicable,Interventional,Netherlands,Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine: a possible preventive approach against COVID-19 (BCG-PLUS),ATMP,Vaccine,Vaccine,100,https://trialregister.nl/trial/8609,,,,2020-06-08,2020-06-08,0,0,,,,,,,,,,,5,,Planned,TRUE,1,,,,,,,,,,,,,,,
2020-11-25 11:28:05,2020-11-25 11:36:42,IP Address,158.181.77.106,100,516,True,2020-11-25 11:36:42,R_3lSkJ9mvTRj4TzF,,,test@test.com,,52.5128021240234375,13.41510009765625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"""corticosteroid"" AND covid AND trial AND Zhenshun",,,,,,,,,,MSH,2020-06-30,ChiCTR2000030481,ChiCTR,2020-03-03,2020-03-01,TRUE,Zhongnan Hospital of Wuhan University,Recruiting,Phase 4,Interventional,China,The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial,Drug,Corticosteroids,Corticosteroids,200,http://www.chictr.org.cn/showproj.aspx?proj=50453,,1,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,,
2020-11-25 11:37:08,2020-11-25 11:38:10,IP Address,158.181.77.106,100,61,True,2020-11-25 11:38:10,R_RJoilZxeYJtYOCB,,,test@test.com,,52.4983062744140625,13.5247039794921875,gl,EN,yes,no,,tumors,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,ChiCTR2000031023,ChiCTR,2020-03-21,2020-03-16,TRUE,Hu'nan Cancer Hospital,Recruiting,Not Applicable,Interventional,China,Perioperative immune prediction and intervention of tumor patients undergoing surgery during the novel coronavirus pneumonia (COVID-19) outbreak period,Prognosis,No Intervention,No Intervention,320,http://www.chictr.org.cn/showproj.aspx?proj=50984,,1,,2020-05-16,2020-05-16,0,0,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,,
2020-11-25 11:29:19,2020-11-25 11:38:50,IP Address,86.31.166.235,100,570,True,2020-11-25 11:38:50,R_12PBOqyQaTnOtOe,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Epigenetic methylation repair AND coronavirus AND Cairo University,Folic Acid AND COVID-19 AND Ahmed Farag,,,,,,,,,MPJ,2020-06-30,PACTR202005599385499,PACTR,2020-04-16,2020-04-20,FALSE,Cairo University,Not Recruiting,Phase 2,Interventional,Egypt,Folic acid: A new suggested prevention and treatment of COVID-19 infection.,Drug,Folic Acid,Folic Acid,60,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10971,,,,2020-05-21,2020-05-21,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-25 11:38:20,2020-11-25 11:43:26,IP Address,158.181.77.106,100,305,True,2020-11-25 11:43:26,R_9B5ti5AcgWsvJKh,,,test@test.com,,52.5128021240234375,13.41510009765625,gl,EN,yes,yes,no,,,yes,,,1,ChiMCTR2000002950,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,ChiCTR2000029434,ChiCTR,2020-02-01,2020-02-01,FALSE,Hebei Yiling Hospital; Renmin Hospital of Wuhan University,Not Recruiting,Phase 4,Interventional,China,"A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule /Granule in the treatment of novel coronavirus pneumonia (COVID-19)",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,240,http://www.chictr.org.cn/showproj.aspx?proj=48889,,1,,2020-12-01,2020-12-01,0,0,,32425361,,http://doi.org/10.1016/j.phymed.2020.153242,,,,,,,3,,,,2,,,,,,,,,,,,,,,
2020-11-25 11:39:02,2020-11-25 11:45:06,IP Address,86.31.166.235,100,363,True,2020-11-25 11:45:06,R_2VIlIZYGvZ5rzjT,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,recombinant interferon alfa 2b AND COVID-19 AND Cuba,Nasalferon AND coronavirus AND Gonzalez Delgado,,,,,,,,,MPJ,2020-06-30,RPCEC00000308,RPCEC,2020-05-03,2020-05-04,FALSE,"Center for Genetic Engineering and Biotechnology (CIGB), Havana",Not Recruiting,Phase 1,Interventional,Cuba,Pharmacodynamics of the Nasalferon in healthy volunteers.,Drug,Nasalferon,Nasalferon,30,https://rpcec.sld.cu/en/trials/RPCEC00000308-En,,,,2020-06-09,2020-06-09,0,0,,,,,,,,,,,5,,Pending,TRUE,1,,,,,,,,,,,,,,,
2020-11-25 11:43:38,2020-11-25 11:49:39,IP Address,158.181.77.106,100,361,True,2020-11-25 11:49:39,R_1Dvv2iLPSppBFZh,,,test@test.com,,52.4983062744140625,13.5247039794921875,gl,EN,yes,no,,"""Outcome: the occurrence of a patient-reported common cold""...but title says COVID, so unclear.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MSH,2020-06-30,ChiCTR2000029479,ChiCTR,2020-02-02,2020-01-30,TRUE,Hospital of Chengdu University of Traditional Chinese Medicine,Not Recruiting,Not Applicable,Interventional,China,Research for Traditional Chinese Medicine Technology Prevention and Control of Novel Coronavirus Pneumonia  (COVID-19) in the Community Population,Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,20000,http://www.chictr.org.cn/showproj.aspx?proj=48773,,1,,2020-05-01,2020-05-01,0,0,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,,
2020-11-25 11:45:15,2020-11-25 11:51:34,IP Address,86.31.166.235,100,379,True,2020-11-25 11:51:34,R_2CQGyjedHDO3udV,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hydroxychloroquine AND Post-Exposure Prophylaxis AND COVID-19 AND Sri Lanka,,,,,,,,,,MPJ,2020-06-30,SLCTR/2020/011,SLCTR,2020-05-04,2020-05-04,FALSE,University of Kelaniya,Not Recruiting,Phase 4,Interventional,Sri Lanka,"Hydroxychloroquine for Post-Exposure Prophylaxis of COVID-19 among naval personnel: a placebo-controlled, randomized, clinical trial",Drug (Chemoprophylaxis),Hydroxychloroquine,Hydroxychloroquine,0,https://slctr.lk/trials/slctr-2020-011,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,5,,Pending,TRUE,1,,,,,,,,,,,,,,,
2020-11-25 11:49:46,2020-11-25 11:59:24,IP Address,158.181.77.106,100,578,True,2020-11-25 11:59:25,R_3HzydK0FVOWlK5Y,,,test@test.com,,52.4983062744140625,13.5247039794921875,gl,EN,yes,yes,yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,I accidentally clicked withdrawn...,team_review,,MSH,2020-06-30,ChiCTR2000029518,ChiCTR,2020-02-03,2020-02-04,FALSE,Zhejiang Chinese Medical University,Recruiting,Not Applicable,Interventional,China,"Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trial",Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,140,http://www.chictr.org.cn/showproj.aspx?proj=48860,,1,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,,
2020-11-25 11:59:35,2020-11-25 12:21:05,IP Address,158.181.77.106,100,1289,True,2020-11-25 12:21:06,R_VPAGTCVIlmSCVMZ,,,test@test.com,,52.5128021240234375,13.41510009765625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"hydroxychloroquine AND COVID AND (""randomized clinical trial"" OR ""randomized controlled trial"" ) AND (Chen OR Yan OR Zhang)",,,,,,,Challenging to refine search string due to common drug and common author names.,,,MSH,2020-06-30,ChiCTR2000029559,ChiCTR,2020-02-04,2020-01-31,TRUE,Renmin Hospital of Wuhan University,Recruiting,Phase 4,Interventional,China,Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19),Drug,Hydroxychloroquine,Hydroxychloroquine,300,http://www.chictr.org.cn/showproj.aspx?proj=48880,,1,,2020-02-29,2020-02-29,0,0,,q8l3ra55,,http://doi.org/10.1101/2020.03.22.20040758,,,,,,,3,,,,2,,,,,,,,,,,,,,,
2020-11-25 12:28:40,2020-11-25 12:36:09,IP Address,158.181.77.106,100,449,True,2020-11-25 12:36:10,R_1pLiK5j1TW8EKwA,,,test@test.com,,52.4983062744140625,13.5247039794921875,gl,EN,yes,yes,no,"unclear whether prospective. seem to recruit participants but also ""medical records based study""",,yes,,,1,ChiMCTR2000003144,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"(""Tou-Jie-Qu-Wen Granules"" OR ""TouJieQuWen Granules"" OR ""Tou Jie Qu Wen Granules"") AND covid",,,,,,,,,,MSH,2020-06-30,ChiCTR2000031089,ChiCTR,2020-03-22,2020-03-13,TRUE,Guangzhou Eighth People's Hospital,Not Recruiting,Not Applicable,Interventional,China,A medical records based study for Tou-Jie-Qu-Wen Granules in the Treatment of mild and moderate patients with novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,300,http://www.chictr.org.cn/showproj.aspx?proj=51136,,1,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,,
2020-11-25 12:36:29,2020-11-25 12:37:55,IP Address,158.181.77.106,100,85,True,2020-11-25 12:37:55,R_20YRGXNVyFTYUBX,,,test@test.com,,52.5128021240234375,13.41510009765625,gl,EN,no,,,Case study of 6 people. Does this count as a trial at such low power?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MSH,2020-06-30,ChiCTR2000033056,ChiCTR,2020-05-19,2020-01-29,TRUE,Guizhou Provincial Jiangjunshan Hospital,Not Recruiting,Not Applicable,Interventional,China,Convalescent Plasma in the treatment of 6 COVID-19 Patients,ATMP,Plasma,Plasma,6,http://www.chictr.org.cn/showproj.aspx?proj=53859,,1,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,,
2020-11-25 12:38:07,2020-11-25 12:41:38,IP Address,158.181.77.106,100,211,True,2020-11-25 12:41:39,R_1Dv9r1uxeBipwu5,,,test@test.com,,52.4983062744140625,13.5247039794921875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,protocol: https://doi.org/10.1186/s13063-020-04454-4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,ISRCTN21363594,ISRCTN,2020-05-18,2020-05-01,TRUE,King Saud Medical City,Recruiting,Not Applicable,Interventional,"Saudi Arabia, Oman, United Arab Emirates",Therapeutic plasma exchange (removal of the non-cell portion of blood) in critically ill adult patients with serious SARS CoV-2 disease (COVID-19),ATMP,Plasma,Plasma,80,http://isrctn.com/ISRCTN21363594,,1,,2020-12-29,2020-12-29,0,1,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,,
2020-11-25 12:41:44,2020-11-25 12:50:50,IP Address,158.181.77.106,100,545,True,2020-11-25 12:50:50,R_21BeleEZmscfc05,,,test@test.com,,52.4983062744140625,13.5247039794921875,gl,EN,yes,yes,no,"Outcome is COVID related but only about 1hr after administration of intervention: ""Plasma cytokine levels 1 hour after the administration of JHQG""",,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,,10.1101/2020.06.08.20124453,,https://www.medrxiv.org/content/10.1101/2020.06.08.20124453v1,,,,,,,,,,,,,2020-06-12,NA,,,,,,,,,,,,,,,,,,,,,,,,"modified search string to remove ""JPRN"" so only ""UMIN"" prefix. We may want to do this programmatically to widen search.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"""Jinhua Qinggan granule"" AND covid AND nakamura",,,,,,,,,,MSH,2020-06-30,JPRN-UMIN000040407,JPRN,2020-05-15,2020-05-15,FALSE,Takanawa Clinic,Not Recruiting,Not Applicable,Interventional,Japan,Immunological efficacy of Jinhua Qinggan Granule for COVID-19,Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,15,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046108,,1,,2020-05-20,2020-05-20,0,0,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,true,
2020-11-25 12:51:56,2020-11-25 13:08:56,IP Address,158.181.77.106,100,1020,True,2020-11-25 13:08:56,R_Tpx9vDQPFDLURr3,,,test@test.com,,52.4983062744140625,13.5247039794921875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,google_scholar,,,,full_results_preprint,other,,,,10.1101/2020.05.27.20110601,,https://www.medrxiv.org/content/10.1101/2020.05.27.20110601v1,,,https://www.preprints.org/manuscript/202009.0240/v1,,,,,,,,,,2020-06-02,,2020-09-11,,,,,,,,,,,,,,,,,,,,,,,"unclear whether the date is last enrollment or last data collection: ""Patients in the study were included from March 31 to April 22 2020""","case study. not finding doi. received date is Sept. 9, so earlier, so use instead?",,,,,Maybe http://revmedmilitar.sld.cu/index.php/mil/article/view/926,google_scholar,,,,,full_results_journal_article,,,,,,,https://austinpublishinggroup.com/pharmacology-therapeutics/download.php?file=fulltext/ajpt-v8-id1119.pdf,,,,,,,,,,,,,2020-09-17,,,,,,,,,,,,,,,,,,,,,,,,,"april 22 unclear whether last enrollment or last data collection; not finding doi; earlier dates for received, etc.",,,,,,"""CIGB-258"" AND covid",,,,,,,odd results. let's discuss,team_review,,MSH,2020-06-30,RPCEC00000313,RPCEC,2020-05-14,2020-03-31,TRUE,"Center for Genetic Engineering and Biotechnology (CIGB), Havana",Not Recruiting,Not Applicable,Interventional,Cuba,CIGB-258 at COVID-19,Drug,CIGB-258,CIGB-258,16,https://rpcec.sld.cu/en/trials/RPCEC00000313-En,,1,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,true,
2020-11-25 13:09:39,2020-11-25 13:17:20,IP Address,158.181.77.106,100,460,True,2020-11-25 13:17:21,R_3gOcLrdjgbmFxwL,,,test@test.com,,52.5363006591796875,13.416900634765625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,,,,,full_results_preprint,,,,,10.1101/2020.09.03.20187112,,https://www.medrxiv.org/content/10.1101/2020.09.03.20187112v2,,,,,,,,,,,,,2020-09-22,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ATENEA-Co-300 AND covid,,,,,,,,,,MSH,2020-06-30,RPCEC00000317,RPCEC,2020-05-28,2020-06-01,FALSE,"Center for Genetic Engineering and Biotechnology (CIGB), Havana",Not Recruiting,Phase 1/Phase 2,Interventional,Cuba,ATENEA-Co-300 study,Drug,CIGB-300,CIGB-300,20,https://rpcec.sld.cu/en/trials/RPCEC00000317-En,,1,,2020-06-29,2020-06-29,0,0,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,true,
2020-11-25 13:17:27,2020-11-25 13:18:48,IP Address,158.181.77.106,100,80,True,2020-11-25 13:18:48,R_29js8oI1AYzYWCS,,,test@test.com,,52.4983062744140625,13.5247039794921875,gl,EN,yes,no,,device comparison,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04385576,ClinicalTrials.gov,2020-04-28,2020-05-15,FALSE,University of Malaya,Recruiting,Not Applicable,Interventional,Malaysia,"Taiwan ""Aerosol Box"" Versus UMMC ""Intubation Box""",Other (physical),Mechanical ventilation,Mechanical ventilation,30,https://clinicaltrials.gov/show/NCT04385576,,1,2020-09-15,2020-12-30,2020-09-15,0,1,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,,
2020-11-25 13:18:53,2020-11-25 13:19:37,IP Address,158.181.77.106,100,43,True,2020-11-25 13:19:38,R_RQxUDDGey3UfvZ7,,,test@test.com,,52.5363006591796875,13.416900634765625,gl,EN,yes,no,,endoscopy during covid times,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04389333,ClinicalTrials.gov,2020-05-09,2020-03-26,TRUE,Changhai Hospital,Recruiting,Not Applicable,Interventional,China,Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic,Other,Other,Other,40,https://clinicaltrials.gov/show/NCT04389333,,1,2020-04-26,2020-05-20,2020-04-26,0,0,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,,
2020-11-25 13:19:42,2020-11-25 13:25:22,IP Address,158.181.77.106,100,339,True,2020-11-25 13:25:22,R_r1gv95oo5khlFDP,,,test@test.com,,52.4983062744140625,13.5247039794921875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"""Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma"" AND covid",,,,,,,,,,MSH,2020-06-30,NCT04389944,ClinicalTrials.gov,2020-05-12,2020-03-31,TRUE,"University Hospital, Basel",Recruiting,Not Applicable,Interventional,Switzerland,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19,ATMP,Plasma,Plasma,15,https://clinicaltrials.gov/show/NCT04389944,,1,2020-06-30,2020-06-30,2020-06-30,0,0,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,,
2020-11-25 13:30:25,2020-11-25 13:38:30,IP Address,158.181.77.106,100,484,True,2020-11-25 13:38:31,R_1rqV2L3lyDufpzQ,,,test@test.com,,52.4983062744140625,13.5247039794921875,gl,EN,yes,yes,no,,,no,2020-05-15,2020-07-16,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,,,,,other,,,,,10.12659/AJCR.926779,32865522,https://www.amjcaserep.com/abstract/index/idArt/926779,,,,,,,,,,,,,2020-08-07,,,,,,,,,,,,,,,,,,,,,,,,,case study,,,,,,"""Photobiomodulation Laser Therapy"" AND Covid AND trial",,,,,,,,,,MSH,2020-06-30,NCT04391712,ClinicalTrials.gov,2020-05-04,2020-04-30,TRUE,Lowell General Hospital,Recruiting,Phase 2,Interventional,United States,Cold Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Other (device),Cold Laser Therapy,Cold Laser Therapy,20,https://clinicaltrials.gov/show/NCT04391712,,1,2020-05-30,2020-06-30,2020-05-30,0,0,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,,2020-07-16
2020-11-25 13:38:45,2020-11-25 13:39:45,IP Address,158.181.77.106,100,59,True,2020-11-25 13:39:45,R_2dKLSL125ovwuPk,,,test@test.com,,52.4983062744140625,13.5247039794921875,gl,EN,yes,no,,room cleaning,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04399005,ClinicalTrials.gov,2020-05-19,2020-05-25,FALSE,The First Affiliated Hospital of Zhejiang Chinese Medical University,Not Recruiting,Not Applicable,Interventional,China,The Efficacy Comparing Daily and After-each-case Room Disinfection.,Other,Other,Other,240,https://clinicaltrials.gov/show/NCT04399005,,1,2020-06-05,2020-06-10,2020-06-05,0,0,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,,
2020-11-25 13:43:34,2020-11-25 13:43:57,IP Address,158.181.77.106,100,22,True,2020-11-25 13:43:57,R_1GU1BTe7VrHrwru,,,test@test.com,,52.5363006591796875,13.416900634765625,gl,EN,yes,no,,medical personnel,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04405999,ClinicalTrials.gov,2020-05-18,2020-05-14,TRUE,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",Recruiting,Phase 4,Interventional,Russian Federation,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease,Drug (Chemoprophylaxis),Bromhexine hydrochloride,Bromhexine hydrochloride,140,https://clinicaltrials.gov/show/NCT04405999,,1,2020-06-20,2020-09-30,2020-06-20,0,0,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,,
2020-11-25 13:44:02,2020-11-25 13:47:21,IP Address,158.181.77.106,100,198,True,2020-11-25 13:47:21,R_stfQNQnygXjTGvL,,,test@test.com,,52.4983062744140625,13.5247039794921875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04407689,ClinicalTrials.gov,2020-05-27,2020-06-08,FALSE,Revimmune,Recruiting,Phase 2,Interventional,France,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort,Drug,Interleukin-7,Interleukin-7,48,https://clinicaltrials.gov/show/NCT04407689,,1,2020-10-30,2020-12-30,2020-10-30,0,1,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,,
2020-11-25 13:47:26,2020-11-25 13:50:36,IP Address,158.181.77.106,100,189,True,2020-11-25 13:50:36,R_3ffLtLiaGP6Srbf,,,test@test.com,,52.5363006591796875,13.416900634765625,gl,EN,yes,yes,no,,,no,2020-06-29,2020-07-06,0,,,,,,summary_results,,,,,,,https://clinicaltrials.gov/ct2/show/results/NCT04410159,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Trial completed before cutoff, but completion date in registry at cutoff was after cutoff, so no results search.",team_review,,MSH,2020-06-30,NCT04410159,ClinicalTrials.gov,2020-05-27,2020-06-22,FALSE,Universiti Sains Islam Malaysia,Recruiting,Phase 2,Interventional,Malaysia,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Drug,Povidone Iodine vs. Essential Oil,Povidone Iodine; Essential Oil,20,https://clinicaltrials.gov/show/NCT04410159,,1,2020-07-15,2020-08-15,2020-07-15,0,1,,,,,,,,,,,3,,,,2,,,,,,,,,,,,,,,2020-07-06
2020-11-25 18:13:23,2020-11-25 18:19:30,IP Address,213.61.225.214,100,366,True,2020-11-25 18:19:30,R_2SxAoVt9rKYmQg3,,,test@test.com,,52.5155029296875,13.4062042236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,,,,,full_results_journal_article,,,,,IRCT20200328046886N1," 32812025",https://academic.oup.com/jac/article/75/11/3373/5889947,,,,,,,,,,,,,2020-08-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Evaluation of efficacy and safety of Sovodak (Sofosbuvir+Daclatasvir) in combination with Ribavirin for mild to moderate hospitalized Covid-19 patients compared to standard care regimen (a randomized controlled trial),Hamideh Abbaspour Kasgari Evaluation of efficacy and safety of Sovodak (Sofosbuvir+Daclatasvir) in combination with Ribavirin for mild to moderate hospitalized Covid-19 patients compared to standard care regimen (a randomized controlled trial),,,,,,,,,PG,2020-06-30,IRCT20200328046886N1,IRCT,2020-04-12,2020-03-05,TRUE,Mazandaran University of Medical Sciences,Not Recruiting,Phase 3,Interventional,Iran,The effectiveness of Sovodak (sofosbuvir+daclatasvir) in Covid-19 patients,Drug,Daclatasvir/sofosbuvir,Daclatasvir/sofosbuvir,48,http://en.irct.ir/trial/46885,,1,,2020-05-04,2020-05-04,0,0,,,,,,,,,,,4,,,,1,,,,,,,,,,,,,true,,
2020-11-25 18:10:18,2020-11-25 21:08:12,IP Address,86.31.166.235,100,10673,True,2020-11-25 21:08:12,R_2ugdlc9AwblaZVf,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04325061,ClinicalTrials.gov,2020-03-25,2020-04-03,TRUE,Dr. Negrin University Hospital,Recruiting,Phase 4,Interventional,Spain,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Drug,Corticosteroids,Dexamethasone,200,https://clinicaltrials.gov/show/NCT04325061,EUCTR2020-001278-31,1,2020-10-30,2020-10-30,2020-10-30,0,1,,,,,,,,,,,4,,,,2,,,,,,,,,,,,,,,
2020-11-25 21:09:25,2020-11-25 21:18:40,IP Address,86.31.166.235,100,554,True,2020-11-25 21:18:41,R_RrUaUWz5oO20nzX,,,test@test.com,,51.4766998291015625,-2.5572052001953125,anonymous,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"https://www.nature.com/articles/s41421-020-00197-3 - is this results or a different paper using the results from ChiCTR2000029822? ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"honeysuckle AND COVID-19 AND Yongxiang Yi ",honeysuckle AND coronavirus AND pneumonia AND Nanjing,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029822,ChiCTR,2020-02-14,2020-02-07,TRUE,Nanjing Second Hospital,Recruiting,Not Applicable,Interventional,No Country Given,A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection,Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,110,http://www.chictr.org.cn/showproj.aspx?proj=49502,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,5,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-25 21:18:45,2020-11-25 21:25:59,IP Address,86.31.166.235,100,434,True,2020-11-25 21:26:00,R_21HXl7N7eh26hER,,,test@test.com,,51.4766998291015625,-2.5572052001953125,anonymous,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"hydroxycholoroquine AND COVID-19 AND Zhuoli Zhang ",Peking University AND coronavirus AND pneumonia AND hydroxycholoroquine,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029740,ChiCTR,2020-02-11,2020-02-11,FALSE,The First Hospital of Peking University,Recruiting,Phase 4,Interventional,China,Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients(randomized open-label control clinical trial),Drug,Hydroxychloroquine,Hydroxychloroquine,78,http://www.chictr.org.cn/showproj.aspx?proj=49317,,,,2020-02-29,2020-02-29,0,0,,,,,,,,,,,5,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-25 21:31:03,2020-11-25 21:36:49,IP Address,86.31.166.235,100,345,True,2020-11-25 21:36:50,R_2fBA9pySdj5QQzM,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,yes,,NA,2020-04-10,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,,10.1101/2020.02.27.20027557,,https://www.medrxiv.org/content/10.1101/2020.02.27.20027557v1,,,,,,,,,,,,,2020-02-29,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Dipyridamole AND COVID-19 AND Qingling Zhang ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030055,ChiCTR,2020-02-22,2020-02-10,TRUE,The First Affiliated Hospital of Guangzhou Medical University,Recruiting,Phase 4,Prognosis,China,Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19),Drug,Dipyridamole,Dipyridamole,460,http://www.chictr.org.cn/showproj.aspx?proj=49864,,,,,,,,,10.1016/j.apsb.2020.04.008,,10.1016/j.apsb.2020.04.008,,full_results_journal_article,,,2020-04-20,,5,,,FALSE,1,32318327,full_results_journal_article,2020-04-20,k7bh8bf7,https://api.elsevier.com/content/article/pii/S2211383520305529; https://doi.org/10.1016/j.apsb.2020.04.008; https://www.ncbi.nlm.nih.gov/pubmed/32318327/; https://www.sciencedirect.com/science/article/pii/S2211383520305529?v=s5,Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19,,,,,,,true,,2020-04-10
2020-11-25 21:37:02,2020-11-25 21:45:22,IP Address,86.31.166.235,100,499,True,2020-11-25 21:45:22,R_3feNMFaTppeLjT9,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,rhIFNα AND nasal drops AND Zhongji Meng,"Shanghai Jiao Tong University AND Medical Staff AND coronavirus ",,,,,,,,,MPJ,2020-06-30,NCT04320238,ClinicalTrials.gov,2020-03-21,2020-01-21,TRUE,Shanghai Jiaotong University,Recruiting,Phase 3,Interventional,China,Experimental Trial of rhIFNa Nasal Drops to Prevent 2019-nCOV in Medical Staff,Drug,Interferon Alpha vs. Interferon Alpha + Thymosin Alpha,Interferon alpha; Thymosin alpha,2944,https://clinicaltrials.gov/show/NCT04320238,,,2020-05-01,2020-06-01,2020-05-01,0,0,,10.1101/2020.04.11.20061473,,10.1101/2020.04.11.20061473,,full_results_preprint,,,2020-04-17,,5,,Recruiting,TRUE,1,,full_results_preprint,2020-04-17,z68tl88x,https://doi.org/10.1101/2020.04.11.20061473,An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area,,,,,,,,true,
2020-11-29 12:12:15,2020-11-29 12:20:19,IP Address,86.31.166.235,100,483,True,2020-11-29 12:20:20,R_3J1WzEJ3XmFw8XZ,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2021-12-01,2031-12-01,0,,,,,,full_results_journal_article,full_results_journal_article,full_results_journal_article,full_results_journal_article,,10.1056/NEJMoa2021436,32678530,https://www.nejm.org/doi/10.1056/NEJMoa2021436,10.1016/S0140-6736(20)32013-4,33031764,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32013-4/fulltext,10.1056/NEJMoa2022926,33031652,https://www.nejm.org/doi/10.1056/NEJMoa2022926,,,,,,,2020-07-17,,2020-10-24,,2020-11-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04381936,ClinicalTrials.gov,2020-05-07,2020-03-19,TRUE,University of Oxford,Recruiting,Phase 2/Phase 3,Interventional,United Kingdom,Randomized Evaluation of COVID-19 Therapy,Drug,Lopinavir/ritonavir vs. corticosteroids vs. hydroxychloroquine vs. azithromycin vs. tocilizumab,Lopinavir/ritonavir; dexamethasone; hydrocortisone;  hydroxychloroquine; azithromycin; tocilizumab,12000,https://clinicaltrials.gov/ct2/show/NCT04381936,"EUCTR2020-001113-21, ISRCTN50189673",,2020-12-01,2021-06-01,2020-12-01,0,0,,10.1101/2020.06.22.20137273,,10.1101/2020.06.22.20137273,,interim_results_preprint,,,2020-06-22,,6,,Recruiting,TRUE,1,,interim_results_preprint,2020-06-22,ocguwlam,http://medrxiv.org/cgi/content/short/2020.06.22.20137273v1?rss=1,Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report,,,,,,,,,2031-12-01
2020-11-29 12:20:36,2020-11-29 12:21:20,IP Address,86.31.166.235,100,43,True,2020-11-29 12:21:21,R_2WA5RoJp4nPhgpp,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,"Diagnostic test ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04445597,ClinicalTrials.gov,2020-06-22,2020-05-07,TRUE,UZ Leuven,Recruiting,Not Applicable,Interventional,Belgium,Unraveling the Mechanisms of Olfactory Dysfunction in COVID-19,Clinical Presentation,No Intervention,No Intervention,8,https://clinicaltrials.gov/show/NCT04445597,,,2020-06-30,2020-06-30,2020-06-30,0,0,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-29 12:21:29,2020-11-29 12:23:32,IP Address,86.31.166.235,100,123,True,2020-11-29 12:23:33,R_cHDrsaHkZZhvia5,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,Use of app to screen patients?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04437719,ClinicalTrials.gov,2020-06-17,2020-06-30,FALSE,Groupe Hospitalier Paris Saint-Joseph,Not Recruiting,Not Applicable,Interventional,France,"Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 Pandemic",Clinical Presentation,No Intervention,No Intervention,100,https://clinicaltrials.gov/show/NCT04437719,,,2021-12-31,2021-12-31,2021-12-31,0,1,,,,,,,,,,,6,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-29 12:23:41,2020-11-29 12:34:34,IP Address,86.31.166.235,100,653,True,2020-11-29 12:34:34,R_2xRAhxDzfI1CRsE,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-07-14,2020-07-27,0,,,,,,summary_results,,,,,,,https://clinicaltrials.gov/ct2/show/results/NCT04422561,,,,,,,,,,,,,2020-08-27,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Prophylactic Ivermectin AND COVID-19 AND Shouman,coronavirus contacts AND Ivermectin AND Zagazig University,,,,,,,,,MPJ,2020-06-30,NCT04422561,ClinicalTrials.gov,2020-06-06,2020-05-31,TRUE,Zagazig University,Recruiting,Phase 2/Phase 3,Interventional,Egypt,Prophylactic Ivermectin in COVID-19 Contacts,Drug (Chemoprophylaxis),Ivermectin,Ivermectin,100,https://clinicaltrials.gov/show/NCT04422561,,,2020-06-01,2020-07-01,2020-06-01,0,0,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2020-07-27
2020-11-29 12:34:41,2020-11-29 12:36:05,IP Address,86.31.166.235,100,84,True,2020-11-29 12:36:06,R_eCKPCc3qGU9m8c9,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,"PPE application check ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,ACTRN12620000688987,ANZCTR,2020-06-19,2020-06-02,TRUE,The Royal Melbourne Hospital,Not Recruiting,Not Applicable,Interventional,Australia,Comparing the user seal check and fit test between two types of N95 respirators - the Halyard N95 Particulate Filter Respirators and the ProShield® N-95 masks,Other (device),Mask,Mask,80,https://anzctr.org.au/ACTRN12620000688987.aspx,,,,2020-06-05,2020-06-05,0,0,,,,,,,,,,,6,,Completed,TRUE,1,,,,,,,,,,,,,,,
2020-11-29 12:36:12,2020-11-29 12:41:07,IP Address,86.31.166.235,100,295,True,2020-11-29 12:41:07,R_28U0VQKNiBr8O1Q,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,"Not certain whether this does/doesn't qualify for inclusion in the study ",,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COVID-19 AND management AND home isolation AND Cairo University,,,,,,,,,,MPJ,2020-06-30,NCT04368923,ClinicalTrials.gov,2020-04-24,2020-03-15,TRUE,Cairo University,Not Recruiting,Not Applicable,Interventional,Egypt,Management of Covid-19 Patients During Home Isolation,Drug,Oxygen,Oxygen,60,https://clinicaltrials.gov/show/NCT04368923,,,2020-06-21,2020-06-23,2020-06-21,0,0,,,,,,,,,,,6,,"Active, not recruiting",TRUE,1,,,,,,,,,,,,,,,
2020-11-29 12:41:27,2020-11-29 12:41:54,IP Address,86.31.166.235,100,27,True,2020-11-29 12:41:55,R_XTld91i1yRkCQpz,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,Recruitment of blood donors by SMS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04431180,ClinicalTrials.gov,2020-06-12,2020-06-13,FALSE,Guangzhou Blood Center,Recruiting,Not Applicable,Interventional,China,Recruit Blood Donors Via SMS During Epidemic of COVID-19 #Second Repeat Trial#,Other,Other,Other,403535,https://clinicaltrials.gov/show/NCT04431180,,,2020-06-13,2020-06-30,2020-06-13,0,0,,,,,,,,,,,6,,Enrolling by invitation,TRUE,1,,,,,,,,,,,,,,,
2020-11-29 12:42:01,2020-11-29 12:46:01,IP Address,86.31.166.235,100,240,True,2020-11-29 12:46:02,R_1NeUUPOUymsO3xE,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Favipiravir AND Hydroxychloroquine AND COVID-19 AND Baqiyatallah University,,,,,,,,,,MPJ,2020-06-30,NCT04376814,ClinicalTrials.gov,2020-05-03,2020-03-29,TRUE,Baqiyatallah Medical Sciences University,Not Recruiting,Not Applicable,Interventional,Iran,Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19,Drug,Favipiravir + Hydroxychloroquine vs. Lopinavir/ritonavir + Hydroxychloroquine,Favipiravir; Hydroxychloroquine; Lopinavir/ritonavir,40,https://clinicaltrials.gov/show/NCT04376814,,,2020-04-05,2020-05-25,2020-04-05,0,0,,,,,,,,,,,6,,Completed,TRUE,1,,,,,,,,,,,,,,,
2020-11-29 12:46:38,2020-11-29 12:47:23,IP Address,86.31.166.235,100,44,True,2020-11-29 12:47:23,R_2YlK9zLwg0BepKK,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,Testing an algorithm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04423991,ClinicalTrials.gov,2020-06-08,2020-03-10,TRUE,Dascena,Not Recruiting,Not Applicable,Interventional,United States,Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning,Other (software),Machine Learning,Machine Learning,290,https://clinicaltrials.gov/show/NCT04423991,,,2020-06-04,2020-06-04,2020-06-04,0,0,,,,,,,,,,,6,,Completed,TRUE,1,,,,,,,,,,,,,,,
2020-11-29 12:47:33,2020-11-29 12:48:15,IP Address,86.31.166.235,100,42,True,2020-11-29 12:48:16,R_3NPR6JkNK5JEGtW,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,Dance classes for Parkinson patients in isolation due to Covid-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04422353,ClinicalTrials.gov,2020-06-07,2020-05-01,TRUE,Federal University of Rio Grande do Sul,Recruiting,Not Applicable,Interventional,Brazil,Video Dance Class and Unsupervised Physical Activity During Covid-19 Pandemic in People With Parkinson's Disease,Other (exercise),Exercise,Exercise,60,https://clinicaltrials.gov/show/NCT04422353,,,2020-12-30,2024-12-30,2020-12-30,0,1,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-29 17:09:38,2020-11-29 17:15:17,IP Address,77.11.199.227,100,339,True,2020-11-29 17:15:18,R_2rPcaELw8lwGYSv,,,test@test.com,,52.5196075439453125,13.4069061279296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"https://clinicaltrials.gov/ProvidedDocs/08/NCT04407208/Prot_000.pdf <-- Protocol ","NCT04407208 marliana plasma ",Marliana  Convalescent Plasma covid-19,marliana plasma Biofarma,,,,,,,,PG,2020-06-30,NCT04407208,ClinicalTrials.gov,2020-05-16,2020-05-01,TRUE,Biofarma,Recruiting,Phase 1,Interventional,Indonesia,Convalescent Plasma Therapy in Patients With COVID-19,ATMP,Plasma,Plasma,10,https://clinicaltrials.gov/show/NCT04407208,,,2020-06-22,2020-06-22,2020-06-22,0,0,,,,,,,,,,,5,,Completed,TRUE,2,,,,,,,,,,,,,,,
2020-11-29 17:15:26,2020-11-29 17:28:50,IP Address,77.11.199.227,100,803,True,2020-11-29 17:28:51,R_yF9OEk3cOB3CMMN,,,test@test.com,,52.5321044921875,13.4011993408203125,gl,EN,yes,yes,no,,,no,2021-08-30,2021-09-15,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,interim_result,,,,,10.21203/rs.3.rs-64465/v1,,https://europepmc.org/article/PPR/PPR211485,,,,,,,,,,,,,2020-09-08,,,,,,,,,,,,,,,,,,,,,,,,,"preliminary report, preprint",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection NCT04408209 ","Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection ""Dimopoulos""",,,,,,"Press release here: https://greece.greekreporter.com/2020/08/24/greek-plasma-therapy-trials-for-covid-19-show-promising-results/ ",,,PG,2020-06-30,NCT04408209,ClinicalTrials.gov,2020-05-25,2020-04-23,TRUE,National and Kapodistrian University of Athens,Recruiting,Not Applicable,Interventional,Greece,Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection,ATMP,Plasma,Plasma,60,https://clinicaltrials.gov/show/NCT04408209,,,2020-06-30,2021-09-15,2020-06-30,0,0,,,,,,,,,,,5,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2021-09-15
2020-11-29 17:28:56,2020-11-29 17:30:13,IP Address,77.11.199.227,100,77,True,2020-11-29 17:30:14,R_1DLKgnuVSiXSwQ0,,,test@test.com,,52.5196075439453125,13.4069061279296875,gl,EN,yes,no,,The goal of this study is to better understand how people predict the future risks of the novel Coronavirus (COVID-19).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"no treatment or prevention ",,,PG,2020-06-30,NCT04410692,ClinicalTrials.gov,2020-05-27,2020-05-15,TRUE,"National University, Singapore",Not Recruiting,Not Applicable,Interventional,Singapore,Can the Prediction Market Improve Predictions of COVID-19?,Other,Other,Other,560,https://clinicaltrials.gov/show/NCT04410692,,,2020-05-16,2020-05-17,2020-05-16,0,0,,,,,,,,,,,5,,Completed,TRUE,2,,,,,,,,,,,,,,,
2020-11-29 17:30:19,2020-11-29 17:36:28,IP Address,77.11.199.227,100,368,True,2020-11-29 17:36:28,R_10Mp6GHEdQsUt27,,,test@test.com,,52.5196075439453125,13.4069061279296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"10.1186/s13063-020-04659-7  <-- DOI of protocol ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Hydroxychloroquine for Post-Exposure Prophylaxis of COVID-19 among naval personnel ",SLCTR/2020/011   U1111-1251-3613,HCQ sri lanka covid 19 naval,,,,,,,,PG,2020-06-30,SLCTR/2020/011,SLCTR,2020-05-04,2020-05-04,FALSE,University of Kelaniya,Not Recruiting,Phase 4,Interventional,Sri Lanka,"Hydroxychloroquine for Post-Exposure Prophylaxis of COVID-19 among naval personnel: a placebo-controlled, randomized, clinical trial",Drug (Chemoprophylaxis),Hydroxychloroquine,Hydroxychloroquine,0,https://slctr.lk/trials/slctr-2020-011,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,5,,Pending,TRUE,2,,,,,,,,,,,,,,,
2020-11-29 17:36:36,2020-11-29 17:43:15,IP Address,77.11.199.227,100,399,True,2020-11-29 17:43:16,R_2YDrk9nv6gcuYTg,,,test@test.com,,52.5321044921875,13.4011993408203125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Folic acid covid 19 egypt Cairo university ","Folic acid covid 19 ""Ouda""",,,,,,,,,PG,2020-06-30,PACTR202005599385499,PACTR,2020-04-16,2020-04-20,FALSE,Cairo University,Not Recruiting,Phase 2,Interventional,Egypt,Folic acid: A new suggested prevention and treatment of COVID-19 infection.,Drug,Folic Acid,Folic Acid,60,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10971,,,,2020-05-21,2020-05-21,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-11-29 17:43:23,2020-11-29 17:44:05,IP Address,77.11.199.227,100,42,True,2020-11-29 17:44:06,R_1f88GCdBnP8lGyY,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,no,,healthy volunteers,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,RPCEC00000308,RPCEC,2020-05-03,2020-05-04,FALSE,"Center for Genetic Engineering and Biotechnology (CIGB), Havana",Not Recruiting,Phase 1,Interventional,Cuba,Pharmacodynamics of the Nasalferon in healthy volunteers.,Drug,Nasalferon,Nasalferon,30,https://rpcec.sld.cu/en/trials/RPCEC00000308-En,,,,2020-06-09,2020-06-09,0,0,,,,,,,,,,,5,,Pending,TRUE,2,,,,,,,,,,,,,,,
2020-11-29 17:44:13,2020-11-29 17:52:18,IP Address,77.11.199.227,100,484,True,2020-11-29 17:52:18,R_pH81ksqeEhP2nS1,,,test@test.com,,52.5321044921875,13.4011993408203125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,full_results_journal_article,,,,,10.1038/s41467-020-19056-6,33082342,https://www.nature.com/articles/s41467-020-19056-6,,,,,,,,,,,,,2020-10-20,2020-05-25,,,,,,,,,,,,,,,,,,,,,,,,"Because of rapidly decreasing incidence of COVID-19 in Norway, the trial was prematurely stopped by the trial sponsor on May 25, 2020",,,,,,10.1186/s13063-020-04420-0  <-- Study protocol,europe_pmc,,,,,full_results_preprint,,,,,"10.21203/rs.3.rs-44055/v1 ",,https://europepmc.org/article/PPR/PPR188875,,,,,,,,,,,,,2020-07-17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04316377,ClinicalTrials.gov,2020-03-13,2020-03-25,FALSE,"University Hospital, Akershus",Not Recruiting,Phase 4,Interventional,Norway,Norwegian Coronavirus Disease 2019 Study,Drug,Hydroxychloroquine,Hydroxychloroquine,53,https://clinicaltrials.gov/show/NCT04316377,,,2020-05-25,2025-03-03,2020-05-25,0,1,,,,,,,,,,,5,,"Active, not recruiting",TRUE,2,,,,,,,,,,,,,true,true,
2020-11-29 17:52:29,2020-11-29 17:55:09,IP Address,77.11.199.227,100,159,True,2020-11-29 17:55:09,R_8f6odKYvIWZjlrr,,,test@test.com,,52.5321044921875,13.4011993408203125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04420260,ClinicalTrials.gov,2020-05-25,2020-07-01,FALSE,Unidad de Investigación Genética Molecular,Not Recruiting,Not Applicable,Interventional,No Country Given,Primary Prevention of Infection by COVID-19 in Health Providers,Drug (Chemoprophylaxis),"Oropharygeal spray, Immunostimulant",Oropharygeal spray; Immunostimulant,300,https://clinicaltrials.gov/show/NCT04420260,,,2020-09-01,2020-09-01,2020-09-01,0,1,,,,,,,,,,,5,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-11-29 17:54:42,2020-11-29 17:56:08,IP Address,86.31.166.235,100,86,True,2020-11-29 17:56:08,R_svOtvv6WVfp50rv,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,"Diagnostic CT for 'community acquired' pneumonia ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04379531,ClinicalTrials.gov,2020-04-30,2020-04-25,TRUE,Department of Health Care of Moscow,Not Recruiting,Not Applicable,Interventional,Russian Federation,LDCT in COVID-19 Pneumonia: a Prospective Moscow Study,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,230,https://clinicaltrials.gov/show/NCT04379531,,,2020-05-22,2020-05-22,2020-05-22,0,0,,,,,,,,,,,6,,Completed,TRUE,1,,,,,,,,,,,,,,,
2020-11-29 17:55:45,2020-11-29 17:57:20,Spam,77.11.199.227,100,94,True,2020-11-29 17:57:20,R_3Du1c7MlGHNTQ1R,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04395170,ClinicalTrials.gov,2020-05-15,2020-06-01,FALSE,Lifefactors Zona Franca,Not Recruiting,Phase 2/Phase 3,Interventional,Colombia,Convalescent Plasma Compared to Anti-COVID-19 Human Immunoglobulin and Standard Treatment (TE) in Hospitalized Patients,ATMP,Plasma vs. Immunoglobulin,Plasma; Immunoglobulin,75,https://clinicaltrials.gov/show/NCT04395170,,,2020-12-01,2021-06-01,2020-12-01,0,1,,,,,,,,,,,5,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-11-29 17:56:15,2020-11-29 17:58:04,IP Address,86.31.166.235,100,109,True,2020-11-29 17:58:04,R_2uqWkcY7mRFUM6G,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04418518,ClinicalTrials.gov,2020-06-03,2020-06-01,TRUE,Weill Medical College of Cornell University,Not Recruiting,Phase 3,Interventional,United States,A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness,ATMP,Plasma,Plasma,1200,https://clinicaltrials.gov/show/NCT04418518,,,2021-06-01,2021-12-01,2021-06-01,0,1,,,,,,,,,,,6,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-29 17:57:26,2020-11-29 17:58:38,Spam,77.11.199.227,100,71,True,2020-11-29 17:58:38,R_reD1OgWmyaIgxqx,,,test@test.com,,52.5196075439453125,13.4069061279296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04426201,ClinicalTrials.gov,2020-06-09,2020-06-22,FALSE,Revimmune,Not Recruiting,Phase 2,Interventional,No Country Given,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-O ),Drug,Interleukin-7,Interleukin-7,48,https://clinicaltrials.gov/show/NCT04426201,,,2020-11-30,2020-12-31,2020-11-30,0,1,,,,,,,,,,,5,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-11-29 17:58:45,2020-11-29 18:02:39,IP Address,77.11.199.227,100,234,True,2020-11-29 18:02:40,R_3KZyFOmTmS5DTDW,,,test@test.com,,52.5321044921875,13.4011993408203125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia,Chloroquine + Losartan Camacho-Ortiz covid 19,IF20-00003 covid 19,,,,,,,,PG,2020-06-30,NCT04428268,ClinicalTrials.gov,2020-04-26,2020-03-10,TRUE,Hospital Universitario Dr. Jose E. Gonzalez,Recruiting,Phase 2,Interventional,Mexico,Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia,Drug,Chloroquine vs. Chloroquine + Losartan,Chloroquine; Losartan,20,https://clinicaltrials.gov/show/NCT04428268,,,2020-06-10,2020-08-30,2020-06-10,0,0,,,,,,,,,,,5,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-11-29 18:02:50,2020-11-29 18:03:10,IP Address,77.11.199.227,100,20,True,2020-11-29 18:03:11,R_PCAnHk6myyTO8Kd,,,test@test.com,,52.5321044921875,13.4011993408203125,gl,EN,yes,no,,Effects of Using Mobile App on Perceived Stress,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Effects of Using Mobile App on Perceived Stress,,,PG,2020-06-30,NCT04329533,ClinicalTrials.gov,2020-03-26,2020-04-13,FALSE,University of Arizona,Recruiting,Not Applicable,Interventional,United States,Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic,Other (psych),Psychological,Psychological,150,https://clinicaltrials.gov/show/NCT04329533,,,2020-06-30,2020-07-30,2020-06-30,0,0,,,,,,,,,,,5,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-11-29 17:58:13,2020-11-29 18:04:09,IP Address,86.31.166.235,100,355,True,2020-11-29 18:04:10,R_3KBcPL3kGAwwpyE,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hydroxychloroquine AND COVID-19 AND Healthcare workers AND Jawad Kirmani,Chemoprevention AND coronavirus AND healthcare workers,,,,,,,,,MPJ,2020-06-30,NCT04345653,ClinicalTrials.gov,2020-04-08,2020-04-14,FALSE,Hackensack Meridian Health,Not Recruiting,Phase 2,Interventional,United States,Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers,Drug (Chemoprophylaxis),Hydroxychloroquine,Hydroxychloroquine,44,https://clinicaltrials.gov/show/NCT04345653,,,2020-06-05,2021-04-08,2020-06-05,0,0,,,,,,,,,,,6,,"Active, not recruiting",TRUE,1,,,,,,,,,,,,,,,
2020-11-29 18:04:21,2020-11-29 18:10:46,IP Address,86.31.166.235,100,385,True,2020-11-29 18:10:47,R_1hxKreJvwR6qliY,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Outer Membrane Vesicle AND COVID-19 AND Toledo Romani,Outer Membrane Vesicle AND COVID-19,,,,,,"Despite not finding any results, the registry says:
'Date of available results: 
30/07/2020
Date of first publication: 
30/09/2020'",,,MPJ,2020-06-30,RPCEC00000314,RPCEC,2020-05-22,2020-04-24,TRUE,Finlay Vaccine Institute (IFV),Recruiting,Not Applicable,Interventional,Cuba,VA-MENGOC-BC to stimulate the innate response against SARS-CoV-2,ATMP,Vaccine,Vaccine,115000,https://rpcec.sld.cu/en/trials/RPCEC00000314-En,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-29 18:03:16,2020-11-29 18:14:37,IP Address,77.11.199.227,100,680,True,2020-11-29 18:14:37,R_2foMCKgOzKxD0BP,,,test@test.com,,52.5321044921875,13.4011993408203125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,full_results_journal_article,,,,,10.1001/jamainternmed.2020.6615,33080005,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2772186,,,,,,,,,,,,,2020-10-20,2020-06-11,,,,,,,,,,,,,,,,,,,,,,,,"On June 11, 2020, the trial Scientific Committee decided to interrupt the study for futility with an enrollment of 126 patients.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Salvarani Early Administration of Tocilizumab covid 19,Azienda Unità Sanitaria Locale Reggio Emilia  Early Administration of Tocilizumab covid 19,,,,,,,,,PG,2020-06-30,NCT04346355,ClinicalTrials.gov,2020-04-12,2020-03-31,TRUE,Azienda Unita Sanitaria Locale Reggio Emilia,Not Recruiting,Phase 2,Interventional,Italy,Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Drug,Tocilizumab,Tocilizumab,126,https://clinicaltrials.gov/show/NCT04346355,EUCTR2020-001386-37,,2020-06-06,2020-06-06,2020-06-06,0,0,,,,,,,,,,,5,,Terminated,TRUE,2,,,,,,,,,,,,,true,,
2020-11-29 18:10:55,2020-11-29 18:16:08,IP Address,86.31.166.235,100,312,True,2020-11-29 18:16:08,R_2qrACmKRnMz4XP0,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,lactic acid bacteria AND COVID-19 AND Japan,,,,,,,,team_review,,MPJ,2020-06-30,JPRN-UMIN000040479,JPRN,2020-05-22,2020-05-22,FALSE,Takanawa Clinic,Recruiting,Not Applicable,Interventional,Japan,Immunological efficacy of lactic acid bacteria for COVID-19,Drug,Lactic acid bacteria,Lactic acid bacteria,30,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046202,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,6,,Open public recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-29 18:14:43,2020-11-29 18:16:39,IP Address,77.11.199.227,100,116,True,2020-11-29 18:16:40,R_1JIOL2gpUBIb5fR,,,test@test.com,,52.5196075439453125,13.4069061279296875,gl,EN,yes,yes,no,,,no,2020-12-01,2021-01-01,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04353674,ClinicalTrials.gov,2020-04-07,2020-04-28,FALSE,Lawson Health Research Institute,Recruiting,Phase 1,Interventional,Canada,Modulation of Hyperinflammation in COVID-19,Other (device),Dialysis,Dialysis,40,https://clinicaltrials.gov/show/NCT04353674,,,2020-07-28,2021-01-01,2020-07-28,0,1,,,,,,,,,,,5,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2021-01-01
2020-11-29 18:16:46,2020-11-29 18:18:00,IP Address,77.11.199.227,100,73,True,2020-11-29 18:18:01,R_32KpklEPuoe2Z43,,,test@test.com,,52.5196075439453125,13.4069061279296875,gl,EN,yes,no,,The aim of the study is to determine which messages are most effective at increasing knowledge and changing behaviors that can protect individuals and their communities from the virus.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The aim of the study is to determine which messages are most effective at increasing knowledge and changing behaviors that can protect individuals and their communities from the virus. --> I would exclude, let's discuss though! ",team_review,,PG,2020-06-30,NCT04371419,ClinicalTrials.gov,2020-04-28,2020-05-13,FALSE,"National Bureau of Economic Research, Inc.",Not Recruiting,Not Applicable,Interventional,United States,COVID-19 Health Messaging to Underserved Communities,Other,Health Education,Health Education,15475,https://clinicaltrials.gov/show/NCT04371419,,,2020-05-24,2020-05-24,2020-05-24,0,0,,,,,,,,,,,5,,Completed,TRUE,2,,,,,,,,,,,,,,,
2020-11-29 18:18:07,2020-11-29 18:19:17,Spam,77.11.199.227,100,70,True,2020-11-29 18:19:18,R_1YP7ANCd2qyH2N3,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04432103,ClinicalTrials.gov,2020-06-12,2020-06-19,FALSE,Centro Medico ABC,Not Recruiting,Phase 3,Interventional,No Country Given,Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma,ATMP,Plasma,Plasma,36,https://clinicaltrials.gov/show/NCT04432103,,,2020-07-30,2020-09-30,2020-07-30,0,1,,,,,,,,,,,5,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-11-29 18:17:04,2020-11-29 18:22:04,IP Address,86.31.166.235,100,300,True,2020-11-29 18:22:05,R_WANSZOQslY0uF8d,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,vitamin A AND COVID-19 AND Qom province,vitamin A AND coronavirus AND Kamkar Hospital,,,,,,,,,MPJ,2020-06-30,IRCT20200314046774N1,IRCT,2020-06-12,2020-05-04,TRUE,Ghoum University of Medical Sciences,Not Recruiting,Phase 3,Interventional,Iran,treatment of COVID-19 whit vitamin A,Drug,Vitamin A,Vitamin A,94,http://en.irct.ir/trial/46519,,,,2020-06-13,2020-06-13,0,0,,,,,,,,,,,6,,Recruitment complete,TRUE,1,,,,,,,,,,,,,,,
2020-11-29 18:22:28,2020-11-29 18:25:45,IP Address,86.31.166.235,100,196,True,2020-11-29 18:25:46,R_1OW5K5rMyp1qnrg,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,no,,,,1,"U1111-1250-8875 ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Found a UTN ('universal trial number') - does this count as a trial ID we need to record? ",,,MPJ,2020-06-30,DRKS00021447,German Clinical Trials Register,2020-04-27,2020-05-01,FALSE,Charité University,Not Recruiting,Phase 2,Interventional,Germany,CytoResc - CytoSorb Rescue for COVID-19 Cytokine Storm,Other (device),Cytokine Adsorber,Cytokine Adsorber,100,http://www.drks.de/DRKS00021447,,,,,,0,1,,,,,,,,,,,6,,Recruiting planned,TRUE,1,,,,,,,,,,,,,,,
2020-11-29 18:25:55,2020-11-29 18:27:29,IP Address,86.31.166.235,100,94,True,2020-11-29 18:27:29,R_1LLF8g8lzH9mVIo,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,"Not certain that this should be included because it is for coronavirus and general 'disease prevention' ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04416919,ClinicalTrials.gov,2020-05-13,2020-06-15,FALSE,University of Oklahoma,Not Recruiting,Not Applicable,Interventional,United States,Assessment of N-95 Facemask for Use in COVID-19 Pandemic in Case of Shortage of Personal Protective Equipment,Other (device),Masks,Masks,20,https://clinicaltrials.gov/show/NCT04416919,,,2025-05-01,2025-05-01,2025-05-01,0,1,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-29 18:27:40,2020-11-29 18:28:59,Spam,86.31.166.235,100,79,True,2020-11-29 18:29:00,R_3dR27p49qo1NwVH,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04356482,ClinicalTrials.gov,2020-04-17,2020-05-20,FALSE,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,Recruiting,Phase 1/Phase 2,Interventional,Mexico,CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19,ATMP,Plasma,Plasma,90,https://clinicaltrials.gov/show/NCT04356482,,,2020-11-01,2020-12-01,2020-11-01,0,1,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-29 18:19:25,2020-11-29 18:29:14,IP Address,77.11.199.227,100,588,True,2020-11-29 18:29:14,R_3g0ML5xa98rV1z0,,,test@test.com,,52.5196075439453125,13.4069061279296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,https://clinicaltrials.gov/ProvidedDocs/24/NCT04441424/Prot_SAP_000.pdf <-- stury protocol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google,google,,,,full_results_preprint,full_results_journal_article,,,,"10.1101/2020.06.24.20121905 ",,https://www.medrxiv.org/content/10.1101/2020.06.24.20121905v1?versioned=true,,"32920571 ",https://europepmc.org/article/med/32920571,,,,,,,,,,2020-06-29,2020-06-01,2020-09-01,,,,,,,,,,,,,,,,,,,,,,,,"weird journal, no DOI",,,,,Convalescent Plasma Abdulamir covid 19,,,,,,,,,,PG,2020-06-30,NCT04441424,ClinicalTrials.gov,2020-06-12,2020-04-03,TRUE,Alkarkh Health Directorate-Baghdad,Not Recruiting,Not Applicable,Interventional,Iraq,Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients,ATMP (+ Drug),Plasma + Hydroxychloroquine + Azithromycin vs. Hydroxychloroquine + Azithromycin,Plasma; Hydroxychloroquine; Azithromycin,49,https://clinicaltrials.gov/show/NCT04441424,,,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,5,,Completed,TRUE,2,,,,,,,,,,,,,,,
2020-11-29 18:30:19,2020-11-29 18:32:00,IP Address,77.11.199.227,100,100,True,2020-11-29 18:32:01,R_3HC7vUzfdneQJ3F,,,test@test.com,,52.5321044921875,13.4011993408203125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"To investigate the feasibility of inhaled volatile anaesthetic agents in reducing the severity of COVID-19-associated ARDS.

--> I believe this study is on using a different kind of sedation to improve oputcomes from lung failure in COVID-19. This is arguably  a symptom of COVID, not the disease itself. I would include. ",team_review,,PG,2020-06-30,NL8523,Netherlands Trial Register,2020-04-13,2020-04-26,FALSE,UMC Utrecht,Not Recruiting,Not Applicable,Interventional,Netherlands,Volatile Anaesthetics in COVID-19 – a pilot study,Drug,Isoflurane,Isoflurane,20,https://trialregister.nl/trial/8523,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,5,,Planned,TRUE,2,,,,,,,,,,,,,,,
2020-11-29 18:32:09,2020-11-29 18:34:06,IP Address,77.11.199.227,100,117,True,2020-11-29 18:34:07,R_2D0jYm8FPlVfKqk,,,test@test.com,,52.5321044921875,13.4011993408203125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The main study parameter is the fold-increase in production of pro-inflammatory cytokines by PBMCs/monocytes following vaccination.

--> This study aims to assess immune response after enhanced BCG vaccination. No COVID involved. (just in the hypothesis) ",,,PG,2020-06-30,NL8609,Netherlands Trial Register,2020-05-11,2020-05-25,FALSE,Radboud University Medical Centre,Not Recruiting,Not Applicable,Interventional,Netherlands,Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine: a possible preventive approach against COVID-19 (BCG-PLUS),ATMP,Vaccine,Vaccine,100,https://trialregister.nl/trial/8609,,,,2020-06-08,2020-06-08,0,0,,,,,,,,,,,5,,Planned,TRUE,2,,,,,,,,,,,,,,,
2020-11-29 18:29:08,2020-11-29 18:35:45,IP Address,86.31.166.235,100,396,True,2020-11-29 18:35:45,R_AMLF7gfRdVi3geB,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-07-31,2020-07-31,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_journal_article,,,,,"10.1016/j.ijantimicag.2020.106224 ","33166694 ",https://www.sciencedirect.com/science/article/pii/S0924857920304350?via%3Dihub,,,,,,,,,,,,,2020-11-06,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Deba Prasad Dhibar AND Hydroxychloroquine AND COVID-19,PEP-CQ AND COVID-19,,,,,,,,,MPJ,2020-06-30,NCT04408456,ClinicalTrials.gov,2020-05-24,2020-03-01,TRUE,Postgraduate Institute of Medical Education and Research,Recruiting,Phase 3,Interventional,India,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,Drug (Chemoprophylaxis),Hydroxychloroquine,Hydroxychloroquine,200,https://clinicaltrials.gov/show/NCT04408456,,,2020-06-30,2020-06-30,2020-06-30,0,0,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,true,,2020-07-31
2020-11-29 18:35:59,2020-11-29 18:38:19,Spam,86.31.166.235,100,139,True,2020-11-29 18:38:19,R_25tkuSXAhFM3dKd,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04344951,ClinicalTrials.gov,2020-04-06,2020-04-06,FALSE,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,Recruiting,Phase 2,Interventional,Greece,"Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial",Drug,Chloroquine,Chloroquine,60,https://clinicaltrials.gov/show/NCT04344951,,,2021-04-01,2021-04-30,2021-04-01,0,1,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-29 18:38:44,2020-11-29 18:39:17,IP Address,86.31.166.235,100,33,True,2020-11-29 18:39:18,R_3HLEEBVzmTuclm4,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,"Treatment for mental health ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04396314,ClinicalTrials.gov,2020-05-15,2020-09-01,FALSE,University of Lleida,Not Recruiting,Not Applicable,Interventional,No Country Given,Effectiveness of Basic Body Awareness Therapy in Survivors of Covid-19 and Health Workers Regarding Post-traumatic Stress Disorders,Other (psych),Psychological,Psychological,54,https://clinicaltrials.gov/show/NCT04396314,,,2020-12-31,2021-04-30,2020-12-31,0,1,,,,,,,,,,,6,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-29 18:34:13,2020-11-29 18:40:28,IP Address,77.11.199.227,100,374,True,2020-11-29 18:40:28,R_12QGFKhAMfJd9ei,,,test@test.com,,52.5196075439453125,13.4069061279296875,gl,EN,yes,yes,no,,yes,,2020-05-07,2020-06-07,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"""CloroCovid-19""",,,,,,,,,,PG,2020-06-30,NCT04323527,,,,,,,,,,,,,,,,,,,,,,,,10.1101/2020.04.07.20056424,,10.1101/2020.04.07.20056424,10.1001/jamanetworkopen.2020.8857,interim_results_preprint,interim_results_journal_article,,2020-04-11,2020-04-24,5,,,FALSE,2,,interim_results_preprint,2020-04-11,ifxm3j4y,https://doi.org/10.1101/2020.04.07.20056424,"Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study)",,,32330277,interim_results_journal_article,2020-04-24,,,,2020-06-07
2020-11-29 18:39:25,2020-11-29 18:43:28,IP Address,86.31.166.235,100,242,True,2020-11-29 18:43:29,R_2ZDdFlslFad6uzp,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-07-27,2020-07-27,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hydroxychloroquine Monotherapy AND COVID-19 AND Novartis,,,,,,,,,,MPJ,2020-06-30,NCT04358081,ClinicalTrials.gov,2020-04-08,2020-05-01,FALSE,Novartis Pharmaceuticals,Recruiting,Phase 3,Interventional,United States,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Drug,Hydroxychloroquine + Azithromycin vs. Hydroxychloroquine,Azithromycin; Hydroxychloroquine,444,https://clinicaltrials.gov/show/NCT04358081,,,2020-06-25,2020-07-24,2020-06-25,0,0,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2020-07-27
2020-11-29 18:43:37,2020-11-29 18:44:47,IP Address,86.31.166.235,100,70,True,2020-11-29 18:44:47,R_2fvfEOLFhC3iYVj,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,"Treatment of acute lung injury associated with covid ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04350736,ClinicalTrials.gov,2020-04-14,2020-04-23,FALSE,Theravance Biopharma,Recruiting,Phase 1,Interventional,United Kingdom,"First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19",Drug,TD-0903,TD-0903,54,https://clinicaltrials.gov/show/NCT04350736,,,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-29 18:44:57,2020-11-29 18:47:33,IP Address,86.31.166.235,100,156,True,2020-11-29 18:47:34,R_3FLmwAMzarG7Jh6,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2021-06-30,2021-12-30,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04341935,ClinicalTrials.gov,2020-04-06,2020-06-30,FALSE,University of Miami,Not Recruiting,Phase 4,Interventional,United States,Effects of DPP4 Inhibition on COVID-19,Drug,Linagliptin,Linagliptin,20,https://clinicaltrials.gov/show/NCT04341935,,,2020-10-30,2020-12-30,2020-10-30,0,1,,,,,,,,,,,6,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,2021-12-30
2020-11-29 18:47:55,2020-11-29 18:54:11,IP Address,86.31.166.235,100,375,True,2020-11-29 18:54:11,R_2fJypLtfUUL5dI7,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-12-20,2020-12-21,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Umberto Maggiore AND Colchicine AND COVID-19,"Umberto Maggiore AND coronavirus AND pneumonia ",,,,,,,,,MPJ,2020-06-30,NCT04322565,ClinicalTrials.gov,2020-03-24,2020-04-20,FALSE,AOU di Parma,Recruiting,Phase 2,Interventional,Italy,Colchicine Counteracting Inflammation in COVID-19 Pneumonia,Drug,Colchicine,Colchicine,310,https://clinicaltrials.gov/show/NCT04322565,,,2020-06-20,2020-07-20,2020-06-20,0,0,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2020-12-21
2020-11-29 18:54:21,2020-11-29 18:55:32,IP Address,86.31.166.235,100,70,True,2020-11-29 18:55:33,R_2tzloxKoy8WD8sW,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-09-24,2020-10-08,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04328961,ClinicalTrials.gov,2020-03-23,2020-03-31,FALSE,University of Washington,Recruiting,Phase 2/Phase 3,Interventional,United States,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),Drug (Chemoprophylaxis),Hydroxychloroquine vs. Vitamin C,Hydroxychloroquine; Vitamin C,2000,https://clinicaltrials.gov/show/NCT04328961,,,2020-09-30,2020-10-31,2020-09-30,0,1,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2020-10-08
2020-11-29 18:55:39,2020-11-29 18:56:08,IP Address,86.31.166.235,100,29,True,2020-11-29 18:56:09,R_1f9RAVt3k64oCXG,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,"Mental health coping strategies ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04382560,ClinicalTrials.gov,2020-05-05,2020-05-02,TRUE,University of Parma,Recruiting,Not Applicable,Interventional,Italy,Coping Strategies and Responsiveness to a Brief Online Intervention During COVID-19 Pandemic,Other (psych),Psychological,Psychological,100,https://clinicaltrials.gov/show/NCT04382560,,,2020-05-31,2020-05-31,2020-05-31,0,0,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-29 18:56:27,2020-11-29 18:57:06,IP Address,86.31.166.235,100,38,True,2020-11-29 18:57:06,R_28BTm58GWaJeOGz,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,Trial re: mental health during the pandemic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04365972,ClinicalTrials.gov,2020-04-24,2020-04-23,TRUE,Tel Aviv University,Not Recruiting,Not Applicable,Interventional,Israel,Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic,Other (psych),Psychological,Psychological,20,https://clinicaltrials.gov/show/NCT04365972,,,2020-04-30,2020-04-30,2020-04-30,0,0,,,,,,,,,,,6,,Completed,TRUE,1,,,,,,,,,,,,,,,
2020-11-29 18:57:12,2020-11-29 19:04:46,IP Address,86.31.166.235,100,454,True,2020-11-29 19:04:46,R_1Qsy6x2uEVKFcLN,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,,,,,full_results_journal_article,,,,,10.21037/apm-20-1387,33222462,http://apm.amegroups.com/article/view/56244/pdf,,,,,,,,,,,,,2020-09-28,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"vitamin C AND coronavirus pneumonia AND Enqiang Mao ",vitamin C AND COVID-19 AND Shanghai,,,,,,,,,MPJ,2020-06-30,ChiCTR2000032716,ChiCTR,2020-05-08,2020-02-05,TRUE,"Ruijin Hospital, Shanghai Jiao Tong University School of Medicine",Not Recruiting,Not Applicable,Interventional,China,High dose intravenous vitamin C might be used as an important rescue therapy for aggravation of severe and critical novel coronavirus pneumonia (COVID-19) patients,Drug,Vitamin C,Vitamin C,12,http://www.chictr.org.cn/showproj.aspx?proj=53389,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,6,,Completed,TRUE,1,,,,,,,,,,,,,true,,
2020-11-30 15:32:42,2020-11-30 15:45:24,IP Address,81.109.92.226,100,761,True,2020-11-30 15:45:25,R_2zeFFMFuIKrzH9d,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ASC09 AND Ritonavir AND Covid,Yunqing Qiu,,,,,,,,,ND,2020-06-30,NCT04261907,ClinicalTrials.gov,2020-02-06,2020-02-07,FALSE,The First Affiliated Hospital of Zhejiang University,Not Recruiting,Not Applicable,Interventional,No Country Given,Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection,Drug,SC09 + ritonavir vs. lopinavir/ritonavir,ASC09; lopinavir/ritonavir,160,https://clinicaltrials.gov/show/NCT04261907,,,2020-05-31,2020-06-30,2020-05-31,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-11-30 15:45:37,2020-11-30 16:13:34,IP Address,81.109.92.226,100,1676,True,2020-11-30 16:13:34,R_3mZYGPPGuCx3sBl,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,,,,,full_results_journal_article,,,,,10.1002/advs.202001435,32837847,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404576/,,,,,,,,,,,,,2020-08-13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Azvudine AND Covid,"Pei Guangzhong ",,,,,,,,,ND,2020-06-30,ChiCTR2000029853,ChiCTR,2020-02-15,2020-02-16,FALSE,People's Hospital of Guangshan County,Recruiting,Not Applicable,Interventional,China,"A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)",Drug,Azvudine,Azvudine,20,http://www.chictr.org.cn/showproj.aspx?proj=49532,,,,2020-04-16,2020-04-16,0,0,,,,,,,,,,,5,,Recruiting,TRUE,2,,,,,,,,,,,,,true,,
2020-11-30 21:17:51,2020-11-30 21:19:22,IP Address,86.31.166.235,100,90,True,2020-11-30 21:19:23,R_2alXPD6UyEVO7RQ,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,"Mental health intervention for post partum depression ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04366817,ClinicalTrials.gov,2020-04-20,2020-04-01,TRUE,Assistance Publique – Hôpitaux de Paris,Not Recruiting,Not Applicable,Interventional,France,Psychological Impact of the Lockdown on Patients Giving Birth During the COVID-19 Epidemic Short Title : Isolement and Childbirth: Psychological Impact,Other (psych),No Intervention,No Intervention,120,https://clinicaltrials.gov/show/NCT04366817,,,2020-04-01,2020-06-01,2020-04-01,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-30 21:19:33,2020-11-30 21:20:23,IP Address,86.31.166.235,100,49,True,2020-11-30 21:20:23,R_2CwaePT8sth87O5,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,For diagnosis not treatment or prevention?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04361448,ClinicalTrials.gov,2020-04-20,2020-04-20,FALSE,Jessa Hospital,Not Recruiting,Not Applicable,Interventional,Belgium,Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,30,https://clinicaltrials.gov/show/NCT04361448,,,2020-05-20,2020-05-20,2020-05-20,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-30 21:20:51,2020-11-30 21:23:15,IP Address,86.31.166.235,100,143,True,2020-11-30 21:23:15,R_1QiOR5wcCQhCdBV,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-11-30,2021-02-28,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04359095,ClinicalTrials.gov,2020-04-15,2020-05-11,FALSE,National University of Colombia,Not Recruiting,Phase 2/Phase 3,Interventional,Colombia,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Drug,Hydroxychloroquine + Azithromycin vs. Hydroxychloroquine + Lopinavir/Ritonavir vs. Hydroxychloroquine,Hydroxychloroquine; Azithromycin; Lopinavir/Ritonavir,1600,https://clinicaltrials.gov/show/NCT04359095,,,2020-10-11,2020-10-31,2020-10-11,0,1,,,,,,,,,,,6,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,2021-02-28
2020-11-30 21:23:21,2020-11-30 21:28:28,IP Address,86.31.166.235,100,306,True,2020-11-30 21:28:28,R_VL7RQJF172UKkW5,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-12-01,2020-12-01,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Subcutaneous Sarilumab AND COVID-19 AND Rosario Garcia de Vicuña,,,,,,,,,,MPJ,2020-06-30,NCT04357808,ClinicalTrials.gov,2020-04-14,2020-04-13,TRUE,Maria del Rosario Garcia de Vicuña Pinedo,Recruiting,Phase 2,Interventional,Spain,Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID),Drug,Sarilumab,Sarilumab,30,https://clinicaltrials.gov/show/NCT04357808,EUCTR2020-001634-36,,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2020-12-01
2020-11-30 21:28:35,2020-11-30 21:35:40,IP Address,86.31.166.235,100,425,True,2020-11-30 21:35:40,R_33fB1p7PT1PQsSE,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hydroxychloroquine and Azithromycin AND COVID-19 AND Azidus,,,,,,,,,,MPJ,2020-06-30,NCT04348474,ClinicalTrials.gov,2020-04-13,2020-04-20,FALSE,Azidus Brasil,Not Recruiting,Phase 1,Interventional,Brazil,Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19,Drug,Hydroxychloroquine + Azithromycin,Hydroxychloroquine; Azithromycin,200,https://clinicaltrials.gov/show/NCT04348474,,,2020-06-30,2020-07-31,2020-06-30,0,0,,,,,,,,,,,6,,Suspended,TRUE,1,,,,,,,,,,,,,,,
2020-11-30 21:35:50,2020-11-30 21:41:06,IP Address,86.31.166.235,100,316,True,2020-11-30 21:41:07,R_32XAREl0d2lml9p,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Convalescent Plasma AND COVID-19 AND Veronika Müller,,,,,,,,,,MPJ,2020-06-30,NCT04345679,ClinicalTrials.gov,2020-04-11,2020-04-14,FALSE,Orthosera Kft.,Not Recruiting,Phase 1,Interventional,No Country Given,Anti COVID-19 Convalescent Plasma Therapy,ATMP,Plasma,Plasma,20,https://clinicaltrials.gov/show/NCT04345679,,,2020-06-01,2021-04-01,2020-06-01,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-30 21:41:17,2020-11-30 21:47:29,IP Address,86.31.166.235,100,371,True,2020-11-30 21:47:29,R_qXD4hIXPkXq4JWh,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Favipiravir AND COVID-19 AND Nucleic Acids AND Peking University ",Guiqiang Wang AND Favipiravir AND coronavirus,,,,,,,,,MPJ,2020-06-30,NCT04333589,ClinicalTrials.gov,2020-04-01,2020-04-01,FALSE,Peking University First Hospital,Recruiting,Not Applicable,Interventional,China,Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive,Drug,Favipiravir,Favipiravir,210,https://clinicaltrials.gov/show/NCT04333589,,,2020-06-01,2020-09-15,2020-06-01,0,1,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-30 21:48:38,2020-11-30 21:51:18,IP Address,86.31.166.235,100,159,True,2020-11-30 21:51:18,R_ukysx78HK1vSoNj,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04326920,ClinicalTrials.gov,2020-03-24,2020-03-24,FALSE,"University Hospital, Ghent",Recruiting,Phase 4,Interventional,"Belgium, Italy",Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),Drug,Sargramostim,Sargramostim,80,https://clinicaltrials.gov/show/NCT04326920,,,2020-10-31,2020-12-31,2020-10-31,0,1,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-11-30 21:51:32,2020-11-30 21:58:38,IP Address,86.31.166.235,100,425,True,2020-11-30 21:58:38,R_2s5t4f0YrPad3Y7,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Shahid Beheshti University AND coronavirus AND Umifenovir,"UAIIC AND COVID-19 AND clinical trial ",,,,,,,,,MPJ,2020-06-30,NCT04350684,ClinicalTrials.gov,2020-04-14,2020-04-15,FALSE,Shahid Beheshti University of Medical Sciences,Recruiting,Phase 4,Interventional,Iran,Umifenovir in Hospitalized COVID-19 Patients,Drug,Umifenovir + Interferon beta + Lopinavir/Ritonavir + Hydroxychloroquine vs. Interferon beta + Lopinavir/Ritonavir + Hydroxycholroquine,Umifenovir; Interferon beta; Lopinavir/Ritonavir; Hydroxychloroquine,40,https://clinicaltrials.gov/show/NCT04350684,,,2020-04-22,2020-04-24,2020-04-22,0,0,,,,,,,,,,,6,,Enrolling by invitation,TRUE,1,,,,,,,,,,,,,,,
2020-11-30 21:58:55,2020-11-30 22:04:46,IP Address,86.31.166.235,100,351,True,2020-11-30 22:04:47,R_2sR1Q26mjUv25E0,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Dexamethasone AND ARDS AND coronavirus AND Francois Stephan,DHYSCO AND clinical trial AND COVID-19,,,,,,,,,MPJ,2020-06-30,NCT04347980,ClinicalTrials.gov,2020-04-09,2020-04-01,TRUE,Centre Chirurgical Marie Lannelongue,Recruiting,Phase 3,Interventional,France,Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19,Drug,Dexamethasone + Hydroxychloroquine vs. Hydroxychloroquine,Dexamethasone; Hydroxychloroquine,122,https://clinicaltrials.gov/show/NCT04347980,,,2020-06-01,2020-08-01,2020-06-01,0,0,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-01 10:07:55,2020-12-01 10:16:05,IP Address,86.31.166.235,100,489,True,2020-12-01 10:16:05,R_1DpviMWEYLRlenJ,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Prone Positioning AND COVID-19 AND Xavier Elharrar,,,,,,,,,,MPJ,2020-06-30,NCT04344106,ClinicalTrials.gov,2020-04-08,2020-04-01,TRUE,ELHARRAR Xavier,Recruiting,Not Applicable,Interventional,France,Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study,Procedure,Positioning,Positioning,25,https://clinicaltrials.gov/show/NCT04344106,,,2020-04-15,2020-05-01,2020-04-15,0,0,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-01 10:16:30,2020-12-01 10:23:31,IP Address,86.31.166.235,100,421,True,2020-12-01 10:23:32,R_1iaq85ZaY7pmNuz,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Xavier Mariette AND COVID-19 AND Anakinra ",Hôpitaux de Paris AND CORIMUNO-ANA AND coronavirus,,,,,,,,,MPJ,2020-06-30,NCT04341584,ClinicalTrials.gov,2020-04-07,2020-04-01,TRUE,Assistance Publique – Hôpitaux de Paris,Not Recruiting,Phase 2,Interventional,No Country Given,CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection,Drug,Anakinra,Anakinra,240,https://clinicaltrials.gov/show/NCT04341584,,,2020-05-01,2020-12-31,2020-05-01,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-01 10:24:13,2020-12-01 10:25:04,IP Address,86.31.166.235,100,51,True,2020-12-01 10:25:05,R_6gk7B3mRIUhDRy9,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04336254,ClinicalTrials.gov,2020-03-28,2020-04-06,FALSE,Renmin Hospital of Wuhan University,Recruiting,Phase 1/Phase 2,Interventional,China,Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients,ATMP,Cells (mesenchymal),Cells (mesenchymal),20,https://clinicaltrials.gov/show/NCT04336254,,,2020-12-31,2021-03-31,2020-12-31,0,1,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-01 10:25:12,2020-12-01 10:30:10,IP Address,86.31.166.235,100,298,True,2020-12-01 10:30:11,R_WuH7rzPSi7djvWh,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Vitamin D AND COVID-19 AND Universidad de Granada,,,,,,,,,,MPJ,2020-06-30,NCT04334005,ClinicalTrials.gov,2020-03-29,2020-04-10,FALSE,University of Granada,Not Recruiting,Not Applicable,Interventional,Spain,Vitamin D on Prevention and Treatment of COVID-19,Drug,Vitamin D,Vitamin D,200,https://clinicaltrials.gov/show/NCT04334005,,,2020-06-30,2020-06-30,2020-06-30,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-01 10:30:45,2020-12-01 10:31:50,IP Address,86.31.166.235,100,64,True,2020-12-01 10:31:50,R_x45zLXRb6TA9mJr,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,ACTRN12620000477921,ANZCTR,2020-04-16,2020-04-20,FALSE,Dr. Michael Soares,Not Recruiting,Not Applicable,Interventional,Australia,The design of an updated iron lung ventilator which can be easily built and used by people with minimal training in situations such as COVID-19 where skilled doctors or normal ventilators are unavailable.,Other (physical),Mechanical ventilation,Mechanical ventilation,1,https://anzctr.org.au/ACTRN12620000477921.aspx,,,,2020-04-20,2020-04-20,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-01 10:47:57,2020-12-01 11:12:31,IP Address,81.109.92.226,100,1474,True,2020-12-01 11:12:32,R_3wlcBNhOyXRfX6p,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,Suspended,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,,,,,full_results_journal_article,,,,,10.1038/s41421-020-00197-3,32802404,,,,,,,,,,,,,,2020-08-05,,,,,,,,,,,,,,,,,,,,,,,,,Correspondence,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,honeysuckle AND (Covid OR SARS-COV-2),Li-Kun Zhou,Yongxiang Yi,,,,,,,,ND,2020-06-30,ChiCTR2000029822,ChiCTR,2020-02-14,2020-02-07,TRUE,Nanjing Second Hospital,Recruiting,Not Applicable,Interventional,No Country Given,A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection,Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,110,http://www.chictr.org.cn/showproj.aspx?proj=49502,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,5,,Recruiting,TRUE,2,,,,,,,,,,,,,true,,
2020-12-01 11:12:57,2020-12-01 11:21:48,IP Address,81.109.92.226,100,531,True,2020-12-01 11:21:48,R_3s02hknbDFWOIu7,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,no,2020-08-05,2020-08-07,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Viusid AND Asbrip AND Covid,Wilson Benites,Mario Mero,,,,,,,,ND,2020-06-30,NCT04407182,ClinicalTrials.gov,2020-05-25,2020-05-04,TRUE,Catalysis SL,Recruiting,Phase 2,Interventional,Ecuador,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19,Supplement,Viusid + Asbrip,Viusid + Asbrip,60,https://clinicaltrials.gov/show/NCT04407182,,,2020-06-13,2020-06-15,2020-06-13,0,0,,,,,,,,,,,5,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2020-08-07
2020-12-01 11:24:25,2020-12-01 11:25:29,IP Address,81.109.92.226,100,64,True,2020-12-01 11:25:29,R_1NDt6yNRXbl0Xjy,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04370886,ClinicalTrials.gov,2020-04-28,2020-04-30,FALSE,Guangzhou Blood Center,Not Recruiting,Not Applicable,Interventional,China,Recruit Blood Donors Via SMS During Epidemic of COVID-19,Other,No Intervention,No Intervention,456517,https://clinicaltrials.gov/show/NCT04370886,,,2020-04-30,2020-05-10,2020-04-30,0,0,,,,,,,,,,,5,,Completed,TRUE,2,,,,,,,,,,,,,,,
2020-12-01 11:25:52,2020-12-01 11:38:03,IP Address,81.109.92.226,100,730,True,2020-12-01 11:38:03,R_3m9N9Pbhyh53PPe,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,Suspended,,no,2021-05-27,2022-05-27,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Hydroxychloroquine AND ""Providence Health & Services""",Brian Kendall AND Covid,,,,,"The PI's name is Kendall with 2 Ls, it appears to be misspelled on CT.gov",,,,ND,2020-06-30,NCT04334967,ClinicalTrials.gov,2020-04-02,2020-03-30,TRUE,Providence Health & Services,Not Recruiting,Phase 4,Interventional,United States,Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care,Drug,Hydroxychloroquine vs. Vitamin C,Hydroxychloroquine; Vitamin C,13,https://clinicaltrials.gov/show/NCT04334967,,,2020-05-27,2020-05-27,2020-05-27,0,0,,,,,,,,,,,5,,Suspended,TRUE,2,,,,,,,,,,,,,,,2022-05-27
2020-12-01 11:41:59,2020-12-01 11:44:44,IP Address,81.109.92.226,100,165,True,2020-12-01 11:44:45,R_82Og0sm8ZttZQ4x,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,no,2021-07-27,2021-11-16,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04362059,ClinicalTrials.gov,2020-04-20,2020-06-27,TRUE,University Hospital Southampton NHS Foundation Trust,Not Recruiting,Not Applicable,Interventional,No Country Given,A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19,Drug,Bovactant,Bovactant,24,https://clinicaltrials.gov/show/NCT04362059,EUCTR2020-001886-35,,2020-07-27,2020-11-02,2020-07-27,0,1,,,,,,,,,,,5,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,2021-11-16
2020-12-01 12:53:41,2020-12-01 12:59:47,IP Address,81.109.92.226,100,366,True,2020-12-01 12:59:48,R_2Tueb9esGDq278g,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The primary completion date in the registration does not match the fact that primary endpoint was apparently finished and reported in the paper (as it's only 7 days follow-up),team_review,,ND,2020-06-30,NCT04313127,ClinicalTrials.gov,2020-03-15,2020-03-16,FALSE,CanSino Biologics Inc.,Not Recruiting,Phase 1,Interventional,China,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,ATMP,Adenovirus vector,Adenovirus vector,108,https://clinicaltrials.gov/show/NCT04313127,,,2020-12-30,2022-12-20,2020-12-30,0,1,,10.1016/S0140-6736(20)31208-3,,10.1016/S0140-6736(20)31208-3,,full_results_journal_article,,,2020-05-22,,5,,"Active, not recruiting",TRUE,2,32450106,full_results_journal_article,2020-05-22,uj5deryi,https://doi.org/10.1016/s0140-6736(20)31208-3; https://www.sciencedirect.com/science/article/pii/S0140673620312083; https://www.ncbi.nlm.nih.gov/pubmed/32450106/; https://api.elsevier.com/content/article/pii/S0140673620312083,"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial",,,,,,,,,
2020-12-01 15:26:21,2020-12-01 15:29:07,IP Address,81.109.92.226,100,166,True,2020-12-01 15:29:07,R_2v0Sl6tgdrvjrmi,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04385043,ClinicalTrials.gov,2020-05-04,2020-05-01,TRUE,University of Catanzaro,Recruiting,Phase 2/Phase 3,Interventional,Italy,Hyperimmune Plasma in Patients With COVID-19 Severe Infection,ATMP,Plasma,Plasma,400,https://clinicaltrials.gov/show/NCT04385043,,,2020-10-15,2021-05-15,2020-10-15,0,1,,,,,,,,,,,5,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-01 15:29:13,2020-12-01 15:30:42,Spam,81.109.92.226,100,88,True,2020-12-01 15:30:44,R_bwNt9REJdvVjrWx,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04340349,ClinicalTrials.gov,2020-04-02,2020-05-11,FALSE,Instituto Nacional de Rehabilitacion,Recruiting,Phase 1,Interventional,Mexico,Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals,Drug (Chemoprophylaxis),Hydroxychloroquine + bromhexine vs. bromhexine,Hydroxychloroquine; bromhexine,140,https://clinicaltrials.gov/show/NCT04340349,,,2020-07-20,2020-08-20,2020-07-20,0,1,,,,,,,,,,,5,,Enrolling by invitation,TRUE,2,,,,,,,,,,,,,,,
2020-12-01 15:30:47,2020-12-01 15:43:48,IP Address,81.109.92.226,100,780,True,2020-12-01 15:43:49,R_dcHhfQ13PtiPEQh,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,full_results_preprint,full_results_journal_article,,,,,,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3605131,10.1111/joim.13185,,,,,,,,,,,,2020-06-16,,2020-10-09,,,,,,,,,,,,,,,,,,,,,,,I don't think this has a full publication yet,This is the pub of the medrxiv preprint.,,,,,I followed the link to the systematic review which included details of these publications. There is another preprint for this trial and we need to make sure we pick the right one to include as the result.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,It looks like this trial is actually completed and has a wrong completion date on the registry (based on the publications) even though we don't know exactly when that is.,team_review,,ND,2020-06-30,NCT04340050,ClinicalTrials.gov,2020-04-07,2020-04-10,FALSE,University of Chicago,Not Recruiting,Phase 1,Interventional,United States,COVID-19 Convalescent Plasma,ATMP,Plasma,Plasma,10,https://clinicaltrials.gov/show/NCT04340050,,,2020-12-31,2021-12-31,2020-12-31,0,0,,10.1101/2020.06.21.20132944,,10.1101/2020.06.21.20132944,,full_results_preprint,,,2020-06-23,,5,,"Active, not recruiting",TRUE,2,,full_results_preprint,2020-06-23,x2t5h5gu,http://medrxiv.org/cgi/content/short/2020.06.21.20132944v1?rss=1,Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial,,,,,,,,,
2020-12-01 15:44:01,2020-12-01 15:50:56,IP Address,81.109.92.226,100,414,True,2020-12-01 15:50:56,R_ZvE1uVG8ajhFaTf,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,unknown,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,CTRI/2020/04/024747,CTRI,2020-04-21,2020-05-01,FALSE,GSL Medical College,Not Recruiting,Not Applicable,Interventional,India,EFFECTIVENESS TO MANAGE COVID 19 PANDEMIC BY  TEACHING  VENTILATORY MANAGEMENT TO NON-ANAESTHESIOLOGY RESIDENTS,Other,Other,Other,26,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43115,,,,,,0,1,,,,,,,,,,,5,,Not Yet Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-01 15:51:20,2020-12-01 15:57:39,IP Address,81.109.92.226,100,379,True,2020-12-01 15:57:39,R_ZrVbwtf8ZzVl8iJ,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PHR160 AND Covid,Pinene-Hydronoplactone-Ribonucleoic,Ahmad Reza Sharifi Olounabadi,,,,,,,,ND,2020-06-30,IRCT20160131026298N2,IRCT,2020-04-20,2020-03-10,TRUE,Bagheiat-allah University of Medical Sciences,Not Recruiting,Phase 2/Phase 3,Interventional,Iran,The effect of PHR spray on patients with coronavirus-19,Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,64,http://en.irct.ir/trial/46733,,,,2020-03-24,2020-03-24,0,0,,,,,,,,,,,5,,Recruitment complete,TRUE,2,,,,,,,,,,,,,,,
2020-12-01 15:57:50,2020-12-01 16:06:27,IP Address,81.109.92.226,100,516,True,2020-12-01 16:06:27,R_3hgSVCQ6DQopy0e,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Protocol: https://pubmed.ncbi.nlm.nih.gov/32493468/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COVIFERON,Seyed Sina Naghibi Irvani,Also checked citations of protocol,,,,,,,,ND,2020-06-30,NCT04343768,ClinicalTrials.gov,2020-04-08,2020-04-09,FALSE,Shahid Beheshti University of Medical Sciences,Not Recruiting,Phase 2,Interventional,Iran,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial",Drug,Hydroxychloroquine + Lopinavir/ritonavir + interferon beta 1a vs. hydroxychloroquine + Lopinavir/ritonavir + interferon beta 1b vs. hydroxychloroquine + Lopinavir/ritonavir,Hydroxychloroquine; Lopinavir/ritonavir; interferon beta,60,https://clinicaltrials.gov/show/NCT04343768,,,2020-04-27,2020-04-27,2020-04-27,0,1,,,,,,,,,,,5,,Completed,TRUE,2,,,,,,,,,,,,,,,
2020-12-01 16:06:47,2020-12-01 16:21:29,IP Address,81.109.92.226,100,881,True,2020-12-01 16:21:29,R_Y3TjCBNrcs9qnXb,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"There is a link to results but it doesn't lead to anything. ""The file does not exist or the file is illegally obtained!""",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Zhijun Xie,Chengping Wen,"""Zhejiang Chinese Medical University"" AND Covid",,,,No specific treatment to search.,,,,ND,2020-06-30,ChiCTR2000029578,ChiCTR,2020-02-05,2020-02-06,FALSE,Zhejiang Chinese Medical University,Recruiting,Not Applicable,Interventional,China,"Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, sing-arm trial",Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,1000,http://www.chictr.org.cn/showproj.aspx?proj=49080,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,5,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-01 16:21:47,2020-12-01 16:30:33,IP Address,81.109.92.226,100,525,True,2020-12-01 16:30:33,R_1Q9j4d2oBtjYOti,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,,,,,full_results_journal_article,,,,,10.1097/CCE.0000000000000263,33134951,,,,,,,,,,,,,,2020-10-21,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,DAS181 AND Covid,Jennifer Hui-Chun Ho,Zuojiong Gong,,,,,,,,ND,2020-06-30,NCT04324489,ClinicalTrials.gov,2020-03-25,2020-03-06,TRUE,Renmin Hospital of Wuhan University,Not Recruiting,Not Applicable,Interventional,China,DAS181 for Severe COVID-19: Compassionate Use,Drug,DAS181,DAS181,4,https://clinicaltrials.gov/show/NCT04324489,,,2020-04-16,2020-04-30,2020-04-16,0,0,,,,,,,,,,,5,,Completed,TRUE,2,,,,,,,,,,,,,true,,
2020-12-01 16:31:43,2020-12-01 16:32:31,IP Address,81.109.92.226,100,47,True,2020-12-01 16:32:31,R_xD6QSozJDPnNwtz,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,no,,"Per discussion, outcome is not directly tx/prevention.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04366947,ClinicalTrials.gov,2020-04-23,2020-04-14,TRUE,Lazarski University,Not Recruiting,Not Applicable,Interventional,Poland,Intravascular Access in Suspected/Confirmed COVID-19 Patient,Other (device),Intraosseous/Intravenous access device,Intraosseous/Intravenous access device,60,https://clinicaltrials.gov/show/NCT04366947,,,2020-05-20,2020-05-20,2020-05-20,0,0,,,,,,,,,,,5,,"Active, not recruiting",TRUE,2,,,,,,,,,,,,,,,
2020-12-01 16:32:38,2020-12-01 16:43:24,IP Address,81.109.92.226,100,646,True,2020-12-01 16:43:25,R_10qp311qM5qRMai,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,no,2020-12,2021-01,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PROVID study,Prone and Covid,Anatole Harrois,,,,,,,,ND,2020-06-30,NCT04366856,ClinicalTrials.gov,2020-04-26,2020-04-01,TRUE,Assistance Publique – Hôpitaux de Paris,Not Recruiting,Not Applicable,Interventional,France,PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study),Procedure,Positioning,Positioning,500,https://clinicaltrials.gov/show/NCT04366856,,,2020-05-01,2020-07-01,2020-05-01,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,2021-01
2020-12-01 16:44:43,2020-12-01 17:35:41,IP Address,81.109.92.226,100,3057,True,2020-12-01 17:35:41,R_2qmI4Y76718T90P,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"""Royan Institute"" AND ""Mesenchymal Stem Cell"" AND Covid",Hossein Baharvand,,,,,,,,,ND,2020-06-30,NCT04366063,ClinicalTrials.gov,2020-04-20,2020-04-05,FALSE,Royan Institute,Recruiting,Phase 2/Phase 3,Interventional,Iran,Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome,ATMP,Cells (mesenchymal),Cells (mesenchymal),60,https://clinicaltrials.gov/show/NCT04366063,IRCT20200217046526N2,,2020-06-06,2020-12-10,2020-06-06,0,0,,,,,,,,,,,5,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-01 17:35:50,2020-12-01 17:38:03,IP Address,81.109.92.226,100,133,True,2020-12-01 17:38:03,R_2QlgQo5ATY6MRAj,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Protocol: https://pubmed.ncbi.nlm.nih.gov/32513308/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04359810,ClinicalTrials.gov,2020-04-21,2020-04-21,FALSE,Max R. O'Donnell,Recruiting,Phase 2,Interventional,United States,Plasma Therapy of COVID-19 in Critically Ill Patients,ATMP,Plasma,Plasma,105,https://clinicaltrials.gov/show/NCT04359810,,,2020-12-01,2021-04-01,2020-12-01,0,1,,,,,,,,,,,5,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-01 17:38:35,2020-12-01 17:51:51,IP Address,81.109.92.226,100,795,True,2020-12-01 17:51:51,R_2Xp0jrowS3DTXn6,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"""Gu Biao Jie Du Ling"" AND Covid",Su Wen,,,,,,,,,ND,2020-06-30,ChiCTR2000029487,ChiCTR,2020-02-02,2020-02-10,FALSE,Wuhan Hospital of Integrated Traditional Chinese and Western Medicine,Not Recruiting,Not Applicable,Prevention,China,Clinical Study for Gu-Biao Jie-Du-Ling in Preventing of Novel Coronavirus Pneumonia (COVID-19) in Children,Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,200,http://www.chictr.org.cn/showproj.aspx?proj=48965,,,,2020-03-31,2020-03-31,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-01 17:52:02,2020-12-01 17:58:11,IP Address,81.109.92.226,100,369,True,2020-12-01 17:58:12,R_3NE4S8QY4KQmWnz,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,no,2021-08,2021-12,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Isotretinoin AND Covid,Lamia Elgarhy,,,,,It appears this study hasn't even started yet according to the registry.,,,,ND,2020-06-30,NCT04361422,ClinicalTrials.gov,2020-04-21,2020-04-21,FALSE,Tanta University,Not Recruiting,Phase 3,Interventional,No Country Given,Isotretinoin in Treatment of COVID-19,Drug,Isotretinoin,Isotretinoin,300,https://clinicaltrials.gov/show/NCT04361422,,,2020-06-01,2020-09-01,2020-06-01,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,2021-12
2020-12-02 09:55:30,2020-12-02 10:09:21,IP Address,86.31.166.235,100,831,True,2020-12-02 10:09:21,R_qQjdMtzsTsLcspz,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Favipiravir AND COVID-19 AND pneumonia AND Japan,Favipiravir AND coronavirus AND fujifilm,,,,,,,,,MPJ,2020-06-30,JPRN-JapicCTI-205238,JPRN,2020-03-27,2020-03-31,FALSE,"FUJIFILM Toyama Chemical Co., Ltd.",Recruiting,Phase 3,Interventional,Japan,Phase 3 Clinical Study of Favipiravir in Patients with COVID-19 Non-Severe Pneumonia,Drug,Favipiravir,Favipiravir,96,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-205238,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,6,,recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-01 10:30:23,2020-12-02 10:18:56,IP Address,86.31.166.235,100,85713,True,2020-12-02 10:18:57,R_w4MLCtULeNlSUNP,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Hydroxychloroquine AND COVID-19 AND Shanghai Public Health Clinical Center	",,,,,,,,,,MPJ,2020-06-30,NCT04261517,ClinicalTrials.gov,2020-02-06,2020-02-06,FALSE,Shanghai Public Health Clinical Center,Not Recruiting,Phase 3,Interventional,China,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Drug,Hydroxychloroquine,Hydroxychloroquine,30,https://clinicaltrials.gov/show/NCT04261517,,,2020-02-25,2020-02-25,2020-02-25,0,1,,10.3785/j.issn.1008-9292.2020.03.03,,10.3785/j.issn.1008-9292.2020.03.03,,full_results_journal_article,,,2020-05-25,,6,,Completed,TRUE,1,32391667,full_results_journal_article,2020-05-25,,,,,,,,,,true,,
2020-12-02 10:19:08,2020-12-02 10:24:59,IP Address,86.31.166.235,100,350,True,2020-12-02 10:25:00,R_24NtMcj8rwRo47p,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2022-02-20,2022-08-31,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Min Liu AND NKG2D-ACE2 CAR-NK Cells AND COVID-19,,,,,,,,,,MPJ,2020-06-30,NCT04324996,ClinicalTrials.gov,2020-03-25,2020-03-21,TRUE,Chongqing Public Health Medical Center,Recruiting,Phase 1/Phase 2,Interventional,China,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19,ATMP,Cells (NK),Cells (NK),90,https://clinicaltrials.gov/show/NCT04324996,,,2020-05-31,2020-09-30,2020-05-31,0,0,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2022-08-31
2020-12-02 10:25:07,2020-12-02 10:30:49,IP Address,86.31.166.235,100,342,True,2020-12-02 10:30:50,R_1mRCyXZyvUpfjGJ,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Interferon Atomization AND COVID-19 AND Tongji Hospital,,,,,,,,,,MPJ,2020-06-30,NCT04254874,ClinicalTrials.gov,2020-02-02,2020-02-01,TRUE,"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,Phase 4,Interventional,China,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia",Drug,Interferon + Umifenovir vs. Umifenovir,Interferon; Umifenovir,100,https://clinicaltrials.gov/show/NCT04254874,,,2020-06-01,2020-07-01,2020-06-01,0,0,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-02 10:31:07,2020-12-02 10:34:45,IP Address,86.31.166.235,100,218,True,2020-12-02 10:34:45,R_Zah9W46BL7hIrcd,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Bufonis Venenum Injection AND COVID-19 AND Hu Xingxing ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030704,ChiCTR,2020-03-10,2020-02-10,TRUE,The First People's Hospital of Jiangxia District,No Status Given,Phase 4,Interventional,China,Observation Of Clinical Efficacy And Safety Of Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,50,http://www.chictr.org.cn/showproj.aspx?proj=50778,,,,2020-03-10,2020-03-10,0,0,,10.1101/2020.05.20.20107607,,10.1101/2020.05.20.20107607,,full_results_preprint,,,2020-05-26,,6,,Suspending,TRUE,1,,full_results_preprint,2020-05-26,1q8972uo,http://medrxiv.org/cgi/content/short/2020.05.20.20107607v1?rss=1,Chansu Injection Improves the Respiratory Function of Severe COVID-19 Patients,,,,,,,,true,
2020-12-02 19:09:51,2020-12-02 19:15:33,IP Address,129.67.118.20,100,341,True,2020-12-02 19:15:33,R_2a8pIRXvMrgIIX5,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,I think this registration doesn't actually exist anymore,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,ND,2020-06-30,ChiCTR2000029381,ChiCTR,2020-01-27,2020-01-24,TRUE,The First Affiliated Hospital of Guangzhou Medical University,Not Recruiting,Phase 4,Interventional,China,A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,400,http://www.chictr.org.cn/showproj.aspx?proj=48768,,,,2020-12-31,2020-12-31,0,0,,10.3760/cma.j.cn121430-20200406-00386,,10.3760/cma.j.cn121430-20200406-00386,,full_results_journal_article,,,2020-04-28,,5,,Completed,TRUE,2,32527346,full_results_journal_article,2020-04-28,,,,,,,,,,,,
2020-12-02 19:16:51,2020-12-02 19:17:38,IP Address,129.67.118.20,100,46,True,2020-12-02 19:17:38,R_1gbWkYFdkUlbLji,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,no,,"Exercise during, not for, covid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,ChiCTR2000030090,ChiCTR,2020-02-22,2020-02-22,FALSE,West China Hospital of Sichuan University,Not Recruiting,Not Applicable,Interventional,China,A Prospective Randomized Controlled Trial for Home Exercise Prescription Intervention During Epidemic of Novel Coronary Pneumonia (COVID-19) in College Students,Other (exercise),Exercise,Exercise,400,http://www.chictr.org.cn/showproj.aspx?proj=49910,,,,2020-03-22,2020-03-22,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-02 19:17:47,2020-12-02 19:26:00,IP Address,129.67.118.20,100,493,True,2020-12-02 19:26:01,R_3oNoyznQobIBUSw,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Lan Chen AND Hydroxychloroquine,Zhen-Yu Yin AND chloroquine,,,,,,,,,ND,2020-06-30,ChiCTR2000030054,ChiCTR,2020-02-22,2020-02-22,FALSE,Zhongshan Hospital Affiliated to Xiamen University,Not Recruiting,Not Applicable,Interventional,China,"A prospective, open label, randomized, control trial for chloroquine or hydroxychloroquine in patients with mild and common novel coronavirus pulmonary (COVIP-19)",Drug,Chloroquine + Hydroxychloroquine,Chloroquine; Hydroxychloroquine,100,http://www.chictr.org.cn/showproj.aspx?proj=49869,,,,2020-05-21,2020-05-21,0,0,,10.1101/2020.06.19.20136093,,10.1101/2020.06.19.20136093,,full_results_preprint,,,,,5,,Not yet recruiting,TRUE,2,,full_results_preprint,,t1vom8f3,http://medrxiv.org/cgi/content/short/2020.06.19.20136093v1?rss=1,Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study,,,,,,,,true,
2020-12-02 19:29:38,2020-12-02 19:46:39,IP Address,129.67.118.20,100,1021,True,2020-12-02 19:46:41,R_ZFg508GfOi3abYt,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,no,2021-04,2021-06,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ICAR AND trial,"""Polyvalent Immunoglobulin"" AND covid",Aurélien Mazeraud,,,,,,,,ND,2020-06-30,NCT04350580,ClinicalTrials.gov,2020-04-08,2020-04-11,TRUE,Centre Hospitalier St. Anne,Recruiting,Phase 3,Interventional,France,Polyvalent Immunoglobulin in COVID-19 Related ARds,ATMP,Immunoglobulin,Immunoglobulin,138,https://clinicaltrials.gov/show/NCT04350580,EUCTR2020-001570-30,,2020-06-01,2020-08-01,2020-06-01,0,0,,,,,,,,,,,5,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2021-06
2020-12-02 19:46:58,2020-12-02 19:51:23,IP Address,129.67.118.20,100,265,True,2020-12-02 19:51:23,R_1gdxB5E8LLLd0Re,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hydroxychloroquine AND Prophylaxis AND Colombia,Carlos Alberto Parra Lopez,,,,,,,,,ND,2020-06-30,NCT04346329,ClinicalTrials.gov,2020-04-10,2020-04-20,FALSE,National University of Colombia,Not Recruiting,Phase 3,Interventional,Colombia,Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19,Drug (Chemoprophylaxis),Hydroxychloroquine,Hydroxychloroquine,86,https://clinicaltrials.gov/show/NCT04346329,,,2020-06-01,2020-10-01,2020-06-01,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-03 00:29:22,2020-12-03 00:30:00,IP Address,81.109.92.226,100,37,True,2020-12-03 00:30:00,R_27jwxuj9JEfGgGR,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04338568,ClinicalTrials.gov,2020-04-04,2020-04-13,FALSE,Hasselt University,Recruiting,Not Applicable,Interventional,Belgium,Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,50,https://clinicaltrials.gov/show/NCT04338568,,,2020-04-30,2020-04-30,2020-04-30,0,1,,,,,,,,,,,5,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-03 00:30:07,2020-12-03 00:30:40,Spam,81.109.92.226,100,33,True,2020-12-03 00:30:40,R_2Vw1EZnC8HjMAPX,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04334434,ClinicalTrials.gov,2020-04-02,2020-04-20,FALSE,Kubra Koce,Not Recruiting,Not Applicable,Interventional,Turkey,Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19),Telehealth,Physio & Rehabilitation,Physio & Rehabilitation,30,https://clinicaltrials.gov/show/NCT04334434,,,2020-06-01,2020-07-31,2020-06-01,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-03 00:30:46,2020-12-03 00:46:13,IP Address,129.67.117.73,100,926,True,2020-12-03 00:46:14,R_2YECqfs8UWy4LYe,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Baricitinib AND Covid,Fabrizio Cantini,Laura Niccoli,,,,"Just a note that this does not appear to be a result for this trial but it looks very similar by the same team:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313480/

",,,,ND,2020-06-30,NCT04320277,ClinicalTrials.gov,2020-03-20,2020-05-16,FALSE,Hospital of Prato,Not Recruiting,Phase 2/Phase 3,Interventional,Italy,"Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.",Drug,Baricitinib,Baricitinib,200,https://clinicaltrials.gov/show/NCT04320277,,,2020-06-30,2020-07-30,2020-06-30,0,1,,,,,,,,,,,5,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-03 00:47:55,2020-12-03 00:52:43,IP Address,129.67.117.73,100,287,True,2020-12-03 00:52:44,R_vYOb5tExoPsRAnn,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Xiangxue AND covid,Wu-Zhi-Fang-Guan-Fang AND Covid,"Feng WANG ",,,,,,,,ND,2020-06-30,ChiCTR2000030033,ChiCTR,2020-02-21,2020-02-24,FALSE,The First Affiliated Hospital of Guangzhou Medical University,Not Recruiting,Not Applicable,Interventional,China,A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,828,http://www.chictr.org.cn/showproj.aspx?proj=49703,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-03 23:36:20,2020-12-03 23:47:41,IP Address,81.109.92.226,100,680,True,2020-12-03 23:47:41,R_2PwkGbSFd1SsKxz,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,no,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Farzaneh Dastan,Payam Tabarsi,Interferon beta 1-a AND Covid,,,,,,,,ND,2020-06-30,IRCT20151227025726N12,IRCT,2020-03-23,2020-03-03,TRUE,Shahid Beheshti University of Medical Sciences,Not Recruiting,Phase 3,Interventional,Iran,Evaluting the therapeutic and adverse effects of Interferon beta 1-a in patients with novel Coronavirus(COVID-19),Drug,Interferon beta + hydroxychloroquine + osletamivir + lopinavir/ritonavir,Interferon beta; hydroxychloroquine; oseltamivir; lopinavir/ritonavir,20,http://en.irct.ir/trial/46561,,,,,,0,0,,10.1016/j.intimp.2020.106688,,10.1016/j.intimp.2020.106688,,full_results_journal_article,,,2020-06-07,,5,,Recruitment complete,TRUE,2,32544867,full_results_journal_article,2020-06-07,m7rx8tv9,https://www.ncbi.nlm.nih.gov/pubmed/32544867/; https://doi.org/10.1016/j.intimp.2020.106688; https://www.sciencedirect.com/science/article/pii/S1567576920312893?v=s5; https://api.elsevier.com/content/article/pii/S1567576920312893,Subcutaneous administration of Interferon beta-1a for COVID-19: A non-controlled prospective trial,,,,,,,true,,
2020-12-03 23:48:04,2020-12-03 23:53:42,IP Address,81.109.92.226,100,338,True,2020-12-03 23:53:43,R_3ebpc6o4R4usSCc,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Interferon alpha 1b AND eyedrops AND covid,Feng Cao AND interferon,Yabin Wang,,,,,,,,ND,2020-06-30,ChiCTR2000029989,ChiCTR,2020-02-18,2020-02-20,FALSE,Chinese PLA General Hospital,Not Recruiting,Phase 4,Interventional,China,A randomized controlled Trial for therapeutic efficacy of Recombinant Human Interferon alpha 1b Eye Drops in the treatment of elderly with novel coronavirus pneumonia (COVID-19),Drug,Interferon alfa,Interferon alfa,300,http://www.chictr.org.cn/showproj.aspx?proj=49720,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-03 23:53:34,2020-12-04 00:01:03,IP Address,81.109.92.226,100,449,True,2020-12-04 00:01:03,R_V2tSt3zr6vGGBXz,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Abidol AND Oseltamivir AND lopinavir,Qing Ning,Meifang Han,,,,,"I don't know what a ""Prospective/Retrospective"" trial is.",team_review,,ND,2020-06-30,NCT04255017,ClinicalTrials.gov,2020-02-02,2020-02-01,TRUE,"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,Phase 4,Interventional,China,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia",Drug,Umeprevir vs. Oseltamivir vs. lopinavir/ritonavir,Umeprevir; Oseltamivir; Lopinavir/ritonavir,400,https://clinicaltrials.gov/show/NCT04255017,,,2020-06-01,2020-07-01,2020-06-01,0,0,,,,,,,,,,,5,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-05 09:14:33,2020-12-05 09:18:01,IP Address,86.31.166.235,100,207,True,2020-12-05 09:18:01,R_xfGVMLEJebLsP3X,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Danoprevir sodium tablet AND ritonavir AND COVID-19 AND Junxue Wang,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000031734,ChiCTR,2020-04-08,2020-03-19,TRUE,Huo-Shen-Shan Hospital,Recruiting,Not Applicable,Interventional,China,"Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel Coronavirus Pneumonia (COVID-19): a randomized, open-label, controlled trial",Drug,Danorevir + ritonavir,Danorevir; ritonavir,40,http://www.chictr.org.cn/showproj.aspx?proj=52103,,,,2020-05-29,2020-05-29,0,0,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-05 09:18:10,2020-12-05 09:25:50,IP Address,86.31.166.235,100,459,True,2020-12-05 09:25:50,R_1FLBqeFXNNeXxXw,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,summary_results,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Excel File,,,,,,,google_scholar,,,,,full_results_journal_article,,,,,10.3389/fphar.2020.561674,,https://www.frontiersin.org/articles/10.3389/fphar.2020.561674/full,,,,,,,,,,,,,2020-11-06,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000031630,ChiCTR,2020-04-05,2020-02-17,TRUE,Guangzhou Eighth People's Hospital,Recruiting,Not Applicable,Interventional,China,Clinical study for Celebrex in the treatment of novel coronavirus pneumonia (COVID-19),Drug,Celecoxib,Celecoxib,60,http://www.chictr.org.cn/showproj.aspx?proj=50474,,,,2020-06-17,2020-06-17,0,0,,10.1101/2020.05.05.20077610,,10.1101/2020.05.05.20077610,,full_results_preprint,,,2020-05-11,,6,,Recruiting,TRUE,1,,full_results_preprint,2020-05-11,a1gf76bu,http://medrxiv.org/cgi/content/short/2020.05.05.20077610v1?rss=1,Celebrex adjuvant therapy on COVID-19: An experimental study,,,,,,,true,true,
2020-12-05 09:26:34,2020-12-05 09:27:52,IP Address,86.31.166.235,100,77,True,2020-12-05 09:27:52,R_2BzDEWlrdi2onJW,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029496,ChiCTR,2020-02-03,2020-01-29,TRUE,The First Hospital of Changsha; The Second Xiangya Hospital of Central South University,Recruiting,Phase 4,Interventional,China,"A randomized, open label, parallel controlled trial of evaluating the efficacy of recombinant cytokine gene-derived protein injection for clearing novel coronavirus in patients with novel coronavirus pneumonia (COVID-19)",ATMP,Gene-derived protein,Gene-derived protein,90,http://www.chictr.org.cn/showproj.aspx?proj=48809,,,,2021-01-29,2021-01-29,0,0,,10.1101/2020.04.24.20077735,,10.1101/2020.04.24.20077735,,full_results_preprint,,,2020-04-29,,6,,Recruiting,TRUE,1,,full_results_preprint,2020-04-29,rq5gh710,http://medrxiv.org/cgi/content/short/2020.04.24.20077735v1?rss=1,"A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19",,,,,,,,,
2020-12-05 09:27:59,2020-12-05 09:36:07,IP Address,86.31.166.235,100,487,True,2020-12-05 09:36:08,R_RVbkr7zO8ND855n,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Chloroquine Phosphate AND COVID-19 AND Zhao Yan,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030718,ChiCTR,2020-03-11,2020-02-12,TRUE,Zhongnan Hospital of Wuhan University,Recruiting,Phase 4,Interventional,China,Randomized controlled trial for Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19),Drug,Chloroquine,Chloroquine,80,http://www.chictr.org.cn/showproj.aspx?proj=50843,,,,2020-05-30,2020-05-30,0,0,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-05 09:36:17,2020-12-05 09:39:26,IP Address,86.31.166.235,100,189,True,2020-12-05 09:39:27,R_3qCicynVzNsrZj0,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Wen Jianli AND dexmedetomidine AND COVID-19,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030853,ChiCTR,2020-03-16,2020-02-01,TRUE,Third Affiliated Hospital of Zunyi Medical University,Not Recruiting,Not Applicable,Interventional,No Country Given,Evaluation of the protective effect of dexmedetomidine on patients with severe novel coronavirus pneumonia (COVID-19),Drug,Dexmedetomidine,Dexmedetomidine,200,http://www.chictr.org.cn/showproj.aspx?proj=51081,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-05 21:32:25,2020-12-05 21:34:40,IP Address,86.31.166.235,100,134,True,2020-12-05 21:34:40,R_2rruDgpRvzJAV0y,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029308,ChiCTR,2020-01-23,2020-01-10,TRUE,Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital),Recruiting,Not Applicable,Interventional,China,"A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with novel coronavirus pneumonia (COVID-19)",Drug,Lopinavir/ritonavir,lopinavir/ritonavir,160,http://www.chictr.org.cn/showproj.aspx?proj=48684,,,,2021-01-10,2021-01-10,0,0,,10.1056/NEJMoa2001282,,10.1056/NEJMoa2001282,,full_results_journal_article,,,2020-03-18,,6,,Recruiting,TRUE,1,32187464,full_results_journal_article,2020-03-18,,,,,,,,,,,,
2020-12-05 21:35:19,2020-12-05 21:38:30,IP Address,86.31.166.235,100,191,True,2020-12-05 21:38:31,R_2wH4FGqWzYV9B3a,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Cytosorb AND COVID-19 AND Xuemei Li ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030475,ChiCTR,2020-03-03,2020-03-04,FALSE,Chinese Academy of Medical Sciences Peking Union Medical College Hospital,Not Recruiting,Not Applicable,Interventional,China,Cytosorb in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19),Other (physical),Blood purification,Blood purification,19,http://www.chictr.org.cn/showproj.aspx?proj=50452,,,,2020-06-25,2020-06-25,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-05 21:38:40,2020-12-05 21:42:11,IP Address,86.31.166.235,100,211,True,2020-12-05 21:42:11,R_3DhIWNx5YB9hjEt,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"ipecacuanha tincture AND COVID-19 AND Liangdan Sun ","Pediatric Huatanzhike granules AND coronavirus AND Anhui Medical University ",,,,,,,,,MPJ,2020-06-30,ChiCTR2000030022,ChiCTR,2020-02-20,2020-02-22,FALSE,The First Affiliated Hospital of Anhui Medical University,Not Recruiting,Phase 4,Interventional,China,"A parallel, randomized controlled clinical trial for the efficacy and safety of Pediatric Huatanzhike granules (containing ipecacuanha tincture) in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,100,http://www.chictr.org.cn/showproj.aspx?proj=49797,,,,2020-05-22,2020-05-22,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-05 21:42:20,2020-12-05 21:46:35,IP Address,86.31.166.235,100,254,True,2020-12-05 21:46:35,R_xnHRd8QFXjPJHO1,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,unknown,'Cancelled by the investigator' - is this withdrawn?,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Tocilizumab AND COVID-19 AND Ma Xiaorong ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030442,ChiCTR,2020-03-02,2020-03-05,FALSE,The Second Affiliated Hospital of Xi'an Jiaotong University,Not Recruiting,Not Applicable,Interventional,No Country Given,"Combination of Tocilizumab, IVIG and CRRT in severe patients with novel coronavirus pneumonia (COVID-19)",Drug (+ ATMP + Other (renal)),Tocilizumab + immunoglobulin + renal replacement therapy,Tocilizumab; Immunoglobulin; Renal replacement therapy,100,http://www.chictr.org.cn/showproj.aspx?proj=50380,,,,2020-05-15,2020-05-15,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-05 21:46:46,2020-12-05 21:50:37,IP Address,86.31.166.235,100,230,True,2020-12-05 21:50:37,R_2BkXp4pe18xCXpx,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Chen Xinyu AND COVID-19 AND Chinese medicine,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029960,ChiCTR,2020-02-17,2020-02-28,FALSE,The First Affiliated Hospital of Hu'nan University of Traditional Chinese Medicine,Not Recruiting,Not Applicable,Interventional,China,Comparative study for integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province,Traditional Medicine + Western Medicine,Traditional Medicine,Traditional Medicine,100,http://www.chictr.org.cn/showproj.aspx?proj=49639,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-05 21:50:48,2020-12-05 21:56:41,IP Address,86.31.166.235,100,353,True,2020-12-05 21:56:42,R_doNg6Z8HvRcxuM1,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Chloroquine Phosphate AND COVID-19 AND Zhao Yan ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029988,ChiCTR,2020-02-18,2020-02-13,TRUE,Zhongnan Hospital of Wuhan University,Recruiting,Phase 4,Interventional,China,Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19),Drug,Chloroquine,Chloroquine,80,http://www.chictr.org.cn/showproj.aspx?proj=49218,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-05 21:56:51,2020-12-05 21:59:40,IP Address,86.31.166.235,100,168,True,2020-12-05 21:59:40,R_1Owz5urQQsDJsI6,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"ozonated autohemotherapy AND COVID-19 AND Chen Xiangdong ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030006,ChiCTR,2020-02-19,2020-02-19,FALSE,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,Not Applicable,Interventional,China,A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19),Drug,Ozone,Ozone,60,http://www.chictr.org.cn/showproj.aspx?proj=49737,,,,2020-05-19,2020-05-19,0,0,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-05 21:59:54,2020-12-05 22:06:13,IP Address,86.31.166.235,100,379,True,2020-12-05 22:06:13,R_RWRZwvzEVbqyk6Z,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,summary_results,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COVID-19 AND Zhang Dingyu AND inactivated plasma,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030010,ChiCTR,2020-02-19,2020-02-19,FALSE,Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital),Not Recruiting,Not Applicable,Interventional,China,"A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)",ATMP,Plasma,Plasma,100,http://www.chictr.org.cn/showproj.aspx?proj=49777,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-05 22:06:23,2020-12-05 22:10:33,IP Address,86.31.166.235,100,250,True,2020-12-05 22:10:33,R_xG9ojNNoEscogzT,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,unknown,"'Cancelled' ",,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"humanistic care AND COVID-19 AND Gong Shouping ",,,,,,,"Is this the same study? https://clinicaltrials.gov/ct2/show/NCT04283825. If so, it is withdrawn. Also query whether it is 'treatment' for Covid-19. ",team_review,,MPJ,2020-06-30,ChiCTR2000030136,ChiCTR,2020-02-24,2020-02-24,FALSE,The Second Affiliated Hospital of Xi'an Jiaotong University,Not Recruiting,Not Applicable,Interventional,China,Humanistic Care in Patients With Novel Coronavirus Pneumonia (COVID-19),Other,Humanistic Care,Humanistic Care,130,http://www.chictr.org.cn/showproj.aspx?proj=50005,,,,2020-05-15,2020-05-15,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-05 22:10:43,2020-12-05 22:16:27,IP Address,86.31.166.235,100,343,True,2020-12-05 22:16:27,R_9mfW1NKpEf8bk5z,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"http://xbyxb.csu.edu.cn/xbwk/CN/10.11817/j.issn.1672-7347.2020.200318

","Le Aiping AND plasma therapy AND COVID-19 ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030179,ChiCTR,2020-02-24,2020-02-24,FALSE,The First Affiliated Hospital of Nanchang University,Recruiting,Not Applicable,Interventional,China,Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19),ATMP,Plasma,Plasma,100,http://www.chictr.org.cn/showproj.aspx?proj=50059,,,,2020-04-24,2020-04-24,0,0,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-05 22:16:34,2020-12-05 22:26:09,IP Address,86.31.166.235,100,574,True,2020-12-05 22:26:09,R_ac7mdyfn2T2Fykp,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,interim_result,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Document in Chinese on the registry ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,," traditional Chinese medicine AND COVID-19 AND Wei Li ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029435,ChiCTR,2020-02-01,2020-02-01,FALSE,Wuhan First Hospital,Not Recruiting,Not Applicable,Interventional,China,Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population,Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,120,http://www.chictr.org.cn/showproj.aspx?proj=48827,,,,2020-03-31,2020-03-31,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-05 22:26:19,2020-12-05 22:29:20,IP Address,86.31.166.235,100,181,True,2020-12-05 22:29:20,R_0r2gZfn1FvSrHXj,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Integrated AND traditional Chinese medicine AND COVID-19 AND Xie Chunguang ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029558,ChiCTR,2020-02-04,2020-01-29,TRUE,Hospital of Chengdu University of Traditional Chinese Medicine,Recruiting,Not Applicable,Interventional,China,Recommendations of Integrated Traditional Chinese and Western Medicine for Diagnosis and Treatment of Novel Coronavirus Pneumonia (COVID-19) in Sichuan Province,Traditional Medicine + Western Medicine,Traditional Medicine,Traditional Medicine,200,http://www.chictr.org.cn/showproj.aspx?proj=48792,,,,2020-05-01,2020-05-01,0,0,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-05 22:29:29,2020-12-05 22:35:16,IP Address,86.31.166.235,100,347,True,2020-12-05 22:35:17,R_2R8JEqI3G8gWLRT,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Shanghai University of Traditional Chinese Medicine AND COVID-19 AND integrated,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029777,ChiCTR,2020-02-13,2020-02-05,TRUE,Huangshi Hospital of Traditional Chinese Medicine,Recruiting,Not Applicable,Interventional,China,"A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy",Traditional Medicine + Western Medicine,Traditional Medicine,Traditional Medicine,160,http://www.chictr.org.cn/showproj.aspx?proj=49380,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-05 22:37:07,2020-12-05 22:46:21,IP Address,86.31.166.235,100,554,True,2020-12-05 22:46:21,R_2aaCqKs3oSsWMqR,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_journal_article,,,,,10.1016/j.biopha.2020.110500,"32768975 ",https://www.sciencedirect.com/science/article/pii/S0753332220306934?via%3Dihub,,,,,,,,,,,,,2020-07-04,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Wei Zhang AND COVID-19 ANDTraditional Chinese Medicine,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029778,ChiCTR,2020-02-13,2020-02-14,FALSE,Shanghai University of Traditional Chinese Medicine,Recruiting,Not Applicable,Interventional,China,Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19),Traditional Medicine + Western Medicine,Traditional Medicine,Traditional Medicine,600,http://www.chictr.org.cn/showproj.aspx?proj=49422,,,,2020-05-13,2020-05-13,0,0,,,,,,,,,,,6,,Recruiting,TRUE,1,,,,,,,,,,,,,true,,
2020-12-05 22:46:35,2020-12-05 22:49:36,IP Address,86.31.166.235,100,180,True,2020-12-05 22:49:36,R_1C7kfHt32Cs2kgz,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Qiu Jun AND COVID-19 AND Deyang AND TCM,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029821,ChiCTR,2020-02-14,2020-02-14,FALSE,Deyang Integrated Traditional Chinese and Western Medicine Hospital,Not Recruiting,Not Applicable,Prevention,China,Based on Delphi Method to Preliminarily Construct a Recommended Protocol for the Prevention of Novel Coronavirus Pneumonia (COVID-19) in Deyang Area by Using Chinese Medicine Technology and its Clinical Application Evaluation,Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,400,http://www.chictr.org.cn/showproj.aspx?proj=49306,,,,2020-06-01,2020-06-01,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-06 12:15:56,2020-12-06 12:24:54,IP Address,86.31.166.235,100,537,True,2020-12-06 12:24:54,R_3JaCVZiL1rPhrQT,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,yes,,2020-05-07,2020-06-07,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Chloroquine Diphosphate AND COVID-19 AND Fundação de Medicina Tropical,"CloroCOVID19 ",,,,,,,,,MPJ,2020-06-30,NCT04323527,,,,,,,,,,,,,,,,,,,,,,,,10.1101/2020.04.07.20056424,,10.1101/2020.04.07.20056424,10.1001/jamanetworkopen.2020.8857,interim_results_preprint,interim_results_journal_article,,2020-04-11,2020-04-24,5,,,FALSE,1,,interim_results_preprint,2020-04-11,ifxm3j4y,https://doi.org/10.1101/2020.04.07.20056424,"Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study)",,,32330277,interim_results_journal_article,2020-04-24,,,,2020-06-07
2020-12-06 20:34:36,2020-12-06 20:34:56,IP Address,81.109.92.226,100,19,True,2020-12-06 20:34:56,R_cUPumQIwOe7WOhH,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,no,,Screening,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04281693,ClinicalTrials.gov,2020-02-20,2020-02-01,TRUE,Affiliated Hospital to Academy of Military Medical Sciences,Not Recruiting,Not Applicable,Interventional,China,A New Screening Strategy for 2019 Novel Coronavirus Infection,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,230,https://clinicaltrials.gov/show/NCT04281693,,,2020-03-01,2020-03-01,2020-03-01,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-06 20:35:04,2020-12-06 20:47:59,IP Address,81.109.92.226,100,775,True,2020-12-06 20:47:59,R_2cnDSfihHgpXXL6,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,interferon alpha AND covid,Jianping Zhao AND interferon,Huilan Zhang AND interferon,,,,,,,,ND,2020-06-30,NCT04293887,ClinicalTrials.gov,2020-02-15,2020-03-01,FALSE,"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology",Not Recruiting,Phase 1,Interventional,No Country Given,Efficacy and Safety of IFN-a2ß in the Treatment of Novel Coronavirus Patients,Drug,Interferon alfa,Interferon alfa,328,https://clinicaltrials.gov/show/NCT04293887,,,2020-05-30,2020-06-30,2020-05-30,0,1,,,,,,,,,,,5,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-06 20:48:13,2020-12-06 20:48:48,IP Address,81.109.92.226,100,34,True,2020-12-06 20:48:48,R_12muuO14mRLXJDB,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,no,,Mask injuries,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,ChiCTR2000032013,ChiCTR,2020-04-17,2020-02-02,TRUE,The Fourth Medical Center of PLA General Hospital,Not Recruiting,Not Applicable,Interventional,China,The prevention and treatment strategy of the protective respirator related facial pressure injuries among healthcare professionals fighting novel coronavirus pneumonia (COVID-19),Other (physical),Mechanical ventilation,Mechanical ventilation,8,http://www.chictr.org.cn/showproj.aspx?proj=52483,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,5,,Completed,TRUE,2,,,,,,,,,,,,,,,
2020-12-06 20:48:58,2020-12-06 20:59:24,IP Address,81.109.92.226,100,626,True,2020-12-06 20:59:25,R_z0xFwtNJ42MbFER,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Yu Wang AND Hydroxychloroquine,Zhuoli Zhang AND hydroxychloroquine,Peking University AND hydroxychloroquine,,,,,,,,ND,2020-06-30,ChiCTR2000029740,ChiCTR,2020-02-11,2020-02-11,FALSE,The First Hospital of Peking University,Recruiting,Phase 4,Interventional,China,Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients(randomized open-label control clinical trial),Drug,Hydroxychloroquine,Hydroxychloroquine,78,http://www.chictr.org.cn/showproj.aspx?proj=49317,,,,2020-02-29,2020-02-29,0,0,,,,,,,,,,,5,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-06 20:59:36,2020-12-06 21:07:27,IP Address,81.109.92.226,100,470,True,2020-12-06 21:07:27,R_24ejJJwt3skZKiw,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,full_results_journal_article,,,,,10.1186/s12967-020-02573-9,33087150,,,,,,,,,,,,,,2020-10-21,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04317092,ClinicalTrials.gov,2020-03-19,2020-03-19,TRUE,National Cancer Institute,Recruiting,Phase 2,Interventional,Italy,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Drug,Tocilizumab,Tocilizumab,400,https://clinicaltrials.gov/show/NCT04317092,EUCTR2020-001110-38,,2020-12-19,2022-12-19,2020-12-19,0,0,,10.1101/2020.06.01.20119149,,10.1101/2020.06.01.20119149,,full_results_preprint,,2020-04-04,2020-06-05,,5,,Recruiting,TRUE,2,,full_results_preprint,2020-06-05,xv0jhsj0,http://medrxiv.org/cgi/content/short/2020.06.01.20119149v1?rss=1,Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial,2020-04-04,EUCTR2020-001110-38,,,,,,,
2020-12-07 12:51:02,2020-12-07 12:51:40,IP Address,81.109.92.226,100,37,True,2020-12-07 12:51:41,R_1ibANncrAQDUfJD,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04306055,ClinicalTrials.gov,2020-03-08,2020-03-13,FALSE,Guangzhou Blood Center,Not Recruiting,Not Applicable,Interventional,China,Blood Donor Recruitment During Epidemic of COVID-19,Other,No Intervention,No Intervention,19491,https://clinicaltrials.gov/show/NCT04306055,,,2020-03-13,2020-04-03,2020-03-13,0,0,,,,,,,,,,,5,,Completed,TRUE,2,,,,,,,,,,,,,,,
2020-12-07 12:51:53,2020-12-07 13:02:11,IP Address,81.109.92.226,100,618,True,2020-12-07 13:02:11,R_1Hda2Ghg0gDJs3G,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Umar Farooq,Hydroxychloroquine AND Pakistan,,,,,,,,,ND,2020-06-30,NCT04328272,ClinicalTrials.gov,2020-03-25,2020-03-28,FALSE,Dr. Umar Farooq,Not Recruiting,Phase 3,Interventional,Pakistan,Effectiveness of Hydroxychloroquine in Covid-19 Patients,Drug,Hydroxychloroquine vs. Hydroxychloroquine + Azithromycin,Hydroxychloroquine; Azithromycin,75,https://clinicaltrials.gov/show/NCT04328272,,,2020-05-28,2020-06-28,2020-05-28,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-07 13:02:17,2020-12-07 13:11:39,IP Address,81.109.92.226,100,562,True,2020-12-07 13:11:40,R_2dW86qk6zpugghv,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Zhongji Meng,Title of Preprint,Interferon AND drops AND covid,,,,,,,,ND,2020-06-30,NCT04320238,ClinicalTrials.gov,2020-03-21,2020-01-21,TRUE,Shanghai Jiaotong University,Recruiting,Phase 3,Interventional,China,Experimental Trial of rhIFNa Nasal Drops to Prevent 2019-nCOV in Medical Staff,Drug,Interferon Alpha vs. Interferon Alpha + Thymosin Alpha,Interferon alpha; Thymosin alpha,2944,https://clinicaltrials.gov/show/NCT04320238,,,2020-05-01,2020-06-01,2020-05-01,0,0,,10.1101/2020.04.11.20061473,,10.1101/2020.04.11.20061473,,full_results_preprint,,,2020-04-17,,5,,Recruiting,TRUE,2,,full_results_preprint,2020-04-17,z68tl88x,https://doi.org/10.1101/2020.04.11.20061473,An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area,,,,,,,,true,
2020-12-07 13:11:53,2020-12-07 13:27:17,IP Address,81.109.92.226,100,923,True,2020-12-07 13:27:17,R_AjJsOx9fFXGXRa9,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bevacizumab AND covid,Yihai Cao,,,,,There is another trial on same drug by same team with a preprint but not the same trial.,,,,ND,2020-06-30,NCT04305106,ClinicalTrials.gov,2020-03-09,2020-03-17,FALSE,Qilu Hospital of Shandong University,Recruiting,Not Applicable,Interventional,China,Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT,Drug,Bevacizumab,Bevacizumab,140,https://clinicaltrials.gov/show/NCT04305106,,,2020-06-30,2020-07-31,2020-06-30,0,0,,,,,,,,,,,5,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-07 13:27:30,2020-12-07 13:36:32,IP Address,81.109.92.226,100,542,True,2020-12-07 13:36:32,R_2qghX0Kipf1yBrw,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,,10.1101/2020.08.02.20166710,,https://www.medrxiv.org/content/10.1101/2020.08.02.20166710v1,,,,,,,,,,,,,2020-08-04,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The registered trial had a control, this one didn't but it's the same study.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Preprint title,Shanshan Chen,,,,,,,,,ND,2020-06-30,ChiCTR2000030627,ChiCTR,2020-03-08,2020-02-01,TRUE,The First Affiliated Hospital of Zhengzhou University,Recruiting,Not Applicable,Interventional,China,Study for using the healed novel coronavirus pneumonia (COVID-19) patients plasma in the treatment of severe critical cases,ATMP,Plasma,Plasma,30,http://www.chictr.org.cn/showproj.aspx?proj=50727,,,,2020-05-30,2020-05-30,0,0,,,,,,,,,,,5,,Recruiting,TRUE,2,,,,,,,,,,,,,,true,
2020-12-07 13:36:59,2020-12-07 13:47:40,IP Address,81.109.92.226,100,640,True,2020-12-07 13:47:41,R_1CfgEL1NtA8LvMd,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,oXiris Membrane AND Covid,xuemei li and covid,Yangzhong Zhou and Covid,,,,,,,,ND,2020-06-30,ChiCTR2000030477,ChiCTR,2020-03-03,2020-03-04,FALSE,Chinese Academy of Medical Sciences Peking Union Medical College Hospital,Not Recruiting,Not Applicable,Interventional,China,oXiris Membrane in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19),Traditional Medicine (Other),Traditional Medicine,Traditional Medicine,19,http://www.chictr.org.cn/showproj.aspx?proj=50458,,,,2020-06-25,2020-06-25,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-07 13:47:50,2020-12-07 13:54:41,IP Address,81.109.92.226,100,410,True,2020-12-07 13:54:41,R_1llrUGFy9s95TJE,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,yes,,NA,2020-04-10,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,dipyridamole AND covid,Xiaoyan Liu,,,,,,,,,ND,2020-06-30,ChiCTR2000030055,ChiCTR,2020-02-22,2020-02-10,TRUE,The First Affiliated Hospital of Guangzhou Medical University,Recruiting,Phase 4,Prognosis,China,Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19),Drug,Dipyridamole,Dipyridamole,460,http://www.chictr.org.cn/showproj.aspx?proj=49864,,,,,,,,,10.1016/j.apsb.2020.04.008,,10.1016/j.apsb.2020.04.008,,full_results_journal_article,,,2020-04-20,,5,,,FALSE,2,32318327,full_results_journal_article,2020-04-20,k7bh8bf7,https://api.elsevier.com/content/article/pii/S2211383520305529; https://doi.org/10.1016/j.apsb.2020.04.008; https://www.ncbi.nlm.nih.gov/pubmed/32318327/; https://www.sciencedirect.com/science/article/pii/S2211383520305529?v=s5,Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19,,,,,,,true,,2020-04-10
2020-12-07 13:55:03,2020-12-07 14:01:07,IP Address,81.109.92.226,100,363,True,2020-12-07 14:01:07,R_12gs8Pt22Mnu1Gb,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ASC09F AND Covid,Qing Ning AND Tongji,,,,,,,,,ND,2020-06-30,NCT04261270,ClinicalTrials.gov,2020-02-04,2020-02-01,TRUE,"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,Phase 3,Interventional,China,"A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia",Drug,ASCO9F + Ritonavir vs. Ritonavir + Oseltamivir vs. Oseltamivir,ASCO9F; Ritonavir; Oseltamivir,60,https://clinicaltrials.gov/show/NCT04261270,,,2020-05-01,2020-07-01,2020-05-01,0,0,,,,,,,,,,,5,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-07 14:01:14,2020-12-07 14:10:02,IP Address,81.109.92.226,100,527,True,2020-12-07 14:10:03,R_1jAJbXkonruGHcP,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Plasma AND Covid AND Renmin,Binghong Zhang,Lianghao Zhang,,,,,,,,ND,2020-06-30,ChiCTR2000030929,ChiCTR,2020-03-17,2020-03-17,FALSE,Renmin Hospital of Wuhan University,Not Recruiting,Not Applicable,Interventional,China,"A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19)",ATMP,Plasma,Plasma,60,http://www.chictr.org.cn/showproj.aspx?proj=50696,,,,2020-06-16,2020-06-16,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-07 14:10:18,2020-12-07 14:11:46,IP Address,81.109.92.226,100,87,True,2020-12-07 14:11:46,R_2COeyrrpwclKNy0,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,unknown,no,This is one sleep quality for people with COVID...not really treating/preventing covid.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,ND,2020-06-30,ChiCTR2000031328,ChiCTR,2020-03-27,2020-03-13,TRUE,The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Recruiting,Not Applicable,Interventional,China,The protective effect of sleep psychology and music therapy of novel coronavirus pneumonia (COVID-19) mild and moderate type patients,Other,Sleep aids,Sleep aids,60,http://www.chictr.org.cn/showproj.aspx?proj=51425,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,5,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-07 14:11:51,2020-12-07 14:15:20,IP Address,81.109.92.226,100,209,True,2020-12-07 14:15:21,R_2BhvZFnzP0UWpPG,,,test@test.com,,51.737701416015625,-1.2053985595703125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bai-Du Duan Fang,Wei Lu AND Covid,,,,,,,,,ND,2020-06-30,ChiCTR2000030940,ChiCTR,2020-03-18,2020-02-01,TRUE,Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Not Recruiting,Not Applicable,Interventional,China,Study for ''Bai-Du Duan Fang'' application on the acupoint in the treatment of general type novel coronavirus pneumonia (COVID-19),Traditional Medicine (Other),Traditional Medicine,Traditional Medicine,76,http://www.chictr.org.cn/showproj.aspx?proj=51061,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,5,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-10 15:48:59,2020-12-10 16:01:46,IP Address,69.123.66.147,100,766,True,2020-12-10 16:01:46,R_3Ms1EDiBuvb04sn,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hydroxychloroquine and dexamethasone and covid,DHYSCO,Lannelongue AND hydroxychloroquine,Francois Stephan,,,,,,,ND,2020-06-30,NCT04347980,ClinicalTrials.gov,2020-04-09,2020-04-01,TRUE,Centre Chirurgical Marie Lannelongue,Recruiting,Phase 3,Interventional,France,Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19,Drug,Dexamethasone + Hydroxychloroquine vs. Hydroxychloroquine,Dexamethasone; Hydroxychloroquine,122,https://clinicaltrials.gov/show/NCT04347980,,,2020-06-01,2020-08-01,2020-06-01,0,0,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-10 16:02:00,2020-12-10 16:07:44,IP Address,69.123.66.147,100,343,True,2020-12-10 16:07:45,R_51fRVdS3VxfkIAp,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Umifenovir AND Covid,Loghman Hakim Hospital AND Umifenovir,,,,,,,,,ND,2020-06-30,NCT04350684,ClinicalTrials.gov,2020-04-14,2020-04-15,FALSE,Shahid Beheshti University of Medical Sciences,Recruiting,Phase 4,Interventional,Iran,Umifenovir in Hospitalized COVID-19 Patients,Drug,Umifenovir + Interferon beta + Lopinavir/Ritonavir + Hydroxychloroquine vs. Interferon beta + Lopinavir/Ritonavir + Hydroxycholroquine,Umifenovir; Interferon beta; Lopinavir/Ritonavir; Hydroxychloroquine,40,https://clinicaltrials.gov/show/NCT04350684,,,2020-04-22,2020-04-24,2020-04-22,0,0,,,,,,,,,,,6,,Enrolling by invitation,TRUE,2,,,,,,,,,,,,,,,
2020-12-10 16:08:08,2020-12-10 16:14:07,IP Address,69.123.66.147,100,359,True,2020-12-10 16:14:07,R_2zI4V1THB3UJAAg,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,no,2021-01-31,2021-03-31,1,EUCTR2020-001254-22,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Protocol: https://pubmed.ncbi.nlm.nih.gov/32503663/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04326920,ClinicalTrials.gov,2020-03-24,2020-03-24,FALSE,"University Hospital, Ghent",Recruiting,Phase 4,Interventional,"Belgium, Italy",Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),Drug,Sargramostim,Sargramostim,80,https://clinicaltrials.gov/show/NCT04326920,,,2020-10-31,2020-12-31,2020-10-31,0,1,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2021-03-31
2020-12-10 16:14:16,2020-12-10 16:21:39,IP Address,69.123.66.147,100,443,True,2020-12-10 16:21:40,R_2drKjyWJdn3oAZ9,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Protocol: https://pubmed.ncbi.nlm.nih.gov/32503657/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Guiqiang Wang AND Favipiravir,Peking University First Hospital AND Favipiravir,,,,,,,,,ND,2020-06-30,NCT04333589,ClinicalTrials.gov,2020-04-01,2020-04-01,FALSE,Peking University First Hospital,Recruiting,Not Applicable,Interventional,China,Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive,Drug,Favipiravir,Favipiravir,210,https://clinicaltrials.gov/show/NCT04333589,,,2020-06-01,2020-09-15,2020-06-01,0,1,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-10 16:21:47,2020-12-10 16:28:44,IP Address,69.123.66.147,100,417,True,2020-12-10 16:28:45,R_3m3LrapzkqYq6bw,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Convalescent Plasma AND Covid AND Orthosera,Veronika Müller AND Plasma,,,,,,,,,ND,2020-06-30,NCT04345679,ClinicalTrials.gov,2020-04-11,2020-04-14,FALSE,Orthosera Kft.,Not Recruiting,Phase 1,Interventional,No Country Given,Anti COVID-19 Convalescent Plasma Therapy,ATMP,Plasma,Plasma,20,https://clinicaltrials.gov/show/NCT04345679,,,2020-06-01,2021-04-01,2020-06-01,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-10 16:29:14,2020-12-10 16:40:51,IP Address,69.123.66.147,100,697,True,2020-12-10 16:40:52,R_1Ka2ptG1VDynRee,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,"Suspended but probably never going to happen: Suspended (Azidus, the CRO hired for this study by Prevent Senior has lost the interest to conduct this study.)",,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,,,,,other,,,,,,,https://static.poder360.com.br/2020/04/2020.04.15-journal-manuscript-final.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Maybe this is a preprint but I'm not sure. It looks like they just released a word document..,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Rodrigo Barbosa Esper,,,,,,More context: https://covexit.com/new-brazilian-study-shows-telemedicine-hydroxychloroquine-treatment-reduce-need-for-hospitalization/,,team_review,,ND,2020-06-30,NCT04348474,ClinicalTrials.gov,2020-04-13,2020-04-20,FALSE,Azidus Brasil,Not Recruiting,Phase 1,Interventional,Brazil,Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19,Drug,Hydroxychloroquine + Azithromycin,Hydroxychloroquine; Azithromycin,200,https://clinicaltrials.gov/show/NCT04348474,,,2020-06-30,2020-07-31,2020-06-30,0,0,,,,,,,,,,,6,,Suspended,TRUE,2,,,,,,,,,,,,,,,
2020-12-10 16:41:05,2020-12-10 16:56:35,IP Address,69.123.66.147,100,930,True,2020-12-10 16:56:36,R_1i98QoTl9Qs2Or1,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,no,2020-12-01,2020-12-01,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Protocol: https://pubmed.ncbi.nlm.nih.gov/32907638/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sarilumab AND covid,,,,,,,,,,ND,2020-06-30,NCT04357808,ClinicalTrials.gov,2020-04-14,2020-04-13,TRUE,Maria del Rosario Garcia de Vicuña Pinedo,Recruiting,Phase 2,Interventional,Spain,Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID),Drug,Sarilumab,Sarilumab,30,https://clinicaltrials.gov/show/NCT04357808,EUCTR2020-001634-36,,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2020-12-01
2020-12-10 16:56:48,2020-12-10 16:58:31,IP Address,69.123.66.147,100,103,True,2020-12-10 16:58:32,R_1gIJgY3CHqVsXAJ,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,no,2020-11-30,2021-02-28,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04359095,ClinicalTrials.gov,2020-04-15,2020-05-11,FALSE,National University of Colombia,Not Recruiting,Phase 2/Phase 3,Interventional,Colombia,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Drug,Hydroxychloroquine + Azithromycin vs. Hydroxychloroquine + Lopinavir/Ritonavir vs. Hydroxychloroquine,Hydroxychloroquine; Azithromycin; Lopinavir/Ritonavir,1600,https://clinicaltrials.gov/show/NCT04359095,,,2020-10-11,2020-10-31,2020-10-11,0,1,,,,,,,,,,,6,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,2021-02-28
2020-12-10 16:58:37,2020-12-10 16:59:14,IP Address,69.123.66.147,100,36,True,2020-12-10 16:59:14,R_3k1X8I9002eBTGT,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04361448,ClinicalTrials.gov,2020-04-20,2020-04-20,FALSE,Jessa Hospital,Not Recruiting,Not Applicable,Interventional,Belgium,Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,30,https://clinicaltrials.gov/show/NCT04361448,,,2020-05-20,2020-05-20,2020-05-20,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-10 16:59:19,2020-12-10 16:59:46,IP Address,69.123.66.147,100,26,True,2020-12-10 16:59:46,R_2S2L4r84HQ9ESgB,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04366817,ClinicalTrials.gov,2020-04-20,2020-04-01,TRUE,Assistance Publique – Hôpitaux de Paris,Not Recruiting,Not Applicable,Interventional,France,Psychological Impact of the Lockdown on Patients Giving Birth During the COVID-19 Epidemic Short Title : Isolement and Childbirth: Psychological Impact,Other (psych),No Intervention,No Intervention,120,https://clinicaltrials.gov/show/NCT04366817,,,2020-04-01,2020-06-01,2020-04-01,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-10 22:12:14,2020-12-10 22:19:17,IP Address,86.31.166.235,100,422,True,2020-12-10 22:19:18,R_22SbzuNIdEiKKxy,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CounterCovid19 AND Netherlands AND Trial ",imatinib AND COVID-19 AND Amsterdam,,,,,,"	2020-001236-10 

EUCTR trial no",team_review,,MPJ,2020-06-30,NL8491,Netherlands Trial Register,2020-03-31,2020-03-31,FALSE,UMC Amsterdam,Recruiting,Not Applicable,Interventional,Netherlands,Countering Lung Damage in COVID-19 infection (CounterCovid) study,Drug,Imatinib,Imatinib,386,https://trialregister.nl/trial/8491,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,7,,Open for patient inclusion,TRUE,1,,,,,,,,,,,,,,,
2020-12-10 22:19:31,2020-12-10 22:39:40,IP Address,86.31.166.235,100,1209,True,2020-12-10 22:39:41,R_2ccQAB54DwunHmO,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2021-06-01,2021-06-01,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_journal_article,,,,,10.1093/ofid/ofaa446,"33134417 ",https://academic.oup.com/ofid/article/7/10/ofaa446/5910201,,,,,,,,,,,,,2020-09-23,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COVID-19 AND Hydroxychloroquine AND State University of New York AND Mark Mulligan,TEACH AND COVID-19 AND NYU,,,,,,,,,MPJ,2020-06-30,NCT04369742,ClinicalTrials.gov,2020-04-25,2020-04-15,TRUE,NYU Langone Health,Not Recruiting,Phase 2,Interventional,United States,Treating COVID-19 With Hydroxychloroquine (TEACH),Drug,Hydroxychloroquine,Hydroxychloroquine,626,https://clinicaltrials.gov/show/NCT04369742,,,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,7,,Suspended,TRUE,1,,,,,,,,,,,,,true,,2021-06-01
2020-12-10 22:39:48,2020-12-10 22:48:38,IP Address,86.31.166.235,100,530,True,2020-12-10 22:48:39,R_Y9Vs4SCscxqNGV3,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-10-01,2020-10-01,0,,,,,,full_results_journal_article,,,,,https://www.nejm.org/doi/10.1056/NEJMoa2028836,33085857,https://www.nejm.org/doi/10.1056/NEJMoa2028836,,,,,,,,,,,,,2020-12-10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tocilizumab AND COVID-19 AND John Stone,,,,,,,,,,MPJ,2020-06-30,NCT04356937,ClinicalTrials.gov,2020-04-19,2020-04-20,FALSE,Massachusetts General Hospital,Recruiting,Phase 3,Interventional,United States,Efficacy of Tocilizumab on Patients With COVID-19,Drug,Tocilizumab,Tocilizumab,278,https://clinicaltrials.gov/show/NCT04356937,,,2020-06-30,2020-08-30,2020-06-30,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,true,,2020-10-01
2020-12-10 22:48:47,2020-12-10 22:57:10,IP Address,86.31.166.235,100,503,True,2020-12-10 22:57:11,R_1QxytvPdgkKYzHI,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Centre Leon Berard AND COVID-19 AND Metastatic Cancer,"IMMUNONCOVID AND France AND Trial ",,,,,,,,,MPJ,2020-06-30,NCT04333914,ClinicalTrials.gov,2020-04-01,2020-04-15,TRUE,Centre Leon Berard,Not Recruiting,Phase 2,Interventional,France,Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,Drug,Chloroquine + Nivolumab + Tocilizumab,Chloroquine; Nivolumab; Tocilizumab,384,https://clinicaltrials.gov/show/NCT04333914,EUCTR2020-001373-70,,2020-06-01,2020-08-01,2020-06-01,0,0,,,,,,,,,,,7,,Suspended,TRUE,1,,,,,,,,,,,,,,,
2020-12-10 22:57:17,2020-12-10 23:04:33,IP Address,86.31.166.235,100,435,True,2020-12-10 23:04:33,R_2OHhuaf59NU4CPw,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Glucocorticoid AND COVID-19 AND Beijing ",,,,,,,,,,MPJ,2020-06-30,NCT04244591,ClinicalTrials.gov,2020-01-23,2020-01-26,FALSE,Peking Union Medical College Hospital,Not Recruiting,Phase 2/Phase 3,Interventional,China,Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure,Drug,Corticosteroids,Methylprednisolone,80,https://clinicaltrials.gov/show/NCT04244591,,,2020-04-13,2020-04-13,2020-04-13,0,0,,,,,,,,,,,7,,Completed,TRUE,1,,,,,,,,,,,,,,,
2020-12-12 23:45:17,2020-12-12 23:46:27,IP Address,129.67.119.92,100,70,True,2020-12-12 23:46:28,R_2a9zAadbwj6e0jd,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,no,,,Retrospective Case Study,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,ChiCTR2000032716,ChiCTR,2020-05-08,2020-02-05,TRUE,"Ruijin Hospital, Shanghai Jiao Tong University School of Medicine",Not Recruiting,Not Applicable,Interventional,China,High dose intravenous vitamin C might be used as an important rescue therapy for aggravation of severe and critical novel coronavirus pneumonia (COVID-19) patients,Drug,Vitamin C,Vitamin C,12,http://www.chictr.org.cn/showproj.aspx?proj=53389,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,6,,Completed,TRUE,2,,,,,,,,,,,,,,,
2020-12-12 23:46:32,2020-12-12 23:47:13,IP Address,129.67.119.92,100,41,True,2020-12-12 23:47:14,R_2xzTMcqrIilVbL6,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04365972,ClinicalTrials.gov,2020-04-24,2020-04-23,TRUE,Tel Aviv University,Not Recruiting,Not Applicable,Interventional,Israel,Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic,Other (psych),Psychological,Psychological,20,https://clinicaltrials.gov/show/NCT04365972,,,2020-04-30,2020-04-30,2020-04-30,0,0,,,,,,,,,,,6,,Completed,TRUE,2,,,,,,,,,,,,,,,
2020-12-12 23:47:19,2020-12-12 23:47:38,Spam,129.67.119.92,100,19,True,2020-12-12 23:47:38,R_1hBhAsMswI3cMOn,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04382560,ClinicalTrials.gov,2020-05-05,2020-05-02,TRUE,University of Parma,Recruiting,Not Applicable,Interventional,Italy,Coping Strategies and Responsiveness to a Brief Online Intervention During COVID-19 Pandemic,Other (psych),Psychological,Psychological,100,https://clinicaltrials.gov/show/NCT04382560,,,2020-05-31,2020-05-31,2020-05-31,0,0,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-12 23:47:43,2020-12-12 23:51:47,IP Address,129.67.119.92,100,243,True,2020-12-12 23:51:47,R_3m3HvXEQrDluf7C,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,no,2020-09-24,2020-10-08,0,,,,,,full_results_journal_article,,,,,10.7326/M20-6519,33284679,,,,,,,,,,,,,,2020-12-08,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Protocol: https://pubmed.ncbi.nlm.nih.gov/32493478/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04328961,ClinicalTrials.gov,2020-03-23,2020-03-31,FALSE,University of Washington,Recruiting,Phase 2/Phase 3,Interventional,United States,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),Drug (Chemoprophylaxis),Hydroxychloroquine vs. Vitamin C,Hydroxychloroquine; Vitamin C,2000,https://clinicaltrials.gov/show/NCT04328961,,,2020-09-30,2020-10-31,2020-09-30,0,1,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2020-10-08
2020-12-12 23:52:06,2020-12-12 23:59:21,IP Address,129.67.119.92,100,434,True,2020-12-12 23:59:22,R_3KvDXmSvEVF5gYU,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,no,2020-12-20,2020-12-21,1,EUCTR2020-001258-23,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ColCOVID-19,Colchicine AND umberto maggiore,,,,,,,,,ND,2020-06-30,NCT04322565,ClinicalTrials.gov,2020-03-24,2020-04-20,FALSE,AOU di Parma,Recruiting,Phase 2,Interventional,Italy,Colchicine Counteracting Inflammation in COVID-19 Pneumonia,Drug,Colchicine,Colchicine,310,https://clinicaltrials.gov/show/NCT04322565,,,2020-06-20,2020-07-20,2020-06-20,0,0,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2020-12-21
2020-12-12 23:59:28,2020-12-13 00:01:39,IP Address,129.67.119.92,100,130,True,2020-12-13 00:01:40,R_OjvoaQU9mmm5hzX,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,no,2021-06-30,2021-12-30,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04341935,ClinicalTrials.gov,2020-04-06,2020-06-30,FALSE,University of Miami,Not Recruiting,Phase 4,Interventional,United States,Effects of DPP4 Inhibition on COVID-19,Drug,Linagliptin,Linagliptin,20,https://clinicaltrials.gov/show/NCT04341935,,,2020-10-30,2020-12-30,2020-10-30,0,1,,,,,,,,,,,6,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,2021-12-30
2020-12-13 00:02:14,2020-12-13 00:13:28,IP Address,129.67.119.92,100,674,True,2020-12-13 00:13:29,R_1QH4lXxSFYqGvEw,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,no,2020-06-24,2020-06-24,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TD-0903,Theravance AND Covid,,,,,,,,,ND,2020-06-30,NCT04350736,ClinicalTrials.gov,2020-04-14,2020-04-23,FALSE,Theravance Biopharma,Recruiting,Phase 1,Interventional,United Kingdom,"First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19",Drug,TD-0903,TD-0903,54,https://clinicaltrials.gov/show/NCT04350736,,,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2020-06-24
2020-12-13 17:56:04,2020-12-13 17:57:18,IP Address,86.31.166.235,100,73,True,2020-12-13 17:57:18,R_RQvEeCOTJZaTlS1,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,Ventilator splitter - so a study of 'device feasibility' rather than treatment of Covid-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04381013,ClinicalTrials.gov,2020-05-07,2020-06-01,FALSE,Stanford University,Not Recruiting,Not Applicable,Interventional,United States,Emergency Ventilator Splitting Between Two or More Patients (COVID-19),Other (device),Other,Other,4,https://clinicaltrials.gov/show/NCT04381013,,,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-13 17:57:24,2020-12-13 18:08:17,IP Address,86.31.166.235,100,652,True,2020-12-13 18:08:17,R_2dSUAOFtniBzXRo,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hydroxychloroquine AND COVID-19 AND Montpellier,"Jacques Reynes AND coronavirus AND Hydroxychloroquine AND Azithromycin ",,,,,,,,,MPJ,2020-06-30,NCT04345861,ClinicalTrials.gov,2020-04-05,2020-04-11,FALSE,"University Hospital, Montpellier",Not Recruiting,Phase 2/Phase 3,Interventional,France,Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial),Drug,Hydroxychloroquine + Azithromycin vs. Hydroxychloroquine,Hydroxychloroquine; azithormycin,7,https://clinicaltrials.gov/show/NCT04345861,,,2020-06-08,2020-06-08,2020-06-08,0,0,,,,,,,,,,,7,,Terminated,TRUE,1,,,,,,,,,,,,,,,
2020-12-13 18:08:26,2020-12-13 18:11:28,IP Address,86.31.166.235,100,181,True,2020-12-13 18:11:29,R_2Ed9WMvEBr5y6qH,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04420806,ClinicalTrials.gov,2020-06-05,2020-03-14,TRUE,University of Erlangen-Nornberg Medical School,Not Recruiting,Not Applicable,Interventional,Germany,Effects of COVID-19 Lockdown in Exercising Early Postmenopausal Women,Other (exercise),Exercise,Exercise,21,https://clinicaltrials.gov/show/NCT04420806,,,2020-06-30,2020-10-01,2020-06-30,0,0,,,,,,,,,,,7,,"Active, not recruiting",TRUE,1,,,,,,,,,,,,,,,
2020-12-13 18:11:35,2020-12-13 18:13:18,IP Address,86.31.166.235,100,103,True,2020-12-13 18:13:19,R_vIaMwXtCpxbDrH3,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,Study on immunity to 'infectious diseases',,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,RPCEC00000315,RPCEC,2020-05-22,2020-05-19,TRUE,Finlay Vaccine Institute (IFV),Recruiting,Not Applicable,Interventional,Cuba,Evaluation of the synergistic effect of  sequential administration of two immunostimulant products: Immuno-1 and Immuno-2 for the stimulation of the immune response in older adults. Exploratory study,Drug,Immunostimulants,Immunostimulants,60,https://rpcec.sld.cu/en/trials/RPCEC00000315-En,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-13 18:14:22,2020-12-13 18:20:00,IP Address,86.31.166.235,100,338,True,2020-12-13 18:20:01,R_9HVeAOxwJKH8jOp,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Measles Vaccine AND COVID-19 AND health workers AND South Africa,,,,,,,,,,MPJ,2020-06-30,PACTR202004693933092,PACTR,2020-04-12,2020-04-15,FALSE,Misr University for Science and Technology,Not Recruiting,Not Applicable,Interventional,Egypt,Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial),ATMP,Vaccine,Vaccine,200,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10953,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-13 22:02:41,2020-12-13 22:12:32,IP Address,86.31.166.235,100,590,True,2020-12-13 22:12:32,R_1CvxgPw5BY2MGtW,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,,https://www.researchsquare.com/article/rs-91430/v1,,https://www.researchsquare.com/article/rs-91430/v1,,,,,,,,,,,,,2020-10-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Umifenovir AND COVID-19 AND Tehran ",Sara Ghaderkhani AND coronavirus AND Arbidol,,,,,,,,,MPJ,2020-06-30,IRCT20200523047550N1,IRCT,2020-06-06,2020-04-20,TRUE,Tehran University of Medical Sciences,Not Recruiting,Phase 3,Interventional,Iran,Effect of Umifenovir in treatment of covid-19,Drug,Umifenovir + Hydroxychloroquine vs Hydroxychloroquine,Umifenovir; Hydroxychloroquine,50,http://en.irct.ir/trial/48495,,,,2020-05-25,2020-05-25,0,0,,,,,,,,,,,7,,Recruitment complete,TRUE,1,,,,,,,,,,,,,,,
2020-12-13 22:12:41,2020-12-13 22:20:21,IP Address,86.31.166.235,100,459,True,2020-12-13 22:20:22,R_DwY3KelhvVSly4p,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,,,,,full_results_journal_article,full_results_journal_article,,,,10.1093/jac/dkaa334,32812039,https://academic.oup.com/jac/article/75/11/3379/5889948,,,,,,,,,,,,,2020-08-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anahita Sadeghi AND Sovodak AND COVID-19,Sofosbuvir AND Daclatasvir AND Iran AND coronavirus,,,,,,,,,MPJ,2020-06-30,IRCT20200128046294N2,IRCT,2020-03-14,2020-03-26,FALSE,Digestive Disease Research Institute,Not Recruiting,Phase 3,Interventional,Iran,Study to Evaluate the Safety and Efficacy of Sofosbuvir/Daclatasvir in Participants with Moderate to Severe Coronavirus Disease (COVID-19),Drug,Sofosbuvir + Daclatasvir,Sofosbuvir; Daclatasvir,70,http://en.irct.ir/trial/46463,,,,2020-05-18,2020-05-18,0,0,,,,,,,,,,,7,,Recruitment complete,TRUE,1,,,,,,,,,,,,,true,,
2020-12-13 22:20:28,2020-12-13 22:22:33,IP Address,86.31.166.235,100,125,True,2020-12-13 22:22:34,R_3JfURO1mOL1CqyU,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-12-18,NA,0,,,,,,full_results_journal_article,,,,," 10.1513/AnnalsATS.202008-940OC",33166179,https://www.atsjournals.org/doi/10.1513/AnnalsATS.202008-940OC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04329832,ClinicalTrials.gov,2020-03-30,2020-03-30,FALSE,"Intermountain Health Care, Inc.",Recruiting,Phase 2,Interventional,United States,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,Drug,Hydroxychloroquine vs. Azithromycin,Hydroxychloroquine; azithromycin,300,https://clinicaltrials.gov/show/NCT04329832,,,2020-12-31,2021-12-31,2020-12-31,0,1,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2020-12-18
2020-12-13 22:22:43,2020-12-13 22:27:02,IP Address,86.31.166.235,100,258,True,2020-12-13 22:27:02,R_1luzilDYB9chQTA,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Baicalein AND COVID-19 AND Xiansheng Zeng,Bicole AND coronavirus AND pneumonia,,,,,,,,,MPJ,2020-06-30,ChiCTR2000033286,ChiCTR,2020-05-26,2020-02-15,TRUE,Xiangyang Central Hospital,Not Recruiting,Not Applicable,Interventional,China,"A Randomized, Double-blind, Placebo-controlled trial for determination of the Efficacy and Safety of Baicalein in Hospitalized Adult  Mild and Moderate Patients of novel coronavirus pneumonia (COVID-19)",Traditional Medicine (Drug),Tradtional Medicine,Tradtional Medicine,60,http://www.chictr.org.cn/showproj.aspx?proj=54176,,,,2020-03-09,2020-03-09,0,0,,,,,,,,,,,7,,Completed,TRUE,1,,,,,,,,,,,,,,,
2020-12-13 22:27:11,2020-12-13 22:36:48,IP Address,86.31.166.235,100,576,True,2020-12-13 22:36:49,R_22JowqAY8CwURcg,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Baricitinib AND COVID-19 AND Francesco Menichetti     ",,,,,,,,,,MPJ,2020-06-30,NCT04393051,ClinicalTrials.gov,2020-05-16,2020-05-20,FALSE,AOU Pisana,Not Recruiting,Phase 2,Interventional,Italy,Baricitinib Compared to Standard Therapy in Patients With COVID-19,Drug,Baricitinib,Baricitinib,126,https://clinicaltrials.gov/show/NCT04393051,,,2020-06-30,2020-07-30,2020-06-30,0,1,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-14 12:42:12,2020-12-14 13:03:13,IP Address,86.31.166.235,100,1261,True,2020-12-14 13:03:15,R_3OiSk2amJWnxlOh,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04392427,ClinicalTrials.gov,2020-05-12,2020-05-01,TRUE,Mansoura University,Not Recruiting,Phase 3,Interventional,Egypt,New Antiviral Drugs for Treatment of COVID-19,Drug,Nitazoxanide + Ribavirin + Ivermectin,Nitazoxanide; Ribavirin; Ivermectin,100,https://clinicaltrials.gov/show/NCT04392427,,,2022-05-01,2022-05-01,2022-05-01,0,1,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-14 13:03:22,2020-12-14 13:04:28,IP Address,86.31.166.235,100,65,True,2020-12-14 13:04:28,R_puDL6kglHM6blwl,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,Testing post-covid - not prevention or treatment?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04392323,ClinicalTrials.gov,2020-05-15,2020-05-13,TRUE,Northwell Health,Recruiting,Not Applicable,Interventional,United States,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Clinical Presentation (Epidemiology),No Intervention,No Intervention,500,https://clinicaltrials.gov/show/NCT04392323,,,2020-07-01,2020-07-31,2020-07-01,0,1,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-14 14:32:46,2020-12-14 14:44:42,IP Address,86.31.166.235,100,715,True,2020-12-14 14:44:43,R_2uqe47pXvBkpVvo,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Corticosteroids AND COVID-19 AND Beijing Chao Yang Hospital,"Methylprednisolone AND Shi Huanzhong AND coronavirus ",,,,,,,,,MPJ,2020-06-30,NCT04273321,ClinicalTrials.gov,2020-02-15,2020-02-14,TRUE,"Beijing Chaoyang Hospital, Capital Medical University",Not Recruiting,Not Applicable,Interventional,China,Efficacy and Safety of Corticosteroids in COVID-19,Drug,Corticosteroids,Methylprednisolone,86,https://clinicaltrials.gov/show/NCT04273321,,,2020-04-15,2020-04-15,2020-04-15,0,0,,,,,,,,,,,7,,Completed,TRUE,1,,,,,,,,,,,,,,,
2020-12-13 18:13:25,2020-12-14 14:46:49,IP Address,86.31.166.235,100,74004,True,2020-12-14 14:46:49,R_1rwF1uvuVsDoEiW,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,"Unsure about how this is unique to Covid patients ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,RBR-2dxyx4,REBEC,2020-06-02,2020-06-04,FALSE,Hospital Universitário Clementino Fraga Filho,Not Recruiting,Not Applicable,Interventional,Brazil,Mechanical ventilator for use in patients with respiratory failure due to Covid-19 (VExCO),Other (physical),Mechanical ventilation,Mechanical ventilation,5,http://www.ensaiosclinicos.gov.br/rg/RBR-2dxyx4/,,,,2020-06-11,2020-06-11,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-14 14:47:09,2020-12-14 14:47:34,IP Address,86.31.166.235,100,24,True,2020-12-14 14:47:34,R_2aXpjxB4Mjk9gXx,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,JPRN-UMIN000040286,JPRN,2020-05-11,2020-05-12,FALSE,University of Tokyo,Not Recruiting,Not Applicable,Interventional,Japan,Study on risk perception and behavioral change related to COVID-19,Other (psych),No Intervention,No Intervention,1980,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045966,,,,2020-05-14,2020-05-14,0,0,,,,,,,,,,,7,,Preinitiation,TRUE,1,,,,,,,,,,,,,,,
2020-12-14 14:47:45,2020-12-14 14:48:42,IP Address,86.31.166.235,100,56,True,2020-12-14 14:48:43,R_30hI9grKDapPUxn,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04379154,ClinicalTrials.gov,2020-04-28,2020-04-14,TRUE,Hôpital Foch,Recruiting,Not Applicable,Interventional,France,Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-CoV-2 (COVID-19),Other,Other,Other,60,https://clinicaltrials.gov/show/NCT04379154,,,2020-06-28,2020-11-16,2020-06-28,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-14 14:48:49,2020-12-14 14:57:10,IP Address,86.31.166.235,100,500,True,2020-12-14 14:57:10,R_bg7W9HCSBu8jq2B,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-07-01,2020-09-01,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Methylene Blue AND COVID-19 AND Ain Shams University,Mohamed Mahmoud Moussa AND coronavirus AND convalescent plasma,,,,,,,,,MPJ,2020-06-30,NCT04376788,ClinicalTrials.gov,2020-05-01,2020-05-05,FALSE,Ain Shams University,Not Recruiting,Phase 2,Interventional,Egypt,Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19,ATMP,Plasma + Methylene Blue,Plasma; Methylene Blue,15,https://clinicaltrials.gov/show/NCT04376788,,,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,2020-09-01
2020-12-14 14:57:16,2020-12-14 14:57:34,Spam,86.31.166.235,100,18,True,2020-12-14 14:57:35,R_Q3M2m7Er7zgNLi1,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04376515,ClinicalTrials.gov,2020-03-31,2020-03-20,TRUE,"University of California, Irvine",Not Recruiting,Not Applicable,Interventional,United States,Harnessing Online Peer Education Online Support Intervention for COVID-19 (HOPE COVID-19),Other (psych),Psychological,Psychological,300,https://clinicaltrials.gov/show/NCT04376515,,,2020-06-01,2020-09-01,2020-06-01,0,0,,,,,,,,,,,7,,"Active, not recruiting",TRUE,1,,,,,,,,,,,,,,,
2020-12-14 14:57:41,2020-12-14 15:09:39,IP Address,86.31.166.235,100,717,True,2020-12-14 15:09:40,R_3KVZE2xHoZ0N2oA,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-12-31,2021-12-31,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hydroxychloroquine AND Henry Ford Health System AND COVID-19,WHIP COVID-19 AND William W. O'Neill,,,,,,,,,MPJ,2020-06-30,NCT04341441,ClinicalTrials.gov,2020-04-07,2020-04-07,FALSE,Henry Ford Health System,Recruiting,Phase 3,Interventional,United States,Will Hydroxychloroquine Impede or Prevent COVID-19,Drug,Hydroxychloroquine,Hydroxychloroquine,3000,https://clinicaltrials.gov/show/NCT04341441,,,2020-06-30,2021-04-30,2020-06-30,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2021-12-31
2020-12-14 15:09:57,2020-12-14 15:13:45,IP Address,86.31.166.235,100,227,True,2020-12-14 15:13:45,R_3KxMFPf5ZeXYJPI,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-05-21,2020-05-21,0,,,,,,summary_results,,,,,,,,,,,,,,,,,,,,2020-09-16,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Revised trial date was before the date originally extracted,team_review,,MPJ,2020-06-30,NCT04280705,ClinicalTrials.gov,2020-02-20,2020-02-21,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),Recruiting,Phase 3,Interventional,"Japan, Spain, South Korea, Greece, United States, Denmark, Germany, Singapore, Mexico, United Kingdom",Adaptive COVID-19 Treatment Trial (ACTT),Drug,Remdesivir,Remdesivir,800,https://clinicaltrials.gov/show/NCT04280705,EUCTR2020-001052-18; JPRN-jRCT2031190264,,2023-04-01,2023-04-01,2023-04-01,0,1,,10.1056/NEJMoa2007764,,10.1056/NEJMoa2007764,,interim_results_journal_article,,,2020-05-22,,7,,Recruiting,TRUE,1,32445440,interim_results_journal_article,2020-05-22,,,,,,,,,,,,2020-05-21
2020-12-14 16:46:34,2020-12-14 16:53:20,IP Address,86.31.166.235,100,406,True,2020-12-14 16:53:21,R_3izlyZJ0gQrB6Rs,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COLVID-19 AND University Of Perugia,Colchicine AND COVID-19 AND Roberto Gerli,,,,,,,,,MPJ,2020-06-30,NCT04375202,ClinicalTrials.gov,2020-04-29,2020-04-18,FALSE,University of Perugia,Recruiting,Phase 2,Interventional,Italy,Colchicine in COVID-19: a Pilot Study,Drug,Colchicine,Colchicine,308,https://clinicaltrials.gov/show/NCT04375202,EUCTR2020-001475-33,,2020-06-30,2020-10-31,2020-06-30,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-14 16:53:31,2020-12-14 16:54:02,IP Address,86.31.166.235,100,31,True,2020-12-14 16:54:02,R_roGj2OqKlR5l7kR,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04372030,ClinicalTrials.gov,2020-04-22,2020-05-01,FALSE,UCLouvain,Not Recruiting,Not Applicable,Interventional,No Country Given,Health Care Use During the Covid19 Crisis,Health System,No Intervention,No Intervention,10000,https://clinicaltrials.gov/show/NCT04372030,,,2020-06-30,2021-10-31,2020-06-30,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-14 16:54:08,2020-12-14 16:59:49,IP Address,86.31.166.235,100,340,True,2020-12-14 16:59:49,R_wUdQxZBfD8NYcjT,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-12-31,2020-12-31,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Avdoralimab AND COVID AND Emilie Garrido-Pradalie,,,,,,,,,,MPJ,2020-06-30,NCT04371367,ClinicalTrials.gov,2020-04-29,2020-04-27,TRUE,Assistance Publique – Hôpitaux de Marseille,Recruiting,Phase 2,Interventional,France,"Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )",Drug,Avdoralimab,Avdoralimab,108,https://clinicaltrials.gov/show/NCT04371367,,,2020-06-27,2020-10-27,2020-06-27,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2020-12-31
2020-12-14 16:59:58,2020-12-14 17:00:48,Spam,86.31.166.235,100,49,True,2020-12-14 17:00:48,R_2zvFlsT6coyXwF1,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04366297,ClinicalTrials.gov,2020-04-23,2020-01-12,TRUE,Lazarski University,Not Recruiting,Not Applicable,Interventional,Poland,Intravascular Access of COVID-19 Patient Under Personal Protective Equipment,Other (device),Intraosseous/Intravenous access device,Intraosseous/Intravenous access device,41,https://clinicaltrials.gov/show/NCT04366297,,,2020-02-25,2020-02-25,2020-02-25,0,0,,,,,,,,,,,7,,Completed,TRUE,1,,,,,,,,,,,,,,,
2020-12-14 17:00:58,2020-12-14 17:07:36,IP Address,86.31.166.235,100,398,True,2020-12-14 17:07:38,R_1rdhB9Fk9DIGlr9,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MTX-loaded Nanoparticles AND COVID-19 AND Brazil,,,,,,,,,,MPJ,2020-06-30,NCT04352465,ClinicalTrials.gov,2020-04-15,2020-05-01,FALSE,Azidus Brasil,Not Recruiting,Phase 1/Phase 2,Interventional,Brazil,Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients,Drug,Methotrexate,Methotrexate,42,https://clinicaltrials.gov/show/NCT04352465,,,2020-06-30,2020-11-30,2020-06-30,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-14 21:02:41,2020-12-14 21:08:25,IP Address,86.31.166.235,100,344,True,2020-12-14 21:08:25,R_pGW7l5iyPVQWVah,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,no,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Corticosteroids AND COVID-19 AND  Instituto de Investigación Sanitaria Valdecilla,GLUCOCOVID,,,,,,,,,MPJ,2020-06-30,EUCTR2020-001934-37-ES,EU Clinical Trials Register,2020-05-08,2020-05-07,TRUE,Instituto de Investigación Marqués de Valdecilla (IDIVAL),Authorised,Phase 4,Interventional,Spain,USE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTION,Drug,Corticosteroids,Methylprednisolone,200,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001934-37,,,,,,,,,10.1101/2020.06.17.20133579,,10.1101/2020.06.17.20133579,,full_results_preprint,,,2020-06-18,,7,,,TRUE,1,,full_results_preprint,2020-06-18,zql4zhyk,http://medrxiv.org/cgi/content/short/2020.06.17.20133579v1?rss=1,GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia,,,,,,,,true,
2020-12-14 21:08:34,2020-12-14 21:10:16,IP Address,86.31.166.235,100,102,True,2020-12-14 21:10:17,R_3M6EmvB4GVM4NwJ,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2021-03-31,2021-03-31,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04345848,ClinicalTrials.gov,2020-04-07,2020-04-28,FALSE,"University Hospital, Geneva",Recruiting,Phase 3,Interventional,Switzerland,Preventing COVID-19 Complications With Low- and High-dose Anticoagulation,Drug,Heparin,Heparin,200,https://clinicaltrials.gov/show/NCT04345848,,,2020-11-30,2020-11-30,2020-11-30,0,1,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2021-03-31
2020-12-14 21:10:25,2020-12-14 21:17:18,IP Address,86.31.166.235,100,413,True,2020-12-14 21:17:18,R_6rluKonfI39MOad,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-12-31,2020-12-31,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Healthcare workers AND COVID-19 AND Rosa Polo,EPICOS AND Plan Nacional sobre el Sida,,,,,,,,,MPJ,2020-06-30,NCT04334928,ClinicalTrials.gov,2020-04-02,2020-04-15,FALSE,Plan Nacional sobre el Sida (PNS),Recruiting,Phase 3,Interventional,Spain,Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel,Drug,Emtricitabine/tenofovir disoproxil + hydroxychloroquine vs. hydroxychloroquine vs. Emtricitabine/tenofovir disoproxil,Emtricitabine/tenofovir disoproxil; hydroxychloroquine,4000,https://clinicaltrials.gov/show/NCT04334928,,,2020-06-30,2020-07-31,2020-06-30,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2020-12-31
2020-12-14 21:18:05,2020-12-14 21:20:08,IP Address,86.31.166.235,100,122,True,2020-12-14 21:20:08,R_3dTl4NMuqmtjigQ,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,This was a self-control study designed to assess the influence of stay-at-home measure during COVID-19 pandemic on cardiovascular risk factors.,,,MPJ,2020-06-30,ChiCTR2000032632,ChiCTR,2020-05-04,2020-03-20,TRUE,The First Affiliated Hospital of Xinjiang Medical University,Recruiting,Not Applicable,Interventional,China,The influence of COVID-19 pandemic on cardiovascular patients,Clinical Presentation,No Intervention,No Intervention,100,http://www.chictr.org.cn/showproj.aspx?proj=53190,,,,2020-05-22,2020-05-22,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-14 21:20:16,2020-12-14 21:20:54,IP Address,86.31.166.235,100,38,True,2020-12-14 21:20:55,R_bQlIZ6PFql2p1YJ,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,Post-covid treatment?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04365738,ClinicalTrials.gov,2020-04-26,2020-03-11,TRUE,Istanbul Bilgi University,Not Recruiting,Not Applicable,Interventional,Turkey,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection,Other (physio),Physio & Rehabilitation,Physio & Rehabilitation,270,https://clinicaltrials.gov/show/NCT04365738,,,2020-04-10,2020-04-26,2020-04-10,0,0,,,,,,,,,,,7,,Completed,TRUE,1,,,,,,,,,,,,,,,
2020-12-14 21:21:01,2020-12-14 21:24:10,IP Address,86.31.166.235,100,188,True,2020-12-14 21:24:10,R_2aPKkeGbjXEuiJO,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Azithromycin AND COVID-19 AND Shahid Beheshti University,,,,,,,,,,MPJ,2020-06-30,NCT04359316,ClinicalTrials.gov,2020-04-18,2020-04-20,FALSE,Shahid Beheshti University of Medical Sciences,Not Recruiting,Phase 4,Interventional,Iran,Azithromycin in Hospitalized COVID-19 Patients,Drug,Azithromycin vs. Hydroxychloroquine,Azithromycin; Hydroxychloroquine,40,https://clinicaltrials.gov/show/NCT04359316,,,2020-05-03,2020-05-05,2020-05-03,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-14 21:24:19,2020-12-14 21:25:41,IP Address,86.31.166.235,100,82,True,2020-12-14 21:25:42,R_3376Njdtjs9uAf4,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04355429,ClinicalTrials.gov,2020-04-17,2020-05-05,FALSE,Assistance Publique – Hôpitaux de Paris,Not Recruiting,Phase 2,Interventional,France,Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID),Drug,Captopril,Captopril,230,https://clinicaltrials.gov/show/NCT04355429,,,2020-07-01,2020-08-01,2020-07-01,0,1,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-14 21:25:55,2020-12-14 21:26:41,IP Address,86.31.166.235,100,46,True,2020-12-14 21:26:42,R_3KpgIdY9PEcIKq2,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04337008,ClinicalTrials.gov,2020-04-03,2020-04-03,FALSE,Assistance Publique – Hôpitaux de Marseille,Recruiting,Not Applicable,Interventional,France,Renin Angiotensin System - CoronaVirus,Clinical Presentation,No Intervention,No Intervention,50,https://clinicaltrials.gov/show/NCT04337008,,,2020-06-03,2020-07-31,2020-06-03,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-14 21:26:48,2020-12-14 21:31:30,IP Address,86.31.166.235,100,281,True,2020-12-14 21:31:31,R_DuilzW3vMC6qoUN,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Azithromycin AND COVID-19 AND Hydroxychloroquine AND Azidus Brasil	",Luciana Ferrara AND coronavirus AND Azithromycin,,,,,,,,,MPJ,2020-06-30,NCT04329572,ClinicalTrials.gov,2020-03-29,2020-04-23,FALSE,Azidus Brasil,Not Recruiting,Phase 1,Interventional,Brazil,Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19,Drug,Hydroxychloroquine + Azithromycin,Hydroxychloroquine; Azithromycin,400,https://clinicaltrials.gov/show/NCT04329572,,,2020-05-31,2020-06-30,2020-05-31,0,0,,,,,,,,,,,7,,Suspended,TRUE,1,,,,,,,,,,,,,,,
2020-12-14 21:42:32,2020-12-14 21:55:42,IP Address,86.31.166.235,100,790,True,2020-12-14 21:55:43,R_2BwzJRvRFgGnWOQ,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,NA,2020-04-14,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,chloroquine AND COVID-19 AND Australia,,,,,,,,,,MPJ,2020-06-30,ACTRN12620000417987,ANZCTR,2020-03-30,2020-03-30,FALSE,Australian Defence Force Malaria and Infectious Disease Institute,Recruiting,Phase 4,Interventional,Australia,Chloroquine Chemorophylaxis Countermeasure against COVID-19,Drug,Chloroquine,Chloroquine,680,https://anzctr.org.au/ACTRN12620000417987.aspx,,,,2020-05-11,2020-05-11,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2020-04-14
2020-12-14 21:55:58,2020-12-14 22:01:33,IP Address,86.31.166.235,100,334,True,2020-12-14 22:01:33,R_1jdms5j9u55BseF,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bromhexine AND Hydroxychloroquine AND COVID-19 AND Miha Mežnar,,,,,,,,,,MPJ,2020-06-30,NCT04355026,ClinicalTrials.gov,2020-04-15,2020-04-10,TRUE,Celje General Hospital,Recruiting,Phase 4,Interventional,Slovenia,Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia,Drug,Bromhexine + Hydroxychloroquine vs. Hydroxychloroquine,Bromhexine; Hydroxychloroquine,90,https://clinicaltrials.gov/show/NCT04355026,,,2020-06-30,2020-07-31,2020-06-30,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-14 22:01:40,2020-12-14 22:07:24,IP Address,86.31.166.235,100,343,True,2020-12-14 22:07:25,R_2v815JUDcvudQV9,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-11-20,2020-12-20,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Antiviral Mouthrinses AND COVID-19 AND Carrouel Florence,BBCovid AND Claude Bernard University,,,,,,,,,MPJ,2020-06-30,NCT04352959,ClinicalTrials.gov,2020-04-15,2020-04-27,FALSE,Claude Bernard University,Not Recruiting,Not Applicable,Interventional,No Country Given,COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses,Drug,Bêta-cyclodextrin + citrox,Bêta-cyclodextrin; citrox,178,https://clinicaltrials.gov/show/NCT04352959,,,2020-05-20,2020-06-20,2020-05-20,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,2020-12-20
2020-12-14 22:07:30,2020-12-14 22:07:53,IP Address,86.31.166.235,100,22,True,2020-12-14 22:07:53,R_1M0S3pKakKeoTHG,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04346927,ClinicalTrials.gov,2020-04-13,2020-04-10,TRUE,Yasemin Çırak,Not Recruiting,Not Applicable,Interventional,No Country Given,Telerehabilitation for Patients Diagnosed With Coronavirus,Telehealth,Physio & Rehabilitation,Physio & Rehabilitation,30,https://clinicaltrials.gov/show/NCT04346927,,,2020-06-10,2020-07-31,2020-06-10,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-14 22:08:01,2020-12-14 22:08:21,Spam,86.31.166.235,100,20,True,2020-12-14 22:08:22,R_1OrkA5Pi2tJtmZb,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04345549,ClinicalTrials.gov,2020-04-10,2020-02-26,TRUE,Aarogyam UK,Not Recruiting,Not Applicable,Interventional,United Kingdom,Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak,Traditional Medicine (Other),Traditional Medicine,Traditional Medicine,18,https://clinicaltrials.gov/show/NCT04345549,,,2020-03-30,2020-03-30,2020-03-30,0,0,,,,,,,,,,,7,,Completed,TRUE,1,,,,,,,,,,,,,,,
2020-12-14 22:08:28,2020-12-15 09:58:30,IP Address,86.31.166.235,100,42602,True,2020-12-15 09:58:31,R_3flANLUn0UAFUWG,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Adoptive Cell Transfer AND COVID-19 AND Carlos Alberto Parra Lopez,Allogeneic NK transfer AND coronavirus AND Colombia,,,,,,,,,MPJ,2020-06-30,NCT04344548,ClinicalTrials.gov,2020-04-10,2020-04-13,FALSE,National University of Colombia,Not Recruiting,Phase 1/Phase 2,Interventional,Colombia,Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia,ATMP,Cells (NK),Cells (NK),10,https://clinicaltrials.gov/show/NCT04344548,,,2020-06-10,2020-11-10,2020-06-10,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-15 09:58:40,2020-12-15 09:59:34,IP Address,86.31.166.235,100,54,True,2020-12-15 09:59:35,R_2wNS1MCa7McNnqf,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04344236,ClinicalTrials.gov,2020-04-08,2020-04-09,FALSE,NYU Langone Health,Recruiting,Phase 2,Interventional,United States,Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19,Drug,Povidone Iodine,Povidone Iodine,48,https://clinicaltrials.gov/show/NCT04344236,,,2020-05-01,2020-05-09,2020-05-01,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-15 09:59:45,2020-12-15 10:00:58,IP Address,86.31.166.235,100,73,True,2020-12-15 10:00:59,R_2f9YOFV4QrZu74i,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04343690,ClinicalTrials.gov,2020-04-09,2020-04-13,FALSE,Duke University,Not Recruiting,Not Applicable,Interventional,United States,COPING With COVID-19( CWC-19),Other (psych),Psychological,Psychological,100,https://clinicaltrials.gov/show/NCT04343690,,,2020-06-30,2020-06-30,2020-06-30,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-15 10:01:04,2020-12-15 10:07:45,IP Address,86.31.166.235,100,400,True,2020-12-15 10:07:46,R_3LX5S4Lir7VQMHE,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Siltuximab AND COVID-19 AND Felipe García,,,,,,,,,,MPJ,2020-06-30,NCT04329650,ClinicalTrials.gov,2020-03-31,2020-04-15,TRUE,Judit Pich Martínez,Recruiting,Phase 2,Interventional,Spain,Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia,Drug,Siltuximab vs. Corticosteroids,Siltuximab; Methylprednisolone,200,https://clinicaltrials.gov/show/NCT04329650,EUCTR2020-001413-20,,2020-05-20,2020-05-20,2020-05-20,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-15 10:07:54,2020-12-15 10:10:59,IP Address,86.31.166.235,100,185,True,2020-12-15 10:11:00,R_3Mbp028hPZWXjqP,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Peter Friedland AND COVID-19 AND Nasodine® Antiseptic Nasal Spray ",,,,,,,,,,MPJ,2020-06-30,ACTRN12620000470998,ANZCTR,2020-04-14,2020-04-20,FALSE,Firebrick Pharma Pty Ltd,Not Recruiting,Not Applicable,Interventional,Australia,Virucidal pilot study of Nasodine® Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.,Drug,Povidone Iodine,Povidone Iodine,20,https://anzctr.org.au/ACTRN12620000470998.aspx,,,,2020-05-01,2020-05-01,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-15 10:11:59,2020-12-15 10:16:59,IP Address,86.31.166.235,100,299,True,2020-12-15 10:16:59,R_yQE7IRoK3Sz9sNX,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Traditional Chinese Medicine AND COVID-19 AND Li Hao,,,,,,,,,,MPJ,2020-06-30,NCT04323332,ClinicalTrials.gov,2020-03-08,2020-03-01,TRUE,"Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine",Not Recruiting,Phase 3,Interventional,China,Traditional Chinese Medicine for Severe COVID-19,Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,50,https://clinicaltrials.gov/show/NCT04323332,,,2020-03-01,2020-04-01,2020-03-01,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-15 10:17:10,2020-12-15 10:17:28,Spam,86.31.166.235,100,18,True,2020-12-15 10:17:28,R_OeRM6kGzzsU5nRD,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000031272,ChiCTR,2020-03-26,2020-02-18,TRUE,China European International Business School (CEIBS),Not Recruiting,Not Applicable,Interventional,China,The effectiveness of mindfulness intervention in improving people's psychological and physical well-being during novel coronavirus pneumonia (COVID-19) outbreak,Other (psych),Psychological,Psychological,110,http://www.chictr.org.cn/showproj.aspx?proj=51455,,,,2020-03-02,2020-03-02,0,0,,,,,,,,,,,7,,Completed,TRUE,1,,,,,,,,,,,,,,,
2020-12-15 10:17:34,2020-12-15 10:32:21,IP Address,86.31.166.235,100,886,True,2020-12-15 10:32:22,R_3hbT3WUD16D1rQ9,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Immunoglobulin AND COVID-19 AND Wuhan Union Hospital," Immunoglobulin AND cured patients AND coronavirus AND Xiang Cheng",,,,,,,,,MPJ,2020-06-30,NCT04264858,ClinicalTrials.gov,2020-02-08,2020-03-17,FALSE,"Wuhan Union Hospital, China",Not Recruiting,Not Applicable,Interventional,China,Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients,ATMP,Immunoglobulin,Immunoglobulin,10,https://clinicaltrials.gov/show/NCT04264858,,,2020-04-30,2020-05-31,2020-04-30,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-15 10:33:48,2020-12-15 10:41:02,IP Address,86.31.166.235,100,433,True,2020-12-15 10:41:02,R_0Pw2ZnOhhyd979v,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Methylprednisolone AND COVID-19 AND Qin Ning,,,,,,,,,,MPJ,2020-06-30,NCT04263402,ClinicalTrials.gov,2020-02-02,2020-02-01,TRUE,"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,Phase 4,Interventional,China,The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia,Drug,Corticosteroids,Methylprednisolone,100,https://clinicaltrials.gov/show/NCT04263402,,,2020-06-01,2020-07-01,2020-06-01,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-15 10:41:21,2020-12-15 10:45:10,IP Address,86.31.166.235,100,228,True,2020-12-15 10:45:11,R_3EuM2NwTMq2ZYOy,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"recombinant cytokine AND COVID-19 AND Li Lanjuan ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029573,ChiCTR,2020-02-05,2020-02-06,FALSE,The First Affiliated Hospital of Zhejiang University School of Medicine,Recruiting,Phase 4,Interventional,China,"A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and safety of recombinant cytokine gene-derived protein injection in combination with standard therapy in patients with novel coronavirus infection",ATMP,Gene-derived protein,Gene-derived protein,480,http://www.chictr.org.cn/showproj.aspx?proj=49065,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-16 01:49:06,2020-12-16 01:59:01,IP Address,74.90.123.184,100,594,True,2020-12-16 01:59:02,R_1jV7SQvahEdCmnD,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,no,2020-07-27,2020-07-27,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The study was terminated but it looks like there was enrollment: https://www.novartis.com/news/media-releases/novartis-discontinues-hydroxychloroquine-clinical-trial-based-slow-enrollment-remains-committed-pandemic-research-efforts,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Novartis AND Hydroxychloroquine AND Covid,,,,,,,,,,ND,2020-06-30,NCT04358081,ClinicalTrials.gov,2020-04-08,2020-05-01,FALSE,Novartis Pharmaceuticals,Recruiting,Phase 3,Interventional,United States,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Drug,Hydroxychloroquine + Azithromycin vs. Hydroxychloroquine,Azithromycin; Hydroxychloroquine,444,https://clinicaltrials.gov/show/NCT04358081,,,2020-06-25,2020-07-24,2020-06-25,0,0,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2020-07-27
2020-12-16 01:59:09,2020-12-16 01:59:36,IP Address,74.90.123.184,100,27,True,2020-12-16 01:59:37,R_2Pj5Dol3ETEKcgF,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04396314,ClinicalTrials.gov,2020-05-15,2020-09-01,FALSE,University of Lleida,Not Recruiting,Not Applicable,Interventional,No Country Given,Effectiveness of Basic Body Awareness Therapy in Survivors of Covid-19 and Health Workers Regarding Post-traumatic Stress Disorders,Other (psych),Psychological,Psychological,54,https://clinicaltrials.gov/show/NCT04396314,,,2020-12-31,2021-04-30,2020-12-31,0,1,,,,,,,,,,,6,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-16 01:59:42,2020-12-16 02:04:55,IP Address,74.90.123.184,100,312,True,2020-12-16 02:04:55,R_8oaUaIBSVG3P9jr,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Found a cross-registration: EUCTR2020-001345-38. Marking for review so we can add in reconciliation.,team_review,,ND,2020-06-30,NCT04344951,ClinicalTrials.gov,2020-04-06,2020-04-06,FALSE,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,Recruiting,Phase 2,Interventional,Greece,"Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial",Drug,Chloroquine,Chloroquine,60,https://clinicaltrials.gov/show/NCT04344951,,,2021-04-01,2021-04-30,2021-04-01,0,1,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-16 02:05:11,2020-12-16 02:12:48,IP Address,74.90.123.184,100,456,True,2020-12-16 02:12:49,R_syV7adw7fNaVMvT,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,no,2020-07-31,2020-07-31,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_journal_article,,,,,10.1016/j.ijantimicag.2020.106224,,,,,,,,,,,,,,,2020-12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Deba P Dhibar,PEP-CQ,,,,,,,,,ND,2020-06-30,NCT04408456,ClinicalTrials.gov,2020-05-24,2020-03-01,TRUE,Postgraduate Institute of Medical Education and Research,Recruiting,Phase 3,Interventional,India,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,Drug (Chemoprophylaxis),Hydroxychloroquine,Hydroxychloroquine,200,https://clinicaltrials.gov/show/NCT04408456,,,2020-06-30,2020-06-30,2020-06-30,0,0,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,true,,2020-07-31
2020-12-16 02:13:09,2020-12-16 02:15:23,IP Address,74.90.123.184,100,133,True,2020-12-16 02:15:24,R_3CIeC3qvdxRAgz4,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04356482,ClinicalTrials.gov,2020-04-17,2020-05-20,FALSE,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,Recruiting,Phase 1/Phase 2,Interventional,Mexico,CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19,ATMP,Plasma,Plasma,90,https://clinicaltrials.gov/show/NCT04356482,,,2020-11-01,2020-12-01,2020-11-01,0,1,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-16 02:15:31,2020-12-16 02:16:29,IP Address,74.90.123.184,100,58,True,2020-12-16 02:16:30,R_10SlAb5wbEiEOaS,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,no,,"The outcomes are about mask fit and things like that, not directly COVID stuff even though it is indirectly about prevention.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04416919,ClinicalTrials.gov,2020-05-13,2020-06-15,FALSE,University of Oklahoma,Not Recruiting,Not Applicable,Interventional,United States,Assessment of N-95 Facemask for Use in COVID-19 Pandemic in Case of Shortage of Personal Protective Equipment,Other (device),Masks,Masks,20,https://clinicaltrials.gov/show/NCT04416919,,,2025-05-01,2025-05-01,2025-05-01,0,1,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-16 02:16:34,2020-12-16 02:19:02,IP Address,74.90.123.184,100,148,True,2020-12-16 02:19:02,R_3en9RN4stPdxfEr,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,no,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Trial protocol in linked in the registry entry and also here: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04501-0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,DRKS00021447,German Clinical Trials Register,2020-04-27,2020-05-01,FALSE,Charité University,Not Recruiting,Phase 2,Interventional,Germany,CytoResc - CytoSorb Rescue for COVID-19 Cytokine Storm,Other (device),Cytokine Adsorber,Cytokine Adsorber,100,http://www.drks.de/DRKS00021447,,,,,,0,1,,,,,,,,,,,6,,Recruiting planned,TRUE,2,,,,,,,,,,,,,,,
2020-12-16 02:19:14,2020-12-16 02:33:45,IP Address,74.90.123.184,100,870,True,2020-12-16 02:33:45,R_24dXZaAXkd3TFto,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,no,2021-12,2031-12,0,,,,,,interim_result,interim_result,full_results_journal_article,interim_result,interim_result,10.1056/NEJMoa2021436,,,10.1101/2020.07.15.20151852,,,10.1056/NEJMoa2022926,,,10.1101/2020.12.10.20245944,,,10.1016/S0140-6736(20)32013-4,,,2020-07-17,,2020-07-15,,2020-11-19,,2020-12-14,,2020-10-05,,,,,,,,,,,,,,,,,,Preprint,,Preprint,Journal Article,,"Many of the final results include very high percentage, but not all, of the outcomes for patients who were randomized. I don't know if that's from loss to follow-up or if they are truly interim though",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04381936,ClinicalTrials.gov,2020-05-07,2020-03-19,TRUE,University of Oxford,Recruiting,Phase 2/Phase 3,Interventional,United Kingdom,Randomized Evaluation of COVID-19 Therapy,Drug,Lopinavir/ritonavir vs. corticosteroids vs. hydroxychloroquine vs. azithromycin vs. tocilizumab,Lopinavir/ritonavir; dexamethasone; hydrocortisone;  hydroxychloroquine; azithromycin; tocilizumab,12000,https://clinicaltrials.gov/ct2/show/NCT04381936,"EUCTR2020-001113-21, ISRCTN50189673",,2020-12-01,2021-06-01,2020-12-01,0,0,,10.1101/2020.06.22.20137273,,10.1101/2020.06.22.20137273,,interim_results_preprint,,,2020-06-22,,6,,Recruiting,TRUE,2,,interim_results_preprint,2020-06-22,ocguwlam,http://medrxiv.org/cgi/content/short/2020.06.22.20137273v1?rss=1,Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report,,,,,,,,,2031-12
2020-12-16 02:33:56,2020-12-16 02:38:02,IP Address,74.90.123.184,100,245,True,2020-12-16 02:38:03,R_D6SjMHHA1X6qMy5,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,vitamin A AND Covid,Majid Farhadifard,,,,,,,,,ND,2020-06-30,IRCT20200314046774N1,IRCT,2020-06-12,2020-05-04,TRUE,Ghoum University of Medical Sciences,Not Recruiting,Phase 3,Interventional,Iran,treatment of COVID-19 whit vitamin A,Drug,Vitamin A,Vitamin A,94,http://en.irct.ir/trial/46519,,,,2020-06-13,2020-06-13,0,0,,,,,,,,,,,6,,Recruitment complete,TRUE,2,,,,,,,,,,,,,,,
2020-12-16 02:40:27,2020-12-16 02:45:21,IP Address,74.90.123.184,100,293,True,2020-12-16 02:45:22,R_2VsDUoMaubdRe2e,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"""Hackensack Meridian Health"" AND Hydroxychloroquine",Jawad Kirmani,,,,,,,,,ND,2020-06-30,NCT04345653,ClinicalTrials.gov,2020-04-08,2020-04-14,FALSE,Hackensack Meridian Health,Not Recruiting,Phase 2,Interventional,United States,Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers,Drug (Chemoprophylaxis),Hydroxychloroquine,Hydroxychloroquine,44,https://clinicaltrials.gov/show/NCT04345653,,,2020-06-05,2021-04-08,2020-06-05,0,0,,,,,,,,,,,6,,"Active, not recruiting",TRUE,2,,,,,,,,,,,,,,,
2020-12-16 02:45:26,2020-12-16 02:47:51,IP Address,74.90.123.184,100,144,True,2020-12-16 02:47:51,R_1irpiNCSPnftey0,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,unknown,no,I don't think this is a COVID trial. They are doing pre-work for COVID but it's in healthy people and the outcomes don't really have to do with COVID,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,ND,2020-06-30,JPRN-UMIN000040479,JPRN,2020-05-22,2020-05-22,FALSE,Takanawa Clinic,Recruiting,Not Applicable,Interventional,Japan,Immunological efficacy of lactic acid bacteria for COVID-19,Drug,Lactic acid bacteria,Lactic acid bacteria,30,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046202,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,6,,Open public recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-16 02:47:59,2020-12-16 02:48:50,Spam,74.90.123.184,100,51,True,2020-12-16 02:48:50,R_6tCaqHzhGRniqQN,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04418518,ClinicalTrials.gov,2020-06-03,2020-06-01,TRUE,Weill Medical College of Cornell University,Not Recruiting,Phase 3,Interventional,United States,A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness,ATMP,Plasma,Plasma,1200,https://clinicaltrials.gov/show/NCT04418518,,,2021-06-01,2021-12-01,2021-06-01,0,1,,,,,,,,,,,6,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-16 02:48:56,2020-12-16 02:49:27,IP Address,74.90.123.184,100,31,True,2020-12-16 02:49:28,R_3qNGwkluW8E3CwA,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,no,,Diagnostic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04379531,ClinicalTrials.gov,2020-04-30,2020-04-25,TRUE,Department of Health Care of Moscow,Not Recruiting,Not Applicable,Interventional,Russian Federation,LDCT in COVID-19 Pneumonia: a Prospective Moscow Study,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,230,https://clinicaltrials.gov/show/NCT04379531,,,2020-05-22,2020-05-22,2020-05-22,0,0,,,,,,,,,,,6,,Completed,TRUE,2,,,,,,,,,,,,,,,
2020-12-16 02:49:34,2020-12-16 02:49:53,Spam,74.90.123.184,100,19,True,2020-12-16 02:49:54,R_6y7MkZSkIPk48Y9,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04422353,ClinicalTrials.gov,2020-06-07,2020-05-01,TRUE,Federal University of Rio Grande do Sul,Recruiting,Not Applicable,Interventional,Brazil,Video Dance Class and Unsupervised Physical Activity During Covid-19 Pandemic in People With Parkinson's Disease,Other (exercise),Exercise,Exercise,60,https://clinicaltrials.gov/show/NCT04422353,,,2020-12-30,2024-12-30,2020-12-30,0,1,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-16 02:49:58,2020-12-16 02:51:22,IP Address,74.90.123.184,100,83,True,2020-12-16 02:51:22,R_3nVfVi5d3e8op1v,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,unknown,unknown,no,It seems to be more of a screening/prognosis thing although the outcome is COVID mortality...,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,ND,2020-06-30,NCT04423991,ClinicalTrials.gov,2020-06-08,2020-03-10,TRUE,Dascena,Not Recruiting,Not Applicable,Interventional,United States,Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning,Other (software),Machine Learning,Machine Learning,290,https://clinicaltrials.gov/show/NCT04423991,,,2020-06-04,2020-06-04,2020-06-04,0,0,,,,,,,,,,,6,,Completed,TRUE,2,,,,,,,,,,,,,,,
2020-12-16 02:51:26,2020-12-16 02:56:01,IP Address,74.90.123.184,100,274,True,2020-12-16 02:56:01,R_eCGUPkyuGiU182t,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Favipiravir AND Baqiyatallah,Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19,,,,,,,,,ND,2020-06-30,NCT04376814,ClinicalTrials.gov,2020-05-03,2020-03-29,TRUE,Baqiyatallah Medical Sciences University,Not Recruiting,Not Applicable,Interventional,Iran,Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19,Drug,Favipiravir + Hydroxychloroquine vs. Lopinavir/ritonavir + Hydroxychloroquine,Favipiravir; Hydroxychloroquine; Lopinavir/ritonavir,40,https://clinicaltrials.gov/show/NCT04376814,,,2020-04-05,2020-05-25,2020-04-05,0,0,,,,,,,,,,,6,,Completed,TRUE,2,,,,,,,,,,,,,,,
2020-12-16 02:56:06,2020-12-16 02:56:24,Spam,74.90.123.184,100,18,True,2020-12-16 02:56:24,R_3hAt0Ksu0fQPUfz,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04431180,ClinicalTrials.gov,2020-06-12,2020-06-13,FALSE,Guangzhou Blood Center,Recruiting,Not Applicable,Interventional,China,Recruit Blood Donors Via SMS During Epidemic of COVID-19 #Second Repeat Trial#,Other,Other,Other,403535,https://clinicaltrials.gov/show/NCT04431180,,,2020-06-13,2020-06-30,2020-06-13,0,0,,,,,,,,,,,6,,Enrolling by invitation,TRUE,2,,,,,,,,,,,,,,,
2020-12-16 02:56:31,2020-12-16 03:02:31,IP Address,74.90.123.184,100,359,True,2020-12-16 03:02:32,R_02mVAX8VzjLkaFH,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,Not much detail but I think this counts,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mahmoud Sedky,COVID AND Cairo AND Home isolation,,,,,,,,,ND,2020-06-30,NCT04368923,ClinicalTrials.gov,2020-04-24,2020-03-15,TRUE,Cairo University,Not Recruiting,Not Applicable,Interventional,Egypt,Management of Covid-19 Patients During Home Isolation,Drug,Oxygen,Oxygen,60,https://clinicaltrials.gov/show/NCT04368923,,,2020-06-21,2020-06-23,2020-06-21,0,0,,,,,,,,,,,6,,"Active, not recruiting",TRUE,2,,,,,,,,,,,,,,,
2020-12-16 18:16:46,2020-12-16 19:10:16,IP Address,74.90.123.184,100,3210,True,2020-12-16 19:10:17,R_1P03m3nEGyL0TTD,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,no,2020-07-14,2020-07-27,0,,,,,,summary_results,,,,,,,https://clinicaltrials.gov/ct2/show/results/NCT04422561,,,,,,,,,,,,,2020-08-27,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Protocol on CT.gov,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Waheed Shouman,Ivermectin AND Covid AND egypt,Zagazig University AND Ivermectin,,,,,,,,ND,2020-06-30,NCT04422561,ClinicalTrials.gov,2020-06-06,2020-05-31,TRUE,Zagazig University,Recruiting,Phase 2/Phase 3,Interventional,Egypt,Prophylactic Ivermectin in COVID-19 Contacts,Drug (Chemoprophylaxis),Ivermectin,Ivermectin,100,https://clinicaltrials.gov/show/NCT04422561,,,2020-06-01,2020-07-01,2020-06-01,0,0,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2020-07-27
2020-12-16 18:16:07,2020-12-16 19:37:12,IP Address,74.90.123.184,100,4864,True,2020-12-16 19:37:12,R_3qVChEEkyvtMqOh,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,VA-MENGOC-BC AND covid,Maria Toledo Romani,,,,,,,,,ND,2020-06-30,RPCEC00000314,RPCEC,2020-05-22,2020-04-24,TRUE,Finlay Vaccine Institute (IFV),Recruiting,Not Applicable,Interventional,Cuba,VA-MENGOC-BC to stimulate the innate response against SARS-CoV-2,ATMP,Vaccine,Vaccine,115000,https://rpcec.sld.cu/en/trials/RPCEC00000314-En,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-16 19:16:17,2020-12-16 19:47:46,IP Address,74.90.123.184,100,1889,True,2020-12-16 19:47:47,R_TtPyUwPNjITe6U9,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04437719,ClinicalTrials.gov,2020-06-17,2020-06-30,FALSE,Groupe Hospitalier Paris Saint-Joseph,Not Recruiting,Not Applicable,Interventional,France,"Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 Pandemic",Clinical Presentation,No Intervention,No Intervention,100,https://clinicaltrials.gov/show/NCT04437719,,,2021-12-31,2021-12-31,2021-12-31,0,1,,,,,,,,,,,6,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-16 19:51:22,2020-12-16 19:51:57,IP Address,74.90.123.184,100,34,True,2020-12-16 19:51:57,R_1TxcvaaPdYyAisx,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,no,,We've been excluding these types of trials as a rule.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,ACTRN12620000688987,ANZCTR,2020-06-19,2020-06-02,TRUE,The Royal Melbourne Hospital,Not Recruiting,Not Applicable,Interventional,Australia,Comparing the user seal check and fit test between two types of N95 respirators - the Halyard N95 Particulate Filter Respirators and the ProShield® N-95 masks,Other (device),Mask,Mask,80,https://anzctr.org.au/ACTRN12620000688987.aspx,,,,2020-06-05,2020-06-05,0,0,,,,,,,,,,,6,,Completed,TRUE,2,,,,,,,,,,,,,,,
2020-12-17 14:41:19,2020-12-17 14:41:46,IP Address,74.90.123.184,100,26,True,2020-12-17 14:41:47,R_1kS9EEu2HNBJGBt,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04445597,ClinicalTrials.gov,2020-06-22,2020-05-07,TRUE,UZ Leuven,Recruiting,Not Applicable,Interventional,Belgium,Unraveling the Mechanisms of Olfactory Dysfunction in COVID-19,Clinical Presentation,No Intervention,No Intervention,8,https://clinicaltrials.gov/show/NCT04445597,,,2020-06-30,2020-06-30,2020-06-30,0,0,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-15 10:45:17,2020-12-20 12:13:14,IP Address,82.33.104.78,100,437276,True,2020-12-20 12:13:14,R_1mn4vkYYR731l18,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030939,ChiCTR,2020-03-18,2020-03-16,TRUE,PLA General Hospital,Recruiting,Not Applicable,Interventional,China,Preliminary evaluation of the safety and efficacy of oral LL-37 antiviral peptide (CAS001) in the treatment of novel coronavirus pneumonia (COVID-19),ATMP,Gene-derived protein,Gene-derived protein,10,http://www.chictr.org.cn/showproj.aspx?proj=51059,,,,2020-10-01,2020-10-01,0,0,,10.1101/2020.05.11.20064584,,10.1101/2020.05.11.20064584,,full_results_preprint,,,2020-05-15,,7,,Recruiting,TRUE,1,,full_results_preprint,2020-05-15,7g3keqx9,http://medrxiv.org/cgi/content/short/2020.05.11.20064584v1?rss=1,"Preliminary evaluation of the safety and efficacy of oral human antimicrobial peptide LL-37 in the treatment of patients of COVID-19, a small-scale, single-arm, exploratory safety study",,,,,,,,,
2020-12-20 12:15:13,2020-12-20 12:21:58,IP Address,82.33.104.78,100,404,True,2020-12-20 12:21:58,R_UrKGN0Y4QIAzs9H,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Jing-Guo Cheng AND COVID-19 AND traditional Chinese medicine,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030759,ChiCTR,2020-03-13,2020-02-15,TRUE,The First Affiliated Hospital of Wenzhou Medical University,Not Recruiting,Not Applicable,Interventional,China,Study for the therapeutic effect and mechanism of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19),Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,70,http://www.chictr.org.cn/showproj.aspx?proj=49284,,,,2020-05-17,2020-05-17,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-15 10:46:12,2020-12-20 12:23:10,IP Address,82.33.104.78,100,437818,True,2020-12-20 12:23:10,R_zUWMXBCB9LOWyIh,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,unknown,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,ChiCTR2000029550,ChiCTR,2020-02-04,2020-01-29,TRUE,Hospital of Chengdu University of Traditional Chinese Medicine,Recruiting,Not Applicable,Interventional,China,Recommendations for Diagnosis and Treatment of Influenza Patients in the Hospital of Chengdu University of Traditional Chinese Medicine Under the Raging of Novel Coronavirus Pneumonia (COVID-19),Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,300,http://www.chictr.org.cn/showproj.aspx?proj=48775,,,,2020-05-01,2020-05-01,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-15 10:45:43,2020-12-20 12:32:09,IP Address,82.33.104.78,100,438385,True,2020-12-20 12:32:10,R_6F3Z8rsmFUZWjIZ,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mesenchymal Stem Cells Exosomes AND COVID-19 AND Jie-ming Qu,coronavirus AND stem cells AND Jie-ming Qu,,,,,,,,,MPJ,2020-06-30,NCT04276987,ClinicalTrials.gov,2020-02-16,2020-02-15,TRUE,Ruijin Hospital,Not Recruiting,Phase 1,Interventional,No Country Given,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,ATMP,Cells (mesenchymal),Cells (mesenchymal),30,https://clinicaltrials.gov/show/NCT04276987,,,2020-05-31,2020-07-31,2020-05-31,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-20 12:32:29,2020-12-20 12:39:37,IP Address,82.33.104.78,100,428,True,2020-12-20 12:39:38,R_3hbeTmhflUxz1QN,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Hydroxychloroquine Sulfate AND COVID-19 AND Shen Ning ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029898,ChiCTR,2020-02-16,2020-02-17,FALSE,Peking University Third Hospital,Recruiting,Phase 4,Interventional,China,"Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-Label, Parallel, Controlled Trial",Drug,Hydroxychloroquine vs. Chloroquine,Chloroquine; Hydroxychloroquine,100,http://www.chictr.org.cn/showproj.aspx?proj=49482,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-20 12:40:27,2020-12-20 13:43:42,IP Address,82.33.104.78,100,3795,True,2020-12-20 13:43:42,R_3luKumn0FeHfGTu,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"tocilizumab AND COVID-19 AND Zhiyong Peng ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030196,ChiCTR,2020-02-25,2020-02-20,TRUE,Central South Hospital of Wuhan University,Not Recruiting,Phase 2,Interventional,China,"A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)",Drug,Tocilizumab,Tocilizumab,60,http://www.chictr.org.cn/showproj.aspx?proj=49883,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-20 13:43:53,2020-12-20 13:47:45,IP Address,82.33.104.78,100,232,True,2020-12-20 13:47:46,R_REbse7S58JXKkx3,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Kelizhi AND COVID-19 AND Xie Liangdong ",Xiyanping Injection AND Ritonavir AND coronavirus AND Ganzhou,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030218,ChiCTR,2020-02-25,2020-01-22,TRUE,The Fifth People's Hospital of Ganzhou,Recruiting,Not Applicable,Interventional,China,Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19),Drug,Lopinavir/ritonavir (+ Tradtional Medicine),Lopinavir; Ritonavir; Traditional Medicine,80,http://www.chictr.org.cn/showproj.aspx?proj=50115,,,,2020-06-25,2020-06-25,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-20 13:48:00,2020-12-20 13:51:51,IP Address,82.33.104.78,100,231,True,2020-12-20 13:51:52,R_28BAwLlNy6wedeS,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Junxue Wang AND COVID-19 AND Danoprevir ",Shanghai Changzheng Hospital AND coronavirus AND ritonavir AND Danoprevir,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030259,ChiCTR,2020-02-26,2020-02-22,TRUE,Shanghai Changzheng Hospital,Recruiting,Not Applicable,Interventional,China,"Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19): a randomized, open and controlled trial",Drug,Danoprevir + Ritonavir,Danoprevir; Ritonavir,60,http://www.chictr.org.cn/showproj.aspx?proj=49918,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-20 13:52:04,2020-12-20 14:00:21,IP Address,82.33.104.78,100,496,True,2020-12-20 14:00:21,R_2YPcurZV4mSZbBY,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,google,,,,full_results_preprint,full_results_preprint,,,,"10.21203/rs.3.rs-99753/v1 ",,https://www.researchsquare.com/article/rs-99753/v1,10.2139/ssrn.3678558,,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3678558,,,,,,,,,,2020-11-02,,2020-10-12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"mesenchymal stem cells exosomes AND COVID-19 AND Meiping Chu ",Wuxi Second People's Hospital AND coronavirus AND stem cell exosomes,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030261,ChiCTR,2020-02-26,2020-03-01,FALSE,Wuxi Fifth People's Hospital,Not Recruiting,Not Applicable,Interventional,China,A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19),ATMP,Cells (mesenchymal),Cells (mesenchymal),26,http://www.chictr.org.cn/showproj.aspx?proj=49963,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,true,
2020-12-15 10:45:54,2020-12-20 14:05:35,IP Address,82.33.104.78,100,443980,True,2020-12-20 14:05:35,R_3KoyPJDHhSKDLow,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,thalidomide AND COVID-19 AND Jinglin Xia,,,,,,,,,,MPJ,2020-06-30,NCT04273529,ClinicalTrials.gov,2020-02-14,2020-02-20,FALSE,The First Affiliated Hospital of Wenzhou Medical University,Not Recruiting,Phase 2,Interventional,No Country Given,The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia,Drug,Thalidomide,Thalidomide,100,https://clinicaltrials.gov/show/NCT04273529,,,2020-05-30,2020-06-30,2020-05-30,0,1,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-15 10:46:20,2020-12-20 14:12:38,IP Address,82.33.104.78,100,444377,True,2020-12-20 14:12:38,R_sTILgUQpRIOs4Rb,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Intravenous Immunoglobulin AND COVID-19 AND Taisheng Li,,,,,,,,,,MPJ,2020-06-30,NCT04261426,ClinicalTrials.gov,2020-02-06,2020-02-10,FALSE,Peking Union Medical College Hospital,Not Recruiting,Phase 2/Phase 3,Interventional,No Country Given,The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia,ATMP,Immunoglobulin,Immunoglobulin,80,https://clinicaltrials.gov/show/NCT04261426,,,2020-04-30,2020-06-30,2020-04-30,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-20 19:06:14,2020-12-20 19:17:12,IP Address,82.33.104.78,100,658,True,2020-12-20 19:17:13,R_cVemMitOBbhtilb,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Shen-Qi Fu-Zheng AND COVID-19 AND Xin Zheng,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029780,ChiCTR,2020-02-13,2020-02-14,FALSE,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,Phase 4,Interventional,China,"A multicenter, randomized, open, controlled trial for the efficacy and safety of Shen-Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19)",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,160,http://www.chictr.org.cn/showproj.aspx?proj=49220,,,,2020-06-09,2020-06-09,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-20 19:17:25,2020-12-20 19:21:37,IP Address,82.33.104.78,100,252,True,2020-12-20 19:21:38,R_1jB1cIgMD9f6Gox,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Alpha lipoic acid AND COVID-19 AND Junbo Ge ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029851,ChiCTR,2020-02-15,2020-02-19,FALSE,"Zhongshan Hospital, Fudan University",Recruiting,Phase 4,Interventional,China,"A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19)",Supplement,Alpha lipoic acid,Alpha lipoic acid,68,http://www.chictr.org.cn/showproj.aspx?proj=49534,,,,2020-03-10,2020-03-10,0,0,,10.1101/2020.04.15.20066266,,10.1101/2020.04.15.20066266,,full_results_preprint,,,2020-04-21,,7,,Recruiting,TRUE,1,,full_results_preprint,2020-04-21,mvsnybbo,http://medrxiv.org/cgi/content/short/2020.04.15.20066266v1?rss=1,"A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of √é¬±-Lipoic acid for critically ill patients with coronavirus disease 2019(COVID-19)",,,,,,,,true,
2020-12-20 19:21:48,2020-12-20 19:30:27,IP Address,82.33.104.78,100,518,True,2020-12-20 19:30:27,R_eqzuzfSVIaU7XZT,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,summary_results,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Results in Chinese ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,,,,,full_results_journal_article,,,,,10.1016/j.eng.2020.08.011,"32923016 ",https://www.sciencedirect.com/science/article/pii/S2095809920302411?via%3Dihub,,,,,,,,,,,,,2020-09-08,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Triazavirin AND COVID-19 AND Baofeng Yang ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030001,ChiCTR,2020-02-19,2020-02-15,TRUE,Health commission of Heilongjiang province,Recruiting,Phase 3,Interventional,China,"The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial",Drug,Triazavirin,Triazavirin,240,http://www.chictr.org.cn/showproj.aspx?proj=49723,,,,2020-05-28,2020-05-28,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-20 19:30:41,2020-12-20 19:34:59,IP Address,82.33.104.78,100,257,True,2020-12-20 19:34:59,R_2ANEckofZIoK09g,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Kequn Chai AND COVID-19 AND traditional Chinese medicine,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030034,ChiCTR,2020-02-21,2020-02-07,TRUE,Tongde Hospital of Zhejiang Province,Recruiting,Not Applicable,Interventional,China,"Traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19): a multicentre, randomized controlled trial",Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,132,http://www.chictr.org.cn/showproj.aspx?proj=49647,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-20 19:35:11,2020-12-20 19:39:25,IP Address,82.33.104.78,100,253,True,2020-12-20 19:39:26,R_po9yjdsFB1iciQN,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,,,,,full_results_journal_article,,,,,10.1007/s12250-020-00258-7,,https://link.springer.com/article/10.1007/s12250-020-00258-7,,,,,,,,,,,,,2020-07-21,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030058,ChiCTR,2020-02-22,2020-03-10,FALSE,Renmin Hospital of Wuhan University,Not Recruiting,Phase 3,Interventional,China,"A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19)",Drug,Leflunomide,Leflunomide,200,http://www.chictr.org.cn/showproj.aspx?proj=49831,,,,2020-05-30,2020-05-30,0,0,,10.1101/2020.05.29.20114223,,10.1101/2020.05.29.20114223,,full_results_preprint,,,2020-06-02,,7,,Not yet recruiting,TRUE,1,,full_results_preprint,2020-06-02,rkf971xn,http://medrxiv.org/cgi/content/short/2020.05.29.20114223v1?rss=1,Efficacy and Safety of Leflunomide for Refractory COVID-19: An Open-label Controlled Study,,,,,,,true,true,
2020-12-20 19:39:48,2020-12-20 19:45:52,IP Address,82.33.104.78,100,364,True,2020-12-20 19:45:53,R_ukcwyzB1xNekl9f,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Qing-Wen Bai-Du-Yin AND COVID-19 AND Yanling Zhao ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030166,ChiCTR,2020-02-24,2020-02-25,FALSE,The Fifth Medical Center of PLA General Hospital,Not Recruiting,Not Applicable,Interventional,China,"Randomized, parallel control, open trial for Qing-Wen Bai-Du-Yin combined with antiviral therapy in the treatment of novel coronavirus pneumonia (COVID-19)",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,20,http://www.chictr.org.cn/showproj.aspx?proj=49696,,,,2020-05-14,2020-05-14,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-20 19:46:03,2020-12-20 19:52:26,IP Address,82.33.104.78,100,382,True,2020-12-20 19:52:26,R_3l1XMfEHRyJwbF7,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Favipiravir AND COVID-19 AND Liu Yingxia ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029600,ChiCTR,2020-02-06,2020-01-30,TRUE,The Third People's Hospital of Shenzhen,Recruiting,Not Applicable,Interventional,China,Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19),Drug,Favipiravir + interferon alpha vs. interferon alpha + Lopinavir/ritonavir + interferon alpha vs. interferon alpha,Favipiravir; interferon alpha; Lopinavir/ritonavir,90,http://www.chictr.org.cn/showproj.aspx?proj=49042,,,,2020-04-29,2020-04-29,0,0,,10.1016/j.eng.2020.03.007,,10.1016/j.eng.2020.03.007,,full_results_journal_article,,,2020-03-18,,7,,Recruiting,TRUE,1,32346491,full_results_journal_article,2020-03-18,8caqxfxv,https://api.elsevier.com/content/article/pii/S2095809920300631; https://www.sciencedirect.com/science/article/pii/S2095809920300631; https://www.ncbi.nlm.nih.gov/pubmed/32346491/; https://doi.org/10.1016/j.eng.2020.03.007,Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study,,,,,,,true,,
2020-12-20 19:52:38,2020-12-20 19:57:11,IP Address,82.33.104.78,100,272,True,2020-12-20 19:57:12,R_OJdPGowCJLae7jH,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Huang Luqi AND COVID-19 AND traditional Chinese medicine,Li Zhiqiang AND coronavirus AND square cabin hospital,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029763,ChiCTR,2020-02-12,2020-02-13,FALSE,China Academy of Chinese Medical Sciences; Zhongnan Hospital of Wuhan University,Recruiting,Not Applicable,Interventional,China,"The efficacy of traditional chinese medicine on Novel Coronavirus Pneumonia (COVID-19) patients treated in square cabin hospital: a prospective, randomized controlled trial",Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,408,http://www.chictr.org.cn/showproj.aspx?proj=49408,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-20 19:57:17,2020-12-20 20:30:34,IP Address,82.33.104.78,100,1996,True,2020-12-20 20:30:34,R_ptkZjHNgKbTMz7z,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,,,,,full_results_preprint,,,,,10.2139/ssrn.3667681,,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681,,,,,,,,,,,,,2020-08-29,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,," tocilizumab AND Xiaoling Xu AND COVID-19 ",tocilizumab AND coronavirus pneumonia AND Anhui Provincial Hospital,,,,,,https://europepmc.org/article/MED/32350134 - is this the same study or a preliminary study to this one?,team_review,,MPJ,2020-06-30,ChiCTR2000029765,ChiCTR,2020-02-13,2020-02-10,TRUE,The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital),Recruiting,Phase 4,Interventional,China,"A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)",Drug,Tocilizumab,Tocilizumab,188,http://www.chictr.org.cn/showproj.aspx?proj=49409,,,,2020-05-10,2020-05-10,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,true,
2020-12-15 10:11:06,2020-12-21 22:30:01,IP Address,82.33.104.78,100,562734,True,2020-12-21 22:30:02,R_2rUzJf6X2Ywc3Cl,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nebulizer AND COVID-19 AND Ze-guang Zheng,Hydrogen-Oxygen Generator AND coronavirus AND Guangdong,,,,,,,,,MPJ,2020-06-30,NCT04336462,ClinicalTrials.gov,2020-03-25,2020-02-15,TRUE,Shanghai Asclepius Meditec Inc.,Recruiting,Not Applicable,Interventional,China,Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19,Drug,Hydrogen + Oxygen vs Oxygen,Hydrogen; oxygen,100,https://clinicaltrials.gov/show/NCT04336462,,,2020-02-21,2020-08-01,2020-02-21,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-20 20:30:43,2020-12-21 22:34:36,IP Address,82.33.104.78,100,93832,True,2020-12-21 22:34:36,R_RsfPzs4YyCDGDwR,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"diammonium glycyrrhizinate AND vitamin C AND COVID-19 AND Jun Lin ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029768,ChiCTR,2020-02-13,2020-02-12,TRUE,Zhongnan Hospital of Wuhan University,Recruiting,Not Applicable,Interventional,China,"A randomized, open, controlled trial for diammonium glycyrrhizinate enteric-coated capsules combined with vitamin C tablets in the treatment of common novel coronavirus pneumonia (COVID-19) in the basic of clinical standard antiviral treatment to evaluate the safety and efficiency",Drug,Diammonium glycyrrhizinate + Vitamin C,Diammonium glycyrrhizinate; Vitamin C,60,http://www.chictr.org.cn/showproj.aspx?proj=49131,,,,2020-05-12,2020-05-12,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-21 22:34:43,2020-12-21 22:37:36,IP Address,82.33.104.78,100,173,True,2020-12-21 22:37:36,R_2TAytrSm4bYRcZO,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Babaodan Capsule AND COVID-19 AND  Lv Dongqing ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029769,ChiCTR,2020-02-13,2020-02-15,FALSE,Enze Hospital of Taizhou Enze Medical Center (Group),Not Recruiting,Not Applicable,Interventional,China,Babaodan Capsule used for the adjuvant treatment of severe novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,40,http://www.chictr.org.cn/showproj.aspx?proj=49415,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2020-12-27 10:29:44,2020-12-27 10:32:47,IP Address,77.11.230.9,100,182,True,2020-12-27 10:32:48,R_3Rkqq1C7vfT7qHb,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,unknown,yes,no,"so this says  Prospective/Retrospective,Randomized Controlled Clinical Study, may be retrospective?",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,PG,2020-06-30,NCT04254874,ClinicalTrials.gov,2020-02-02,2020-02-01,TRUE,"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,Phase 4,Interventional,China,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia",Drug,Interferon + Umifenovir vs. Umifenovir,Interferon; Umifenovir,100,https://clinicaltrials.gov/show/NCT04254874,,,2020-06-01,2020-07-01,2020-06-01,0,0,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-27 10:33:01,2020-12-27 10:38:34,IP Address,77.11.230.9,100,332,True,2020-12-27 10:38:34,R_1louPwGZjDB0XCN,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,yes,yes,no,,,no,2022-02-20,2020-08-31,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19,,,,,,,"Car-NK cell therapy, estimated completion date 2022",,,PG,2020-06-30,NCT04324996,ClinicalTrials.gov,2020-03-25,2020-03-21,TRUE,Chongqing Public Health Medical Center,Recruiting,Phase 1/Phase 2,Interventional,China,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19,ATMP,Cells (NK),Cells (NK),90,https://clinicaltrials.gov/show/NCT04324996,,,2020-05-31,2020-09-30,2020-05-31,0,0,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2020-08-31
2020-12-27 10:38:46,2020-12-27 10:46:19,IP Address,77.11.230.9,100,453,True,2020-12-27 10:46:20,R_2ZOjUskvcKWtpRC,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"""COVITD-19"" granada trial","vitamin d covid-19 ""Garzón"" trial",,,,,,,,,PG,2020-06-30,NCT04334005,ClinicalTrials.gov,2020-03-29,2020-04-10,FALSE,University of Granada,Not Recruiting,Not Applicable,Interventional,Spain,Vitamin D on Prevention and Treatment of COVID-19,Drug,Vitamin D,Vitamin D,200,https://clinicaltrials.gov/show/NCT04334005,,,2020-06-30,2020-06-30,2020-06-30,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-27 10:46:33,2020-12-27 10:52:40,IP Address,77.11.230.9,100,367,True,2020-12-27 10:52:41,R_2v7y7gl17SXO8Wt,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,only found the previously identified article,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NCT04261517 Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,,,,,,,,,,PG,2020-06-30,NCT04261517,ClinicalTrials.gov,2020-02-06,2020-02-06,FALSE,Shanghai Public Health Clinical Center,Not Recruiting,Phase 3,Interventional,China,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Drug,Hydroxychloroquine,Hydroxychloroquine,30,https://clinicaltrials.gov/show/NCT04261517,,,2020-02-25,2020-02-25,2020-02-25,0,1,,10.3785/j.issn.1008-9292.2020.03.03,,10.3785/j.issn.1008-9292.2020.03.03,,full_results_journal_article,,,2020-05-25,,6,,Completed,TRUE,2,32391667,full_results_journal_article,2020-05-25,,,,,,,,,,true,,
2020-12-27 10:52:59,2020-12-27 10:55:02,IP Address,77.11.230.9,100,123,True,2020-12-27 10:55:02,R_1Cg35iWu9r5iaQK,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,"Protocol: https://pubmed.ncbi.nlm.nih.gov/32532356/ ",,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04336254,ClinicalTrials.gov,2020-03-28,2020-04-06,FALSE,Renmin Hospital of Wuhan University,Recruiting,Phase 1/Phase 2,Interventional,China,Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients,ATMP,Cells (mesenchymal),Cells (mesenchymal),20,https://clinicaltrials.gov/show/NCT04336254,,,2020-12-31,2021-03-31,2020-12-31,0,1,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-27 10:55:45,2020-12-27 11:01:31,IP Address,77.11.230.9,100,346,True,2020-12-27 11:01:33,R_2EsdYQeduF2o7bs,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CORIMUNO-ANA covid,covid Mariette anakinra,,,,,,,,,PG,2020-06-30,NCT04341584,ClinicalTrials.gov,2020-04-07,2020-04-01,TRUE,Assistance Publique – Hôpitaux de Paris,Not Recruiting,Phase 2,Interventional,No Country Given,CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection,Drug,Anakinra,Anakinra,240,https://clinicaltrials.gov/show/NCT04341584,,,2020-05-01,2020-12-31,2020-05-01,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-27 11:01:40,2020-12-27 11:02:31,IP Address,77.11.230.9,100,51,True,2020-12-27 11:02:31,R_3F4qcLpJelnyITD,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,no,,Treats symptoms of COVID: Prone positioning will not cure or prevent COVID,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04344106,ClinicalTrials.gov,2020-04-08,2020-04-01,TRUE,ELHARRAR Xavier,Recruiting,Not Applicable,Interventional,France,Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study,Procedure,Positioning,Positioning,25,https://clinicaltrials.gov/show/NCT04344106,,,2020-04-15,2020-05-01,2020-04-15,0,0,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-27 15:35:21,2020-12-27 15:39:13,IP Address,77.11.230.9,100,231,True,2020-12-27 15:39:13,R_2ebrx0PFgf1mBTb,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Seems to be Using Delphi only/planning of using TCM. 

--> Delphy Method to preliminarily construct the recommended plan of using traditional Chinese medicine technology to prevent ""Novel Coronavirus Pneumonia"" in Deyang area and to provide reference for further and comprehensive standardization of ""Novel Coronavirus Pneumonia"" in the region. ",,,PG,2020-06-30,ChiCTR2000029821,ChiCTR,2020-02-14,2020-02-14,FALSE,Deyang Integrated Traditional Chinese and Western Medicine Hospital,Not Recruiting,Not Applicable,Prevention,China,Based on Delphi Method to Preliminarily Construct a Recommended Protocol for the Prevention of Novel Coronavirus Pneumonia (COVID-19) in Deyang Area by Using Chinese Medicine Technology and its Clinical Application Evaluation,Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,400,http://www.chictr.org.cn/showproj.aspx?proj=49306,,,,2020-06-01,2020-06-01,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-27 15:39:19,2020-12-27 15:48:43,IP Address,77.11.230.9,100,563,True,2020-12-27 15:48:43,R_3CNtD2FLVDtW48h,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_journal_article,,,,,10.1016/j.biopha.2020.110500,,https://www.sciencedirect.com/science/article/pii/S0753332220306934?via%3Dihub,,,,,,,,,,,,,2020-07-04,,,,,,,,,,,,,,,,,,,,,,,,,"retrospective, should be excluded",,,,,,"Found a publication, but it's a retrospective study and should be excluded!",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,https://www.sciencedirect.com/science/article/pii/S0753332220306934?via%3Dihub,,,,,,,,team_review,,PG,2020-06-30,ChiCTR2000029778,ChiCTR,2020-02-13,2020-02-14,FALSE,Shanghai University of Traditional Chinese Medicine,Recruiting,Not Applicable,Interventional,China,Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19),Traditional Medicine + Western Medicine,Traditional Medicine,Traditional Medicine,600,http://www.chictr.org.cn/showproj.aspx?proj=49422,,,,2020-05-13,2020-05-13,0,0,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,true,,
2020-12-27 15:48:52,2020-12-27 15:54:49,IP Address,77.11.230.9,100,357,True,2020-12-27 15:54:50,R_2SJjLW6Jcu7FKMk,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,S,"Study protocol here: https://pubmed.ncbi.nlm.nih.gov/32580752/ ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy ","ChiCTR2000029777, Tingrong Huang, Bangjiang Fang",,,,,,,,,PG,2020-06-30,ChiCTR2000029777,ChiCTR,2020-02-13,2020-02-05,TRUE,Huangshi Hospital of Traditional Chinese Medicine,Recruiting,Not Applicable,Interventional,China,"A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy",Traditional Medicine + Western Medicine,Traditional Medicine,Traditional Medicine,160,http://www.chictr.org.cn/showproj.aspx?proj=49380,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-27 15:54:55,2020-12-27 15:56:06,IP Address,77.11.230.9,100,70,True,2020-12-27 15:56:06,R_2BfkM0IoHesU7u4,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Not a trial:

_Observation_ on the curative effect of integrated traditional Chinese and western medicine in treating 2019-nCoV pneumonia. ",,,PG,2020-06-30,ChiCTR2000029558,ChiCTR,2020-02-04,2020-01-29,TRUE,Hospital of Chengdu University of Traditional Chinese Medicine,Recruiting,Not Applicable,Interventional,China,Recommendations of Integrated Traditional Chinese and Western Medicine for Diagnosis and Treatment of Novel Coronavirus Pneumonia (COVID-19) in Sichuan Province,Traditional Medicine + Western Medicine,Traditional Medicine,Traditional Medicine,200,http://www.chictr.org.cn/showproj.aspx?proj=48792,,,,2020-05-01,2020-05-01,0,0,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-27 15:56:15,2020-12-27 16:08:30,IP Address,77.11.230.9,100,735,True,2020-12-27 16:08:31,R_1OvEmxfvpshLyub,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,other,,,,,,,https://drive.google.com/file/d/1YoFZfgHNpfrKhvhad24Ej7aiTnPadWjS/view?usp=sharing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"this was linked on the registry side, I could not copy the URL, hence I downloaded it and uploaded to our drive. It is all in mandarin and likely of no use. ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Luo Dan Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population,"Luo Dan Wei Li Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population ",,,,,,Let's discuss what to do with the uploaded word document,team_review,,PG,2020-06-30,ChiCTR2000029435,ChiCTR,2020-02-01,2020-02-01,FALSE,Wuhan First Hospital,Not Recruiting,Not Applicable,Interventional,China,Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population,Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,120,http://www.chictr.org.cn/showproj.aspx?proj=48827,,,,2020-03-31,2020-03-31,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-27 17:22:48,2020-12-27 17:29:40,IP Address,77.11.230.9,100,411,True,2020-12-27 17:29:40,R_yDu0i9qByzHxNPb,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,other,,,,,,,https://drive.google.com/file/d/1E88CDMrgichIvQozs4NrCFGcu4t49Reu/view?usp=sharing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,uploaded file I found in registry to our drive (could not copy ling),,,,,,,europe_pmc,,,,,full_results_journal_article,,,,," 10.3389/fphar.2020.561674 ","33312125 ",https://europepmc.org/article/MED/33312125,,,,,,,,,,,,,2020-11-06,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"found a small excel sheet with efficacy results on registry, what to do with it?",team_review,,PG,2020-06-30,ChiCTR2000031630,ChiCTR,2020-04-05,2020-02-17,TRUE,Guangzhou Eighth People's Hospital,Recruiting,Not Applicable,Interventional,China,Clinical study for Celebrex in the treatment of novel coronavirus pneumonia (COVID-19),Drug,Celecoxib,Celecoxib,60,http://www.chictr.org.cn/showproj.aspx?proj=50474,,,,2020-06-17,2020-06-17,0,0,,10.1101/2020.05.05.20077610,,10.1101/2020.05.05.20077610,,full_results_preprint,,,2020-05-11,,6,,Recruiting,TRUE,2,,full_results_preprint,2020-05-11,a1gf76bu,http://medrxiv.org/cgi/content/short/2020.05.05.20077610v1?rss=1,Celebrex adjuvant therapy on COVID-19: An experimental study,,,,,,,true,true,
2020-12-27 17:29:50,2020-12-27 17:41:07,IP Address,77.11.230.9,100,677,True,2020-12-27 17:41:08,R_2rj7lb0mGLx2UqB,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Evaluation Danoprevir sodium tablets combined with ritonavir in the treatment of novel Coronavirus Pneumonia (COVID-19): a randomized, open-label, controlled trial ","NCT04345276 Danoprevir ritonavir ",,,,,"Only found cross-registration late: NCT04345276

There is another trial with a same title on CT.gov: https://clinicaltrials.gov/ct2/show/NCT04291729 .

It is in collaboration with the same pharma company, but at a different hospital with a different PI.-- published here: https://journals.lww.com/md-journal/fulltext/2020/11250/first_clinical_study_using_hcv_protease_inhibitor.53.aspx ","Found crossregistration late: https://clinicaltrials.gov/ct2/show/NCT04345276 

still no results!",,,PG,2020-06-30,ChiCTR2000031734,ChiCTR,2020-04-08,2020-03-19,TRUE,Huo-Shen-Shan Hospital,Recruiting,Not Applicable,Interventional,China,"Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel Coronavirus Pneumonia (COVID-19): a randomized, open-label, controlled trial",Drug,Danorevir + ritonavir,Danorevir; ritonavir,40,http://www.chictr.org.cn/showproj.aspx?proj=52103,,,,2020-05-29,2020-05-29,0,0,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-27 17:41:22,2020-12-27 17:42:15,IP Address,77.11.230.9,100,52,True,2020-12-27 17:42:15,R_2QQfSw56K3Ch8sx,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,no,,,volunteer,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,ACTRN12620000477921,ANZCTR,2020-04-16,2020-04-20,FALSE,Dr. Michael Soares,Not Recruiting,Not Applicable,Interventional,Australia,The design of an updated iron lung ventilator which can be easily built and used by people with minimal training in situations such as COVID-19 where skilled doctors or normal ventilators are unavailable.,Other (physical),Mechanical ventilation,Mechanical ventilation,1,https://anzctr.org.au/ACTRN12620000477921.aspx,,,,2020-04-20,2020-04-20,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-27 10:55:20,2020-12-27 17:57:17,IP Address,77.11.230.9,100,25317,True,2020-12-27 17:57:18,R_2xViORHyI1Jv724,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google,,,,,other,,,,,,,https://www.fujifilm.com/jp/en/news/hq/5451#,,,,,,,,,,,,,2020-09-23,,,,,,,,,,,,,,,,,,,,,,,,,"press release published in September, as of today (2020-12-27) I could not identify a full publication",,,,,,Phase 3 Clinical Study of Favipiravir in Patients with COVID-19 Non-Severe Pneumonia,Fujifilm Toyama Chemical avigan phase 3 covid,Phase 3 Clinical Study of Favipiravir in Patients with COVID-19 Non-Severe Pneumonia FUJIFILM,,,,,,,,PG,2020-06-30,JPRN-JapicCTI-205238,JPRN,2020-03-27,2020-03-31,FALSE,"FUJIFILM Toyama Chemical Co., Ltd.",Recruiting,Phase 3,Interventional,Japan,Phase 3 Clinical Study of Favipiravir in Patients with COVID-19 Non-Severe Pneumonia,Drug,Favipiravir,Favipiravir,96,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-205238,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,6,,recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-27 17:57:37,2020-12-27 18:01:21,IP Address,77.11.230.9,100,223,True,2020-12-27 18:01:21,R_2qscH892xuilbwt,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Chansu Injection covid 19,Chansu Injection covid 19 Hu Xingxing,,,,,,,,,PG,2020-06-30,ChiCTR2000030704,ChiCTR,2020-03-10,2020-02-10,TRUE,The First People's Hospital of Jiangxia District,No Status Given,Phase 4,Interventional,China,Observation Of Clinical Efficacy And Safety Of Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,50,http://www.chictr.org.cn/showproj.aspx?proj=50778,,,,2020-03-10,2020-03-10,0,0,,10.1101/2020.05.20.20107607,,10.1101/2020.05.20.20107607,,full_results_preprint,,,2020-05-26,,6,,Suspending,TRUE,2,,full_results_preprint,2020-05-26,1q8972uo,http://medrxiv.org/cgi/content/short/2020.05.20.20107607v1?rss=1,Chansu Injection Improves the Respiratory Function of Severe COVID-19 Patients,,,,,,,,true,
2020-12-27 18:01:30,2020-12-27 18:02:43,IP Address,77.11.230.9,100,73,True,2020-12-27 18:02:44,R_2v0uJ2qqSWxMZ6I,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,ChiCTR2000029542,ChiCTR,2020-02-03,2020-02-03,FALSE,Sun Yat sen Memorial Hospital of Sun Yat sen University,Recruiting,Phase 4,Interventional,China,Study for the efficacy of chloroquine in patients with novel coronavirus pneumonia (COVID-19),Drug,Chloroquine,Chloroquine,20,http://www.chictr.org.cn/showproj.aspx?proj=48968,,1,,2020-07-30,2020-07-30,0,0,,http://doi.org/10.1093/jmcb/mjaa014,,http://doi.org/10.1093/jmcb/mjaa014,,,,,,,1,,,,3,,,,,,,,,,,,,,,
2020-12-27 18:02:49,2020-12-27 18:04:29,IP Address,77.11.230.9,100,100,True,2020-12-27 18:04:30,R_11YiPlWFhJTWucQ,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,yes,"Cancelled by the investigator Humanistic Care in Patients With Novel Coronavirus Pneumonia (COVID-19) ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"It says in title: Cancelled by the investigator Humanistic Care in Patients With Novel Coronavirus Pneumonia (COVID-19) ",,,PG,2020-06-30,ChiCTR2000030136,ChiCTR,2020-02-24,2020-02-24,FALSE,The Second Affiliated Hospital of Xi'an Jiaotong University,Not Recruiting,Not Applicable,Interventional,China,Humanistic Care in Patients With Novel Coronavirus Pneumonia (COVID-19),Other,Humanistic Care,Humanistic Care,130,http://www.chictr.org.cn/showproj.aspx?proj=50005,,,,2020-05-15,2020-05-15,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-27 18:04:36,2020-12-27 18:14:38,IP Address,77.11.230.9,100,601,True,2020-12-27 18:14:39,R_SH3fvxX9Z4sBHEZ,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19) ",Wuhan Infectious Diseases Hospital anti-SARS-CoV-2 virus inactivated plasma COVID-19,,,,,,,,,PG,2020-06-30,ChiCTR2000030010,ChiCTR,2020-02-19,2020-02-19,FALSE,Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital),Not Recruiting,Not Applicable,Interventional,China,"A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)",ATMP,Plasma,Plasma,100,http://www.chictr.org.cn/showproj.aspx?proj=49777,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-27 18:14:45,2020-12-27 18:23:05,IP Address,77.11.230.9,100,499,True,2020-12-27 18:23:05,R_2uD6n8KDdtHxrJW,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tongji Medical College covid Ozonated autohemotherapy trial,A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of novel coronavirus pneumonia (COVID‐19).,,,,,,,,,PG,2020-06-30,ChiCTR2000030006,ChiCTR,2020-02-19,2020-02-19,FALSE,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,Not Applicable,Interventional,China,A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19),Drug,Ozone,Ozone,60,http://www.chictr.org.cn/showproj.aspx?proj=49737,,,,2020-05-19,2020-05-19,0,0,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-27 18:24:45,2020-12-27 18:27:32,IP Address,77.11.230.9,100,166,True,2020-12-27 18:27:33,R_TuNYxHoZ7jTZijD,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Comparative study for integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province,integrate Chinese and conventional medicine the the treatment of COVID-19Hu'nan province Huzhi,,,,,,,,,PG,2020-06-30,ChiCTR2000029960,ChiCTR,2020-02-17,2020-02-28,FALSE,The First Affiliated Hospital of Hu'nan University of Traditional Chinese Medicine,Not Recruiting,Not Applicable,Interventional,China,Comparative study for integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province,Traditional Medicine + Western Medicine,Traditional Medicine,Traditional Medicine,100,http://www.chictr.org.cn/showproj.aspx?proj=49639,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-27 18:27:39,2020-12-27 18:30:09,IP Address,77.11.230.9,100,150,True,2020-12-27 18:30:11,R_2rpdTxaTyIFggmf,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Just realized now: 
	

Cancelled by the investigator",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,," 	  Cancelled by the investigator Combination of Tocilizumab, IVIG and CRRT in severe patients with novel coronavirus pneumonia (COVID-19) ",,,,,,,"Only realized while searching: 
	

Cancelled by the investigator Combination of Tocilizumab, IVIG and CRRT in severe patients with novel coronavirus pneumonia (COVID-19)  

Unclear if they ever recruited. 
--> No results found if we still include",team_review,,PG,2020-06-30,ChiCTR2000030442,ChiCTR,2020-03-02,2020-03-05,FALSE,The Second Affiliated Hospital of Xi'an Jiaotong University,Not Recruiting,Not Applicable,Interventional,No Country Given,"Combination of Tocilizumab, IVIG and CRRT in severe patients with novel coronavirus pneumonia (COVID-19)",Drug (+ ATMP + Other (renal)),Tocilizumab + immunoglobulin + renal replacement therapy,Tocilizumab; Immunoglobulin; Renal replacement therapy,100,http://www.chictr.org.cn/showproj.aspx?proj=50380,,,,2020-05-15,2020-05-15,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-27 18:30:25,2020-12-27 18:40:58,IP Address,77.11.230.9,100,633,True,2020-12-27 18:40:58,R_1LvrYkHyxpJOk3I,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,,,,,full_results_journal_article,,,,,10.1097/JBR.0000000000000076,,https://journals.lww.com/jbioxresearch/Abstract/9000/Clinical_efficacy_of_low_dose_emetine_for_patients.99938.aspx,,,,,,,,,,,,,2020-12-03,,,,,,,,,,,,,,,,,,,,,,,,,"pdf only, they got all the dates wrong (2019)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Fan emetine COVID-19 trial,,,,,,,,,,PG,2020-06-30,ChiCTR2000030022,ChiCTR,2020-02-20,2020-02-22,FALSE,The First Affiliated Hospital of Anhui Medical University,Not Recruiting,Phase 4,Interventional,China,"A parallel, randomized controlled clinical trial for the efficacy and safety of Pediatric Huatanzhike granules (containing ipecacuanha tincture) in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,100,http://www.chictr.org.cn/showproj.aspx?proj=49797,,,,2020-05-22,2020-05-22,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,true,,
2020-12-27 18:41:06,2020-12-27 18:45:54,IP Address,77.11.230.9,100,288,True,2020-12-27 18:45:55,R_1DTQcvdWR3yJTTz,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Cytosorb COVID-19 Zhou Shuai-Fu-Yuan,Cytosorb COVID-19 Zhou trial,Cytosorb COVID-19 Zhou Peking Union Medical College Hospital,,,,,,,,PG,2020-06-30,ChiCTR2000030475,ChiCTR,2020-03-03,2020-03-04,FALSE,Chinese Academy of Medical Sciences Peking Union Medical College Hospital,Not Recruiting,Not Applicable,Interventional,China,Cytosorb in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19),Other (physical),Blood purification,Blood purification,19,http://www.chictr.org.cn/showproj.aspx?proj=50452,,,,2020-06-25,2020-06-25,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-27 18:46:07,2020-12-27 18:47:44,IP Address,77.11.230.9,100,97,True,2020-12-27 18:47:45,R_1cS00exvTvgPNhK,,,test@test.com,,52.5312042236328125,13.3878021240234375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"weird, there are results published (we found them, they were indexed) but the study is far from completed",,,PG,2020-06-30,ChiCTR2000029308,ChiCTR,2020-01-23,2020-01-10,TRUE,Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital),Recruiting,Not Applicable,Interventional,China,"A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with novel coronavirus pneumonia (COVID-19)",Drug,Lopinavir/ritonavir,lopinavir/ritonavir,160,http://www.chictr.org.cn/showproj.aspx?proj=48684,,,,2021-01-10,2021-01-10,0,0,,10.1056/NEJMoa2001282,,10.1056/NEJMoa2001282,,full_results_journal_article,,,2020-03-18,,6,,Recruiting,TRUE,2,32187464,full_results_journal_article,2020-03-18,,,,,,,,,,,,
2020-12-27 18:47:53,2020-12-27 18:50:38,IP Address,77.11.230.9,100,164,True,2020-12-27 18:50:39,R_3j3edqh19mYOmvx,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,," Evaluation of the protective effect of dexmedetomidine on patients with severe novel coronavirus pneumonia (COVID-19) ","dexmedetomidine ""Jianli"" covid-19 trial",,,,,,,,,PG,2020-06-30,ChiCTR2000030853,ChiCTR,2020-03-16,2020-02-01,TRUE,Third Affiliated Hospital of Zunyi Medical University,Not Recruiting,Not Applicable,Interventional,No Country Given,Evaluation of the protective effect of dexmedetomidine on patients with severe novel coronavirus pneumonia (COVID-19),Drug,Dexmedetomidine,Dexmedetomidine,200,http://www.chictr.org.cn/showproj.aspx?proj=51081,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,6,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-27 18:50:43,2020-12-27 18:54:54,IP Address,77.11.230.9,100,250,True,2020-12-27 18:54:54,R_2QmUcSZgTuY7MtD,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Clinical Study of Chloroquine Phosphate in the Treatment of 2019-nCoV Infection ""Xianlong""",Chloroquine Phosphate 2019-nCoV Zhongnan Hospital trial,Chloroquine Phosphate 2019-nCoV Zhongnan Hospital,,,,,,,,PG,2020-06-30,ChiCTR2000030718,ChiCTR,2020-03-11,2020-02-12,TRUE,Zhongnan Hospital of Wuhan University,Recruiting,Phase 4,Interventional,China,Randomized controlled trial for Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19),Drug,Chloroquine,Chloroquine,80,http://www.chictr.org.cn/showproj.aspx?proj=50843,,,,2020-05-30,2020-05-30,0,0,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-27 18:55:18,2020-12-27 18:56:57,IP Address,77.11.230.9,100,98,True,2020-12-27 18:56:57,R_R81pPJokrcOzxYt,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,published before completion date,,,PG,2020-06-30,ChiCTR2000029496,ChiCTR,2020-02-03,2020-01-29,TRUE,The First Hospital of Changsha; The Second Xiangya Hospital of Central South University,Recruiting,Phase 4,Interventional,China,"A randomized, open label, parallel controlled trial of evaluating the efficacy of recombinant cytokine gene-derived protein injection for clearing novel coronavirus in patients with novel coronavirus pneumonia (COVID-19)",ATMP,Gene-derived protein,Gene-derived protein,90,http://www.chictr.org.cn/showproj.aspx?proj=48809,,,,2021-01-29,2021-01-29,0,0,,10.1101/2020.04.24.20077735,,10.1101/2020.04.24.20077735,,full_results_preprint,,,2020-04-29,,6,,Recruiting,TRUE,2,,full_results_preprint,2020-04-29,rq5gh710,http://medrxiv.org/cgi/content/short/2020.04.24.20077735v1?rss=1,"A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19",,,,,,,,,
2020-12-28 13:18:47,2020-12-28 15:40:35,IP Address,77.13.189.131,100,8508,True,2020-12-28 15:40:35,R_2tl3TaioFy4B3MJ,,,test@test.com,,52.5196075439453125,13.4069061279296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nanchang University plasma therapy covid-19 trial,"Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19) ",,,,,,,,,PG,2020-06-30,ChiCTR2000030179,ChiCTR,2020-02-24,2020-02-24,FALSE,The First Affiliated Hospital of Nanchang University,Recruiting,Not Applicable,Interventional,China,Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19),ATMP,Plasma,Plasma,100,http://www.chictr.org.cn/showproj.aspx?proj=50059,,,,2020-04-24,2020-04-24,0,0,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-28 15:09:24,2020-12-28 15:45:02,IP Address,77.13.189.131,100,2137,True,2020-12-28 15:45:02,R_1gAuBAUMOi1x4zL,,,test@test.com,,52.49920654296875,13.3141937255859375,anonymous,EN,yes,yes,no,,,no,NA,"2020-06-30 ",0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hubei Clinical Research Center for Emergency and Resuscitation  Chloroquine Phosphate covid-19 trial,"Chloroquine Phosphate covid-19 trial ""Zhou Xianlong""",,,,,,,,,PG,2020-06-30,ChiCTR2000029988,ChiCTR,2020-02-18,2020-02-13,TRUE,Zhongnan Hospital of Wuhan University,Recruiting,Phase 4,Interventional,China,Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19),Drug,Chloroquine,Chloroquine,80,http://www.chictr.org.cn/showproj.aspx?proj=49218,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,6,,Recruiting,TRUE,2,,,,,,,,,,,,,,,"2020-06-30 "
2020-12-28 16:16:08,2020-12-28 16:19:56,IP Address,69.123.66.147,100,227,True,2020-12-28 16:19:56,R_3kdLpYjR5a6n9HX,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"This trial probably never happened. This preprint (https://dx.doi.org/10.2139/ssrn.3696870) contains this line:

""Early this year, we initiated a randomized controlled trials in China, to evaluate the benefit of high-dose IVIg in severe COVID-19 patients comparing with standard care (NCT04261426). Unfortunately, the randomization was not carried out due to force majeure at that time in China. However, high-dose IVIg was used as planned in severe COVID-19 patients in participating centers.""",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Did not do b/c of findings,,,,,,,"This trial probably never happened. This preprint (https://dx.doi.org/10.2139/ssrn.3696870) contains this line:

""Early this year, we initiated a randomized controlled trials in China, to evaluate the benefit of high-dose IVIg in severe COVID-19 patients comparing with standard care (NCT04261426). Unfortunately, the randomization was not carried out due to force majeure at that time in China. However, high-dose IVIg was used as planned in severe COVID-19 patients in participating centers.""",team_review,,ND,2020-06-30,NCT04261426,ClinicalTrials.gov,2020-02-06,2020-02-10,FALSE,Peking Union Medical College Hospital,Not Recruiting,Phase 2/Phase 3,Interventional,No Country Given,The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia,ATMP,Immunoglobulin,Immunoglobulin,80,https://clinicaltrials.gov/show/NCT04261426,,,2020-04-30,2020-06-30,2020-04-30,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-28 16:20:24,2020-12-28 16:35:35,IP Address,69.123.66.147,100,910,True,2020-12-28 16:35:36,R_2xUYvFVhvqixDcQ,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Babaodan AND Covid,Jiang Yongpo AND Covid,,,,,,,,,ND,2020-06-30,ChiCTR2000029769,ChiCTR,2020-02-13,2020-02-15,FALSE,Enze Hospital of Taizhou Enze Medical Center (Group),Not Recruiting,Not Applicable,Interventional,China,Babaodan Capsule used for the adjuvant treatment of severe novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,40,http://www.chictr.org.cn/showproj.aspx?proj=49415,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-28 16:35:41,2020-12-28 16:45:24,IP Address,69.123.66.147,100,583,True,2020-12-28 16:45:24,R_1MLOf4LWxKimuzE,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Diammonium Glycyrrhizinate AND Covid,Jun Lin AND Covid,,,,,,,,,ND,2020-06-30,ChiCTR2000029768,ChiCTR,2020-02-13,2020-02-12,TRUE,Zhongnan Hospital of Wuhan University,Recruiting,Not Applicable,Interventional,China,"A randomized, open, controlled trial for diammonium glycyrrhizinate enteric-coated capsules combined with vitamin C tablets in the treatment of common novel coronavirus pneumonia (COVID-19) in the basic of clinical standard antiviral treatment to evaluate the safety and efficiency",Drug,Diammonium glycyrrhizinate + Vitamin C,Diammonium glycyrrhizinate; Vitamin C,60,http://www.chictr.org.cn/showproj.aspx?proj=49131,,,,2020-05-12,2020-05-12,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-28 16:45:36,2020-12-28 16:58:51,IP Address,69.123.66.147,100,794,True,2020-12-28 16:58:51,R_yPxQdt8mbgmYYpP,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,,,,,full_results_preprint,,,,,10.2139/ssrn.3667681,,,,,,,,,,,,,,,2020-08-29,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Dongsheng Wang AND tocilizumab,Preprint title,,,,,,,,,ND,2020-06-30,ChiCTR2000029765,ChiCTR,2020-02-13,2020-02-10,TRUE,The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital),Recruiting,Phase 4,Interventional,China,"A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)",Drug,Tocilizumab,Tocilizumab,188,http://www.chictr.org.cn/showproj.aspx?proj=49409,,,,2020-05-10,2020-05-10,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,true,
2020-12-28 16:59:02,2020-12-28 17:51:49,IP Address,129.67.116.235,100,3166,True,2020-12-28 17:51:50,R_1gOrF1r1A24iBe1,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"""Traditional Chinese Medicine"" AND Covid AND China Academy of Chinese Medical Sciences ",Zhao Chen AND covid,Huang Luqi AND Covid,,,,,,,,ND,2020-06-30,ChiCTR2000029763,ChiCTR,2020-02-12,2020-02-13,FALSE,China Academy of Chinese Medical Sciences; Zhongnan Hospital of Wuhan University,Recruiting,Not Applicable,Interventional,China,"The efficacy of traditional chinese medicine on Novel Coronavirus Pneumonia (COVID-19) patients treated in square cabin hospital: a prospective, randomized controlled trial",Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,408,http://www.chictr.org.cn/showproj.aspx?proj=49408,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-29 02:18:10,2020-12-29 02:23:04,IP Address,129.67.117.158,100,293,True,2020-12-29 02:23:04,R_29nSDkkSDEPluUB,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study,Qingxian Cai,,,,,,,,,ND,2020-06-30,ChiCTR2000029600,ChiCTR,2020-02-06,2020-01-30,TRUE,The Third People's Hospital of Shenzhen,Recruiting,Not Applicable,Interventional,China,Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19),Drug,Favipiravir + interferon alpha vs. interferon alpha + Lopinavir/ritonavir + interferon alpha vs. interferon alpha,Favipiravir; interferon alpha; Lopinavir/ritonavir,90,http://www.chictr.org.cn/showproj.aspx?proj=49042,,,,2020-04-29,2020-04-29,0,0,,10.1016/j.eng.2020.03.007,,10.1016/j.eng.2020.03.007,,full_results_journal_article,,,2020-03-18,,7,,Recruiting,TRUE,2,32346491,full_results_journal_article,2020-03-18,8caqxfxv,https://api.elsevier.com/content/article/pii/S2095809920300631; https://www.sciencedirect.com/science/article/pii/S2095809920300631; https://www.ncbi.nlm.nih.gov/pubmed/32346491/; https://doi.org/10.1016/j.eng.2020.03.007,Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study,,,,,,,true,,
2020-12-29 02:23:15,2020-12-29 02:36:06,IP Address,129.67.117.158,100,770,True,2020-12-29 02:36:07,R_3oYfS1eRMRDKsmQ,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Qing-Wen Bai-Du-Yin AND Covid,Manyi Jing AND Covid,Yanling Zhao AND Covid,Qingwen Baidu AND Covid,,,,,,,ND,2020-06-30,ChiCTR2000030166,ChiCTR,2020-02-24,2020-02-25,FALSE,The Fifth Medical Center of PLA General Hospital,Not Recruiting,Not Applicable,Interventional,China,"Randomized, parallel control, open trial for Qing-Wen Bai-Du-Yin combined with antiviral therapy in the treatment of novel coronavirus pneumonia (COVID-19)",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,20,http://www.chictr.org.cn/showproj.aspx?proj=49696,,,,2020-05-14,2020-05-14,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-29 02:36:22,2020-12-29 02:43:46,IP Address,129.67.117.158,100,443,True,2020-12-29 02:43:46,R_2sdS4AD8R1d4Mb1,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Thalidomide AND covid,Jinglin Xia AND Thalidomide,,,,,,,,,ND,2020-06-30,NCT04273529,ClinicalTrials.gov,2020-02-14,2020-02-20,FALSE,The First Affiliated Hospital of Wenzhou Medical University,Not Recruiting,Phase 2,Interventional,No Country Given,The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia,Drug,Thalidomide,Thalidomide,100,https://clinicaltrials.gov/show/NCT04273529,,,2020-05-30,2020-06-30,2020-05-30,0,1,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-29 22:47:44,2020-12-29 23:00:17,IP Address,129.67.118.148,100,753,True,2020-12-29 23:00:18,R_21EueAY9jqtQXlG,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,europe_pmc,,,,full_results_journal_article,full_results_journal_article,,,,10.1093/cid/ciaa1417,,,10.1007/s12250-020-00258-7,,,,,,,,,,,,2020-09-21,,2020-07-21,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The preprint results we found are incorrectly linked to this trial. It is for ChiCTR2000033372 (but references that it was in advance of this trial: ChiCTR2000030058).

This is the trial I wrote the letter to the editor about so two papers reference this trial ID although it's somewhat unclear which one belongs to which.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Need to change result we have linked already and figure our how the handle the 2 different results.,team_review,,ND,2020-06-30,ChiCTR2000030058,ChiCTR,2020-02-22,2020-03-10,FALSE,Renmin Hospital of Wuhan University,Not Recruiting,Phase 3,Interventional,China,"A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19)",Drug,Leflunomide,Leflunomide,200,http://www.chictr.org.cn/showproj.aspx?proj=49831,,,,2020-05-30,2020-05-30,0,0,,10.1101/2020.05.29.20114223,,10.1101/2020.05.29.20114223,,full_results_preprint,,,2020-06-02,,7,,Not yet recruiting,TRUE,2,,full_results_preprint,2020-06-02,rkf971xn,http://medrxiv.org/cgi/content/short/2020.05.29.20114223v1?rss=1,Efficacy and Safety of Leflunomide for Refractory COVID-19: An Open-label Controlled Study,,,,,,,true,true,
2020-12-29 23:07:47,2020-12-29 23:21:02,IP Address,129.67.118.148,100,795,True,2020-12-29 23:21:02,R_z6dlbzWCsOHXcI1,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Methotrexate AND Covid AND Brazil,Methotrexate Nanoparticles AND Covid,Rodrido Esper AND Methotrexate,,,,,,,,ND,2020-06-30,NCT04352465,ClinicalTrials.gov,2020-04-15,2020-05-01,FALSE,Azidus Brasil,Not Recruiting,Phase 1/Phase 2,Interventional,Brazil,Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients,Drug,Methotrexate,Methotrexate,42,https://clinicaltrials.gov/show/NCT04352465,,,2020-06-30,2020-11-30,2020-06-30,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-29 23:21:19,2020-12-29 23:23:32,IP Address,129.67.118.148,100,132,True,2020-12-29 23:23:33,R_bw7oIoKoDqE8qlP,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,no,2021-03-31,2021-03-31,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04345848,ClinicalTrials.gov,2020-04-07,2020-04-28,FALSE,"University Hospital, Geneva",Recruiting,Phase 3,Interventional,Switzerland,Preventing COVID-19 Complications With Low- and High-dose Anticoagulation,Drug,Heparin,Heparin,200,https://clinicaltrials.gov/show/NCT04345848,,,2020-11-30,2020-11-30,2020-11-30,0,1,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2021-03-31
2020-12-29 23:23:41,2020-12-29 23:37:11,IP Address,129.67.118.148,100,809,True,2020-12-29 23:37:12,R_PMSnM6tm2zjpTcB,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,no,2020-12-31,2020-12-31,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,EPICOS AND Covid,Emtricitabine AND tenofovir AND Covid,,,,,,,,,ND,2020-06-30,NCT04334928,ClinicalTrials.gov,2020-04-02,2020-04-15,FALSE,Plan Nacional sobre el Sida (PNS),Recruiting,Phase 3,Interventional,Spain,Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel,Drug,Emtricitabine/tenofovir disoproxil + hydroxychloroquine vs. hydroxychloroquine vs. Emtricitabine/tenofovir disoproxil,Emtricitabine/tenofovir disoproxil; hydroxychloroquine,4000,https://clinicaltrials.gov/show/NCT04334928,,,2020-06-30,2020-07-31,2020-06-30,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2020-12-31
2020-12-29 23:37:31,2020-12-29 23:46:08,IP Address,129.67.118.148,100,516,True,2020-12-29 23:46:09,R_TtvaHwaJInz14DD,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,,,,,full_results_journal_article,,,,,10.1111/cts.12881,"32881359 ",,,,,,,,,,,,,,2020-10-10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bromhexine Hydrochloride AND Covid,"""Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID-19: An Open-Label Randomized Controlled Pilot Study""",,,,,,,,,ND,2020-06-30,NCT04273763,ClinicalTrials.gov,2020-02-14,2020-02-16,FALSE,The Second Affiliated Hospital of Wenzhou Medical University,Not Recruiting,Not Applicable,Interventional,China,Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),Drug,Bromhexine + Umifenovir + Interferon alpha vs. Umifenovir + interferon alpha,Bromhexine; Umifenovir; interferon alpha,18,https://clinicaltrials.gov/show/NCT04273763,,,2020-05-10,2020-06-01,2020-05-10,0,0,,,,,,,,,,,7,,"Active, not recruiting",TRUE,2,,,,,,,,,,,,,true,,
2020-12-29 23:46:26,2020-12-29 23:46:58,IP Address,129.67.118.148,100,31,True,2020-12-29 23:46:58,R_27NfmTmhw91rvMA,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Case series,,,ND,2020-06-30,ChiCTR2000032632,ChiCTR,2020-05-04,2020-03-20,TRUE,The First Affiliated Hospital of Xinjiang Medical University,Recruiting,Not Applicable,Interventional,China,The influence of COVID-19 pandemic on cardiovascular patients,Clinical Presentation,No Intervention,No Intervention,100,http://www.chictr.org.cn/showproj.aspx?proj=53190,,,,2020-05-22,2020-05-22,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-29 23:47:06,2020-12-29 23:49:00,IP Address,129.67.118.148,100,113,True,2020-12-29 23:49:00,R_1rvrtcgC8eX4vlQ,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,unknown,no,This is rehab from Covid positive ptx specifically so we need to discuss inclusion.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,ND,2020-06-30,NCT04365738,ClinicalTrials.gov,2020-04-26,2020-03-11,TRUE,Istanbul Bilgi University,Not Recruiting,Not Applicable,Interventional,Turkey,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection,Other (physio),Physio & Rehabilitation,Physio & Rehabilitation,270,https://clinicaltrials.gov/show/NCT04365738,,,2020-04-10,2020-04-26,2020-04-10,0,0,,,,,,,,,,,7,,Completed,TRUE,2,,,,,,,,,,,,,,,
2020-12-29 23:49:23,2020-12-29 23:57:04,IP Address,129.67.118.148,100,460,True,2020-12-29 23:57:04,R_RyKDxQlwqma1cEV,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Azithromycin AND Covid AND Shahid Beheshti University,Seyed Sina Naghibi Irvani AND Covid,,,,,,,,,ND,2020-06-30,NCT04359316,ClinicalTrials.gov,2020-04-18,2020-04-20,FALSE,Shahid Beheshti University of Medical Sciences,Not Recruiting,Phase 4,Interventional,Iran,Azithromycin in Hospitalized COVID-19 Patients,Drug,Azithromycin vs. Hydroxychloroquine,Azithromycin; Hydroxychloroquine,40,https://clinicaltrials.gov/show/NCT04359316,,,2020-05-03,2020-05-05,2020-05-03,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-29 23:59:58,2020-12-30 00:01:25,IP Address,129.67.118.148,100,86,True,2020-12-30 00:01:26,R_1lzrOM1AaeJjfEC,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04355429,ClinicalTrials.gov,2020-04-17,2020-05-05,FALSE,Assistance Publique – Hôpitaux de Paris,Not Recruiting,Phase 2,Interventional,France,Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID),Drug,Captopril,Captopril,230,https://clinicaltrials.gov/show/NCT04355429,,,2020-07-01,2020-08-01,2020-07-01,0,1,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-30 00:01:32,2020-12-30 00:02:36,IP Address,129.67.118.148,100,64,True,2020-12-30 00:02:36,R_214k822WxTLLBeF,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04337008,ClinicalTrials.gov,2020-04-03,2020-04-03,FALSE,Assistance Publique – Hôpitaux de Marseille,Recruiting,Not Applicable,Interventional,France,Renin Angiotensin System - CoronaVirus,Clinical Presentation,No Intervention,No Intervention,50,https://clinicaltrials.gov/show/NCT04337008,,,2020-06-03,2020-07-31,2020-06-03,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-30 00:02:44,2020-12-30 00:12:18,IP Address,129.67.118.148,100,573,True,2020-12-30 00:12:19,R_1oIkGyBc0m5Kw06,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,Suspended,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hydroxychloroquine AND Azithromycin AND Azidus Brasil,Luciana Ferrara,,,,,,,,,ND,2020-06-30,NCT04329572,ClinicalTrials.gov,2020-03-29,2020-04-23,FALSE,Azidus Brasil,Not Recruiting,Phase 1,Interventional,Brazil,Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19,Drug,Hydroxychloroquine + Azithromycin,Hydroxychloroquine; Azithromycin,400,https://clinicaltrials.gov/show/NCT04329572,,,2020-05-31,2020-06-30,2020-05-31,0,0,,,,,,,,,,,7,,Suspended,TRUE,2,,,,,,,,,,,,,,,
2020-12-29 23:07:34,2020-12-30 00:28:09,IP Address,69.123.66.147,100,4835,True,2020-12-30 00:28:10,R_T7QEln09Ym0ceIN,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Yaping Li AND covid,Kequn Chai AND Covid,,,,,Few options for search terms,,,,ND,2020-06-30,ChiCTR2000030034,ChiCTR,2020-02-21,2020-02-07,TRUE,Tongde Hospital of Zhejiang Province,Recruiting,Not Applicable,Interventional,China,"Traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19): a multicentre, randomized controlled trial",Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,132,http://www.chictr.org.cn/showproj.aspx?proj=49647,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-30 00:28:27,2020-12-30 00:30:16,IP Address,69.123.66.147,100,108,True,2020-12-30 00:30:16,R_1im8YFujgLgVchK,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,no,,"It is treating a side-effect (digestion issues) from Covid, not Covid itself.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,ChiCTR2000032237,ChiCTR,2020-04-23,2020-04-01,TRUE,Ezhou Hospital of Traditional Chinese Medicine,Recruiting,Not Applicable,Interventional,No Country Given,"A multicenter, randomized, double-blind, placebo-controlled trial for Xiang-Sha-Liu-Jun Pill in the treatment of novel coronavirus pneumonia (COVID-19) decline in digestive function during convalescence",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,200,http://www.chictr.org.cn/showproj.aspx?proj=52699,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-30 00:36:02,2020-12-30 00:42:27,IP Address,69.123.66.147,100,384,True,2020-12-30 00:42:28,R_1jUFlh4PM0PBVrA,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,no,NA,2020-09-28,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Christopher Moller AND Covid,chloroquine AND covid AND australia,chloroquine and covid and australia AND chemoprophylaxis,,,,,,,,ND,2020-06-30,ACTRN12620000417987,ANZCTR,2020-03-30,2020-03-30,FALSE,Australian Defence Force Malaria and Infectious Disease Institute,Recruiting,Phase 4,Interventional,Australia,Chloroquine Chemorophylaxis Countermeasure against COVID-19,Drug,Chloroquine,Chloroquine,680,https://anzctr.org.au/ACTRN12620000417987.aspx,,,,2020-05-11,2020-05-11,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2020-09-28
2020-12-30 00:42:58,2020-12-30 00:54:25,IP Address,69.123.66.147,100,686,True,2020-12-30 00:54:26,R_1igFspfAZEeUBMz,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bromhexine AND Hydroxychloroquine AND covid,Miha Mežnar,Matej Podbregar,Celje AND bromhexine,,,,,,,ND,2020-06-30,NCT04355026,ClinicalTrials.gov,2020-04-15,2020-04-10,TRUE,Celje General Hospital,Recruiting,Phase 4,Interventional,Slovenia,Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia,Drug,Bromhexine + Hydroxychloroquine vs. Hydroxychloroquine,Bromhexine; Hydroxychloroquine,90,https://clinicaltrials.gov/show/NCT04355026,,,2020-06-30,2020-07-31,2020-06-30,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-30 00:54:49,2020-12-30 01:06:14,IP Address,129.67.116.76,100,684,True,2020-12-30 01:06:14,R_6KKjfT13CzJD4lj,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,This is a bit odd but I think it counts. It's basically a prevention trial.,,no,2020-11-20,2020-12-20,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Protocol: https://pubmed.ncbi.nlm.nih.gov/33138848/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BBCovid,mouthrinse AND Covid AND Claude Bernard,,,,,,,,,ND,2020-06-30,NCT04352959,ClinicalTrials.gov,2020-04-15,2020-04-27,FALSE,Claude Bernard University,Not Recruiting,Not Applicable,Interventional,No Country Given,COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses,Drug,Bêta-cyclodextrin + citrox,Bêta-cyclodextrin; citrox,178,https://clinicaltrials.gov/show/NCT04352959,,,2020-05-20,2020-06-20,2020-05-20,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,2020-12-20
2020-12-30 01:06:22,2020-12-30 01:16:30,IP Address,129.67.116.76,100,608,True,2020-12-30 01:16:31,R_6X8AL4Aw0DsUrER,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,summary_results,,,,,,,http://www.chictr.org.cn/showproj.aspx?proj=49723,,,,,,,,,,,,,2020-06-17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Results are in Chinese - saved in drive,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,,,,,other,,,,,10.1016/j.eng.2020.08.011,32923016,,,,,,,,,,,,,,2020-09-08,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Triazavirin AND Covid,Xiaoke Wu Triazavirin,,,,,Trial completion might be 2020-03-06 because they had no new enrollments for a week and it seems like follow-up was generally 3 days. Not sure though.,,,,ND,2020-06-30,ChiCTR2000030001,ChiCTR,2020-02-19,2020-02-15,TRUE,Health commission of Heilongjiang province,Recruiting,Phase 3,Interventional,China,"The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial",Drug,Triazavirin,Triazavirin,240,http://www.chictr.org.cn/showproj.aspx?proj=49723,,,,2020-05-28,2020-05-28,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-30 01:16:59,2020-12-30 01:19:39,IP Address,129.67.116.76,100,160,True,2020-12-30 01:19:39,R_1ifiFzQuWt0Dpol,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,unknown,no,Rehab but for people directly with Covid so I think this counts?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Doing a quick search around, there doesn't seem to be results for this anyway.",,,ND,2020-06-30,NCT04346927,ClinicalTrials.gov,2020-04-13,2020-04-10,TRUE,Yasemin Çırak,Not Recruiting,Not Applicable,Interventional,No Country Given,Telerehabilitation for Patients Diagnosed With Coronavirus,Telehealth,Physio & Rehabilitation,Physio & Rehabilitation,30,https://clinicaltrials.gov/show/NCT04346927,,,2020-06-10,2020-07-31,2020-06-10,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-30 01:19:48,2020-12-30 01:26:33,IP Address,129.67.116.76,100,405,True,2020-12-30 01:26:34,R_1QgcrvCr65xLChG,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ayurveda AND Covid AND Aarogyam,Neha Sharma AND covid,,,,,"This looks like, but I don't think is, this trial: https://europepmc.org/article/PPR/PPR217885",,,,ND,2020-06-30,NCT04345549,ClinicalTrials.gov,2020-04-10,2020-02-26,TRUE,Aarogyam UK,Not Recruiting,Not Applicable,Interventional,United Kingdom,Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak,Traditional Medicine (Other),Traditional Medicine,Traditional Medicine,18,https://clinicaltrials.gov/show/NCT04345549,,,2020-03-30,2020-03-30,2020-03-30,0,0,,,,,,,,,,,7,,Completed,TRUE,2,,,,,,,,,,,,,,,
2020-12-31 21:50:13,2020-12-31 21:55:58,IP Address,129.67.118.219,100,345,True,2020-12-31 21:55:58,R_1Q4wOT7rcH0iR3S,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,lipoic acid AND covid,Ming Zhong,,,,,,,,,ND,2020-06-30,ChiCTR2000029851,ChiCTR,2020-02-15,2020-02-19,FALSE,"Zhongshan Hospital, Fudan University",Recruiting,Phase 4,Interventional,China,"A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19)",Supplement,Alpha lipoic acid,Alpha lipoic acid,68,http://www.chictr.org.cn/showproj.aspx?proj=49534,,,,2020-03-10,2020-03-10,0,0,,10.1101/2020.04.15.20066266,,10.1101/2020.04.15.20066266,,full_results_preprint,,,2020-04-21,,7,,Recruiting,TRUE,2,,full_results_preprint,2020-04-21,mvsnybbo,http://medrxiv.org/cgi/content/short/2020.04.15.20066266v1?rss=1,"A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of √é¬±-Lipoic acid for critically ill patients with coronavirus disease 2019(COVID-19)",,,,,,,,true,
2020-12-31 21:56:17,2020-12-31 22:08:44,IP Address,129.67.118.219,100,747,True,2020-12-31 22:08:45,R_3HHNZ4DnukLJdKl,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Covid AND Adoptive Cellular Transfer,natural killer cells AND covid,David A Bernal,Carlos A Parra-Lopez,,,,,,,ND,2020-06-30,NCT04344548,ClinicalTrials.gov,2020-04-10,2020-04-13,FALSE,National University of Colombia,Not Recruiting,Phase 1/Phase 2,Interventional,Colombia,Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia,ATMP,Cells (NK),Cells (NK),10,https://clinicaltrials.gov/show/NCT04344548,,,2020-06-10,2020-11-10,2020-06-10,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-31 22:08:50,2020-12-31 22:20:31,IP Address,129.67.118.219,100,700,True,2020-12-31 22:20:31,R_3lKtLJZPBmeFO98,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Povidone Iodine AND Chlorhexidine AND Covid,Scott Rickert,,,,,,,,,ND,2020-06-30,NCT04344236,ClinicalTrials.gov,2020-04-08,2020-04-09,FALSE,NYU Langone Health,Recruiting,Phase 2,Interventional,United States,Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19,Drug,Povidone Iodine,Povidone Iodine,48,https://clinicaltrials.gov/show/NCT04344236,,,2020-05-01,2020-05-09,2020-05-01,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-31 22:20:47,2020-12-31 22:29:57,IP Address,129.67.118.219,100,549,True,2020-12-31 22:29:58,R_e4crPmlDbj3peNj,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Shenqi Fuzheng AND covid,Hong Sun AND covid,,,,,,,,,ND,2020-06-30,ChiCTR2000029780,ChiCTR,2020-02-13,2020-02-14,FALSE,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,Phase 4,Interventional,China,"A multicenter, randomized, open, controlled trial for the efficacy and safety of Shen-Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19)",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,160,http://www.chictr.org.cn/showproj.aspx?proj=49220,,,,2020-06-09,2020-06-09,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-31 22:30:09,2020-12-31 22:30:45,IP Address,129.67.118.219,100,36,True,2020-12-31 22:30:46,R_2ZQ6YtY9NYg2TQQ,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,unknown,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04343690,ClinicalTrials.gov,2020-04-09,2020-04-13,FALSE,Duke University,Not Recruiting,Not Applicable,Interventional,United States,COPING With COVID-19( CWC-19),Other (psych),Psychological,Psychological,100,https://clinicaltrials.gov/show/NCT04343690,,,2020-06-30,2020-06-30,2020-06-30,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-31 22:30:52,2020-12-31 22:40:18,IP Address,129.67.118.219,100,566,True,2020-12-31 22:40:18,R_3sBWDcujMD8U8Ua,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Siltuximab AND covid,Siltuximab AND Methylprednisolone AND covid,Felipe García AND Siltuximab,,,,,,,,ND,2020-06-30,NCT04329650,ClinicalTrials.gov,2020-03-31,2020-04-15,TRUE,Judit Pich Martínez,Recruiting,Phase 2,Interventional,Spain,Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia,Drug,Siltuximab vs. Corticosteroids,Siltuximab; Methylprednisolone,200,https://clinicaltrials.gov/show/NCT04329650,EUCTR2020-001413-20,,2020-05-20,2020-05-20,2020-05-20,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-31 22:40:23,2020-12-31 22:54:47,IP Address,129.67.118.219,100,864,True,2020-12-31 22:54:49,R_3efPRgti8f2X03p,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,"Registration is ""provisional"" so not sure if ever became official. I think reducing someone's viral load counts as prevention/treatment.",,no,NA,2020-06-30,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Peter Friedland,Nasodine AND covid,,,,,,,,,ND,2020-06-30,ACTRN12620000470998,ANZCTR,2020-04-14,2020-04-20,FALSE,Firebrick Pharma Pty Ltd,Not Recruiting,Not Applicable,Interventional,Australia,Virucidal pilot study of Nasodine® Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.,Drug,Povidone Iodine,Povidone Iodine,20,https://anzctr.org.au/ACTRN12620000470998.aspx,,,,2020-05-01,2020-05-01,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,2020-06-30
2020-12-31 22:55:07,2020-12-31 23:04:47,IP Address,129.67.118.219,100,580,True,2020-12-31 23:04:48,R_1qUKsTrjytcSRen,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hydrogen Oxygen AND Nebulizer AND Covid,Hydrogen-Oxygen Generator AND covid,Zhang Ze Guang,,,,,,,,ND,2020-06-30,NCT04336462,ClinicalTrials.gov,2020-03-25,2020-02-15,TRUE,Shanghai Asclepius Meditec Inc.,Recruiting,Not Applicable,Interventional,China,Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19,Drug,Hydrogen + Oxygen vs Oxygen,Hydrogen; oxygen,100,https://clinicaltrials.gov/show/NCT04336462,,,2020-02-21,2020-08-01,2020-02-21,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-31 23:05:16,2020-12-31 23:13:05,IP Address,129.67.118.219,100,468,True,2020-12-31 23:13:05,R_1r94A1Kk6kFt2lX,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hao Li AND Xiyuan,,,,,,,No good search terms...just TCM,,,ND,2020-06-30,NCT04323332,ClinicalTrials.gov,2020-03-08,2020-03-01,TRUE,"Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine",Not Recruiting,Phase 3,Interventional,China,Traditional Chinese Medicine for Severe COVID-19,Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,50,https://clinicaltrials.gov/show/NCT04323332,,,2020-03-01,2020-04-01,2020-03-01,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-31 23:13:20,2020-12-31 23:24:05,IP Address,129.67.118.219,100,644,True,2020-12-31 23:24:05,R_2Yoo6paQpLWqrEx,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,full_results_preprint,full_results_preprint,,,,10.2139/ssrn.3678558,,,10.21203/rs.3.rs-99753/v1,,,,,,,,,,,,2020-10-12,2020-04-30,2020-11-02,2020-04-30,,,,,,,,,,,,,,,,,,,,,,,,,,,,Interestingly one preprint contains 6 subjects and the other 7.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,See note below,,,,,,ResearchSquare says this paper is currently under review: https://www.researchsquare.com/article/rs-99753/v1,,,,ND,2020-06-30,ChiCTR2000030261,ChiCTR,2020-02-26,2020-03-01,FALSE,Wuxi Fifth People's Hospital,Not Recruiting,Not Applicable,Interventional,China,A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19),ATMP,Cells (mesenchymal),Cells (mesenchymal),26,http://www.chictr.org.cn/showproj.aspx?proj=49963,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,true,
2020-12-31 23:26:37,2020-12-31 23:35:47,IP Address,129.67.118.219,100,550,True,2020-12-31 23:35:48,R_2V23N98pKkZNPEN,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Danoprevir AND ritonavir AND covid,Junxue Wang,,,,,Similar looking results for NCT04291729 but not the same.,,,,ND,2020-06-30,ChiCTR2000030259,ChiCTR,2020-02-26,2020-02-22,TRUE,Shanghai Changzheng Hospital,Recruiting,Not Applicable,Interventional,China,"Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19): a randomized, open and controlled trial",Drug,Danoprevir + Ritonavir,Danoprevir; Ritonavir,60,http://www.chictr.org.cn/showproj.aspx?proj=49918,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-31 23:36:01,2020-12-31 23:43:15,IP Address,129.67.118.219,100,433,True,2020-12-31 23:43:15,R_3QWO8OWha6fdsVs,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Lopinavir AND ritonavir AND Xiyanping,Xie Liangdong,Ganzhou AND Xiyanping,,,,,,,,ND,2020-06-30,ChiCTR2000030218,ChiCTR,2020-02-25,2020-01-22,TRUE,The Fifth People's Hospital of Ganzhou,Recruiting,Not Applicable,Interventional,China,Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19),Drug,Lopinavir/ritonavir (+ Tradtional Medicine),Lopinavir; Ritonavir; Traditional Medicine,80,http://www.chictr.org.cn/showproj.aspx?proj=50115,,,,2020-06-25,2020-06-25,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-31 23:43:21,2020-12-31 23:43:44,IP Address,129.67.118.219,100,22,True,2020-12-31 23:43:45,R_1dmdgefsRdH9ttZ,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,ChiCTR2000031272,ChiCTR,2020-03-26,2020-02-18,TRUE,China European International Business School (CEIBS),Not Recruiting,Not Applicable,Interventional,China,The effectiveness of mindfulness intervention in improving people's psychological and physical well-being during novel coronavirus pneumonia (COVID-19) outbreak,Other (psych),Psychological,Psychological,110,http://www.chictr.org.cn/showproj.aspx?proj=51455,,,,2020-03-02,2020-03-02,0,0,,,,,,,,,,,7,,Completed,TRUE,2,,,,,,,,,,,,,,,
2020-12-31 23:43:51,2020-12-31 23:49:04,IP Address,129.67.118.219,100,312,True,2020-12-31 23:49:04,R_8CwGqwA7Qsg231T,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Immunoglobulin AND Covid AND Wuhan Union,Immunoglobulin AND Xiang Cheng,,,,,,,,,ND,2020-06-30,NCT04264858,ClinicalTrials.gov,2020-02-08,2020-03-17,FALSE,"Wuhan Union Hospital, China",Not Recruiting,Not Applicable,Interventional,China,Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients,ATMP,Immunoglobulin,Immunoglobulin,10,https://clinicaltrials.gov/show/NCT04264858,,,2020-04-30,2020-05-31,2020-04-30,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2020-12-31 23:49:32,2020-12-31 23:57:16,IP Address,129.67.118.219,100,464,True,2020-12-31 23:57:18,R_28SD8YOCV2UMsx7,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Qin Ning AND Covid,Methylprednisolone AND Covid AND Tongji,,,,,,,,,ND,2020-06-30,NCT04263402,ClinicalTrials.gov,2020-02-02,2020-02-01,TRUE,"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,Phase 4,Interventional,China,The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia,Drug,Corticosteroids,Methylprednisolone,100,https://clinicaltrials.gov/show/NCT04263402,,,2020-06-01,2020-07-01,2020-06-01,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-01 17:29:43,2021-01-01 18:21:02,IP Address,69.123.66.147,100,3079,True,2021-01-01 18:21:03,R_2Ya08SCRvCQqD8i,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,no,,,"Says ""Case Series"". This appears to be toeing the line between ""prospective cohort study"" and ""single arm trial"". Conflicting data.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,ND,2020-06-30,ChiCTR2000030196,ChiCTR,2020-02-25,2020-02-20,TRUE,Central South Hospital of Wuhan University,Not Recruiting,Phase 2,Interventional,China,"A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)",Drug,Tocilizumab,Tocilizumab,60,http://www.chictr.org.cn/showproj.aspx?proj=49883,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-01 18:21:42,2021-01-01 18:29:08,IP Address,69.123.66.147,100,445,True,2021-01-01 18:29:08,R_1mRFVjhb9ihUZRc,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hydroxychloroquine AND Covid AND Peking University,Shen Ning AND Hydroxychloroquine,,,,,,,,,ND,2020-06-30,ChiCTR2000029898,ChiCTR,2020-02-16,2020-02-17,FALSE,Peking University Third Hospital,Recruiting,Phase 4,Interventional,China,"Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-Label, Parallel, Controlled Trial",Drug,Hydroxychloroquine vs. Chloroquine,Chloroquine; Hydroxychloroquine,100,http://www.chictr.org.cn/showproj.aspx?proj=49482,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-01 18:29:13,2021-01-01 18:44:51,IP Address,69.123.66.147,100,937,True,2021-01-01 18:44:52,R_pa5aJoGnzXIBdbr,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"There are results currently under review:
https://clinicaltrials.gov/ct2/show/results/NCT04276987",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,mesenchymal AND exosomes AND covid,mesenchymal AND exosomes AND covid AND Ruijin,Jie-ming Qu AND Ruijin AND mesenchymal,,,,,,,,ND,2020-06-30,NCT04276987,ClinicalTrials.gov,2020-02-16,2020-02-15,TRUE,Ruijin Hospital,Not Recruiting,Phase 1,Interventional,No Country Given,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,ATMP,Cells (mesenchymal),Cells (mesenchymal),30,https://clinicaltrials.gov/show/NCT04276987,,,2020-05-31,2020-07-31,2020-05-31,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-01 18:45:08,2021-01-01 18:46:02,IP Address,69.123.66.147,100,54,True,2021-01-01 18:46:03,R_32Q6j1Y0Bfmb1i8,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,no,,"Treatment of flu during covid, not covid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,ChiCTR2000029550,ChiCTR,2020-02-04,2020-01-29,TRUE,Hospital of Chengdu University of Traditional Chinese Medicine,Recruiting,Not Applicable,Interventional,China,Recommendations for Diagnosis and Treatment of Influenza Patients in the Hospital of Chengdu University of Traditional Chinese Medicine Under the Raging of Novel Coronavirus Pneumonia (COVID-19),Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,300,http://www.chictr.org.cn/showproj.aspx?proj=48775,,,,2020-05-01,2020-05-01,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-01 18:46:09,2021-01-01 18:53:22,IP Address,69.123.66.147,100,432,True,2021-01-01 18:53:22,R_27xwyZlpBFR9tKR,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Protocol: 10.1186/s13063-020-04970-3 & 10.21203/rs.3.rs-25172/v1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,maxingshigan-weijing AND covid,Zheng-Zhong Yuan,Jing-Guo Cheng,,,,,,,,ND,2020-06-30,ChiCTR2000030759,ChiCTR,2020-03-13,2020-02-15,TRUE,The First Affiliated Hospital of Wenzhou Medical University,Not Recruiting,Not Applicable,Interventional,China,Study for the therapeutic effect and mechanism of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19),Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,70,http://www.chictr.org.cn/showproj.aspx?proj=49284,,,,2020-05-17,2020-05-17,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-01 18:53:28,2021-01-01 18:58:02,IP Address,69.123.66.147,100,273,True,2021-01-01 18:58:02,R_1Q4lzKUToM0JntR,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,I think this counts as it's treatment to make you survive covid better by preventing VTE.,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,heparin AND covid AND VTE,Chunli Liu,,,,,,,,,ND,2020-06-30,ChiCTR2000030946,ChiCTR,2020-03-19,2020-02-10,TRUE,The First Affiliated Hospital of Guangzhou Medical University,Recruiting,Phase 4,Interventional,China,Effects of different VTE prevention methods on the prognosis of hospitalized patients with novel coronavirus pneumonia (COVID-19),Drug,Heparin,Heparin,120,http://www.chictr.org.cn/showproj.aspx?proj=51265,,,,2020-04-10,2020-04-10,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-01 18:58:09,2021-01-01 19:00:11,IP Address,69.123.66.147,100,121,True,2021-01-01 19:00:11,R_uk6KArTOvsRumLn,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,unknown,yes,no,Says Case Series,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Results preprint here if we count: https://doi.org/10.1101/2020.05.11.20064584,team_review,,ND,2020-06-30,ChiCTR2000030939,ChiCTR,2020-03-18,2020-03-16,TRUE,PLA General Hospital,Recruiting,Not Applicable,Interventional,China,Preliminary evaluation of the safety and efficacy of oral LL-37 antiviral peptide (CAS001) in the treatment of novel coronavirus pneumonia (COVID-19),ATMP,Gene-derived protein,Gene-derived protein,10,http://www.chictr.org.cn/showproj.aspx?proj=51059,,,,2020-10-01,2020-10-01,0,0,,10.1101/2020.05.11.20064584,,10.1101/2020.05.11.20064584,,full_results_preprint,,,2020-05-15,,7,,Recruiting,TRUE,2,,full_results_preprint,2020-05-15,7g3keqx9,http://medrxiv.org/cgi/content/short/2020.05.11.20064584v1?rss=1,"Preliminary evaluation of the safety and efficacy of oral human antimicrobial peptide LL-37 in the treatment of patients of COVID-19, a small-scale, single-arm, exploratory safety study",,,,,,,,,
2021-01-01 19:00:17,2021-01-01 19:11:21,IP Address,69.123.66.147,100,663,True,2021-01-01 19:11:22,R_svdpmAoe2uZLuZr,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,(abidol OR Umifenovir) and COVID,Jianrong Huang,Li Lanjuan,,,,,,,,ND,2020-06-30,ChiCTR2000029573,ChiCTR,2020-02-05,2020-02-06,FALSE,The First Affiliated Hospital of Zhejiang University School of Medicine,Recruiting,Phase 4,Interventional,China,"A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and safety of recombinant cytokine gene-derived protein injection in combination with standard therapy in patients with novel coronavirus infection",ATMP,Gene-derived protein,Gene-derived protein,480,http://www.chictr.org.cn/showproj.aspx?proj=49065,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-04 09:39:12,2021-01-04 09:39:58,IP Address,82.33.104.78,100,46,True,2021-01-04 09:39:59,R_2Xie2WgDAsi5Imu,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,no,,Social media intervention,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NL8483,Netherlands Trial Register,2020-03-26,2020-03-16,TRUE,Fred Foundation; Noaber Foundation,Recruiting,Not Applicable,Interventional,Netherlands,A weapon against COVID-19: (Social) media and influencers,Other,Other,Other,17000,https://trialregister.nl/trial/8483,,,,2020-03-29,2020-03-29,0,0,,,,,,,,,,,8,,Open for patient inclusion,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 09:40:10,2021-01-04 09:42:48,IP Address,82.33.104.78,100,158,True,2021-01-04 09:42:48,R_2wz6gMln57VzIIM,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,no,2020-12-30,2021-03-31,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04442178,ClinicalTrials.gov,2020-06-19,2020-06-30,FALSE,Revimmune,Not Recruiting,Phase 2,Interventional,No Country Given,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ),Drug,Interleukin-7,Interleukin-7,48,https://clinicaltrials.gov/show/NCT04442178,,,2020-11-30,2020-12-31,2020-11-30,0,1,,,,,,,,,,,8,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,2021-03-31
2021-01-04 09:42:57,2021-01-04 09:56:07,IP Address,82.33.104.78,100,790,True,2021-01-04 09:56:08,R_12G8psdrlZAjjyR,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,no,2020-06-15,2020-07-09,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,,"10.1101/2020.11.02.20224303 ",,https://www.medrxiv.org/content/10.1101/2020.11.02.20224303v1,,,,,,,,,,,,,2020-11-04,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Manaf Al Qahtani AND SARS-CoV 2 AND convalescent plasma,Bahrain AND COVID-19 AND convalescent plasma,,,,,,,,,MPJ,2020-06-30,NCT04356534,ClinicalTrials.gov,2020-04-15,2020-04-19,FALSE,Royal College of Surgeons in Ireland - Medical University of Bahrain,Recruiting,Not Applicable,Interventional,Bahrain,Convalescent Plasma Trial in COVID -19 Patients,ATMP,Plasma,Plasma,40,https://clinicaltrials.gov/show/NCT04356534,,,2020-06-30,2020-06-30,2020-06-30,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,true,2020-07-09
2021-01-04 09:56:15,2021-01-04 10:07:52,IP Address,82.33.104.78,100,697,True,2021-01-04 10:07:52,R_42RZYiUyDuFqFW1,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,,"10.1101/2020.10.25.20219337 ",,https://www.medrxiv.org/content/10.1101/2020.10.25.20219337v1,,,,,,,,,,,,,2020-10-27,2020-05-30,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Severely Sick AND COVID-19 AND clinical trial AND India,"Convalescent Plasma AND SARS-CoV-2 AND Institute of Liver and Biliary Sciences, India",,,,,,,,,MPJ,2020-06-30,NCT04346446,ClinicalTrials.gov,2020-04-14,2020-04-20,FALSE,"Institute of Liver and Biliary Sciences, India",Not Recruiting,Phase 2,Interventional,India,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,ATMP,Plasma,Plasma,29,https://clinicaltrials.gov/show/NCT04346446,,,2020-05-30,2020-05-30,2020-05-30,0,0,,,,,,,,,,,8,,Completed,TRUE,1,,,,,,,,,,,,,,true,
2021-01-04 10:08:02,2021-01-04 10:13:49,IP Address,82.33.104.78,100,347,True,2021-01-04 10:13:50,R_3PKOZbTdocPrUPB,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,no,2021-09-28,2021-09-28,1,2020-003056-32,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Sirukumab AND coronavirus AND Belgium ","Janssen Pharmaceutical AND COVID-19 AND Sirukumab ",,,,,,,,,MPJ,2020-06-30,NCT04380961,ClinicalTrials.gov,2020-05-07,2020-04-24,TRUE,Janssen Pharmaceutical,Recruiting,Phase 2,Interventional,United States,A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19,Drug,Sirukumab,Sirukumab,270,https://clinicaltrials.gov/show/NCT04380961,,,2020-06-25,2020-09-16,2020-06-25,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2021-09-28
2021-01-04 10:13:57,2021-01-04 10:14:28,IP Address,82.33.104.78,100,30,True,2021-01-04 10:14:28,R_29nSZKuR1lVh7nj,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04393636,ClinicalTrials.gov,2020-05-11,2020-06-05,FALSE,Academic Hospital Maastricht,Recruiting,Not Applicable,Interventional,Netherlands,Digital Cardiac Counseling Trial: DCC Trial,Other (software),eHealth,eHealth,394,https://clinicaltrials.gov/show/NCT04393636,,,2022-12-31,2022-12-31,2022-12-31,0,1,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 10:14:34,2021-01-04 10:18:22,IP Address,82.33.104.78,100,228,True,2021-01-04 10:18:22,R_1jkum6gQxNM6Di9,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hydroxychloroquine AND Post-Exposure Prophylaxis AND COVID-19 AND Sanford Health,,,,,,,,,,MPJ,2020-06-30,NCT04372017,ClinicalTrials.gov,2020-04-25,2020-05-14,FALSE,Sanford Health,Not Recruiting,Phase 3,Interventional,United States,Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection,Drug (Chemoprophylaxis),Hydroxychloroquine,Hydroxychloroquine,1,https://clinicaltrials.gov/show/NCT04372017,,,2020-06-04,2021-06-04,2020-06-04,0,0,,,,,,,,,,,8,,"Active, not recruiting",TRUE,1,,,,,,,,,,,,,,,
2021-01-04 10:18:41,2021-01-04 10:19:44,IP Address,82.33.104.78,100,62,True,2021-01-04 10:19:44,R_2YEPF2P0MnUpNrl,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,unknown,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04346420,ClinicalTrials.gov,2020-04-08,2020-04-09,FALSE,"University Clinic, UCLouvain",Not Recruiting,Not Applicable,Interventional,Belgium,Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19,Other (device),Masks,Masks,12,https://clinicaltrials.gov/show/NCT04346420,,,2020-05-01,2020-05-01,2020-05-01,0,0,,,,,,,,,,,8,,Completed,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 10:19:53,2021-01-04 10:20:40,Spam,82.33.104.78,100,46,True,2021-01-04 10:20:40,R_1ewx7tFqJDhGXql,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04335279,ClinicalTrials.gov,2020-04-01,2020-04-09,FALSE,Lady Davis Institute,Recruiting,Not Applicable,Interventional,Canada,Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program,Other (psych),Psychological,Psychological,195,https://clinicaltrials.gov/show/NCT04335279,,,2020-06-03,2020-07-24,2020-06-03,0,0,,,,,,,,,,,8,,"Active, not recruiting",TRUE,1,,,,,,,,,,,,,,,
2021-01-04 10:20:47,2021-01-04 10:22:12,IP Address,82.33.104.78,100,85,True,2021-01-04 10:22:12,R_3EPSqlk30nYWY2m,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,unknown,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04416308,ClinicalTrials.gov,2020-05-27,2020-05-29,FALSE,Rennes University Hospital,Recruiting,Not Applicable,Interventional,France,COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB),Clinical Presentation (Epidemiology),No Intervention,No Intervention,13000,https://clinicaltrials.gov/show/NCT04416308,,,2020-06-15,2020-11-10,2020-06-15,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 10:22:24,2021-01-04 10:24:24,IP Address,82.33.104.78,100,119,True,2021-01-04 10:24:24,R_232F0wg0jF0LaUh,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04411446,ClinicalTrials.gov,2020-05-26,2020-06-15,FALSE,Vitamin D Study Group,Not Recruiting,Phase 4,Interventional,Argentina,Cholecalciferol to Improve the Outcomes of COVID-19 Patients,Drug,Vitamin D,Vitamin D,1265,https://clinicaltrials.gov/show/NCT04411446,,,2020-12-15,2020-12-28,2020-12-15,0,1,,,,,,,,,,,8,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 10:24:34,2021-01-04 10:26:04,Spam,82.33.104.78,100,90,True,2021-01-04 10:26:05,R_1d9Q5Qboi5EHXcK,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04385901,ClinicalTrials.gov,2020-05-06,2020-05-19,FALSE,University of Missouri-Columbia,Recruiting,Not Applicable,Interventional,United States,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Telehealth,Physio & Rehabilitation,Physio & Rehabilitation,72,https://clinicaltrials.gov/show/NCT04385901,,,2022-04-19,2022-04-19,2022-04-19,0,1,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 10:26:11,2021-01-04 10:37:52,IP Address,82.33.104.78,100,701,True,2021-01-04 10:37:53,R_33a6anxum3C04tp,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ganovo AND Ritonavir AND SARS-CoV-2 AND Yahong Chen,Danoprevir AND COVID-19 AND Huoshenshan Hospital,,,,,,,,,MPJ,2020-06-30,NCT04345276,ClinicalTrials.gov,2020-04-10,2020-03-18,TRUE,Huo-Shen-Shan Hospital,Not Recruiting,Phase 4,Interventional,China,Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Drug,Danoprevir + Ritonavir,Danoprevir; Ritonavir,10,https://clinicaltrials.gov/show/NCT04345276,,,2020-04-15,2020-04-15,2020-04-15,0,0,,,,,,,,,,,8,,Completed,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 10:38:08,2021-01-04 10:50:14,IP Address,82.33.104.78,100,725,True,2021-01-04 10:50:14,R_3iwM7dkvyCi4JBf,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,summary_results,,,,,,,,,,,,,,,,,,,,2020-11-04,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,full_results_preprint,,,,,"10.1101/2020.07.07.20145979 ",,https://www.medrxiv.org/content/10.1101/2020.07.07.20145979v1,,,,,,,,,,,,,2020-07-08,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ivermectin AND COVID 19 AND University of Baghdad,Ivermectin AND Effectiveness AND coronavirus AND Faiq I Gorial,,,,,,,,,MPJ,2020-06-30,NCT04343092,ClinicalTrials.gov,2020-04-05,2020-04-18,FALSE,University of Baghdad,Not Recruiting,Phase 1,Interventional,Iraq,Efficacy of Ivermectin as Add on Therapy in COVID19 Patients,Drug,Ivermectin + hydroxychloroquine vs. hydroxychloroquine,Ivermectin; hydroxychloroquine,100,https://clinicaltrials.gov/show/NCT04343092,,,2020-05-31,2020-06-01,2020-05-31,0,0,,,,,,,,,,,8,,Completed,TRUE,1,,,,,,,,,,,,,,true,
2021-01-04 10:50:31,2021-01-04 10:52:28,IP Address,82.33.104.78,100,117,True,2021-01-04 10:52:28,R_31t1GKVtJXreHZW,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,unknown,unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Withdrawn should be 'no', this is diagnostic not treatment?",,,MPJ,2020-06-30,NCT04410549,ClinicalTrials.gov,2020-05-21,2020-05-27,FALSE,IRCCS Ospedale San Raffaele,Recruiting,Not Applicable,Interventional,Italy,Pulmonary Optical Coherence Tomography in COVID-19 Patients,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,10,https://clinicaltrials.gov/show/NCT04410549,,,2020-06-30,2020-06-30,2020-06-30,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 10:52:42,2021-01-04 10:52:59,Spam,82.33.104.78,100,17,True,2021-01-04 10:53:00,R_Ab5Tj5WlJUrlbLr,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04410458,ClinicalTrials.gov,2020-05-29,2020-05-31,FALSE,Guangzhou Blood Center,Recruiting,Not Applicable,Interventional,China,Recruit Blood Donors Via SMS During Epidemic of COVID-19 (Repeat Trial),Other,Other,Other,506517,https://clinicaltrials.gov/show/NCT04410458,,,2020-05-31,2020-06-12,2020-05-31,0,0,,,,,,,,,,,8,,Enrolling by invitation,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 10:53:07,2021-01-04 11:03:51,Spam,82.33.104.78,100,643,True,2021-01-04 11:03:51,R_25zmj6XhSwzLz1k,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04348513,ClinicalTrials.gov,2020-04-09,2020-05-29,FALSE,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,Recruiting,Phase 2,Interventional,Greece,Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection,Drug,Triiodothyronine,Triiodothyronine,60,https://clinicaltrials.gov/show/NCT04348513,,,2021-05-02,2021-05-31,2021-05-02,0,1,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 11:03:57,2021-01-04 11:17:43,IP Address,82.33.104.78,100,825,True,2021-01-04 11:17:44,R_3RrPDFE6vnb9nRI,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,no,2020-04-09,2020-06-30,1,ISRCTN15874265,,,,,summary_results,,,,,,,,,,,,,,,,,,,,2020-12-31,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Remdesivir AND COVID-19 AND Gilead Sciences ","GS-5734™ AND COVID-19 AND Gilead ",,,,,,,,,MPJ,2020-06-30,NCT04292899,ClinicalTrials.gov,2020-02-28,2020-03-06,TRUE,Gilead Sciences,Not Recruiting,Phase 3,Interventional,"Japan, Spain, Netherlands, South Korea, Switzerland, United States, Hong Kong, Italy, Taiwan, China, Germany, Singapore, France, Sweden, United Kingdom",Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Drug,Remdesivir,Remdesivir,6000,https://clinicaltrials.gov/show/NCT04292899,EUCTR2020-000841-15,,2020-06-01,2020-06-01,2020-06-01,0,1,,10.1056/NEJMoa2015301,,10.1056/NEJMoa2015301,,full_results_journal_article,,,2020-05-27,,8,,"Active, not recruiting",TRUE,1,32459919,full_results_journal_article,2020-05-27,,,,,,,,,,true,,2020-06-30
2021-01-04 11:17:54,2021-01-04 11:18:33,Spam,82.33.104.78,100,38,True,2021-01-04 11:18:34,R_295lJrE2tmnTDBm,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,unknown,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04402918,ClinicalTrials.gov,2020-05-18,2020-05-17,TRUE,CHU de Besançon,Recruiting,Not Applicable,Interventional,France,Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 (COVID-19) During Pregnancy,Clinical Presentation,No Intervention,No Intervention,160,https://clinicaltrials.gov/show/NCT04402918,,,2020-05-19,2020-12-31,2020-05-19,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 11:18:43,2021-01-04 11:19:41,IP Address,82.33.104.78,100,58,True,2021-01-04 11:19:41,R_30oShLdJIpTmLVl,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,unknown,no,"Diagnostic tool ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04364594,ClinicalTrials.gov,2020-04-22,2020-03-26,TRUE,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Not Recruiting,Not Applicable,Interventional,Italy,COVID-19 Search in Conjunctival Cells,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,50,https://clinicaltrials.gov/show/NCT04364594,,,2020-05-24,2020-05-30,2020-05-24,0,0,,,,,,,,,,,8,,"Active, not recruiting",TRUE,1,,,,,,,,,,,,,,,
2021-01-04 11:19:51,2021-01-04 11:20:23,Spam,82.33.104.78,100,32,True,2021-01-04 11:20:24,R_27VcRzPO8Lv0EEt,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04359264,ClinicalTrials.gov,2020-04-16,2020-04-20,FALSE,"St. Michael's Hospital, Toronto",Not Recruiting,Not Applicable,Interventional,Canada,Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial,Other,Other,Other,392,https://clinicaltrials.gov/show/NCT04359264,,,2020-05-29,2020-06-30,2020-05-29,0,0,,,,,,,,,,,8,,"Active, not recruiting",TRUE,1,,,,,,,,,,,,,,,
2021-01-04 11:20:29,2021-01-04 11:21:36,Spam,82.33.104.78,100,66,True,2021-01-04 11:21:36,R_21hAmf2901M7oT6,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04306393,ClinicalTrials.gov,2020-03-10,2020-03-21,TRUE,Massachusetts General Hospital,Recruiting,Phase 2,Interventional,United States,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,Drug,Nitric oxide,Nitric oxide,200,https://clinicaltrials.gov/show/NCT04306393,EUCTR2020-001490-68,,2021-03-21,2022-03-21,2021-03-21,0,1,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 11:21:43,2021-01-04 11:23:41,Spam,82.33.104.78,100,117,True,2021-01-04 11:23:41,R_0BAEM4n4P8VKcmd,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04367831,ClinicalTrials.gov,2020-04-27,2020-05-02,FALSE,Columbia University,Recruiting,Phase 4,Interventional,United States,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19,Drug,Enoxaparin,Enoxaparin,100,https://clinicaltrials.gov/show/NCT04367831,,,2020-11-01,2021-04-01,2020-11-01,0,1,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 11:23:47,2021-01-04 11:29:40,IP Address,82.33.104.78,100,353,True,2021-01-04 11:29:40,R_1jHOi5sgz5XJXvH,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Convalescent Plasma AND SARS-CoV-2 AND Danderyd Hospital,Convalescent Plasma AND COVID-19 AND Johan Ursing,,,,,,,,,MPJ,2020-06-30,NCT04390178,ClinicalTrials.gov,2020-04-10,2020-04-10,FALSE,Joakim Dillner,Not Recruiting,Phase 1/Phase 2,Interventional,Sweden,Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19),ATMP,Plasma,Plasma,10,https://clinicaltrials.gov/show/NCT04390178,,,2020-06-01,2020-12-01,2020-06-01,0,0,,,,,,,,,,,8,,"Active, not recruiting",TRUE,1,,,,,,,,,,,,,,,
2021-01-04 11:29:54,2021-01-04 11:38:52,IP Address,82.33.104.78,100,538,True,2021-01-04 11:38:53,R_2TvpQY3keFO9PBw,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,,,,,full_results_journal_article,,,,,10.21037/jtd-2020-062,32944383,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475564/,,,,,,,,,,,,,2020-06-15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hydrogen/Oxygen AND COVID-19 AND Weijie Guan,Mixed Gas AND coronavirus AND Dyspnea AND Guangzhou Institute of Respiratory Disease,,,,,,,,,MPJ,2020-06-30,NCT04378712,ClinicalTrials.gov,2020-04-29,2020-01-21,TRUE,Guangzhou Institute of Respiratory Disease,Not Recruiting,Not Applicable,Interventional,China,Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19),Drug,Hydrogen + Oxygen,Hydrogen; Oxygen,90,https://clinicaltrials.gov/show/NCT04378712,,,2020-03-23,2020-03-23,2020-03-23,0,0,,,,,,,,,,,8,,Completed,TRUE,1,,,,,,,,,,,,,true,,
2021-01-04 11:39:06,2021-01-04 11:46:53,IP Address,82.33.104.78,100,467,True,2021-01-04 11:46:53,R_3DvYvuDdblpUTHG,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,no,2021-03-30,NA,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sitagliptin AND COVID-19 AND diabetes AND University of Milan,SIDIACO AND Paolo Fiorina,,,,,,,,,MPJ,2020-06-30,NCT04365517,ClinicalTrials.gov,2020-04-14,2020-05-29,FALSE,University of Milan,Not Recruiting,Phase 3,Interventional,Italy,The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients,Drug,Sitagliptin,Sitagliptin,170,https://clinicaltrials.gov/show/NCT04365517,,,2020-06-30,2020-12-30,2020-06-30,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,2021-03-30
2021-01-04 11:47:04,2021-01-04 11:53:22,IP Address,82.33.104.78,100,377,True,2021-01-04 11:53:22,R_21hXL7GsmosGfGS,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,no,2020-05-31,2020-05-31,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_journal_article,,,,,10.1371/journal.pone.0242763," 33264337",https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0242763,,,,,,,,,,,,,2020-12-02,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Hydroxychloroquine AND COVID-19 AND Taiwan AND Efficacy ",,,,,,,,,,MPJ,2020-06-30,NCT04384380,ClinicalTrials.gov,2020-04-07,2020-04-01,TRUE,Taoyuan General Hospital,Recruiting,Phase 4,Interventional,Taiwan,Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,Drug,Hydroxychloroquine,Hydroxychloroquine,45,https://clinicaltrials.gov/show/NCT04384380,,,2020-06-30,2020-09-30,2020-06-30,0,1,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,true,,2020-05-31
2021-01-04 11:53:29,2021-01-04 11:54:05,Spam,82.33.104.78,100,36,True,2021-01-04 11:54:06,R_1GKb7B3G1Ux9BCx,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,unknown,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04383587,ClinicalTrials.gov,2020-05-07,2020-05-06,TRUE,Mayo Clinic,Recruiting,Not Applicable,Interventional,United States,Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers,Clinical Presentation (Epidemiology),No Intervention,No Intervention,300,https://clinicaltrials.gov/show/NCT04383587,,,2020-05-29,2020-06-12,2020-05-29,0,0,,,,,,,,,,,8,,Enrolling by invitation,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 11:54:12,2021-01-04 11:56:03,IP Address,82.33.104.78,100,111,True,2021-01-04 11:56:04,R_33x2NAIJ3hk2RD8,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,no,,Treatment of co-infections of Covid-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04382092,ClinicalTrials.gov,2020-05-06,2020-03-23,TRUE,"University Clinic, UCLouvain",Not Recruiting,Not Applicable,Interventional,Belgium,Co-infection Management in COVID-19 Critically Ill,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,32,https://clinicaltrials.gov/show/NCT04382092,,,2020-04-24,2020-04-24,2020-04-24,0,0,,,,,,,,,,,8,,Completed,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 11:56:21,2021-01-04 11:57:54,Spam,82.33.104.78,100,92,True,2021-01-04 11:57:55,R_3qwZMp42yw4s8ch,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04322396,ClinicalTrials.gov,2020-03-23,2020-04-06,FALSE,Chronic Obstructive Pulmonary Disease Trial Network,Recruiting,Phase 2,Interventional,Denmark,Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,Drug (Chemoprophylaxis),Hydroxychloroquine + Azithromycin,Hydroxychloroquine; azithromycin,226,https://clinicaltrials.gov/show/NCT04322396,,,2020-10-31,2021-03-31,2020-10-31,0,1,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 11:58:09,2021-01-04 12:03:06,IP Address,82.33.104.78,100,296,True,2021-01-04 12:03:06,R_3rIokvjgSPEJJjo,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,early tracheostomy AND COVID-19 AND Shahriar Najafizadeh,,,,,,,,,,MPJ,2020-06-30,IRCT20180129038542N1,IRCT,2020-04-13,2020-04-06,TRUE,University of Baqiyatallah,Not Recruiting,Not Applicable,Interventional,Iran,Early tracheostomy in COVID-19,Other (physical),Mechanical ventilation,Mechanical ventilation,30,http://en.irct.ir/trial/47013,,,,2020-04-13,2020-04-13,0,0,,,,,,,,,,,8,,Recruitment complete,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 12:03:22,2021-01-04 12:04:41,Spam,82.33.104.78,100,78,True,2021-01-04 12:04:41,R_3EbQd2kPsjx6Aut,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04377997,ClinicalTrials.gov,2020-05-01,2020-05-15,FALSE,Massachusetts General Hospital,Not Recruiting,Phase 2,Interventional,No Country Given,Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19,Drug,Enoxaparin,Enoxaparin,300,https://clinicaltrials.gov/show/NCT04377997,,,2021-01-01,2022-01-01,2021-01-01,0,1,,,,,,,,,,,8,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 12:04:50,2021-01-04 12:09:09,IP Address,82.33.104.78,100,259,True,2021-01-04 12:09:10,R_vwaTYnogmp7DZol,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,," Hydroxychloroquine AND Zinc AND COVID-19 AND Military Healthcare Workers",COVID-Milit AND Military Hospital of Tunis,,,,,,,,,MPJ,2020-06-30,NCT04377646,ClinicalTrials.gov,2020-05-01,2020-05-04,FALSE,Military Hospital of Tunis,Not Recruiting,Phase 3,Interventional,Tunisia,A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers,Drug (Chemoprophylaxis),Hydroxychloroquine + Zinc,Hydroxychloroquine + Zinc,660,https://clinicaltrials.gov/show/NCT04377646,,,2020-05-24,2020-07-31,2020-05-24,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 12:09:33,2021-01-04 12:13:02,IP Address,82.33.104.78,100,208,True,2021-01-04 12:13:03,R_2413di5QyEmfm5A,,,test@test.com,,51.4535064697265625,-2.591705322265625,anonymous,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Guangzhou Medical University AND heparin AND COVID-19 ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030946,ChiCTR,2020-03-19,2020-02-10,TRUE,The First Affiliated Hospital of Guangzhou Medical University,Recruiting,Phase 4,Interventional,China,Effects of different VTE prevention methods on the prognosis of hospitalized patients with novel coronavirus pneumonia (COVID-19),Drug,Heparin,Heparin,120,http://www.chictr.org.cn/showproj.aspx?proj=51265,,,,2020-04-10,2020-04-10,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 12:13:09,2021-01-04 12:17:42,IP Address,82.33.104.78,100,272,True,2021-01-04 12:17:42,R_3iEJ1Zf6KBdNKOL,,,test@test.com,,51.4535064697265625,-2.591705322265625,anonymous,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_journal_article,,,,,"10.1111/cts.12881 ","32881359 ",https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.12881,,,,,,,,,,,,,2020-09-03,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bromhexine Hydrochloride AND COVID-19 AND Wenzhou Medical University,,,,,,,,,,MPJ,2020-06-30,NCT04273763,ClinicalTrials.gov,2020-02-14,2020-02-16,FALSE,The Second Affiliated Hospital of Wenzhou Medical University,Not Recruiting,Not Applicable,Interventional,China,Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),Drug,Bromhexine + Umifenovir + Interferon alpha vs. Umifenovir + interferon alpha,Bromhexine; Umifenovir; interferon alpha,18,https://clinicaltrials.gov/show/NCT04273763,,,2020-05-10,2020-06-01,2020-05-10,0,0,,,,,,,,,,,7,,"Active, not recruiting",TRUE,1,,,,,,,,,,,,,true,,
2021-01-04 12:13:06,2021-01-04 12:17:59,IP Address,82.33.104.78,100,293,True,2021-01-04 12:18:00,R_1lfpqlzSqtWzpEG,,,test@test.com,,51.4535064697265625,-2.591705322265625,anonymous,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,ChiCTR2000032237,ChiCTR,2020-04-23,2020-04-01,TRUE,Ezhou Hospital of Traditional Chinese Medicine,Recruiting,Not Applicable,Interventional,No Country Given,"A multicenter, randomized, double-blind, placebo-controlled trial for Xiang-Sha-Liu-Jun Pill in the treatment of novel coronavirus pneumonia (COVID-19) decline in digestive function during convalescence",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,200,http://www.chictr.org.cn/showproj.aspx?proj=52699,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,7,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 12:22:16,2021-01-04 12:25:31,IP Address,82.33.104.78,100,194,True,2021-01-04 12:25:31,R_3fvYQTrovipzsFU,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hydroxychloroquine Chemoprophylaxis AND COVID-19 AND Dr. Saira Burney,,,,,,,,,,MPJ,2020-06-30,NCT04370015,ClinicalTrials.gov,2020-04-27,2020-05-15,FALSE,"Services Institute of Medical Sciences, Pakistan",Not Recruiting,Not Applicable,Interventional,No Country Given,Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers.,Drug (Chemoprophylaxis),Hydroxychloroquine,Hydroxychloroquine,374,https://clinicaltrials.gov/show/NCT04370015,,,2020-06-30,2020-10-15,2020-06-30,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 12:25:37,2021-01-04 12:30:08,IP Address,82.33.104.78,100,270,True,2021-01-04 12:30:09,R_3oSEEu2K27eFRhp,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Immune Modulatory Drugs AND COVID-19 AND Hôpitaux de Paris,CORIMUNO-19 - VIRO AND trial AND Hôpitaux de Paris,,,,,,,,,MPJ,2020-06-30,NCT04341870,ClinicalTrials.gov,2020-04-06,2020-04-11,FALSE,Assistance Publique – Hôpitaux de Paris,Not Recruiting,Phase 2/Phase 3,Interventional,France,"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",Drug,Sarilumab + Azithromycin + Hydroxychloroquine vs. Sarilumab,Sarilumab; azithromycin; hydroxychloroquine,27,https://clinicaltrials.gov/show/NCT04341870,,,2020-05-08,2020-08-01,2020-05-08,0,0,,,,,,,,,,,8,,Suspended,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 12:30:14,2021-01-04 12:31:05,Spam,82.33.104.78,100,51,True,2021-01-04 12:31:06,R_YQuOTqKLQmmqlMJ,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04368156,ClinicalTrials.gov,2020-04-20,2020-04-20,FALSE,Carlos Tornero,Recruiting,Not Applicable,Interventional,Spain,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,Other (device),Vagus nerve stimulation,Vagus nerve stimulation,90,https://clinicaltrials.gov/show/NCT04368156,,,2020-07-31,2020-07-31,2020-07-31,0,1,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 12:31:12,2021-01-04 12:34:42,IP Address,82.33.104.78,100,210,True,2021-01-04 12:34:43,R_29uZtERakLZPR92,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Probiotics AND COVID-19 Prevention AND Raquel Rodriguez Blanque,Lactobacillus Coryniformis K8 AND COVID-19 AND Healthcare Workers,,,,,,,,,MPJ,2020-06-30,NCT04366180,ClinicalTrials.gov,2020-04-27,2020-04-24,TRUE,Biosearch S.A.,Recruiting,Not Applicable,Interventional,Spain,Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers,Supplement,Probiotics,Probiotics,314,https://clinicaltrials.gov/show/NCT04366180,,,2020-06-01,2020-10-01,2020-06-01,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 12:34:49,2021-01-04 12:35:55,Spam,82.33.104.78,100,65,True,2021-01-04 12:35:55,R_cA4pxQwbthe20x3,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04366089,ClinicalTrials.gov,2020-04-22,2020-03-26,TRUE,Dr. Roberto Poscia,Recruiting,Phase 2,Interventional,Italy,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,Drug,Oxygen + Ozone,Oxygen; Ozone,152,https://clinicaltrials.gov/show/NCT04366089,,,2020-10-30,2020-12-31,2020-10-30,0,1,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 12:36:04,2021-01-04 12:36:45,Spam,82.33.104.78,100,41,True,2021-01-04 12:36:46,R_1156I0keWzDpXt5,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04361942,ClinicalTrials.gov,2020-04-17,2020-04-01,FALSE,Red de Terapia Celular,Recruiting,Phase 2,Interventional,Spain,Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV),ATMP,Cells (mesenchymal),Cells (mesenchymal),24,https://clinicaltrials.gov/show/NCT04361942,EUCTR2020-001682-36,,2020-11-30,2020-12-31,2020-11-30,0,1,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 12:36:52,2021-01-04 12:41:33,IP Address,82.33.104.78,100,281,True,2021-01-04 12:41:34,R_3EGCA6kVAIMkkuK,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,choloroquinE AND Prophylaxis AND COVID-19 AND Ammar Sarwar,"PRECISE AND Government of Punjab, Specialized Healthcare and Medical Education Department",,,,,,,,,MPJ,2020-06-30,NCT04351191,ClinicalTrials.gov,2020-04-14,2020-04-15,FALSE,"Government of Punjab, Specialized Healthcare and Medical Education Department",Recruiting,Phase 4,Interventional,Pakistan,PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds,Drug (Chemoprophylaxis),Hydroxychloroquine vs. Chloroquine,Hydroxychloroquine; Chloroquine,400,https://clinicaltrials.gov/show/NCT04351191,,,2020-05-30,2020-06-30,2020-05-30,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 12:41:55,2021-01-04 12:44:42,IP Address,82.33.104.78,100,166,True,2021-01-04 12:44:42,R_1QTfDAW4Fl51LEt,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Perseverance Research Center AND Hydroxychloroquine AND Indomethacin AND Zithromax ",,,,,,,,,,MPJ,2020-06-30,NCT04344457,ClinicalTrials.gov,2020-04-08,2020-04-16,FALSE,"Perseverance Research Center, LLC",Recruiting,Phase 1/Phase 2,Interventional,United States,"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19",Drug,Hydroxychloroquine + Indomethacin + Azithromycin,Hydroxychloroquine; Indomethacin; Azithromycin,80,https://clinicaltrials.gov/show/NCT04344457,,,2020-06-20,2020-09-30,2020-06-20,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 12:45:04,2021-01-04 12:50:09,IP Address,82.33.104.78,100,305,True,2021-01-04 12:50:10,R_31towe5aSIs7GB5,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,no,2021-03-30,2021-03-30,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Colchicine AND COVID-19 AND Estudios Clínicos Latino América,ECLA PHRI COLCOVID Trial,,,,,,,,,MPJ,2020-06-30,NCT04328480,ClinicalTrials.gov,2020-03-30,2020-04-17,FALSE,Estudios Clínicos Latino América,Recruiting,Phase 3,Interventional,Argentina,The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.,Drug,Colchicine,Colchicine,2500,https://clinicaltrials.gov/show/NCT04328480,,,2020-06-30,2020-08-30,2020-06-30,0,1,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2021-03-30
2021-01-04 12:50:14,2021-01-04 12:55:23,IP Address,82.33.104.78,100,308,True,2021-01-04 12:55:23,R_3IYnjLP4TFKUyhM,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,interim_result,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"START AND trial AND Iran AND COVID-19 ",Siddha AND COVID-19 AND Gopalakrishnan Thanicakachalam,,,,,,,,,MPJ,2020-06-30,ISRCTN13311119,ISRCTN,2020-04-24,2020-04-30,FALSE,Eminentlabs GmbH,Recruiting,Phase 2,Interventional,India,START (Siddha Treatment Accelerating Recovery from SARS-CoV-2 Test) trial of Siddha treatment for patients with novel coronavirus infectious disease (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,116,http://isrctn.com/ISRCTN13311119,,,,2020-06-26,2020-06-26,0,0,,,,,,,,,,,8,,No longer recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 12:55:34,2021-01-04 12:56:49,Spam,82.33.104.78,100,74,True,2021-01-04 12:56:49,R_4OYVkaSJbdohXgd,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04361435,ClinicalTrials.gov,2020-04-12,2020-05-01,FALSE,St. Justine's Hospital,Not Recruiting,Not Applicable,Interventional,No Country Given,Lung Recruitment Device for COVID-19,Other (physio),Physio & Rehabilitation,Physio & Rehabilitation,50,https://clinicaltrials.gov/show/NCT04361435,,,2020-07-31,2020-12-31,2020-07-31,0,1,,,,,,,,,,,8,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 12:56:56,2021-01-04 12:57:23,IP Address,82.33.104.78,100,26,True,2021-01-04 12:57:24,R_1nQ118X3UnP8Wvg,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,unknown,no,Diagnostic rather than treatment or prevention,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04357327,ClinicalTrials.gov,2020-04-15,2020-04-16,FALSE,Université Libre de Bruxelles,Recruiting,Not Applicable,Interventional,Italy,Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19),Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,100,https://clinicaltrials.gov/show/NCT04357327,,,2020-05-31,2020-07-31,2020-05-31,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 13:48:12,2021-01-04 13:49:42,IP Address,82.33.104.78,100,90,True,2021-01-04 13:49:43,R_25XU4uFE9uc5oiB,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2021-01-01,2021-03-01,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04330638,ClinicalTrials.gov,2020-03-31,2020-04-01,FALSE,"University Hospital, Ghent",Recruiting,Phase 3,Interventional,Belgium,Treatment of COVID-19 Patients With Anti-interleukin Drugs,Drug,Anakinta + Siltuximab vs. Tocilizumab + Anakinra vs. Tocilizumab vs. Siltuximab vs. Anakinra,Anakinra; Siltuximab; Tocilizumab,342,https://clinicaltrials.gov/show/NCT04330638,,,2020-09-01,2020-12-01,2020-09-01,0,1,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2021-03-01
2021-01-04 13:49:49,2021-01-04 13:52:34,IP Address,82.33.104.78,100,165,True,2021-01-04 13:52:35,R_2vcxf0JfDjnlE7o,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,vitamin C AND COVID-19 AND Enqiang Mao,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000032400,ChiCTR,2020-04-27,2020-01-01,TRUE,"Ruijin Hospital, Shanghai Jiao Tong University School of Medicine",Recruiting,Not Applicable,Interventional,China,"the efficacy and safety of high dose intravenous vitamin C in the treatment of novel coronavirus pneumonia (COVID-19): a prospective, randomize, controlled trial",Drug,Vitamin C,Vitamin C,120,http://www.chictr.org.cn/showproj.aspx?proj=52958,,,,2020-06-01,2020-06-01,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 13:52:42,2021-01-04 13:53:07,IP Address,82.33.104.78,100,25,True,2021-01-04 13:53:07,R_1OZx8cXu2TzpAyt,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04351542,ClinicalTrials.gov,2020-04-14,2020-03-06,TRUE,Aarogyam UK,Not Recruiting,Not Applicable,Interventional,United Kingdom,Ayurveda for Flu Like Illness During Covid-19 Outbreak,Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,32,https://clinicaltrials.gov/show/NCT04351542,,,2020-04-06,2020-04-12,2020-04-06,0,0,,,,,,,,,,,8,,Completed,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 13:53:12,2021-01-04 13:53:27,Spam,82.33.104.78,100,14,True,2021-01-04 13:53:27,R_4Zz7dJa1trY6BEZ,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04346953,ClinicalTrials.gov,2020-04-13,2020-04-20,FALSE,Istinye University,Not Recruiting,Not Applicable,Interventional,No Country Given,Video-Based Exercise for Individuals With Social Isolation Due to Coronavirus (COVID-19),Other (exercise),Exercise,Exercise,128,https://clinicaltrials.gov/show/NCT04346953,,,2020-06-01,2020-07-31,2020-06-01,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 13:53:34,2021-01-04 13:53:59,Spam,82.33.104.78,100,25,True,2021-01-04 13:53:59,R_3HzbH1dpXtW8AMj,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04324190,ClinicalTrials.gov,2020-03-26,2020-04-08,FALSE,Gunther Meinlschmidt,Recruiting,Not Applicable,Interventional,Germany,DIgital Online SuPport for COVID-19 StrEss,Other (psych),Psychological,Psychological,600,https://clinicaltrials.gov/show/NCT04324190,,,2020-06-01,2021-12-01,2020-06-01,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 13:54:10,2021-01-04 13:58:05,IP Address,82.33.104.78,100,234,True,2021-01-04 13:58:05,R_3sty6lguPEXtWLv,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,no,2021-03-06,2021-07-06,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Piclidenoson AND COVID-19 AND Zivit Harpaz,,,,,,,,,,MPJ,2020-06-30,NCT04333472,ClinicalTrials.gov,2020-04-01,2020-04-06,FALSE,Can-Fite BioPharma,Not Recruiting,Phase 2,Interventional,Israel,Piclidenoson for Treatment of COVID-19,Drug,Piclidenoson,Piclidenoson,40,https://clinicaltrials.gov/show/NCT04333472,,,2020-06-06,2020-07-06,2020-06-06,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,2021-07-06
2021-01-04 13:58:40,2021-01-04 14:06:48,IP Address,82.33.104.78,100,487,True,2021-01-04 14:06:48,R_3Jqm3Wl39vL34lj,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,full_results_journal_article,,,,,10.1186/s13063-020-04352-9,PMC7245636,https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04352-9,,,,,,,,,,,,,2020-05-24,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Remdesivir AND COVID-19 AND Capital Medical University,,,,,,,,,,MPJ,2020-06-30,NCT04257656,ClinicalTrials.gov,2020-01-31,2020-02-06,FALSE,Capital Medical University,Not Recruiting,Phase 3,Interventional,China,A Trial of Remdesivir in Adults With Severe COVID-19,Drug,Remdesivir,Remdesivir,237,https://clinicaltrials.gov/show/NCT04257656,,,2020-03-30,2020-04-10,2020-03-30,0,1,,10.1016/S0140-6736(20)31022-9,,10.1016/S0140-6736(20)31022-9,,interim_results_journal_article,,2020-04-10,2020-04-29,,8,,Terminated,TRUE,1,32423584,interim_results_journal_article,2020-04-29,bzeqs5oh,https://doi.org/10.1016/s0140-6736(20)31022-9; https://api.elsevier.com/content/article/pii/S0140673620310229; https://www.sciencedirect.com/science/article/pii/S0140673620310229; https://www.ncbi.nlm.nih.gov/pubmed/32423584/,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",2020-04-10,,,,,,true,,
2021-01-04 14:07:23,2021-01-04 14:13:01,IP Address,82.33.104.78,100,338,True,2021-01-04 14:13:01,R_QcUnuk2RR0syBuF,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,no,2020-12-31,2020-12-31,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ciclesonide AND COVID-19 AND Joon Young Song,Ciclesonide AND inhaler AND coronavirus AND Korea University Guro Hospital,,,,,,,,,MPJ,2020-06-30,NCT04330586,ClinicalTrials.gov,2020-03-31,2020-04-01,FALSE,Korea University Guro Hospital,Not Recruiting,Phase 2,Interventional,No Country Given,A Trial of Ciclesonide in Adults With Mild COVID-19,Drug,Ciclesonide + hydroxychloroquine vs. hydroxychloroquine,Ciclesonide; hydroxychloroquine,141,https://clinicaltrials.gov/show/NCT04330586,,,2020-06-30,2020-09-30,2020-06-30,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,2020-12-31
2021-01-04 14:13:19,2021-01-04 14:18:48,IP Address,82.33.104.78,100,328,True,2021-01-04 14:18:49,R_RFzWn5eTbb6k5UJ,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,no,2020-04-05,2020-05-02,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,," 10.1101/2020.07.26.20159756 ",,https://www.medrxiv.org/content/10.1101/2020.07.26.20159756v1,,,,,,,,,,,,,2020-07-29,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bevacizumab AND COVID-19 AND Yuguo Chen,,,,,,,,,,MPJ,2020-06-30,NCT04275414,ClinicalTrials.gov,2020-02-14,2020-02-15,FALSE,Qilu Hospital of Shandong University,Recruiting,Phase 2/Phase 3,Interventional,"China, Italy",Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,Drug,Bevacizumab,Bevacizumab,20,https://clinicaltrials.gov/show/NCT04275414,,,2020-04-01,2020-05-01,2020-04-01,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2020-05-02
2021-01-04 14:18:57,2021-01-04 14:21:58,IP Address,82.33.104.78,100,181,True,2021-01-04 14:21:58,R_3KVDuKeCU8cXw4B,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,interim_result,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"chloroquine phosphate AND COVID-19 AND Jin Ronghua ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000031204,ChiCTR,2020-03-24,2020-01-30,TRUE,"Beijing You'an Hospital, Capital Medical University",Recruiting,Phase 2,Interventional,China,"A multicenter, single-blind, randomized controlled clinical trial for chloroquine phosphate in the treatment of novel coronavirus pneumonia (COVID-19)",Drug,Chloroquine,Chloroquine,300,http://www.chictr.org.cn/showproj.aspx?proj=49420,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 14:22:11,2021-01-04 14:26:39,IP Address,82.33.104.78,100,268,True,2021-01-04 14:26:39,R_1jeyK1KhiF0ZC6m,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sildenafil AND COVID-19 AND Tongji Hospital,Sildenafil citrate AND coronavirus AND Qin Ning,,,,,,,,,MPJ,2020-06-30,NCT04304313,ClinicalTrials.gov,2020-02-14,2020-02-09,TRUE,"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,Phase 3,Interventional,China,A Pilot Study of Sildenafil in COVID-19,Drug,Sildenafil,Sildenafil,10,https://clinicaltrials.gov/show/NCT04304313,,,2020-03-01,2020-11-09,2020-03-01,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 14:27:48,2021-01-04 14:32:19,IP Address,82.33.104.78,100,270,True,2021-01-04 14:32:20,R_w6Rzpuix9EO8Tcd,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,,"10.1101/2020.03.17.20037432 ",,https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v4,,,,,,,,,,,,,2020-04-15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,," Favipiravir AND COVID-19 AND Xinghuan Wang ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030254,ChiCTR,2020-02-26,2020-02-20,TRUE,Zhongnan Hospital of Wuhan University,Not Recruiting,Not Applicable,Interventional,China,"the Efficacy and Safety of Favipiravir for novel coronavirus–infected pneumonia: A multicenter, randomized, open, positive, parallel-controlled clinical study",Drug,Favipiravir vs. Umifenovir,Favipiravir; Umifenovir,240,http://www.chictr.org.cn/showproj.aspx?proj=50137,,,,2020-03-20,2020-03-20,0,0,,,,,,,,,,,8,,Completed,TRUE,1,,,,,,,,,,,,,,true,
2021-01-04 14:32:28,2021-01-04 14:35:07,IP Address,82.33.104.78,100,158,True,2021-01-04 14:35:07,R_1IsaTHZxKCUPB8Z,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"traditional Chinese medicine AND COVID-19 AND Li Xugui ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030810,ChiCTR,2020-03-15,2020-02-23,TRUE,Hubei Provincial Hospital of Integrated Chinese and Western Medicine,Recruiting,Phase 1,Interventional,China,Clinical observation and evaluation of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in Hubei 672 Orthopaedics Hospital of Integrated Chinese&Western Medicine,Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,100,http://www.chictr.org.cn/showproj.aspx?proj=50986,,,,2020-03-30,2020-03-30,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 14:35:24,2021-01-04 14:40:44,IP Address,82.33.104.78,100,319,True,2021-01-04 14:40:45,R_2DUBnUN0Ze4Ez6u,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Truncated Torsion AND COVID-19 AND Bangjiang Fang ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030836,ChiCTR,2020-03-15,2020-02-01,TRUE,Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Not Recruiting,Phase 4,Interventional,China,Novel coronavirus pneumonia (COVID-19) combined with Chinese and Western medicine based on ''Internal and External Relieving -Truncated Torsion'' strategy,Traditional Medicine + Western Medicine,Traditional Medicine,Traditional Medicine,300,http://www.chictr.org.cn/showproj.aspx?proj=51054,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 14:40:53,2021-01-04 14:44:45,IP Address,82.33.104.78,100,231,True,2021-01-04 14:44:45,R_t01ihCkINmOHwM9,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Immunoglobulin AND COVID-19 AND  Tongji Medical College,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030841,ChiCTR,2020-03-15,2020-02-17,TRUE,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,Not Applicable,Interventional,China,Exploratory study for Immunoglobulin From Cured COVID-19 Patients in the Treatment of Acute Severe novel coronavirus pneuvirus (COVID-19),ATMP,Immunoglobulin,Immunoglobulin,10,http://www.chictr.org.cn/showproj.aspx?proj=51072,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 16:17:53,2021-01-04 16:22:34,IP Address,82.33.104.78,100,280,True,2021-01-04 16:22:35,R_2qeIEgBpiesJVWm,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"external diaphragmatic pacing AND COVID-19 AND Wen Jianli ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030855,ChiCTR,2020-03-16,2020-02-01,TRUE,Third Affiliated Hospital of Zunyi Medical University,Not Recruiting,Phase 1,Interventional,No Country Given,Study for the effect of external diaphragmatic pacing assisted invasive ventilation and weaning in patients with severe novel coronavirus pneumonia (COVID-19),Other (physical),Mechanical ventilation,Mechanical ventilation,200,http://www.chictr.org.cn/showproj.aspx?proj=51090,,,,2020-05-01,2020-05-01,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 16:23:22,2021-01-04 16:26:27,IP Address,82.33.104.78,100,184,True,2021-01-04 16:26:27,R_2q96CAzXmjmCvaV,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,azvudine AND COVID-19 AND Li Suyun AND He'nan Sincere Biotechnology Co,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030487,ChiCTR,2020-03-04,2020-03-04,FALSE,The First Affiliated Hospital of He'nan University of Chinese Medicine,Recruiting,Not Applicable,Interventional,China,"A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)",Drug,Azvudine,Azvudine,10,http://www.chictr.org.cn/showproj.aspx?proj=50507,,,,2020-05-04,2020-05-04,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-04 16:27:02,2021-01-05 11:47:59,IP Address,82.33.104.78,100,69656,True,2021-01-05 11:47:59,R_2VmA8A0FxxbGXSX,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"diammonium glycyrrhizinate AND  hydrogen-rich water AND COVID-19 AND Changhai Hospital ",Wang Hao AND coronavirus AND diammonium glycyrrhizinate,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030490,ChiCTR,2020-03-04,2020-02-01,TRUE,Huo-Shen-Shan Hospital,Recruiting,Not Applicable,Interventional,No Country Given,To evaluate the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsules combined with hydrogen-rich water in the treatment of novel coronavirus pneumonia (COVID-19),Drug,Diammonium glycyrrhizinate + Hydrogen,Diammonium glycyrrhizinate; Hydrogen,100,http://www.chictr.org.cn/showproj.aspx?proj=50487,,,,2020-03-31,2020-03-31,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-05 11:50:51,2021-01-05 11:53:52,IP Address,82.33.104.78,100,180,True,2021-01-05 11:53:52,R_z8xPilDm2vLYle9,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Ebastine AND COVID-19 AND Mianyang Central Hospital ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030535,ChiCTR,2020-03-06,2020-02-20,TRUE,Wuhan Red Cross Hospital,Recruiting,Phase 4,Interventional,China,Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine,Drug,Ebastine + Interferon alpha + Lopinavir vs. Interferon alpha + Lopinavir,Ebastine; interferon alpha; lopinavir,100,http://www.chictr.org.cn/showproj.aspx?proj=49790,,,,2020-03-30,2020-03-30,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-05 11:53:58,2021-01-05 12:01:55,IP Address,82.33.104.78,100,476,True,2021-01-05 12:01:56,R_3FVBtoO5ePeTSWZ,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Hydroxychloroquine Sulfate AND Phosphate Chloroquine AND COVID-19 AND Peking University Third Hospital ","COVID-19 AND Hydroxychloroquine Sulfate AND pneumonia AND Shen Ning ",,,,,,,,,MPJ,2020-06-30,ChiCTR2000029899,ChiCTR,2020-02-16,2020-02-17,FALSE,Peking University Third Hospital,Recruiting,Phase 4,Interventional,China,"Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial",Drug,Hydroxychloroquine vs. Chloroquine,Chloroquine; Hydroxychloroquine,100,http://www.chictr.org.cn/showproj.aspx?proj=49536,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-05 12:02:16,2021-01-05 12:03:09,IP Address,82.33.104.78,100,52,True,2021-01-05 12:03:09,R_DUBghjOXJUgsC41,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030091,ChiCTR,2020-02-23,2020-02-22,TRUE,West China Hospital of Sichuan University,Not Recruiting,Not Applicable,Interventional,China,A prospective randomized controlled trial for the home exercise prescription intervention in nursing students during epidemic of novel coronary pneumonia (COVID-19),Other (exercise),Exercise,Exercise,200,http://www.chictr.org.cn/showproj.aspx?proj=49914,,,,2020-03-22,2020-03-22,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-05 12:03:17,2021-01-05 12:18:53,IP Address,82.33.104.78,100,935,True,2021-01-05 12:18:54,R_31yeAFbRwnV3cOp,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ma-Xing-Shi-Gan-Tang AND Sheng-Jiang-San AND COVID-19 AND Xiangyang Central Hospital,"traditional Chinese medicine AND COVID-19 AND children AND 	 Rui Pan ",,,,,,,,,MPJ,2020-06-30,ChiCTR2000030314,ChiCTR,2020-02-28,2020-02-28,FALSE,"Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences",Not Recruiting,Not Applicable,Interventional,No Country Given,Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San in the treatment of children with novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,40,http://www.chictr.org.cn/showproj.aspx?proj=50248,,,,2020-04-28,2020-04-28,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-05 12:19:04,2021-01-05 12:27:55,IP Address,82.33.104.78,100,531,True,2021-01-05 12:27:56,R_8Dp0TpKmCbjzGU1,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Thalidomide AND COVID-19 AND Wenzhou Medical University,Low-dose Hormones AND coronavirus AND pneumonia AND Jinglin Xia,,,,,,,,,MPJ,2020-06-30,NCT04273581,ClinicalTrials.gov,2020-02-14,2020-02-18,FALSE,The First Affiliated Hospital of Wenzhou Medical University,Not Recruiting,Phase 2,Interventional,No Country Given,The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19,Drug,Thalidomide + Corticosteroids,Thalidomide; Methylprednisolone,40,https://clinicaltrials.gov/show/NCT04273581,,,2020-04-30,2020-05-30,2020-04-30,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-05 15:05:08,2021-01-05 15:08:17,IP Address,82.33.104.78,100,188,True,2021-01-05 15:08:17,R_bNMgtS5zKqGJ2il,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ultra Short Wave Electrotherapy AND COVID-19 AND Tongji Hospital,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029972,ChiCTR,2020-02-17,2020-02-17,FALSE,"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,Not Applicable,Interventional,China,A randomized controlled trial for the Efficacy of Ultra Short Wave Electrotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19),Other (physical),Ultra short wave electrotherapy,Ultra short wave electrotherapy,40,http://www.chictr.org.cn/showproj.aspx?proj=49664,,,,2020-05-17,2020-05-17,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-05 15:08:25,2021-01-05 15:14:34,IP Address,82.33.104.78,100,368,True,2021-01-05 15:14:35,R_9RIBewve6SQ4Wnn,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,mesenchymal stem cells AND COVID-19 AND Robert Chunhua Zhao,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029990,ChiCTR,2020-02-18,2020-01-30,TRUE,"Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences",Recruiting,Phase 1/Phase 2,Interventional,China,Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19),ATMP,Cells (mesenchymal),Cells (mesenchymal),120,http://www.chictr.org.cn/showproj.aspx?proj=49674,,,,2020-03-31,2020-03-31,0,0,,10.14336/ad.2020.0228,,10.14336/ad.2020.0228,,full_results_journal_article,,,2020-03-13,,8,,Recruiting,TRUE,1,32257537,full_results_journal_article,2020-03-13,ghfrwccu,https://www.ncbi.nlm.nih.gov/pubmed/32257537/; https://doi.org/10.14336/ad.2020.0228,Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia,,,,,,,true,,
2021-01-05 15:14:41,2021-01-05 15:19:49,IP Address,82.33.104.78,100,308,True,2021-01-05 15:19:50,R_1NFAiFFW1FbD0uB,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,," fapilavir AND COVID-19 AND Zhaohui Tong ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029996,ChiCTR,2020-02-20,2020-02-20,FALSE,"Beijing Chaoyang Hospital, Capital Medical University",Recruiting,Phase 2,Interventional,China,"A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)",Drug,Favipiravir,Favipiravir,60,http://www.chictr.org.cn/showproj.aspx?proj=49510,,,,2020-04-20,2020-04-20,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-05 15:19:56,2021-01-05 15:24:51,IP Address,82.33.104.78,100,295,True,2021-01-05 15:24:52,R_30iaklhPofGxgVm,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"suramin sodium AND Zhejiang University School of Medicine AND COVID-19 ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030029,ChiCTR,2020-02-21,2020-02-20,TRUE,The First Affiliated Hospital of Zhejiang University School of Medicine,Not Recruiting,Not Applicable,Interventional,China,A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19),Drug,Suramin,Suramin,20,http://www.chictr.org.cn/showproj.aspx?proj=49824,,,,2020-05-30,2020-05-30,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-05 15:24:38,2021-01-05 15:31:18,IP Address,82.33.104.78,100,400,True,2021-01-05 15:31:19,R_25GB44gu1aLksjY,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mesenchymal Stem Cells AND COVID-19 AND 	 Chinese PLA General Hospital ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030138,ChiCTR,2020-02-24,2020-02-24,FALSE,Chinese PLA General Hospital,Not Recruiting,Phase 2,Interventional,China,Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19),ATMP,Cells (mesenchymal),Cells (mesenchymal),60,http://www.chictr.org.cn/showproj.aspx?proj=50004,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-05 15:31:26,2021-01-05 15:37:43,IP Address,82.33.104.78,100,376,True,2021-01-05 15:37:43,R_e5SkWDK9wCZvouR,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"umbilical cord AND mesenchymal stem cells AND COVID-19 AND Xue Zhigang ",,,,,,,"There is discrepancy between 'study execute time' (2020-04-17) and 'recruiting time' (2020-12-01) - which date do we include? ",team_review,,MPJ,2020-06-30,ChiCTR2000030173,ChiCTR,2020-02-24,2020-02-17,TRUE,"Hunan yuanpin Cell Biotechnology Co., Ltd",Not Recruiting,Not Applicable,Interventional,China,Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration,ATMP,Cells (mesenchymal),Cells (mesenchymal),60,http://www.chictr.org.cn/showproj.aspx?proj=49229,,,,2020-04-17,2020-04-17,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-05 15:37:52,2021-01-05 15:44:23,IP Address,82.33.104.78,100,390,True,2021-01-05 15:44:23,R_3iF6H76EY471fTE,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Immunoregulatory Therapy AND COVID-19 AND Jianfeng Xie,Thymosin AND coronavirus AND Jianfeng Xie,,,,,,,,,MPJ,2020-06-30,NCT04268537,ClinicalTrials.gov,2020-02-08,2020-02-10,FALSE,"Southeast University, China",Not Recruiting,Phase 2,Interventional,No Country Given,Immunoregulatory Therapy for 2019-nCoV,Drug,PD1 vs. thymosin,PD1; Thymosin,120,https://clinicaltrials.gov/show/NCT04268537,,,2020-04-30,2020-10-31,2020-04-30,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-05 15:45:38,2021-01-05 15:52:22,IP Address,82.33.104.78,100,404,True,2021-01-05 15:52:23,R_3Jaq0cXKMZN5ncz,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Tanreqing AND COVID-19 AND Guangzhou University of Chinese Medicine ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029432,ChiCTR,2020-02-01,2020-02-01,FALSE,The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine,Not Recruiting,Phase 4,Interventional,China,A Real World Study for the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,72,http://www.chictr.org.cn/showproj.aspx?proj=48881,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-05 15:52:34,2021-01-05 15:56:29,IP Address,82.33.104.78,100,234,True,2021-01-05 15:56:29,R_2YMwUEl3o6NFqxb,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"traditional Chinese medicine AND COVID-19 AND Chengping Wen AND Zhejiang Chinese Medical University ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029517,ChiCTR,2020-02-03,2020-02-04,FALSE,Zhejiang Chinese Medical University,Recruiting,Not Applicable,Interventional,China,"Chinese medicine prevention and treatment program for suspected novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trial",Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,100,http://www.chictr.org.cn/showproj.aspx?proj=48861,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-05 15:56:36,2021-01-05 16:03:34,IP Address,82.33.104.78,100,418,True,2021-01-05 16:03:35,R_vPIwNxdsDK1nUhr,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,," 10.1101/2020.04.29.20085761",,https://www.medrxiv.org/content/10.1101/2020.04.29.20085761v1,,,,,,,,,,,,,2020-05-05,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,,,,,full_results_journal_article,,,,,10.1016/j.ejps.2020.105631,33115675,https://www.sciencedirect.com/science/article/abs/pii/S092809872030419X?via%3Dihub,,,,,,,,,,,,,2020-10-25,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,," Baloxavir Marboxil AND  Favipiravir AND COVID-19 AND  Zhejiang University's Medical School",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029544,ChiCTR,2020-02-03,2020-02-04,FALSE,The First Affiliated Hospital of Zhejiang University School of Medicine,Not Recruiting,Not Applicable,Interventional,China,"A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy",Drug,Baloxavir + Marboxil vs. Favipiravir,Baloxavir; Marboxil; Favipiravir,30,http://www.chictr.org.cn/showproj.aspx?proj=49013,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,true,
2021-01-05 16:03:40,2021-01-05 16:08:20,IP Address,82.33.104.78,100,279,True,2021-01-05 16:08:20,R_0PxSSiAET1W3jsR,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,," ASC09/Ritonavir AND COVID-19 AND Lopinavir/Ritonavir AND Qiu Yunqing ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029603,ChiCTR,2020-02-06,2020-02-06,FALSE,The First Affiliated Hospital of Zhejiang University School of Medicine,Recruiting,Not Applicable,Interventional,China,"A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19)",Drug,ASCO9 + Ritonavir vs. Lopinavir/ritonavir,ASC09; Ritonavir; Lopinavir/ritonavir,160,http://www.chictr.org.cn/showproj.aspx?proj=49075,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,8,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-05 16:09:45,2021-01-05 16:26:12,IP Address,82.33.104.78,100,986,True,2021-01-05 16:26:14,R_2rOaZxQUBkV1X7I,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"corticosteroids AND COVID-19 AND Wuhan Pulmonary Hospital AND Ronghui Du  ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029656,ChiCTR,2020-02-09,2020-02-14,FALSE,Wuhan Pulmonary Hosptial,Not Recruiting,Not Applicable,Interventional,China,"A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19)",Drug,Corticosteroids,Methylprednisolone,100,http://www.chictr.org.cn/showproj.aspx?proj=49086,,,,2020-04-14,2020-04-14,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 11:57:14,2021-01-06 12:00:18,IP Address,77.13.188.144,100,184,True,2021-01-06 12:00:19,R_1Opk5opGkfZXW0y,,,test@test.com,,52.49920654296875,13.3141937255859375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,other,other,,,,10.1186/s13063-020-04409-9,,,10.1186/s13063-020-04795-0,,,,,,,,,,,,2020-06-01,,2020-10-01,,,,,,,,,,,,,,,,,,,,,,,protocol,statistical analysis plan,,,,"
Sivapalan P, Ulrik CS, Lappere TS, Eklöf JV, Shaker SB, Bødtger UCS, Browatzki A, Meyer CN, Weinreich UM, Laursen CB, Biering-Sørensen T, Knop FK, Lundgren JD, Jensen JS. Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan. Trials. 2020 Oct 20;21(1):867. doi: 10.1186/s13063-020-04795-0.
Sivapalan P, Ulrik CS, Bojesen RD, Lapperre TS, Eklöf JV, Håkansson KEJ, Browatzki A, Tidemansen C, Wilcke JT, Janner J, Gottlieb V, Meteran H, Porsbjerg C, Madsen BL, Moberg M, Pedersen L, Benfield TL, Lundgren JD, Knop FK, Biering-Sørensen T, Ghanizada M, Sonne TP, Bødtger UCS, Jensen SG, Rasmussen DB, Brøndum E, Tupper OD, Sørensen SW, Alstrup G, Laursen CB, Møller UW, Sverrild A, Jensen JS. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jun 10;21(1):513. doi: 10.1186/s13063-020-04409-9.
",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04322396,ClinicalTrials.gov,2020-03-23,2020-04-06,FALSE,Chronic Obstructive Pulmonary Disease Trial Network,Recruiting,Phase 2,Interventional,Denmark,Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,Drug (Chemoprophylaxis),Hydroxychloroquine + Azithromycin,Hydroxychloroquine; azithromycin,226,https://clinicaltrials.gov/show/NCT04322396,,,2020-10-31,2021-03-31,2020-10-31,0,1,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-06 12:06:04,2021-01-06 12:06:58,IP Address,77.13.188.144,100,53,True,2021-01-06 12:06:58,R_9KwpyZ5jjQHIvwB,,,test@test.com,,52.5196075439453125,13.4069061279296875,gl,EN,yes,no,,"he purpose of this study is to identify healthcare workers with SARS CoV 2 antibodies who have not been previously diagnosed and are presumed COVID-19 negative, then determine the level of immunity in this population which could inform further decisions about widespread antibody testing in a healthcare worker population.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,seroprevalence study,,,PG,2020-06-30,NCT04383587,ClinicalTrials.gov,2020-05-07,2020-05-06,TRUE,Mayo Clinic,Recruiting,Not Applicable,Interventional,United States,Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers,Clinical Presentation (Epidemiology),No Intervention,No Intervention,300,https://clinicaltrials.gov/show/NCT04383587,,,2020-05-29,2020-06-12,2020-05-29,0,0,,,,,,,,,,,8,,Enrolling by invitation,TRUE,2,,,,,,,,,,,,,,,
2021-01-06 12:07:06,2021-01-06 12:13:16,IP Address,77.13.188.144,100,370,True,2021-01-06 12:13:17,R_27mwZHm6soYt0KL,,,test@test.com,,52.5196075439453125,13.4069061279296875,gl,EN,yes,yes,no,,,no,2020-05-31,2020-05-31,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,europe_pmc,,,,full_results_journal_article,full_results_preprint,,,,10.1371/journal.pone.0242763,33264337,https://europepmc.org/article/MED/33264337,10.1101/2020.07.08.20148841,,https://europepmc.org/article/PPR/PPR185879,,,,,,,,,,2020-12-02,,2020-07-10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04384380,ClinicalTrials.gov,2020-04-07,2020-04-01,TRUE,Taoyuan General Hospital,Recruiting,Phase 4,Interventional,Taiwan,Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,Drug,Hydroxychloroquine,Hydroxychloroquine,45,https://clinicaltrials.gov/show/NCT04384380,,,2020-06-30,2020-09-30,2020-06-30,0,1,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,true,true,2020-05-31
2021-01-06 12:13:22,2021-01-06 12:14:49,IP Address,77.13.188.144,100,86,True,2021-01-06 12:14:50,R_UGA4ygc2CLNPaKd,,,test@test.com,,52.5196075439453125,13.4069061279296875,gl,EN,yes,yes,no,,,no,2021-03-30,2021-12-30,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,study not yet started,,,,,,,,,,PG,2020-06-30,NCT04365517,ClinicalTrials.gov,2020-04-14,2020-05-29,FALSE,University of Milan,Not Recruiting,Phase 3,Interventional,Italy,The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients,Drug,Sitagliptin,Sitagliptin,170,https://clinicaltrials.gov/show/NCT04365517,,,2020-06-30,2020-12-30,2020-06-30,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,2021-12-30
2021-01-06 12:15:12,2021-01-06 12:21:36,IP Address,77.13.188.144,100,384,True,2021-01-06 12:21:36,R_5cnZxQpgjcKVAmR,,,test@test.com,,52.49920654296875,13.3141937255859375,gl,EN,yes,yes,no,"tricky one, it is about an improved gas mix of oxygen/hydrogen to treat COVID ....",,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_journal_article,,,,,10.21037/jtd-2020-057,"32642277 ",http://jtd.amegroups.com/article/view/40994/html,,,,,,,,,,,,,2020-06-01,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NCT04378712 hydrogen oxigen covid," hydrogen oxigen covid",Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19),,,,,,,,PG,2020-06-30,NCT04378712,ClinicalTrials.gov,2020-04-29,2020-01-21,TRUE,Guangzhou Institute of Respiratory Disease,Not Recruiting,Not Applicable,Interventional,China,Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19),Drug,Hydrogen + Oxygen,Hydrogen; Oxygen,90,https://clinicaltrials.gov/show/NCT04378712,,,2020-03-23,2020-03-23,2020-03-23,0,0,,,,,,,,,,,8,,Completed,TRUE,2,,,,,,,,,,,,,true,,
2021-01-06 12:18:12,2021-01-06 12:23:53,IP Address,82.33.104.78,100,341,True,2021-01-06 12:23:53,R_3LYilqn4y9OanTY,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bagcilar Training and Research Hospital AND coronavirus ARDS AND Convalescent Plasma,Salih SS Sevdi AND COVID-19 AND Convalescent Immune Plasma,,,,,,,,,MPJ,2020-06-30,NCT04442958,ClinicalTrials.gov,2020-06-17,2020-05-15,TRUE,Bagcilar Training and Research Hospital,Not Recruiting,Not Applicable,Interventional,Turkey,Effectiveness of Convalescent Immune Plasma Therapy,ATMP,Plasma,Plasma,60,https://clinicaltrials.gov/show/NCT04442958,,,2020-06-15,2020-06-17,2020-06-15,0,0,,,,,,,,,,,9,,Completed,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 12:21:43,2021-01-06 12:24:18,IP Address,77.13.188.144,100,154,True,2021-01-06 12:24:18,R_2rTm5THi8bAf80L,,,test@test.com,,52.49920654296875,13.3141937255859375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19) Karolinska Institutet,Plasma From Individuals Who Have Recovered From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection as Treatment for Acute COVID-19 Disease,,,,,,,,,PG,2020-06-30,NCT04390178,ClinicalTrials.gov,2020-04-10,2020-04-10,FALSE,Joakim Dillner,Not Recruiting,Phase 1/Phase 2,Interventional,Sweden,Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19),ATMP,Plasma,Plasma,10,https://clinicaltrials.gov/show/NCT04390178,,,2020-06-01,2020-12-01,2020-06-01,0,0,,,,,,,,,,,8,,"Active, not recruiting",TRUE,2,,,,,,,,,,,,,,,
2021-01-06 12:24:03,2021-01-06 12:25:03,IP Address,82.33.104.78,100,60,True,2021-01-06 12:25:03,R_2ieYXhMrz1tS1hf,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04438837,ClinicalTrials.gov,2020-06-18,2020-06-01,TRUE,Rambam Health Care Campus,Not Recruiting,Not Applicable,Interventional,Israel,Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers,Drug (Chemoprophylaxis),Hydroxychloroquine,Hydroxychloroquine,582,https://clinicaltrials.gov/show/NCT04438837,,,2022-06-01,2022-06-01,2022-06-01,0,1,,,,,,,,,,,9,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 12:24:36,2021-01-06 12:26:16,IP Address,77.13.188.144,100,100,True,2021-01-06 12:26:17,R_Rab06KjuLr2yvLz,,,test@test.com,,52.49920654296875,13.3141937255859375,gl,EN,yes,no,,treats complication of COVID-19 (thrombosis),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Primary outcome: Total Number of Patients with Clinically Relevant Venous or Arterial Thrombotic Events in ICU [ Time Frame: Discharge from ICU or 30 days ],,,PG,2020-06-30,NCT04367831,ClinicalTrials.gov,2020-04-27,2020-05-02,FALSE,Columbia University,Recruiting,Phase 4,Interventional,United States,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19,Drug,Enoxaparin,Enoxaparin,100,https://clinicaltrials.gov/show/NCT04367831,,,2020-11-01,2021-04-01,2020-11-01,0,1,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-06 12:26:23,2021-01-06 12:27:43,IP Address,77.13.188.144,100,79,True,2021-01-06 12:27:43,R_2bH99MU5WYEnQLs,,,test@test.com,,52.49920654296875,13.3141937255859375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"protocol as preprint:  10.1101/2020.03.09.20033530  ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04306393,ClinicalTrials.gov,2020-03-10,2020-03-21,TRUE,Massachusetts General Hospital,Recruiting,Phase 2,Interventional,United States,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,Drug,Nitric oxide,Nitric oxide,200,https://clinicaltrials.gov/show/NCT04306393,EUCTR2020-001490-68,,2021-03-21,2022-03-21,2021-03-21,0,1,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-06 12:27:56,2021-01-06 12:28:54,IP Address,77.13.188.144,100,57,True,2021-01-06 12:28:54,R_3nG9owEQI8rHM2r,,,test@test.com,,52.49920654296875,13.3141937255859375,gl,EN,yes,no,,treating COVID with $,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,This is a clinical trial of a cash transfer on symptoms consistent with COVID-19 and adherence to physical distancing guidance.,,,PG,2020-06-30,NCT04359264,ClinicalTrials.gov,2020-04-16,2020-04-20,FALSE,"St. Michael's Hospital, Toronto",Not Recruiting,Not Applicable,Interventional,Canada,Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial,Other,Other,Other,392,https://clinicaltrials.gov/show/NCT04359264,,,2020-05-29,2020-06-30,2020-05-29,0,0,,,,,,,,,,,8,,"Active, not recruiting",TRUE,2,,,,,,,,,,,,,,,
2021-01-06 12:25:10,2021-01-06 12:35:04,IP Address,82.33.104.78,100,593,True,2021-01-06 12:35:05,R_bQV9tmIwiXa9Lhv,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,full_results_journal_article,,,,,10.1093/cid/ciaa1177,32785710,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1177/5891816,,,,,,,,,,,,,2020-08-12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Methylprednisolone AND COVID-19 AND Heitor Vieira Dourado,"MetCOVID AND Fundação de Medicina Tropical ",,,,,,,,,MPJ,2020-06-30,NCT04343729,ClinicalTrials.gov,2020-04-09,2020-04-18,FALSE,Fundação de Medicina Tropical Dr. Heitor Vieira Dourado,Not Recruiting,Phase 2,Interventional,Brazil,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,Drug,Corticosteroids,Methylprednisolone,425,https://clinicaltrials.gov/show/NCT04343729,,,2020-06-16,2020-09-01,2020-06-16,0,0,,,,,,,,,,,9,,"Active, not recruiting",TRUE,1,,,,,,,,,,,,,true,,
2021-01-06 12:35:30,2021-01-06 12:37:45,IP Address,82.33.104.78,100,135,True,2021-01-06 12:37:46,R_XXHg3tb8x3qz28h,,,test@test.com,,51.476898193359375,-2.55340576171875,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,ACTRN12620000500954,ANZCTR,2020-04-22,2020-05-01,FALSE,Western Health,Not Recruiting,Not Applicable,Interventional,Australia,A reusable personalised ventilation hood: A phase 1 safety study of a new device (McMonty) in patients with suspected or confirmed COVID-19.,Other (device),Hood,Hood,20,https://anzctr.org.au/ACTRN12620000500954.aspx,,,,2020-06-01,2020-06-01,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 12:35:58,2021-01-06 12:38:20,Spam,82.33.104.78,100,142,True,2021-01-06 12:38:20,R_1JX94li5eGZK2G8,,,test@test.com,,51.476898193359375,-2.55340576171875,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04425499,ClinicalTrials.gov,2020-06-08,2020-06-01,TRUE,University of Montreal,Not Recruiting,Not Applicable,Interventional,No Country Given,A Gamified Network for Surgical Education During COVID-19: A Randomized Controlled Trial,Other,Other,Other,60,https://clinicaltrials.gov/show/NCT04425499,,,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 12:38:27,2021-01-06 12:40:32,IP Address,82.33.104.78,100,125,True,2021-01-06 12:40:32,R_1Fys7MWQKFYbcgp,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,unknown,no,Is this treating Covid or an symptom resulting from Covid?,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04361474,ClinicalTrials.gov,2020-04-22,2020-05-18,TRUE,Fondation Ophtalmologique Adolphe de Rothschild,Recruiting,Phase 3,Interventional,France,Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,Drug,Corticosteroids,Budesonide,120,https://clinicaltrials.gov/show/NCT04361474,EUCTR2020-001667-85,,2020-05-18,2021-05-25,2020-05-18,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 12:40:42,2021-01-06 12:44:54,IP Address,82.33.104.78,100,251,True,2021-01-06 12:44:54,R_9ov3LfLL1Jkx0tj,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,no,2020-08-10,2020-08-21,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mycobacterium AND COVID-19 AND Anil Avhad,,,,,,,,,,MPJ,2020-06-30,NCT04347174,ClinicalTrials.gov,2020-03-31,2020-04-30,FALSE,Cadila Pharnmaceuticals,Recruiting,Not Applicable,Interventional,India,A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients,Drug,Mycobacterium,Mycobacterium,40,https://clinicaltrials.gov/show/NCT04347174,,,2020-06-30,2020-07-30,2020-06-30,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2020-08-21
2021-01-06 12:45:04,2021-01-06 12:46:16,IP Address,82.33.104.78,100,72,True,2021-01-06 12:46:16,R_3LbVa7qUqTmBxxj,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,unknown,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04367662,ClinicalTrials.gov,2020-04-16,2020-04-09,TRUE,"University Hospital, Rouen",Not Recruiting,Not Applicable,Interventional,France,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Clinical Presentation,No Intervention,No Intervention,99,https://clinicaltrials.gov/show/NCT04367662,,,2020-05-14,2020-05-14,2020-05-14,0,0,,,,,,,,,,,9,,Completed,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 12:46:23,2021-01-06 12:46:35,Spam,82.33.104.78,100,12,True,2021-01-06 12:46:35,R_1JQ2t3iw5Prp6Ha,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04335851,ClinicalTrials.gov,2020-04-02,2020-04-06,FALSE,Biruni University,Not Recruiting,Not Applicable,Interventional,Turkey,Video-Based Exercises and Well-Being During Social Isolation,Other (exercise),Exercise,Exercise,68,https://clinicaltrials.gov/show/NCT04335851,,,2020-05-15,2020-06-03,2020-05-15,0,0,,,,,,,,,,,9,,Completed,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 12:46:44,2021-01-06 12:50:29,IP Address,82.33.104.78,100,224,True,2021-01-06 12:50:30,R_2CNhqVpFvSvoO39,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,convalescent plasma AND COVID-19 AND  Pedro Kurtz,,,,,,,,,,MPJ,2020-06-30,RBR-4vm3yy,REBEC,2020-05-15,2020-04-19,TRUE,Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti,Recruiting,Not Applicable,Interventional,Brazil,Effect of convalescent plasma in patients with severe COVI-19,ATMP,Plasma,Plasma,20,http://www.ensaiosclinicos.gov.br/rg/RBR-4vm3yy/,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 12:50:40,2021-01-06 12:59:17,IP Address,82.33.104.78,100,516,True,2021-01-06 12:59:17,R_sAqZqvsbZsDMAQp,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,,"10.1101/2020.07.13.20146175 ",,https://www.medrxiv.org/content/10.1101/2020.07.13.20146175v1,,,,,,,,,,,,,2020-07-20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Qing Fei Pai Du Tang AND COVID-19 AND University of Tokyo,,,,,,,,,,MPJ,2020-06-30,JPRN-UMIN000040341,JPRN,2020-05-09,2020-05-09,FALSE,Takanawa Clinic,Not Recruiting,Not Applicable,Interventional,Japan,Immunological efficacy of Qing Fei Pai Du Tang for COVID-19,Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,15,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046023,,,,2020-05-16,2020-05-16,0,0,,,,,,,,,,,9,,No longer recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 14:02:21,2021-01-06 14:03:07,IP Address,82.33.104.78,100,45,True,2021-01-06 14:03:08,R_2B4YylG57Zym6Ww,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,no,,"Diagnostic tool for Covid-19, not treatment or prevention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,DRKS00021420,German Clinical Trials Register,2020-04-16,2020-04-01,TRUE,Technische Universität München,Recruiting,Phase 1,Interventional,Germany,Observational clinical trial for the evaluation of an automated nasal and pharyngeal swab exam to test COVID-19 patients,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,30,http://www.drks.de/DRKS00021420,,,,,,0,1,,,,,,,,,,,9,,Recruiting ongoing,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 14:03:12,2021-01-06 14:05:15,IP Address,82.33.104.78,100,122,True,2021-01-06 14:05:15,R_3qsUnvnI9MJSaB7,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,no,2020-11-02,2020-11-30,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04355936,ClinicalTrials.gov,2020-04-17,2020-05-19,FALSE,Laboratorio Elea,Recruiting,Phase 2,Interventional,Argentina,Telmisartan for Treatment of COVID-19 Patients,Drug,Telmisartan,Telmisartan,400,https://clinicaltrials.gov/show/NCT04355936,,,2020-10-01,2020-10-01,2020-10-01,0,1,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2020-11-30
2021-01-06 14:05:26,2021-01-06 14:10:35,IP Address,82.33.104.78,100,308,True,2021-01-06 14:10:36,R_2Ehpssa4dziruQZ,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pulmonary Physiotherapy AND COVID-19 AND Tehran University of Medical Sciences,Pulmonary Physiotherapy AND coronavirus AND pneumonia AND Mohammad Javaherian,,,,,,,,,MPJ,2020-06-30,NCT04357340,ClinicalTrials.gov,2020-04-13,2020-04-02,TRUE,Tehran University of Medical Sciences,Not Recruiting,Not Applicable,Interventional,Iran,The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19,Other (physio),Physio & Rehabilitation,Physio & Rehabilitation,40,https://clinicaltrials.gov/show/NCT04357340,,,2020-04-30,2020-05-30,2020-04-30,0,0,,,,,,,,,,,9,,Completed,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 14:10:41,2021-01-06 14:16:14,IP Address,82.33.104.78,100,332,True,2021-01-06 14:16:14,R_5anlrUSOnz8orIZ,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,unknown,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,ISRCTN11384058,ISRCTN,2020-05-26,2020-04-01,TRUE,Policlinico San Martino Genoa,Recruiting,Not Applicable,Interventional,Italy,"A collaborative pilot study to monitor and optimise access to urgent surgery during the period of reduced resources in Genoa, Italy caused by the COVID-19 pandemic, using a bespoke referral process and the SWALIS 2020 model to prioritise surgery by clinical urgency and waiting time",Health System,No Intervention,No Intervention,300,http://isrctn.com/ISRCTN11384058,,,,2020-06-15,2020-06-15,0,0,,,,,,,,,,,9,,No longer recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 14:16:21,2021-01-06 14:21:07,IP Address,82.33.104.78,100,285,True,2021-01-06 14:21:08,R_cZm93YLdwJA1Nrb,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,other,,,,," 10.1186/s13054-020-03288-5 ",32977854,https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03288-5,,,,,,,,,,,,,2020-09-25,,,,,,,,,,,,,,,,,,,,,,,,,Research Letter (No Results),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Favipiravir AND COVID-19 AND Jiqiu Wen ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000033491,ChiCTR,2020-06-02,2020-02-11,TRUE,Huo-Shen-Shan Hospital,Not Recruiting,Phase 4,Interventional,China,Oral Favipiravir for Patients with Delayed SARS-Cov-2 viral RNA Clearance,Drug,Favipiravir,Favipiravir,9,http://www.chictr.org.cn/showproj.aspx?proj=54278,,,,2020-05-12,2020-05-12,0,0,,,,,,,,,,,9,,Completed,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 14:21:29,2021-01-06 14:22:26,IP Address,82.33.104.78,100,57,True,2021-01-06 14:22:27,R_1F5mBFWjFZAEwUI,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04407507,ClinicalTrials.gov,2020-05-27,2020-06-01,FALSE,Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.,Not Recruiting,Phase 2,Interventional,No Country Given,"Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms",Drug,Ivermectin,Ivermectin,66,https://clinicaltrials.gov/show/NCT04407507,,,2020-08-01,2020-10-01,2020-08-01,0,1,,,,,,,,,,,9,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 14:22:32,2021-01-06 14:29:01,IP Address,82.33.104.78,100,388,True,2021-01-06 14:29:01,R_3EuIuCOWqbc63Wg,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Convalescent Plasma AND COVID-19 AND Karolinska University Hospital,"Joakim Dillner AND coronavirus AND Convalescent Plasma ",,,,,,,,,MPJ,2020-06-30,NCT04384497,ClinicalTrials.gov,2020-05-07,2020-05-07,FALSE,Joakim Dillner,Recruiting,Phase 1/Phase 2,Interventional,Sweden,Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study,ATMP,Plasma,Plasma,50,https://clinicaltrials.gov/show/NCT04384497,,,2020-06-01,2020-12-01,2020-06-01,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 14:29:06,2021-01-06 14:37:38,IP Address,82.33.104.78,100,511,True,2021-01-06 14:37:39,R_bNGuodY1grjBcS5,,,test@test.com,,51.476898193359375,-2.55340576171875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_journal_article,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hyperimmune plasma AND COVID-19 AND Cesare Perotti,,,,,,,,,,MPJ,2020-06-30,NCT04321421,ClinicalTrials.gov,2020-03-23,2020-03-17,TRUE,Foundation IRCCS San Matteo Hospital,Not Recruiting,Not Applicable,Interventional,Italy,Hyperimmune Plasma for Critical Patients With COVID-19,ATMP,Plasma,Plasma,49,https://clinicaltrials.gov/show/NCT04321421,,,2020-04-28,2020-05-07,2020-04-28,0,1,,10.1101/2020.05.26.20113373,,10.1101/2020.05.26.20113373,,full_results_preprint,,2020-04-28,2020-05-29,,9,,Completed,TRUE,1,,full_results_preprint,2020-05-29,ze4bvjkt,http://medrxiv.org/cgi/content/short/2020.05.26.20113373v1?rss=1,Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial,2020-04-28,,,,,,,true,
2021-01-06 14:37:50,2021-01-06 14:45:18,IP Address,82.33.104.78,100,447,True,2021-01-06 14:45:18,R_3mmdNrYSvQONeYM,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,summary_results,,,,,,,,,,,,,,,,,,,,2020-05-28,,,,,,,,,,,,,,,,,,,,,,,,,Document available to download on registry,,,,,,,europe_pmc,,,,,full_results_journal_article,,,,,10.1016/j.amsu.2020.06.018,,https://www.sciencedirect.com/science/article/pii/S2049080120301576?via%3Dihub,,,,,,,,,,,,,2020-06-24,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,," Convalescent Plasma AND COVID-19 AND University of Sulaimani","coronavirus AND case series AND  Convalescent Plasma AND Fahmi Hussein Kakamad ",,,,,,,,,MPJ,2020-06-30,ChiCTR2000033323,ChiCTR,2020-05-28,2020-05-11,TRUE,No Sponsor Name Given,Not Recruiting,Not Applicable,Interventional,Iraq,Severe Reluctant COVID-19 Patients Responding to Convalescent  Plasma; A case series,Drug,Plasma,Plasma,24,http://www.chictr.org.cn/showproj.aspx?proj=54346,,,,2020-05-19,2020-05-19,0,0,,,,,,,,,,,9,,Completed,TRUE,1,,,,,,,,,,,,,true,,
2021-01-06 15:12:05,2021-01-06 15:21:01,IP Address,82.33.104.78,100,535,True,2021-01-06 15:21:02,R_3GCmhjoT9NmCABn,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,google_scholar,,,,full_results_journal_article,full_results_journal_article,,,,,,https://www.biomedres.info/biomedical-research/effects-of-ivermectinazithromycincholecalciferol-combined-therapy-on-covid19-infected-patients-a-proof-of-concept-study-14435.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ivermectin-Azithromycin-Cholecalciferol AND COVID-19 AND Guadalupe Espitia Hernandez,"IvAzCol AND COVID-19 ",,,,,,,,,MPJ,2020-06-30,NCT04399746,ClinicalTrials.gov,2020-05-19,2020-03-15,TRUE,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,Recruiting,Not Applicable,Interventional,Mexico,Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19,Drug,Ivermectin + Azithromycin + Cholecalciferol,Ivermectin; Azithromycin; Cholecalciferol,30,https://clinicaltrials.gov/show/NCT04399746,,,2020-05-20,2020-06-10,2020-05-20,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 15:21:14,2021-01-06 15:24:25,IP Address,82.33.104.78,100,191,True,2021-01-06 15:24:25,R_2s4Ji972fH0yrab,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,unknown,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MPJ,2020-06-30,NCT04360837,ClinicalTrials.gov,2020-04-22,2020-05-06,FALSE,Szeged University,Recruiting,Not Applicable,Interventional,Hungary,PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,10,https://clinicaltrials.gov/show/NCT04360837,,,2021-06-01,2021-06-01,2021-06-01,0,1,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 15:24:32,2021-01-06 15:26:18,IP Address,82.33.104.78,100,106,True,2021-01-06 15:26:19,R_1IYoMEA7xtOCz8P,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,no,,Not an intervention to treat/prevent Covid-19 but to diagnose and measure rates,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04355533,ClinicalTrials.gov,2020-04-17,2020-06-01,FALSE,Assistance Publique – Hôpitaux de Paris,Not Recruiting,Not Applicable,Interventional,France,Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,1920,https://clinicaltrials.gov/show/NCT04355533,,,2020-06-01,2021-09-01,2020-06-01,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 15:26:26,2021-01-06 15:27:20,IP Address,82.33.104.78,100,53,True,2021-01-06 15:27:20,R_30qlRnuH9tr7emM,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,ACTRN12620000579998,ANZCTR,2020-05-19,2020-05-20,FALSE,Mackay Hospital and Health Service,Not Recruiting,Not Applicable,Interventional,Australia,"In a simulation environment, is there a difference in time taken for consultant anaesthetists to perform spinal anaesthesia as compared to general anaesthesia on women, with suspected or confirmed COVID-19, who require emergency caesarean delivery?",Other,No Intervention,No Intervention,10,https://anzctr.org.au/ACTRN12620000579998.aspx,,,,2020-06-01,2020-06-01,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 15:27:34,2021-01-06 15:27:52,IP Address,82.33.104.78,100,17,True,2021-01-06 15:27:53,R_3HXNbc6Q2cxLODL,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04381000,ClinicalTrials.gov,2020-05-07,2020-04-01,TRUE,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory,Recruiting,Not Applicable,Interventional,Greece,Quarantine and Telerehabilitation in Chronic Pain Patients During COVID-19 Pandemic.,Telehealth,Physio & Rehabilitation,Physio & Rehabilitation,170,https://clinicaltrials.gov/show/NCT04381000,,,2020-05-29,2020-06-10,2020-05-29,0,0,,,,,,,,,,,9,,Completed,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 15:28:00,2021-01-06 15:29:01,Spam,82.33.104.78,100,61,True,2021-01-06 15:29:01,R_2Ytdx9uaS6edOM6,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04379453,ClinicalTrials.gov,2020-04-27,2020-04-27,FALSE,Hospital Israelita Albert Einstein,Recruiting,Not Applicable,Interventional,Brazil,Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses,Procedure,Percutaneous Cardiovascular Intervention,Percutaneous Cardiovascular Intervention,10,https://clinicaltrials.gov/show/NCT04379453,,,2020-04-27,2020-04-27,2020-04-27,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 15:29:09,2021-01-06 15:33:27,IP Address,82.33.104.78,100,257,True,2021-01-06 15:33:27,R_SUESeVqqopNjHe9,,,test@test.com,,51.476898193359375,-2.55340576171875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tocilizumab AND COVID-19 AND Hadassah Medical Organization,Juli Benbenisty AND coronavirus AND pneumonia AND Tocilizumab,,,,,,,,,MPJ,2020-06-30,NCT04377750,ClinicalTrials.gov,2020-04-23,2020-04-08,TRUE,Hadassah Medical Organization,Recruiting,Phase 4,Interventional,Israel,The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,Drug,Tocilizumab,Tocilizumab,500,https://clinicaltrials.gov/show/NCT04377750,,,2020-04-29,2021-05-08,2020-04-29,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 15:33:41,2021-01-06 15:33:57,Spam,82.33.104.78,100,16,True,2021-01-06 15:33:58,R_3hgPPtMmpJrbqPC,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04372693,ClinicalTrials.gov,2020-04-27,2020-02-01,TRUE,Kasr El Aini Hospital,Recruiting,Not Applicable,Interventional,Egypt,Unplanned Shifting to Online Distance Learning: Nursing Students' Perception and Achievement,Other,Other,Other,180,https://clinicaltrials.gov/show/NCT04372693,,,2020-05-30,2020-06-30,2020-05-30,0,0,,,,,,,,,,,9,,Enrolling by invitation,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 15:34:06,2021-01-06 15:38:30,IP Address,82.33.104.78,100,264,True,2021-01-06 15:38:31,R_3Ho9vCgxfgHLE02,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,no,2020-10-15,2020-11-01,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hyperbaric Oxygen AND COVID-19 AND Amir Hadanny,HBOTCOVID19 AND Assaf-Harofeh Medical Center,,,,,,,,,MPJ,2020-06-30,NCT04358926,ClinicalTrials.gov,2020-04-21,2020-04-30,FALSE,Assaf-Harofeh Medical Center,Recruiting,Not Applicable,Interventional,Israel,Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),Drug,Oxygen,Oxygen,30,https://clinicaltrials.gov/show/NCT04358926,,,2020-06-30,2020-07-30,2020-06-30,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2020-11-01
2021-01-06 15:38:37,2021-01-06 15:39:17,IP Address,82.33.104.78,100,40,True,2021-01-06 15:39:17,R_28Gau5ry116LtWu,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04333550,ClinicalTrials.gov,2020-04-01,2020-04-01,FALSE,Kermanshah University of Medical Sciences,Recruiting,Phase 1/Phase 2,Interventional,Iran,Application of Desferal to Treat COVID-19,Drug,Deferoxamine,Deferoxamine,50,https://clinicaltrials.gov/show/NCT04333550,,,2020-09-01,2021-03-01,2020-09-01,0,1,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 15:48:13,2021-01-06 15:55:56,IP Address,82.33.104.78,100,463,True,2021-01-06 15:55:57,R_2V1maQWmrlpovwU,,,test@test.com,,51.476898193359375,-2.55340576171875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"University of Milan AND Platelet Inhibition AND COVID-19 ",Pierachille Santus AND GP IIb/IIIa Inhibitor AND coronavirus,,,,,,,,,MPJ,2020-06-30,NCT04368377,ClinicalTrials.gov,2020-04-23,2020-04-06,TRUE,University of Milan,Not Recruiting,Phase 2,Interventional,Italy,Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19,Drug,Tirofiban + Clopidogrel + Aspirin + Fondaparinux,Tirofiban; Clopidogrel; Aspirin; Fondaparinux,5,https://clinicaltrials.gov/show/NCT04368377,,,2020-04-23,2020-04-23,2020-04-23,0,0,,10.1016/j.phrs.2020.104950,,10.1016/j.phrs.2020.104950,,full_results_journal_article,,,2020-05-23,,9,,Completed,TRUE,1,32450344,full_results_journal_article,2020-05-23,qx677js6,https://www.sciencedirect.com/science/article/pii/S1043661820312585?v=s5; https://api.elsevier.com/content/article/pii/S1043661820312585; https://www.ncbi.nlm.nih.gov/pubmed/32450344/; https://doi.org/10.1016/j.phrs.2020.104950,"Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study",,,,,,,true,,
2021-01-06 15:56:03,2021-01-06 15:56:30,Spam,82.33.104.78,100,26,True,2021-01-06 15:56:30,R_sXuHFvqQeR8qgDL,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04365608,ClinicalTrials.gov,2020-04-24,2020-03-20,TRUE,Lazarski University,Recruiting,Not Applicable,Interventional,Poland,Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment,Other (physical),Mechanical ventilation,Mechanical ventilation,90,https://clinicaltrials.gov/show/NCT04365608,,,2020-05-20,2020-05-20,2020-05-20,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 16:21:39,2021-01-06 16:22:22,IP Address,77.13.188.144,100,42,True,2021-01-06 16:22:22,R_3kHdWMadC8yxxUn,,,test@test.com,,52.5196075439453125,13.4069061279296875,gl,EN,yes,no,,Primary Purpose: 	Diagnostic,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04364594,ClinicalTrials.gov,2020-04-22,2020-03-26,TRUE,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Not Recruiting,Not Applicable,Interventional,Italy,COVID-19 Search in Conjunctival Cells,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,50,https://clinicaltrials.gov/show/NCT04364594,,,2020-05-24,2020-05-30,2020-05-24,0,0,,,,,,,,,,,8,,"Active, not recruiting",TRUE,2,,,,,,,,,,,,,,,
2021-01-06 16:22:29,2021-01-06 16:23:12,IP Address,77.13.188.144,100,43,True,2021-01-06 16:23:12,R_VR2SdUj8musNwoF,,,test@test.com,,52.49920654296875,13.3141937255859375,gl,EN,yes,no,,Diagnostic Test: biological samples day of delivery,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04402918,ClinicalTrials.gov,2020-05-18,2020-05-17,TRUE,CHU de Besançon,Recruiting,Not Applicable,Interventional,France,Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 (COVID-19) During Pregnancy,Clinical Presentation,No Intervention,No Intervention,160,https://clinicaltrials.gov/show/NCT04402918,,,2020-05-19,2020-12-31,2020-05-19,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-06 16:23:19,2021-01-06 16:32:07,IP Address,77.13.188.144,100,527,True,2021-01-06 16:32:07,R_sNd1AhTZfMFlkkx,,,test@test.com,,52.5196075439453125,13.4069061279296875,gl,EN,yes,yes,no,,,no,2020-04-09,2020-06-30,1,"ISRCTN15874265 ",,,,,summary_results,,,,,,,https://clinicaltrials.gov/ct2/show/results/NCT04292899,,,,,,,,,,,,,2020-12-31,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,protocol: https://www.nejm.org/doi/suppl/10.1056/NEJMoa2015301/suppl_file/nejmoa2015301_protocol.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NCT04292899 Remdesivir preprint,,,,,,,,,,PG,2020-06-30,NCT04292899,ClinicalTrials.gov,2020-02-28,2020-03-06,TRUE,Gilead Sciences,Not Recruiting,Phase 3,Interventional,"Japan, Spain, Netherlands, South Korea, Switzerland, United States, Hong Kong, Italy, Taiwan, China, Germany, Singapore, France, Sweden, United Kingdom",Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Drug,Remdesivir,Remdesivir,6000,https://clinicaltrials.gov/show/NCT04292899,EUCTR2020-000841-15,,2020-06-01,2020-06-01,2020-06-01,0,1,,10.1056/NEJMoa2015301,,10.1056/NEJMoa2015301,,full_results_journal_article,,,2020-05-27,,8,,"Active, not recruiting",TRUE,2,32459919,full_results_journal_article,2020-05-27,,,,,,,,,,true,,2020-06-30
2021-01-06 16:32:13,2021-01-06 16:33:29,IP Address,77.13.188.144,100,75,True,2021-01-06 16:33:29,R_3oTUoTmBfVw2flr,,,test@test.com,,52.5196075439453125,13.4069061279296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"protocol: https://pubmed.ncbi.nlm.nih.gov/32586399/ ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04348513,ClinicalTrials.gov,2020-04-09,2020-05-29,FALSE,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,Recruiting,Phase 2,Interventional,Greece,Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection,Drug,Triiodothyronine,Triiodothyronine,60,https://clinicaltrials.gov/show/NCT04348513,,,2021-05-02,2021-05-31,2021-05-02,0,1,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-06 16:33:45,2021-01-06 16:35:12,IP Address,77.13.188.144,100,87,True,2021-01-06 16:35:13,R_2ymieZIpNeBImFK,,,test@test.com,,52.49920654296875,13.3141937255859375,gl,EN,yes,no,,recruitment of blood donors,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04410458,ClinicalTrials.gov,2020-05-29,2020-05-31,FALSE,Guangzhou Blood Center,Recruiting,Not Applicable,Interventional,China,Recruit Blood Donors Via SMS During Epidemic of COVID-19 (Repeat Trial),Other,Other,Other,506517,https://clinicaltrials.gov/show/NCT04410458,,,2020-05-31,2020-06-12,2020-05-31,0,0,,,,,,,,,,,8,,Enrolling by invitation,TRUE,2,,,,,,,,,,,,,,,
2021-01-06 16:35:11,2021-01-06 16:37:09,IP Address,77.13.188.144,100,118,True,2021-01-06 16:37:10,R_3qfISlOIgDZFRrZ,,,test@test.com,,52.5196075439453125,13.4069061279296875,gl,EN,yes,no,,diagnosis of a complication of COVID: thrombosis.  Via Pulmonary Optical Coherence Tomography,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04410549,ClinicalTrials.gov,2020-05-21,2020-05-27,FALSE,IRCCS Ospedale San Raffaele,Recruiting,Not Applicable,Interventional,Italy,Pulmonary Optical Coherence Tomography in COVID-19 Patients,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,10,https://clinicaltrials.gov/show/NCT04410549,,,2020-06-30,2020-06-30,2020-06-30,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-06 16:37:15,2021-01-06 16:45:13,IP Address,77.13.188.144,100,478,True,2021-01-06 16:45:14,R_3q8cYjI5oEjADLW,,,test@test.com,,52.5196075439453125,13.4069061279296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,summary_results,,,,,,,https://clinicaltrials.gov/ct2/show/results/NCT04343092,,,,,,,,,,,,,2020-11-04,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,," 10.1101/2020.07.07.20145979",,https://www.medrxiv.org/content/10.1101/2020.07.07.20145979v1,,,,,,,,,,,,,2020-07-08,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Gorial ivermectin COVID 19,,,,,,,,,,PG,2020-06-30,NCT04343092,ClinicalTrials.gov,2020-04-05,2020-04-18,FALSE,University of Baghdad,Not Recruiting,Phase 1,Interventional,Iraq,Efficacy of Ivermectin as Add on Therapy in COVID19 Patients,Drug,Ivermectin + hydroxychloroquine vs. hydroxychloroquine,Ivermectin; hydroxychloroquine,100,https://clinicaltrials.gov/show/NCT04343092,,,2020-05-31,2020-06-01,2020-05-31,0,0,,,,,,,,,,,8,,Completed,TRUE,2,,,,,,,,,,,,,,true,
2021-01-06 16:45:12,2021-01-06 16:50:43,IP Address,77.13.188.144,100,330,True,2021-01-06 16:50:43,R_1ItwpRUy3u5j0SJ,,,test@test.com,,52.5196075439453125,13.4069061279296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Chen Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,"""ASC-CTP-HS-01"" chen covid 19",,,,,,,,,PG,2020-06-30,NCT04345276,ClinicalTrials.gov,2020-04-10,2020-03-18,TRUE,Huo-Shen-Shan Hospital,Not Recruiting,Phase 4,Interventional,China,Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Drug,Danoprevir + Ritonavir,Danoprevir; Ritonavir,10,https://clinicaltrials.gov/show/NCT04345276,,,2020-04-15,2020-04-15,2020-04-15,0,0,,,,,,,,,,,8,,Completed,TRUE,2,,,,,,,,,,,,,,,
2021-01-06 16:50:52,2021-01-06 16:56:04,IP Address,77.13.188.144,100,312,True,2021-01-06 16:56:04,R_3kujunf0psgfTfa,,,test@test.com,,52.49920654296875,13.3141937255859375,gl,EN,yes,no,,this is on rehabilitation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"do we generally exclude rehab, let's discuss!",team_review,,PG,2020-06-30,NCT04385901,ClinicalTrials.gov,2020-05-06,2020-05-19,FALSE,University of Missouri-Columbia,Recruiting,Not Applicable,Interventional,United States,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Telehealth,Physio & Rehabilitation,Physio & Rehabilitation,72,https://clinicaltrials.gov/show/NCT04385901,,,2022-04-19,2022-04-19,2022-04-19,0,1,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-06 20:52:51,2021-01-06 20:54:07,IP Address,82.33.104.78,100,76,True,2021-01-06 20:54:08,R_x3nVOonfVEL6KWJ,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,no,2021-03-31,2021-04-30,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04328441,ClinicalTrials.gov,2020-03-27,2020-03-25,TRUE,UMC Utrecht,Recruiting,Phase 3,Interventional,Netherlands,Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine,ATMP,Vaccine,Vaccine,1500,https://clinicaltrials.gov/show/NCT04328441,,,2020-10-25,2020-12-25,2020-10-25,0,1,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2021-04-30
2021-01-06 20:54:13,2021-01-06 20:55:36,IP Address,82.33.104.78,100,83,True,2021-01-06 20:55:37,R_1oj8Z61L3JmdVZi,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,no,2022-04-01,2022-06-01,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04363541,ClinicalTrials.gov,2020-04-23,2020-04-01,TRUE,Instituto Nacional de Perinatología,Not Recruiting,Not Applicable,Interventional,No Country Given,Local Thermotherapy for Patients With Moderate Symptoms of COVID-19,Other (device),Heating pad,Heating pad,298,https://clinicaltrials.gov/show/NCT04363541,,,2020-09-01,2020-11-01,2020-09-01,0,1,,,,,,,,,,,9,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,2022-06-01
2021-01-06 20:55:47,2021-01-06 21:00:21,IP Address,82.33.104.78,100,273,True,2021-01-06 21:00:21,R_1pmROq2YpWuXk2J,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,no,2021-09-01,2021-11-30,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Colchicine AND COVID-19 AND Nooshin dalili,,,,,,,,,,MPJ,2020-06-30,NCT04360980,ClinicalTrials.gov,2020-04-22,2020-03-20,TRUE,Shahid Beheshti University of Medical Sciences,Recruiting,Phase 2,Interventional,Iran,The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection,Drug,Colchicine,Colchicine,80,https://clinicaltrials.gov/show/NCT04360980,,,2020-05-20,2020-05-30,2020-05-20,0,1,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2021-11-30
2021-01-06 21:01:24,2021-01-06 21:02:14,IP Address,82.33.104.78,100,49,True,2021-01-06 21:02:15,R_3p3m42z120jgvj2,,,test@test.com,,51.476898193359375,-2.55340576171875,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04359875,ClinicalTrials.gov,2020-04-18,2020-04-01,TRUE,CHU de Tours,Not Recruiting,Not Applicable,Interventional,France,A Phone-call With a Student/General Practitioner Team to Impact Morbidity of Chronic Patients During COVID-19 Containment,Telehealth,Telehealth,Telehealth,22000,https://clinicaltrials.gov/show/NCT04359875,,,2020-06-01,2020-12-01,2020-06-01,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-06 21:02:22,2021-01-07 10:48:28,IP Address,82.33.104.78,100,49566,True,2021-01-07 10:48:29,R_Ckm9iYnptZpi7xT,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Favipiravir AND COVID-19 AND Shahid Beheshti University of Medical Sciences,Mohammad Fathi AND coronavirus AND Favipiravir,,,,,,,,,MPJ,2020-06-30,NCT04359615,ClinicalTrials.gov,2020-04-18,2020-04-20,FALSE,Shahid Beheshti University of Medical Sciences,Not Recruiting,Phase 4,Interventional,Iran,Favipiravir in Hospitalized COVID-19 Patients,Drug,Favipiravir + Hydroxychloroquine vs. Hydroxychloroquine,Favipiravir; Hydroxychloroquine,40,https://clinicaltrials.gov/show/NCT04359615,,,2020-05-03,2020-05-05,2020-05-03,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-07 11:49:10,2021-01-07 13:03:43,IP Address,78.55.227.26,100,4473,True,2021-01-07 13:03:43,R_ZfVelzC1GY2pTMt,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,no,,"Primary outcome
Elevation of proper hygiene behaviour (behavioural change)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NL8483,Netherlands Trial Register,2020-03-26,2020-03-16,TRUE,Fred Foundation; Noaber Foundation,Recruiting,Not Applicable,Interventional,Netherlands,A weapon against COVID-19: (Social) media and influencers,Other,Other,Other,17000,https://trialregister.nl/trial/8483,,,,2020-03-29,2020-03-29,0,0,,,,,,,,,,,8,,Open for patient inclusion,TRUE,2,,,,,,,,,,,,,,,
2021-01-07 13:03:50,2021-01-07 13:05:41,IP Address,78.55.227.26,100,110,True,2021-01-07 13:05:41,R_3oXhxp0LWu3yfca,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,no,2020-12-30,2021-03-31,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04442178,ClinicalTrials.gov,2020-06-19,2020-06-30,FALSE,Revimmune,Not Recruiting,Phase 2,Interventional,No Country Given,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ),Drug,Interleukin-7,Interleukin-7,48,https://clinicaltrials.gov/show/NCT04442178,,,2020-11-30,2020-12-31,2020-11-30,0,1,,,,,,,,,,,8,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,2021-03-31
2021-01-07 13:05:47,2021-01-07 13:13:36,IP Address,78.55.227.26,100,469,True,2021-01-07 13:13:37,R_Q5nDAJDiLTGdDrP,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,no,2020-06-16,2020-07-09,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,,"10.1101/2020.11.02.20224303 ",,https://www.medrxiv.org/content/10.1101/2020.11.02.20224303v1.full-text,,,,,,,,,,,,,2020-11-04,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Convalescent Plasma Trial in COVID-19 Patients bahrain ",,,,,,,,,,PG,2020-06-30,NCT04356534,ClinicalTrials.gov,2020-04-15,2020-04-19,FALSE,Royal College of Surgeons in Ireland - Medical University of Bahrain,Recruiting,Not Applicable,Interventional,Bahrain,Convalescent Plasma Trial in COVID -19 Patients,ATMP,Plasma,Plasma,40,https://clinicaltrials.gov/show/NCT04356534,,,2020-06-30,2020-06-30,2020-06-30,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,true,2020-07-09
2021-01-07 13:13:44,2021-01-07 13:23:07,IP Address,78.55.227.26,100,563,True,2021-01-07 13:23:08,R_74dGXMAACkXwkH7,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,,,,,,10.1101/2020.10.25.20219337,,https://www.medrxiv.org/content/10.1101/2020.10.25.20219337v1,,,,,,,,,,,,,2020-10-27,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ILBS-COVID-02 covid 19,NCT04346446 Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,,,,,,,,,PG,2020-06-30,NCT04346446,ClinicalTrials.gov,2020-04-14,2020-04-20,FALSE,"Institute of Liver and Biliary Sciences, India",Not Recruiting,Phase 2,Interventional,India,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,ATMP,Plasma,Plasma,29,https://clinicaltrials.gov/show/NCT04346446,,,2020-05-30,2020-05-30,2020-05-30,0,0,,,,,,,,,,,8,,Completed,TRUE,2,,,,,,,,,,,,,,,
2021-01-07 13:23:14,2021-01-07 13:24:46,IP Address,78.55.227.26,100,92,True,2021-01-07 13:24:47,R_qXeid9JgFcDVhfz,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,no,2021-09-28,2021-09-28,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,still ongoing,,,,,,,,,,PG,2020-06-30,NCT04380961,ClinicalTrials.gov,2020-05-07,2020-04-24,TRUE,Janssen Pharmaceutical,Recruiting,Phase 2,Interventional,United States,A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19,Drug,Sirukumab,Sirukumab,270,https://clinicaltrials.gov/show/NCT04380961,,,2020-06-25,2020-09-16,2020-06-25,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2021-09-28
2021-01-07 13:24:52,2021-01-07 13:25:56,IP Address,78.55.227.26,100,63,True,2021-01-07 13:25:56,R_PZmVRqynIkzuOTn,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,no,,rationale of the current study is to evaluate whether Digital Cardiac Counseling (DCC) would improve outcomes of the patients waiting for an elective cardiac operation.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,not on COVID but delayed surgery for cardiac patients,,,PG,2020-06-30,NCT04393636,ClinicalTrials.gov,2020-05-11,2020-06-05,FALSE,Academic Hospital Maastricht,Recruiting,Not Applicable,Interventional,Netherlands,Digital Cardiac Counseling Trial: DCC Trial,Other (software),eHealth,eHealth,394,https://clinicaltrials.gov/show/NCT04393636,,,2022-12-31,2022-12-31,2022-12-31,0,1,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-07 13:26:03,2021-01-07 13:29:01,IP Address,78.55.227.26,100,177,True,2021-01-07 13:29:01,R_3qJpLFTBoPuw6RZ,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection sanford health,,,,,,,"Weird trial, says actual recruitment 1 and not recruiting at the moment....probably never happened/will never happen",,,PG,2020-06-30,NCT04372017,ClinicalTrials.gov,2020-04-25,2020-05-14,FALSE,Sanford Health,Not Recruiting,Phase 3,Interventional,United States,Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection,Drug (Chemoprophylaxis),Hydroxychloroquine,Hydroxychloroquine,1,https://clinicaltrials.gov/show/NCT04372017,,,2020-06-04,2021-06-04,2020-06-04,0,0,,,,,,,,,,,8,,"Active, not recruiting",TRUE,2,,,,,,,,,,,,,,,
2021-01-07 13:29:08,2021-01-07 13:30:02,IP Address,78.55.227.26,100,54,True,2021-01-07 13:30:03,R_b8Ct3zdoTdzkJW1,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,no,,Primary Purpose: 	Supportive Care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04346420,ClinicalTrials.gov,2020-04-08,2020-04-09,FALSE,"University Clinic, UCLouvain",Not Recruiting,Not Applicable,Interventional,Belgium,Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19,Other (device),Masks,Masks,12,https://clinicaltrials.gov/show/NCT04346420,,,2020-05-01,2020-05-01,2020-05-01,0,0,,,,,,,,,,,8,,Completed,TRUE,2,,,,,,,,,,,,,,,
2021-01-07 13:30:08,2021-01-07 13:30:45,IP Address,78.55.227.26,100,36,True,2021-01-07 13:30:45,R_1mO87yICAJjLy0n,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,no,,Primary Purpose: 	Supportive Care,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The objective of The Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Trial is to evaluate a videoconference-based intervention designed to improve symptoms of anxiety and other mental health outcomes among individuals with systemic sclerosis at risk of poor mental health during the COVID-19 pandemic.,,,PG,2020-06-30,NCT04335279,ClinicalTrials.gov,2020-04-01,2020-04-09,FALSE,Lady Davis Institute,Recruiting,Not Applicable,Interventional,Canada,Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program,Other (psych),Psychological,Psychological,195,https://clinicaltrials.gov/show/NCT04335279,,,2020-06-03,2020-07-24,2020-06-03,0,0,,,,,,,,,,,8,,"Active, not recruiting",TRUE,2,,,,,,,,,,,,,,,
2021-01-07 13:30:50,2021-01-07 13:31:28,IP Address,78.55.227.26,100,37,True,2021-01-07 13:31:28,R_3Jl8ztfvIXNXeqt,,,test@test.com,,52.5352935791015625,13.4459075927734375,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"seroprevalence study ",,,PG,2020-06-30,NCT04416308,ClinicalTrials.gov,2020-05-27,2020-05-29,FALSE,Rennes University Hospital,Recruiting,Not Applicable,Interventional,France,COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB),Clinical Presentation (Epidemiology),No Intervention,No Intervention,13000,https://clinicaltrials.gov/show/NCT04416308,,,2020-06-15,2020-11-10,2020-06-15,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-07 13:31:34,2021-01-07 13:32:46,IP Address,78.55.227.26,100,72,True,2021-01-07 13:32:46,R_3MtcgFoXkpD13YW,,,test@test.com,,52.520294189453125,13.3849029541015625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04411446,ClinicalTrials.gov,2020-05-26,2020-06-15,FALSE,Vitamin D Study Group,Not Recruiting,Phase 4,Interventional,Argentina,Cholecalciferol to Improve the Outcomes of COVID-19 Patients,Drug,Vitamin D,Vitamin D,1265,https://clinicaltrials.gov/show/NCT04411446,,,2020-12-15,2020-12-28,2020-12-15,0,1,,,,,,,,,,,8,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-07 10:48:36,2021-01-07 14:31:27,IP Address,82.33.104.78,100,13371,True,2021-01-07 14:31:27,R_03dwROUoUec5DRD,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,," PEEP AND COVID-19 AND Zhongda hospital"," PEEP AND coronavirus AND ARDS AND Chun C Pan	",,,,,,,,,MPJ,2020-06-30,NCT04359251,ClinicalTrials.gov,2020-04-13,2020-03-05,TRUE,"Southeast University, China",Not Recruiting,Not Applicable,Interventional,China,Different PEEP Settings of COVID-19 Induced ARDS,Other (physical),Mechanical ventilation,Mechanical ventilation,20,https://clinicaltrials.gov/show/NCT04359251,,,2020-03-25,2020-03-25,2020-03-25,0,0,,,,,,,,,,,9,,Completed,TRUE,1,,,,,,,,,,,,,,,
2021-01-07 11:55:44,2021-01-07 14:37:57,IP Address,82.33.104.78,100,9733,True,2021-01-07 14:37:58,R_2z5RvIG6wOVayj0,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,no,2020-10-13,2020-10-13,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,AVoCaDO AND trial AND coronavirus,Intravenous Vitamin C AND COVID-19 AND Brian C. Davis,,,,,,,,,MPJ,2020-06-30,NCT04357782,ClinicalTrials.gov,2020-04-17,2020-04-16,TRUE,Veteran Affairs Medical Center,Recruiting,Phase 1/Phase 2,Interventional,United States,Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation,Drug,Vitamin C,Vitamin C,20,https://clinicaltrials.gov/show/NCT04357782,,,2020-06-01,2020-08-01,2020-06-01,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2020-10-13
2021-01-07 14:38:35,2021-01-07 14:41:00,IP Address,82.33.104.78,100,144,True,2021-01-07 14:41:01,R_1H5d30fbMKv6dy1,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04341493,ClinicalTrials.gov,2020-04-07,2020-04-06,TRUE,Hugo Mendieta Zeron,Recruiting,Phase 4,Interventional,Mexico,Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19,Drug,Hydroxychloroquine vs. Nitazoxanide,Hydroxychloroquine; nitazoxanide,86,https://clinicaltrials.gov/show/NCT04341493,,,2020-08-30,2020-12-30,2020-08-30,0,1,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-07 14:41:07,2021-01-07 14:45:14,IP Address,82.33.104.78,100,246,True,2021-01-07 14:45:15,R_1Luv6rq30qHOPoL,,,test@test.com,,51.476898193359375,-2.55340576171875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hydroxychloroquine AND COVID-19 AND Ambulatory Patients AND University of Chicago,,,,,,,,,,MPJ,2020-06-30,NCT04351620,ClinicalTrials.gov,2020-04-14,2020-04-01,TRUE,University of Chicago,Recruiting,Phase 1,Interventional,United States,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,Drug,Hydroxychloroquine,Hydroxychloroquine,20,https://clinicaltrials.gov/show/NCT04351620,,,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-07 14:57:20,2021-01-07 17:10:11,IP Address,82.33.104.78,100,7970,True,2021-01-07 17:10:12,R_9NdujHdPfAcuRxf,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Seyed Sina Naghibi Irvani AND COVID-19 AND Interferon Beta 1a ","Shahid Beheshti University of Medical Sciences AND coronavirus AND Interferon Beta 1a ",,,,,,,,,MPJ,2020-06-30,NCT04350671,ClinicalTrials.gov,2020-04-14,2020-04-15,FALSE,Shahid Beheshti University of Medical Sciences,Recruiting,Phase 4,Interventional,Iran,Interferon Beta 1a in Hospitalized COVID-19 Patients,Drug,Interferon beta + Lopinavir/Ritonavir + Hydroxychlroquine vs. Lopinavir/Ritonavir + Hydroxychloroquine,Interferon beta; Lopinavir/Ritonavir; Hydroxychloroquine,40,https://clinicaltrials.gov/show/NCT04350671,,,2020-04-20,2020-04-24,2020-04-20,0,0,,,,,,,,,,,9,,Enrolling by invitation,TRUE,1,,,,,,,,,,,,,,,
2021-01-07 17:10:33,2021-01-07 17:10:51,IP Address,82.33.104.78,100,18,True,2021-01-07 17:10:52,R_2ScLKhW1nBBIDHO,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04320953,ClinicalTrials.gov,2020-03-21,2020-03-16,TRUE,Changhai Hospital,Not Recruiting,Not Applicable,Interventional,China,Non-contact Endoscopy at Covid-19 Outbreak,Other (device),Non-contact Endoscopy,Non-contact Endoscopy,5,https://clinicaltrials.gov/show/NCT04320953,,,2020-03-26,2020-04-09,2020-03-26,0,0,,,,,,,,,,,9,,Completed,TRUE,1,,,,,,,,,,,,,,,
2021-01-07 17:11:02,2021-01-07 17:20:10,IP Address,82.33.104.78,100,547,True,2021-01-07 17:20:11,R_2rH0fHDPA6bzIdd,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The University of Hong Kong AND coronavirus AND Lopinavir/ Ritonavir,Ivan FN Hung AND COVID-19 AND Lopinavir/ Ritonavir,,,,,,,,,MPJ,2020-06-30,NCT04276688,ClinicalTrials.gov,2020-02-11,2020-02-10,TRUE,University of Hong Kong,Not Recruiting,Phase 2,Interventional,Hong Kong,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment",Drug,Lopinavir/ritonavir + Ribavirin + Interferon beta,Lopinavir/ritonavir; Ribavirin; Interferon beta,127,https://clinicaltrials.gov/show/NCT04276688,,,2020-03-30,2020-03-31,2020-03-30,0,1,,10.1016/S0140-6736(20)31042-4,,10.1016/S0140-6736(20)31042-4,,full_results_journal_article,,,2020-05-08,,9,,Completed,TRUE,1,32401715,full_results_journal_article,2020-05-08,8ljnxihr,https://www.sciencedirect.com/science/article/pii/S0140673620310424; https://doi.org/10.1016/s0140-6736(20)31042-4; https://api.elsevier.com/content/article/pii/S0140673620310424; https://www.ncbi.nlm.nih.gov/pubmed/32401715/,"Triple combination of interferon beta-1b, lopinavir‚Äìritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial",,,,,,,true,,
2021-01-07 17:20:21,2021-01-07 17:25:37,IP Address,82.33.104.78,100,316,True,2021-01-07 17:25:38,R_3iJdNI3r3Z0RqDD,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,yes,,NA,NA,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,,,,,full_results_journal_article,,,,," 10.1128/AAC.01061-20",32661006,https://aac.asm.org/content/64/9/e01061-20,,,,,,,,,,,,,2020-08-20,,,,,,,,,,,,,,,,,,,,,,,,,"The automatic result does note that the results are now published here ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,IRCT20100228003449N28,IRCT,2020-03-19,2020-03-15,TRUE,Tehran University of Medical Sciences,Not Recruiting,Phase 2/Phase 3,Interventional,Iran,Interferon in treatment of COVID-19,Drug,Interferon beta vs. hydroxychloroquine + oseltamivir + Lopinavir/ritonavir,Interferon beta; hydroxychloroquine; oseltamivir; lopinavir/ritonavir,30,http://en.irct.ir/trial/46538,,,,,,0,0,,10.1101/2020.05.28.20116467,,10.1101/2020.05.28.20116467,,full_results_preprint,,2020-05-03,2020-05-30,,9,,Recruitment complete,TRUE,1,,full_results_preprint,2020-05-30,ipvog4m8,http://medrxiv.org/cgi/content/short/2020.05.28.20116467v1?rss=1,Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial,2020-05-03,,,,,,true,true,
2021-01-07 17:25:47,2021-01-07 17:31:09,IP Address,82.33.104.78,100,321,True,2021-01-07 17:31:09,R_3MrQP9sIJtx05PB,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,other,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Hyperbaric Oxygen Therapy AND COVID-19 AND Shuyi Pan ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000032011,ChiCTR,2020-04-17,2020-04-17,FALSE,The Sixth Medical Center of PLA General Hospital,Not Recruiting,Not Applicable,Interventional,China,Effecacy and Safety of Hyperbaric Oxygen Therapy to patients with novel coronavirus pneumonia (COVID-19),Drug,Oxygen,Oxygen,45,http://www.chictr.org.cn/showproj.aspx?proj=52142,,,,2020-05-17,2020-05-17,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-07 17:31:23,2021-01-07 17:35:37,IP Address,82.33.104.78,100,253,True,2021-01-07 17:35:37,R_1eRj7fkRg6mS6pF,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Methylprednisolone AND COVID-19 AND Xavier Solanich,TACROVID AND Hospital Universitari de Bellvitge,,,,,,,,,MPJ,2020-06-30,NCT04341038,ClinicalTrials.gov,2020-04-07,2020-04-01,FALSE,Hospital Universitari de Bellvitge,Recruiting,Phase 3,Interventional,Spain,Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury,Drug,Tacrolimus + Corticosteroids,Tacrolimus; Methylprednisolone,84,https://clinicaltrials.gov/show/NCT04341038,EUCTR2020-001445-39,,2020-06-01,2020-07-01,2020-06-01,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-07 17:35:45,2021-01-07 17:42:25,IP Address,82.33.104.78,100,400,True,2021-01-07 17:42:26,R_2xWxozN59TI0fX5,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mesenchymal Stem Cells AND COVID-19 AND Wuhan University of Science and Technology,,,,,,,,,,MPJ,2020-06-30,NCT04339660,ClinicalTrials.gov,2020-04-02,2020-02-01,TRUE,Puren Hospital Affiliated to Wuhan University of Science and Technology,Recruiting,Phase 1/Phase 2,Interventional,China,Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia,ATMP,Cells (mesenchymal),Cells (mesenchymal),30,https://clinicaltrials.gov/show/NCT04339660,,,2020-06-30,2020-06-30,2020-06-30,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-07 17:49:02,2021-01-08 11:08:22,IP Address,82.33.104.78,100,62359,True,2021-01-08 11:08:23,R_32LqGwlHGgTsDzW,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,full_results_journal_article,,,,,10.1016/j.biopha.2020.110825,33378989,https://www.sciencedirect.com/science/article/pii/S0753332220310180?via%3Dihub,,,,,,,,,,,,,2020-09-30,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Favipiravir AND Tocilizumab AND COVID-19 AND Peking University First Hospital,,,,,,,,,,MPJ,2020-06-30,NCT04310228,ClinicalTrials.gov,2020-03-09,2020-03-08,FALSE,Peking University First Hospital,Recruiting,Not Applicable,Interventional,China,Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,Drug,Favipiravir + tocilizumab vs. favipiravir vs. tocilizumab,Favipiravir; tocilizumab,150,https://clinicaltrials.gov/show/NCT04310228,ChiCTR2000030894,,2020-05-01,2020-05-01,2020-05-01,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,true,,
2021-01-08 11:08:32,2021-01-08 11:15:45,IP Address,82.33.104.78,100,432,True,2021-01-08 11:15:45,R_2P6iiE6HHWA3BWo,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,google_scholar,,,,full_results_preprint,full_results_journal_article,,,,"10.1101/2020.03.22.20034041 ",,https://www.medrxiv.org/content/10.1101/2020.03.22.20034041v1,10.1097/MD.0000000000023357,33235105,https://journals.lww.com/md-journal/Fulltext/2020/11250/First_clinical_study_using_HCV_protease_inhibitor.53.aspx,,,,,,,,,,2020-03-24,,2020-11-25,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04291729,ClinicalTrials.gov,2020-02-27,2020-02-17,TRUE,The Ninth Hospital of Nanchang,Not Recruiting,Phase 4,Interventional,China,Evaluation of Ganovo (Danoprevir ) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Drug,Danoprevir + Ritonavir (w/ or w/o Interferon),Danoprevir; Ritonavir; Interferon,11,https://clinicaltrials.gov/show/NCT04291729,,,2020-03-19,2020-03-19,2020-03-19,0,0,,,,,,,,,,,9,,Completed,TRUE,1,,,,,,,,,,,,,true,true,
2021-01-08 11:15:55,2021-01-08 11:19:15,IP Address,82.33.104.78,100,200,True,2021-01-08 11:19:16,R_1N8N8TllN4Nafsu,,,test@test.com,,51.476898193359375,-2.55340576171875,gl,EN,yes,yes,no,,,no,2021-03-27,2021-03-27,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,bidirectional oxygenation mouthpiece AND COVID-19 AND Jeffrey Miller,,,,,,,,,,MPJ,2020-06-30,NCT04326452,ClinicalTrials.gov,2020-03-25,2020-03-27,FALSE,TMC HealthCare,Recruiting,Not Applicable,Interventional,United States,Treating COVID-19 With a Bidirectional Oxygenation Valve,Other (device),Bidirectional Oxygenation Valve,Bidirectional Oxygenation Valve,15,https://clinicaltrials.gov/show/NCT04326452,,,2020-05-01,2020-06-01,2020-05-01,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,2021-03-27
2021-01-08 11:20:13,2021-01-08 11:23:22,IP Address,82.33.104.78,100,188,True,2021-01-08 11:23:22,R_urnZ3TYWq9aMU0h,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Lei Genping AND COVID-19 AND traditional Chinese medicine,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030923,ChiCTR,2020-03-17,2020-02-15,TRUE,Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine,Recruiting,Not Applicable,Interventional,China,The treatment and diagnosis plan of integrated traditional Chinese and Western medicine for novel coronavirus pneumonia (COVID-19),Traditional Medicine + Western Medicine,Traditional Medicine,Traditional Medicine,400,http://www.chictr.org.cn/showproj.aspx?proj=51139,,,,2020-04-16,2020-04-16,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-08 11:23:30,2021-01-08 11:27:59,IP Address,82.33.104.78,100,268,True,2021-01-08 11:27:59,R_putBGDUyxZ6Kx1v,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Xinguan AND COVID-19 AND Chengdu University,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030936,ChiCTR,2020-03-18,2020-03-10,TRUE,Hospital of Chengdu University of Traditional Chinese Medicine,Recruiting,Not Applicable,Interventional,China,A real-world study for the Chinese medicines ''Xinguan 2'' and ''Xinguan 3'' in the treatment of novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,2840,http://www.chictr.org.cn/showproj.aspx?proj=51100,,,,2020-05-10,2020-05-10,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-08 11:28:10,2021-01-08 11:44:13,IP Address,82.33.104.78,100,963,True,2021-01-08 11:44:14,R_1jE8ppGgjThqra1,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Hua-Shi Bai-Du AND COVID-19 AND Guangdong Provincial Hospital of Chinese Medicine ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030988,ChiCTR,2020-03-20,2020-03-23,FALSE,Guangdong Provincial Hospital of Chinese Medicine,Not Recruiting,Not Applicable,Interventional,China,A RCT for Hua-Shi Bai-Du granules in patients with novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,204,http://www.chictr.org.cn/showproj.aspx?proj=51317,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-08 11:44:19,2021-01-08 11:46:57,IP Address,82.33.104.78,100,158,True,2021-01-08 11:46:58,R_1E5NlhyFM04yRi0,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,no,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,EUCTR2020-000890-25-FR,EU Clinical Trials Register,2020-03-10,2020-03-05,TRUE,Fondation Méditerranée Infection (FMI) - IHU Méditerranée Infection,Authorised,Phase 3,Interventional,France,Hydroxychloroquine as a treatment for coronavirus disease COVID-19,Drug,Hydroxychloroquine,Hydroxychloroquine,25,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000890-25,,,,,,,,,10.1101/2020.03.16.20037135,,10.1101/2020.03.16.20037135,10.1016/j.ijantimicag.2020.105949,full_results_preprint,full_results_journal_article,,2020-03-20,2020-03-20,9,,,TRUE,1,,full_results_preprint,2020-03-20,tdlcb9bf,https://doi.org/10.1101/2020.03.16.20037135,Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial,,,32205204,full_results_journal_article,2020-03-20,,true,true,
2021-01-08 11:47:08,2021-01-08 11:54:38,IP Address,82.33.104.78,100,450,True,2021-01-08 11:54:39,R_UmRjaPamRBc0Bix,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Lopinavir AND Ritonavir AND COVID-19 AND Wei Xiao ","Lopinavir AND Ritonavir AND coronavirus AND Jingzhou First People's Hospital ",,,,,,,,,MPJ,2020-06-30,ChiCTR2000030187,ChiCTR,2020-02-24,2020-02-25,FALSE,Jingzhou First People's Hospital,Recruiting,Not Applicable,Interventional,China,Clinical study for Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19),Drug,Lopinavir/ritonavir,lopinavir/ritonavir,60,http://www.chictr.org.cn/showproj.aspx?proj=50057,,,,2020-03-25,2020-03-25,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-08 11:54:52,2021-01-08 12:03:49,IP Address,82.33.104.78,100,536,True,2021-01-08 12:03:50,R_2DRLE5vnSaVbpCv,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"tozumab AND adamumab AND COVID-19 AND Shanghai General Hospital ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030580,ChiCTR,2020-03-08,2020-02-01,TRUE,Shanghai General Hospital,Recruiting,Phase 4,Interventional,China,Efficacy and safety of tozumab combined with adamumab(Qletli) in severe and critical patients with novel coronavirus pneumonia (COVID-19),Drug,Adamumab,Adamumab,60,http://www.chictr.org.cn/showproj.aspx?proj=50693,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-08 12:04:45,2021-01-08 12:13:24,IP Address,82.33.104.78,100,518,True,2021-01-08 12:13:24,R_2rPzzWw6TDC86qp,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"renal replacement therapy AND COVID-19 AND Shanghai Jiaotong University ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030761,ChiCTR,2020-03-13,2020-05-31,FALSE,"Renji Hospital, Shanghai Jiaotong University School of Medicine",Not Recruiting,Not Applicable,Interventional,China,Continuous renal replacement therapy (CRRT) alleviating inflammatory response in severe patients with novel coronavirus pneumonia (COVID-19) associated with renal injury: A Prospective study,Other (renal),Renal replacement therapy,Renal replacement therapy,20,http://www.chictr.org.cn/showproj.aspx?proj=50956,,,,2020-04-01,2020-04-01,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-08 12:13:30,2021-01-08 12:21:13,IP Address,82.33.104.78,100,463,True,2021-01-08 12:21:14,R_p4PtjlgTPtn2JvX,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Chengdu University AND COVID-19 AND integrated AND traditional Chinese medicine ","coronavirus AND pneumonia AND traditional Chinese medicine AND Xie Chunguang ",,,,,,,,,MPJ,2020-06-30,ChiCTR2000029549,ChiCTR,2020-02-04,2020-02-03,TRUE,Hospital of Chengdu University of Traditional Chinese Medicine,Recruiting,Not Applicable,Interventional,China,Recommendations of Integrated Traditional Chinese and Western Medicine for Novel Coronavirus Pneumonia (COVID-19),Traditional Medicine + Western Medicine,Traditional Medicine,Traditional Medicine,400,http://www.chictr.org.cn/showproj.aspx?proj=49014,,,,2020-05-01,2020-05-01,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-08 12:21:20,2021-01-08 12:22:28,IP Address,82.33.104.78,100,67,True,2021-01-08 12:22:28,R_stj7hSvlc95GEXD,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029757,ChiCTR,2020-02-12,2020-02-14,FALSE,China-Japan Friendship Hospital,Recruiting,Not Applicable,Interventional,China,Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial,ATMP,Plasma,Plasma,200,http://www.chictr.org.cn/showproj.aspx?proj=49081,,,,2021-02-05,2021-02-05,0,0,,10.1001/jama.2020.10044,,10.1001/jama.2020.10044,,full_results_journal_article,,2020-04-28,2020-06-03,,9,,Recruiting,TRUE,1,32492084,full_results_journal_article,2020-06-03,,,,2020-04-28,,,,,,,,
2021-01-08 12:22:43,2021-01-08 12:26:33,IP Address,82.33.104.78,100,230,True,2021-01-08 12:26:33,R_3FXSgs6Nk9sleIl,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ganovo AND ritonavir AND COVID-19 AND 	 Shenyang Sixth People's Hospital,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030472,ChiCTR,2020-03-03,2020-02-25,TRUE,Shenyang Sixth People's Hospital,Recruiting,Not Applicable,Interventional,China,An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19),Traditional Medicine + Western Medicine,Traditional Medicine,Traditional Medicine,20,http://www.chictr.org.cn/showproj.aspx?proj=49753,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-08 12:28:13,2021-01-08 12:32:19,IP Address,82.33.104.78,100,245,True,2021-01-08 12:32:20,R_WxqG6H2NQCcQVvH,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Zedoary Turmeric Oil AND COVID-19 AND Wenzhou Medical University ","coronavirus AND turmeric AND injection AND Yuanrong Dai ",,,,,,,,,MPJ,2020-06-30,ChiCTR2000030518,ChiCTR,2020-03-05,2020-02-29,TRUE,The Second Affiliated Hospital of Wenzhou Medical University,Recruiting,Not Applicable,Interventional,China,"Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia (COVID-19): a randomized, open, controlled trial",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,60,http://www.chictr.org.cn/showproj.aspx?proj=50586,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-08 12:33:48,2021-01-08 12:38:47,IP Address,82.33.104.78,100,299,True,2021-01-08 12:38:48,R_22AeychUJALhjgp,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"renal replacement therapy AND COVID-19 AND Tongji Hospital ",,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030540,ChiCTR,2020-03-06,2020-03-08,FALSE,"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology",Not Recruiting,Not Applicable,Interventional,China,Research for the mechanism of improvement of novel coronavirus pneumonia (COVID-19) patients' pulmonary exudation by continuous renal replacement therapy,Other (renal),Renal replacement therapy,Renal replacement therapy,152,http://www.chictr.org.cn/showproj.aspx?proj=50658,,,,2020-06-08,2020-06-08,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-07 19:53:25,2021-01-08 12:47:30,IP Address,82.33.104.78,100,60845,True,2021-01-08 12:47:32,R_3HoSO18B4Q0s5mu,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Pirfenidone AND COVID-19 AND Tongji Hospital,Huilan Zhang AND coronavirus AND Pirfenidone,,,,,,,,,MPJ,2020-06-30,NCT04282902,ClinicalTrials.gov,2020-02-10,2020-02-04,TRUE,Huilan Zhang,Recruiting,Phase 3,Interventional,China,A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection,Drug,Pirfenidone,Pirfenidone,294,https://clinicaltrials.gov/show/NCT04282902,,,2020-04-30,2020-06-01,2020-04-30,0,1,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-07 19:53:09,2021-01-08 12:50:38,IP Address,82.33.104.78,100,61048,True,2021-01-08 12:50:38,R_2EtStyCBpaAVj7Z,,,test@test.com,,51.476898193359375,-2.55340576171875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,NCT04252885,ClinicalTrials.gov,2020-01-30,2020-01-28,TRUE,Guangzhou 8th People's Hospital,Recruiting,Phase 4,Interventional,China,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,Drug,Lopinavir/ritonavir vs. umifenovir,Lopinavir/ritonavir; Umifenovir,125,https://clinicaltrials.gov/show/NCT04252885,,,2020-04-30,2020-05-31,2020-04-30,0,0,,10.1101/2020.03.19.20038984,,10.1101/2020.03.19.20038984,10.1016/j.medj.2020.04.001,full_results_preprint,full_results_journal_article,,2020-04-15,2020-05-04,9,,Completed,TRUE,1,,full_results_preprint,2020-04-15,9hknw4ws,https://doi.org/10.1101/2020.03.19.20038984,An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI),,,,full_results_journal_article,2020-05-04,,true,true,
2021-01-08 12:51:04,2021-01-08 12:54:17,IP Address,82.33.104.78,100,193,True,2021-01-08 12:54:18,R_3fvoOonXQQgwQzX,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Jingyebaidu AND COVID-19 AND Tongji Medical College,"Jingyebaidu AND coronavirus AND pneumonia AND Liu Dong ",,,,,,,,,MPJ,2020-06-30,ChiCTR2000029755,ChiCTR,2020-02-12,2020-02-15,FALSE,"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,Phase 4,Interventional,China,"A randomized, open, parallel-controlled clinical trial on the efficacy and safety of Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19)",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,120,http://www.chictr.org.cn/showproj.aspx?proj=49301,,,,2020-05-30,2020-05-30,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-08 12:54:26,2021-01-08 12:59:21,IP Address,82.33.104.78,100,295,True,2021-01-08 12:59:22,R_3iqIXWaRj9ocNFo,,,test@test.com,,51.476898193359375,-2.55340576171875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,," interferon alpha 1b AND spray AND COVID-19 AND Chinese PLA General Hospital "," interferon alpha 1b AND coronavirus AND medical staff AND Feng Cao ",,,,,,,,,MPJ,2020-06-30,ChiCTR2000030013,ChiCTR,2020-02-19,2020-02-20,FALSE,Chinese PLA General Hospital,Not Recruiting,Phase 4,Interventional,China,A prospective clinical study for recombinant human interferon alpha 1b spray in the prevention of novel coronavirus (COVID-19) infection in highly exposed medical staffs.,Drug,Interferon alfa,Interferon alfa,450,http://www.chictr.org.cn/showproj.aspx?proj=49796,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-08 12:59:41,2021-01-08 13:02:51,IP Address,82.33.104.78,100,190,True,2021-01-08 13:02:52,R_ZKWN9jNR9zhUZQR,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Zang-Fu Point-pressing AND COVID-19 AND Ming Chen ",children AND massage AND coronavirus AND Xiangyang Central Hospital,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030324,ChiCTR,2020-02-28,2020-02-28,FALSE,"Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences",Not Recruiting,Not Applicable,Interventional,China,Traditional Chinese Medicine 'Zang-Fu Point-pressing' massage for children with novel coronavirus pneumonia (COVID-19),Traditional Medicine (Other),Traditional Medicine,Traditional Medicine,40,http://www.chictr.org.cn/showproj.aspx?proj=50231,,,,2020-05-28,2020-05-28,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-08 14:04:14,2021-01-08 14:13:18,IP Address,82.33.104.78,100,543,True,2021-01-08 14:13:19,R_3KrviJDPR6E2zlx,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Kang-Bing-Du AND COVID-19 AND Xin Zheng ",coronavirus AND pneumonia AND Kang-Bing-Du 	AND Sichuan,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029781,ChiCTR,2020-02-13,2020-02-14,FALSE,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,Phase 4,Interventional,China,"A multicenter, randomized, open and controlled trial for the efficacy and safety of Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19)",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,160,http://www.chictr.org.cn/showproj.aspx?proj=49138,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-08 14:13:27,2021-01-08 14:19:38,IP Address,82.33.104.78,100,370,True,2021-01-08 14:19:39,R_URYY5NuIRldzUhr,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"honeysuckle AND COVID-19 AND Hubei Hospital of Traditional Chinese Medicine ",coronavirus AND pneumonia AND honeysuckle AND Yang Yi,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029954,ChiCTR,2020-02-17,2020-04-30,FALSE,Hubei Hospital of Traditional Chinese Medicine,Recruiting,Phase 4,Interventional,China,"Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,300,http://www.chictr.org.cn/showproj.aspx?proj=49402,,,,2020-02-10,2020-02-10,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-08 14:19:48,2021-01-08 14:25:47,IP Address,82.33.104.78,100,358,True,2021-01-08 14:25:48,R_3O7g7MzFXihqqku,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"hydroxychloroquine AND COVID-19 AND Xiamen University ",coronavirus pneumonia AND hydroxychloroquine AND chloroquine AND Yin Zhenyu,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029992,ChiCTR,2020-02-18,2020-02-17,TRUE,Zhongshan Hospital Affiliated to Xiamen University,Not Recruiting,Phase 4,Interventional,China,"A prospective, randomized, open label, controlled trial for chloroquine and hydroxychloroquine in patients with severe novel coronavirus pneumonia (COVID-19)",Drug,Chloroquine + Hydroxychloroquine,Chloroquine; Hydroxychloroquine,100,http://www.chictr.org.cn/showproj.aspx?proj=49574,,,,2020-05-20,2020-05-20,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-08 14:25:55,2021-01-08 14:33:39,IP Address,82.33.104.78,100,463,True,2021-01-08 14:33:40,R_parQlxFFBh7B4ad,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,,,,,full_results_journal_article,,,,,https://doi.org/10.1001/jamainternmed.2020.5503,32910179,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2770680,,,,,,,,,,,,,2020-09-10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,," rhG-CSF AND COVID-19 AND Guangzhou Medical University ",Guangzhou Medical University AND COVID-19 AND Recombinant Human Granulocyte Colony-Stimulating Factor,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030007,ChiCTR,2020-02-19,2020-02-03,TRUE,The First Affiliated Hospital of Guangzhou Medical University,Not Recruiting,Not Applicable,Interventional,China,Multicenter randomized controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19),Drug,G-CSF,G-CSF,200,http://www.chictr.org.cn/showproj.aspx?proj=49619,,,,2020-04-10,2020-04-10,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,true,,
2021-01-08 14:33:45,2021-01-08 14:44:56,IP Address,82.33.104.78,100,670,True,2021-01-08 14:44:57,R_1NlYsdrx9rdDhPx,,,test@test.com,,51.476898193359375,-2.55340576171875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,,,,,full_results_journal_article,,,,,10.1016/j.nmni.2020.100814," 33204428",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661912/,,,,,,,,,,,,,2020-11-13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"convalescent plasma AND COVID-19 AND Xuebing Yan ","convalescent plasma AND coronavirus AND pneumonia AND Xuzhou Medical University ",,,,,,,,,MPJ,2020-06-30,ChiCTR2000030039,ChiCTR,2020-02-21,2020-05-31,FALSE,Affiliated Hospital of Xuzhou Medical University,Recruiting,Not Applicable,Interventional,China,Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19),ATMP,Plasma,Plasma,90,http://www.chictr.org.cn/showproj.aspx?proj=49544,,,,2020-02-01,2020-02-01,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-08 14:46:41,2021-01-08 14:47:22,IP Address,82.33.104.78,100,40,True,2021-01-08 14:47:22,R_10rczDaKFQQhR00,,,test@test.com,,51.4766998291015625,-2.5572052001953125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000029418,ChiCTR,2020-01-30,2020-02-03,FALSE,Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine,Recruiting,Not Applicable,Interventional,China,Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a Randomized Controlled Trial,Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,42,http://www.chictr.org.cn/showproj.aspx?proj=48886,,,,2020-08-31,2020-08-31,0,0,,10.1101/2020.03.27.20044974,,10.1101/2020.03.27.20044974,10.3389/fmed.2020.00256,full_results_preprint,full_results_journal_article,,2020-04-01,2020-05-27,9,,Recruiting,TRUE,1,,full_results_preprint,2020-04-01,4as055wh,http://medrxiv.org/cgi/content/short/2020.03.27.20044974v1?rss=1,Guideline-based Chinese herbal medicine treatment plus standard care for severe coronavirus disease 2019 (G-CHAMPS): evidence from China,,,32574340,full_results_journal_article,2020-05-27,,,,
2021-01-08 14:47:28,2021-01-08 14:52:35,IP Address,82.33.104.78,100,307,True,2021-01-08 14:52:35,R_240FDOGsjdipLri,,,test@test.com,,51.476898193359375,-2.55340576171875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Favipiravir AND COVID-19 AND Shenzhen the 3rd People's Hospital ","Favipiravir AND coronavirus AND pneumonia AND Liu Yingxia ",,,,,,,,,MPJ,2020-06-30,ChiCTR2000030113,ChiCTR,2020-02-23,2020-02-22,TRUE,The Third People's Hospital of Shenzhen,Recruiting,Not Applicable,Interventional,No Country Given,Randomized controlled trial for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir,Drug,Favipiravir vs. ritonavir,Favipiravir,30,http://www.chictr.org.cn/showproj.aspx?proj=49988,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-08 14:52:41,2021-01-08 14:55:43,IP Address,82.33.104.78,100,181,True,2021-01-08 14:55:44,R_3OeNwWo8BcQ41o3,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"ozone autohemotherapy AND coronavirus AND Xiaoguang Tong ","ozone autohemotherapy AND COVID-19 AND Tianjin Huanhu Hospital ",,,,,,,,,MPJ,2020-06-30,ChiCTR2000030102,ChiCTR,2020-02-23,2020-02-24,FALSE,Tianjin Huanhu Hospital,Recruiting,Not Applicable,Interventional,China,A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19),Drug,Ozone,Ozone,180,http://www.chictr.org.cn/showproj.aspx?proj=49747,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-10 00:31:13,2021-01-10 00:33:58,IP Address,129.170.194.78,100,165,True,2021-01-10 00:33:58,R_TtP8IWgj2CPg1qN,,,test@test.com,,43.701904296875,-72.2826995849609375,gl,EN,yes,no,,"""Simulation"" trial about paramedics wearing PPE and inserting cannulas into COVID patients. Since it's about the ability to insert the cannulas, not sure if this counts for treatment/prevention.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MSH,2020-06-30,NCT04366297,ClinicalTrials.gov,2020-04-23,2020-01-12,TRUE,Lazarski University,Not Recruiting,Not Applicable,Interventional,Poland,Intravascular Access of COVID-19 Patient Under Personal Protective Equipment,Other (device),Intraosseous/Intravenous access device,Intraosseous/Intravenous access device,41,https://clinicaltrials.gov/show/NCT04366297,,,2020-02-25,2020-02-25,2020-02-25,0,0,,,,,,,,,,,7,,Completed,TRUE,2,,,,,,,,,,,,,,,
2021-01-11 19:55:56,2021-01-11 20:02:05,IP Address,129.67.117.64,100,368,True,2021-01-11 20:02:06,R_1Cg5h1ZroeybLKt,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ronghui Du AND Covid,Li Li AND Covid AND Corticosteroids,,,,,,,,,ND,2020-06-30,ChiCTR2000029656,ChiCTR,2020-02-09,2020-02-14,FALSE,Wuhan Pulmonary Hosptial,Not Recruiting,Not Applicable,Interventional,China,"A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19)",Drug,Corticosteroids,Methylprednisolone,100,http://www.chictr.org.cn/showproj.aspx?proj=49086,,,,2020-04-14,2020-04-14,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-11 20:02:15,2021-01-11 20:07:30,IP Address,129.67.117.64,100,314,True,2021-01-11 20:07:31,R_OcJJGCniL2ATXmF,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,tracheostomy AND Covid,tracheostomy AND Covid AND Iran,Shahriar Najafizadeh AND Covid,,,,,,,,ND,2020-06-30,IRCT20180129038542N1,IRCT,2020-04-13,2020-04-06,TRUE,University of Baqiyatallah,Not Recruiting,Not Applicable,Interventional,Iran,Early tracheostomy in COVID-19,Other (physical),Mechanical ventilation,Mechanical ventilation,30,http://en.irct.ir/trial/47013,,,,2020-04-13,2020-04-13,0,0,,,,,,,,,,,8,,Recruitment complete,TRUE,2,,,,,,,,,,,,,,,
2021-01-11 20:07:39,2021-01-11 20:09:01,IP Address,129.67.117.64,100,81,True,2021-01-11 20:09:01,R_1OGD34b112pqSqG,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04377997,ClinicalTrials.gov,2020-05-01,2020-05-15,FALSE,Massachusetts General Hospital,Not Recruiting,Phase 2,Interventional,No Country Given,Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19,Drug,Enoxaparin,Enoxaparin,300,https://clinicaltrials.gov/show/NCT04377997,,,2021-01-01,2022-01-01,2021-01-01,0,1,,,,,,,,,,,8,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-11 20:09:07,2021-01-11 20:17:47,IP Address,129.67.117.64,100,520,True,2021-01-11 20:17:47,R_AtFvHPjy88p5hUR,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Faida Ajili,Nejla Mrabet,Tunisia AND hydroxychloroquine,,,,,,,,ND,2020-06-30,NCT04377646,ClinicalTrials.gov,2020-05-01,2020-05-04,FALSE,Military Hospital of Tunis,Not Recruiting,Phase 3,Interventional,Tunisia,A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers,Drug (Chemoprophylaxis),Hydroxychloroquine + Zinc,Hydroxychloroquine + Zinc,660,https://clinicaltrials.gov/show/NCT04377646,,,2020-05-24,2020-07-31,2020-05-24,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-11 20:17:53,2021-01-11 20:36:40,IP Address,129.67.117.64,100,1126,True,2021-01-11 20:36:41,R_29uKT0sUrnHbxmH,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Saira Burney,Hydroxychloroquine AND Covid AND Pakistan,,,,,,,,,ND,2020-06-30,NCT04370015,ClinicalTrials.gov,2020-04-27,2020-05-15,FALSE,"Services Institute of Medical Sciences, Pakistan",Not Recruiting,Not Applicable,Interventional,No Country Given,Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers.,Drug (Chemoprophylaxis),Hydroxychloroquine,Hydroxychloroquine,374,https://clinicaltrials.gov/show/NCT04370015,,,2020-06-30,2020-10-15,2020-06-30,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-11 20:36:52,2021-01-11 20:51:30,IP Address,129.67.117.64,100,878,True,2021-01-11 20:51:31,R_2ahRNM2M2Y8BzoI,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,Suspended,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CORIMUNO-VIRO,Sarilumab AND Hydroxychloroquine AND Azithromycin AND Hôpitaux de Paris,,,,,,,,,ND,2020-06-30,NCT04341870,ClinicalTrials.gov,2020-04-06,2020-04-11,FALSE,Assistance Publique – Hôpitaux de Paris,Not Recruiting,Phase 2/Phase 3,Interventional,France,"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",Drug,Sarilumab + Azithromycin + Hydroxychloroquine vs. Sarilumab,Sarilumab; azithromycin; hydroxychloroquine,27,https://clinicaltrials.gov/show/NCT04341870,,,2020-05-08,2020-08-01,2020-05-08,0,0,,,,,,,,,,,8,,Suspended,TRUE,2,,,,,,,,,,,,,,,
2021-01-11 20:51:36,2021-01-11 20:53:26,IP Address,129.67.117.64,100,110,True,2021-01-11 20:53:27,R_1AZTBDqmLW5po8p,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Protocol: https://pubmed.ncbi.nlm.nih.gov/32586395/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04368156,ClinicalTrials.gov,2020-04-20,2020-04-20,FALSE,Carlos Tornero,Recruiting,Not Applicable,Interventional,Spain,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,Other (device),Vagus nerve stimulation,Vagus nerve stimulation,90,https://clinicaltrials.gov/show/NCT04368156,,,2020-07-31,2020-07-31,2020-07-31,0,1,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-11 20:53:33,2021-01-11 21:06:55,IP Address,129.67.117.64,100,801,True,2021-01-11 21:06:55,R_1Q6kqJODndgtjTU,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Lactobacillus AND Covid,Raquel Rodriguez Blanque,,,,,,,,,ND,2020-06-30,NCT04366180,ClinicalTrials.gov,2020-04-27,2020-04-24,TRUE,Biosearch S.A.,Recruiting,Not Applicable,Interventional,Spain,Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers,Supplement,Probiotics,Probiotics,314,https://clinicaltrials.gov/show/NCT04366180,,,2020-06-01,2020-10-01,2020-06-01,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-11 21:07:05,2021-01-11 21:09:11,Spam,129.67.117.64,100,125,True,2021-01-11 21:09:12,R_2P0zG9FcLArngVT,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04366089,ClinicalTrials.gov,2020-04-22,2020-03-26,TRUE,Dr. Roberto Poscia,Recruiting,Phase 2,Interventional,Italy,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,Drug,Oxygen + Ozone,Oxygen; Ozone,152,https://clinicaltrials.gov/show/NCT04366089,,,2020-10-30,2020-12-31,2020-10-30,0,1,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-11 21:09:26,2021-01-11 21:10:48,Spam,129.67.117.64,100,82,True,2021-01-11 21:10:49,R_cSfQpeRmxJWMty1,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04361942,ClinicalTrials.gov,2020-04-17,2020-04-01,FALSE,Red de Terapia Celular,Recruiting,Phase 2,Interventional,Spain,Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV),ATMP,Cells (mesenchymal),Cells (mesenchymal),24,https://clinicaltrials.gov/show/NCT04361942,EUCTR2020-001682-36,,2020-11-30,2020-12-31,2020-11-30,0,1,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-12 20:26:17,2021-01-12 20:35:47,IP Address,129.67.117.94,100,569,True,2021-01-12 20:35:48,R_3Hka2nHocBoKf82,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ammar Sarwar AND Hydroxychloroquine,PRECISE AND Hydroxychloroquine,Mayo Hospital Lahore AND Hydroxychloroquine,,,,,,,,ND,2020-06-30,NCT04351191,ClinicalTrials.gov,2020-04-14,2020-04-15,FALSE,"Government of Punjab, Specialized Healthcare and Medical Education Department",Recruiting,Phase 4,Interventional,Pakistan,PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds,Drug (Chemoprophylaxis),Hydroxychloroquine vs. Chloroquine,Hydroxychloroquine; Chloroquine,400,https://clinicaltrials.gov/show/NCT04351191,,,2020-05-30,2020-06-30,2020-05-30,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-12 20:36:00,2021-01-12 20:45:36,IP Address,129.67.117.94,100,575,True,2021-01-12 20:45:36,R_OQeOTcSD3MoYzgB,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hydroxychloroquine AND Indomethacin AND Covid,Hydroxychloroquine AND Perseverance Research Center,Teresa Gaither,Nicole C. Hank,,,,,,,ND,2020-06-30,NCT04344457,ClinicalTrials.gov,2020-04-08,2020-04-16,FALSE,"Perseverance Research Center, LLC",Recruiting,Phase 1/Phase 2,Interventional,United States,"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19",Drug,Hydroxychloroquine + Indomethacin + Azithromycin,Hydroxychloroquine; Indomethacin; Azithromycin,80,https://clinicaltrials.gov/show/NCT04344457,,,2020-06-20,2020-09-30,2020-06-20,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-12 20:46:17,2021-01-12 20:58:32,IP Address,129.67.117.94,100,734,True,2021-01-12 20:58:32,R_2OGUKCuGxNfqCvr,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Siddha AND Covid,Gopalakrishnan Thanicakachalam,,,,,I don't think this is the same trial despite similarities: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04823-z,,,,ND,2020-06-30,ISRCTN13311119,ISRCTN,2020-04-24,2020-04-30,FALSE,Eminentlabs GmbH,Recruiting,Phase 2,Interventional,India,START (Siddha Treatment Accelerating Recovery from SARS-CoV-2 Test) trial of Siddha treatment for patients with novel coronavirus infectious disease (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,116,http://isrctn.com/ISRCTN13311119,,,,2020-06-26,2020-06-26,0,0,,,,,,,,,,,8,,No longer recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-12 20:58:41,2021-01-12 21:00:31,IP Address,129.67.117.94,100,109,True,2021-01-12 21:00:31,R_r3wT6yhOw7qCB5n,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Protocol: https://pubmed.ncbi.nlm.nih.gov/32620174/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04361435,ClinicalTrials.gov,2020-04-12,2020-05-01,FALSE,St. Justine's Hospital,Not Recruiting,Not Applicable,Interventional,No Country Given,Lung Recruitment Device for COVID-19,Other (physio),Physio & Rehabilitation,Physio & Rehabilitation,50,https://clinicaltrials.gov/show/NCT04361435,,,2020-07-31,2020-12-31,2020-07-31,0,1,,,,,,,,,,,8,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-12 21:04:49,2021-01-12 21:05:08,IP Address,129.67.117.94,100,19,True,2021-01-12 21:05:08,R_2cedo89I9M3eXMz,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04357327,ClinicalTrials.gov,2020-04-15,2020-04-16,FALSE,Université Libre de Bruxelles,Recruiting,Not Applicable,Interventional,Italy,Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19),Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,100,https://clinicaltrials.gov/show/NCT04357327,,,2020-05-31,2020-07-31,2020-05-31,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-12 21:05:16,2021-01-12 21:07:07,IP Address,129.67.117.94,100,111,True,2021-01-12 21:07:08,R_2dhGPeiYB1BZxYY,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,no,2021-01,2021-03,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Protocol: https://pubmed.ncbi.nlm.nih.gov/32493441/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04330638,ClinicalTrials.gov,2020-03-31,2020-04-01,FALSE,"University Hospital, Ghent",Recruiting,Phase 3,Interventional,Belgium,Treatment of COVID-19 Patients With Anti-interleukin Drugs,Drug,Anakinta + Siltuximab vs. Tocilizumab + Anakinra vs. Tocilizumab vs. Siltuximab vs. Anakinra,Anakinra; Siltuximab; Tocilizumab,342,https://clinicaltrials.gov/show/NCT04330638,,,2020-09-01,2020-12-01,2020-09-01,0,1,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2021-03
2021-01-12 21:07:27,2021-01-12 21:28:01,IP Address,129.67.117.94,100,1233,True,2021-01-12 21:28:02,R_1q9RSweF4NaENzs,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ASC09 AND Lopinavir AND Ritonavir AND Covid,Liu Jian AND Zhejiang,Qiu Yunqing AND Ritonavir,,,,,,,,ND,2020-06-30,ChiCTR2000029603,ChiCTR,2020-02-06,2020-02-06,FALSE,The First Affiliated Hospital of Zhejiang University School of Medicine,Recruiting,Not Applicable,Interventional,China,"A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19)",Drug,ASCO9 + Ritonavir vs. Lopinavir/ritonavir,ASC09; Ritonavir; Lopinavir/ritonavir,160,http://www.chictr.org.cn/showproj.aspx?proj=49075,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-12 21:28:16,2021-01-12 21:37:29,IP Address,129.67.117.94,100,553,True,2021-01-12 21:37:30,R_zZ1ONCY4LdrOJix,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Vitamin C AND Covid,Bing Zhao AND Covid,Enqiang Mao AND vitamin c,,,,,,,,ND,2020-06-30,ChiCTR2000032400,ChiCTR,2020-04-27,2020-01-01,TRUE,"Ruijin Hospital, Shanghai Jiao Tong University School of Medicine",Recruiting,Not Applicable,Interventional,China,"the efficacy and safety of high dose intravenous vitamin C in the treatment of novel coronavirus pneumonia (COVID-19): a prospective, randomize, controlled trial",Drug,Vitamin C,Vitamin C,120,http://www.chictr.org.cn/showproj.aspx?proj=52958,,,,2020-06-01,2020-06-01,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-12 21:37:36,2021-01-12 21:38:23,IP Address,129.67.117.94,100,46,True,2021-01-12 21:38:23,R_2PbXyOkLxdbQ0xu,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,no,,"It's for flu-like illness during Covid, not Covid",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04351542,ClinicalTrials.gov,2020-04-14,2020-03-06,TRUE,Aarogyam UK,Not Recruiting,Not Applicable,Interventional,United Kingdom,Ayurveda for Flu Like Illness During Covid-19 Outbreak,Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,32,https://clinicaltrials.gov/show/NCT04351542,,,2020-04-06,2020-04-12,2020-04-06,0,0,,,,,,,,,,,8,,Completed,TRUE,2,,,,,,,,,,,,,,,
2021-01-12 21:38:28,2021-01-12 21:38:53,IP Address,129.67.117.94,100,24,True,2021-01-12 21:38:53,R_3oyxez9Qakfzbgd,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,no,,Exercise for isolation during covid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04346953,ClinicalTrials.gov,2020-04-13,2020-04-20,FALSE,Istinye University,Not Recruiting,Not Applicable,Interventional,No Country Given,Video-Based Exercise for Individuals With Social Isolation Due to Coronavirus (COVID-19),Other (exercise),Exercise,Exercise,128,https://clinicaltrials.gov/show/NCT04346953,,,2020-06-01,2020-07-31,2020-06-01,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-12 21:38:59,2021-01-12 21:39:20,IP Address,129.67.117.94,100,20,True,2021-01-12 21:39:20,R_2Bgi7PUvF7SxQh5,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,no,,mental health,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04324190,ClinicalTrials.gov,2020-03-26,2020-04-08,FALSE,Gunther Meinlschmidt,Recruiting,Not Applicable,Interventional,Germany,DIgital Online SuPport for COVID-19 StrEss,Other (psych),Psychological,Psychological,600,https://clinicaltrials.gov/show/NCT04324190,,,2020-06-01,2021-12-01,2020-06-01,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-12 21:39:26,2021-01-12 21:45:34,IP Address,129.67.117.94,100,367,True,2021-01-12 21:45:35,R_2YJrJvfBU8OXAbw,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,Terminated,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Searched existing trial title and authors,,,,,,,,,,ND,2020-06-30,NCT04257656,ClinicalTrials.gov,2020-01-31,2020-02-06,FALSE,Capital Medical University,Not Recruiting,Phase 3,Interventional,China,A Trial of Remdesivir in Adults With Severe COVID-19,Drug,Remdesivir,Remdesivir,237,https://clinicaltrials.gov/show/NCT04257656,,,2020-03-30,2020-04-10,2020-03-30,0,1,,10.1016/S0140-6736(20)31022-9,,10.1016/S0140-6736(20)31022-9,,interim_results_journal_article,,2020-04-10,2020-04-29,,8,,Terminated,TRUE,2,32423584,interim_results_journal_article,2020-04-29,bzeqs5oh,https://doi.org/10.1016/s0140-6736(20)31022-9; https://api.elsevier.com/content/article/pii/S0140673620310229; https://www.sciencedirect.com/science/article/pii/S0140673620310229; https://www.ncbi.nlm.nih.gov/pubmed/32423584/,"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial",2020-04-10,,,,,,,,
2021-01-12 21:45:48,2021-01-12 21:51:28,IP Address,129.67.117.94,100,339,True,2021-01-12 21:51:29,R_2CsjyLe0a2LY0x6,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,no,2021-03-06,2021-07-06,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Piclidenoson AND Covid,Zivit Harpaz,,,,,,,,,ND,2020-06-30,NCT04333472,ClinicalTrials.gov,2020-04-01,2020-04-06,FALSE,Can-Fite BioPharma,Not Recruiting,Phase 2,Interventional,Israel,Piclidenoson for Treatment of COVID-19,Drug,Piclidenoson,Piclidenoson,40,https://clinicaltrials.gov/show/NCT04333472,,,2020-06-06,2020-07-06,2020-06-06,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,2021-07-06
2021-01-12 21:51:45,2021-01-12 22:23:53,IP Address,129.67.117.94,100,1928,True,2021-01-12 22:23:54,R_3Hi6Mz21x3Zw0Gx,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,no,2020-12-31,2020-12-31,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ciclesonide AND Covid,Joon Young Song,,,,,,"Korean registry entry says 2021-04-16 for completion date

https://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=16795",,,ND,2020-06-30,NCT04330586,ClinicalTrials.gov,2020-03-31,2020-04-01,FALSE,Korea University Guro Hospital,Not Recruiting,Phase 2,Interventional,No Country Given,A Trial of Ciclesonide in Adults With Mild COVID-19,Drug,Ciclesonide + hydroxychloroquine vs. hydroxychloroquine,Ciclesonide; hydroxychloroquine,141,https://clinicaltrials.gov/show/NCT04330586,,,2020-06-30,2020-09-30,2020-06-30,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,2020-12-31
2021-01-12 22:24:03,2021-01-12 22:36:51,IP Address,129.67.117.94,100,768,True,2021-01-12 22:36:52,R_3MGKuivbhLnmtcC,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,no,2020-04-05,2020-05-02,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,,,,,full_results_preprint,,,,,10.1101/2020.07.26.20159756,,https://www.medrxiv.org/content/10.1101/2020.07.26.20159756v1,,,,,,,,,,,,,2020-07-29,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Bevacizumab AND Covid,Preprint authors and title,,,,,,,,,ND,2020-06-30,NCT04275414,ClinicalTrials.gov,2020-02-14,2020-02-15,FALSE,Qilu Hospital of Shandong University,Recruiting,Phase 2/Phase 3,Interventional,"China, Italy",Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,Drug,Bevacizumab,Bevacizumab,20,https://clinicaltrials.gov/show/NCT04275414,,,2020-04-01,2020-05-01,2020-04-01,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,true,2020-05-02
2021-01-14 03:57:42,2021-01-14 04:03:33,IP Address,129.67.119.127,100,350,True,2021-01-14 04:03:34,R_3qUpASeFw5uzkJb,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,europe_pmc,,,,full_results_preprint,full_results_journal_article,,,,10.1101/2020.04.29.20085761,,,10.1016/j.ejps.2020.105631,,,,,,,,,,,,2020-05-05,,2020-10-25,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,ChiCTR2000029544,ChiCTR,2020-02-03,2020-02-04,FALSE,The First Affiliated Hospital of Zhejiang University School of Medicine,Not Recruiting,Not Applicable,Interventional,China,"A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy",Drug,Baloxavir + Marboxil vs. Favipiravir,Baloxavir; Marboxil; Favipiravir,30,http://www.chictr.org.cn/showproj.aspx?proj=49013,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,true,true,
2021-01-14 04:03:52,2021-01-14 04:12:01,IP Address,129.67.119.127,100,489,True,2021-01-14 04:12:02,R_02jxqyY4E9wfs2t,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Zhijun Xie AND covid,Chengping Wen AND covid,,,,,,,,,ND,2020-06-30,ChiCTR2000029517,ChiCTR,2020-02-03,2020-02-04,FALSE,Zhejiang Chinese Medical University,Recruiting,Not Applicable,Interventional,China,"Chinese medicine prevention and treatment program for suspected novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trial",Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,100,http://www.chictr.org.cn/showproj.aspx?proj=48861,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-14 04:12:23,2021-01-14 04:17:16,IP Address,129.67.119.127,100,293,True,2021-01-14 04:17:16,R_2uvNIuYw1LZhaun,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,"Looks like a ""single arm trial""",,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tanreqing Injection AND Covid,Yanping Du,,,,,,,,,ND,2020-06-30,ChiCTR2000029432,ChiCTR,2020-02-01,2020-02-01,FALSE,The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine,Not Recruiting,Phase 4,Interventional,China,A Real World Study for the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,72,http://www.chictr.org.cn/showproj.aspx?proj=48881,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-14 04:17:20,2021-01-14 04:24:11,IP Address,129.67.119.127,100,410,True,2021-01-14 04:24:12,R_1cUE2ifeJgdolLR,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Thymosin AND PD-1 AND covid,Jianfeng Xie,,,,,,,,,ND,2020-06-30,NCT04268537,ClinicalTrials.gov,2020-02-08,2020-02-10,FALSE,"Southeast University, China",Not Recruiting,Phase 2,Interventional,No Country Given,Immunoregulatory Therapy for 2019-nCoV,Drug,PD1 vs. thymosin,PD1; Thymosin,120,https://clinicaltrials.gov/show/NCT04268537,,,2020-04-30,2020-10-31,2020-04-30,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-14 04:24:38,2021-01-14 04:28:59,IP Address,129.67.119.127,100,261,True,2021-01-14 04:29:00,R_vB5GrZztfvkFdol,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Li Weilin AND stem cells,Xue Zhigang AND Stem cells,,,,,,,,,ND,2020-06-30,ChiCTR2000030173,ChiCTR,2020-02-24,2020-02-17,TRUE,"Hunan yuanpin Cell Biotechnology Co., Ltd",Not Recruiting,Not Applicable,Interventional,China,Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration,ATMP,Cells (mesenchymal),Cells (mesenchymal),60,http://www.chictr.org.cn/showproj.aspx?proj=49229,,,,2020-04-17,2020-04-17,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-14 04:29:07,2021-01-14 04:35:46,IP Address,129.67.119.127,100,399,True,2021-01-14 04:35:47,R_1j9gZCZfnir4UyI,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Beijing Institute of Pharmacology and Toxicology AND chloroquine,Zhong Wu AND Chloroquine,Jin Ronghua AND Chloroquine,,,,,,,,ND,2020-06-30,ChiCTR2000031204,ChiCTR,2020-03-24,2020-01-30,TRUE,"Beijing You'an Hospital, Capital Medical University",Recruiting,Phase 2,Interventional,China,"A multicenter, single-blind, randomized controlled clinical trial for chloroquine phosphate in the treatment of novel coronavirus pneumonia (COVID-19)",Drug,Chloroquine,Chloroquine,300,http://www.chictr.org.cn/showproj.aspx?proj=49420,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-14 04:36:00,2021-01-14 04:40:50,IP Address,129.67.119.127,100,290,True,2021-01-14 04:40:51,R_plxYfTyTx7BpMCl,,,test@test.com,,51.7657012939453125,-1.279693603515625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Sildenafil AND covid,Qin Ning AND covid,Tongji Hospital AND Sildenafil,,,,,,,,ND,2020-06-30,NCT04304313,ClinicalTrials.gov,2020-02-14,2020-02-09,TRUE,"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,Phase 3,Interventional,China,A Pilot Study of Sildenafil in COVID-19,Drug,Sildenafil,Sildenafil,10,https://clinicaltrials.gov/show/NCT04304313,,,2020-03-01,2020-11-09,2020-03-01,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-14 14:37:21,2021-01-14 14:52:38,IP Address,158.181.79.178,100,917,True,2021-01-14 14:52:39,R_WBevjeCCFbasjqV,,,test@test.com,,52.5294952392578125,13.4694976806640625,gl,EN,yes,yes,no,pragmatic trial which is unclear to me,no,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,glucocovid,"glucocovid AND ""Corral-Gudino""",,,,,,pragmatic trial,team_review,,MSH,2020-06-30,EUCTR2020-001934-37-ES,EU Clinical Trials Register,2020-05-08,2020-05-07,TRUE,Instituto de Investigación Marqués de Valdecilla (IDIVAL),Authorised,Phase 4,Interventional,Spain,USE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTION,Drug,Corticosteroids,Methylprednisolone,200,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001934-37,,,,,,,,,10.1101/2020.06.17.20133579,,10.1101/2020.06.17.20133579,,full_results_preprint,,,2020-06-18,,7,,,TRUE,2,,full_results_preprint,2020-06-18,zql4zhyk,http://medrxiv.org/cgi/content/short/2020.06.17.20133579v1?rss=1,GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia,,,,,,,,true,
2021-01-14 14:52:53,2021-01-14 14:53:43,IP Address,158.181.79.178,100,50,True,2021-01-14 14:53:44,R_VKBHatIaI7sx6qR,,,test@test.com,,52.5294952392578125,13.4694976806640625,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,JPRN-UMIN000040286,JPRN,2020-05-11,2020-05-12,FALSE,University of Tokyo,Not Recruiting,Not Applicable,Interventional,Japan,Study on risk perception and behavioral change related to COVID-19,Other (psych),No Intervention,No Intervention,1980,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045966,,,,2020-05-14,2020-05-14,0,0,,,,,,,,,,,7,,Preinitiation,TRUE,2,,,,,,,,,,,,,,,
2021-01-14 14:53:59,2021-01-14 15:01:54,IP Address,158.181.79.178,100,474,True,2021-01-14 15:01:54,R_RWf2fEldHN69jNf,,,test@test.com,,52.5294952392578125,13.4694976806640625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,baicalein AND covid AND trial,,,,,,,,,,MSH,2020-06-30,ChiCTR2000033286,ChiCTR,2020-05-26,2020-02-15,TRUE,Xiangyang Central Hospital,Not Recruiting,Not Applicable,Interventional,China,"A Randomized, Double-blind, Placebo-controlled trial for determination of the Efficacy and Safety of Baicalein in Hospitalized Adult  Mild and Moderate Patients of novel coronavirus pneumonia (COVID-19)",Traditional Medicine (Drug),Tradtional Medicine,Tradtional Medicine,60,http://www.chictr.org.cn/showproj.aspx?proj=54176,,,,2020-03-09,2020-03-09,0,0,,,,,,,,,,,7,,Completed,TRUE,2,,,,,,,,,,,,,,,
2021-01-14 15:06:28,2021-01-14 15:32:19,IP Address,158.181.79.178,100,1550,True,2021-01-14 15:32:19,R_1OAJ4ah3rYzrhur,,,test@test.com,,52.5294952392578125,13.4694976806640625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"""measles vaccine"" AND covid","""measles vaccine"" AND covid AND trial","""measles vaccine"" AND covid AND trial AND Alfishawy","""measles vaccine"" AND covid AND trial AND Alfishawy",,,,,,,MSH,2020-06-30,PACTR202004693933092,PACTR,2020-04-12,2020-04-15,FALSE,Misr University for Science and Technology,Not Recruiting,Not Applicable,Interventional,Egypt,Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial),ATMP,Vaccine,Vaccine,200,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=10953,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-14 15:35:18,2021-01-14 15:39:45,IP Address,158.181.79.178,100,267,True,2021-01-14 15:39:45,R_2qpJrvCkGsopeE2,,,test@test.com,,52.5294952392578125,13.4694976806640625,gl,EN,yes,unknown,no,Unclear whether specific to COVID or just general disease prevention,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MSH,2020-06-30,RPCEC00000315,RPCEC,2020-05-22,2020-05-19,TRUE,Finlay Vaccine Institute (IFV),Recruiting,Not Applicable,Interventional,Cuba,Evaluation of the synergistic effect of  sequential administration of two immunostimulant products: Immuno-1 and Immuno-2 for the stimulation of the immune response in older adults. Exploratory study,Drug,Immunostimulants,Immunostimulants,60,https://rpcec.sld.cu/en/trials/RPCEC00000315-En,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-14 15:40:12,2021-01-14 15:49:36,IP Address,158.181.79.178,100,563,True,2021-01-14 15:49:37,R_25QuIPgFuKtM112,,,test@test.com,,52.5294952392578125,13.4694976806640625,gl,EN,yes,yes,no,"Only 5 patients and no control group, but seems prospective",,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"""mechanical ventilator"" AND covid AND brazil","""mechanical ventilator"" AND covid AND (Ribeiro OR Salgado)",,,,,,,,,MSH,2020-06-30,RBR-2dxyx4,REBEC,2020-06-02,2020-06-04,FALSE,Hospital Universitário Clementino Fraga Filho,Not Recruiting,Not Applicable,Interventional,Brazil,Mechanical ventilator for use in patients with respiratory failure due to Covid-19 (VExCO),Other (physical),Mechanical ventilation,Mechanical ventilation,5,http://www.ensaiosclinicos.gov.br/rg/RBR-2dxyx4/,,,,2020-06-11,2020-06-11,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-14 17:37:00,2021-01-14 17:55:26,IP Address,158.181.79.178,100,1106,True,2021-01-14 17:55:26,R_2w0PcZHl9V4cCn1,,,test@test.com,,52.5294952392578125,13.4694976806640625,gl,EN,yes,yes,no,Trials says it's about reducing the burden of disease but looks at time on respirator which is related to treatment of COVID,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CounterCovid,imatinib AND covid AND trial,,,,,Found a cross-registration: EUCTR2020-001236-10-NL,,,,MSH,2020-06-30,NL8491,Netherlands Trial Register,2020-03-31,2020-03-31,FALSE,UMC Amsterdam,Recruiting,Not Applicable,Interventional,Netherlands,Countering Lung Damage in COVID-19 infection (CounterCovid) study,Drug,Imatinib,Imatinib,386,https://trialregister.nl/trial/8491,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,7,,Open for patient inclusion,TRUE,2,,,,,,,,,,,,,,,
2021-01-14 19:28:08,2021-01-14 20:35:16,IP Address,74.90.123.184,100,4028,True,2021-01-14 20:35:17,R_2wBwNdkFdqO2CjH,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mesenchymal Stem Cells AND ""PLA General Hospital"" AND Covid",Mesenchymal Stem Cells AND Covid AND trial,Jian Bo AND covid,Chuanzhu Li AND covid,,,,,,,ND,2020-06-30,ChiCTR2000030138,ChiCTR,2020-02-24,2020-02-24,FALSE,Chinese PLA General Hospital,Not Recruiting,Phase 2,Interventional,China,Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19),ATMP,Cells (mesenchymal),Cells (mesenchymal),60,http://www.chictr.org.cn/showproj.aspx?proj=50004,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-14 20:35:30,2021-01-14 20:39:14,IP Address,74.90.123.184,100,224,True,2021-01-14 20:39:14,R_1ojtUqZUd8i1djh,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,suramin sodium AND Covid,Wu Guolan AND Covid,Shentu Jianzhong AND Covid,,,,,,,,ND,2020-06-30,ChiCTR2000030029,ChiCTR,2020-02-21,2020-02-20,TRUE,The First Affiliated Hospital of Zhejiang University School of Medicine,Not Recruiting,Not Applicable,Interventional,China,A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19),Drug,Suramin,Suramin,20,http://www.chictr.org.cn/showproj.aspx?proj=49824,,,,2020-05-30,2020-05-30,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-14 20:39:19,2021-01-14 20:52:08,IP Address,74.90.123.184,100,769,True,2021-01-14 20:52:09,R_23eluYnV1CRoRoZ,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Favipiravir AND Covid AND Trial,Zhaohong Nie AND Covid,Zhaohui Tong AND Covid,,,,,,,,ND,2020-06-30,ChiCTR2000029996,ChiCTR,2020-02-20,2020-02-20,FALSE,"Beijing Chaoyang Hospital, Capital Medical University",Recruiting,Phase 2,Interventional,China,"A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)",Drug,Favipiravir,Favipiravir,60,http://www.chictr.org.cn/showproj.aspx?proj=49510,,,,2020-04-20,2020-04-20,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-14 21:17:40,2021-01-14 21:23:12,IP Address,74.90.123.184,100,331,True,2021-01-14 21:23:12,R_3EyworFCV2iiQrQ,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Protocol: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04534-5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Short Wave Electrotherapy AND Covid,Hong Chen AND Covid,,,,,,,,,ND,2020-06-30,ChiCTR2000029972,ChiCTR,2020-02-17,2020-02-17,FALSE,"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,Not Applicable,Interventional,China,A randomized controlled trial for the Efficacy of Ultra Short Wave Electrotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19),Other (physical),Ultra short wave electrotherapy,Ultra short wave electrotherapy,40,http://www.chictr.org.cn/showproj.aspx?proj=49664,,,,2020-05-17,2020-05-17,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-14 21:23:22,2021-01-14 21:29:07,IP Address,74.90.123.184,100,345,True,2021-01-14 21:29:08,R_WcA41CFdmg1A5Lb,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Thalidomide AND Covid,Jinglin Xia AND Thalidomide,,,,,,,,,ND,2020-06-30,NCT04273581,ClinicalTrials.gov,2020-02-14,2020-02-18,FALSE,The First Affiliated Hospital of Wenzhou Medical University,Not Recruiting,Phase 2,Interventional,No Country Given,The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19,Drug,Thalidomide + Corticosteroids,Thalidomide; Methylprednisolone,40,https://clinicaltrials.gov/show/NCT04273581,,,2020-04-30,2020-05-30,2020-04-30,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-14 21:29:25,2021-01-14 21:34:42,IP Address,74.90.123.184,100,316,True,2021-01-14 21:34:42,R_DqQMj81h8JxTb0d,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ma-Xing-Shi-Gan-Tang AND Covid,Sheng-Jiang-San AND Covid,Rui Pan AND Covid,,,,,,,,ND,2020-06-30,ChiCTR2000030314,ChiCTR,2020-02-28,2020-02-28,FALSE,"Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences",Not Recruiting,Not Applicable,Interventional,No Country Given,Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San in the treatment of children with novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,40,http://www.chictr.org.cn/showproj.aspx?proj=50248,,,,2020-04-28,2020-04-28,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-14 21:36:27,2021-01-14 21:36:45,IP Address,74.90.123.184,100,17,True,2021-01-14 21:36:45,R_UftIQbfqXKgdlv3,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,ChiCTR2000030091,ChiCTR,2020-02-23,2020-02-22,TRUE,West China Hospital of Sichuan University,Not Recruiting,Not Applicable,Interventional,China,A prospective randomized controlled trial for the home exercise prescription intervention in nursing students during epidemic of novel coronary pneumonia (COVID-19),Other (exercise),Exercise,Exercise,200,http://www.chictr.org.cn/showproj.aspx?proj=49914,,,,2020-03-22,2020-03-22,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-14 21:36:50,2021-01-14 22:12:34,IP Address,74.90.123.184,100,2144,True,2021-01-14 22:12:35,R_2YlbPL9pq358zVk,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Shen Ning AND Covid,Hydroxychloroquine AND Peking University Third Hospital,,,,,,,,,ND,2020-06-30,ChiCTR2000029899,ChiCTR,2020-02-16,2020-02-17,FALSE,Peking University Third Hospital,Recruiting,Phase 4,Interventional,China,"Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial",Drug,Hydroxychloroquine vs. Chloroquine,Chloroquine; Hydroxychloroquine,100,http://www.chictr.org.cn/showproj.aspx?proj=49536,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-15 04:23:34,2021-01-15 04:28:48,IP Address,74.90.123.184,100,313,True,2021-01-15 04:28:49,R_3hyE0U9E07Fg07r,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ebastine AND Covid,Zhang Dan AND Ebastine,Xu Zhihua AND Covid,,,,,,,,ND,2020-06-30,ChiCTR2000030535,ChiCTR,2020-03-06,2020-02-20,TRUE,Wuhan Red Cross Hospital,Recruiting,Phase 4,Interventional,China,Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine,Drug,Ebastine + Interferon alpha + Lopinavir vs. Interferon alpha + Lopinavir,Ebastine; interferon alpha; lopinavir,100,http://www.chictr.org.cn/showproj.aspx?proj=49790,,,,2020-03-30,2020-03-30,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-15 04:29:02,2021-01-15 04:35:13,IP Address,74.90.123.184,100,371,True,2021-01-15 04:35:14,R_1FeNQiprHOVDv54,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,,10.1101/2020.03.17.20037432,,https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v4,,,,,,,,,,,,,2020-03-20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Preprint Authors,Favipiravir AND arbidol AND covid AND trial,,,,,,,,,ND,2020-06-30,ChiCTR2000030254,ChiCTR,2020-02-26,2020-02-20,TRUE,Zhongnan Hospital of Wuhan University,Not Recruiting,Not Applicable,Interventional,China,"the Efficacy and Safety of Favipiravir for novel coronavirus–infected pneumonia: A multicenter, randomized, open, positive, parallel-controlled clinical study",Drug,Favipiravir vs. Umifenovir,Favipiravir; Umifenovir,240,http://www.chictr.org.cn/showproj.aspx?proj=50137,,,,2020-03-20,2020-03-20,0,0,,,,,,,,,,,8,,Completed,TRUE,2,,,,,,,,,,,,,,true,
2021-01-15 04:35:28,2021-01-15 04:40:23,IP Address,74.90.123.184,100,294,True,2021-01-15 04:40:23,R_1ONLPXgNy4A3BPc,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Qingfei Paidu AND Covid,Zhou Shijing,Li Xugui,,,,,,,,ND,2020-06-30,ChiCTR2000030810,ChiCTR,2020-03-15,2020-02-23,TRUE,Hubei Provincial Hospital of Integrated Chinese and Western Medicine,Recruiting,Phase 1,Interventional,China,Clinical observation and evaluation of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in Hubei 672 Orthopaedics Hospital of Integrated Chinese&Western Medicine,Traditional Medicine (Unspecified),Traditional Medicine,Traditional Medicine,100,http://www.chictr.org.cn/showproj.aspx?proj=50986,,,,2020-03-30,2020-03-30,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-15 04:40:29,2021-01-15 04:45:22,IP Address,74.90.123.184,100,293,True,2021-01-15 04:45:22,R_1LUqsew4e39POz6,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Protocol: https://dx.doi.org/10.1097%2FMD.0000000000023874,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Truncated Torsion AND covid,,,,,,Protocol notes follow-up ongoing,,,,ND,2020-06-30,ChiCTR2000030836,ChiCTR,2020-03-15,2020-02-01,TRUE,Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Not Recruiting,Phase 4,Interventional,China,Novel coronavirus pneumonia (COVID-19) combined with Chinese and Western medicine based on ''Internal and External Relieving -Truncated Torsion'' strategy,Traditional Medicine + Western Medicine,Traditional Medicine,Traditional Medicine,300,http://www.chictr.org.cn/showproj.aspx?proj=51054,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-15 04:45:33,2021-01-15 04:52:23,IP Address,74.90.123.184,100,410,True,2021-01-15 04:52:23,R_1gMIcJzL2j9QC3b,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Immunoglobulin AND covid AND trial AND Tongji,Xiang Cheng AND covid AND immuniglobulin,,,,,,,,,ND,2020-06-30,ChiCTR2000030841,ChiCTR,2020-03-15,2020-02-17,TRUE,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,Not Applicable,Interventional,China,Exploratory study for Immunoglobulin From Cured COVID-19 Patients in the Treatment of Acute Severe novel coronavirus pneuvirus (COVID-19),ATMP,Immunoglobulin,Immunoglobulin,10,http://www.chictr.org.cn/showproj.aspx?proj=51072,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-15 04:53:50,2021-01-15 04:55:44,IP Address,74.90.123.184,100,114,True,2021-01-15 04:55:44,R_0Nh1LxMPrStG8yl,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,unknown,no,Questionable as to if this is actually a trial. Trial ID search turned up nothing.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,ND,2020-06-30,ChiCTR2000030855,ChiCTR,2020-03-16,2020-02-01,TRUE,Third Affiliated Hospital of Zunyi Medical University,Not Recruiting,Phase 1,Interventional,No Country Given,Study for the effect of external diaphragmatic pacing assisted invasive ventilation and weaning in patients with severe novel coronavirus pneumonia (COVID-19),Other (physical),Mechanical ventilation,Mechanical ventilation,200,http://www.chictr.org.cn/showproj.aspx?proj=51090,,,,2020-05-01,2020-05-01,0,0,,,,,,,,,,,8,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-15 04:55:55,2021-01-15 05:04:25,IP Address,74.90.123.184,100,510,True,2021-01-15 05:04:25,R_1eJg9dxgpcZVgnp,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,azvudine AND covid,Wan Yuanhao AND covid,Li Suyun AND covid,,,,,,,,ND,2020-06-30,ChiCTR2000030487,ChiCTR,2020-03-04,2020-03-04,FALSE,The First Affiliated Hospital of He'nan University of Chinese Medicine,Recruiting,Not Applicable,Interventional,China,"A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)",Drug,Azvudine,Azvudine,10,http://www.chictr.org.cn/showproj.aspx?proj=50507,,,,2020-05-04,2020-05-04,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-15 05:04:35,2021-01-15 05:06:00,IP Address,74.90.123.184,100,85,True,2021-01-15 05:06:01,R_6XAVtkSUadN4eL7,,,test@test.com,,40.77459716796875,-73.47609710693359375,gl,EN,yes,unknown,no,"Toeing the line between ""cohort study"" and ""single arm trial."" Also appears to not be approved by ethics. ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,ND,2020-06-30,ChiCTR2000030490,ChiCTR,2020-03-04,2020-02-01,TRUE,Huo-Shen-Shan Hospital,Recruiting,Not Applicable,Interventional,No Country Given,To evaluate the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsules combined with hydrogen-rich water in the treatment of novel coronavirus pneumonia (COVID-19),Drug,Diammonium glycyrrhizinate + Hydrogen,Diammonium glycyrrhizinate; Hydrogen,100,http://www.chictr.org.cn/showproj.aspx?proj=50487,,,,2020-03-31,2020-03-31,0,0,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-15 15:18:28,2021-01-15 15:25:57,IP Address,82.33.104.78,100,448,True,2021-01-15 15:25:57,R_1OE2LlxnNRDGOgd,,,test@test.com,,51.4535064697265625,-2.591705322265625,anonymous,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Favipiravir AND COVID-19 AND  Chloroquine Phosphate AND Lihong Liu,Favipiravir AND COVID-19 AND Beijing Chao Yang Hospital,,,,,,,,,MPJ,2020-06-30,NCT04319900,ClinicalTrials.gov,2020-03-20,2020-03-05,FALSE,"Beijing Chaoyang Hospital, Capital Medical University",Recruiting,Phase 2/Phase 3,Interventional,China,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Drug,Chloroquine + Favipiravir vs. Favipiravir,Chloroquine; favipiravir,150,https://clinicaltrials.gov/show/NCT04319900,ChiCTR2000030987,,2020-04-30,2020-06-25,2020-04-30,0,0,,,,,,,,,,,9,,Recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-15 15:26:03,2021-01-15 15:26:45,IP Address,82.33.104.78,100,42,True,2021-01-15 15:26:46,R_2uPMd60Z4HpSsAU,,,test@test.com,,51.4535064697265625,-2.591705322265625,anonymous,EN,yes,yes,no,,,no,2020-04-07,NA,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MPJ,2020-06-30,ChiCTR2000030046,ChiCTR,2020-02-21,2020-02-07,TRUE,"The First People's Hospital of Jiangxia District, Wuhan (Union Jiangnan Hospital)",Recruiting,Not Applicable,Interventional,China,A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19),ATMP,Plasma,Plasma,10,http://www.chictr.org.cn/showproj.aspx?proj=49861,,,,2020-08-31,2020-08-31,0,0,,10.1073/pnas.2004168117,,10.1073/pnas.2004168117,,full_results_journal_article,,,2020-04-06,,9,,Recruiting,TRUE,1,32253318,full_results_journal_article,2020-04-06,rbgoabfk,https://www.ncbi.nlm.nih.gov/pubmed/32253318/; https://doi.org/10.1073/pnas.2004168117,Effectiveness of convalescent plasma therapy in severe COVID-19 patients,,,,,,,,,2020-04-07
2021-01-15 15:26:50,2021-01-15 15:29:58,IP Address,82.33.104.78,100,187,True,2021-01-15 15:29:58,R_30vOnIZEHjjdf1h,,,test@test.com,,51.4535064697265625,-2.591705322265625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,," Azivudine AND COVID-19 AND Cheng Zhenshun "," Azivudine AND  coronavirus AND pneumonia AND Wuhan University  ",,,,,,,,,MPJ,2020-06-30,ChiCTR2000030041,ChiCTR,2020-02-21,2020-02-25,FALSE,Zhongnan Hospital of Wuhan University,Not Recruiting,Not Applicable,Interventional,China,"A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19)",Drug,Azvudine,Azvudine,40,http://www.chictr.org.cn/showproj.aspx?proj=49891,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,1,,,,,,,,,,,,,,,
2021-01-15 20:59:42,2021-01-16 11:43:33,IP Address,89.12.199.243,100,53030,True,2021-01-16 11:43:33,R_1l5zX4cQSf9j95A,,,test@test.com,,50.8531036376953125,12.894195556640625,gl,EN,yes,no,,Co-infections in COVID-19 Critically Ill and Antibiotic Management,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04382092,ClinicalTrials.gov,2020-05-06,2020-03-23,TRUE,"University Clinic, UCLouvain",Not Recruiting,Not Applicable,Interventional,Belgium,Co-infection Management in COVID-19 Critically Ill,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,32,https://clinicaltrials.gov/show/NCT04382092,,,2020-04-24,2020-04-24,2020-04-24,0,0,,,,,,,,,,,8,,Completed,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 12:54:19,2021-01-17 12:57:00,IP Address,78.55.131.112,100,160,True,2021-01-17 12:57:00,R_3nVPbZQ4KZ90Onq,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04252885,ClinicalTrials.gov,2020-01-30,2020-01-28,TRUE,Guangzhou 8th People's Hospital,Recruiting,Phase 4,Interventional,China,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,Drug,Lopinavir/ritonavir vs. umifenovir,Lopinavir/ritonavir; Umifenovir,125,https://clinicaltrials.gov/show/NCT04252885,,,2020-04-30,2020-05-31,2020-04-30,0,0,,10.1101/2020.03.19.20038984,,10.1101/2020.03.19.20038984,10.1016/j.medj.2020.04.001,full_results_preprint,full_results_journal_article,,2020-04-15,2020-05-04,9,,Completed,TRUE,2,,full_results_preprint,2020-04-15,9hknw4ws,https://doi.org/10.1101/2020.03.19.20038984,An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI),,,,full_results_journal_article,2020-05-04,,true,true,
2021-01-17 12:57:10,2021-01-17 13:03:19,IP Address,78.55.131.112,100,368,True,2021-01-17 13:03:19,R_2DRFw372RPM3Vsm,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"ChiCTR2000030333  ",,,,,,,,,,,,,,,Just found th,,,,,,A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection,"A randomized, open-label study to evaluate the efficacy and safety of Pirfenidone in patients with severe and critical novel coronavirus infection (COVID-19)",Pirfenidone  Huilan Zhang covid 19,,,,"ChiCTR2000030333  <-- just found out that this trial maps to that registry entry. Add during reconcilation! ",,,,PG,2020-06-30,NCT04282902,ClinicalTrials.gov,2020-02-10,2020-02-04,TRUE,Huilan Zhang,Recruiting,Phase 3,Interventional,China,A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection,Drug,Pirfenidone,Pirfenidone,294,https://clinicaltrials.gov/show/NCT04282902,,,2020-04-30,2020-06-01,2020-04-30,0,1,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 13:03:31,2021-01-17 13:07:37,IP Address,78.55.131.112,100,245,True,2021-01-17 13:07:37,R_DDmDWgLq0nnWTQZ,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Favipiravir Tablets Combine With Chloroquine Phosphate Lihong Liu covid 19,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,,,,,,,,,PG,2020-06-30,NCT04319900,ClinicalTrials.gov,2020-03-20,2020-03-05,FALSE,"Beijing Chaoyang Hospital, Capital Medical University",Recruiting,Phase 2/Phase 3,Interventional,China,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Drug,Chloroquine + Favipiravir vs. Favipiravir,Chloroquine; favipiravir,150,https://clinicaltrials.gov/show/NCT04319900,ChiCTR2000030987,,2020-04-30,2020-06-25,2020-04-30,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 13:07:44,2021-01-17 13:14:56,IP Address,78.55.131.112,100,431,True,2021-01-17 13:14:57,R_9WXW5aUKflfg6Z3,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,europe_pmc,,,,full_results_preprint,full_results_journal_article,,,,10.1101/2020.03.22.20034041,,https://www.medrxiv.org/content/10.1101/2020.03.22.20034041v1,10.1097/MD.0000000000023357,"33235105 ",https://journals.lww.com/md-journal/Fulltext/2020/11250/First_clinical_study_using_HCV_protease_inhibitor.53.aspx,,,,,,,,,,2020-03-24,,2020-11-25,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04291729,ClinicalTrials.gov,2020-02-27,2020-02-17,TRUE,The Ninth Hospital of Nanchang,Not Recruiting,Phase 4,Interventional,China,Evaluation of Ganovo (Danoprevir ) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Drug,Danoprevir + Ritonavir (w/ or w/o Interferon),Danoprevir; Ritonavir; Interferon,11,https://clinicaltrials.gov/show/NCT04291729,,,2020-03-19,2020-03-19,2020-03-19,0,0,,,,,,,,,,,9,,Completed,TRUE,2,,,,,,,,,,,,,true,true,
2021-01-17 13:15:03,2021-01-17 13:16:44,IP Address,78.55.131.112,100,100,True,2021-01-17 13:16:44,R_1oA1ZfCCHXuZVnT,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,no,,"They test an extra device for ventilation, does not really count as treating COVID IMO:
The purpose of this study is to compare the use of our bidirectional oxygenation mouthpiece with conventional oxygen support versus conventional oxygen support",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,NCT04326452,ClinicalTrials.gov,2020-03-25,2020-03-27,FALSE,TMC HealthCare,Recruiting,Not Applicable,Interventional,United States,Treating COVID-19 With a Bidirectional Oxygenation Valve,Other (device),Bidirectional Oxygenation Valve,Bidirectional Oxygenation Valve,15,https://clinicaltrials.gov/show/NCT04326452,,,2020-05-01,2020-06-01,2020-05-01,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 13:16:58,2021-01-17 13:18:30,IP Address,78.55.131.112,100,92,True,2021-01-17 13:18:30,R_1k18igyMmjaD636,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,no,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,EUCTR2020-000890-25-FR,EU Clinical Trials Register,2020-03-10,2020-03-05,TRUE,Fondation Méditerranée Infection (FMI) - IHU Méditerranée Infection,Authorised,Phase 3,Interventional,France,Hydroxychloroquine as a treatment for coronavirus disease COVID-19,Drug,Hydroxychloroquine,Hydroxychloroquine,25,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000890-25,,,,,,,,,10.1101/2020.03.16.20037135,,10.1101/2020.03.16.20037135,10.1016/j.ijantimicag.2020.105949,full_results_preprint,full_results_journal_article,,2020-03-20,2020-03-20,9,,,TRUE,2,,full_results_preprint,2020-03-20,tdlcb9bf,https://doi.org/10.1101/2020.03.16.20037135,Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial,,,32205204,full_results_journal_article,2020-03-20,,true,true,
2021-01-17 13:18:40,2021-01-17 13:19:16,IP Address,78.55.131.112,100,36,True,2021-01-17 13:19:17,R_pz4wTG7ALpLrv57,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,ChiCTR2000029418,ChiCTR,2020-01-30,2020-02-03,FALSE,Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine,Recruiting,Not Applicable,Interventional,China,Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a Randomized Controlled Trial,Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,42,http://www.chictr.org.cn/showproj.aspx?proj=48886,,,,2020-08-31,2020-08-31,0,0,,10.1101/2020.03.27.20044974,,10.1101/2020.03.27.20044974,10.3389/fmed.2020.00256,full_results_preprint,full_results_journal_article,,2020-04-01,2020-05-27,9,,Recruiting,TRUE,2,,full_results_preprint,2020-04-01,4as055wh,http://medrxiv.org/cgi/content/short/2020.03.27.20044974v1?rss=1,Guideline-based Chinese herbal medicine treatment plus standard care for severe coronavirus disease 2019 (G-CHAMPS): evidence from China,,,32574340,full_results_journal_article,2020-05-27,,,,
2021-01-17 13:19:23,2021-01-17 13:24:44,IP Address,78.55.131.112,100,321,True,2021-01-17 13:24:45,R_1gvaNeEkm8Dei4c,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Randomized controlled trial for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir ",Qingxian Favipiravir covid-19,,,,,,,,,PG,2020-06-30,ChiCTR2000030113,ChiCTR,2020-02-23,2020-02-22,TRUE,The Third People's Hospital of Shenzhen,Recruiting,Not Applicable,Interventional,No Country Given,Randomized controlled trial for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir,Drug,Favipiravir vs. ritonavir,Favipiravir,30,http://www.chictr.org.cn/showproj.aspx?proj=49988,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 13:24:55,2021-01-17 13:27:57,IP Address,78.55.131.112,100,182,True,2021-01-17 13:27:58,R_2EAYeBIb06ftWFt,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ozone autohemotherapy Huang Huiling  covid-19,,,,,,,,,,PG,2020-06-30,ChiCTR2000030102,ChiCTR,2020-02-23,2020-02-24,FALSE,Tianjin Huanhu Hospital,Recruiting,Not Applicable,Interventional,China,A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19),Drug,Ozone,Ozone,180,http://www.chictr.org.cn/showproj.aspx?proj=49747,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 13:28:04,2021-01-17 13:30:10,IP Address,78.55.131.112,100,125,True,2021-01-17 13:30:11,R_2pLB67CJhelt5fh,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,no,NA,2020-04-07,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"here it seems like they have reviewed the completion date and accounted for an earlier trial end,  and indeed, we found a PNAS publication via automatic search! Posterchild on how it should be done?",team_review,,PG,2020-06-30,ChiCTR2000030046,ChiCTR,2020-02-21,2020-02-07,TRUE,"The First People's Hospital of Jiangxia District, Wuhan (Union Jiangnan Hospital)",Recruiting,Not Applicable,Interventional,China,A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19),ATMP,Plasma,Plasma,10,http://www.chictr.org.cn/showproj.aspx?proj=49861,,,,2020-08-31,2020-08-31,0,0,,10.1073/pnas.2004168117,,10.1073/pnas.2004168117,,full_results_journal_article,,,2020-04-06,,9,,Recruiting,TRUE,2,32253318,full_results_journal_article,2020-04-06,rbgoabfk,https://www.ncbi.nlm.nih.gov/pubmed/32253318/; https://doi.org/10.1073/pnas.2004168117,Effectiveness of convalescent plasma therapy in severe COVID-19 patients,,,,,,,,,2020-04-07
2021-01-17 13:30:15,2021-01-17 13:34:01,IP Address,78.55.131.112,100,225,True,2021-01-17 13:34:01,R_273tkFFFqXAPl6L,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,," A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19) ",Azivudine Wan Yuanhao Henan Zhenshi Biotechnology covid 19,,,,,,,,,PG,2020-06-30,ChiCTR2000030041,ChiCTR,2020-02-21,2020-02-25,FALSE,Zhongnan Hospital of Wuhan University,Not Recruiting,Not Applicable,Interventional,China,"A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19)",Drug,Azvudine,Azvudine,40,http://www.chictr.org.cn/showproj.aspx?proj=49891,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 13:34:08,2021-01-17 13:36:54,IP Address,78.55.131.112,100,166,True,2021-01-17 13:36:55,R_1jJopK3nFPR0XBp,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,no,NA,2020-05-31,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19),,,,,,,,,,PG,2020-06-30,ChiCTR2000030039,ChiCTR,2020-02-21,2020-05-31,FALSE,Affiliated Hospital of Xuzhou Medical University,Recruiting,Not Applicable,Interventional,China,Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19),ATMP,Plasma,Plasma,90,http://www.chictr.org.cn/showproj.aspx?proj=49544,,,,2020-02-01,2020-02-01,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2020-05-31
2021-01-17 13:37:01,2021-01-17 13:42:40,IP Address,78.55.131.112,100,338,True,2021-01-17 13:42:41,R_32ScVXSHDoNWRFL,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,,,,,full_results_journal_article,,,,,10.1001/jamainternmed.2020.5503," 32910179",https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2770680,,,,,,,,,,,,,2020-09-10,2020-04-10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Multicenter randomized controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19),preprint Multicenter randomized controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19),,,,,,,,,PG,2020-06-30,ChiCTR2000030007,ChiCTR,2020-02-19,2020-02-03,TRUE,The First Affiliated Hospital of Guangzhou Medical University,Not Recruiting,Not Applicable,Interventional,China,Multicenter randomized controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19),Drug,G-CSF,G-CSF,200,http://www.chictr.org.cn/showproj.aspx?proj=49619,,,,2020-04-10,2020-04-10,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,true,,
2021-01-17 13:42:46,2021-01-17 13:47:21,IP Address,78.55.131.112,100,274,True,2021-01-17 13:47:21,R_27UxW0QtdJejA3q,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"A prospective, randomized, open label, controlled trial for chloroquine and hydroxychloroquine in patients with severe novel coronavirus pneumonia (COVID-19) ",chloroquine and hydroxychloroquine COVID-19 Zhongshan Hospital,,,,,,,,,PG,2020-06-30,ChiCTR2000029992,ChiCTR,2020-02-18,2020-02-17,TRUE,Zhongshan Hospital Affiliated to Xiamen University,Not Recruiting,Phase 4,Interventional,China,"A prospective, randomized, open label, controlled trial for chloroquine and hydroxychloroquine in patients with severe novel coronavirus pneumonia (COVID-19)",Drug,Chloroquine + Hydroxychloroquine,Chloroquine; Hydroxychloroquine,100,http://www.chictr.org.cn/showproj.aspx?proj=49574,,,,2020-05-20,2020-05-20,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 13:47:29,2021-01-17 13:50:46,IP Address,78.55.131.112,100,197,True,2021-01-17 13:50:46,R_SVSmLxPCKlpxd7z,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,no,NA,2020-04-30,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial ",honeysuckle hubei covid 19,honeysuckle hubei covid 19 Tao,,,,,,,,PG,2020-06-30,ChiCTR2000029954,ChiCTR,2020-02-17,2020-04-30,FALSE,Hubei Hospital of Traditional Chinese Medicine,Recruiting,Phase 4,Interventional,China,"Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,300,http://www.chictr.org.cn/showproj.aspx?proj=49402,,,,2020-02-10,2020-02-10,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2020-04-30
2021-01-17 13:50:53,2021-01-17 13:54:01,IP Address,78.55.131.112,100,187,True,2021-01-17 13:54:01,R_xEJR0AcaIKGdkUp,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,," 	  A multicenter, randomized, open and controlled trial for the efficacy and safety of Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19) ",Kang-Bing-Du granules COVID-19 Sichuan Guangda,,,,,,,,,PG,2020-06-30,ChiCTR2000029781,ChiCTR,2020-02-13,2020-02-14,FALSE,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,Phase 4,Interventional,China,"A multicenter, randomized, open and controlled trial for the efficacy and safety of Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19)",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,160,http://www.chictr.org.cn/showproj.aspx?proj=49138,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 13:54:15,2021-01-17 13:55:28,IP Address,78.55.131.112,100,72,True,2021-01-17 13:55:28,R_1G68rhGa6Z8JNjr,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,no,,this is on massage for COVID 19 kids...I am okay with searching for honeysuckle....but this is not really what we set out to do!,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,ChiCTR2000030324,ChiCTR,2020-02-28,2020-02-28,FALSE,"Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences",Not Recruiting,Not Applicable,Interventional,China,Traditional Chinese Medicine 'Zang-Fu Point-pressing' massage for children with novel coronavirus pneumonia (COVID-19),Traditional Medicine (Other),Traditional Medicine,Traditional Medicine,40,http://www.chictr.org.cn/showproj.aspx?proj=50231,,,,2020-05-28,2020-05-28,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 13:55:35,2021-01-17 13:59:56,IP Address,78.55.131.112,100,261,True,2021-01-17 13:59:56,R_3sbIfCdpFvEkwwC,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"A prospective clinical study for recombinant human interferon alpha 1b spray in the prevention of novel coronavirus (COVID-19) infection in highly exposed medical staffs. ",recombinant human interferon alpha 1b spray prevention COVID-19 Wang,,,,,,,,,PG,2020-06-30,ChiCTR2000030013,ChiCTR,2020-02-19,2020-02-20,FALSE,Chinese PLA General Hospital,Not Recruiting,Phase 4,Interventional,China,A prospective clinical study for recombinant human interferon alpha 1b spray in the prevention of novel coronavirus (COVID-19) infection in highly exposed medical staffs.,Drug,Interferon alfa,Interferon alfa,450,http://www.chictr.org.cn/showproj.aspx?proj=49796,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 14:00:02,2021-01-17 14:02:29,IP Address,78.55.131.112,100,146,True,2021-01-17 14:02:30,R_RgxZaBSt2gHXRnP,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"A randomized, open, parallel-controlled clinical trial on the efficacy and safety of Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19)",Jingyebaidu granules COVID-19 Tongji Hospital,,,,,,,,,PG,2020-06-30,ChiCTR2000029755,ChiCTR,2020-02-12,2020-02-15,FALSE,"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,Phase 4,Interventional,China,"A randomized, open, parallel-controlled clinical trial on the efficacy and safety of Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19)",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,120,http://www.chictr.org.cn/showproj.aspx?proj=49301,,,,2020-05-30,2020-05-30,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 14:02:44,2021-01-17 14:03:46,IP Address,78.55.131.112,100,61,True,2021-01-17 14:03:46,R_8jHMPal8VJe4GXv,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,no,,"They are just looking at the effects of renal replacement therapy The study focuses on the evaluation of ARDS and the severity of pulmonary exudation by the indexes of oxygenation index, extravascular pulmonary water, pulmonary capillary permeability index, inflammatory factor level, TK level and so on. Through the dynamic changes of each index in the course of CRRT treatment monitoring, ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The study focuses on the evaluation of ARDS and the severity of pulmonary exudation by the indexes of oxygenation index, extravascular pulmonary water, pulmonary capillary permeability index, inflammatory factor level, TK level and so on. Through the dynamic changes of each index in the course of CRRT treatment monitoring,",,,PG,2020-06-30,ChiCTR2000030540,ChiCTR,2020-03-06,2020-03-08,FALSE,"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology",Not Recruiting,Not Applicable,Interventional,China,Research for the mechanism of improvement of novel coronavirus pneumonia (COVID-19) patients' pulmonary exudation by continuous renal replacement therapy,Other (renal),Renal replacement therapy,Renal replacement therapy,152,http://www.chictr.org.cn/showproj.aspx?proj=50658,,,,2020-06-08,2020-06-08,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 14:03:53,2021-01-17 14:07:05,IP Address,78.55.131.112,100,192,True,2021-01-17 14:07:06,R_1DSY8OLzfFbvWI9,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia (COVID-19): a randomized, open, controlled trial ",Zedoary Turmeric Oil COVID-19 Hefei Future Pharma Co,Zedoary Turmeric Oil COVID-19 zhang dei,,,,,,,,PG,2020-06-30,ChiCTR2000030518,ChiCTR,2020-03-05,2020-02-29,TRUE,The Second Affiliated Hospital of Wenzhou Medical University,Recruiting,Not Applicable,Interventional,China,"Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia (COVID-19): a randomized, open, controlled trial",Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,60,http://www.chictr.org.cn/showproj.aspx?proj=50586,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 14:07:14,2021-01-17 14:10:36,IP Address,78.55.131.112,100,201,True,2021-01-17 14:10:37,R_33DUUHqf8sgaxcz,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) ",Shenyang Ganovo combined with ritonavir COVID-19,,,,,,,,,PG,2020-06-30,ChiCTR2000030472,ChiCTR,2020-03-03,2020-02-25,TRUE,Shenyang Sixth People's Hospital,Recruiting,Not Applicable,Interventional,China,An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19),Traditional Medicine + Western Medicine,Traditional Medicine,Traditional Medicine,20,http://www.chictr.org.cn/showproj.aspx?proj=49753,,,,2020-06-30,2020-06-30,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 14:10:47,2021-01-17 14:12:50,Spam,78.55.131.112,100,122,True,2021-01-17 14:12:50,R_bKQLiiEVir6deDL,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PG,2020-06-30,ChiCTR2000029757,ChiCTR,2020-02-12,2020-02-14,FALSE,China-Japan Friendship Hospital,Recruiting,Not Applicable,Interventional,China,Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial,ATMP,Plasma,Plasma,200,http://www.chictr.org.cn/showproj.aspx?proj=49081,,,,2021-02-05,2021-02-05,0,0,,10.1001/jama.2020.10044,,10.1001/jama.2020.10044,,full_results_journal_article,,2020-04-28,2020-06-03,,9,,Recruiting,TRUE,2,32492084,full_results_journal_article,2020-06-03,,,,2020-04-28,,,,,,,,
2021-01-17 14:12:58,2021-01-17 14:14:11,IP Address,78.55.131.112,100,73,True,2021-01-17 14:14:12,R_bPjkJiZzh9RG8jn,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,no,,,Sounds like observational only,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Observation of the efficacy of integrated traditional Chinese and western medicine and western medicine alone in the treatment of 2019-nCoV Pneumonia infection in the epidemic situation of 2019-nCoV Pneumonia.,,,PG,2020-06-30,ChiCTR2000029549,ChiCTR,2020-02-04,2020-02-03,TRUE,Hospital of Chengdu University of Traditional Chinese Medicine,Recruiting,Not Applicable,Interventional,China,Recommendations of Integrated Traditional Chinese and Western Medicine for Novel Coronavirus Pneumonia (COVID-19),Traditional Medicine + Western Medicine,Traditional Medicine,Traditional Medicine,400,http://www.chictr.org.cn/showproj.aspx?proj=49014,,,,2020-05-01,2020-05-01,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 14:14:18,2021-01-17 14:16:54,IP Address,78.55.131.112,100,155,True,2021-01-17 14:16:54,R_x9huBqZKUqN8PW9,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,"This is tough, their hypothesis is that renal replacement therapy helps clear out cytokine response and therefore treat COVID. I'd include. ",,no,NA,2020-05-31,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,," 	  Continuous renal replacement therapy (CRRT) alleviating inflammatory response in severe patients with novel coronavirus pneumonia (COVID-19) associated with renal injury: A Prospective study ",,,,,,,,,,PG,2020-06-30,ChiCTR2000030761,ChiCTR,2020-03-13,2020-05-31,FALSE,"Renji Hospital, Shanghai Jiaotong University School of Medicine",Not Recruiting,Not Applicable,Interventional,China,Continuous renal replacement therapy (CRRT) alleviating inflammatory response in severe patients with novel coronavirus pneumonia (COVID-19) associated with renal injury: A Prospective study,Other (renal),Renal replacement therapy,Renal replacement therapy,20,http://www.chictr.org.cn/showproj.aspx?proj=50956,,,,2020-04-01,2020-04-01,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,2020-05-31
2021-01-17 14:17:03,2021-01-17 14:19:34,IP Address,78.55.131.112,100,150,True,2021-01-17 14:19:35,R_3oHhGi6qD98gNKX,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"This retrospective study has been registered in Chinese Clinical Trial Registry(ChiCTR2000030580, www.chictr.org.cn) <-- exclude!",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"This retrospective study has been registered in Chinese Clinical Trial Registry(ChiCTR2000030580, www.chictr.org.cn)",,,,,,,"There is a result ( https://assets.researchsquare.com/files/rs-35520/v1/541401ca-5ac0-447b-8a0d-4519160a88ac.pdf) but it says:
This retrospective study has been registered in Chinese Clinical Trial Registry(ChiCTR2000030580, www.chictr.org.cn) 

--> Exclude!",team_review,,PG,2020-06-30,ChiCTR2000030580,ChiCTR,2020-03-08,2020-02-01,TRUE,Shanghai General Hospital,Recruiting,Phase 4,Interventional,China,Efficacy and safety of tozumab combined with adamumab(Qletli) in severe and critical patients with novel coronavirus pneumonia (COVID-19),Drug,Adamumab,Adamumab,60,http://www.chictr.org.cn/showproj.aspx?proj=50693,,,,2020-04-30,2020-04-30,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 14:19:43,2021-01-17 14:22:36,IP Address,78.55.131.112,100,173,True,2021-01-17 14:22:36,R_2BhpR5vff0rpfGP,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Jingzhou First People's Hospital Efficacy and safety of Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) ",,,,,,,,,,PG,2020-06-30,ChiCTR2000030187,ChiCTR,2020-02-24,2020-02-25,FALSE,Jingzhou First People's Hospital,Recruiting,Not Applicable,Interventional,China,Clinical study for Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19),Drug,Lopinavir/ritonavir,lopinavir/ritonavir,60,http://www.chictr.org.cn/showproj.aspx?proj=50057,,,,2020-03-25,2020-03-25,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 14:22:45,2021-01-17 14:24:56,IP Address,78.55.131.112,100,130,True,2021-01-17 14:24:56,R_3D1FmXSU3lZa8Ox,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Efficacy and safety of Chinese Herb Medicine Hua-Shi Bai-Du granules in patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China: a prospective, randomized, controlled, open-label trial ",Hua-Shi Bai-Du granules COVID-19 Wuhan,Hua-Shi Bai-Du granules COVID-19 Wuhan Guangdong Provincial Hospital,,,,,,,,PG,2020-06-30,ChiCTR2000030988,ChiCTR,2020-03-20,2020-03-23,FALSE,Guangdong Provincial Hospital of Chinese Medicine,Not Recruiting,Not Applicable,Interventional,China,A RCT for Hua-Shi Bai-Du granules in patients with novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,204,http://www.chictr.org.cn/showproj.aspx?proj=51317,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 14:25:03,2021-01-17 14:27:25,IP Address,78.55.131.112,100,141,True,2021-01-17 14:27:26,R_299XM7cJo8CD6qH,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"''Xinguan 2'' and ''Xinguan 3"" COVID-19 Kong","''Xinguan 2'' and ''Xinguan 3"" COVID-19 Gao ","''Xinguan 2'' and ''Xinguan 3"" ""ChiMCTR2000003149""",,,,,,,,PG,2020-06-30,ChiCTR2000030936,ChiCTR,2020-03-18,2020-03-10,TRUE,Hospital of Chengdu University of Traditional Chinese Medicine,Recruiting,Not Applicable,Interventional,China,A real-world study for the Chinese medicines ''Xinguan 2'' and ''Xinguan 3'' in the treatment of novel coronavirus pneumonia (COVID-19),Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,2840,http://www.chictr.org.cn/showproj.aspx?proj=51100,,,,2020-05-10,2020-05-10,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 14:27:33,2021-01-17 14:30:18,IP Address,78.55.131.112,100,165,True,2021-01-17 14:30:18,R_WxmtaKBI3PitmPD,,,test@test.com,,52.4770965576171875,13.43719482421875,gl,EN,yes,yes,no,"weird protocol of differentz traditional medicines, I'd give it the benefit of the doubt and search for results...",,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The treatment and diagnosis plan of integrated traditional Chinese and Western medicine for novel coronavirus pneumonia (COVID-19) ""Genping """,,,,,,,,,,PG,2020-06-30,ChiCTR2000030923,ChiCTR,2020-03-17,2020-02-15,TRUE,Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine,Recruiting,Not Applicable,Interventional,China,The treatment and diagnosis plan of integrated traditional Chinese and Western medicine for novel coronavirus pneumonia (COVID-19),Traditional Medicine + Western Medicine,Traditional Medicine,Traditional Medicine,400,http://www.chictr.org.cn/showproj.aspx?proj=51139,,,,2020-04-16,2020-04-16,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 15:16:37,2021-01-17 15:19:47,IP Address,69.123.66.147,100,190,True,2021-01-17 15:19:48,R_2qq6XCsQtDeGYnM,,,test@test.com,,41.0550994873046875,-72.42890167236328125,anonymous,EN,yes,yes,no,,,no,2021-03-30,2021-03-30,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COLCOVID,Colchicine AND Argentina,,,,,,,,,ND,2020-06-30,NCT04328480,ClinicalTrials.gov,2020-03-30,2020-04-17,FALSE,Estudios Clínicos Latino América,Recruiting,Phase 3,Interventional,Argentina,The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.,Drug,Colchicine,Colchicine,2500,https://clinicaltrials.gov/show/NCT04328480,,,2020-06-30,2020-08-30,2020-06-30,0,1,,,,,,,,,,,8,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2021-03-30
2021-01-15 20:59:41,2021-01-17 15:29:43,IP Address,69.123.66.147,100,153002,True,2021-01-17 15:29:45,R_piVuwvOHhtH4JFv,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Searched article name and 1st/last authors,,,,,,,,,,ND,2020-06-30,ChiCTR2000029990,ChiCTR,2020-02-18,2020-01-30,TRUE,"Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences",Recruiting,Phase 1/Phase 2,Interventional,China,Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19),ATMP,Cells (mesenchymal),Cells (mesenchymal),120,http://www.chictr.org.cn/showproj.aspx?proj=49674,,,,2020-03-31,2020-03-31,0,0,,10.14336/ad.2020.0228,,10.14336/ad.2020.0228,,full_results_journal_article,,,2020-03-13,,8,,Recruiting,TRUE,2,32257537,full_results_journal_article,2020-03-13,ghfrwccu,https://www.ncbi.nlm.nih.gov/pubmed/32257537/; https://doi.org/10.14336/ad.2020.0228,Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia,,,,,,,true,,
2021-01-17 15:30:25,2021-01-17 16:55:36,IP Address,69.123.66.147,100,5111,True,2021-01-17 16:55:37,R_2YMlz3WTZ2gpSyx,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,full_results_journal_article,,,,,10.1016/j.biopha.2020.110825,33378989,,,,,,,,,,,,,,2020-09-30,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Searched article title and 1st/last authors for preprint,,,,,,,,,,ND,2020-06-30,NCT04310228,ClinicalTrials.gov,2020-03-09,2020-03-08,FALSE,Peking University First Hospital,Recruiting,Not Applicable,Interventional,China,Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,Drug,Favipiravir + tocilizumab vs. favipiravir vs. tocilizumab,Favipiravir; tocilizumab,150,https://clinicaltrials.gov/show/NCT04310228,ChiCTR2000030894,,2020-05-01,2020-05-01,2020-05-01,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,true,,
2021-01-17 15:30:28,2021-01-17 17:16:44,IP Address,69.123.66.147,100,6375,True,2021-01-17 17:16:44,R_2ZZvrZyQJeI9eFG,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,This is a single case-report from this study: https://europepmc.org/article/MED/33061476,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Puren Hospital AND Mesenchymal Stem Cells AND Covid,Yan Liu AND Covid,Yue Zhu AND Covid,,,,,,,,ND,2020-06-30,NCT04339660,ClinicalTrials.gov,2020-04-02,2020-02-01,TRUE,Puren Hospital Affiliated to Wuhan University of Science and Technology,Recruiting,Phase 1/Phase 2,Interventional,China,Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia,ATMP,Cells (mesenchymal),Cells (mesenchymal),30,https://clinicaltrials.gov/show/NCT04339660,,,2020-06-30,2020-06-30,2020-06-30,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 17:16:54,2021-01-17 17:46:23,IP Address,69.123.66.147,100,1768,True,2021-01-17 17:46:23,R_2U9j3BjugTzBIPK,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,"This is listed a ""Prematurely Ended"" on the EUCTR",,no,NA,2020-06-29,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Protocol: https://doi.org/10.1101/2021.01.09.21249263

Oddly enough the EUCTR entry says ""Prematurely ended"" but they just published the protocol.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2020-001445-39,Methylprednisolone AND Tacrolimus AND covid,Xavier Solanich,,,,,,,,ND,2020-06-30,NCT04341038,ClinicalTrials.gov,2020-04-07,2020-04-01,FALSE,Hospital Universitari de Bellvitge,Recruiting,Phase 3,Interventional,Spain,Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury,Drug,Tacrolimus + Corticosteroids,Tacrolimus; Methylprednisolone,84,https://clinicaltrials.gov/show/NCT04341038,EUCTR2020-001445-39,,2020-06-01,2020-07-01,2020-06-01,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2020-06-29
2021-01-17 17:46:38,2021-01-17 17:57:09,IP Address,69.123.66.147,100,630,True,2021-01-17 17:57:10,R_ptrj8ZJoxCVDGsF,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Hyperbaric Oxygen AND Covid,Dazhi Guo,Shuyi Pan,,,,,,,,ND,2020-06-30,ChiCTR2000032011,ChiCTR,2020-04-17,2020-04-17,FALSE,The Sixth Medical Center of PLA General Hospital,Not Recruiting,Not Applicable,Interventional,China,Effecacy and Safety of Hyperbaric Oxygen Therapy to patients with novel coronavirus pneumonia (COVID-19),Drug,Oxygen,Oxygen,45,http://www.chictr.org.cn/showproj.aspx?proj=52142,,,,2020-05-17,2020-05-17,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 17:57:39,2021-01-17 18:09:12,IP Address,69.123.66.147,100,692,True,2021-01-17 18:09:13,R_10TwPKOeuZyaUGN,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,no,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,,,,,full_results_journal_article,,,,,10.1128/AAC.01061-20,32661006,,,,,,,,,,,,,,2020-08-20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,IRCT20100228003449N28,IRCT,2020-03-19,2020-03-15,TRUE,Tehran University of Medical Sciences,Not Recruiting,Phase 2/Phase 3,Interventional,Iran,Interferon in treatment of COVID-19,Drug,Interferon beta vs. hydroxychloroquine + oseltamivir + Lopinavir/ritonavir,Interferon beta; hydroxychloroquine; oseltamivir; lopinavir/ritonavir,30,http://en.irct.ir/trial/46538,,,,,,0,0,,10.1101/2020.05.28.20116467,,10.1101/2020.05.28.20116467,,full_results_preprint,,2020-05-03,2020-05-30,,9,,Recruitment complete,TRUE,2,,full_results_preprint,2020-05-30,ipvog4m8,http://medrxiv.org/cgi/content/short/2020.05.28.20116467v1?rss=1,Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial,2020-05-03,,,,,,true,true,
2021-01-17 18:13:02,2021-01-17 18:21:11,IP Address,69.123.66.147,100,489,True,2021-01-17 18:21:12,R_2agDq44kTlPcxkR,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Looking for title/author in preprints,,,,,,,,,,ND,2020-06-30,NCT04276688,ClinicalTrials.gov,2020-02-11,2020-02-10,TRUE,University of Hong Kong,Not Recruiting,Phase 2,Interventional,Hong Kong,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment",Drug,Lopinavir/ritonavir + Ribavirin + Interferon beta,Lopinavir/ritonavir; Ribavirin; Interferon beta,127,https://clinicaltrials.gov/show/NCT04276688,,,2020-03-30,2020-03-31,2020-03-30,0,1,,10.1016/S0140-6736(20)31042-4,,10.1016/S0140-6736(20)31042-4,,full_results_journal_article,,,2020-05-08,,9,,Completed,TRUE,2,32401715,full_results_journal_article,2020-05-08,8ljnxihr,https://www.sciencedirect.com/science/article/pii/S0140673620310424; https://doi.org/10.1016/s0140-6736(20)31042-4; https://api.elsevier.com/content/article/pii/S0140673620310424; https://www.ncbi.nlm.nih.gov/pubmed/32401715/,"Triple combination of interferon beta-1b, lopinavir‚Äìritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial",,,,,,,true,,
2021-01-17 18:21:27,2021-01-17 18:21:57,IP Address,69.123.66.147,100,29,True,2021-01-17 18:21:57,R_3nk2Ru2imRDrAYr,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,no,,This is about doing endoscopy's differently during covid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04320953,ClinicalTrials.gov,2020-03-21,2020-03-16,TRUE,Changhai Hospital,Not Recruiting,Not Applicable,Interventional,China,Non-contact Endoscopy at Covid-19 Outbreak,Other (device),Non-contact Endoscopy,Non-contact Endoscopy,5,https://clinicaltrials.gov/show/NCT04320953,,,2020-03-26,2020-04-09,2020-03-26,0,0,,,,,,,,,,,9,,Completed,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 18:22:06,2021-01-17 18:34:29,IP Address,129.67.118.176,100,742,True,2021-01-17 18:34:29,R_1eKsyVXsOTOgaIe,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Interferon Beta AND covid AND Iran,Mohammadreza Haji Esmaelie,Seyed Sina Naghibi Irvani,,,,,,,,ND,2020-06-30,NCT04350671,ClinicalTrials.gov,2020-04-14,2020-04-15,FALSE,Shahid Beheshti University of Medical Sciences,Recruiting,Phase 4,Interventional,Iran,Interferon Beta 1a in Hospitalized COVID-19 Patients,Drug,Interferon beta + Lopinavir/Ritonavir + Hydroxychlroquine vs. Lopinavir/Ritonavir + Hydroxychloroquine,Interferon beta; Lopinavir/Ritonavir; Hydroxychloroquine,40,https://clinicaltrials.gov/show/NCT04350671,,,2020-04-20,2020-04-24,2020-04-20,0,0,,,,,,,,,,,9,,Enrolling by invitation,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 18:34:53,2021-01-17 18:42:48,IP Address,129.67.118.176,100,475,True,2021-01-17 18:42:49,R_3piqJJNGAai3gvg,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google,,,,,other,,,,,,,https://acrabstracts.org/abstract/phase-i-trial-of-high-dose-hydroxychloroquine-for-the-treatment-of-ambulatory-patients-with-mild-covid-19-a-study-in-the-effects-of-shifting-public-opinion-on-patient-enrollment/,,,,,,,,,,,,,2020-11-09,2020-05-29,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Reem Jan,University of Chicago AND Hydroxychloroquine,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,,,,This trial was terminated per the conference abstract.,,,,ND,2020-06-30,NCT04351620,ClinicalTrials.gov,2020-04-14,2020-04-01,TRUE,University of Chicago,Recruiting,Phase 1,Interventional,United States,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,Drug,Hydroxychloroquine,Hydroxychloroquine,20,https://clinicaltrials.gov/show/NCT04351620,,,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 18:43:08,2021-01-17 18:44:10,IP Address,129.67.118.176,100,61,True,2021-01-17 18:44:10,R_7WZHrgjtIRBKqSR,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Protocol: https://pubmed.ncbi.nlm.nih.gov/32513231/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04341493,ClinicalTrials.gov,2020-04-07,2020-04-06,TRUE,Hugo Mendieta Zeron,Recruiting,Phase 4,Interventional,Mexico,Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19,Drug,Hydroxychloroquine vs. Nitazoxanide,Hydroxychloroquine; nitazoxanide,86,https://clinicaltrials.gov/show/NCT04341493,,,2020-08-30,2020-12-30,2020-08-30,0,1,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 18:44:25,2021-01-17 18:51:56,IP Address,129.67.118.176,100,451,True,2021-01-17 18:51:57,R_2afvktFeh3KBAyC,,,test@test.com,,51.7154998779296875,-1.2926025390625,gl,EN,yes,yes,no,,,no,2020-10-13,2020-10-13,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Vitamin C AND covid AND trial,AVoCaDO trial AND Covid,,,,,,,,,ND,2020-06-30,NCT04357782,ClinicalTrials.gov,2020-04-17,2020-04-16,TRUE,Veteran Affairs Medical Center,Recruiting,Phase 1/Phase 2,Interventional,United States,Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation,Drug,Vitamin C,Vitamin C,20,https://clinicaltrials.gov/show/NCT04357782,,,2020-06-01,2020-08-01,2020-06-01,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2020-10-13
2021-01-17 21:39:05,2021-01-17 21:43:27,IP Address,69.123.66.147,100,261,True,2021-01-17 21:43:27,R_31G9l3nepB3DPyI,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,unknown,no,Not sure if PEEP settings meets our inclusion criteria.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,ND,2020-06-30,NCT04359251,ClinicalTrials.gov,2020-04-13,2020-03-05,TRUE,"Southeast University, China",Not Recruiting,Not Applicable,Interventional,China,Different PEEP Settings of COVID-19 Induced ARDS,Other (physical),Mechanical ventilation,Mechanical ventilation,20,https://clinicaltrials.gov/show/NCT04359251,,,2020-03-25,2020-03-25,2020-03-25,0,0,,,,,,,,,,,9,,Completed,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 21:44:41,2021-01-17 21:49:10,IP Address,69.123.66.147,100,268,True,2021-01-17 21:49:10,R_qU6Bbp0Hp3FwCkh,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Seyed Sina Naghibi Irvani AND Favipiravir,Sanaz Zargar Balaye Jam AND Favipiravir,Nader Markazi AND Favipiravir,,,,,,,,ND,2020-06-30,NCT04359615,ClinicalTrials.gov,2020-04-18,2020-04-20,FALSE,Shahid Beheshti University of Medical Sciences,Not Recruiting,Phase 4,Interventional,Iran,Favipiravir in Hospitalized COVID-19 Patients,Drug,Favipiravir + Hydroxychloroquine vs. Hydroxychloroquine,Favipiravir; Hydroxychloroquine,40,https://clinicaltrials.gov/show/NCT04359615,,,2020-05-03,2020-05-05,2020-05-03,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 21:49:26,2021-01-17 21:49:51,IP Address,69.123.66.147,100,24,True,2021-01-17 21:49:51,R_xxyod4jp31SmZvH,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04359875,ClinicalTrials.gov,2020-04-18,2020-04-01,TRUE,CHU de Tours,Not Recruiting,Not Applicable,Interventional,France,A Phone-call With a Student/General Practitioner Team to Impact Morbidity of Chronic Patients During COVID-19 Containment,Telehealth,Telehealth,Telehealth,22000,https://clinicaltrials.gov/show/NCT04359875,,,2020-06-01,2020-12-01,2020-06-01,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 21:49:58,2021-01-17 22:04:44,IP Address,69.123.66.147,100,885,True,2021-01-17 22:04:44,R_tGKUUZGwDvrx73j,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,no,2020-09-01,2020-11-30,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Protocol: https://pubmed.ncbi.nlm.nih.gov/32503620/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nooshin Dalili AND Colchicine,Colchicine AND Covid AND trial,,,,,,,,,ND,2020-06-30,NCT04360980,ClinicalTrials.gov,2020-04-22,2020-03-20,TRUE,Shahid Beheshti University of Medical Sciences,Recruiting,Phase 2,Interventional,Iran,The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection,Drug,Colchicine,Colchicine,80,https://clinicaltrials.gov/show/NCT04360980,,,2020-05-20,2020-05-30,2020-05-20,0,1,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2020-11-30
2021-01-17 22:04:57,2021-01-17 22:06:27,IP Address,69.123.66.147,100,89,True,2021-01-17 22:06:27,R_2s6ztlU6r3JFAuN,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,no,2022-04,2022-06,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04363541,ClinicalTrials.gov,2020-04-23,2020-04-01,TRUE,Instituto Nacional de Perinatología,Not Recruiting,Not Applicable,Interventional,No Country Given,Local Thermotherapy for Patients With Moderate Symptoms of COVID-19,Other (device),Heating pad,Heating pad,298,https://clinicaltrials.gov/show/NCT04363541,,,2020-09-01,2020-11-01,2020-09-01,0,1,,,,,,,,,,,9,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,2022-06
2021-01-17 22:06:34,2021-01-17 22:09:09,IP Address,69.123.66.147,100,155,True,2021-01-17 22:09:09,R_2fvbyxJlccbSnCY,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,"This is marginal, as the primary outcome is not specific to Covid but some of the secondary outcomes are.",,no,2021-03-31,2021-04-30,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Protocol: https://pubmed.ncbi.nlm.nih.gov/32503602/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04328441,ClinicalTrials.gov,2020-03-27,2020-03-25,TRUE,UMC Utrecht,Recruiting,Phase 3,Interventional,Netherlands,Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine,ATMP,Vaccine,Vaccine,1500,https://clinicaltrials.gov/show/NCT04328441,,,2020-10-25,2020-12-25,2020-10-25,0,1,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2021-04-30
2021-01-17 22:09:22,2021-01-17 22:10:03,IP Address,69.123.66.147,100,41,True,2021-01-17 22:10:04,R_3rNzAr2eDxsQEzz,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,no,,This is about more safely intubating COVID patients but not about specifically treating/preventing covid.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04365608,ClinicalTrials.gov,2020-04-24,2020-03-20,TRUE,Lazarski University,Recruiting,Not Applicable,Interventional,Poland,Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment,Other (physical),Mechanical ventilation,Mechanical ventilation,90,https://clinicaltrials.gov/show/NCT04365608,,,2020-05-20,2020-05-20,2020-05-20,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 22:10:08,2021-01-17 22:13:31,IP Address,69.123.66.147,100,202,True,2021-01-17 22:13:31,R_215HasdYYlkGPUU,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Checking article title/authors for preprint,,,,,,,,,,ND,2020-06-30,NCT04368377,ClinicalTrials.gov,2020-04-23,2020-04-06,TRUE,University of Milan,Not Recruiting,Phase 2,Interventional,Italy,Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19,Drug,Tirofiban + Clopidogrel + Aspirin + Fondaparinux,Tirofiban; Clopidogrel; Aspirin; Fondaparinux,5,https://clinicaltrials.gov/show/NCT04368377,,,2020-04-23,2020-04-23,2020-04-23,0,0,,10.1016/j.phrs.2020.104950,,10.1016/j.phrs.2020.104950,,full_results_journal_article,,,2020-05-23,,9,,Completed,TRUE,2,32450344,full_results_journal_article,2020-05-23,qx677js6,https://www.sciencedirect.com/science/article/pii/S1043661820312585?v=s5; https://api.elsevier.com/content/article/pii/S1043661820312585; https://www.ncbi.nlm.nih.gov/pubmed/32450344/; https://doi.org/10.1016/j.phrs.2020.104950,"Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study",,,,,,,true,,
2021-01-17 22:13:40,2021-01-17 22:14:54,IP Address,69.123.66.147,100,74,True,2021-01-17 22:14:55,R_cuUzGgn4odntU6R,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04333550,ClinicalTrials.gov,2020-04-01,2020-04-01,FALSE,Kermanshah University of Medical Sciences,Recruiting,Phase 1/Phase 2,Interventional,Iran,Application of Desferal to Treat COVID-19,Drug,Deferoxamine,Deferoxamine,50,https://clinicaltrials.gov/show/NCT04333550,,,2020-09-01,2021-03-01,2020-09-01,0,1,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 22:14:59,2021-01-17 22:45:05,IP Address,69.123.66.147,100,1806,True,2021-01-17 22:45:06,R_8i86xAJTPe7YZyN,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,no,2020-10-15,2020-11-01,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,HBOTCOVID19,Amir Hadanny,,,,,,,,,ND,2020-06-30,NCT04358926,ClinicalTrials.gov,2020-04-21,2020-04-30,FALSE,Assaf-Harofeh Medical Center,Recruiting,Not Applicable,Interventional,Israel,Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),Drug,Oxygen,Oxygen,30,https://clinicaltrials.gov/show/NCT04358926,,,2020-06-30,2020-07-30,2020-06-30,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2020-11-01
2021-01-17 22:45:15,2021-01-17 22:51:58,IP Address,69.123.66.147,100,402,True,2021-01-17 22:51:59,R_10TOkoP0OYDJjFm,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04372693,ClinicalTrials.gov,2020-04-27,2020-02-01,TRUE,Kasr El Aini Hospital,Recruiting,Not Applicable,Interventional,Egypt,Unplanned Shifting to Online Distance Learning: Nursing Students' Perception and Achievement,Other,Other,Other,180,https://clinicaltrials.gov/show/NCT04372693,,,2020-05-30,2020-06-30,2020-05-30,0,0,,,,,,,,,,,9,,Enrolling by invitation,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 23:01:34,2021-01-17 23:22:51,IP Address,69.123.66.147,100,1277,True,2021-01-17 23:22:52,R_27kyYnUjK9v7FWN,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Juli Benbenisty,Tocilizumab AND severe covid AND israel,,,,,,,,,ND,2020-06-30,NCT04377750,ClinicalTrials.gov,2020-04-23,2020-04-08,TRUE,Hadassah Medical Organization,Recruiting,Phase 4,Interventional,Israel,The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,Drug,Tocilizumab,Tocilizumab,500,https://clinicaltrials.gov/show/NCT04377750,,,2020-04-29,2021-05-08,2020-04-29,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 23:22:57,2021-01-17 23:23:24,IP Address,69.123.66.147,100,26,True,2021-01-17 23:23:24,R_3RdYgkhpeJieSAz,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,no,,Reduction of contamination for covid but not direct tx or prevention.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04379453,ClinicalTrials.gov,2020-04-27,2020-04-27,FALSE,Hospital Israelita Albert Einstein,Recruiting,Not Applicable,Interventional,Brazil,Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses,Procedure,Percutaneous Cardiovascular Intervention,Percutaneous Cardiovascular Intervention,10,https://clinicaltrials.gov/show/NCT04379453,,,2020-04-27,2020-04-27,2020-04-27,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-17 23:23:28,2021-01-17 23:23:38,IP Address,69.123.66.147,100,9,True,2021-01-17 23:23:38,R_qxA6ekRpuGmwAw1,,,test@test.com,,41.0550994873046875,-72.42890167236328125,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,ND,2020-06-30,NCT04381000,ClinicalTrials.gov,2020-05-07,2020-04-01,TRUE,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory,Recruiting,Not Applicable,Interventional,Greece,Quarantine and Telerehabilitation in Chronic Pain Patients During COVID-19 Pandemic.,Telehealth,Physio & Rehabilitation,Physio & Rehabilitation,170,https://clinicaltrials.gov/show/NCT04381000,,,2020-05-29,2020-06-10,2020-05-29,0,0,,,,,,,,,,,9,,Completed,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 08:52:58,2021-01-18 08:53:45,IP Address,158.181.71.94,100,47,True,2021-01-18 08:53:45,R_3fId3mxJSWlGDTu,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,no,,,case series,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,ChiCTR2000033323,ChiCTR,2020-05-28,2020-05-11,TRUE,No Sponsor Name Given,Not Recruiting,Not Applicable,Interventional,Iraq,Severe Reluctant COVID-19 Patients Responding to Convalescent  Plasma; A case series,Drug,Plasma,Plasma,24,http://www.chictr.org.cn/showproj.aspx?proj=54346,,,,2020-05-19,2020-05-19,0,0,,,,,,,,,,,9,,Completed,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 08:53:53,2021-01-18 09:00:28,IP Address,158.181.71.94,100,395,True,2021-01-18 09:00:29,R_3nNm7Bq0AN7c1r3,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,unknown,yes,no,"under ""interventional,"" specified as ""case study"" so not sure whether to count for CT since design unclear",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MSH,2020-06-30,ChiCTR2000033491,ChiCTR,2020-06-02,2020-02-11,TRUE,Huo-Shen-Shan Hospital,Not Recruiting,Phase 4,Interventional,China,Oral Favipiravir for Patients with Delayed SARS-Cov-2 viral RNA Clearance,Drug,Favipiravir,Favipiravir,9,http://www.chictr.org.cn/showproj.aspx?proj=54278,,,,2020-05-12,2020-05-12,0,0,,,,,,,,,,,9,,Completed,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 09:08:59,2021-01-18 09:19:01,IP Address,158.181.71.94,100,602,True,2021-01-18 09:19:02,R_1YOGZVRaIf3BU5P,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google_scholar,,,,,full_results_preprint,,,,,10.1101/2020.07.13.20146175,,https://www.medrxiv.org/content/10.1101/2020.07.13.20146175v1,,,,,,,,,,,,,2020-07-20,NA,,,,,,,,,,,,,,,,,,,,,,,,trial number (UMIN000040341) reported in full-text,,,,,,"""Qing Fei Pai Du Tang"" AND covid",,,,,,,,,,MSH,2020-06-30,JPRN-UMIN000040341,JPRN,2020-05-09,2020-05-09,FALSE,Takanawa Clinic,Not Recruiting,Not Applicable,Interventional,Japan,Immunological efficacy of Qing Fei Pai Du Tang for COVID-19,Traditional Medicine (Drug),Traditional Medicine,Traditional Medicine,15,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046023,,,,2020-05-16,2020-05-16,0,0,,,,,,,,,,,9,,No longer recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 09:19:24,2021-01-18 09:30:45,IP Address,158.181.71.94,100,681,True,2021-01-18 09:30:46,R_1gTRYxe54n4VoDI,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600.pub3/references says it includes results from this study but not finding link: RBR‐4vm3yy {published data only} RBR-4vm3yy. Effect of convalescent plasma in patients with severe COVID-19. www.ensaiosclinicos.gov.br/rg/RBR-4vm3yy/ (first received 11 May 2020).,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"""convalescent plasma"" AND covid AND trial AND (kurtz OR brazil)","""convalescent plasma"" AND covid AND trial AND kurtz",,,,,,,,,MSH,2020-06-30,RBR-4vm3yy,REBEC,2020-05-15,2020-04-19,TRUE,Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti,Recruiting,Not Applicable,Interventional,Brazil,Effect of convalescent plasma in patients with severe COVI-19,ATMP,Plasma,Plasma,20,http://www.ensaiosclinicos.gov.br/rg/RBR-4vm3yy/,,,,2020-05-31,2020-05-31,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 09:31:08,2021-01-18 09:34:47,IP Address,158.181.71.94,100,219,True,2021-01-18 09:34:48,R_3CJzKxIL7lqCV61,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,no,,,hospital resources during COVID,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,ISRCTN11384058,ISRCTN,2020-05-26,2020-04-01,TRUE,Policlinico San Martino Genoa,Recruiting,Not Applicable,Interventional,Italy,"A collaborative pilot study to monitor and optimise access to urgent surgery during the period of reduced resources in Genoa, Italy caused by the COVID-19 pandemic, using a bespoke referral process and the SWALIS 2020 model to prioritise surgery by clinical urgency and waiting time",Health System,No Intervention,No Intervention,300,http://isrctn.com/ISRCTN11384058,,,,2020-06-15,2020-06-15,0,0,,,,,,,,,,,9,,No longer recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 09:34:55,2021-01-18 09:36:31,IP Address,158.181.71.94,100,95,True,2021-01-18 09:36:31,R_5jUysUK3JjyC1gZ,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,no,,,"Observational, evaluate robot to do covid swabs on hospital staff",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,DRKS00021420,German Clinical Trials Register,2020-04-16,2020-04-01,TRUE,Technische Universität München,Recruiting,Phase 1,Interventional,Germany,Observational clinical trial for the evaluation of an automated nasal and pharyngeal swab exam to test COVID-19 patients,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,30,http://www.drks.de/DRKS00021420,,,,,,0,1,,,,,,,,,,,9,,Recruiting ongoing,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 09:36:41,2021-01-18 09:39:08,IP Address,158.181.71.94,100,146,True,2021-01-18 09:39:08,R_1IznkkOi85hFps4,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,no,,"ventilation hood for covid and other respiratory diseases, but outcomes about the device not covid treatment or prevention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,ACTRN12620000500954,ANZCTR,2020-04-22,2020-05-01,FALSE,Western Health,Not Recruiting,Not Applicable,Interventional,Australia,A reusable personalised ventilation hood: A phase 1 safety study of a new device (McMonty) in patients with suspected or confirmed COVID-19.,Other (device),Hood,Hood,20,https://anzctr.org.au/ACTRN12620000500954.aspx,,,,2020-06-01,2020-06-01,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 09:39:17,2021-01-18 09:40:18,IP Address,158.181.71.94,100,61,True,2021-01-18 09:40:18,R_2t6a3Wr7mawmy7e,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,no,,,"simulation, no humans",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,ACTRN12620000579998,ANZCTR,2020-05-19,2020-05-20,FALSE,Mackay Hospital and Health Service,Not Recruiting,Not Applicable,Interventional,Australia,"In a simulation environment, is there a difference in time taken for consultant anaesthetists to perform spinal anaesthesia as compared to general anaesthesia on women, with suspected or confirmed COVID-19, who require emergency caesarean delivery?",Other,No Intervention,No Intervention,10,https://anzctr.org.au/ACTRN12620000579998.aspx,,,,2020-06-01,2020-06-01,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 09:40:24,2021-01-18 09:52:36,IP Address,158.181.71.94,100,732,True,2021-01-18 09:52:37,R_eevxBee5xvtmEwh,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,,,,,full_results_journal_article,,,,,10.1093/jac/dkaa334,32812039,,,,,,,,,,,,,,2020-08-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sofosbuvir AND daclatasvir AND sadeghi,,,,,,,,,,MSH,2020-06-30,IRCT20200128046294N2,IRCT,2020-03-14,2020-03-26,FALSE,Digestive Disease Research Institute,Not Recruiting,Phase 3,Interventional,Iran,Study to Evaluate the Safety and Efficacy of Sofosbuvir/Daclatasvir in Participants with Moderate to Severe Coronavirus Disease (COVID-19),Drug,Sofosbuvir + Daclatasvir,Sofosbuvir; Daclatasvir,70,http://en.irct.ir/trial/46463,,,,2020-05-18,2020-05-18,0,0,,,,,,,,,,,7,,Recruitment complete,TRUE,2,,,,,,,,,,,,,true,,
2021-01-18 09:52:51,2021-01-18 10:06:35,IP Address,158.181.71.94,100,823,True,2021-01-18 10:06:35,R_Ufhu3kKkJq42lVv,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,europe_pmc,,,,,full_results_preprint,,,,," 10.21203/rs.3.rs-91430/v1",,https://www.researchsquare.com/article/rs-91430/v1,,,,,,,,,,,,,2020-10-19,2020-06-04,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,(hydroxychloroquine AND arbidol) OR Umifenovir AND covid AND tehran,hydroxychloroquine AND (arbidol OR Umifenovir) AND covid AND tehran,,,,,,,,,MSH,2020-06-30,IRCT20200523047550N1,IRCT,2020-06-06,2020-04-20,TRUE,Tehran University of Medical Sciences,Not Recruiting,Phase 3,Interventional,Iran,Effect of Umifenovir in treatment of covid-19,Drug,Umifenovir + Hydroxychloroquine vs Hydroxychloroquine,Umifenovir; Hydroxychloroquine,50,http://en.irct.ir/trial/48495,,,,2020-05-25,2020-05-25,0,0,,,,,,,,,,,7,,Recruitment complete,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 10:21:11,2021-01-18 10:37:44,IP Address,158.181.71.94,100,992,True,2021-01-18 10:37:45,R_2Ey1PkEI2kFCEiB,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"methylprednisolone AND ""Glucocorticoid therapy"" AND covid AND trial","(TITLE:""(methylprednisolone OR glucocorticoid) AND covid"")","(TITLE:""methylprednisolone AND covid"")",,,,,,,,MSH,2020-06-30,NCT04244591,ClinicalTrials.gov,2020-01-23,2020-01-26,FALSE,Peking Union Medical College Hospital,Not Recruiting,Phase 2/Phase 3,Interventional,China,Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure,Drug,Corticosteroids,Methylprednisolone,80,https://clinicaltrials.gov/show/NCT04244591,,,2020-04-13,2020-04-13,2020-04-13,0,0,,,,,,,,,,,7,,Completed,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 10:37:54,2021-01-18 10:43:55,IP Address,158.181.71.94,100,361,True,2021-01-18 10:43:56,R_2w0pRhdtAMrSxpB,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,methylprednisolone AND glucocorticoid AND covid AND huanzhong,"methylprednisolone AND glucocorticoid AND covid AND ""huanzhong""",,,,,,,,,MSH,2020-06-30,NCT04273321,ClinicalTrials.gov,2020-02-15,2020-02-14,TRUE,"Beijing Chaoyang Hospital, Capital Medical University",Not Recruiting,Not Applicable,Interventional,China,Efficacy and Safety of Corticosteroids in COVID-19,Drug,Corticosteroids,Methylprednisolone,86,https://clinicaltrials.gov/show/NCT04273321,,,2020-04-15,2020-04-15,2020-04-15,0,0,,,,,,,,,,,7,,Completed,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 10:44:08,2021-01-18 10:55:12,IP Address,158.181.71.94,100,664,True,2021-01-18 10:55:13,R_2PdrAt0xzrUTne9,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,no,2021-05-21,2021-05-21,0,,,,,,full_results_journal_article,other,other,summary_results,,10.1056/NEJMoa2007764,32445440,https://www.nejm.org/doi/10.1056/NEJMoa2007764,,,https://clinicaltrials.gov/ProvidedDocs/05/NCT04280705/Prot_001.pdf,,,https://clinicaltrials.gov/ProvidedDocs/05/NCT04280705/SAP_002.pdf,,,https://clinicaltrials.gov/ct2/show/results/NCT04280705,,,,2020-10-08,2020-04-22,2020-04-02,,2020-05-29,,2020-09-25,,,,,,,,,,,,,,,,,,,"Same as interim result we found with updates. What date to use? ""A preliminary version of this article was published on May 22, 2020, at NEJM.org. This article was published on October 8, 2020, and updated on October 9, 2020, at NEJM.org.""",Protocol v3,Statistical Analysis Plan (SAP) v3,Updated 2020-12-09,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Discuss as full team,team_review,,MSH,2020-06-30,NCT04280705,ClinicalTrials.gov,2020-02-20,2020-02-21,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),Recruiting,Phase 3,Interventional,"Japan, Spain, South Korea, Greece, United States, Denmark, Germany, Singapore, Mexico, United Kingdom",Adaptive COVID-19 Treatment Trial (ACTT),Drug,Remdesivir,Remdesivir,800,https://clinicaltrials.gov/show/NCT04280705,EUCTR2020-001052-18; JPRN-jRCT2031190264,,2023-04-01,2023-04-01,2023-04-01,0,1,,10.1056/NEJMoa2007764,,10.1056/NEJMoa2007764,,interim_results_journal_article,,,2020-05-22,,7,,Recruiting,TRUE,2,32445440,interim_results_journal_article,2020-05-22,,,,,,,,,,,,2021-05-21
2021-01-18 10:55:23,2021-01-18 11:05:19,IP Address,158.181.71.94,100,595,True,2021-01-18 11:05:19,R_79eOlKVhTYIhktz,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,no,2020-12-18,2021-12-31,0,,,,,,full_results_journal_article,other,,,,10.1513/AnnalsATS.202008-940OC,33166179,https://www.atsjournals.org/doi/10.1513/AnnalsATS.202008-940OC,10.1513/AnnalsATS.202004-309SD,32425051,https://www.atsjournals.org/doi/abs/10.1513/AnnalsATS.202004-309SD,,,,,,,,,,2020-11-09,,2020-08,,,,,,,,,,,,,,,,,,,,,,,,Protocol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Should we do full results search (i.e. for preprint)? Full result journal article indicates trial is complete (as of July-ish).,team_review,,MSH,2020-06-30,NCT04329832,ClinicalTrials.gov,2020-03-30,2020-03-30,FALSE,"Intermountain Health Care, Inc.",Recruiting,Phase 2,Interventional,United States,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,Drug,Hydroxychloroquine vs. Azithromycin,Hydroxychloroquine; azithromycin,300,https://clinicaltrials.gov/show/NCT04329832,,,2020-12-31,2021-12-31,2020-12-31,0,1,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2021-12-31
2021-01-18 11:05:24,2021-01-18 11:15:39,IP Address,158.181.71.94,100,614,True,2021-01-18 11:15:39,R_2YabVYVQeYaEOBO,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,"covid + cancer, and looking at survival and some covid measures",,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,,,,,other,,,,,10.1016/j.ejca.2020.05.028,32540204,https://www.ejcancer.com/article/S0959-8049(20)30314-2/fulltext,,,,,,,,,,,,,2020-06-07,,,,,,,,,,,,,,,,,,,,,,,,,found via trial id search. includes interim results in other paper...,,,,,,avrillon AND blay AND cancer AND covid AND immunoncovid,,,,,,,"noted a pub that includes interim result in study population, but not a formal interim result publication",team_review,,MSH,2020-06-30,NCT04333914,ClinicalTrials.gov,2020-04-01,2020-04-15,TRUE,Centre Leon Berard,Not Recruiting,Phase 2,Interventional,France,Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,Drug,Chloroquine + Nivolumab + Tocilizumab,Chloroquine; Nivolumab; Tocilizumab,384,https://clinicaltrials.gov/show/NCT04333914,EUCTR2020-001373-70,,2020-06-01,2020-08-01,2020-06-01,0,0,,,,,,,,,,,7,,Suspended,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 11:15:51,2021-01-18 11:16:49,IP Address,158.181.71.94,100,57,True,2021-01-18 11:16:49,R_XZjxcMeayTEMmTD,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,yes,"Terminated (Interim analysis did not reveal any safety concerns by the DSMB, but unblinded data did not provide support to continue. Event rate did not meet projected magnitude; given low recruitment potential, it is unlikely that a positive result will occur.)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04341441,ClinicalTrials.gov,2020-04-07,2020-04-07,FALSE,Henry Ford Health System,Recruiting,Phase 3,Interventional,United States,Will Hydroxychloroquine Impede or Prevent COVID-19,Drug,Hydroxychloroquine,Hydroxychloroquine,3000,https://clinicaltrials.gov/show/NCT04341441,,,2020-06-30,2021-04-30,2020-06-30,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 11:16:58,2021-01-18 11:17:23,IP Address,158.181.71.94,100,25,True,2021-01-18 11:17:23,R_2P5bkuGH91hVGqO,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,yes,Terminated (halted prematurely.),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04345861,ClinicalTrials.gov,2020-04-05,2020-04-11,FALSE,"University Hospital, Montpellier",Not Recruiting,Phase 2/Phase 3,Interventional,France,Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial),Drug,Hydroxychloroquine + Azithromycin vs. Hydroxychloroquine,Hydroxychloroquine; azithormycin,7,https://clinicaltrials.gov/show/NCT04345861,,,2020-06-08,2020-06-08,2020-06-08,0,0,,,,,,,,,,,7,,Terminated,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 11:17:31,2021-01-18 11:28:39,IP Address,158.181.71.94,100,667,True,2021-01-18 11:28:40,R_5myCDIezMfCMXFn,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,no,2020-07-13,2020-08-27,0,,,,,,full_results_journal_article,,,,,10.1056/NEJMoa2028836,33085857,https://www.nejm.org/doi/10.1056/NEJMoa2028836,,,,,,,,,,,,,2020-10-21,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tocilizumab AND Stone,"""Tocilizumab""[Title] AND stone[Author - First]","(AUTH:""stone"") AND (TITLE:""Tocilizumab"")",allintitle: Tocilizumab covid author:stone,tocilizumab AND covid AND stone,,,,,,MSH,2020-06-30,NCT04356937,ClinicalTrials.gov,2020-04-19,2020-04-20,FALSE,Massachusetts General Hospital,Recruiting,Phase 3,Interventional,United States,Efficacy of Tocilizumab on Patients With COVID-19,Drug,Tocilizumab,Tocilizumab,278,https://clinicaltrials.gov/show/NCT04356937,,,2020-06-30,2020-08-30,2020-06-30,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,true,,2020-08-27
2021-01-18 11:29:10,2021-01-18 11:29:33,IP Address,158.181.71.94,100,22,True,2021-01-18 11:29:33,R_DT43OfhJCyV3urT,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,yes,Suspended (Investigator decision),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04369742,ClinicalTrials.gov,2020-04-25,2020-04-15,TRUE,NYU Langone Health,Not Recruiting,Phase 2,Interventional,United States,Treating COVID-19 With Hydroxychloroquine (TEACH),Drug,Hydroxychloroquine,Hydroxychloroquine,626,https://clinicaltrials.gov/show/NCT04369742,,,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,7,,Suspended,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 11:29:39,2021-01-18 11:34:52,IP Address,158.181.71.94,100,312,True,2021-01-18 11:34:52,R_3O1zypQq7w7miIq,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,no,2021-03-01,2021-03-01,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google,,,,,other,,,,,,,https://www.innate-pharma.com/media/all-press-releases/first-patient-dosed-avdoralimab-phase-ii-clinical-trial-covid-19-patients-severe-pneumonia,,,,,,,,,,,,,2020-04-28,,,,,,,,,,,,,,,,,,,,,,,,,Press release that first patient dosed,,,,,,"FORCE AND covid AND ""Anti-C5aR Antibody""","Pneumonia AND covid AND ""Anti-C5aR Antibody""",,,,,,,,,MSH,2020-06-30,NCT04371367,ClinicalTrials.gov,2020-04-29,2020-04-27,TRUE,Assistance Publique – Hôpitaux de Marseille,Recruiting,Phase 2,Interventional,France,"Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )",Drug,Avdoralimab,Avdoralimab,108,https://clinicaltrials.gov/show/NCT04371367,,,2020-06-27,2020-10-27,2020-06-27,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2021-03-01
2021-01-18 11:51:04,2021-01-18 11:51:29,IP Address,158.181.71.94,100,24,True,2021-01-18 11:51:29,R_2f9SEilawQMyiHK,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,no,,,survey on health care use during COVID,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04372030,ClinicalTrials.gov,2020-04-22,2020-05-01,FALSE,UCLouvain,Not Recruiting,Not Applicable,Interventional,No Country Given,Health Care Use During the Covid19 Crisis,Health System,No Intervention,No Intervention,10000,https://clinicaltrials.gov/show/NCT04372030,,,2020-06-30,2021-10-31,2020-06-30,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 11:51:33,2021-01-18 11:57:04,IP Address,158.181.71.94,100,331,True,2021-01-18 11:57:05,R_uw6MISRk6eQfAhX,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,no,2021-06-30,2021-10-31,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Gerli AND Colchicine AND COVID AND COLVID-19,Gerli AND Colchicine AND COVID,,,,,,,,,MSH,2020-06-30,NCT04375202,ClinicalTrials.gov,2020-04-29,2020-04-18,FALSE,University of Perugia,Recruiting,Phase 2,Interventional,Italy,Colchicine in COVID-19: a Pilot Study,Drug,Colchicine,Colchicine,308,https://clinicaltrials.gov/show/NCT04375202,EUCTR2020-001475-33,,2020-06-30,2020-10-31,2020-06-30,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2021-10-31
2021-01-18 12:20:11,2021-01-18 12:20:39,IP Address,158.181.71.94,100,28,True,2021-01-18 12:20:39,R_1E72pRFOVXAQof8,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,no,,behavioral health in COVID,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04376515,ClinicalTrials.gov,2020-03-31,2020-03-20,TRUE,"University of California, Irvine",Not Recruiting,Not Applicable,Interventional,United States,Harnessing Online Peer Education Online Support Intervention for COVID-19 (HOPE COVID-19),Other (psych),Psychological,Psychological,300,https://clinicaltrials.gov/show/NCT04376515,,,2020-06-01,2020-09-01,2020-06-01,0,0,,,,,,,,,,,7,,"Active, not recruiting",TRUE,2,,,,,,,,,,,,,,,
2021-01-18 12:20:46,2021-01-18 12:25:10,IP Address,158.181.71.94,100,264,True,2021-01-18 12:25:11,R_1IXIIbtE1HvKMlX,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,no,2020-07-01,2020-09-01,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"""Methylene Blue"" AND ""exchange transfusion"" and covid",,,,,,,,,,MSH,2020-06-30,NCT04376788,ClinicalTrials.gov,2020-05-01,2020-05-05,FALSE,Ain Shams University,Not Recruiting,Phase 2,Interventional,Egypt,Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19,ATMP,Plasma + Methylene Blue,Plasma; Methylene Blue,15,https://clinicaltrials.gov/show/NCT04376788,,,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,2020-09-01
2021-01-18 12:25:15,2021-01-18 12:26:59,IP Address,158.181.71.94,100,104,True,2021-01-18 12:27:00,R_2wGFLmh4Yqe7I1Q,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,no,,,"no conditions for patients. looks at compounds in air around patients using ""electronic nose""",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04379154,ClinicalTrials.gov,2020-04-28,2020-04-14,TRUE,Hôpital Foch,Recruiting,Not Applicable,Interventional,France,Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-CoV-2 (COVID-19),Other,Other,Other,60,https://clinicaltrials.gov/show/NCT04379154,,,2020-06-28,2020-11-16,2020-06-28,0,0,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 12:27:14,2021-01-18 12:29:25,IP Address,158.181.71.94,100,130,True,2021-01-18 12:29:25,R_10rD0dKuAwnuHje,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,unknown,no,,"primary outcome about whether device works, not whether it helps patient so not covid treatment?",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MSH,2020-06-30,NCT04381013,ClinicalTrials.gov,2020-05-07,2020-06-01,FALSE,Stanford University,Not Recruiting,Not Applicable,Interventional,United States,Emergency Ventilator Splitting Between Two or More Patients (COVID-19),Other (device),Other,Other,4,https://clinicaltrials.gov/show/NCT04381013,,,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 12:29:31,2021-01-18 12:30:40,IP Address,158.181.71.94,100,69,True,2021-01-18 12:30:41,R_12rkVr0LtGhhzyt,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,no,,,"observations, also not covid treatment or prevention (measure of incidence)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04392323,ClinicalTrials.gov,2020-05-15,2020-05-13,TRUE,Northwell Health,Recruiting,Not Applicable,Interventional,United States,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Clinical Presentation (Epidemiology),No Intervention,No Intervention,500,https://clinicaltrials.gov/show/NCT04392323,,,2020-07-01,2020-07-31,2020-07-01,0,1,,,,,,,,,,,7,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 12:30:46,2021-01-18 12:32:12,IP Address,158.181.71.94,100,86,True,2021-01-18 12:32:12,R_3nDARbjAJMtKJiA,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04392427,ClinicalTrials.gov,2020-05-12,2020-05-01,TRUE,Mansoura University,Not Recruiting,Phase 3,Interventional,Egypt,New Antiviral Drugs for Treatment of COVID-19,Drug,Nitazoxanide + Ribavirin + Ivermectin,Nitazoxanide; Ribavirin; Ivermectin,100,https://clinicaltrials.gov/show/NCT04392427,,,2022-05-01,2022-05-01,2022-05-01,0,1,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 12:32:18,2021-01-18 12:38:55,IP Address,158.181.71.94,100,396,True,2021-01-18 12:38:55,R_0VTvQKhMeNCPmRr,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google,,,,,other,,,,,,,https://www.simit.org/formazione/protocolli-covid-19/56-baricivid-19-study-multicentre-randomised-phase-iia-clinical-trial-evaluating-efficacy-and-tolerability-of-baricitinib-as-add-on-treatment-of-patients-with-covid-19-compared-to-standard-therapy,,,,,,,,,,,,,2020-04-22,,,,,,,,,,,,,,,,,,,,,,,,,Protocol,,,,,,Baricitinib AND covid AND BARICIVID-19 AND (Menichetti OR Ospedaliero),Baricitinib AND covid AND BARICIVID-19,,,,,,,,,MSH,2020-06-30,NCT04393051,ClinicalTrials.gov,2020-05-16,2020-05-20,FALSE,AOU Pisana,Not Recruiting,Phase 2,Interventional,Italy,Baricitinib Compared to Standard Therapy in Patients With COVID-19,Drug,Baricitinib,Baricitinib,126,https://clinicaltrials.gov/show/NCT04393051,,,2020-06-30,2020-07-30,2020-06-30,0,1,,,,,,,,,,,7,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 12:39:05,2021-01-18 12:39:42,IP Address,158.181.71.94,100,37,True,2021-01-18 12:39:42,R_XjPDNcxJoFsTXBD,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,no,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04420806,ClinicalTrials.gov,2020-06-05,2020-03-14,TRUE,University of Erlangen-Nornberg Medical School,Not Recruiting,Not Applicable,Interventional,Germany,Effects of COVID-19 Lockdown in Exercising Early Postmenopausal Women,Other (exercise),Exercise,Exercise,21,https://clinicaltrials.gov/show/NCT04420806,,,2020-06-30,2020-10-01,2020-06-30,0,0,,,,,,,,,,,7,,"Active, not recruiting",TRUE,2,,,,,,,,,,,,,,,
2021-01-18 12:43:00,2021-01-18 12:50:49,IP Address,158.181.71.94,100,469,True,2021-01-18 12:50:49,R_1QxzKk6HEReri4U,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,other,,,,,10.1007/s11739-020-02384-2,32468508,https://link.springer.com/article/10.1007%2Fs11739-020-02384-2,,,,,,,,,,,,,2020-05-28,,,,,,,,,,,,,,,,,,,,,,,,,Protocol,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pubmed,,,,,full_results_journal_article,,,,,10.3324/haematol.2020.261784,33256382,https://haematologica.org/article/view/9826,,,,,,,,,,,,,2020-07-23,2020-04-28,,,,,,,,,,,,,,,,,,,,,,,,pre-published date,,,,,,"Look at protocol ""Cited by"" publications for author name",,,,,,,,,,MSH,2020-06-30,NCT04321421,ClinicalTrials.gov,2020-03-23,2020-03-17,TRUE,Foundation IRCCS San Matteo Hospital,Not Recruiting,Not Applicable,Interventional,Italy,Hyperimmune Plasma for Critical Patients With COVID-19,ATMP,Plasma,Plasma,49,https://clinicaltrials.gov/show/NCT04321421,,,2020-04-28,2020-05-07,2020-04-28,0,1,,10.1101/2020.05.26.20113373,,10.1101/2020.05.26.20113373,,full_results_preprint,,2020-04-28,2020-05-29,,9,,Completed,TRUE,2,,full_results_preprint,2020-05-29,ze4bvjkt,http://medrxiv.org/cgi/content/short/2020.05.26.20113373v1?rss=1,Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial,2020-04-28,,,,,,,true,
2021-01-18 13:14:39,2021-01-18 13:15:23,IP Address,158.181.71.94,100,43,True,2021-01-18 13:15:23,R_247OoW1mTwlhf3J,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,no,,well-being in covid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04335851,ClinicalTrials.gov,2020-04-02,2020-04-06,FALSE,Biruni University,Not Recruiting,Not Applicable,Interventional,Turkey,Video-Based Exercises and Well-Being During Social Isolation,Other (exercise),Exercise,Exercise,68,https://clinicaltrials.gov/show/NCT04335851,,,2020-05-15,2020-06-03,2020-05-15,0,0,,,,,,,,,,,9,,Completed,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 13:15:28,2021-01-18 13:23:59,IP Address,158.181.71.94,100,511,True,2021-01-18 13:24:00,R_3NCdgzdR1ZCgoQC,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,full_results_journal_article,,,,,10.1093/cid/ciaa1177,32785710,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1177/5891816,,,,,,,,,,,,,2020-08-12,2020-06-16,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Methylprednisolone AND jeronimo,,,,,,,,,,MSH,2020-06-30,NCT04343729,ClinicalTrials.gov,2020-04-09,2020-04-18,FALSE,Fundação de Medicina Tropical Dr. Heitor Vieira Dourado,Not Recruiting,Phase 2,Interventional,Brazil,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,Drug,Corticosteroids,Methylprednisolone,425,https://clinicaltrials.gov/show/NCT04343729,,,2020-06-16,2020-09-01,2020-06-16,0,0,,,,,,,,,,,9,,"Active, not recruiting",TRUE,2,,,,,,,,,,,,,true,,
2021-01-18 13:24:08,2021-01-18 13:34:31,IP Address,158.181.71.94,100,623,True,2021-01-18 13:34:32,R_3oEAsfDq9m0567K,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,no,2020-08-10,2020-08-21,1,CTRI/2020/04/024846,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,mycobacterium[Title] AND covid[Title],mycobacterium AND covid AND patel,,,,,,,,,MSH,2020-06-30,NCT04347174,ClinicalTrials.gov,2020-03-31,2020-04-30,FALSE,Cadila Pharnmaceuticals,Recruiting,Not Applicable,Interventional,India,A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients,Drug,Mycobacterium,Mycobacterium,40,https://clinicaltrials.gov/show/NCT04347174,,,2020-06-30,2020-07-30,2020-06-30,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2020-08-21
2021-01-18 13:34:44,2021-01-18 13:35:07,IP Address,158.181.71.94,100,23,True,2021-01-18 13:35:07,R_3iPa4KpJXYcFWol,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,no,,,observational,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04355533,ClinicalTrials.gov,2020-04-17,2020-06-01,FALSE,Assistance Publique – Hôpitaux de Paris,Not Recruiting,Not Applicable,Interventional,France,Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,1920,https://clinicaltrials.gov/show/NCT04355533,,,2020-06-01,2021-09-01,2020-06-01,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 13:35:13,2021-01-18 13:38:31,IP Address,158.181.71.94,100,197,True,2021-01-18 13:38:31,R_2ckjzBBaJj8Bmw8,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,no,2020-11-02,2020-11-30,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04355936,ClinicalTrials.gov,2020-04-17,2020-05-19,FALSE,Laboratorio Elea,Recruiting,Phase 2,Interventional,Argentina,Telmisartan for Treatment of COVID-19 Patients,Drug,Telmisartan,Telmisartan,400,https://clinicaltrials.gov/show/NCT04355936,,,2020-10-01,2020-10-01,2020-10-01,0,1,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,2020-11-30
2021-01-18 13:41:16,2021-01-18 13:42:59,IP Address,158.181.71.94,100,102,True,2021-01-18 13:43:00,R_3KPC9QDzZUFR1k6,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,no,,hyposmia (loss of smell) following covid but not covid itself,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MSH,2020-06-30,NCT04361474,ClinicalTrials.gov,2020-04-22,2020-05-18,TRUE,Fondation Ophtalmologique Adolphe de Rothschild,Recruiting,Phase 3,Interventional,France,Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,Drug,Corticosteroids,Budesonide,120,https://clinicaltrials.gov/show/NCT04361474,EUCTR2020-001667-85,,2020-05-18,2021-05-25,2020-05-18,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 14:00:37,2021-01-18 14:01:35,IP Address,158.181.71.94,100,58,True,2021-01-18 14:01:35,R_3eqcjykmtBum9ZG,,,test@test.com,,51.4700927734375,11.967498779296875,anonymous,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"covid AND ""Convalescent Immune Plasma"" AND Sevdi","covid AND ""Convalescent Immune Plasma"" AND Bagcilar",,,,,,Possible other registration number but not resolving at EUCTR: 2020.05.2.14.070 (I tried 2020-052140-70),,,MSH,2020-06-30,NCT04442958,ClinicalTrials.gov,2020-06-17,2020-05-15,TRUE,Bagcilar Training and Research Hospital,Not Recruiting,Not Applicable,Interventional,Turkey,Effectiveness of Convalescent Immune Plasma Therapy,ATMP,Plasma,Plasma,60,https://clinicaltrials.gov/show/NCT04442958,,,2020-06-15,2020-06-17,2020-06-15,0,0,,,,,,,,,,,9,,Completed,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 14:01:42,2021-01-18 14:03:21,IP Address,158.181.71.94,100,98,True,2021-01-18 14:03:22,R_2yrulzexoVQGBqM,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04438837,ClinicalTrials.gov,2020-06-18,2020-06-01,TRUE,Rambam Health Care Campus,Not Recruiting,Not Applicable,Interventional,Israel,Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers,Drug (Chemoprophylaxis),Hydroxychloroquine,Hydroxychloroquine,582,https://clinicaltrials.gov/show/NCT04438837,,,2022-06-01,2022-06-01,2022-06-01,0,1,,,,,,,,,,,9,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 13:43:20,2021-01-18 13:48:44,IP Address,158.181.71.94,100,323,True,2021-01-18 14:03:51,R_2BmKQxxh5yTwUya,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,outcome measures have to do with breathing so not direct covid measure,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,team_review,,MSH,2020-06-30,NCT04360837,ClinicalTrials.gov,2020-04-22,2020-05-06,FALSE,Szeged University,Recruiting,Not Applicable,Interventional,Hungary,PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients,Diagnostics,Diagnostic Test or Assessment,Diagnostic Test or Assessment,10,https://clinicaltrials.gov/show/NCT04360837,,,2021-06-01,2021-06-01,2021-06-01,0,1,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 14:03:25,2021-01-18 14:03:59,IP Address,158.181.71.94,100,33,True,2021-01-18 14:04:00,R_2zwmJXIF0dYH674,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,no,,learning suturing during covid,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04425499,ClinicalTrials.gov,2020-06-08,2020-06-01,TRUE,University of Montreal,Not Recruiting,Not Applicable,Interventional,No Country Given,A Gamified Network for Surgical Education During COVID-19: A Randomized Controlled Trial,Other,Other,Other,60,https://clinicaltrials.gov/show/NCT04425499,,,2020-06-01,2020-06-01,2020-06-01,0,0,,,,,,,,,,,9,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 14:04:06,2021-01-18 14:05:36,Spam,158.181.71.94,100,89,True,2021-01-18 14:05:36,R_3GCJClPCXcCo11t,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04407507,ClinicalTrials.gov,2020-05-27,2020-06-01,FALSE,Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.,Not Recruiting,Phase 2,Interventional,No Country Given,"Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms",Drug,Ivermectin,Ivermectin,66,https://clinicaltrials.gov/show/NCT04407507,,,2020-08-01,2020-10-01,2020-08-01,0,1,,,,,,,,,,,9,,Not yet recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 14:05:42,2021-01-18 14:12:49,IP Address,158.181.71.94,100,426,True,2021-01-18 14:12:49,R_30oxOsl3knGuFK6,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,google,,,,,other,,,,,,,https://www.biomedres.info/biomedical-research/effects-of-ivermectinazithromycincholecalciferol-combined-therapy-on-covid19-infected-patients-a-proof-of-concept-study-14435.html,,,,,,,,,,,,,2020-08-15,,,,,,,,,,,,,,,,,,,,,,,,,May be result of pilot preceding registered trial,,,,,,"(""Ivermectin-Azithromycin-Cholecalciferol"" OR IvAzCol) AND COVID",,,,,,,,,,MSH,2020-06-30,NCT04399746,ClinicalTrials.gov,2020-05-19,2020-03-15,TRUE,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,Recruiting,Not Applicable,Interventional,Mexico,Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19,Drug,Ivermectin + Azithromycin + Cholecalciferol,Ivermectin; Azithromycin; Cholecalciferol,30,https://clinicaltrials.gov/show/NCT04399746,,,2020-05-20,2020-06-10,2020-05-20,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 14:12:54,2021-01-18 14:16:59,IP Address,158.181.71.94,100,244,True,2021-01-18 14:16:59,R_AokQwbvLcx8QHap,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Dillner AND ""Convalescent Plasma"" AND covid",,,,,,,,,,MSH,2020-06-30,NCT04384497,ClinicalTrials.gov,2020-05-07,2020-05-07,FALSE,Joakim Dillner,Recruiting,Phase 1/Phase 2,Interventional,Sweden,Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study,ATMP,Plasma,Plasma,50,https://clinicaltrials.gov/show/NCT04384497,,,2020-06-01,2020-12-01,2020-06-01,0,0,,,,,,,,,,,9,,Recruiting,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 14:17:39,2021-01-18 14:18:10,IP Address,158.181.71.94,100,30,True,2021-01-18 14:18:10,R_1lowukDGJCnVK0K,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,no,,,"observational, blood samples",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,MSH,2020-06-30,NCT04367662,ClinicalTrials.gov,2020-04-16,2020-04-09,TRUE,"University Hospital, Rouen",Not Recruiting,Not Applicable,Interventional,France,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Clinical Presentation,No Intervention,No Intervention,99,https://clinicaltrials.gov/show/NCT04367662,,,2020-05-14,2020-05-14,2020-05-14,0,0,,,,,,,,,,,9,,Completed,TRUE,2,,,,,,,,,,,,,,,
2021-01-18 13:46:58,2021-01-18 14:24:50,IP Address,158.181.71.94,100,2272,True,2021-01-18 14:24:51,R_1gAvHWdzEPEXJgB,,,test@test.com,,51.4700927734375,11.967498779296875,gl,EN,yes,yes,no,,,yes,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"""Pulmonary Physiotherapy"" AND covid","""Pulmonary Physiotherapy"" AND covid AND Javaherian",,,,,,,,,MSH,2020-06-30,NCT04357340,ClinicalTrials.gov,2020-04-13,2020-04-02,TRUE,Tehran University of Medical Sciences,Not Recruiting,Not Applicable,Interventional,Iran,The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19,Other (physio),Physio & Rehabilitation,Physio & Rehabilitation,40,https://clinicaltrials.gov/show/NCT04357340,,,2020-04-30,2020-05-30,2020-04-30,0,0,,,,,,,,,,,9,,Completed,TRUE,2,,,,,,,,,,,,,,,
